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Visceral leishmaniasis (VL) or Kala-azar is the most severe form of  
leishmaniasis.  It is estimated that 500,000 new cases world wide of VL are 
diagnosed annually.  90% of VL cases occur in developing countries: India 
(especially Bihar), Bangladesh, Nepal, North Eastern Brazil and Sudan.  For the 
past 100 years, antimony has been the first line of treatment for VL cases despite 
considerable toxicity and the requirement for 4 weeks hospitalization. 
 
Resistance to antimony coupled with emergence of HIV associated with VL is on 
the increase. New and improved treatment options are urgently needed to replace 
or complement the few currently available drugs.  The wide variety of 
epidemiological situations and clinical presentations of this disease further warrant 
a series of treatment options instead of one single treatment or control strategy for 
the affected populations.   
 
During 2003, experts in VL together with representatives of regulatory authorities 
and health ministries from Kenya, Ethiopia and Sudan met (Nairobi, May 2003, 
Khartoum, August 2003) to discuss the development of new treatment options for 
this fatal but neglected disease. 
 
This research proposal will be a multicentre, prospective, open label, parallel 
group, comparative trial to determine the efficacy and safety of   sodium 
stibogluconate (SSG) 20mg/kg/day given for 30 days, Paromomycin (PM) 
15mg/kg/day for 21 days, and a combination of SSG and PM, 20mg/kg/day, 
15mg/kg/day respectively, given for 17days in the treatment of patients suffering 





The leishmaniases are a group of diseases caused by Leishmania parasites, of 
which at least 20 different species can cause human disease. Leishmania infection 
is transmitted by the bite of female sandflies. The disease occurs in three forms: 
self-healing cutaneous leishmaniasis (CL), mutilating mucosal leishmaniasis (ML 
or MCL) and life-threatening visceral leishmaniasis (VL). Each form varies in 
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Today, of the estimated 350 million people at risk in 88 countries, 12 million 
people are thought to be affected by leishmaniasis in its different forms, with an 
estimated 1.5 -2 million new cases occurring annually (1-1.5 million cases of 
CL/MCL and 500,000 cases of VL) (WHO 2000). In the past decade, the number 
of leishmaniasis cases has risen (Desjeux 2001) due to increased human exposure 
to the sandfly vector as well as the spread of AIDS and other immunosuppressive 
conditions that have increased the risk of Leishmania-infected people developing 
the disease. 
 
Visceral leishmaniasis (VL) or kala-azar is the most severe form of the disease. If 
untreated, VL has a mortality rate of almost 100%. In 1999, there were 57,000 
(reported) deaths due to kala-azar. Ninety per cent of VL cases occur in five 
developing countries: India (especially Bihar), Bangladesh, Nepal, North Eastern 
Brazil, and Sudan.   
 
Distribution of Visceral Leishmaniasis in Eastern Africa 
 
In Eastern Africa, especially Sudan, Ethiopia and Kenya, visceral leishmaniasis is 
by far the most common form of the disease and is the cause of much death and 
disease.   
 
VL in Ethiopia has been reported from over 40 localities in different parts of the 
country. The infection is either due to L. donovani, L. infantum or L. archbaldi. 
Most infections are acquired in north-west Ethiopia in the lowlands of Metema and 
Humera, south-west Ethiopia in the Segen, Woitu and Omo river basins, and in 
other isolated foci in the rift valley. The north-western Metema-Humera focus 
(which extends northwards to Eritrea and westwards into eastern Sudan) is a major 
VL focus which presently accounts for approximately 60% of the total disease 
burden in Ethiopia. This focus extends over a huge land mass in two regions, 
Region 1 (Tigray) and Region 3 (Amhara). In this focus MSF-H is actively 
involved in treatment of cases, with at least 2000 cases benefiting from treatment 
every year. The patients in this focus are mostly migrant laborers, and one would 
expect up to 40% of the cases to be HIV co-infected. VL foci in Segen, Woitu and 
Omo river basins represent typical endemicty. The VL cases from these foci, 
account for approximately 20% of the  total burden in the country, and HIV co-
infection is less than 2%. These foci are located in the Southern Nations, 
Nationalities and Peoples Regional Government (SNNPRG). Other foci are in 
Region 4 (Oromia), Region 5 (Somali), and Region 2 (Afar). Sporadic case reports 
are known from other smaller localities. For instance, in Moyale, at the borders 
LEAP 0104a Appendices
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with Kenya and in areas northeast of Lake Abaya.  Members of the Ethiopian 
Army and Police Forces who acquire VL in the endemic areas are admitted in 
Addis Ababa referral hospitals. This is a special risk group and HIV co-infection 
could be expected to be more than 50%. (Hailu 2004, Ayele 2004) 
 
In Eritrea, the Red Sea littoral (localities like Nakfa, Afabet, Algena, Keren) and 
the district of Teseney also in Eritrea (North of Humera) are endemic.  
 
Eastern Sudan (Gedarif State), Upper Nile and Western-Upper Nile are known 
endemic areas for visceral leishmaniasis in the Sudan. VL is among the most 
important health problems in the Sudan with more than 24,660 cases and 1193 
deaths that has been reported during 1996-2001. The number of reported cases is 
mainly a reflection of reporting rather than the actual disease transmission. Reports 
and published work from Sudan showed that the disease affects mainly children 
with few adult cases. The disease is reported to be more prevalent among poor 
people, malnourished, vagrant, farmers, laborers, water carrier, and those out of 
country, who have a very limited capacity to assume the costs of the disease 
(Sudan Manual 2004). 
 
In Kenya, the endemic foci of VL include Baringo, Turkana, West Pokot, Kitui, 
Meru, and Machakos districts. The first 3 districts are in Rift Valley province while 
the latter are in Eastern province. Numerous outbreaks of VL were reported from 
these areas in the late nineteen seventies with over 2000 cases reported from Meru 
and Kitui districts only (WHO 1990). All these areas are generally semi-arid, 
sparsely populated with low rainfall and high temperatures. Low agricultural and 
economic productivity has resulted in poor social economic status (SES) of the 
population in these areas.  
 
Population displacements as a result of war, drought, famine, or rural-urban 
migration have exacerbated the spread of the disease. For instance, the epidemic in 
western Upper Nile, an area where VL was previously not endemic, caused an 
estimated 100,000 deaths between 1984 and 1992, or a population mortality of up 
to 36% (Seaman et al. 1996) 
 
Clinical Aspects of Leishmaniasis in Eastern Africa 
 
Visceral leishmaniasis, is a devastating illness, fatal if left untreated. Patients with 
VL present with fever, malaise, cough, abdominal pain, diarrhoea, epistaxis, 
splenomegaly, hepatomegaly, cachexia, anaemia, pancytopenia, lymhadenopathy 
and malnutrition. 
LEAP 0104a Appendices
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Not all infected people develop clinical kala azar; some have a sub clinical 
infection that spontaneously resolves. The ratio of those with clinical disease to 
those with sub clinical disease varies remarkably from place to place, and during 
periods of epidemics. In eastern Sudan, the ratio of clinical cases to mild or sub 
clinical diseases was 1.6:1, and increased to 3.3:1 during a recent outbreak.  The 
scenario is less critical in Brazil where, during an outbreak, the ratio was 1:8 or 
1:16 (showing much less disease per infection); in Iran, it is 1:12 (MSFH 2003)   
Malnutrition, anaemia and immune depression increase the likelihood that 
infection will progress to the disease.  In Ethiopia, Kenya, and Sudan the problems 
of infected children are compounded by these very reasons, as well as 
opportunistic infections such as tuberculosis and pneumonia.  Infected adults also 
bear the brunt of these problems – in Ethiopia HIV is found in association with 
kala-azar in approximately 35-50% of cases ( Dr Asrat Hailu – personal 
communication). 
 
The incubation period for VL varies widely and it is estimated to be between 2 – 6 
months. Malnutrition, anaemia and immune depression increase the likelihood that 
infection will progress to the disease. 
A complication of visceral leishmaniasis, especially prevalent in Sudan (and to a 
lesser extent Ethiopia, and Kenya) is post-kala-azar dermal leishmaniasis (PKDL) 
(Zijlstra et al 2003) occurring in people who have recovered from VL following 
treatment. 
Main treatment options for visceral leishmaniasis. 
Treatment of VL cases in Eastern Africa always presents with challenges such as 
patients coming late when they are extremely ill and may die during treatment due 
to the illness as well as toxicity of the drugs used.  The other challenges include 
availability of drugs, drug resistance, and cost of treatment (drugs and 
hospitalization). In VL endemic areas, facilities may not be available for accurate 
diagnosis and follow up, and the increasing prevalence of HIV co-infection is an 









Page 12 of 756
FINAL VERSION LEAP 0104  31 JULY 2004 CONFIDENTIAL    
 10 
 
Table 1: Current treatment options for patients with visceral leishmaniasis 
 
Drugs available for use  Associated problems 
Pentavalent antimonials Toxic, parasite resistance growing 
30 day IV/IM treatment in hospital 
Amphotericin B Used in case of antimonial resistance but dose-limiting 
toxicity, 15-20 day IV treatment in hospital 
Liposomal Amphotericin B Less toxic but prohibitively expensive 
Miltefosine Teratogenic, only registered in India, and expensive 
 
Need for new treatment options 
  
In eastern Africa, the first line treatment today in most endemic areas is antimonial 
therapy for 4 weeks sodium stibugluconate,(Pentostam® from GSK in Kenya or 
generic SSG from Albert David in Sudan and Ethiopia) used at 20 mg/kg/day for 
28-30 days). Although the efficacy of this treatment is not yet  compromised by 
resistance in this region (in contrast to Bihar – India), the painful daily injections, 
the need for four weeks of hospitalisation, the toxicity when using longer 
treatments, the low efficacy in HIV co-infected patients and the risk of inevitable 
drug resistance, as observed in India, make alternative options a necessity. Second 
line treatments are either toxic or prohibitively expensive.   
 
In 2002-3, a combination of SSG and PM given for 17 days was used in an 
epidemic situation in Southern Sudan, with an initial cure rate of 97% (personal 
communication from Koert Ritmeijer, Médecins Sans Frontières). These findings 
were in line with previous published experience in the same area (Seaman et al, 
1993) and experience in Kenya (Chunge et al, 1990). The proposed study aims to 




Despite the shortcomings listed in table 1, sodium stibogluconate (SSG) is still the 
most widely used drug for VL in Eastern Africa. SSG is known to cause cardiac, 
muscle, joint and renal problems. Emergence of resistance as has occurred in the 
Indian subcontinent (Bihar state) make investigating combination schedules a 
priority. 
LEAP 0104a Appendices
Page 13 of 756





Paromomycin (PM) is a broad-spectrum aminoglycoside antibiotic produced from 
culture filtrates of Streptomyces krestomyceticus and is identical to aminosidine 
(Shilling & Shaffner, 1961). PM is very poorly absorbed from the gut, an oral 
formulation is available for the treatment of infections caused by bacteria, protozoa 
and worms from the intestinal lumen. For the treatment of systemic infections, for 
example VL, a parenteral formulation is required. 
An injectable formulation of 500 mg of PM sulphate has been marketed in several 
countries for over 35 years for the treatment of bacterial and parasitic infections, 
however it has not been licensed specifically for the treatment of VL.  
 
The anti-leishmanial activity of injectable paromomycin was first demonstrated in 
the 1960s and subsequently confirmed in vitro and in vivo. Since then, it has also 
been shown to be effective against visceral leishmaniasis (Chunge 1990, and 
others) and is affordable and well tolerated.  
Efficacy of PM has also been shown in Bihar, India, the region with the greatest 
incidence of kala azar and the highest rates of antimony resistance (Thakur 2000) 
  
Historical Product Profile – Farmitalia dossier  
 
Summary data are available on a total of 2,397 patients treated with injectable 
paromomycin for various infectious diseases. Patient population ranged from 
newborn infants to the elderly. In most cases, adults received up to 2g/d for 30 
days, although patients with skin infections were given up to 1.5g/d for 49 days. 
 
Summary of results:  
Paromomycin was well tolerated. Adverse events (AEs) involving hearing function 
were reported in 10 (0.4%); two patients had renal function decrease and one 
albuminuria; 21 additional patients had other AEs. The occurrence of AEs was not 
related to the age of patients. AEs involving hearing tended to occur in patients 
administered large dose of PM and/or multiple-drug regimens. 
 
Safety Data - Historical Japanese Post Marketing Data: 
Pre and post marketing safety surveillance safety data is available from 2220 
patients. The incidence of adverse reactions is as follows: Pain at injection site 94 
(4.2%), local rash 30 (1.4%), tinnitus 8 (0.4%), malaise 9 (0.4%), skin rash 5 
(0.2%), nausea/vomiting 4 (0.2%), diarrhea 2 (0.1%). The major dose limiting 
toxicities of injectable paromomycin are the same as other drug in the 
LEAP 0104a Appendices
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aminoglycoside class (e.g. streptomycin, gentamycin) being oto- and renal toxicity. 




Mutagenicity/Genotoxicity: GLP Institute Pasteur Lille  
 Mutagenicity test on bacteria using  Ames technique 
 Genotoxic activity using the micronucleus test 
 Mutation assay at the TK locus in L5178Y Mouse lymphoma cells using a 
microtitre cloning technique 
 Test for chromosomal aberrations by in vitro human lymphocyte metaphase 
analysis 
Results: All tests were negative for mutagenicity/genotoxicity 
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Animal toxicology  
 
Table 2:  Animal toxicology studies – part 1 
 
Study Species Route Dose/Duration Sponsor GLP Main results 
Acute Mouse, 
Rat 
IV, IM, IP, 
IC, SC, PO 
Mice- LD50 g/kg 
- IV 0.106- 0.110 
- IP 0.750 
- SC 0.70 - 1.06 
- IC 0.023 
- PO 15.0 –17.8 
Rat – LD50 g/kg 
- IM 1.20 
- SC 0.87 
- PO 21.62 
FCE No The LD50 is 8-10x greater 





IM Mice mg/kg/day 
- 400 for 60 days 
Rats mg/kg/day 
- 264 for 82 days 
Cats mg/kg/day 
- 50 for 37 days 





IM Mice mg/kg/day 
- 400 for 60 days 
Rats mg/kg/day 
- 264 for 82 days 
Cats mg/kg/day 
- 50 for 37 days 
FCE No Mice moderate renal damage 
Rats slight renal damage 
Cats moderate renal damage 
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Table 3:  Animal toxicology studies – part 2 
 






SC Rats mg/kg/day 
- 200, 264 for 60 days 
G. Pigs mg/kg/day 
- 50, 100, 200, 400 for 30 days 
- 20 for 60 days 
- 200 for 28 days comparative trial with 
KM and DHSM 
FCE No Rat dose related cumulative 
effect on acoustic sensitivity 
Guinea Pig dose related 
cumulative effect for oto-
toxicity. In the comparative 
trial AM was less ototoxic 








- 100, 200, 300 IM for 7 days  
Rats mg/kg/day 
- 100, 200, 300 IM for 7 days 
Embryo-fetal 
Rats mg/kg/day 
- 100, 200 SC for 19 days 
Rabbits mg/kg/day 
- 12.5, 25 SC for 28 days 
FCE No No teratogenic effect 
detected. 






Dogs IM Dogs mg/kg/day 
30, 100 for 13 weeks 
SoloPak 
 
Yes Low dose dogs slight to 
minimal renal damage, and a 
frequency dependent hearing 
loss at high tones. High 
doses dogs severe chronic 
nephropathy, and renal 
tubular degeneration. Unable 
to detect audiometric hearing 
frequencies Swelling and 
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An HPLC assay was developed at the University of Illinois at Chicago under GLP 
conditions in order to be able to determine the concentration of paromomycin in 
biological fluids (e.g. urine and plasma) 
Single Dose Intramuscular Pharmacokinetics in Healthy Normal Volunteers 
Sixteen HNVs were given a single IM dose of paromomycin base either 12 or 15 
mg /kg (8 per group)  
 






















12 21.6 1.19 6.27 0.23 86.3 117.7 0.35 2.21 
15 23.4 1.51 2.65 0.20 104.5 126.0 0.41 2.64 
 
Dose finding Studies 
 
1) Randomized phase II clinical study: Kala-azar Research Centre, Muzaffarpur, 








Relapses Defaulters Definitive Cure 
180d (%) 
PM 12 x 21d 30 30 2 5 0 23/30 (76.7) 
PM 16 x 21d 30 30 0 1 1 28/29 (96.5) 
PM 20 x 21d 30 30 0 1 0 29/30 (96.7) 
SB 20 x 28d 30 30 8 3 0 19/30 (63.3) 
 
2) Randomized phase II clinical study: Patna Medical College, Patna, Bihar, India; 








Relapses Defaulters Definitive Cure 
180d (%) 
PM 12 x 21d 30 30 0 3 0 27/30 (90.0) 
PM 16 x 21d 30 30 0 3 3 24/27 (88.9) 
PM 20 x 21d 30 30 0 4 1 25/29 (86.2) 
SB 20 x 28d 30 30 8 1 1 20/29 (69.0) 
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3) Randomized, comparative, open-label trial of the safety and efficacy of 
Paromomycin (PM) + sodium stibogluconate (SB) versus sodium stibogluconate 
alone for the treatment of visceral leishmaniasis: Patna Medical College, Patna, 







Relapses Defaulters Definitive Cure 
180d (%) 
PM12+SBx 21d 52 51 3 1 0 48/52 (92.3) 
PM18+SBx 21d 48 46 2 1 0 45/48 (93.8) 
SB20 x 28d 50 46 21 1 1 27/50 (54.0) 
 
Clinical Experience with injectable paromomycin in the Treatment of VL 
 
Previously, clinical trials with injectable PM either alone or in combination with 
SB for the treatment of VL have been conducted in Africa (Kenya and Sudan), 
India (Bihar), and in cases imported into the United Kingdom (Jha, et al., 1998, 
Hassan M, et al., 1995 Thakur et al., 1995; Seaman et al, 1993, Thakur et al, 1992, 
Scott et al, 1992, Chunge et al., 1990). In all the studies the investigators reported 
that PM, used as a single agent or combined with SB was highly efficacious and 
well tolerated in the treatment of VL caused by L. donovani or infantum. 
 












6    40 India (Thakur) 
12 60  India (30 Jha, 
30 Thakur) 
120 India (96 Thakur, 
24 Thakur) 
14-16 19 Kenya 
(Chunge) 
124 Kenya and Sudan 
(23 Chunge, 101 
Seaman) 
16 60 India (30 Jha, 
30 Thakur) 
  
18   50 India (Thakur) 
20 60 India (30 Jha, 
30 Thakur) 
  
Total Patients 199  384  
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TRIAL OBJECTIVES AND PURPOSE 
 
Currently in the three countries, Sudan, Kenya and Ethiopia many of the patients 
present themselves in remote areas and need to be treated in relative resource poor 
settings. It is for this reason that standardised treatment with proven efficacy is 
much needed. A shorter course of treatment is not only advantageous for the 
patient but also reduces the overall case load in the clinics thus reducing the risk of 
disease outbreaks in already immuno-compromised kala-azar patients. 
Paromomycin, either alone or in combination with SSG would decrease the 
treatment duration substantially. An additional added value of combination therapy 
is that it is likely to reduce the chances of development of parasite resistance 
against the individual drugs.  
   
Leishmaniasis experts in the three countries are in agreement that there are 
potential benefits of the combination treatment of SSG and PM and that its efficacy 
should be evaluated with the view to introduce this protocol if proven efficacious 
and safe. There is ample circumstantial evidence of the use of this combination 
therapy and its efficacy and tolerability as a standardized protocol. This can only 




That a combination course of SSG and PM (17 days) is similar in efficacy to either 
PM alone(21 days) or SSG alone (30 days) and that the shorter course combination 
(17 days) is not more toxic than PM or SSG alone. 
 
OBJECTIVES OF THE TRIAL 
 
1) To assess the efficacy and safety of SSG 30 days alone in the treatment of 
patients with VL. 
 
2) To assess the efficacy and safety of PM 21 days alone in the treatment of 
patients with VL. 
 
3) To assess the efficacy and safety of SSG and PM as a combination course of 
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This will be a multi-centre, prospective, open, parallel group, comparative trial of 
efficacy and safety of SSG alone given IM/IV (according to usual hospital 
practice) for 30 days versus paromomycin alone given IM for 21 days versus a 
combination of SSG and PM given for 17 days, in the treatment of patients 
suffering from VL in Ethiopia, Kenya and Sudan. 
Patients who have clinical symptoms and a confirmed parasitological diagnosis of 
VL by splenic aspirate, lymph nodes aspirate or bone marrow aspirate (to be 
specified for each hospital site) and who have fulfilled the inclusion/exclusion 
criteria will be enrolled. 
The primary endpoint will be cure rate at 6 months post treatment. Secondary 
endpoints will be cure rate at end of treatment (Day 31 for SSG, Day 22 for PM, 
Day 18 for PM + SSG) and at three months post treatment. 
 
STUDY SITES 
The study will be conducted at the following sites;  
 
Ethiopia:  
 Arba Minch hospital 
 Gondar hospital 
 
Kenya:  




 Kassab Hospital  




Patients who fulfill the following inclusion criteria will be enrolled into the study:- 
 
1) Patients for whom written informed consent has been signed by the patients 
themselves (if aged 18 years and over) or by parents(s) or legal guardian for 
patients under 18 years of age.  
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2) Patients aged between 4 and 60 years (inclusive) who are able to comply 
with the protocol. It is justified to include children because they represent 
more than 50% of VL cases. 
3) Patients with  clinical signs and symptoms of VL and diagnosis confirmed 
by visualization of parasites in tissue samples (spleen, lymph node or bone 




 Patients with the following will be excluded from the study: 
 
1) Patients who have received any anti-leishmanial drug in the last 6 months. 
2) Patients with a negative splenic / lymph node / bone marrow smears. 
3) Patients with a clinical contraindication to splenic/lymph node/ bone marrow 
aspirates. 
4) Patients with severe protein and or caloric malnutrition (Kwashiokor or 
marasmus) 
5) Patients with previous hypersensitivity reaction to SSG or aminoglycosides. 
6) Patients suffering from a concomitant severe infection such as TB or any other 
serious underlying disease (cardiac, renal, hepatic) which would preclude 
evaluation of the patients response to study medication.  
7) Patients suffering from other conditions associated with splenomegaly such as 
schistosomiasis. 
8) Patients with previous history of cardiac arrhythmia or an abnormal ECG 
9) Patients who are pregnant or lactating. 
10) Patients with haemoglobin < 5gm/dl. 
11) Patients with WBC < 1 x 10³/mm³. 
12) Patients with platelets < 40,000/mm³. 
13) Patients with liver function tests more than three times the normal range 
14) Patients with serum creatinine outside the normal range for age and gender 
15) Patients with pre-existing clinical hearing loss. 
NB 
Relevant tests will be done to exclude the above listed conditions. 
 
HIV-status and VCT 
  
All patients will be offered counseling and screening for HIV (voluntary 
counseling and testing programme (VCT). This may either  be done at the same 
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time as consent is obtained for inclusion in the trial or at  a  later date according to 
hospital practice. HIV positive patients will not be excluded from the clinical trial.  
Subset analysis will be performed to assess any differences in response. 
 
CRITERIA FOR PATIENT WITHDRAWAL 
 
Patients will be considered to have completed the study if they satisfy all entry 
criteria, complete the course of treatment and attend the 6 month follow-up visit.  
 
Patients will be considered to have withdrawn from the study if they had entered 
into the study (i.e. gave informed consent and received at least one day’s 
treatment) but did not complete the treatment period and follow up period. 
 
Treatment failure will be defined as no change or an increase in the patient’s 
disease severity i.e. in signs and symptoms of VL, and parasitology, such that the 
patient is withdrawn from the study and alternative therapy given. 
 
A patient may be withdrawn from the study at any stage if the investigator or the 
DSMB considers there is a serious risk to the patient from continuation in the 
protocol.  Alternative therapy will be provided to the patient if needed, upon 
withdrawal from the study. 
 
A patient may withdraw, or be withdrawn, from the study for one of the following 
reasons: 
• Serious adverse events (drug related or not) 
• Deviation from protocol (including non-compliance) 
• Lost to follow-up 
• Termination by the sponsor 
• Withdrawal of consent 
 
The reason for termination will be recorded on the CRF. Patients withdrawn from 
the study will be followed-up at 3 and 6 months for monitoring of adverse events 
wherever possible.  Every effort will be made to follow up withdrawn patients in 
order to determine the final outcome. This information will be recorded in the CRF 
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Randomization in the Clinical Trial (RCT)    
The multi-country study adopted restricted randomization in a three-arm study per 
country. This approach prevents the potential pitfall/imbalance in study numbers 
that could have resulted if one used simple random sampling. In order to avoid 
manipulation of blocks of small sizes, blocks of size 15 will be used in 
randomization. This approach ensures that the study balances after the 15th patient. 
In the allocation of the drugs to the patients concealment will be used in order to 
minimize selection bias. Opaque envelopes will be numbered sequentially and then 
sealed.  This process will be carried out at the coordinating centre at KEMRI. 
 
RCT PM (21 days) 
  
 SSG (30 days) 
 
 SSG + PM (17 days) 
 
Fig 1: The structure of the RCT 
 
Sample size Determination 
 
The sample size will be used to test the following statistical hypothesis as 
stipulated earlier: 
 
Hypothesis: The three therapies differ by clinically relevant amounts 
Alternative Hypothesis: The three therapies do not differ by clinically relevant 
amounts 
 
A cure rate of 85% to 95% was used in the sample size calculation, where 85% 
represents the worst-case scenario and 95% the best outcome. The difference of 
these two proportions gives the size of the treatment effect sought in the 
randomized clinical trials.  
This means that we are dealing with a dichotomous variable where the patients will 
be categorized as cured or not cured. A power of 90% and 5% level of significance 
are also required. The calculated sample size was adjusted for attrition and other 
covariates such as HIV/AIDS which was observed to be high in some of the 
participating countries. 
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Allocation adopted – uniform and equal allocation where λ=nt/nc=1  
The sample size n=r*nt  [r is the number of active groups] which is calculated as 
follows:- 
  
nt [per arm]=k* [(p1(1-p1) + p2(1-p2))/(p1-p2)2] 
 
Where: 
nt = sample size 
za/2 = the corresponding value to the 95% CI 
zβ  = The corresponding value to power of 90% 
p1 = anticipated cure rate = 95% 
p2= worst case scenario = 85% 
q1 = 1- p1 
q2 = 1- p2 




 nt >= 10.5 [(0.85(0.15) + 0.95(0.05))/0.01 = 184 
 
The sample size was adjusted to account for attrition rate due to loss to follow up, 
which is anticipated to be 15%. Thus the minimum sample size becomes  n = 217. 
 
HIV/AIDS was likely to be a covariate that could affect the primary variable-cure 
rate, especially in Ethiopia where the co-infection rate is estimated to be above 
20%. This necessitated a further adjustment of the sample size for Ethiopia by 20% 
in order to be able to attribute the true treatment effect of the test drugs after 
controlling for HIV/AIDS. Thus the total for the three arms is 695. 
 
The participating teams from Kenya, Ethiopia, Sudan and MSF were asked to 
specify the number of cases they could conveniently handle given the existing 
capacity and available infrastructure. This approach was used in absence of any 
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Table 1: Sample size per group 
 
Teams Expected Sample per 
Group(rounded to complete 
block of 15) 
Kenya   60 
Sudan MSF 150 
Sudan MOH 225 












Eligible patients for whom informed consent has been obtained will be randomized 
to either of the three treatment regimens using a computer generated randomization 




SSG will be given IM or IV at a dosage of 20mg/kg/day* for 30 days.  
PM will be given IM at a dosage of 15 mg/kg/day for 21 days.   
SSG + PM combination: SSG will be given IM or IV at a dosage of 20mg/kg/day* 
for 17 days and PM at a dosage of 15 mg/kg/day IV/IM for 17days 
*The maximum dosage of SSG per day for any patient is 850mg (8.5ml)  
 
Treatment will be given by the clinicians/nurse at the same time each day and a 
treatment sheet indicating time of dosing bearing the signature of the attending 
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In the event of failure to respond to treatment, clinical deterioration or relapse at 
any time during the study, rescue treatment consisting of IV Ambisome® ( a 
liposomal formulation of amphotericin B) at a dosage of 3 mg/kg/day for 5 days or 
according to local Ambisome® rescue protocol, the exact regimen used at each 
trial site to be documented in the case report form.. 
 
Prior and Concomitant Medications 
 
No additional anti-leishmanial therapy will be permitted during the course of the 
study.  If such therapy becomes necessary, the patient will be withdrawn from the 
study and considered a treatment failure. 
 
Concomitant medication necessary for the health of the patient will be permitted 
during the course of the study.  This will include the concomitant use of drugs such 
as paracetamol as an analgesic/antipyretic. Details of all concomitant medication 
taken during the study will be recorded in the CRF with indication, daily dose, 
route and dates of administration. 
 
In the case of a patient presenting with co-infection, eg. pneumonia or malaria, 
these infections should be treated first. The patient should be re-assessed for 




Efficacy will be assessed using clinical, haematological, biochemical and 
parasitological responses. 
  
• Clinical Assessment 
The clinical evaluation will involve measuring the spleen size by palpation below 
the left coastal margin, temperature, blood pressure, body weight on days 0, 7, 14, 
21 and end of treatment (18, 22, 31), 3 months and 6 months post treatment.  
ECG and audiometry will be done at baseline, day 14, end of treatment and 6 
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• Haematological and biochemical assessment 
Blood will be analyzed for haemoglobin, WBC, platelets, urea, creatinine, and 
liver function tests on days 0, 7, 14, 21 and end of treatment (18, 22, 31), 3 months 
6 months post-treatment. 
 
• Uninalysis 
Urinalysis will be performed on days 0, 7, 14, 21 and end of treatment (18,22,31) 3 
months and 6 months post-treatment. 
 
• Parasitological assessment 
Parasitological assessment involves aspirating the spleen, lymph node or bone 
marrow at baseline, end of treatment (18, 22, 31 days depending on treatment arm) 
on, and at 3 months and 6 months follow up visits for all study patients. In 
addition, at selected sites aspirates will be cultured.  Each patient will have a 
maximum of four aspirates. Patients who are clinically well with no signs or 
symptoms of VL and no palpable lymph nodes / spleen at the three months visit do 
not to have any aspirate at this visit. All patients will have an aspirate at 6 months 
post treatment.  
  
 
The source of parasitological specimens should remain unchanged throughout the 
treatment and follow up periods, unless the spleen / lymph node initially chosen as 
the source of parasitological specimens becomes unpalpable, in which bone 
marrow aspirate should be performed. 
 
Since bone marrow, lymph node and splenic aspirates are invasive procedures, 
these should only be performed at other times if clinically indicated.   
 
PRIMARY EFFICACY ENDPOINT 
 
The primary efficacy variable is parasitological clearance at 6 months post 
treatment by splenic, lymph node, or bone marrow smear.  
 
SECONDARY EFFICACY ENDPOINT 
 
The secondary efficacy endpoint will be parasitological clearance at the end of 
treatment (18, 22, 31 days depending on treatment arm – Test of cure (TOC)) and 
at 3 months post treatment. 
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During treatment and at follow up, safety will be assessed by means of 
haematological, urinalysis and biochemical monitoring as above, and by ECG and 
audiometry at selected sites. In addition, patients will be asked at each visit if they 
have suffered any side-effects or other unexpected adverse events. 
 
Adverse events  
 
An adverse event will be defined as any noxious, pathological or unintended 
change in anatomical, physiological or metabolic functions as indicated by 
physical signs, symptoms and/or laboratory changes occurring in any phase of the 
clinical study, whether or not they are considered to be associated with the study 
drug. This includes an exacerbation of pre-existing conditions or events, 
intercurrent illnesses, drug interaction, or the significant worsening of the disease 
under investigation that is not recorded elsewhere in the CRF under specific 
efficacy assessments.  Anticipated day to day fluctuations of pre-existing 
conditions, including the disease under study, that does not represent a clinically 
significant exacerbation or worsening of the condition, will not to be considered 
adverse events. 
 
All adverse events occurring after the start of the study (defined as when informed 
consent was obtained) are to be reported.   This is regardless of whether or not they  
are considered to be drug related.  Adverse event (AEs) elicited by the investigator 
asking the patient or the patient’s parent or guardian a non-leading question such as 
“Do you/has your child felt different in any way since starting the new 
treatment/the last assessment?”  If the response was “Yes”, the nature of the event, 
the date and time (where appropriate) of onset, the duration, maximum intensity 
(see below) and relationship to treatment are to be established (see below).  Details 
of any changes to the dosage schedule or any corrective treatment are to be 
recorded on the appropriate pages of the CRF. 
 
Assessment of Intensity/Severity 
 
The assessment of intensity/severity will be based on the investigator’s clinical 




Page 29 of 756






Mild:  An adverse event, which is easily tolerated by the patient, causing 
minimal discomfort and not interfering with every day activities. 
 
Moderate: An adverse event, which is sufficiently discomforting to interfere 
with normal everyday activities. 
 
Severe:  An adverse event, which prevents normal everyday activities. 
 
Assessment of Causality 
 
The investigator will use clinical judgment to determine the degree of certainty 
with which adverse event is attributed to drug treatment.  Alternative causes, such 
as natural history of the underlying diseases, concomitant therapy, etc are to be 
considered taking into account the known pharmacology of the drug, any previous 
reactions, literature reports and relationship to time of drug ingestion or recurrence 
on re challenge.  Causality will be assessed using the following categories; not 
related, unlikely, suspected (reasonable possibility) or probable. Patients with 
adverse events will be followed-up until the event disappears or the condition  
stabilizes.  
 
Serious Adverse Events 
 
A serious adverse event will be defined as any event which  is fatal, life 
threatening, disabling or incapacitating or results in hospitalization, prolonged 
hospital stay or is associated with congenital abnormality, cancer or overdose 
(either accidental or intentional).  In addition, any experience which the 
investigator regards as serious or which suggests any significant hazard, 
contraindication, side effect or precaution that might be associated with the use of 
the drug will  be reported as a serious event. Any serious adverse event occurring 
either during the study or within 30 days, or 5 half lives (whichever is longer), of 
receiving the last dose of study medication, is to be reported by telephone to the 
study monitor within 24 hours. This will be followed by a full written summary 
containing relevant hospital case records and autopsy reports where applicable. 
  
As treatment is by parenteral injection, over dosage is not anticipated. However, in 
the event of over dosage (error of dosage calculation or administration) will be 
communicated to the study coordinator, Dr. Monique Wasunna, within 24 hours or 
as soon as possible thereafter. Details of any signs or symptoms and their 
management will be recorded in the CRF including details of any antidote(s) 
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administered. As there are no specific antidotes available for the medications to be 
used in this study, patients will receive all supportive care needed at discretion of 
the treating physician and after consultation with the study coordinator above. 
 
 
DATA COLLECTION, STORAGE AND ANALYSIS  
Data Management   
  
In order to ensure data quality, a uniform hard copy i.e case report form (CRF) will 
be designed for use at all the sites. Data will then be sent to the coordinating sitefor 
data entry. It will be the responsibility of the investigator to ensure that the CRF is 
correctly completed to avoid unnecessary delays.    
 
The software of choice will be EpiInfo 2003 which has an adequate electronic data 
capture (EDC) module especially for double entry. The data will be entered using 
pre-designed screens matching the data collection tool for ease of entry and 
validation. The entry program will also have in-built checks to minimize entry 
errors such as minimum and maximum, allowable values, legal values, jumps and 
values one must fill.  
This exercise will be carried out by well-trained data entry personnel who will 
manage the data under the guidance of the biostatistician at the Centre for Clinical 
Research Centre of KEMRI. 
Analysis    
In the analytical approach intention to treat will be used. The aim is to estimate the 
difference in treatment outcomes for the three arms. The intention to treat 
analytical method will take care of events such as patent withdrawal from the trial, 
failure to comply with treatment, change in treatment and lost to follow-up. 
 
There are two basic options:  
Analyse final outcome only for those who complied perfectly with each treatment  
Analyse data for all subjects in the groups to which they were randomized. This is 
referred to as 'Intention to treat' analysis or the 'pragmatic approach'.   
The second option will be adopted, analysis will be carried out according to the 
original treatment assignment regardless of adherence to treatment or protocol. 
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There will be no exclusion of patients or events. Drop-outs will be checked to 
establish whether they were systematic or non-random. The analysis will, as 
much as possible stick to the protocol to avoid data dredging as part of post ad 
hoc analysis. 
 
Note: Specific country analysis will be of little value because it lacks power. The 
data will have to be pooled for it to achieve the necessary power in the efficacy 
analysis.  
 
Summary statistical measures to be computed  
The summary statistics will include the χ2 and risk ratios per arm for the overall 
efficacy comparison. The analysis and interpretation will heavily rely on 
confidence intervals of the cure rates among the three arms of the RCT. Other 
estimations to be made will be the calculation of the power finally achieved by the 
trial. This will be followed by the presentation of the results in terms of basic 
descriptive statistics and statistical diagrams.  Finally multivariate analysis will be 




QUALITY CONTROL AND QUALITY ASSURANCE 
 
All study sites and data generated during the study will be regularly monitored by 
GCP trained clinical monitors. Wherever possible, CRF data will be verified 





The study protocol together with patient information and consent forms will be 
submitted to the local scientific and ethics committee and any other regional or 
national regulatory authorities as required in the three countries, Kenya, Sudan and 
Ethiopia, before the study starts and any patient receives study medication. 
 
The patients who participate in this study will be hospitalized and under close 
monitoring. The invasive diagnostic methods used in the study are those used in 
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normal clinical practice when treating patients with VL. However, the frequency of 
testing might be increased depending on the patient’s response to treatment.  
 
Children will be included in this study because they represent more than 50% of 
VL cases in this region. 
 
The effective treatment of VL benefits not only the individual patient but also the 
community by reducing the reservoir of infection for onward transmission by the 
sandfly vector. The evaluation of new and better treatments for VL, including 
shorter courses and combinations is anticipated to have a positive effect on 
development of parasite resistance and will reduce hospitalisation costs. If 
paromomycin is found to be efficacious and safe, it will be registered for the 
treatment of VL, providing a new alternative to treatments already available. 
 
Patients will experience some pain while blood is drawn during venepuncture. The 
amount of blood to be drawn will be 10 mls before treatment and 7 mls at each 
subsequent visit, with a total of 42 mls (PM alone and a combination of PM and 
SSG), 49 mls (SSG alone) over the 6 months study period.   
 
SSG has been extensively used in Sudan, Ethiopia and Kenya. Known adverse 
events include cardiac, muscle, joint and renal toxicity. PM has been used in 
clinical trials in Sudan and Kenya during the 1990’s, and more recently in 
humanitarian emergency setting in Sudan. Known adverse events of the 
aminoglycosides include ototoxicity and renal toxicity. 
 
Patients who are found to be HIV positive will be offered anti retroviral treatment 
at no cost in accordance with national guidelines for treatment. 
 
A Data Safety and Monitoring Board (DSMB) will be set up to regularly review 
safety data. 
 
Patients will be reimbursed for travel to and from the study site and will not 
receive any payment for trial participation. Any medication that is required during 
the trial period will be provided free of charge to the patient.   
 
INSURANCE AND LIABILITY 
 
DNDi is insured to indemnify the collaborating investigator for any injury or harm 
which occurs during the performance of the trial according to the protocol signed 
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by the investigator. Furthermore, DNDi will in accordance with the declaration of 
Helsinki on Ethical principles for medical research involving human subjects, 
make all reasonable efforts to protect patients from any harm which may occur 
during the trial, and will wherever possible ensure that any patient that does suffer 
harm will receive the best possible treatment available in that country to alleviate 






The study is expected to start in October 2004 and will last 12 to 18 months (6-12 
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PATIENT INFORMATION AND CONSENT  
  
 TITLE:  A MULTICENTRE COMPARATIVE TRIAL OF EFFICACY AND 
SAFETY OF SODIUM STIBOGLUCONATE (SSG) VERSUS 
PAROMOMYCIN (PM) VERSUS COMBINATION OF SSG AND 
PM AS THE FIRST LINE TREATMENT FOR VISCERAL 
LEISHMANIASIS IN ETHIOPIA, KENYA AND SUDAN 
 
PRINCIPAL INVESTIGATOR(S): ETHIOPIA  Dr. Asrat Hailu 
     KENYA  Dr. K.M. Wasunna 
     SUDAN  Dr. Musa Amudawi 
     SUDAN  Dr. Getahun Mengistu  
     MSFH  Dr. Manica Balasegaram 
       
SPONSOR: Drugs for Neglected Diseases Initiative, Geneva, Switzerland 
 
Introduction 
We are   studying kala-azar disease, which is common in our countries. The test 
you have had performed indicates that  you have been infected by a parasite called 
Leishmania that causes the illness kala-azar. We are studying new drug treatments 
for this disease, and would like you to participate in this  trial to test a new drug 
called paromomycin. We wish to compare it with the usual treatment called SSG, 
and a combination of both drugs used together. 
Paromomycin alone and the combination with SSG have been shown to be useful 
in small studies in some countries but we do not have sufficient evidence of safety 
and efficacy to enable us to get paromomycin registered in this country. 
The study is expected to start in 2004 and will last for 12-18 months. A total of 705 
patients will participate. 
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Procedures during the trial 
Because we do not know which treatment is most effective, you will be allocated 
to one of the three treatment choices by a process called randomization, which 
means that the chances of you getting any of the three treatments is the same.  
You will be admitted to the ward for the duration of the treatment. This is given as 
a daily injection into a vein or muscle for up to 30 days, depending on which 
treatment choice you are allocated. 
Known side effects of these drugs include, pain at the injection site, skin rash, 
nausea and vomiting, diarrhea, feeling tired, ringing in the ears and rarely damage 
to the heart, kidneys or hearing. During the trial we will regularly assess your 
progress by means of blood tests, urine tests, heart tracings and hearing tests. A 
total of 10 mls of blood (two tea spoons) will be drawn at the beginning of the trial 
and 7 mls (one and a half tea spoons) at each subsequent weekly assessment during 
treatment and at follow up.  We shall also need to repeat the test on your lymph 
nodes/spleen/bone marrow to make sure that the drugs are killing the kala- azar 
parasites. These tests are necessary but not without risk. 
 
Occasionally splenic aspiration  may result in internal bleeding. This is very 
unlikely but may occur as a complication in approximately 1 in 1,000 patients. The 
risks can be minimized in a number of ways. For instance, we will determine any 
bleeding problem you may have by a blood test. If this test indicates you are at risk 
of bleeding, we will use lymph node (LN) aspiration or bone marrow (BM) 
aspiration instead. If it is necessary to do a bone marrow test we will perform it 
under local anesthesia, to reduce the pain of this procedure. Special precautions 
will be taken in cases of children. The child must be calm and still during the 
procedure, so will be held gently onto the bed by a nurse to avoid movement.   
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Local anaesthetic and mild sedation will be given. In case bleeding occurs we will 
look after you until you are fully recovered. 
On rare occasions there might be  failure of treatment using the study drugs. In this 
case, you will receive treatment with another drug called liposomal amphotericin-B 
(AmBisome). This drug is known to be very effective and safe. It is not available 
in Ethiopia, Kenya and Sudan because it is very expensive, however, we shall 
make this drug available to you, at no cost, to make sure we can cure your disease.  
We need to assess the long term effects of the drugs and therefore we shall need 
you to attend two follow up appointments at 3 months and 6 months after your 
treatment has finished. For school children, this will mean absence from school on 
those days.  
 
Benefits  
The main benefit of participation in the study is that you will be cured of the 
disease  called kala azar. If the study is successful it means that an alternative 
shorter treatment will be available for this disease which will benefit your 
community and may reduce the likelihood of other people getting the disease. 
 
Confidentiality 
At the end of the study, we plan to write a report about the results of the study. The 
reports will not bear any information relating to you personally e.g. your name or 
identity. We assure you of the confidentiality of such information. Thus, we also 
need your permission to use the test results for writing a report.  
In addition, clinical monitors of the sponsor (DNDi) or the regulatory authorities 
may wish to inspect your records.  
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Right to refuse or withdraw 
You do not have to take part in this research, your participation is voluntary. If you 
do not wish to do so and this will not affect your treatment at this centre in any 
way.  You will still have the benefit of treatment for your disease at this centre. 
If you do decide to participate and then change your mind later, you may do so, at 
any time, without losing any of your rights as a patient. 
 
It is also possible that we may decide to withdraw you from the study if we believe 
it is in your best interests, in which case you will continue to receive the usual 
treatment for kala-azar until you are better.. 
 
The sponsor (DNDi) may also decide to terminate the study. In this event we will 
continue to treat you until you are better. 
 
In the event that you suffer an injury or illness related to participating in this trial, 
DNDi  will pay all costs relating to treatment of the injury or illness.   
 
You will not receive any money for your participation in the study, however, we 
will pay your travel expenses to attend the hospital for treatment and hospital 
follow up visits at 3 and 6 months. In the rare event that you suffer complications 
due to study treatment, we will do everything possible to ensure you receive the 
necessary medical care and treatment for this complication.  
If you agree to participate in the study, we will ask you to read and sign the 
consent form. 
Do you have any questions?  
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Patient information for HIV testing  
 
As we have explained to you, you have kala-azar infection and we are treating you 
with one of the three trial drug treatments.   We are now asking you to be tested for 
another infection.  It is a test for HIV infection. We have very important reasons to 
test you for HIV, which we would like you to understand.  
 If you are HIV positive you may not respond to treatment and we may need to 
give you additional treatment. In case you are HIV positive, it will be beneficial for 
you to know, both for your own well being, and also for your family, friends and 
other persons living with you.   
We advise you to consider being tested. If you wish to be tested, a counselor will 
hold confidential discussions with you before and after the test. We will inform 
you of the test results. If you are HIV positive we will treat you for kala-azar first 
and then treat you for the HIV infection afterwards. 
If you fulfill the national criteria for anti-retroviral therapy, we will provide you 
with anti-retroviral therapy for the duration of the project (18 months) or as 
required by national guidelines, at no cost to you. 
 
If you do not wish to be tested for HIV, you will still benefit from the treatment  
for your kala-azar.  
 
There is no obligation for you to accept the HIV test within this study, and if you 
refuse it, or do not wish to be informed of the results of your test, you will not be 
deprived of any other medical care that we offer you. You may wish to take time to 
think about being tested.  If you change your mind later, and would like to be 
tested, we will do this for you at any time during this trial.   
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Consent Form:  
I, the undersigned, confirm that, as I give consent to participate in the study, it is 
with a clear understanding of the objectives and conditions of the study and with 
the recognition of my right to withdraw from the study if I change my mind.  
I ……………………….. do hereby give consent to Dr …………………………… 
to include me in the proposed research and the treatment. I have been given the 
necessary information and understand that there might be some risks involved in 
the treatment procedures. I have also been assured that I can withdraw my consent 
at any time without penalty or a loss of benefits. The proposal has been explained 
to me in the language I understand.  
 
Name of patient : _____________________  
 
Patient’s Signature:   ____________ 
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CONSENT FOR MINORS (UNDER 18 YRS) 
 
I Mr/Ms ________________________________ being a person aged 18 years and 
over and being the Parent/Lawful guardian of 
master/miss______________________ 
 
hereby consent to Dr_____________________ 
to include Master/Miss _____________________________ in the intended 
research  as explained and understood by me. 
 
I have understood the implications, risks and immediate benefits of the tests and 
treatment to Master/Miss _______________________________.  
I accept the tests and treatment to be carried out and the risks attached .  
 
I understand that I have the right to withdraw  
Master/Miss ________________________ from the research at any time, for any 
reason without penalty or harm. In case of withdrawal, I understand that the 
Physicians will  continue to take care of Master/Miss 
_________________________________ like any other patient. 
 
 
All the above conditions have been explained to me in 
_________________________ 
language  which I understand  
 
___________________________________ Guardian’s full name      
 




___________________________________ Child’s full name 
 
___________________________________ Person obtaining consent  
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Consent Form for HIV testing:  
I, the undersigned,  confirm that, as I give consent to HIV testing, it is with a clear 
understanding of the objectives of HIV testing in this study, 
the availability of counseling services, 
the confidentiality of the test results 
and in the case that I am positive for HIV, the possibility of receiving anti-
retroviral therapy for the duration of the trial (18 months) should I fulfil the criteria 
set by the  national guidelines 
I ………………………..  hereby give consent to Dr __________________ 
To perform this test. 
 I have been given the necessary information  in a language that I understand. 
  
Name of patient : _____________________  
 
Patient’s Signature:   ____________ 
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Contact persons (to be customized for each study site) 
  
1. Name and address of study site investigator 
 
2. Name and address of next of kin of study patient 
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Protocol Amendment on dosage and pharmacokinetic evaluation (PK) 
for paromomycin monotherapy arm of trial LEAP 0104 following 
preliminary analysis of efficacy data presented to a meeting of the  
Principal Investigators held at the  Kenyan Medical Research Institute 
(KEMRI) Nairobi, Kenya on 20th and 21st  June 2005 
 
Title: A multicentre, randomised, comparative trial of efficacy and safety of sodium 
stibogluconate (SSG) versus paromomycin (PM) versus a combination of SSG and 
PM as first line treatment for visceral leishmaniasis (VL) in Ethiopia, Kenya and 
Sudan.  
 
Reason for amendment 
Initial results from the trial LEAP 0104 which commenced in November 2004, from 2 
trial sites in Sudan (n = 90 Um el Kher, and n = 45 Kassab), indicate that paromomycin at 
a dosage of 15mg/kg/day for 21 days is less effective, for the treatment of acute, 
symptomatic treatment of visceral leishmaniasis, based on parasitological test of cure 
(TOC) at the end of treatment (day 22), by lymph node aspiration, in accordance with 
national VL policy in Sudan. Table. 1. This dosage may, however, be effective in Kenya 
(based on a small sample size, n=32)   
 
 Explanation for table 1: 
 
Table 1: Complete Parasite Clearance by site and treatment 
 Combination PM SSG P-Value 
Um El Kher 25 / 30 (83.3) 10 / 30 (33.3) 26 / 30 (86.7) < 0.001 
Kassab 12 / 15 (80.0)   9 / 15 (60.0) 14 / 15 (93.3) 0.113 
Kenya 10 / 11 (90.9) 11 / 11 (100) 10 / 10 (100) 1.00 
P-Value* .981 < 0.001  0. 571  
P-value from Fisher’s exact test 
 
 *  Column one shows that there were no significant inter-site differences in response to 
combination (p=0.981) and SSG (p=0.571) 
Column two shows that there were significant differences in response to PM at the 
different sites (p < 0.001). 
 
The majority of cases of VL in the disease endemic area of the Horn of Africa occur in 
Sudan, therefore it is considered essential to find a dose which is effective in Sudan if 
paromomycin is to be a useful alternative therapy for visceral leishmaniasis in this region. 
 
No efficacy data are yet available from Ethiopia as final approval was received from the 
relevant Ethics and Regulatory agencies in that country only in May 2005 and 
recruitment only commenced in mid-June ‘05. 
 
Safety and tolerability of the test drug paromomycin appears to be acceptable based on 
the data available from adverse and serious adverse event reports Tables 2a and 2b. 
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These results are in stark contrast to those obtained in a recent study of an apparently 
similar patient population with VL in India. (Shyam Sundar personal communication). 
 
Table 3. Efficacy Results of Trial VLPM01 
A randomised controlled trial of Paromomycin (PM) versus amphothericin B in patients 






Initial Cure rate TOC at 4 weeks 99% 98.8% 
Final Cure at 6 Months 94.6% 98.8% 
 
 
Only limited PK data in healthy volunteers are available, Kanyok et al  1997,Table 4.   
 
Table 4. Pharmacokinetics of Paromomycin in Health Volunteers (Kanyok et al 
1997.) 
RESULTS  
 12 mg / kg 
(N = 8) 
15 mg / kg 
(N = 7) 
Cmax (µg/mL) 21.6 23.4 
Tmax (h) 1.19 1.51 
T ½ (h) 2.21 2.64 
AUC 86.3 104.5 
Renal Clearance 79.6 76.1 
Recovery in time (24h) 67.8% 60.1% 
Analytical technique HPLC 
 
No data are yet available in patients from the study in India. It is therefore considered to 
be essential to include PK assessment in a limited number of patients, during the 
assessment of two further PM dosing schedules in Sudan. See appendix 1. 
 
Previous studies in patients with VL over the last 15 years in both Africa (Kenya and 
Sudan) and in India have indicated that a dosage of 15mg/kg can be expected to be both 
effective and well tolerated. Table 5 (-redrawn and with additional detail from Table 5 of  
the protocol of 31st July 2004.) 
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Table 5. Summary of clinical studies using PM 
 
Drug and dosage schedules Treatment Outcome 
 
TOC                         DC 
Statistic References / Comments 
Combination therapy versus  
PM or SSG as a single-agent Tx 
G1 = PM14-16 mg./kg/day  
         20days  
         SSG20mg./kg/day  
         20days;  (n = 23) 
 
G2= PM14-16 mg./kg/day  
        20days;  (n = 19) 
 
G3 =SSG20mg./kg/day  
        20days; [Standard Tx]     


























P<0.05 [G1 – G2] 











Clinical cure rate 100% in each 
group at end of treatment. 
 
Epistaxis associated with SSG 
Combination therapy 
versus Standard SSG Tx 
G1 = PM 15 mg./kg/day  
         17days, and SSG  
         20mg./kg/day 17days;  
         (n = 61) 
 
G2 = SSG 20mg./kg/day;  





























Clinical cure rate 100% in both 
groups 
Combination therapy 
versus Standard SSG Tx 
G1 = PM 15 mg./kg/day  
         17days, and SSG  
         20mg./kg/day 17days;  
         (n = 61) 
 
G2 = SSG 20mg./kg/day;  
         30 days; [Standard Tx] 
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Table 5. Summary of clinical studies using PM (table cont’d) 
 
Drug and dosage schedules Treatment Outcome 
 
TOC                         DC 
Statistic References / Comments 
PM 12mg + SSG 20mg 
20 days 
(n=24) 
82%  82% n.a. Ref: [3] 
2 deaths on Tx 
- splenic rupture 
- renal failure 
G1a = PM 12mg + SSG 20mg 
           (n=32) 20 days 
G1b = PM 12mg + SSG 10mg 
           (n= 32) 20 days 
G1c = PM 12mg + SSG 5mg 
           (n=32) 20 days 
 
G2a = PM 6mg + SSG 20mg 
           (n=13) 20 days 
G2b = PM 6mg + SSG 10mg 
           (n=12) 20 days 
G2c = PM 6mg + SSG 5mg 


































Only 50% attended FU. 
5 relapses 
8 slow responders 
 
PM 6mg dosage groups stopped 
prematurely due to inefficacy 
 
Safety: 
- No renal toxicity 
- Increase in liver enzymes 
common  
- ECG normal 
- Audiometry: data inadequate 
PM single agent therapy 
versus Standard SSG Tx 
G1 = PM 12 mg./kg/day  
         21days;  (n = 30) 
 
G2 = PM 16 mg./kg/day  
         21days; (n =30) 
 
G3 = PM 20 mg./kg/day  
         21days; (n = 30) 
 
G4 = SSG 20mg./kg/day  
         28days[Standard Tx] 




























P = 0.26 [G1 – G4] 
 
 
P<0.005 [G2 – G4] 
 
 








All treatments well tolerated 
- No renal toxicity 
- No ototoxicity 
- No clinically relevant 
differences in laboratory values 
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Table 5. Summary of clinical studies using PM (table cont’d) 
 
Drug and dosage schedules Treatment Outcome 
 
TOC                       DC 
Statistic References / Comments 
Combination therapy, and 
PM Dose finding 
G1 = PM12 mg./kg/day  
          21days  
          SSG20mg./kg/day  
          21days; (n = 52) 
 
G2 = PM18 mg./kg/day  
         21days  
         SSG20mg./kg/day  
         21days; (n = 48) 
 
G3 = SSG20mg./kg/day  
         30days; [Standard Tx] 
















































1 case of myocarditis on SSG. 
 
Audiometry data inadequate for 
analysis. 
 
Lab values – no significant 
changes from baseline values. 
PM Single-agent Tx (Dose 
finding) versus standard Tx 
G1 = PM 12 mg./kg/day  
         21days; (n = 30) 
 
G2 = PM 16 mg./kg/day  
         21days; (n = 30) 
 
G3 = PM 20 mg./kg/day  
         21days; (n = 30) 
 
G4 = SSG 20mg./kg/day  
         28days [Standard Tx] 



























P< 0.05 for 
G1 – G4 
G2 – G4 





No important AEs reported. 
 
No renal toxicity observed. 
 
ECG and audiometry data 





TOC = Test of Cure at end of treatment   n.s. = Not Significant    n.d. = Not Done 
DC = Definitive Cure at 6 month follow up   n.a. = Not Available
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The only study from Africa of paromomycin monotherapy; Chunge et al which reported a 
TOC of 100% and a definitive cure (DC) at six months of 87% was performed 15 years 
ago in Kenya.  Seaman et al, in Sudan in 1993 studied a combination of paromomycin 
and SSG and obtained a 95% TOC at day 30.  
Studies in India from Thakur et al and Jha et al have consistently reported high test of 
cure  with  paromomycin monotherapy at doses ranging from 12 -20mg/kg/day but doses 
of 16-20mg/kg have been required to deliver definitive cure rates at six months of 90%. 
 
 













0 5 10 15 20 25










Tolerability and safety have been acceptable in all studies performed so far, using 
intramuscular injection as the mode of drug administration, with no significant renal 
toxicity. Only 3 cases of ototoxicity,  (<1%) and all reversible, were seen in the large 
phase III trial from India of 500 patients (Sundar et al personal communication) 
In the 20mg/kg studies of Jha et al 1995 and Thakur et al 2000, Jha reported 2 cases of 
ototoxicity, 1 reversible and one irreversible and Thakur had inadequate data for 
assessment of ototoxicity. 
In contrast administration by intravenous injection in the 14-16mg dose range Scott et al 
1992 in UK, triggered autotoxicity in 3 of 7 patients in a small case series of imported 
cases of VL in returned travellers (Table 5). 
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Based on the evidence above the following protocol amendment is proposed to 
further elucidate the failure of paromomycin in Sudan. 
 
 
Group A:  Paromomycin 20 mg/kg/day for a total treatment duration of 21 days 
Group B:  Paromomycin 15mg/kg/day for a treatment duration of 28 days  
 
 
A total of 42 patients (21 in each treatment arm) will be allocated to receive one of two 
treatment regimens using a computer-generated randomisation list 
The first six patients in each treatment group above, with a body weight of 30kg or more,  
will have additional venous blood and urine sampling for pharmacokinetic evaluation as 
outlined in Appendix 1. 
Inclusion and exclusion criteria are otherwise unchanged from those in the original 
protocol. (pages 18-19). An amended consent form will be used Appendix 2. 
 
Patients who are symptomatic and HIV positive will be excluded from participation in 
this protocol amendment but will be offered treatment with SSG and rescue with 
Ambisome in the event of treatment failure.  
 
Efficacy The two treatment regimens A and B above will be assessed for efficacy in the 
42 patients on the basis of parasitological test of cure following bone marrow aspiration 
on day 29 or 30, this test being acknowledged to be more sensitive but also more 
invasive and potentially more painful than lymph node aspiration. 
Note: Splenic aspiration for parasitological assessment of VL is not allowed in Sudan. 
 
Rescue. Patients who fail to respond to treatment will be given rescue therapy with 
AmBisome as in the original protocol (Page 24) 
 
Safety will be assessed using the same weekly assessment tests  as in the original 
protocol LEAP 0104 of 31st July 2004 (page 26) -all patients will have ECG and 
audiometry assessments! 
 
It is expected that following completion of this 42 patient  amendment an effective dosing 
regimen for paromomycin monotherapy in Sudan will have  been identified.  
This regimen will then be substituted for the current paromomycin only treatment arm, in 
the 3 arm comparison of the original protocol. Sample size may need to be re-calculated 
in the light of this new information when it becomes available. A further amendment will 




Page 65 of 756







Other trial sites  
During the period of recruitment and treatment for the 42 patients above at Kassab, 
Sudan, the trial will be put on hold at KEMRI, Nairobi, Kenya, but recruitment will 
continue in Ethiopia to n=45 at each trial site (Gondar and Arba Minch hospitals) to 
obtain contemporaneous information of efficacy and safety of paromomycin at a dosage 
of 15mg/kg/day for 21 days, as it cannot be assumed that patient response in Ethiopia will 
match either that in Sudan or Kenya. 
The trial site at Um el Kher has been closed by Medecins sans Frontieres (MSF) for 
operational reasons unrelated to this trial, and will not be available for future patient 
recruitment to the trial. 
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(Trial Medical Coordinator) 
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Dr. Musa A Mudawi   ……………………  
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Trial Manager 
Dr Juma Rashid    …………………… 
 
Trial Statistician 
Mr. Lawrence Muthami   …………………… 
 
Project Manager 
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Appendix 1 
Pharmacokinetic  sampling schedule for patients with a body weight of 30kg or 
more who consent to participate in the PK part of the study. 
 
 
Venous sampling for PK patients in group A (n=12) 
 
Day 1 of treatment: 
At time 0, 0.25, 0.5, 1.0, 2, 4, 6, 8, 12, and 24 hours after dosing 
 
Day 14 of treatment; 
At time 0 before the day 14 dose 0.25, 0.5, 1.0, 2, 4, 6, 8, 12, and 24 hours post dosing. 
 
 
Venous sampling for patients in group B (n=12) 
 
Day 1 of treatment: 
At time 0, 0.25, 0.5, 1.0, 2, 4, 6, 8, 12, and 24 hours after dosing  
 
Day 26 of treatment; 
 
At time 0 before the day 26 dose 0.25, 0.5, 1.0, 2, 4, 6, 8, 12, and 24 hours post dosing. 
 
 
5 ml of blood at each sampling point will be taken to ensure sufficient plasma is 
obtained for duplicate test analysis. 




Both groups A and B will also have 24 hour urine collections on PK venous sampling 
days, collected in aliquots 0-2h, 2-4h, 4-6h, 6-8h, 8-12 and 12-24h.  
 
Safety assessments 
Safety assessments (blood biochemistry, haematology, urinalysis, ECG and audiometry,) 
will be performed as in the original LEAP 0104 protocol before treatment, on day 7, 14 
for both groups and additionally on day 22 for group A and day  26  for group B so that 
direct correlations can be made with the PK data. 
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Appendix 2 
Consent form for Patients participating in PK sampling. 
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Dr Nurelign Gashu (Site PI) 
Dr Asfaweseen 
Dr Sisay Yifru 
 
Abar Minch: 
Dr Samson Tesfaye (Site PI) 
Dr Gabriell Teklu 
 
Kenya: 
Dr M Wasunna 
Dr J R Rashid 
Dr Jane Mbui 
Dr F Kirui 
 
Sudan: 
Dr. Ahmed Musa Mudawi 
Prof. E A G Khalil 
Dr. Osama M ahmed 
 
Monitors: 
Dr Shibru Berhanu 
Dr Hilda O’hara 
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Protocol Amendment- 30th June 2006.  
Increased dosage for paromomycin monotherapy arm of trial LEAP 
0104 following  analysis of efficacy, safety and PK data presented to 
a meeting of the  Principal Investigators held at the  Kenyan Medical 
Research Institute (KEMRI) Nairobi, Kenya on 8th and 9th June 2006 
 
Protocol Title: A multicentre, randomised, comparative trial of efficacy and safety 
of sodium stibogluconate (SSG) versus paromomycin (PM) versus a combination of 
SSG and PM as first line treatment for visceral leishmaniasis (VL) in Ethiopia, 
Kenya and Sudan.  
 
Reason for amendment 
Initial results from the trial LEAP 0104 which commenced in November 2004, from 2 
trial sites in Sudan (n = 90 Um el Kher, and n = 45 Kassab), indicated that paromomycin 
at a dosage of 15mg/kg/day for 21 days was inadequate for the treatment of acute, 
symptomatic treatment of visceral leishmaniasis, based on parasitological test of cure 
(TOC) at the end of treatment (day 22), by lymph node aspiration, in accordance with 
national VL policy in Sudan. Table. 1. at that time, it was thought to  be effective in 
Kenya (based on a small sample size, n=32)   
 
 
Table 1: Complete Parasite Clearance by site and treatment 
 Combination PM SSG P-Value 
Um El Kher 25 / 30 (83.3) 10 / 30 (33.3) 26 / 30 (86.7) < 0.001 
Kassab 12 / 15 (80.0)   9 / 15 (60.0) 14 / 15 (93.3) 0.113 
Kenya 10 / 11 (90.9) 11 / 11 (100) 10 / 10 (100) 1.00 
P-Value* .981 < 0.001  0. 571  
P-value from Fisher’s exact test 
 
 Explanation for table 1: 
Column one shows that there were no significant inter-site differences in response to 
combination (p=0.981) and SSG (p=0.571) 
Column two shows that there were significant differences in response to PM at the 
different sites (p < 0.001). 
 
The majority of cases of VL in the disease endemic area of the Horn of Africa occur in 
Sudan, therefore it was considered essential to find a dose which would be effective in 
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Based on the evidence above the following protocol amendment was proposed to further 
elucidate the failure of paromomycin in Sudan. 
 
Group A:  Paromomycin 20 mg/kg/day for a total treatment duration of 21 days 
Group B:  Paromomycin 15mg/kg/day for a treatment duration of 28 days  
 
 
Between September 2005 and March 2006 a total of 42 patients (21 in each treatment 
arm) were allocated to receive one of two treatment regimens using a computer-generated 
randomisation list. Inclusion and exclusion criteria were otherwise unchanged from those 












5 / 21 
(23.8%)
















3 monthsEnd of Treatment 
(TOC)
 
There was no difference in efficacy either at end of treatment or at 3 month follow up, 
with an overall efficacy rate of 76% for both groups. 
 
No serous adverse events were reported and there were no other signs of increased 
toxicity with either the increased daily  dose or duration of treatment.  
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In particular there was no evidence of renal toxicity or ototoxicity. No patients 
experienced clinical hearing loss. 
 
It was planned that the first six patients in each treatment group above, with a body 
weight of 30kg or more,  would have additional venous blood and urine sampling for 
pharmacokinetic evaluation. 
A total of 10 patients consented to participate in the PK sampling, 6 in the 15mg/kg/day 
arm and 4 in the 20mg/kg/day arm. Figure 1 
 
Figure 1 Mean aminosidine concentrations
Time (h)



























Footnote: Aminosidine is the name by which paromomycin was formerly known 
 
 
Time to peak plasma concentration was similar for both doses (1.5-2h) Figure 1 indicates 
that somewhat better  concentrations were achieved with the 20mg dose, however patient 
numbers are small. Blood levels were undetectable after the 8 hour sampling point. 
Excretion in urine was rapid and complete by 24h.  
 
Discussion of these results by the Principal Investigators of trial LEAP 0104 concluded 
that both dosing regimens appeared equally effective and were well tolerated. 
Whilst the currently available efficacy results at end of treatment and 3 month follow up, 
indicate only moderate efficacy for paromomycin, all 5 patients who were still positive 
for parasites at TOC had improved clinically and had  achieved a significant reduction in 
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parasite load of more than 2 log. ie more than 99% clearance in comparison with parasite 
load at entry. 
 
 
The unanimous decision of the trial investigators  was to adopt the 20mg/kg/day 
dose given for 21 days, into the original protocol and to re-commence the 3 arm 










Principal Investigators    SIGNATURE DATE 
    
Dr   Monique Wasunna   ……………………  
(Trial Medical Coordinator) 
 
Prof. Asrat Hailu     ……………………  
 
Dr. Getahun Mengistu   ……………………  
 
Dr. Musa A Mudawi   ……………………  
 
Dr. Manica Balasegaram   ……………………  
 
Trial Manager 
Dr Juma Rashid    …………………… 
 
Trial Statistician 
Mr. Lawrence Muthami   …………………… 
 
Project Manager 
Dr Catherine Royce   …………………… 
LEAP 01 4a Appendices
Page 75 of 756









Dr Sisay Yifru (Site PI) 
Dr Zewdu Hurissa 
 
Abar Minch: 
Dr Samson Tesfaye (Site PI) 
Dr Teklu  Wolde-Gabriel 
 
Kenya: 
Dr M Wasunna (PI) 
Dr J R Rashid 
Dr Jane Mbui 
Dr F Kirui 
 
Sudan: 
Dr. Ahmed Musa Mudawi (PI) 
Prof. E A G Khalil 
 
Monitors: 
Dr Hilda O’Hara 
Dr. Robert Balikuddembe 






LEAP 01 4a Appendices
Page 76 of 756
 LEAP 0104a Appendices
Page 77 of 756
       LEAP 0104 Protocol amendment Number 8: dated 14 December 2006 
 1 of 4 
Protocol Title: A multicentre, randomised, comparative trial of efficacy and 
safety of sodium stibogluconate (SSG) versus paromomycin (PM) versus a 
combination of SSG and PM as first line treatment for visceral 
leishmaniasis (VL) in Ethiopia, Kenya and Sudan.  
 
This protocol amendment outlines a revision to the sample size and 
analysis plan for the study including the addition of interim analyses  
 
Reason for Amendment 
The following replaces the statistical section of the LEAP 0104 Protocol dated 
31st Jul 2004 (Page 21 and 22) 
 
Design: 
• The trial will initially run with 3 arms: SSG, PM and Combination.   
• The null hypothesis is that there is no difference across treatment arms / 
no difference between SSG and PM and no difference between SSG and 
Combination regimens  
• A statistically significant p-value would provide evidence of a statistically 
significant difference between regimens. 
• It is thought from LEAP0104 that the standard SSG regimen will clear 
parasites in approximately 85% of patients at 6 months 
• It was considered that a case could be made for licensing PM (for use in 
combination therapy) if the difference in efficacy of SSG and PM was no 
more than 15% 
• The trial will be powered to test for a statistically significant difference 
between SSG and PM if the efficacy of SSG is 85% and the efficacy of PM 
is 70% or less. 
• This will require approximately 195 patients per arm for 90% power. 
 
1a) Interim Analysis PM: After recruitment into the trial of 100 patients per 
arm, an interim analysis will be carried out to compare the end of treatment 
efficacy (TOC) of SSG and PM. 
• If the lower bound of the 95% CI of the difference in efficacy is greater 
than the maximum acceptable difference of 15% then there will be 
evidence to support decision to stop PM and question continuation of the 
trial. A decision will have to be made in such circumstances if it is 
worthwhile to continue with SSG and Combination arms only. 
• If the lower bound of the 95% CI of the difference in efficacy is less than 
the maximum acceptable difference of 15% then continue recruitment to 
195 patients per arm 
1b) Efficacy Analysis PM: After recruitment of 195 patients per arm, stop 
recruiting into the PM arm and when all patients in that arm have reached 6 
months follow-up compare the 6 months efficacy (DC) of SSG and PM and 
test for a difference.  If there is no evidence of significant difference, then 
conclude that there is no evidence to suggest that the efficacy of PM is more 
than 15% lower than the efficacy of SSG. 
• Continue the trial with just 2 arms (SSG and Combination) and continue to 
recruit patients until there are 404 patients per arm 
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2a) Interim Analysis Combination: Compare the efficacy of SSG and 
Combination regimens at 6 months (DC) with 195 patients per arm followed-
up for 6 months. 
• Consider stopping the trial if the lower 95% confidence bound on the 
difference is greater than 10%.   
• Combine the efficacy data from the SSG and Combination arms from 
0104(A) and 0104(B) to include the historic data and repeat the interim 
analysis. 
• Otherwise, continue until there are 404 patients per arm.  
2b) Efficacy Analysis Combination: 404 patients per arm will provide 90% 
power to test for a statistically significant difference if the efficacy of SSG is 
85% and the efficacy of the Combination regimen is 75% or less.   
• Combine the efficacy data from the SSG and Combination arms from 
0104(A) and 0104(B) to include the historic data and repeat the efficacy 
analysis.   
 
Flow diagram of Recruitment and Analysis: 
Following the end of the 1st phase 0104(A), patients will be randomised to receive 
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Primary Endpoint and Efficacy Estimation 
The definitive cure is measured at 6 months follow-up and the denominators for 
the efficacy analyses are the number of patients randomised to each treatment 
arm and entered 6 or more months previously.  The numerators for the efficacy 
estimates are the number of patients who received no other VL treatment other 
than the randomised regimen and who were found to be 
• Parasite free at end of treatment or parasite positive at end of treatment 
with at least 2 log reduction in parasite count (slow responder) 
and 
• parasite free at 6 months follow-up  
Treatment Effect Estimation 




• The efficacy data will be analysed overall, not by site 
• The trial is not powered for by site analyses 
• Interim and final analyses will be carried out only as specified 
• Adjustments to the sample size have been made to power the study for a 
sub-group analysis in HIV negative patients if 10% of patients overall are 
known to be infected and also to allow for loss-to-follow-up (LTFU) of 10% 
at 6 months.   
• Table 1 gives the numbers needed per arm after adjusting for HIV (10%) 
and LTFU at 6 months (10%) based on two-sided probabilities with 90% 
power.  
Table 1. Number of patients required per regimen to detect a statistically 
significant difference, at the 5% level with 90% power, between the efficacies 
shown based on a two-sided test for ITT.  Estimates are adjusted for 10% to 
allow for an adequate number of HIV negative patients in sub-group analyses 
and also for 10% loss-to-follow-up at 6 months. 
  % cured in comparative regimen 
% 
cured 
SSG 0.5 0.6 0.65 0.7 0.75 0.8 0.85 0.9 0.95 
0.6 627                 
0.65 274 2381               
0.7 150 576 2229             
0.75 93 245 531 2025           
0.8 62 131 223 474 1771         
0.85 43 79 117 195 404 1466       
0.9 31 50 68 99 161 322 1110     
0.95 22 34 43 56 79 121 226 703   
0.98 19 27 33 41 54 74 114 222 952 
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Protocol Title: A multicentre, randomised, comparative trial of efficacy and 
safety of sodium stibogluconate (SSG) versus paromomycin (PM) versus a 
combination of SSG and PM as first line treatment for visceral 
leishmaniasis (VL) in Ethiopia, Kenya and Sudan.  
 
This protocol amendment outlines the Further pharmacokinetic (PK) evaluation of 
Paromomycin (PM), Sodium Stibogluconate (SSG), and the combination of PM 
and SSG in consenting patients of LEAP 0104 trial following preliminary analysis 
of initial Pharmacokinetic data presented to a meeting of the  Principal and Site 
Investigators held in Nairobi, Kenya on 22nd Sep 2006.  
This amendment applies to sites in Kenya and Sudan only 
 
Addition of Intensive Pharmacokinetic evaluation in Kenya and Sudan 
 
Reason for amendment 
Initial results from 2 trial sites in Sudan (n = 90 Um el Kher, and n = 45 Kassab) 
in the LEAP 0104 trial indicated that paromomycin at a dosage of 15mg/kg/day 
for 21 days was less effective, for the treatment of acute, symptomatic visceral 
leishmaniasis.   
The majority of cases of VL in the disease endemic area of the Horn of Africa 
occur in Sudan, therefore it was considered essential to find a dose which is 
effective in Sudan if paromomycin is to be a useful alternative therapy for VL in 
this region.  Therefore, between September 2005 and March 2006, a total of 42 
patients (21 in each treatment arm) were allocated to receive one of two 
Paromomycin treatment regimens. Results are shown in Table 1. 
 
Table 1:  











15mg for 28 days 21 19 2 3 16/21 (76.2%)
20mg for 21 days 21 18 3 2 16/21 (76.2%)
Total 42 37 5 5  
 
There was no difference in efficacy either at end of treatment or at 3 and 6 month 
follow up, with an overall efficacy rate of 76% for both groups.  
 
It was planned that the first six patients in each treatment group, with a body 
weight of 30kg or more, would have additional venous blood and urine sampling 
for pharmacokinetic evaluation. A total of 10 patients consented to participate in 
the PK sampling, 6 in the 15mg/kg/day arm and 4 in the 20mg/kg/day arm.  
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Figure 1 Mean aminosidine concentrations
Time (h)



























Footnote: Aminosidine is the name by which paromomycin was formerly known 
 
The time to peak plasma concentration (tmax) was similar for both doses (1.5-2h). 
Fig 1 indicates that somewhat better concentrations were achieved with the 20mg 
dose, however patient numbers are small.  Blood levels were undetectable after 
the 8 hour sampling point. Excretion in urine was rapid and complete at 24h.  
 
Only limited published PK data for paromomycin in healthy volunteers are 
available, Kanyok et al 1997.  These data indicate that American healthy 
volunteers achieved a Cmax of 23.4ug/ml. 
 
A small pharmacokinetic study (unpublished: Fig 2) was carried out in healthy 
Sudanese volunteers which demonstrated that they achieved similar maximum 
concentration to that of the published data and higher than that of the Sudanese 
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Initial data from Indian VL patients treated with PM 15mg/kg/day demonstrated 
results (Mordenti et al 2006) similar to those previously published, Kanok et al.  
 
There is also very limited published data on the pharmacokinetics of the 
combination of SSG and PM.   P Ormas et al 1995 investigated the 
pharmacokinetics of Paromomycin and SSG alone and in combination in dogs. 
 
Based on the evidence above the following protocol amendment is proposed to 
further elucidate the pharmacokinetics of PM, SSG and Combination of SSG and 
PM in a greater number of Kenyan, and Sudanese patients.  
  
Amendment 
All potentially eligible patients participating in the LEAP 0104 study in Kenya and 
Sudan will be asked to participate in this pharmacokinetic sub-study.  A total of 
72 adult patients, 36 in KEMRI and 36 from the Sudanese site in Khasab (12 in 
each treatment arm) with a body weight of 30kg or more will participate in the 
intensive pharmacokinetic sampling. 
 
The dosing schedule will remain the same as that described in LEAP 0104 
Protocol amendment dated 30th June 2006 
 
The first twelve consenting patients in each treatment group, will have additional 
venous blood and urine sampling for pharmacokinetic evaluation as outlined in 
Appendix 1. 
 
Inclusion and exclusion criteria are otherwise unchanged from those in the 
original protocol. (pages 18-19). An additional pharmacokinetic consent form will 
be used Appendix 2. 
 
Patients who are HIV positive will be excluded from participation in the 
Pharmacokinetic sub-study.  
 
Efficacy, Safety and rescue medication All Patients will undergo the same 
efficacy and safety evaluations and, if required, the same rescue therapy as in 
the original protocol LEAP 0104 of 31st July 2004 (page 26) and all relevant 






1. Kanyok, T.P., et al., Pharmacokinetics of intramuscularly administered 
aminosidine in healthy subjects. Antimicrob Agents Chemother, 1997. 
41(5): p. 982-6. 
2. Mordenti, J., et al, Paromomycin: An old drug gives birth to a new 
treatment for Visceral Leishmaniasis  ICOPA 2006 
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Appendix 1 
Pharmacokinetic  sampling schedule for patients with a body weight of 
30kg or more who consent to participate in the PK part of the study. 
 
Plasma Sampling 
Venous sampling for PK patients receiving all treatments (n=12 per treatment 
arm) 
 
Day 1 and End of treatment (Day 21 for PM arm, Day 30 for SSG arm and 
Day 17 for SSG and PM combination arm): 
At time 0, 0.5, 1.0, 3, 6, 10, and 24 hours after dosing 
 
10 ml of blood at each sampling point will be taken to ensure sufficient plasma is 
obtained for duplicate test analysis. 
Total blood volume taken for PK on each sampling day is 70ml. 
Total blood volume for the Pharmacokinetic sampling during the treatment period 
will be 140ml. 
 
Each sample will be collected in a heparinised tube.  Samples will be centrifuged 
at 3000rpm for 10 minutes and plasma will be decanted off and stored in 3 
aliquots at - 20°C. 
 
All tubes will be labelled with the Protocol Number LEAP 0104, Centre and 
Patient number, patient initials, date of sample and time point.  
 
Urine sampling 
All patients participating in the sub-study will also have 24 hour urine collections 
on PK venous sampling days, collected in aliquots 0-2h, 2-4h, 4-6h, 6-8h, 8-10 
and 10-24h.  
 
All tubes will be labelled with the Protocol Number LEAP 0104, Centre and 
Patient number, patient initials, date of sample and time point.  
 
Safety assessments 
Safety assessments (blood biochemistry, haematology, urinalysis, ECG and 
audiometry) will be performed as for other patients participating in the study. 
Sample analysis 
All samples will be shipped, with prior notice, to Prof Gilbert Kokwaro for analysis 
Prof Gilbert Kokwaro,  
KEMRI/Wellcome Trust Programme 
Dept. of Clinical Pharmacology, 
Next to National Public Health Laboratories, 
On the Grounds of Kenyatta National Hospital, 
PO Box 43640-00100, Nairobi, Kenya 
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Appendix 2 
Consent form for Patients participating in PK sampling. 
 
PATIENT INFORMATION AND CONSENT - Pharmacokinetic sub-study 
  
 TITLE:  A MULTICENTRE COMPARATIVE TRIAL OF EFFICACY AND 
SAFETY OF SODIUM STIBOGLUCONATE (SSG) VERSUS 
PAROMOMYCIN (PM) VERSUS COMBINATION OF SSG AND PM 
AS THE FIRST LINE TREATMENT FOR VISCERAL 
LEISHMANIASIS IN ETHIOPIA, KENYA AND SUDAN  
 
 
PRINCIPAL INVESTIGATOR(S):  ETHIOPIA   
     KENYA      
    SUDAN 
       
SPONSOR: Drugs for Neglected Diseases Initiative, Geneva, Switzerland 
 
Introduction 
We are studying the disease, Kala-azar and new drug treatments for this disease.  
As well as the trial that you have agreed to take part in comparing paromomycin 
with, SSG, and a combination of both drugs used together, we are conducting a 
pharmacokinetic (PK) sub-study which looks at the way your body responds to 
the study drugs.  We would like to ask you to participate in this research study. 
 
Procedures during the sub-study 
If you agree and you weigh more than 30Kg additional blood samples will be 
collected on the first day of treatment and again on the last day of treatment.  A 
total of 7 samples will be taken at these times: before study drug, 0.5, 1.0, 3, 6, 
10, and 24 hours after study drug. 
Approximately 10 ml of blood (about 2 teaspoons) will be taken at each sampling 
point.  The blood volume taken on one day will be approximately 70ml (about 5 
tablespoons).  A further 70ml of blood will be taken on the last day of treatment. 
 
On the same day as the blood sampling, you will also have 24 hour urine 
collection.  It is planned that this will be collected during the following times 0-2h, 
2-4h, 4-6h, 6-8h, 8-10 and 10-24h.  
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At the site where blood was taken you may have some bruising and it may be 
painful for a short while. 
 
Benefits  
Your participation in this sub-study helps us to know more about your condition 
which could result in an improved treatment.  There is no direct benefit to you but 
this new knowledge will benefit your community and may reduce the likelihood of 
other people getting the disease. 
  
Confidentiality 
At the end of the study, we plan to write a report about the results of the study. 
The reports will not bear any information relating to you personally e.g. your 
name or identity. We assure you of the confidentiality of such information. Thus, 
we also need your permission to use the test results for writing a report.  
We also seek your permission to store any left over samples (blood, tissues) for 
future studies.  We will seek permission from a relevant ethical review committee 
before any analysis not described in this document is carried out. 
 
In addition, clinical monitors of the sponsor (DNDi) or the regulatory authorities 
may wish to inspect your records.  
 
Right to refuse or withdraw 
You do not have to take part in this research, if you do not wish to do so.  This 
will not affect your treatment at this centre in any way.  You will still have the 
benefit of treatment for your disease at this centre. 
If you do decide to participate and then change your mind later, you may do so, 
at any time, without losing any of your rights as a patient. 
 
In the event that you suffer an injury or illness related to participating in this trial, 
DNDi will pay all costs relating to treatment of the injury or illness.   
 
If you agree to participate in the study, we will ask you to read and sign the 
consent form.   
Do you have any questions?  
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Consent Form:  
I, the undersigned, confirm that, I give consent to participate in the study, it is with 
a clear understanding of the objectives and conditions of the study and with the 
recognition of my right to withdraw from the study if I change my mind.  
 
I ……………………….. do hereby give consent to Dr …………………………… 
to include me in the proposed research. I have been given the necessary 
information and understand that there might be some risks involved in the 
treatment procedures. I have also been assured that I can withdraw my consent 
at any time without penalty or a loss of benefits. The proposal has been 
explained to me in the language I understand.  
 
Name of patient: _____________________  
 
Patient’s Signature:   ____________ 
 
Name of Doctor: _________________________  
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Protocol Title: A multicentre, randomised, comparative trial of efficacy and 
safety of sodium stibogluconate (SSG) versus paromomycin (PM) versus a 
combination of SSG and PM as first line treatment for visceral 
leishmaniasis (VL) in Ethiopia, Kenya and Sudan.  
 
This protocol amendment outlines the following changes to the LEAP 0104 
protocol: 
1. Further pharmacokinetic (PK) evaluation (sparse sampling) of 
Paromomycin (PM), Sodium Stibogluconate (SSG), and the combination 
of PM and SSG in consenting patients of LEAP 0104 trial following 
preliminary analysis of initial Pharmacokinetic data presented to a meeting 
of the LEAP Investigators held in Nairobi, Kenya on 22nd Sep 2006.  
This amendment applies to sites in Ethiopia only 
 
 
Addition of Sparse Pharmacokinetic evaluation in Ethiopia 
 
Reason for amendment 
Currently there is limited pharmacokinetic data available on SSG and 
Paromomycin and no pharmacokinetic data in man on the combination of 
Paromomycin and SSG.   
 
Preliminary intensive pharmacokinetic evaluation of 2 treatment regimens of 
paromomycin, 15mg/kg/day for 28 days or 20mg/kg/day for 21 days was carried 
out in 10 Sudanese patients with a body weight of 30kg or more. The time to 
peak plasma concentration (tmax) was similar for both doses (1.5-2h). Fig 1 
indicates that somewhat better concentrations were achieved with the 20mg 
dose, however patient numbers are small.  Blood levels were undetectable after 
the 8 hour sampling point. Excretion in urine was rapid and complete at 24h.  
Figure 1 Mean aminosidine concentrations
Time (h)



























Footnote: Aminosidine is the name by which paromomycin was formerly known 
Only limited published PK data for paromomycin in healthy volunteers are 
available, Kanyok et al 1997.  These data indicate that American healthy 
volunteers achieved a Cmax of 23.4ug/ml. 
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A small pharmacokinetic study (unpublished: Fig 2) was carried out in healthy 
Sudanese volunteers which demonstrated that they achieved similar maximum 
concentration to that of the published data and higher than that of the Sudanese 



















Initial data from Indian VL patients treated with PM 15mg/kg/day demonstrated 
results (Mordenti et al 2006) similar to those previously published, Kanok et al.  
 
There is also very limited published data on the pharmacokinetics of the 
combination of SSG and PM.   P Ormas et al 1995 investigated the 
pharmacokinetics of Paromomycin and SSG alone and in combination in dogs. 
 
Based on the evidence above and recent experience from the ongoing trial which 
indicates that more than 50% of patients may be children the following protocol 
amendment is proposed to further elucidate the population pharmacokinetics of 
PM, SSG and Combination of SSG and PM in a greater number of Ethiopian 




All patients aged 7 years and above participating in the LEAP 0104 study will be 
asked to participate in this sparse sampling pharmacokinetic sub-study.   
 
Patients who are HIV positive will be excluded from participation in the 
Pharmacokinetic sub-study.  
 
Inclusion and exclusion criteria are otherwise unchanged from those in the 
original protocol (pages 18-19). An additional pharmacokinetic consent form will 
be used Appendix 1. 
 
All consenting patients will be randomly allocated to one of 6 sample schedules.  
Each schedule will specify 3 timepoints at which 3 additional venous blood 
Time (hours)
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samples will be taken for pharmacokinetic evaluation.  The procedure and 
sample scheduled is outlined in Appendix 2. A randomisation list will be 
prepared for each treatment arm. 
 
The dosing schedule will remain the same as that described in LEAP 0104 
Protocol amendment dated 30th June 2006 
 
Efficacy, Safety and rescue medication All Patients will undergo the same 
efficacy and safety evaluations and, if required, the same rescue therapy as in 
the original protocol LEAP 0104 of 31st July 2004 (page 26) and all relevant 





1. Kanyok, T.P., et al., Pharmacokinetics of intramuscularly administered 
aminosidine in healthy subjects. Antimicrob Agents Chemother, 1997. 
41(5): p. 982-6. 
2. Mordenti, J., et al, Paromomycin: An old drug gives birth to a new 
treatment for Visceral Leishmaniasis  ICOPA 2006 
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 Appendix 2 
Consent form for Patients participating in PK sampling. 
 
PATIENT INFORMATION AND CONSENT - Pharmacokinetic sub-study 
  
 TITLE:  A MULTICENTRE COMPARATIVE TRIAL OF EFFICACY AND 
SAFETY OF SODIUM STIBOGLUCONATE (SSG) VERSUS 
PAROMOMYCIN (PM) VERSUS COMBINATION OF SSG AND PM 
AS THE FIRST LINE TREATMENT FOR VISCERAL 
LEISHMANIASIS IN ETHIOPIA, KENYA AND SUDAN  
 
 
PRINCIPAL INVESTIGATOR(S):  ETHIOPIA   
     KENYA      
    SUDAN 
       
SPONSOR: Drugs for Neglected Diseases Initiative, Geneva, Switzerland 
 
Introduction 
We are studying the disease, Kala-azar and new drug treatments for this disease.  
As well as the trial that you have agreed to take part in comparing paromomycin 
with, SSG, and a combination of both drugs used together, we are conducting a 
pharmacokinetic (PK) sub-study which looks at the way your body absorbs, 
distributes and gets rid of the study drugs.  We would like to ask you to 
participate in this research study. 
 
Procedures during the sub-study 
If you agree 3 additional blood samples will be collected on one treatment day. 
Approximately 5 or 10 ml of blood (about 1 or 2 teaspoons) will be taken at each 
sampling point.  The blood volume taken will be approximately 15 or 30ml (about 
3 to 6 teaspoons).  The volume of blood taken will depend on which treatment 
you are receiving. 
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There are no benefits to your participation in this sub-study. If the study is 
successful it means that more will be known about the treatments for kala-azar 
which could result in improved or shorter treatment periods.  This will benefit your 
community and may reduce the likelihood of other people getting the disease. 
 
Confidentiality 
At the end of the study, we plan to write a report about the results of the study. 
The reports will not bear any information relating to you personally e.g. your 
name or identity. We assure you of the confidentiality of such information. Thus, 
we also need your permission to use the test results for writing a report.  
 
In addition, clinical monitors of the sponsor (DNDi) or the regulatory authorities 
may wish to inspect your records.  
 
Right to refuse or withdraw 
You do not have to take part in this research, if you do not wish to do so.  This 
will not affect your treatment at this centre in any way.  You will still have the 
benefit of treatment for your disease at this centre. 
If you do decide to participate and then change your mind later, you may do so, 
at any time, without losing any of your rights as a patient. 
 
In the event that you suffer an injury or illness related to participating in this trial, 
DNDi will pay all costs relating to treatment of the injury or illness.   
 
If you agree to participate in the study, we will ask you to read and sign the 
consent form.   
Do you have any questions?  
 
LEAP 0104a Appendices
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Consent Form:  
I, the undersigned, confirm that, I give consent to participate in the study, it is with 
a clear understanding of the objectives and conditions of the study and with the 
recognition of my right to withdraw from the study if I change my mind.  
 
I ……………………….. do hereby give consent to Dr …………………………… 
to include me in the proposed research. I have been given the necessary 
information and understand that there might be some risks involved in the 
treatment procedures. I have also been assured that I can withdraw my consent 
at any time without penalty or a loss of benefits. The proposal has been 
explained to me in the language I understand.  
 
Name of patient: _____________________  
 
Patient’s Signature:   ____________ 
 
Name of Doctor: _________________________  
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CONSENT FOR MINORS (UNDER 18 YRS) 
 
 
I Mr/Ms ________________________ being a person aged 18 years or over and 
being the Parent/Lawful guardian of Master/Miss _________________________ 
consent to Dr________________________ to include 
Master/Miss___________________   in the intended research as explained and 
understood by me. 
 
I have understood the implications, risks and immediate benefits of the tests to 
him / her.  I accept the tests to be carried out and the risks attached.  
 
I understand that I have the right to withdraw him / her from the research at any 
time, for any reason without penalty or harm. In case of withdrawal, I understand 
that the Physicians will continue to take care of him/her like any other patient. 
 
All the above conditions have been explained to me in a language, which I 
understand. 
 
Guardian’s full name  ___________________________________    
 




Child’s full name ___________________________________  
 
Person obtaining consent ___________________________________  
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MINORS ASSENT FORM FOR INCLUSION IN THE TRIAL (12-17 years old) 
(for signatures)  
 
I, the undersigned, confirm that, as I give my assent to participate in the study, it 
is with a clear understanding of the objectives and conditions of the study and 
with the recognition of my right to withdraw from the study if I change my mind. I  
 
……………………….. do hereby give  my assent to Dr ……………………………to 
include me in the proposed research. I have been given the necessary 
information and understand that there might be some risks involved in the 
treatment procedures.  
 
I have also been assured that I can withdraw my assent at any time without 
penalty or loss of the benefit of treatment. The study has been explained to me in 
the language I understand.  
 
I agree to participate 
 
Name of Minor: _____________________  
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Appendix 2 
Sparse Pharmacokinetic sampling procedure 
 
Plasma Sampling 





Day of sampling Timepoint post drug 
administration 
1 7 0.5, 1, 3 h 
2 7 6,10, 24 h 
3 14 0.5, 1, 3 h 
4 14 6,10, 24 h 
5 End of treatment 0.5, 1, 3 h 
6 End of treatment 6,10, 24 h 
 
5ml blood for PM and SSG alone and 10 ml of blood for combination at each 
sampling point will be taken to ensure sufficient plasma is obtained for duplicate 
test analysis. 
Total blood volume taken for pharmacokinetic analysis is 15 ml for PM or SSG 
alone and 30ml for SSG and PM combination. 
 
Each sample will be collected in a heparinised tube.  Samples will be centrifuged 
at 3000rpm for 10 minutes and plasma will be decanted off and stored in 3 
aliquots at -20°C. 
 
All tubes will be labelled with the Protocol Number LEAP 0104, Centre and 




Safety assessments (blood biochemistry, haematology, urinalysis, ECG and 
audiometry) will be performed as for other patients participating in the study. 
Sample analysis 
Prior to shipping a Material transfer agreement with ESTA will be put in place.   
All samples will be shipped, with prior notice, to Prof Gilbert Kokwaro for analysis 
Prof Gilbert Kokwaro,  
KEMRI/Wellcome Trust Programme 
Dept. of Clinical Pharmacology, 
Next to National Public Health Laboratories, 
On the Grounds of Kenyatta National Hospital, 
PO Box 43640-00100, Nairobi, Kenya 
 
LEAP 0104a Appendices
Page 99 of 756
 LEAP0104_Final Protocol amendment 11 dated 20th Mar 2008 
Page 1 of 2 
LEAP 0104 Final Protocol amendment Number 11: dated 20th March 2008 
 
Protocol Title: A multicentre, randomised, comparative trial of efficacy and 
safety of sodium stibogluconate (SSG) versus paromomycin (PM) versus a 
combination of SSG and PM as first line treatment for visceral 
leishmaniasis (VL) in Ethiopia, Kenya, Sudan and Uganda. 
 
This protocol amendment outlines a revision to the recruitment strategy of the protocol.  The overall 
sample size remains unchanged and is as described in Protocol amendment number 8 dated 14 Dec 
2006.  The change will be to the number of patients that are recruited by each site.   
 
Reason for Amendment 
Due to the addition of a new site in Uganda and the length of the ethical review process in Ethiopia 
and in order to minimize the time taken to recruit the remaining patients into the clinical trial the 
recruitment strategy for the study will be revised. As of 17 March 2008 440 patients have been 
recruited under the LEAP 0104B protocol amendment 
 
Details of the Protocol Amendment 
The recruitment strategy will be revised and recruitment will continue in all countries, with the required 
ethical and regulatory approvals until the required sample size is achieved.  The total sample size 
remains and is as described in Protocol amendment number 8 dated 14 Dec 2006. 
 
SSG vs PM 
− 195 Patients per arm for SSG (20mg/kg/day for 30 days) vs Paromomycin (20mg/kg/day for 
21 days) 
− Total patients to be recruited for SSG vs PM Analysis = 390 patients (195 per treatment arm) 
 
SSG vs Combination 
− 404 Patients for SSG arm vs 404 patients for Combination of SSG and Paromomycin arm 
− Total patients to be recruited for SSG vs Combination of SSG + PM Analysis = 808 patients 
− 808 patients comprise the following: 
o 538 out of 808 (269 per arm) are to be recruited in the current LEAP 0104B 
amendment no. 8 dated 14 December 2006. 
o 270 patients so far out of 808 (135 per arm (SSG and Combination only) have been 
recruited under the original protocol dated 31 July 2004)  
 
The total number of patients to be recruited to complete both analyses (SSG vs PM and SSG vs 
Combination) is 1003.  As of 17 March 2008, there have been 710 patients recruited (440 from 0104B 
and 270 from 0104A).  There are 293 patients still to be recruited to complete all analyses. 
 
The current recruitment as of 17 mar 2008 and Amended maximum number of patients to be recruited 
into LEAP 0104B at each site will be: 
Country  Patient recruited in 0104a & 
0104b to 17 Mar 2008 
Maximum number of patients recruited per 
site (maximum patients recruited in 0104B) 
Sudan  440 up to 590 patients (500) 
Kenya   120 up to 205 patients (175) 
Ethiopia  150 up to 240 patients (90) 
Uganda   up to 60 patients (60) 
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CASE REPORT FORM: BOOK ONE (ON DIAGNOSIS AND 
TREATMENT: PRE-TREATMENT TO DAY 18) 
 









A MULTICENTRE COMPARATIVE TRIAL OF  
 
EFFICACY AND SAFETY OF SODIUM STIBO- 
 
GLUCONATE (SSG) VERSUS PAROMOMYCIN  
 
(PM) VERSUS COMBINATION OF SSG AND PM 
 
AS THE FIRST LINE TREATMENT FOR  
 
VISCERAL LEISHMANIASIS IN ETHIOPIA, 
 

























                                                                                                           Patient’s Hospital 
Number _____________ 
Country _____________ Centre No_____________ 
Patient Study No. _________________Date of Admission _________  
Patient’s initials____________________________ 
Patient’s Occupation _______________________ 
Date of Birth (DoB) ___________ 
Age of the patient (in years): ________________  If DoB is not given provide an  estimated 
age of the patient in years. 
Gender:  Male      Female 
Level of Education: 0: None 1: Primary 2: Secondary 3: Post secondary 
Complete Address of the patient 
Province/Region: _______________________ 
District: _______________________ 
Location: ________________Name of the Chief ______________ 
Sub-Location: _____________Name of Assistant Chief _________ 
Village: _________________ Name of the Village Head ____________ 







Randomized to receive Drug Regimen: ___________________ 
 






















    PATIENTS’ SYMPTOMS 
 
 Complaints Yes No Duration 
 
Fever    
Headache    
Fatigue    
Body Weakness    
Malaise    
Epistaxis    
Abdominal pains    
Abdominal 
swellings 
   
Swelling of legs    
Cough    
Breathlessness    
Night Sweats    
Loss of appetite    
Weight loss    
Diarrhoea    
Skin lesions    
Others (specify)    
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HISTORY OF PAST ILLNESSES 








   
Other causes of   
significant 
previous hospital  
admissions 
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Weight:                                                                   Kg 
(Light clothes, rounded up to the nearest Kg) 
 
Height                                             •                  cm 
 
Blood Pressure:                                                              
(After 5mins,sitting)                          /                          mmHg 
 
Heart Rate:                                                        bpm     
 
Axillary Temperature:                           •            °C 
 
Indicate present or absent for each of the characteristics below 
 
Characteristics Present Absent 
Mucosal pallor    
Jaundice    
Cervical lymphadenopathy    
Axillary lymphadenopathy    
Inguinal lymphadenopathy    
Muscle Wasting     
Petechial haemorrhages    
Other (specify)   
   
   
   
   
   
 
Abdominal palpation 
Abdominal palpation for spleen size (cm) (by palpation below left costal margin in the 
anterior axillary line)  __________cm    
                          
 Abdominal palpation for liver size (cm) (by palpation below right costal margin in the mid-
clavicular line)  __________cm 
























1.  Positive                                          
                                     
 2.   Negative                          
 
9.   Not Tested     
 
 Clinical Chemistry Examination  
Date sample 
Analysed                
 
 
Day   Mth      Yr  
Laboratory Test Units Value 
SGOT/AST   
SGPT/ALT   




Albumin   




Creatinine   
BUN   
Sodium   
Potassium   
Amylase   
Others   
   
   
   




Analysed            
 
 




Haemoglobin   
WBC (total)   
Platelets   
Note: Please note that being HIV     
positive is not an inclusion 
/exclusion criteria. 
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Parasitologic Examination  
 
Date sample Analysed     ____________________ 
Spleen/bone Marrow /lymphnode Aspirate and enter the appropriate value in the box 
provided: 
                                       6+ 100,000/1000 oil emersion x 100 
 5+ 10,000-100,000/1000 oil emersion x 100 
                                       4+  1,000-10,000/1000 oil emersion x 100                    
                                       3+   100-1,000/1000 oil emersion x 100   
                                        2+   10-100/1000   oil emersion x 100      
                                       1+    1-10/1000 oil emersion x 100   
                                      0       0/1000 oil emersion x 100  
________________________________________________ 
Urinalysis (Dipstick Test and Microscopy) 
 
Dipstick Tests  
Colour  
Specific Gravity  
pH  









White Blood cell count (Pus cell)  
Red blood cell count  

























Chest X-Ray (CXR)/Posterior –Anterior (if indicated) 
 
 
Date performed:                 
 
                                 Day      Mth          Yr 
Please describe the subject’s x-ray by ticking one the boxes below: 
 
              Normal (no clinical significant abnormality) 
 
             Clinically significant abnormality         Record a summary of the 
significant radiological findings in the space provided below: -            
             ______________________________________________________ 
             _______________________________________________________ 




















12-Lead Electrocardiographic Examination 
 
 
Date performed:  
                                 Day     Mth    Yr 
 
Please describe the subject’s12-lead electrocardiogram by ticking one of the 
boxes below: 
 
            Normal / no clinically significant abnormality 
 
            Clinically significant abnormality       Record a summary of the 
significant electrocardiographic findings in the space provided below:-            
             ______________________________________________________ 
             _______________________________________________________ 
              ______________________________________________________ 
    





Date performed:  
                                 Day      Mth      Yr 
Please describe the subjects audiometry by ticking one of the following boxes 
below 
       Normal/no clinically significant abnormality. 
 
       Clinically significant abnormality       Record a summary of the 
significant audiometric findings in the space provided below :-            
             ______________________________________________________ 
             _______________________________________________________ 
           _______________________________________________  























Baseline concomitant diseases  
Are there any concomitant Diseases ?Yes / No 
If yes, Specify 
     Start date Recovery date 
1._____________________ _________ ___________ 
 
2._____________________ _________ ___________ 
 
3. ____________________ _________ ___________ 
 
4._____________________ _________ ___________ 
 
5._____________________      _________ ___________ 
 
6._____________________   _________ ___________ 
 
7.______________________ _________ ___________ 
 
8.______________________ _________ ___________ 
 
9._____________________ _________ ___________ 
 
10.____________________ _________ ___________ 
 




























VISCERAL LEISHMANIASIS SEVERITY ASSESSMENTS 
Clinical Examination 
 
Weight:                                                                          Kg 
(Light clothes, rounded  
up to the nearest Kg) 
Blood Pressure:                                                              
(After 5mins,sitting)                          /                          mmHg 
 
Heart Rate:                                                        bpm     
 
Axillary Temperature:                           •            °C 
 
 
Indicate present or absent for each of the characteristics below 
 
Characteristics Present Absent 
Mucosal pallor    
Jaundice    
Cervical lymphadenopathy    
Axillary lymphadenopathy    
Inguinal lymphadenopathy    
Muscle Wasting     
Petechial haemorrhages    
Other (specify)   
   
   
   
   




Abdominal palpation for spleen size (cm) (by palpation below left costal margin in the 
anterior axillary line)         __________________cm      
 
 Abdominal palpation for liver size (cm) (by palpation below right costal margin in the mid-
clavicular line)  __________cm      




















12-Lead Electrocardiographic Examination  
 
 
Date performed:  
                                   Day     Mth         Yr 
Please describe the patient’s12-lead electrocardiogram by ticking one of the 
boxes below: 
 
            Normal / no clinically significant abnormality 
 
            Clinically significant abnormality         Record a summary of 
significant findings in the space provided below:  
_____________________________________________________________ 





 Date performed: 
                      Day   Mth      Yr 
 
 
Please describe the patients’ audiometry by ticking one of the following 
boxes below 
       Normal/no clinically significant abnormality. 
 
       Clinically significant abnormality        Record a summary of significant 

































Analysed            
 
 














Clinical Chemistry Examination  
 
Date sample Analysed                          
 
Day   Mth      Yr  




SGPT/ALT   










Prothrombin Time   
Creatinine   
BUN   
Sodium   
Potassium   
Amylase   
Others   
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Urinalysis (Dipstick Test and Microscopy) 
 
Dipstick Tests  
Colour  
Specific Gravity  
pH  








Microscopy  HPF  
White Blood cell count   
Red blood cell count  








Adverse Experiences  
 
Has this patient experienced any adverse event since the last assessment? 
 
No              YES 
 
 If   YES   Please record the details in the report form in the adverse events 
section. 
Please note, for every adverse event requiring treatment, fill in the “Concomitant 




















Assessment of clinical response: 
 
Based on the clinical assessment at the screening visit, mark the boxes 
which best describe the patient’s clinical outcome so far:                 
      
Improving:  Achievement of at least one of the 
following changes: 
i) Subject becomes afebrile. 
ii) Increase in Haemoglobin by 2.0g/dl. 
iii) White blood cell count value 
increased 5 x 103/mm3. 
 Continue with study medication. 
 
Stable:     No change yet in the values of the above 
parameters (i) to (iii) from baseline. 
Continue with study medication.     
                                                                     
Deteriorating:  Worsening of the values of the above 
parameters   
 (i) to (iii) above from baseline.  
 
If the patient’s condition is deteriorating,  please withdraw the patient    
from the study and start Ambisome treatment, complete Ambisome 
medication section; early study conclusion section; and clinical response 




Investigator’s name ________________ Date _________________ 
 
Signature        ________________________ 
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VISCERAL LEISHMANIASIS SERVERITY ASSESSMENTS 
Clinical Examination 
 
Weight:                                                                          Kg 
(Light clothes, rounded  
up to the nearest Kg) 
Blood Pressure:                                                              
(After 5mins,sitting)                          /                          mmHg 
 
Heart Rate:                                                        bpm     
 
Axillary Temperature:                           •            °C 
 
 
Indicate present or absent for each of the characteristics below 
 
Characteristics Present Absent 
Mucosal pallor    
Jaundice    
Cervical lymphadenopathy    
Axillary lymphadenopathy    
Inguinal lymphadenopathy    
Muscle Wasting     
Petechial haemorrhages    
Other (specify)   
   
   
   
   




Abdominal palpation for spleen size (cm) (by palpation below left costal margin in the 
anterior axillary line)         __________________cm      
 
 Abdominal palpation for liver size (cm) (by palpation below right costal margin in the mid-
clavicular line)  __________cm      
                  
LEAP 0104a Appendices
















12-Lead Electrocardiographic Examination  
 
 
Date performed:  
                                   Day     Mth         Yr 
Please describe the patient’s12-lead electrocardiogram by ticking one of the 
boxes below: 
 
            Normal / no clinically significant abnormality 
 
            Clinically significant abnormality         Record a summary of 
significant findings in the space provided below:  
_____________________________________________________________ 
              
Audiometric Examination 
  
 Date performed: 
                      Day   Mth      Yr 
 
 
Please describe the patients’ audiometry by ticking one of the following 
boxes below 
       Normal/no clinically significant abnormality. 
 
       Clinically significant abnormality        Record a summary of significant 









Analysed            
 
 




Haemoglobin   
WBC (total)   
Platelets   
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Clinical Chemistry Examination  
 
Date sample Analysed            
 
Day   Mth      Yr  
Laboratory Test Units Value 
SGOT/AST   
SGPT/ALT   




Albumin   
Globulin   
Prothrombin Time   
Creatinine   
BUN   
Sodium   
Potassium   
Amylase   
Others   
   
   
   

































Urinalysis (Dipstick Test and Microscopy) 
Dipstick Tests  
Colour  
Specific Gravity  
pH  








Microscopy   HPF  
White Blood cell count   
Red blood cell count  









Adverse Experiences  
 
Has this patient experienced any adverse event since the last assessment? 
 
No              YES 
 
 If   YES   Please record the details in the appropriate report form in adverse 
events section. 





















 Assessment of clinical response: 
 
Based on the clinical assessment at the screening visit, mark the  boxes 
which best describe the patient’s clinical outcome so far: 
 
Improving:  Achievement of at least one of the 
following changes: 
i) Subject becomes afebrile. 
ii) Increase in Haemoglobin by 2.0g/dl. 
iii) White blood cell count value 
increased 5 x 103/mm3. 
Continue with study medication. 
 
Stable:     No change yet in the values of the above 
parameters (i)  to (iii) above from 
baseline. Continue with study 
medication.                                                
      
 
Deteriorating:  Worsening of the values of the above 
parameters   
(i) to (iii) above from baseline. 
 
If the patient’s condition is deteriorating, please withdraw the patient    
from the study and start Ambisome treatment complete Ambisome 
medication section; early study conclusion section; and clinical response 




Investigator’s name ________________ Date _________________ 
 

























Day 18  
 
VISCERAL LEISHMANIASIS SEVERITY ASSESSMENTS 
Clinical Examination 
 
Weight:                                                                          Kg 
(Light clothes, rounded up to the nearest Kg) 
Blood Pressure:                                                              
(After 5mins,sitting)                          /                          mmHg 
 
Heart Rate:                                                        bpm     
 




Indicate present or absent for each of the characteristics below 
 
Characteristics Present Absent 
Mucosal pallor    
Jaundice    
Cervical lymphadenopathy    
Axillary lymphadenopathy    
Inguinal lymphadenopathy    
Muscle Wasting     
Petechial haemorrhages    
Other (specify)   
   
   
   
   




Abdominal palpation for spleen size (cm) (by palpation below left costal margin in the 
anterior axillary line)         __________________cm                             
 
Abdominal palpation for liver size (cm) (by palpation below right costal margin in the mid-
clavicular line)  __________cm      
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12-Lead Electrocardiographic Examination  
 
 
Date performed:  
                                   Day     Mth         Yr 
Please describe the patient’s12-lead electrocardiogram by ticking one of the 
boxes below: 
 
            Normal / no clinically significant abnormality 
 
            Clinically significant abnormality         Record a summary of 




              
  
Audiometric Examination  
 
  
 Date performed: 
                      Day   Mth      Yr 
 
Please describe the patients’ audiometry by ticking one of the following 
boxes below 
       Normal/no clinically significant abnormality. 
 
       Clinically significant abnormality        Record a summary of            



























 Day 18  




Analysed            
 
 




Haemoglobin   
WBC (total)   
Platelets   
 
Parasitologic Examination  
Date sample Analysed     ____________________ 
 
Spleen/bone Marrow /lymphnode aspirate (Leishmania Index).Enter the appropriate index in 
the box provided. 
                                       6+  
 5+ 
                                       4+                        
                                       3+    
                                       2+ 
                                       1+  
                            0 
_____________________________________________________ 
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 Day 18  
Clinical Chemistry Examination  
 
Date sample Analysed      
 







SGOT/AST   




Albumin   
Globulin   
Prothrombin Time   
Creatinine   
BUN   
Sodium   
Potassium   
Amylase   
Others   
   
   
   

































Urinalysis (Dipstick Test and Microscopy) 
 
Dipstick Tests  
Colour  
Specific Gravity  
pH  








Microscopy  HPF  
White Blood cell count   
Red blood cell count  
























Adverse Experiences  
 
Has this patient experienced any adverse event since the last assessment? 
 
No              YES 
 If   YES   Please record the details in the report form. 
Please note, for every adverse event requiring treatment, fill in the “Concomitant 
medication section. 
Assessment of Treatment Response 
Based on the clinical/physical assessment at the screening visit, 
mark the  box or boxes which best describe the subject’s clinical 
outcome so far: 
 
 CLINICAL  RESPONSE:                                
COMPLETE 
 
 Resolution of all signs and symptoms of VL 
 
 
PARTIAL  Some signs or symptoms of VL persist 
 




 -Smear negative after counting 1000 
fields 










Smear positive but ≥99%parasite 
reduction 







 Smear positive and <99% parasite 
reduction 
[<2 log reduction] compared with pre-
treatment slide. 
 
Investigator’s name ________________ Date _________________ 
 
Signature        ________________________ 
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If patient misses a dose for any reason write “not given” in medication column and specify 


































12    
 
 






























































CONCOMITANT MEDICATION (Excluding Ambisome medication) 
 
Please record all baseline medications and all concomitant medication taken during the 
study. 
Mark box below or complete page with concomitant medication details. 
           
                       Please mark box if no concomitant medication is    
                       being used. 
Any new medical illness/diagnosis (or symptoms in the absence of a diagnosis) should 


















in absence of 
diagnosis 
Start date( be 
precise as 
possible) 
Day  Mth   Yr 
End date 
 
Day  Mth   Yr 
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CONCOMITANT MEDICATION (Excluding Ambisome medication) 
 
Please record all baseline medications and all concomitant medication taken during the 
study. 
Mark box below or complete page with concomitant medication details. 
           
                       Please mark box if no concomitant medication is    
                       being used. 
Any new medical illness/diagnosis (or symptoms in the absence of a diagnosis) should 


















in absence of 
diagnosis 
Start date( be 
precise as 
possible) 
Day  Mth   Yr 
End date 
 
Day  Mth   Yr 
 
 
      
  
 
     
  
 
     
  
 
     
  
 
     
   
 




   
 































Cause of Death:_____________________________________ 
 
Date of Death:                                                    Complete adverse 
                                         Day   Mth    Yr          experience form with regard     
                                                                             to death: 
Was a post-mortem examination carried out? 
 
        No 
 





















Physician’s Name __________________________ Date  
 
             Signature __________________________ 
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STUDY CONCLUSION- Early withdrawal ONLY 
 
 
 Please give the reason for withdrawal by marking the one most appropriate 
category below: Then complete the date of last dose, date of last visit and 
assessment of clinical response. 
 
1          Adverse experience, (complete adverse experience section) 
 
2         Lack of response 
 
3         Deviation from protocol (including non-compliance) 
 
4         Lost to follow-up 
 
5         Termination by sponsor 
 




Date of last visit:                                      Date of last dose:  
                                Day   Mth   Yr                                          Day    Mth   Yr 
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TREATMENT WITH AMBISOME   
 
Did this patient require rescue medication?    Yes/No   If yes please fill in the table below 
details of Ambisome medication. 
Please record all other Anti-Leishmanial drugs taken during the study. 
 
        Please mark box if Ambisome medication was not given.  












Day  Mth  Yr 
End date 
Day Mth  Yr 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 























 ADVERSE EXPERIENCE REPORT FORM (NON SERIOUS) 
 
Record any adverse experiences (using standard medical terminology) Please 
provide the diagnosis not symptoms where possible. One adverse experience per 
column. 











Day   Mth       Yr 
 









          Resolved 
 




               Resolved 
 




 Intensity (maximum)         Mild  
 
          Moderate 
 
          Severe 
 
        Mild  
 
          Moderate 
 
          Severe 
 
Action taken with 
respect to 
investigational drug 
         None 
          Dose reduced 
           
 
          Drug 
interrupted/reduced 
         
            Drug stopped 
  
       None 
        
        Dose reduced 
      
       Drug interrupted/restarted 
 
       Drug stopped. 
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ADVERSE EXPERIENCE REPORT FORM (NON SERIOUS) Cont. 
Relationship to 
investigational drug 
           
          Not related  
          
          Unlikely  
                                   
          possible        
         Probable 
 
           
         Not related  
          
          Unlikely  
                                  
            Possible 
          









            Yes             No 
 




Was the subject 
withdrawn due to this 
specific AE? 
  
          Yes                    No 
 
            Yes                       No 
 
Investigator’s Name  ______________________________________________ 
 



































ADVERSE EXPERIENCE REPORT FORM (NON SERIOUS) 
 
Record any adverse experiences (using standard medical terminology) Please 
provide the diagnosis not symptoms where possible. One adverse experience per 
column. 











Day   Mth       Yr 
 









          Resolved 
 




               Resolved 
 




 Intensity (maximum)         Mild  
 
          Moderate 
 
          Severe 
 
        Mild  
 
          Moderate 
 
          Severe 
 
Action taken with 
respect to 
investigational drug 
         None 
          Dose reduced 
           
 
          Drug 
interrupted/reduced 
         
            Drug stopped 
  
       None 
        
        Dose reduced 
      
       Drug interrupted/restarted 
 
       Drug stopped. 
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ADVERSE EXPERIENCE REPORT FORM (NON SERIOUS) Cont. 
Relationship to 
investigational drug 
           
          Not related  
          
          Unlikely  
                                   
          possible        
         Probable 
 
           
         Not related  
          
          Unlikely  
                                  
            Possible 
          









            Yes             No 
 




Was the subject 
withdrawn due to this 
specific AE? 
  
          Yes                    No 
 
            Yes                       No 
 
Investigator’s Name  ______________________________________________ 
 



































ADVERSE EXPERIENCE REPORT FORM (NON SERIOUS) 
 
Record any adverse experiences (using standard medical terminology) Please 
provide the diagnosis not symptoms where possible. One adverse experience per 
column. 











Day   Mth       Yr 
 









          Resolved 
 




               Resolved 
 




 Intensity (maximum)         Mild  
 
          Moderate 
 
          Severe 
 
        Mild  
 
          Moderate 
 
          Severe 
 
Action taken with 
respect to 
investigational drug 
         None 
          Dose reduced 
           
 
          Drug 
interrupted/reduced 
         
            Drug stopped 
  
       None 
        
        Dose reduced 
      
       Drug interrupted/restarted 
 
       Drug stopped. 
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ADVERSE EXPERIENCE REPORT FORM (NON SERIOUS) Cont. 
Relationship to 
investigational drug 
           
          Not related  
          
          Unlikely  
                                   
          possible        
         Probable 
 
           
         Not related  
          
          Unlikely  
                                  
            Possible 
          









            Yes             No 
 




Was the subject 
withdrawn due to this 
specific AE? 
  
          Yes                    No 
 
            Yes                       No 
 
Investigator’s Name  ______________________________________________ 
 



































ADVERSE EXPERIENCE REPORT FORM (NON SERIOUS) 
 
Record any adverse experiences (using standard medical terminology) Please 
provide the diagnosis not symptoms where possible. One adverse experience per 
column. 











Day   Mth       Yr 
 









          Resolved 
 




               Resolved 
 




 Intensity (maximum)         Mild  
 
          Moderate 
 
          Severe 
 
        Mild  
 
          Moderate 
 
          Severe 
 
Action taken with 
respect to 
investigational drug 
         None 
          Dose reduced 
           
 
          Drug 
interrupted/reduced 
         
            Drug stopped 
  
       None 
        
        Dose reduced 
      
       Drug interrupted/restarted 
 
       Drug stopped. 
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ADVERSE EXPERIENCE REPORT FORM (NON-SERIOUS) Cont. 
Relationship to 
investigational drug 
           
          Not related  
          
          Unlikely  
                                   
          possible        
         Probable 
 
           
         Not related  
          
          Unlikely  
                                  
            Possible 
          









            Yes             No 
 




Was the subject 
withdrawn due to this 
specific AE? 
  
          Yes                    No 
 
            Yes                       No 
 
Investigator’s Name  ______________________________________________ 
 



































ADVERSE EXPERIENCE REPORT FORM (NON-SERIOUS) 
 
Record any adverse experiences (using standard medical terminology) Please 
provide the diagnosis not symptoms where possible. One adverse experience per 
column. 











Day   Mth       Yr 
 









          Resolved 
 




               Resolved 
 




 Intensity (maximum)         Mild  
 
          Moderate 
 
          Severe 
 
        Mild  
 
          Moderate 
 
          Severe 
 
Action taken with 
respect to 
investigational drug 
         None 
          Dose reduced 
           
 
          Drug 
interrupted/reduced 
         
            Drug stopped 
  
       None 
        
        Dose reduced 
      
       Drug interrupted/restarted 
 
       Drug stopped. 
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ADVERSE EXPERIENCE REPORT FORM (NON-SERIOUS) Cont. 
Relationship to 
investigational drug 
           
          Not related  
          
          Unlikely  
                                   
          possible        
         Probable 
 
           
         Not related  
          
          Unlikely  
                                  
            Possible 
          









            Yes             No 
 




Was the subject 
withdrawn due to this 
specific AE? 
  
          Yes                    No 
 
            Yes                       No 
 
Investigator’s Name  ______________________________________________ 
 



































ADVERSE EXPERIENCE REPORT FORM (NON SERIOUS) 
 
Record any adverse experiences (using standard medical terminology) Please 
provide the diagnosis not symptoms where possible. One adverse experience per 
column. 











Day   Mth       Yr 
 









          Resolved 
 




               Resolved 
 




 Intensity (maximum)         Mild  
 
          Moderate 
 
          Severe 
 
        Mild  
 
          Moderate 
 
          Severe 
 
Action taken with 
respect to 
investigational drug 
         None 
          Dose reduced 
           
 
          Drug 
interrupted/reduced 
         
            Drug stopped 
  
       None 
        
        Dose reduced 
      
       Drug interrupted/restarted 
 
       Drug stopped. 
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ADVERSE EXPERIENCE REPORT FORM (NON SERIOUS) Cont. 
Relationship to 
investigational drug 
           
          Not related  
          
          Unlikely  
                                   
          possible        
         Probable 
 
           
         Not related  
          
          Unlikely  
                                  
            Possible 
          









            Yes             No 
 




Was the subject 
withdrawn due to this 
specific AE? 
  
          Yes                    No 
 
            Yes                       No 
 
Investigator’s Name  ______________________________________________ 
 



































ADVERSE EXPERIENCE REPORT FORM (NON SERIOUS) 
 
Record any adverse experiences (using standard medical terminology) Please 
provide the diagnosis not symptoms where possible. One adverse experience per 
column. 











Day   Mth       Yr 
 









          Resolved 
 




               Resolved 
 




 Intensity (maximum)         Mild  
 
          Moderate 
 
          Severe 
 
        Mild  
 
          Moderate 
 
          Severe 
 
Action taken with 
respect to 
investigational drug 
         None 
          Dose reduced 
           
 
          Drug 
interrupted/reduced 
         
            Drug stopped 
  
       None 
        
        Dose reduced 
      
       Drug interrupted/restarted 
 
       Drug stopped. 
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ADVERSE EXPERIENCE REPORT FORM (NON-SERIOUS) Cont.  
Relationship to 
investigational drug 
           
          Not related  
          
          Unlikely  
                                   
          possible        
         Probable 
 
           
         Not related  
          
          Unlikely  
                                  
            Possible 
          









            Yes             No 
 




Was the subject 
withdrawn due to this 
specific AE? 
  
          Yes                    No 
 
            Yes                       No 
 
Investigator’s Name  ______________________________________________ 
 























6 months follow-up 
 
VISCERAL LEISHMANIASIS SEVERITY ASSESSMENTS 
Clinical Examination 
 
Weight:                                                                          Kg 
(Light clothes, rounded up to the nearest Kg) 
Blood Pressure:                                                              
(After 5mins,sitting)                          /                          mmHg 
 
Heart Rate:                                                        bpm     
 




Indicate present or absent for each of the characteristics below 
 
Characteristics Present Absent 
Mucosal pallor    
Jaundice    
Cervical lymphadenopathy    
Axillary lymphadenopathy    
Inguinal lymphadenopathy    
Muscle Wasting     
Petechial haemorrhages    
Other (specify)   
   
   
   
   
   
Abdominal palpation 
 
Abdominal palpation for spleen size (cm) (by palpation below left costal margin 
in the anterior axillary line)         __________________cm                             
 
Abdominal palpation for liver size (cm) (by palpation below right costal margin 
in the mid-clavicular line)  __________cm      
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6 months follow-up 
 
12-Lead Electrocardiographic Examination  
 
 
Date performed:  
                                   Day     Mth         Yr 
Please describe the patient’s12-lead electrocardiogram by ticking one of the 
boxes below: 
 
            Normal / no clinically significant abnormality 
 
            Clinically significant abnormality         Record a summary of  





              
  
Audiometric Examination  
 
  
 Date performed: 
                    Day   Mth      Yr 
 
Please describe the patients’ audiometry by ticking one of the following boxes 
below 
 
           Normal/no clinically significant abnormality. 
 
          Clinically significant abnormality        Record a summary of            

























 6 months follow-up  
Haematologic Examination  
  
Date the sample Analysed                       
 
Day   Mth      Yr  
Laboratory Test Units Value 
Haemoglobin   
WBC (total)   
Platelets   
 
Parasitologic Examination  
Date sample was taken     ____________________ 
 
Spleen/bone Marrow /lymphnode aspirate (Leishmania Index).Enter the 
appropriate index in the box provided. 
                                       
   6+  
 
 5+   
 
                                       4+     
                    
                                       3+    
 
                                       2+ 
 
                                       1+  
 




*Bone marrow to be done in cases where lymph node or spleen is       
not palpable.
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 6 months follow-up  
Clinical Chemistry Examination  
 
Date sample Analysed                          
 
                   Day   Mth    Yr  
Laboratory Test Units Value 
SGOT/AST   
SGPT/ALT   
Alkaline Phosphatase   
Albumin   
Globulin   
Prothrombin Time   
Creatinine   
BUN   
Sodium   
Potassium   
Amylase   
Others   
   
   
   


























6 months follow-up 
Urinalysis (Dipstick Test and Microscopy) 
 
Dipstick Tests Values/Units 
Colour  
Specific Gravity  
pH  








Microscopy  PER HIGH POWER FIELD 
White Blood cell count   
Red blood cell count  























6 months follow-up 
Adverse Experiences  
 Are there any adverse events from the previous follow up to be carried forward? 
 
No              YES 
 If   YES   Please record the details in the adverse events section. 
 
Has this patient experienced any new adverse events since the last assessment 
  
NO                      YES 
If   YES   Please record the details in the adverse events section. 
Please note, for every adverse event requiring treatment, fill in the “Concomitant 
medication” section. 
Assessment of Treatment Response 
Based on the clinical/physical assessment at the screening visit, 
mark the  box that best describes or boxes that best describe the 
subject’s clinical outcome so far: 
 CLINICAL  RESPONSE:                                
COMPLETE 
 
 Resolution of all signs and symptoms of 
VL 
 
PARTIAL  Some signs or symptoms of VL persist 
 




 -Smear negative after counting 1000 
fields 










Smear positive but ≥99%parasite 
reduction 







 Smear positive and <99% parasite 
reduction 
[<2 log reduction] compared with pre-
treatment slide. 
 
Investigator’s name ________________ Date _________________ 
Signature        ________________________ 
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    6 months follow-up 
 CONCOMITANT MEDICATION (Excluding Ambisome medication) 
 
 
                      Please mark box if no new concomitant medications are    
                       being used during this follow-up. 
  
Please record all concomitant medications carried forward if any from the last 
follow-up and all other new concomitant medications taken since the last  
follow-up in the spaces provided below. 
 
Any new medical illness/diagnosis (or symptoms in the absence of a diagnosis) 



















in absence of 
diagnosis 
Start date( be 
precise as 
possible) 
Day  Mth   Yr 
End date 
 
Day  Mth   Yr 
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   6 months follow-up 
CONCOMITANT MEDICATION (Excluding Ambisome medication) 
 
          
                     Please mark box if no new concomitant medication are    
                       being used during this follow-up. 
 
Please record all concomitant medications carried forward if any from the last 
follow-up and all other new concomitant medications taken since the last  
follow-up in the spaces provided below. 
  
Any new medical illness/diagnosis (or symptoms in the absence of a diagnosis) 



















in absence of 
diagnosis 
Start date( be 
precise as 
possible) 
Day  Mth   Yr 
End date 
 
Day  Mth   Yr 
 
 
      
  
 
     
  
 
     
  
 
     
  
 
     
   
 




   
 
































Cause of Death:_____________________________________ 
 
Date of Death:                                                    Complete serious adverse 
                                         Day   Mth    Yr          experience form with regard     
                                                                             to death: 
Was a post-mortem examination carried out? 
 
        No 
 





















Physician’s Name __________________________ Date  
 
             Signature __________________________ 
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   6 months follow-up 
STUDY CONCLUSION- Early withdrawal ONLY 
 
 
 Please give the reason for withdrawal by marking the one most appropriate 
category below: Then complete the date of last dose, date of last visit and 
assessment of clinical response. 
 
1          Adverse experience, (complete adverse experience section) 
 
2         Lack of response 
 
3         Deviation from protocol (including non-compliance) 
 
4         Lost to follow-up 
 
5         Termination by sponsor 
 




Date of last visit:                                       
                                                          Day    Mth    Yr                                           
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   6 months follow-up 
TREATMENT WITH AMBISOME   
 
Did this patient require rescue medication?    Yes/No   If yes please fill in the 
table below details of Ambisome medication. 
 
         
         Please mark box if Ambisome medication was not given.  
           
 














Day  Mth  Yr 
End date 
Day Mth  Yr 
      
 
 
      
 
 
      
 
 
      
 
 
      
 
 

































  6 months follow-up 
ADVERSE EXPERIENCE REPORT FORM (NON SERIOUS) 
 
              If no new adverse experiences during this follow-up, please mark this       
box   and sign form below. 
 
Record any adverse experiences (both carried forward  if any and/or new 
ones),using standard medical terminology. Please provide the diagnosis not 








Day   Mth      Yr 
 









           
            Resolved 
 
          Ongoing 
 
 
                
             Resolved 
 




 Intensity (maximum)          
           Mild  
 
            Moderate 
 
            Severe 
 
         
          Mild  
 
          Moderate 
 
          Severe 
 
Action taken with 
respect to 
investigational drug 
         None 
          Dose reduced 
           
          Drug        
interrupted/reduced 
         
            Drug stopped 
  
       None 
       Dose reduced 
 
      Drug 
interrupted/restarted 
 





















               6 months follow-up 
ADVERSE  EXPERIENCES (NON_SERIOUS) Cont. 
Relationship to 
investigational drug 
           
          Not related  
          
          Unlikely  
         
            Suspected            
          (reasonably 
            possible)       
         Probable 
 
           
         Not related  
          
          Unlikely  
         
             Suspected              
          (reasonably 
            possible)       
         Probable 
Corrective Therapy 
If ‘yes’, please record 
Concomittant 
Medication section and 
/or Resource utilization 
section if appropiriate. 
 
 
            Yes             No 
 




Was the subject 
withdrawn due to this 
specific AE? 
  
          Yes                    No 
 




                     Signature:______________________________________________ 
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 6 months follow-up 
ADVERSE EXPERIENCE REPORT FORM (NON SERIOUS) 
 
         If no new adverse experiences during this follow-up, please mark this box     
and sign form below. 
 
Record any adverse experiences (both carried forward  if any and/or new 
ones),using standard medical terminology. Please provide the diagnosis not 










Day   Mth      Yr 
 









           
            Resolved 
 
          Ongoing 
 
 
                
             Resolved 
 




 Intensity (maximum)          
           Mild  
 
            Moderate 
 
            Severe 
 
         
          Mild  
 
          Moderate 
 
          Severe 
 
Action taken with 
respect to 
investigational drug 
         None 
          Dose reduced 
           
          Drug        
interrupted/reduced 
         
            Drug stopped 
  
       None 
       Dose reduced 
 
      Drug 
interrupted/restarted 
 
       Drug stopped. 
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                                    6 months follow-up 
 
ADVERSE  EXPERIENCES (NON_SERIOUS) Cont. 
Relationship to 
investigational drug 
           
          Not related  
          
          Unlikely  
         
            Suspected            
          (reasonably 
            possible)       
         Probable 
           
         Not related  
          
          Unlikely  
         
             Suspected              
          (reasonably 
            possible)       
         Probable 
Corrective Therapy 
If ‘yes’, please record 
Concomittant 
Medication section and 
/or Resource utilization 
section if appropiriate. 
 
 
            Yes             No 
 




Was the subject 
withdrawn due to this 
specific AE? 
  
          Yes                    No 
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16.1.2 List of IECs and patient information and consent forms 
Appendix 3 List of IECs  
LIST OF ETHICS COMMITTEES FOR LEAP 0104 A 
 
SUDAN 
1. Ethics Committee for the Federal Ministry of Health 
2. Institute of Endemic Diseases, University of Khartoum 
3. MSF Ethics Review Board Ethics Committee, 
ETHIOPIA  
1. University of Addis Ababa Ethics Committee 
2. Gondar Ollege of Medical Sciences  Institutional Ethics Committee  
3. Awasa Regional Ethics Committee 
4. Bahir-Dar Regional Ethics Committee 
5. National Ethical Clearance Committee 
KENYA 
1. Scientific Review Committee, KEMRI 
2. Kenya Medical Research Institute Ethics Committee 
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Appendix 4 Samples of patient information sheets and consent forms 
 
See Appendix 1 
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16.1.3 List of investigators and other study personnel 
Appendix 5 List of principal and co-investigators, affiliations and roles# 
Centre 11 (Gondar) and 12 (Arba Minch) 
NAME INSTITUTION RESPONSIBILITY 
Asrat Hailu University of Addis Ababa Principle Investigator  
Eyasu Makonnen University of Addis Ababa Investigator 
Yalemtsehay Mekonnen University of Addis Ababa Investigator 
Afewesen Gebre-Yohannes Gondar University Hospital Investigator 
Sisay Yifru Gondar University Hospital Investigator 
Abiye Tesfaye Gondar University Hospital Investigator 
Nurelign Gashu Gondar University Hospital Investigator 
Samson Tesfaye Arba Minch Hospital Site Investigator  
Yewubnesh Hailu Arba Minch Hospital Investigator 
Degu Jerene Arba Minch Hospital Investigator 
 
Centre 23: Kenya 
NAME INSTITUTION RESPONSIBILITY 
Monique Wasunna KEMRI Principle Investigator  
Juma Rashid KEMRI Investigator 
J. Mbui KEMRI Investigator 
G. Mucee KEMRI Investigator 
V. Manduku KEMRI Investigator 
A. Musibi  KEMRI Investigator 
Z. Mutuma KEMRI Investigator 
F. Kirui KEMRI Investigator 
H. Lodenyo KEMRI Investigator 
K. Bhatt University of Nairobi Investigator 
 
Centre 34: Um el Kher  
NAME INSTITUTION RESPONSIBILITY 
Manica Balasegaram MSF Principle Investigator  
Marius Mueller MSF Investigator 
Peter Young MSF Investigator 
Yousif Koummuki MSF Investigator 
Thomas Allam MSF Investigator 
Omer Elamin Hassan MSF Investigator 
Koert Ritmeijer MSF Investigator 
 
Centre 35: Kassab 
NAME INSTITUTION RESPONSIBILITY 
Musa Amudawi IEND Principle Investigator  
A. M. ElHassan IEND Investigator 
M. E. Ebrahim IEND Investigator 
I.M. ElHassan IEND Investigator 
Ahmed Abdalla Gedarif University Sudan Investigator 
Fawzi Abdeirahim Mahjoub National Ribat University Investigator 
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Appendix 6 CVs of principal and co-investigators  
See Appendix  5 for list of Investigators and Trial Master file for signed and dated CVs
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Appendix 7 List of DSMB members and their affiliation  
 
Dr. Faiza Osman Mohammed, Institute of Endemic Diseases, University of Khartoum, SUDAN 
Dr. Phelgona Otieno, Centre for Clinical Research, Kenya Medical Research Institute, KENYA 
Dr. Khalid Abd ElMutalab ElMardi, National Malaria Control Programme, Federal Ministry of 
Health, SUDAN 
Dr. Nuha Hamid Mahamoud, World Health Organization (WHO), SUDAN 
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Appendix 8 List of monitors 
 
LEAP 0104A  
Dr. Robert Balikuddembe, Makerere University, UGANDA 
Dr. Sarah Nanzigu, Makerere University, UGANDA 
Dr. Shibru Berhum, ETHIOPIA 
Dr. Hildah O’hara, KEMRI, KENYA 
Dr. Lydia Kivihya, KEMRI, KENYA 
Dr. Isaiah Mwangi, Centre for Respiratory Diseases, Kenya Medical Research Institute, KENYA 
Dr. Mona Elfakii Eltahir, Institute of Endemic Diseases, University of Khartoum, SUDAN 
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16.2.4 Signatures of principal or coordinating investigator(s) or sponsor’s 
responsible medical officer 
Appendix 9 Signatures 
Sponsor (DNDi) Name  
Country Switzerland 
Phone +41 22 906 9230 
E-mail  
Sponsor 
Senior Project Manager 
Fax  
Signature Date of Signature (ddmmyyyy) 
 
 
Time (24-hour clock, place) 
 
 
Kenya Medical Research 
Research Institute 
Name Dr. Monique Wasunna 
Country Kenya 
Phone +254 20 273 0076 
E-mail africa@dndi.org 
Medical Coordinator / Head 
of DNDi Africa  /LEAP Data 
centre 
Fax  
Signature Date of Signature: (ddmmmyyy) 
 
 
Time (24-hour clock, place) 
 
Faculty of Medicine 
Addis Ababa University 
Name Prof. Asrat Hailu 
Country Ethiopia 







Date of Signature (ddmmyyyy) Time (24-hour clock, place) 
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Institute of Endemic 
Diseases, University of 
Khartoum, Sudan  
Name Prof. Eltahir Khalil 
Country Sudan 




Signature Date of Signature (ddmmyyyy) 
 
Time (24-hour clock, place) 
 
Institute of Endemic 
Diseases, University of 
Khartoum, Sudan 
Name Dr Ahmed Musa 
Country Sudan 
Phone +249-9-123-75740 (office) 
E-mail  
Site Lead Investigator  
(Kassab site) 
Fax  
Signature Date of Signature (ddmmyyyy) 
 
Time (24-hour clock, place) 
 
MSF-Holland Name Dr Manica Balasegaram 
Country Switzerland 
Phone +41 22 906 9230 
E-mail mbalasegaram@dndi.org 
Site Lead Investigator  
(Um el Kher site) 
Fax  
Signature Date of Signature (ddmmyyyy) 
 
 
Time (24-hour clock, place) 
 
London School of Hygiene 
and Medicine 
Name Tansy Edwards 
(Statistician) 
Country United Kingdom 
Phone +44 (20) 7927 2240 
E-mail tansy.edwards@lshtm.ac.uk  Statistician 
Fax  
Signature Date of Signature (ddmmyyyy) 
 
 
Time (24-hour clock, place) 
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16.2.5 Listing of patients receiving test drugs from specific batches, where more 
than one batch was used 





Batch Number Expiry date 
Centre Patient numbers 
FB301X 1 Sep 2006 
Gondar (11) 
Arba Minch (12) 
KEMRI (23) 
Um el Kher (34) 
Kassab (35) 
001- 090 
241 - 330 
361 - 405 
451 - 540 
646 - 690 
FB501X 1 Jan 2008 Gondar (11) 
Arba Minch (12) 
091-135 






Batch Number Expiry date 
Centre Patient numbers 
4P12004 
 
 Feb 2007 
 
Gondar (11) 
Arba Minch (12) 
KEMRI (23)  
Um el Kher (34) 
Kassab (35) 
001- 135 
241 – 330 
361 – 405 
451 – 540 
646 - 690 
4P12010 Mar 2007 Gondar (11)  001- 135 
5P12036 Aug 2007 Gondar (11)  
Arba Minch (12) 
001- 135 
241 – 330 
5P12037 Aug 2007 Gondar (11)  
Arba Minch (12) 
001- 135 
241 – 330 
6P12001 Feb 2008 Arba Minch (12) 241 - 330 
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16.2.6 Randomisation scheme and codes 
Appendix 11 Randomisation master list  
Randomization List for Gondar- Ethiopia 
 
COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
1 1 1 1 1 1 55 1 
1 1 2 3 1 1 56 2 
1 1 3   3 1 1 57 3 
1 1 4      1 1 1 58 3 
1 1 5      1 1 1 59 1 
1 1 6 3 1 1 60 3 
1 1 7 1 1 1 61 1 
1 1 8 2 1 1 62 2 
1 1   9 2 1 1 63 2 
1 1 10 2 1 1 64 2 
1 1   11 3 1 1 65 1 
1 1 12 3 1 1 66 3 
1 1 13 2 1 1 67 1 
1 1 14 2 1 1 68 2 
1 1 15 1 1 1 69 3 
1 1 16 3 1 1 70 3 
1 1 17 3 1 1 71 3 
1 1 18 2 1 1 72 2 
1 1 19 3 1 1 73 1 
1 1 20 2 1 1 74 1 
1 1 21 2 1 1 75 3 
1 1 22 2 1 1 76 1 
1 1 23 1 1 1 77 1 
1 1 24 1 1 1 78 2 
1 1 25 2 1 1 79 1 
1 1 26 3 1 1 80 1 
1 1 27 1 1 1 81 3 
1 1 28 3 1 1 82 2 
1 1 29 1 1 1 83 2 
1 1 30 1 1 1 84 2 
1 1 31 2 1 1 85 2 
1 1 32 3 1 1 86 3 
1 1 33 2 1 1 87 3 
1 1 34 1 1 1 88 1 
1 1 35 2 1 1 89 3 
1 1 36 2 1 1 90 3 
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COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
1 1 37 3 1 1 91 1 
1 1 38 1 1 1 92 3 
1 1 39 1 1 1 93 2 
1 1 40 1 1 1 94 2 
1 1 41 3 1 1 95 2 
1 1 42 3 1 1 96 3 
1 1 43 2 1 1 97 3 
1 1 44 1 1 1 98 1 
1 1 45 3 1 1 99 2 
1 1 46 2 1 1 100 1 
1 1 47 2 1 1 101 1 
1 1 48 3 1 1 102 3 
1 1 49 2 1 1 103 3 
1 1 50 1 1 1 104 1 
1 1 51 3 1 1 105 2 
1 1 52 1 1 1 106 3 
1 1 53 2 1 1 107 1 
1 1 54 1 1 1 108 1 
1 1 109 2 1 1 165 3 
1 1 110 1 1 1 166 1 
1 1 111 3 1 1 167 3 
1 1 112 3 1 1 168 2 
1 1 113 2 1 1 169 3 
1 1 114 2 1 1 170 2 
1 1 115 3 1 1 171 1 
1 1 116 2 1 1 172 3 
1 1 117 1 1 1 173 1 
1 1 118 1 1 1 174 3 
1 1 119 2 1 1 175 1 
1 1 120 3 1 1 176 2 
1 1 121 3 1 1 177 3 
1 1 122 2 1 1 178 1 
1 1 123 2 1 1 179 2 
1 1 124 2 1 1 180 2 
1 1 125 2 1 1 181 1 
1 1 126 3 1 1 182 2 
1 1 127 1 1 1 183 2 
1 1 128 3 1 1 184 3 
1 1 129 1 1 1 185 1 
1 1 130 3 1 1 186 1 
1 1 131 1 1 1 187 1 
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COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
1 1 132 2 1 1 188 3 
1 1 133 3 1 1 189 3 
1 1 134 1 1 1 190 2 
1 1 135 1 1 1 191 2 
1 1 136 1 1 1 192 1 
1 1 137 2 1 1 193 3 
1 1 138 2 1 1 194 3 
1 1 139 1 1 1 195 2 
1 1 140 3 1 1 196 1 
1 1 141 3 1 1 197 3 
1 1 142 2 1 1 198 3 
1 1 143 3 1 1 199 2 
1 1 144 1 1 1 200 3 
1 1 145 2 1 1 201 2 
1 1 146 1 1 1 202 1 
1 1 147 1 1 1 203 1 
1 1 148 3 1 1 204 3 
1 1 149 3 1 1 205 1 
1 1 150 2 1 1 206 2 
1 1 151 3 1 1 207 3 
1 1 152 2 1 1 208 1 
1 1 153 1 1 1 209 2 
1 1 154 2 1 1 210 2 
1 1 155 2 1 1 211 3 
1 1 156 3 1 1 212 2 
1 1 157 3 1 1 213 1 
1 1 158 1 1 1 214 1 
1 1 159 2 1 1 215 2 
1 1 160 1 1 1 216 3 
1 1 161 2 1 1 217 2 
1 1 162 1 1 1 218 2 
1 1 163 3 1 1 219 2 
1 1 164 1 1 1 220 1 
1 1 221 3 1 1 231 2 
1 1 222 3 1 1 232 2 
1 1 223 1 1 1 233 1 
1 1 224 3 1 1 234 1 
1 1 225 1 1 1 235 3 
1 1 226 3 1 1 236 1 
1 1 227 2 1 1 237 2 
1 1 228 3 1 1 238 2 
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COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
1 1 229 3 1 1 239 1 
1 1 230 3 1 1 240 1 
 
Number of cases read:  240    Number of cases listed:  240 
  
 Frequency Percent Valid Percent Cumulative Percent 
Valid 1  PM 80 33.3 33.3 33.3 
 2  SSG 80 33.3 33.3 66.7 
 3  SSG+PM 80 33.3 33.3 100.0 
 Total 240 100.0 100.0   
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Randomization List for Arba Minch – Ethiopia 
 
COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
1 2 241 3 1 2 295 3 
1 2 242 2 1 2 296 1 
1 2 243   1 1 2 297 2 
1 2 244      2 1 2 298 1 
1 2 245    1 1 2 299 3 
1 2 246 1 1 2 300 1 
1 2 247 1 1 2 301 2 
1 2 248 1 1 2 302 2 
1 2  24 9 3 1 2 303 1 
1 2 250 2 1 2 304 3 
1 2  251 3 1 2 305 1 
1 2 252 2 1 2 306 3 
1 2 253 2 1 2 307 3 
1 2 254 3 1 2 308 1 
1 2 255 3 1 2 309 1 
1 2 256 3 1 2 310 2 
1 2 257 2 1 2 311 2 
1 2 258 2 1 2 312 3 
1 2 259 1 1 2 313 1 
1 2 260 1 1 2 314 2 
1 2 261 3 1 2 315 3 
1 2 262 1 1 2 316 2 
1 2 263 2 1 2 317 2 
1 2 264 3 1 2 318 3 
1 2 265 2 1 2 319 3 
1 2 266 2 1 2 320 3 
1 2 267 2 1 2 321 3 
1 2 268 1 1 2 322 1 
1 2 269 3 1 2 323 2 
1 2 270 3 1 2 324 2 
1 2 271 2 1 2 325 1 
1 2 272 1 1 2 326 1 
1 2 273 2 1 2 327 3 
1 2 274 2 1 2 328 1 
1 2 275 3 1 2 329 2 
1 2 276 1 1 2 330 1 
1 2 277 3 1 2 331 1 
1 2 278 2 1 2 332 2 
1 2 279 1 1 2 333 3 
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COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
1 2 280 2 1 2 334 3 
1 2 281 3 1 2 335 1 
1 2 282 1 1 2 336 2 
1 2 283 1 1 2 337 3 
1 2 284 3 1 2 338 2 
1 2 285 3 1 2 339 1 
1 2 286 1 1 2 340 2 
1 2 287 2 1 2 341 1 
1 2 288 3 1 2 342 2 
1 2 289 3 1 2 343 1 
1 2 290 2 1 2 344 3 
1 2 291 2 1 2 345 3 
1 2 292 1 1 2 346 1 
1 2 293 2 1 2 347 3 
1 2 294 3 1 2 348 2 
1 2 349 2 1 2 355 2 
1 2 350 3 1 2 356 2 
1 2 351 1 1 2 357 1 
1 2 352 3 1 2 358 1 
1 2 353 3 1 2 359 3 
1 2 354 2 1 2 360 1 
  
   
Number of cases read:  120    Number of cases listed:  120 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 1  PM 40 33.3 33.3 33.3 
 2  SSG 40 33.3 33.3 66.7 
 3  SSG+PM 40 33.3 33.3 100.0 
 Total 120 100.0 100.0   
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Randomization list for Kenya 
 
COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
2 3 361 3 2 3 406 2 
2 3 362 1 2 3 407 3 
2 3 363 1 2 3 408 1 
2 3 364 3 2 3 409 2 
2 3 365 2 2 3 410 1 
2 3 366 3 2 3 411 1 
2 3 367 2 2 3 412 3 
2 3 368 1 2 3 413 1 
2 3 369 3 2 3 414 2 
2 3 370 2 2 3 415 2 
2 3 371 1 2 3 416 3 
2 3 372 1 2 3 417 3 
2 3 373 2 2 3 418 2 
2 3 374 2 2 3 419 3 
2 3 375 3 2 3 420 1 
2 3 376 2 2 3 421 1 
2 3 377 3 2 3 422 3 
2 3 378 3 2 3 423 2 
2 3 379 1 2 3 424 3 
2 3 380 2 2 3 425 2 
2 3 381 1 2 3 426 1 
2 3 382 3 2 3 427 1 
2 3 383 1 2 3 428 1 
2 3 384 2 2 3 429 3 
2 3 385 2 2 3 430 2 
2 3 386 3 2 3 431 3 
2 3 387 3 2 3 432 1 
2 3 388 1 2 3 433 2 
2 3 389 2 2 3 434 3 
2 3 390 1 2 3 435 2 
2 3 391 3 2 3 436 3 
2 3 392 3 2 3 437 2 
2 3 393 2 2 3 438 1 
2 3 394 1 2 3 439 2 
2 3 395 1 2 3 440 1 
2 3 396 2 2 3 441 1 
2 3 397 2 2 3 442 3 
2 3 398 3 2 3 443 3 
2 3 399 1 2 3 444 2 
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COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
2 3 400 1 2 3 445 2 
2 3 401 3 2 3 446 3 
2 3 402 3 2 3 447 3 
2 3 403 2 2 3 448 1 
2 3 404 2 2 3 449 2 
2 3 405 1 2 3 450 1 
 
  Number of cases read:  90    Number of cases listed:  90 
  
 Frequency Percent Valid Percent Cumulative Percent 
Valid  PM 30 33.3 33.3 33.3 
SSG 30 33.3 33.3 66.7 
SSG+PM 30 33.3 33.3 100.0 
Total 90 100.0 100.0  
 
Randomization List for Um el Kher - Sudan 
 
COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
3 4 451 3 3 4 505 2 
3 4 452 1 3 4 506 2 
3 4 453 1 3 4 507 2 
3 4 454 3 3 4 508 1 
3 4 455 1 3 4 509 1 
3 4 456 2 3 4 510 3 
3 4 457 3 3 4 511 3 
3 4 458 1 3 4 512 1 
3 4 459 3 3 4 513 3 
3 4 460 1 3 4 514 2 
3 4 461 2 3 4 515 2 
3 4 462 2 3 4 516 1 
3 4 463 3 3 4 517 1 
3 4 464 2 3 4 518 2 
3 4 465 2 3 4 519 1 
3 4 466 3 3 4 520 2 
3 4 467 1 3 4 521 1 
3 4 468 3 3 4 522 3 
3 4 469 2 3 4 523 2 
3 4 470 3 3 4 524 3 
3 4 471 1 3 4 525 3 
3 4 472 2 3 4 526 2 
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COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
3 4 473 1 3 4 527 3 
3 4 474 3 3 4 528 1 
3 4 475 1 3 4 529 3 
3 4 476 1 3 4 530 3 
3 4 477 2 3 4 531 2 
3 4 478 3 3 4 532 3 
3 4 479 2 3 4 533 2 
3 4 480 2 3 4 534 1 
3 4 481 3 3 4 535 1 
3 4 482 3 3 4 536 1 
3 4 483 1 3 4 537 2 
3 4 484 1 3 4 538 1 
3 4 485 3 3 4 539 3 
3 4 486 3 3 4 540 2 
3 4 487 2 3 4 541 1 
3 4 488 2 3 4 542 2 
3 4 489 2 3 4 543 1 
3 4 490 1 3 4 544 1 
3 4 491 1 3 4 545 2 
3 4 492 1 3 4 546 3 
3 4 493 2 3 4 547 3 
3 4 494 3 3 4 548 2 
3 4 495 2 3 4 549 2 
3 4 496 2 3 4 550 3 
3 4 497 1 3 4 551 2 
3 4 498 2 3 4 552 1 
3 4 499 3 3 4 553 1 
3 4 500 1 3 4 554 3 
3 4 501 3 3 4 555 3 
3 4 502 3 3 4 556 2 
3 4 503 1 3 4 557 2 
3 4 504 3 3 4 558 3 
3 4 559 2 3 4 603 2 
3 4 560 1 3 4 604 1 
3 4 561 2 3 4 605 1 
3 4 562 1 3 4 606 1 
3 4 563 1 3 4 607 2 
3 4 564 2 3 4 608 3 
3 4 565 1 3 4 609 1 
3 4 566 3 3 4 610 2 
3 4 567 3 3 4 611 2 
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COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
3 4 568 3 3 4 612 3 
3 4 569 3 3 4 613 1 
3 4 570 1 3 4 614 3 
3 4 571 1 3 4 615 3 
3 4 572 3 3 4 616 2 
3 4 573 1 3 4 617 2 
3 4 574 3 3 4 618 1 
3 4 575 1 3 4 619 1 
3 4 576 2 3 4 620 3 
3 4 577 3 3 4 621 3 
3 4 578 1 3 4 622 2 
3 4 579 2 3 4 623 1 
3 4 580 2 3 4 624 3 
3 4 581 3 3 4 625 2 
3 4 582 2 3 4 626 3 
3 4 583 3 3 4 627 1 
3 4 584 1 3 4 628 2 
3 4 585 2 3 4 629 3 
3 4 586 1 3 4 630 1 
3 4 587 1 3 4 631 3 
3 4 588 2 3 4 632 2 
3 4 589 2 3 4 633 1 
3 4 590 3 3 4 634 3 
3 4 591 3 3 4 635 2 
3 4 592 3 3 4 636 1 
3 4 593 2 3 4 637 2 
3 4 594 2 3 4 638 2 
3 4 595 1 3 4 639 1 
3 4 596 1 3 4 640 2 
3 4 597 2 3 4 641 3 
3 4 598 1 3 4 642 3 
3 4 599 3 3 4 643 1 
3 4 600 3 3 4 644 1 
3 4 601 2 3 4 645 3 
3 4 602 3     
       
    Number of cases read:  195    Number of cases listed:  195 
 
 Frequency Percent Valid Percent Cumulative Percent 
Valid  PM 65 33.3 33.3 33.3 
SSG 65 33.3 33.3 66.7 
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SSG+PM 65 33.3 33.3 100.0 
Total 195 100.0 100.0  
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Randomization list for Kassab – Sudan 
 
COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
3 35 646 1 3 35 701 1 
3 35 647 1 3 35 702 3 
3 35 648 3 3 35 703 2 
3 35 649 3 3 35 704 1 
3 35 650 2 3 35 705 1 
3 35 651 2 3 35 706 1 
3 35 652 1 3 35 707 3 
3 35 653 3 3 35 708 3 
3 35 654 2 3 35 709 2 
3 35 655 3 3 35 710 1 
3 35 656 2 3 35 711 3 
3 35 657 1 3 35 712 1 
3 35 658 3 3 35 713 3 
3 35 659 2 3 35 714 2 
3 35 660 1 3 35 715 2 
3 35 661 3 3 35 716 1 
3 35 662 1 3 35 717 3 
3 35 663 2 3 35 718 2 
3 35 664 3 3 35 719 1 
3 35 665 2 3 35 720 2 
3 35 666 2 3 35 721 2 
3 35 667 3 3 35 722 3 
3 35 668 1 3 35 723 3 
3 35 669 1 3 35 724 3 
3 35 670 2 3 35 725 2 
3 35 671 1 3 35 726 2 
3 35 672 3 3 35 727 1 
3 35 673 2 3 35 728 1 
3 35 674 3 3 35 729 2 
3 35 675 1 3 35 730 2 
3 35 676 1 3 35 731 1 
3 35 677 2 3 35 732 1 
3 35 678 3 3 35 733 1 
3 35 679 2 3 35 734 3 
3 35 680 3 3 35 735 3 
3 35 681 3 3 35 736 3 
3 35 682 1 3 35 737 2 
3 35 683 3 3 35 738 3 
3 35 684 2 3 35 739 2 
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COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
3 35 685 1 3 35 740 3 
3 35 686 1 3 35 741 3 
3 35 687 2 3 35 742 3 
3 35 688 1 3 35 743 1 
3 35 689 3 3 35 744 2 
3 35 690 2 3 35 745 1 
3 35 691 2 3 35 746 1 
3 35 692 1 3 35 747 2 
3 35 693 3 3 35 748 1 
3 35 694 2 3 35 749 2 
3 35 695 2 3 35 750 1 
3 35 696 3 3 35 751 3 
3 35 697 3 3 35 752 3 
3 35 698 3 3 35 753 2 
3 35 699 2 3 35 754 2 
3 35 700 1 3 35 755 1 
3 35 756 2 3 35 812 2 
3 35 757 1 3 35 813 3 
3 35 758 2 3 35 814 3 
3 35 759 1 3 35 815 2 
3 35 760 3 3 35 816 2 
3 35 761 2 3 35 817 1 
3 35 762 3 3 35 818 1 
3 35 763 1 3 35 819 3 
3 35 764 1 3 35 820 1 
3 35 765 3 3 35 821 2 
3 35 766 3 3 35 822 2 
3 35 767 3 3 35 823 1 
3 35 768 1 3 35 824 3 
3 35 769 1 3 35 825 1 
3 35 770 3 3 35 826 3 
3 35 771 2 3 35 827 2 
3 35 772 2 3 35 828 3 
3 35 773 2 3 35 829 2 
3 35 774 1 3 35 830 1 
3 35 775 3 3 35 831 2 
3 35 776 1 3 35 832 1 
3 35 777 2 3 35 833 1 
3 35 778 2 3 35 834 2 
3 35 779 1 3 35 835 3 
3 35 780 3 3 35 836 1 
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COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
3 35 781 1 3 35 837 2 
3 35 782 3 3 35 838 3 
3 35 783 3 3 35 839 2 
3 35 784 1 3 35 840 3 
3 35 785 1 3 35 841 1 
3 35 786 3 3 35 842 2 
3 35 787 1 3 35 843 3 
3 35 788 2 3 35 844 3 
3 35 789 3 3 35 845 2 
3 35 790 2 3 35 846 2 
3 35 791 1 3 35 847 1 
3 35 792 2 3 35 848 3 
3 35 793 2 3 35 849 2 
3 35 794 2 3 35 850 1 
3 35 795 3 3 35 851 1 
3 35 796 1 3 35 852 2 
3 35 797 1 3 35 853 1 
3 35 798 2 3 35 854 3 
3 35 799 3 3 35 855 3 
3 35 800 3 3 35 856 3 
3 35 801 3 3 35 857 3 
3 35 802 1 3 35 858 2 
3 35 803 2 3 35 859 2 
3 35 804 2 3 35 860 2 
3 35 805 2 3 35 861 1 
3 35 806 1 3 35 862 1 
3 35 807 2 3 35 863 1 
3 35 808 1 3 35 864 3 
3 35 809 3 3 35 865 1 
3 35 810 3 3 35 866 2 
3 35 811 3 3 35 867 3 
3 35 868 1 3 35 892 2 
3 35 869 2 3 35 893 3 
3 35 870 3 3 35 894 1 
3 35 871 2 3 35 895 3 
3 35 872 2 3 35 896 1 
3 35 873 1 3 35 897 1 
3 35 874 3 3 35 898 2 
3 35 875 1 3 35 899 3 
3 35 876 1 3 35 900 1 
3 35 877 2 3 35 901 2 
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COUNTRY SITE PATIENT 
NUMBER 
DRUG COUNTRY SITE PATIENT 
NUMBER 
DRUG 
3 35 878 3 3 35 902 2 
3 35 879 1 3 35 903 3 
3 35 880 3 3 35 904 1 
3 35 881 2 3 35 905 3 
3 35 882 1 3 35 906 1 
3 35 883 3 3 35 907 3 
3 35 884 2 3 35 908 3 
3 35 885 3 3 35 909 2 
3 35 886 3 3 35 910 2 
3 35 887 3 3 35 911 1 
3 35 888 2 3 35 912 1 
3 35 889 1 3 35 913 2 
3 35 890 2 3 35 914 3 
3 35 891 2 3 35 915 1 
                
Number of cases read:  270    Number of cases listed:  270 
 Frequency Percent Valid Percent Cumulative Percent 
Valid 1  PM 90 33.3 33.3 33.3 
 2  SSG 90 33.3 33.3 66.7 
 3  SSG+PM 90 33.3 33.3 100.0 
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16.2.7 Audit certificates 
Appendix 12: Clinical Audit  
The following GCP audit were conducted on the Trial Master Files held at KEMRI 
1. Date of audit 27th-29th March 2006 
 
The following GCP audit site audits were conducted  
 
2. KEMRI, Kenya   25th November – 1st December 2006 
3. Kassab, Sudan   5th -10th  March 2007 
4. Arba Minch Ethiopia  8th-12th December 2006 
5. Gondar, Ethiopia    7th – 9th March 2007 
 
Appendix 13: Laboratory Audit  
The following Clinical audit focussing on Laboratory were conducted  
 
6. KEMRI, Kenya   22nd April 2007 
7. Kassab, Sudan   24th – 25th April 2007 
8. Arba Minch Ethiopia  13th – 14th May 2007 
9. Gondar, Ethiopia   9th – 11th May 2007 
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Appendix 14: Parasitology Quality Control 
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LEAP 0104A – Parasitology Quality Control conducted be Tony Moody 
 
Slide Review - UM EL KHER Q1 2005 
 
Slide preparation 
The slides were un-mounted but well labelled with a diamond marker.  
There was some confusion on the labelling as the DAT number was used on the slide and both the 
DAT and Study number was present in the box chart. The statistician required the study number but 
this was easily corrected. The boxes were 100 spaces and the slides were easily identified by their 
position. 
The majority of the slides were well prepared with the aspirate adequately distributed and having good 
cellularity. In most cases the staining with Giemsa stain was excellent and the parasites clearly seen at 
1000x.  
A few slides did not stain well or were poor aspirates and these are indicated in the report.  Some 
dates were obscured 
 
Um El Kher         
 
 LN DIAGNOSTIC      FIRST FOLLOW UP  
No. of slides examined:  90   No. found positive:  6 
No. found positive:   85   No. found negative:  9 
No. found negative:  5 (5.5%)  No. found unreadable:   1 (no cells) 
 
TOC AFTER AMBISONE TREATMENT  TOC AFTER INITIAL TREATMENT   
No of slides examined:  65   No of slides examined:  92 
No found positive:   15    No. found positive:  14 
No found negative:   49    No found negative:  78 
No. unsuitable for examination:   1          No. unsuitable for examination:   0 
 
STUDY FOLLOW UP NEG 
No. of slides examined:  62 
No. found positive:   2   
No. found negative:   60 (1 peripheral blood)  
 
Slide 
number Patient id Date Result Comment 
93 3447G 19/1/05 Neg   
52 4452 6/6/2005 Neg   
87 4452 15/2/05 Neg   
9 4452 19/1/05 Neg   
86 4452 24/1/05 Neg   
95 12564 15/11/04 Neg   
88 17974 5/2/2005 Neg   
94 19256   Neg   
89 20490 5/2/2005 Neg   
38 24777 3/6/2005 Neg   
39 24777 15/12/04 3+   
39 24977 10/1/2005 1+   
8 26876 11/12/2004 1+   
10 26876 9/2/2005 Neg   
8 26876 19/11/04 4+   
9 26876 19/2/05 Neg   
3 26912 9/12/2004 Neg   
3 26912 2/1/2005 3+   
4 26912 7/1/2005 Neg   
62 26912 12/1/2005 1+   
61 26912 17/1/05 Neg   
3 26912 17/11/04 4+   
1 26932 4/12/2004 Neg   
36 26932 3/6/2005 Neg   
1 26932 16/11/04 2+   
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Slide 
number Patient id Date Result Comment 
2 26937 6/12/2004 Neg Also 15/12/04 Neg 
2 26937 6/1/2005 Neg   
2 26937 16/11/04 2+   
4 26964 8/12/2004 Neg   
54 26964 7/6/2005 Neg   
4 26964 18/11/04 4+   
5 26968 10/12/2004 Neg   
6 26968 3/1/2005 Neg   
5 26968 18/11/04 3+   
5 26968 24/12/04 Neg   
6 26969 18/11/04 3+   
6 26969 19/12/04 Neg   
7 26969 20/2/05 1+   
2 26969 25/1/05 3+   
8 26969 25/2/05 Neg   
7 26976 6/12/2004 1+   
7 26976 18/11/04 3+   
9 27013 7/12/2004 Neg   
37 27013 3/6/2005 Neg   
4 27013 7/1/2005 Neg   
9 27013 20/11/04 3+   
11 27059 24/11/04 3+   
11 27059 26/12/04 Neg   
11 27081 17/1/05 Neg   
12 27081 17/1/05 Neg   
10 27081 22/11/04 2+   
19 27081 31/5/05 Neg   
10 27087 15/12/04 Neg   
57 27132 7/6/2005 Neg   
12 27132 25/11/04 4+   
12 27132 25/12/04 Neg   
13 27143 4/12/2004 Neg   
1 27143 16/6/05 1+   
13 27143 27/11/04 1+   
30 27159 2/6/2005 Neg   
14 27159 26/12/04 Neg   
14 27159 27/11/04 2+   
31 27194 3/6/2005 Neg   
15 27194 27/11/04 1+   
15 27194 29/12/04 Neg   
24 27203 1/6/2005 Neg   
14 27203 16/1/05 Neg   
16 27203 17/12/04 Neg   
16 27203 27/11/04 1+   
14 27220 5/2/2005 Neg   
15 27229 1/3/2005 Neg           
16 27229 6/3/2005 NegVPS   
17 27229 20/12/04 Neg   
17 27229 28/11/04 2+   
39 27236 4/6/2005 Neg   
18 27236 28/11/04 1+   
20 27238 9/12/2004 Neg   
9 27238 10/6/2005 Neg   
19 27238 28/11/04 2+   
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Slide 
number Patient id Date Result Comment 
55 27239 7/6/2005 Neg   
18 27239 16/12/04 Neg   
20 27239 29/11/04 3+   
17 27241 3/1/2005 Neg   
21 27241 29/11/04 2+   
22 27269 1/12/2004 2+   
22 27269 3/1/2005 Neg   
11 27269 9/6/2005 Neg   
23 27273 1/12/2004 1+   
19 27273 15/1/05 Neg   
20 27273 23/1/05 Neg   
23 27273 24/12/05 Neg   
26 27301 4/12/2004 5+   
23 27301 3/2/2005 Neg   
5 27301 9/1/2005 3+   
26 27301 26/12/04 4+   
24 27301   Neg   
24 27302 3/12/2004 3+   
25 27302 1/6/2005 Neg   
24 27302 21/12/04 Neg   
25 27330 4/12/2004 6+   
60 27330 8/6/2005 Neg   
21 27330 19/1/05 1+   
25 27330 20/12/04 5+   
22 27330 23/2/05 unsuitable v.poor slide 
67 27330 29/1/05 3+   
21 27341 20/12/04 Neg   
27 27360 6/12/2004 1+   
27 27360 5/1/2005 Neg   
28 27361 6/12/2004 4+   
40 27361 5/6/2005 Neg   
49 27361 7/1/2005 Neg   
28 27361 24/12/04 Neg   
29 27393 8/12/2004 1+   
23 27393 1/6/2005 Neg   
29 27393 7/1/2005 Neg   
32 27405 9/12/2004 2+   
41 27405 5/6/2005 Neg   
32 27405 29/12/05 Neg   
30 27415 8/12/2004 2+   
30 27415 8/1/2005 Neg   
7 27415 13/6/05 Neg   
31 27429 9/12/2004 2+   
34 27429 3/6/2005 Neg   
31 27429 27/12/04 1+   
33 27430 9/12/2004 Neg   
12 27430 10/4/2005 Neg   
33 27430 29/12/04 Neg   
16 27430 31/5/06 Neg   
34 27454 10/12/2004 2+   
25 27454 2/1/2005 Neg   
47 27454 6/6/2005 Neg   
34 27454 17/1/05 Neg   
35 27458 10/12/2004 4+   
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Slide 
number Patient id Date Result Comment 
50 27458 6/6/2005 Neg   
35 27458 30/12/04 Neg   
36 27473 11/12/2004 1+   
58 27473 7/6/2005 Neg   
36 27473 30/12/04 Neg   
37 27482 12/12/2004 2+   
26 27482 1/6/2005 Neg   
37 27482 12/1/2005 Neg   
3 27498 7/2/2005 Neg   
53 27498 7/6/2005 Neg   
38 27498 13/1/05 Neg   
38 27498 13/12/04 5+   
66 27516 27/1/05 Neg   
40 27543 6/1/2005 Neg   
3 27543 15/6/05 Neg   
40 27543 16/12/04 4+   
11 27548 2/11/2004 Neg   
29 27548 2/6/2005 Neg (peripheral blood) 
42 27548 9/1/2005 Neg   
42 27548 16/12/04 1+   
28 27555 3/1/2005 Neg   
27 27555 5/2/2005 Neg   
41 27555 7/1/2005 Neg   
41 27555 16/12/04 3+   
44 27561 17/12/04 1+   
46 27564 6/6/2005 Neg   
15 27564 12/4/2005 Neg   
43 27564 17/12/04 5+   
1 27564 19/5/05 Neg Peripheral blood 
44 27567 3/1/2005 Neg   
32 27567 3/6/2005 Neg   
65 27584 5/1/2005 1+   
27 27586 2/6/2005 Neg   
45 27586 12/1/2005 Neg   
45 27586 17/12/04 1+   
28 27601 2/6/2005 Neg   
46 27601 18/1/05 Neg   
46 27602 18/12/04 2+   
29 27612 9/3/2005 Neg   
10 27612 11/7/2005 Neg   
30 27612 13/3/05 Neg   
47 27612 20/12/04 Neg   
59 27645 7/6/2005 Neg   
50 27645 12/1/2005 Neg   
50 27645 20/12/04 1+   
49 27654 6/6/2005 Neg   
48 27654 20/12/04 2+   
48 27654 21/1/05 Neg   
51 27655 6/6/2005 Neg   
49 27655 20/12/04 2+   
51 27662 8/1/2005 Neg   
61 27662 8/6/2005 Neg   
51 27662 21/12/04 5+   
62 27687 8/6/2005 Neg   
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Slide 
number Patient id Date Result Comment 
52 27687 9/1/2005 Neg   
52 27687 22/12/04 Neg   
31 27716 9/2/2005 Neg   
32 27716 14/2/05 Neg   
53 27716 15/1/05 Neg   
53 27716 24/12/04 Neg   
33 27756 6/2/2005 2+   
68 27756 11/2/2005 Neg   
54 27756 13/1/05 2+   
34 27756 16/2/05 Neg   
54 27756 26/12/04 3+   
22 27768 1/6/2005 Neg   
55 27768 27/1/05 Neg   
55 27768 27/12/04 4+   
57 27770 29/12/04 5+   
57 27770 31/1/05 1+   
14 27770 31/5/05 Neg   
56 27786 30/1/05 Neg   
56 27786 30/12/04 1+   
36 27790 8/2/2005 Neg   
35 27790 14/2/05 Neg   
58 27790 21/1/05 Neg   
58 27790 31/12/04 2+   
69 27795 16/2/05 Neg   
37 27795 21/2/05 Neg   
59 27795 23/1/05 2+   
38 27795 26/2/05 Neg   
59 27795 31/12/04 4+   
6 27797 13/6/05 Neg   
60 27797 18/1/05 Neg   
60 27797 31/12/04 2+   
61 27808 1/1/2005 2+   
10 27808 10/6/2005 Neg   
61 27808 18/1/05 Neg   
62 27817 1/1/2005 4+   
39 27817 17/2/05 Neg   
40 27817 22/1/05 1+   
62 27817 23/1/05 4+   
63 27828 2/1/2005 6+   
63 27828 20/1/05 Neg   
16 27828 28/2/05 1+   
17 27828 31/5/06 Neg   
64 27835 3/1/2005 1+   
56 27835 7/6/2005 Neg   
91 27835 11/1/2005 Neg   
64 27835 3/2/05 ? Neg   
66 27842 5/1/2005 Neg   
48 27842 6/6/2005 Neg   
96 27849 5/2/2005 Neg   
65 27854 4/2/2005 Neg   
6 27854 13/5/05 Neg   
67 27871 6/1/2005 4+   
42 27877 1/3/2005 1+   
41 27877 21/2/05 1+   
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Slide 
number Patient id Date Result Comment 
92 27877 26/12/04 Neg   
97 27878 27/1/05 3+   
35 27881 3/6/2005 Neg   
68 27881 6/1/2005 4+   
68 27881 8/2/2005 Neg   
7 27884 2/4/2005 1+ Degenerate  parasites 
43 27884 2/5/2005 Neg   
69 27884 6/1/2005 1+   
71 27884 8/5/2005 Neg   
8 27884 22/3 /05      1+ Degenerate parasites 
44 27884 25/3/05 1+   
70 27884 27/4/05 Neg   
69 27884 28/1/05 Neg   
67 27887 27/1/05 4+   
42 27935 5/6/2005 Neg   
70 27935 10/1/2005 1+   
70 27935 10/2/2005 Neg   
71 27962 1/2/2005 Neg   
46 27962 3/3/2005 Neg   
71 27962 10/1/2005 1+   
45 27962 26/2/05 Neg   
72 27969 11/1/2005 1+   
98 27969 11/1/2005 2+   
72 27969 28/1/05 Neg   
44 27973 5/6/2005 Neg   
74 27973 12/1/2005 2+   
74 27973 30/1/05 Neg   
21 27983 1/6/2005 Neg   
73 27983 12/1/2005 2+   
73 27983 13/2/05 Neg   
13 27994 9/6/2005 Neg   
75 27994 12/1/2005 1+   
75 27994 30/1/05 Neg   
90 27997 5/2/2005 Neg   
2 28007 4/6/2005 1+   
76 28007 13/1/05 2+   
48 28007 13/7/05 Neg   
77 28013 1/2/2005 Neg   
77 28013 14/1/05 1+   
20 28013 31/5/05 Neg   
49 28041 4/4/2005 Neg   
79 28041 7/2/2005 3+   
50 28041 9/4/2005 Neg   
78 28041 14/1/05 3+   
80 28049 4/2/2005 Neg   
5 28049 14/6/05 Neg   
79 28049 15/1/05 3+   
52 28059 6/3/2005 Neg   
81 28059 20/1/05 2+   
82 28059 20/2/05 1+   
51 28059 21/3/05 Neg   
33 28061 3/6/2005 Neg   
82 28061 20/1/05 4+   
81 28062 6/2/2005 2+   
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4 28062 14/6/05 Neg   
80 28062 19/1/05 4+   
53 28074 11/3/2005 Neg   
54 28074 3-Jun Neg   
85 28074 15/2/05 2+ 28074 14/2/05 3+ 
84 28074 23/1/05 2+   
12 28080 9/6/2005 Neg   
83 28080 22/1/05 1+   
84 28080 22/2/05 Neg   
86 28087 14/2/05 Neg   
56 28087 18/4/05 Neg   
85 28087 23/1/05 2+   
72 28087 23/4/05 Neg   
13 28087 24/3/05 Unsuitable No cells 
55 28087 Missing     
43 28090 5/6/2005 Neg   
90 28090 12/2/2005 Neg   
89 28090 25/1/05 1+   
87 28100 24/1/05 1+   
88 28100 24/2/05 ? 1+   
15 28100 31/5/05 Neg   
59 28105 12/3/2005 1+   
89 28105 16/2/05 3+   
58 28105 17/3/05 2+   
57 28105 22/3/05 2+   
88 28105 24/1/05 3+   
90 28119 26/1/05 2+   
91 28119 26/2/05 Neg   
18 28119 31/5/05 Neg   
66 26876     (1)   5/1/2005 2+   
65 26876    (2)    10/2/05 Neg   
64 26876    (3)   2/2/2005 Neg   
45 27360/1 5/6/2005 Neg (slide labeled 27360) 
8 27786 
(27772) 
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KASSAB-SUDAN – Q1 2005 
INITIAL DIAGNOSTIC SLIDES      TOC SLIDES   
No. of initial slides:    56   No. of TOC slides:  51 
No. found positive:   54   No. found positive:    8 
No. found negative:  2    No. found negative:  42 





Number Date Result  Comment 
1 1001 ln 26/1/05 1+ Parasites lysed 
2 1001 ln toc 17/2/05 Neg   
3 1001 ln fu 6/7/2005 Neg ?lysed cytoplasm 
4 1001 bm fu 6/7/2005 3+ ?lysed cytoplasm 
5 1003 27/1/05 2+   
6 1003 toc 19/2/05 Neg   
7 1004 27/1/05 4+   
8 1004 toc 16/2/05 Neg   
9 1005 29/1/05 4+   
10 1005 toc No date 2+   
11 1006 28/1/05 1+   
12 1006 toc 1/3/2005 Neg   
13 1007 28/1/05 1+   
14 1007 toc 1/3/2005 Neg   
15 1008 30/1/05 3+   
16 1008 toc 22/2/05 neg Poor slide 
17 1009 1/2/2005 5+   
18 1009 toc 19/2/05 Neg   
19 1010     missing 
20 1011 bm 1/2/2005 2+   
21 1011 bm toc 5/3/2005 Neg   
22 1012       missing 
23 1013       missing 
24 1014 1/2/2005 1+   
25 1014 toc 18/2/05 Neg   
26 1015 5/2/2005 1+   
27 1015 toc 3/3/2005 Neg   
28 1016       missing 
29 1017 1/2/2005 1+   
30 1017 toc 5/3/2005 Neg   
31 1018       missing 
32 1019       missing 
33 1020       missing 
34 1021       missing 
35 1022       missing 
36 1023       missing 
37 1024       missing 
38 1025 bm 7/2/2005 Neg   
39 1025 bm toc 1/3/2005 Neg   
40 1026       missing 
41 1027 6/2/2005 1+   
42 1027 toc 25/2/05 Neg   
43 1028       missing 
44 1029 7/2/2005 3+   
45 1029 toc 10/3/2005   Unreadable 
46 1030       missing 
47 1031       missing 
48 1032 8/2/2005 4+   
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Number Date Result  Comment 
49 1032 toc 30/3/05 2+ Degenerated 
50 1033     missing 
51 1034     missing 
52 1035     missing 
53 1036     missing 
54 1037     missing 
55 1038 14/2/05 3+   
56 1038 toc 15/3/05 Neg   
57 1039     missing 
58 1040     missing 
59 1041 ln 19/2/05 5+   
60 1041 ln toc 12/3/2005 4+   
61 1041 bm No date 4+   
62 1041 bm toc 14/3/05 2+   
63 1042 No date 4+   
64 1042 toc No date Neg   
65 1042  bm No date 3+   
66 1043 bm No date 2+   
67 1043 bm toc No date Neg   
68 1044 21/2/05 1+   
69 1044 toc 26/3/05 Neg   
70 1045     missing 
71 1046 24/2/05 3+   
72 1046 toc 28/3/05 Neg   
73 1047     missing 
74 1048     missing 
75 1049     missing 
76 1050     missing 
77 1051 No date 3+   
78 1051 No date 1+ Poor slide 
79 1051 toc 17/3/05 Neg   
80 1052 No date 1+   
81 1052 No date Neg   
82 1052 toc No date Neg   
83 1053 No date 4+   
84 1053 No date 5+   
85 1053 bm toc No date Neg   
86 1053 ln toc No date 4+   
87 1054 No date   missing 
88 1055 No date 3+   
89 1055 toc No date Neg   
90 1056 No date   missing 
91 1057 No date   missing 
92 1058 No date 4+   
93 1058 ln toc No date 5+ Some degenerate 
94 1058 bm toc No date 3+   
95 1059 No date   missing 
96 1060 9/3/2005 1+   
97 1060 toc 28/3/05 Neg   
98 1061 No date   missing 
99 1062 No date   missing 
100 1063 No date 4+   
101 1063 toc No date Neg   
102 1064 No date 3+   
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Number Date Result  Comment 
103 1064 toc No date Neg   
104 1065 No date   missing 
105 1066 No date   missing 
106 1067 No date   missing 
107 1068 No date 4+   
108 1068 toc No date ? 1+   
109 1069 No date   missing 
110 1070 No date 1+   
111 1070 toc No date Neg   
112 1071m No date   missing 
113 1072 No date 1+   
114 1072 toc No date Neg   
115 1073m No date   missing 
116 1074 No date 2+   
117 1074 toc No date Neg   
118 1075 No date 2+   
119 1075 toc No date Neg   
120 1076 No date 2+   
121 1076 toc No date Neg   
123 1077 No date 2+   
124 1077 toc No date Neg   
125 1078 No date  1+ Very poor slide 
126 1078 toc No date Neg   
127 1079     missing 
128 1079     missing 
129 1080 No date 1+   
130 1080 toc No date Neg   
131 1081 No date   missing 
132 1082 No date   missing 
133 1083 No date   missing 
134 1084 No date   missing 
135 1085 No date   missing 
136 1086 No date   missing 
137 1087 No date   missing 
138 1088 bm No date Neg   
139 1088 bm No date Neg   
140 1089 No date   missing 
141 1090 No date   missing 
142 1091 No date   missing 
143 1092 6/4/2005 4+   
144 1092 toc No date Neg   
145 1093 No date   missing 
146 1094 No date 1+   
147 1094 toc No date Neg   
148 1095 No date   missing 
149 1096 bm No date 3+   
150 1096 bm No date Neg   
151 1097 No date 1+   
152 1097 No date Neg   
153 1098 No date   missing 
154 1099 No date   missing 
155 1100 bm No date 3+   
156 1100 bm toc No date Neg   
157 1100 ln No date 1+ Very scanty 
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Number Date Result  Comment 
158 1100 ln toc No date Neg   
159 1101 No date   missing 
160 1102 ln No date 3+   
161 1102 bm 14/4/05 2+   
162 1102 bm toc No date Neg   
163 1102 ln toc No date Neg   
164 11073 bm No date Neg   
165 11073 ln No date Neg   
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Study Slides for Leishmania from KEMRI 
Examined by A Moody October 2005 
 
General comment: many slides had very poor staining with little red stain or differentiation, water 
bubbles in the mounting media was considerable and obscured the field. 13 Diagnostic slides and 20 
TOC slides were poorly or very poorly stained or presented 
 
Initial diagnostic slides      TOC slides   
No. of initial slides  45     No. of TOC slides  45 
No. found positive   43    No. found positive    1 
No. found negative   1    No. found negative   39    











Day Microscopic Comment 
1 2408 1 17.01.05 D 4+ Very poor stain 
2 2408 1 06.02.05 TOC Negative Very poor stain 
3 2410 2 17.01.05 D 4+  
4 2410 2 10.02.05 TOC Negative Very poor stain 
5 2411 3 17.01.05 D 4+  
6 2411 3 10.02.05 TOC Unreadable Very poor stain 
7 2412 4 17.01.05 D 5+  
8 2412 4 06.02.05 TOC Negative  
9 2413 5 17.01.05 D 4+  
10 2413 5 19.02.05 TOC Negative  
11 2414 6 27.01.05 D 6+  
12 2414 6 21.02.05 TOC Negative Very poor stain 
13 2415 7 27.01.05 D 3+  
14 2415 7 18.02.05 TOC Negative  
15 2416 8 27.01.05 D 4+  
16 2416 8 03.03.05 TOC Negative Very poor stain 
17 2417 9 27.01.05 D 4+  
18 2417 9 22.02.05 TOC Negative  
19 2418 10 27.01.05 D 4+  
20 2418 10 06.03.05 TOC Negative  
21 2419 11 03.02.05 D 1+ Very poor stain 
22 2419 11 25.02.05 TOC Negative  
23 2422 12 10.02.05 D 3+ poor stain 
24 2422 12 04.03.05 TOC Negative  
25 2423 13 16.02.05 D 3+ poor stain 
26 2423 13 20.03.05 TOC Negative  
27 2424 14 17.02.05 D 4+  
28 2424 14 26.03.05 TOC Negative  
29 2449 28 14.04.05 D Negative  
30 2449 28 10.05.05 TOC Negative  
31 2428 15 23.02.05 D ?2+ Very poor stain 
32 2428 15 14.03.05 TOC Negative  
33 2429 19 23.02.05 D 5+ Very poor stain 
34 2429 19 31.03.05 TOC Negative poor stain 
35 2430 16 25.02.05 D 4+  
36 2430 16 31.03.05 TOC Negative  
37 2433 20 08.03.05 D 4+ Very poor stain 
38 2433 20 14.04.05 TOC Negative Very poor stain 
39 2434 17 08.03.05 D 3+  
40 2434 17 23.03.05 TOC Negative  
41 2435 21 08.03.05 D 1+ Very poor stain 
42 2435 21 05.04.05 TOC Negative Very poor stain 
43 2436 18 08.03.05 D 5+  
44 2436 18 26.03.06 TOC Negative Very poor stain 
45 2438 22 17.03.05 D 4+ Very poor stain 
46 2438 22 04.04.05 TOC Negative Very poor stain 
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Day Microscopic Comment 
47 2440 24 24.03.05 D 3+ poor stain 
48 2440 24 05.05.05 TOC Negative  
49 2441 23 24.03.05 D 4+ Very poor stain 
50 2441 23 26.04.05 TOC Negative Very poor stain 
51 2442 25 31.03.05 D 3+  
52 2442 25 17.05.05 TOC Unreadable  
53 2446 26 14.04.05 D 4+  
54 2446 26 02.05.05 TOC Negative  
55 2447 27 14.04.05 D 4+  
56 2447 27 06.05.05 TOC Negative  
57 2448 34 14.04.05 D 2+  
58 2448 34 17.05.05 TOC Negative Very poor stain 
59 2450 29 14.04.05 D 4+  
60 2450 29 20.05.05 TOC Negative Lymphocytes ++ 
61 2451 30 14.04.05 D 2+  
62 2451 30 11.05.05 TOC Negative Plasma cells +, 
lymphocytes ++ 
63 2453 31 20.04.05 D 1+ Plasma cells +, 
lymphocytes ++ 
64 2453 31 09.05.05 TOC Negative  
65 2454 32 20.04.05 D 4+  
66 2454 32 05.05.05 TOC Negative Very poor stain 
67 2455 33 20.04.05 D 3+  
68 2455 33 23.05.05 TOC Negative  
69 2456 35 11.05.05 D 4+  
70 2456 35 12.06.05 TOC 1+  
71 2457 36 11.05.05 D 5+  
72 2457 36 12.06.05 TOC Negative Very poor stain 
73 2458 37 13.05.05 D 3+  
74 2458 37 24.06.05 TOC Negative Very poor stain 
75 2461 40 13.05.05 D 3+ Very poor stain 
76 2461 40 24.06.05 TOC Negative poor stain 
77 2462 39 13.05.05 D Unreadable  
78 2462 39 08.06.05 TOC Unreadable  
79 2465 45 01.06,05 D 3+  
80 2465 45 01.07.05 TOC Negative Very poor stain 
81 2466 41 01.06.05 D 4+  
82 2466 41 20.06.05 TOC Unreadable Very poor stain 
83 2467 42 01.06.05 D 6+  
84 2467 42 20.06.05 TOC Unreadable Very poor stain 
85 2468 43 01.06.05 D 5+  
86 2468 43 04.07.05 TOC Negative  
87 2469 44 01.06.05 D 3+  
88 2469 44 04.07.05 TOC Negative  
89 2459 38 13.05.05 D 4+ Very poor stain 
90 2459 38 04.06.05 TOC Negative Very poor stain 
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Review of slides from Gondar site 13th- 17th Feb 2006 
 
Initial diagnostic slides     TOC slides 
No. of initial slides:   45    No. of TOC slides: 45 
No. found positive: 9    No. found positive: 0      
No. found negative: 25 (many inadequate)  No. found negative: 29   (many inadequate)  
 No. found unreadable:  11     No. found unreadable:   16   
 
Problems associated with set of slides from Gondar: 
 Cover slips applied prior to staining leaving tiny viewable area 
 Poor staining  or over differentiation of stain, inadequate material on some 
 ? Wrights’ stain used instead of Giemsa 
 Most slides that were readable had adequate suitable material 
 All Day 0 slides that were negative were reviewed twice 
 Frosted slides obscured diamond labelling, lab number on slides were visible but no date or 
indication of day taken was available 
 
General comment 
This centred mostly on ability to provide adequate information to the statisticians to collate the given 
information from the slide reports with the patient Data forms. 
Suggested conformity of slide labelling was the most useful approach. 
Training of laboratory staff is also an important future consideration and will be a necessary part of the 
future programme. 
 
Follow up visit to Gondar hospital 13-17th February 2006 
1. During the visit I initially met and toured the laboratories and familiarised myself with the 
capabilities and conditions of the hospital laboratories and technicians. The staff  are very 
friendly and Yegnesew has been able to establish his section in an area of the blood bank. 
This has sufficient space and light to make an adequate laboratory facility for the project. 
2. I was introduced to Dr Zewdu and to Tegist the study nurse, they were very welcoming and 
showed me the ward facility. 
3. Yegnesew and I then worked together to re-plan the laboratory space to accommodate a 
staining bench which was accomplished. Obtaining Giemsa stain, calibrating water pH and 
stain dilutions and organising stain troughs now means that patient slides can now be 
prepared, stained and examined in one area.  
4. Investigation into possible problems with mounting media for the slides was conducted. 
Polystyrene mounting media prepared and Canada Balsam obtained from the Histopathology 
laboratory. 
Neither had a deleterious effect on the stained slides up to the time I left and so the possible 
mounting media effect on the preparation of the earlier set of slides can be discounted. The 
problem still remains a mystery. 
5. Three 6 month follow up patients attended during my visit and were a test for the new set up 
which worked well. Both Yegnesew and Dr Zewdu were able to stain and spend time 
searching spleen and bone marrow aspirate slides. 
6. The Biochemical tests that were being performed were well done and I was particularly 
pleased to hear about a quality control sample obtained from Addis had been used for 
calibration/QC and was well within the expected limits for the tests performed. I recommended 
that a QC sample with results outside the normal range be obtained next to further stretch the 
QC system. 
7. I attended a meeting with the Hospital Director, senior doctors and the project manager to 
meet with and discuss how we could help the Pathologist but unfortunately he did not attend 
the meeting. Subsequent decisions on this matter can be seen in the Project managers report. 
I left Gondar with high hopes that there is now an efficient team in place who will be able to produce 
good slide data and who are capable of knowing when to contact Asrat for help if needed. 
 
 
ID Day Microscopy comment ID Day Microscopy comment 
001 Day 0 Negative Main body unstained, 
tiny edge only viewable
024 19/8/05 Unsuitable for 
searching 
No stain differentiation
001 Day 22 Unsuitable for 
searching 
Not stained 024 10/9/05 Negative  
002 Day 0 Unsuitable for 
searching 
Not stained 025 18/8/05 3+ Tiny edge area only, 
main slide unstained 
002 Day 28 Unsuitable for Not stained 025 19/9/05 Negative  
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ID Day Microscopy comment ID Day Microscopy comment 
searching 
003 No day 3+ Tiny end only 
P malariae present 
026 3/8/05 Unsuitable for 
searching 
unstained 
003 No day Negative Tiny end only 
P malariae present 
026 7/9/05 Unsuitable for 
searching 
unstained 
004 No day Negative Very poor slide 027 16/9/05 5+ 
 
Very small area on 
edge, rest unstained 
cover slipped 
004 No day Negative  027 No date Unsuitable for 
searching 
unstained 
005 No day Negative Very poor slide 
P falciparum 
028 Day 0 Unsuitable for 
searching 
VPS 
005 No day Negative Very poor slide 
P falciparum 
028 Day 18 Negative  
006 No day Negative  029 Day 0 1+  
006 No day Negative  029 Day 22 Negative  
007 No day Negative Tiny edge only viewable
P falciparum 
030 20/9/05 Unsuitable for 
searching 
 
007 2/7/05 Negative  030 13/10/0
5 
Negative  
008 No day Negative  031 Day 0 Negative  
008 1/7/05 Negative  031 Day 31 Negative P falciparum 
009 1/7/05 Negative Very poor slide 
P malariae 
032 Day 0 Unsuitable for 
searching 
Very poor stain 
009 No date Negative  032 Day18 Negative  
010 1/9/05 Negative Very poor slide 
P malariae 
033 No date VPS Unsuitable 
for searching 
 
010 No date Unsuitable for 
searching 
 033 No slide   
011 6/7/05 Negative Very poor slide 
Main body unstained, 
tiny edge only viewable
P malariae, Pigment ++
034 Day 0 4+  
011 Day 18 Negative  034 Day 22 Negative P falciparum 
012 1/7/05 Negative Malaria+ 035 Day 0 3+  
012 25/7/05 Negative Malaria Pf 035 Day 22 Negative  
013 Day 0 Negative  036 Day 0 1+  
013 10/8/05 Unsuitable for 
searching 
Small amount material, 
very poor stain 
036 Day 21 Negative  
014 Day 0 Negative Small edge only 
viewable 
037 No date Peripheral blood 
Negative 
P falciparum 
014 No date Unsuitable for 
searching 
Pink stain??  037 No slide   
015 11/7/05 Negative Unstained  
Very small area 
viewable 
038 No date Peripheral blood 
Negative 
 
015 No date Unsuitable for 
searching 
Unstained 038 No slide  
 
 
016 8/7/05 Negative Unstained  
Very small area 
viewable 
039 Day 0 Negative 
 
 
016 1/8/05 Negative  039 Day 22 Negative  
017 Day 0 Negative Edge only 040 Day 0 2+  
017 Day 18 Unsuitable for 
searching 
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AT 46 3+ 0 ND 0 3+ 0 ND 0 
TA 47 4+ 0 ND  4+ 0 ND  
TG 48 4+ 0 ND 0 4+ 0 ND 0 
WM 49 1+ 0 ND 0 1+ 0 ND 0 
DG 50 3+ 2+ 0 0 3+ 2+ 0 0 
OY 51 3+ 0 ND 0 3+ 0 ND 0 
WA 52 3+ 0 0  3+ 0 0  
AW 53 5+ 0 ND 0 5+ 0 ND 0 
DM 54 6+ 5+ 5+ 5+ 6+ 5+ 5+ 5+ 
GS 55 2+ 1+ ND 0 2+ 1+ ND 0 
MG 56 6+ 0 0 0 6+ 0 0 0 
KW 57 4+ 0 0 0 4+ 0 0 0 
AA 58 4+ 0 ND 0 4+ 0 ND 0 
SM 59 4+ 0 ND 0 4+ 0 ND 0 
DS 60 3+ 0 0 0 3+ 0 0 0 
ET 61 2+ 0 ND 0 2+ 0 ND 0 
AM 62 2+ 0 ND 0 2+ 0 ND 0 
GG 63 6+ 2+ 0 0 6+ 2+ 0 0 
GA 64 2+ 0 ND 0 2+ 0 ND 0 
FM 65 2+ 0 ND  2+ 0 ND  
MB 66 3+ 0 ND 0 3+ 0 ND 0 
NB. Eos 
++ 
ME 67 4+ 0 ND 0 4+ 0 ND 0 
EB 68 4+ 0 0 0 4+ 0 0 0 
TF 69 1+ 0 0 0 1+ 0 0 0 
AG 70 4+ 0 ND 0 4+ 0 ND 0 
GT 71 6+ 5+ 5+  6+ 5+ 5+  
AT 72 6+ ND ND 0 6+ ND ND 0 
GT 73 1+ 0 0  1+ 0 0  
AY 74 2+ 0 ND 0 2+ 0 ND 0 
AS 75 6+ 3+ 3+  6+ 3+ 3+  
YA 76 2+ 0 ND 0 2+ 0 ND 0 
AS 77 3+ 0 0 0 3+ 0 0 0 
AG 78 2+ 0 0 0 2+ 0 0 0 
AT 79 4+ 0 0  4+ 0 0  
FA 80 4+ 0 ND  4+ 0 ND  
AM 81 6+ 0 0 0 6+ 0 0 0 
AY 82 3+ 0 ND 0 3+ 0 ND 0 
SA 83 5+ 0 ND 0 5+ 0 ND 0 
GA 84 4+ 0 ND 0 4+ 0 ND 0 
BT 85 5+ 0 ND  5+ 0 ND  
DY 86 3+ 0 ND 0 3+ 0 ND 0 
AT 87 2+ 0 ND 0 2+ 0 ND 0 
AG 88 1+ 0 ND 0 1+ 0 ND 0 
SD 89 2+ 0 0  2+ 0 0  
HT 90 2+ 0 ND  3+ 0 ND  
 
Code: ND = Not done 
 
Reviewers comment: Slides were prepared and stained to a high quality and the results were excellent 
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Report of visit by Tony Moody as external reviewer to Arba Minch Leishmania Treatment and 
Research Centre 8-13th April 2006  
 
Purpose of visit:  
This visit was made on behalf of DNDi to to review the laboratory performance of this centre and 
provide audit of patient slides currently available that had not previously been seen by the external 
reviewer.  
 
ArbaMinch Leishmania treatment and Research Department is a recently opened facility dedicated to 
the treatment and care of patients from surrounding villages suffering with Visceral Leishmaniasis. I 
had the pleasure of spending two days at this centre and was warmly welcomed and offered full co-
operation during my visit. 
 
Dr Samson Tesfaye the responsible physician for this unit and Negussu Abebe the laboratory 
BioMedical Scientist provided all the facilities and information I needed and also organised the other 
laboratory staff and some of the Medical staff to attend some lectures I was able to give in addition. 
 
The laboratory. 
The laboratory is well designed for its purpose but as yet is still incomplete. There are no working sink 
drains which means the patient slides are still stained in the main hospital laboratory and all 
haematological and Biochemical tests are still performed in the hospital laboratory (see comments on 
hospital laboratory). The space and patient base does mean that both patient sample examination and 
potential research opportunities will eventually be performed in the unit. 
There are other laboratory personnel involved in the project who provide help and cover for Negussu 




Together with Negussu I examined all 33 archived positive slides and 30% of the 52 negative slides. 
The slides were a mixture of splenic aspirates, bone marrow aspirates and one LN aspirate. 
Preparation and staining by Giemsa stain was excellent and apart from very few slight adjustments 
from 3+ to 4+ or 4+ to 3+ there was complete correlation and agreement on the readings (results 
attached). Negussu had a very efficient and satisfactory system of slide labelling and archiving and his 
record keeping was very satisfactory. 
I have no adverse comments to make about the laboratory work and look forward to its further 
development as equipment becomes available. 
 
Hospital main Laboratory   
Dr Samson had arranged for me to visit the main hospital laboratory and I was shown round by the 
Senior BioMedical Scientist. 
The laboratory is not large and does not have a medical consultant. There is a limited amount of 
automation for the haematology and Clinical Chemistry sections but no Microbiology beyond basic 
staining for TB and gram stain is available. A limited blood bank is present using tile grouping and 
xmatching. Parasitology is basic and limited but potential is enormous given the presence of endemic 
malaria and HIV. 
 
The Biochemisry available to the Leishmania unit is adequate using an automated system with a good 
backup facility. Quality control is performed with preci-normal sera but a range of abnormal sera would 
enhance this. There did not seem to be QC available for any of the haematology parameters. 
The laboratory is a busy department and the visit was interesting and again emphasis the need for 
additional training opportunities for staff. 
 
Summary 
The laboratory department of the Leishmaniasis unit is functioning efficiently and the standard of work 
is satisfactory. There is great potential for further interesting development within the laboratory once 
the deficient structural work is completed and the involvement of Negussu and his colleagues in this 
work will be a rewarding stimulus. 
I thank Dr Samson for his hospitality and care which helped to make my visit successful. 
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Collection Date Result 
8 4018 Day 0 22-10-05 4 
24 4018 Day 18 06-03-98 E.C NO LD SEEN 
12 4018 3 month 3/3/2006 NO LD SEEN 
3 4019 Day 0 25-10-05 4 
22 4019 Day 31 16-03-98 E.C NO LD SEEN 
2 4362 Day 0 28-10-05 5 
23 4362 Day 18 16-11-05 NO LD SEEN 
29 4364 Day 31 29-111-05 NO LD SEEN 
5 4364 Day 0 28-10-05 3 
28 4365 Day 31 29-11-05 NO LD SEEN 
6 4365 Day 0 28-10-05 2 
21 4366 Day 0 28-10-05 NO LD SEEN 
20 4367 Day 0 28-10-05 NO LD SEEN 
7 4433 Day 0 28-10-05 3 
26 4433 Day 18 16-11-05 NO LD SEEN 
32 4615 Day 31 31-11-05 NO LD SEEN 
10 4615 Day 0 31-10-05 3 
19 4616 Day 0 31-10-05 NO LD SEEN 
9 5752 Day 0 14-11-05 4 
25 5752 Day 18 05-12-98 E.C NO LD SEEN 
41 5753 Day 31 18-12-05 NO LD SEEN 
13 5753 Day 0 14-11-05 3 
29 7282 Day 0 21-03-98 3 
34 7282 Day 31 15-01-06 NO LD SEEN 
31 7283 Day 0   NO LD SEEN 
27 7284 Day 0   NO LD SEEN 
30 7285 Day 0   NO LD SEEN 
21 9265 Day 0 28 -12-05 4 
36 9265 Day 18 20-01-06 NO LD SEEN 
12 9266 Day 0 29-12-05 5 
33 9267 Day 0 29-11-05 NO LD SEEN 
11 9268 Day 0 29-12-05 5 
37 9268 Day 22 22-01-06 NO LD SEEN 
14 9270 Day 0 28-12-05 2 
38 9270 Day 22 22-01-06 NO LD SEEN 
16 9271 Day 0 28-12-05 2 
40 9271 Day 22 22-01-06 NO LD SEEN 
49 9272 Day 0   NO LD SEEN 
35 9282 Day 0 28-12-05 NO LD SEEN 
9 11065 Day 31 25-02-06 NO LD SEEN 
22 11065 Day 0 23-01-06 3 
39 11067 Day 0 23-01-06 NO LD SEEN 
17 13340* Day 0 11/2/2006 4 
15 13141 Day 0 11/2/2006 4 
3 13141 Day 18 4/3/2006 NO LD SEEN 
5 13142 Day  0 11/2/2006 NO LD SEEN 
6 13338 Day  0 11/2/2006 NO LD SEEN 
7 13339 Day  0 11/2/2006 NO LD SEEN 
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Collection Date Result 
19 13341 Day 0 9/2/2006 4 
2 13341 Day  22 8/3/2006 NO LD SEEN 
46 13342 Day 31 17-03-06 NO LD SEEN 
18 13342 Day 0 11/2/2006 4 
8 13343 Day  0 11/2/2006 NO LD SEEN 
4 13378 Day 0 11/2/2006 NO LD SEEN 
20 15151 Day 0 8/3/2006 3 
48 15151 Day 22 3/4/2006 NO LD SEEN 
1 15152 Day  0 8/3/2006 NO LD SEEN 
44 15153 Day 0 8/3/2006 NO LD SEEN 
18 15301 Day 0 31-10-05 NO LD SEEN 
24 15793 Day 0 15-03-06 5 
45 15793 Day 18 3/4/2006 NO LD SEEN 
26 15794 Day 0 15-03-06 6 
43 15794 Day 18 3/4/2006 NO LD SEEN 
27 16355 Day 0 23-03-06 5 
25 16681 Day 0 3/4/2006 4 
23 16814 Day 0 3/4/2006 3 
52 17419 Day 0 7/4/2006 NO LD SEEN 
51 17422 Day 0 7/4/2006 NO LD SEEN 
33 17423 Day 0 7/4/2006 4 
31 17425 Day 0 7/4/2006 3 
32 17426 Day 0 7/4/2006 4 
11 24641 6 month 11/2/2006 NO LD SEEN 
42 24642 6 month 5/4/2006 NO LD SEEN 
47 24646 3 month 26-10-05 NO LD SEEN 
10 24646 6 month 11/2/2006 NO LD SEEN 
4 27952 3 month 16-11-05 5 
1 29636 Day  31 19-11-97 E.C 4 
50 29636 6 month 3/1/2006 NO LD SEEN 
30 29636 Day 0 2/8/2005 5 
17 29944 Day 0 28-09-05 NO LD SEEN 
14 29945 Day 0 28-09-05 NO LD SEEN 
13 33376 Day 0 28-09-05 NO LD SEEN 
16 33378 Day 0 28-09-05 NO LD SEEN 
28 33380 Day 0 4/1/1998 4 
15 33381 Day 22 14-10-05 NO LD SEEN 
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AE Adverse event 
ALT Alanine aminotransferase (SGPT) 
AP Alkaline Phosphatase 
AST Aspartate aminotransferase (SGOT) 
CBC Complete blood count 
CRF Case report form 
DNDi Drugs for neglected diseases initiative 
IEC Independent ethics committee 
FDA Food and Drug Administration 
GCP Good clinical practice 
ICH International Conferences on Harmonization 
IV Intravenous 
PI Principal investigator (see note Section 13) 
SAE Serious adverse event 
ULN Upper limit of normal 
WBC White blood cell 
WHO World Health Organization 
WNL Within normal limits 
SSG Sodium Stibogluconate 
PM Paromomycin 
Comb SSG and PM Combination treatment  
CI Confidence Interval 
VCT Voluntary counselling and testing 
TOC Test of Cure 
SD Standard Deviation 
IQR Interquartile range 
DC   
Definitive Cure, parasite free 6 months post treatment, no rescue 
or additional VL medication required 
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1. Trial Objectives  
To compare the efficacy and safety of: 
o Sodium Stibogluconate (SSG) monotherapy 
o Paromomycin (PM) monotherapy  
o SSG and PM in a combination therapy (Comb) 
 
2. Study Design 
Multi-centre individually randomised controlled trial. 
 
2.1 Study Sites 
• Kenya:  
o KEMRI, Nairobi (Co-ordinating Centre) 
• Sudan:  
o Um El Kher (UeK) 
o Kassab 
• Ethiopia:  
o Gondar 
o Arba Minch 
 
 2.2 Inclusion Criteria 
• Patients for whom written informed consent has been signed by the 
patients themselves (if aged 18 years and over) or by parents(s) or legal 
guardian for patients under 18 years of age.  
• Patients aged between 4 and 60 years (inclusive). 
• Patients with clinical signs and symptoms of VL and diagnosis confirmed 
by visualization of parasites in tissue samples (spleen, lymph node or 
bone marrow) on microscopy. 
 
 2.3 Exclusion Criteria 
• Patients who have received any anti-leishmanial drug in the last 6 
months. 
• Patients with a clinical contraindication to splenic/lymph node/ bone 
marrow aspirates. 
• Patients with severe protein and or caloric malnutrition (Kwashiokor or 
marasmus) 
• Patients with previous hypersensitivity reaction to SSG or 
aminoglycosides. 
• Patients suffering from a concomitant severe infection such as TB or any 
other serious underlying disease (cardiac, renal, hepatic) which would 
preclude evaluation of the patient’s response to study medication.  
• Patients suffering from other conditions associated with splenomegaly 
such as schistosomiasis. 
• Patients with previous history of cardiac arrhythmia or an abnormal ECG 
• Patients who are pregnant or lactating. 
• Patients with haemoglobin < 5gm/dl.  
• Patients with WBC < 1 x 10³/mm 
• Patients with platelets < 40,000/mm 
• Patients with liver function tests more than three times the normal range  
• Patients with serum creatinine outside the normal range for age and 
gender. 
• Patients with pre-existing clinical hearing loss  
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 2.4 HIV-status and VCT 
 All patients were offered counselling and screening for HIV under a voluntary 
counselling and testing programme (VCT). This was either to be done at the 
same time as consent was obtained for inclusion in the trial or at a later date 
according to hospital practice. A HIV positive result is not an exclusion 
criterion. 
Subset analysis will be performed to assess any differences in response within 
the strata  
• HIV negative 
• HIV positive 
• HIV status unknown 
 
 2.5 Dose Schedule 
Treatment was administered by IM or IV at the same time each day according to 
the following schedule for each regimen; 
 
• SSG monotherapy: 20mg/kg/day for 30 days, with a maximum daily dose 
of 850mg (8.5ml) per patient except in Sudan where there was no 
maximum dose 
• PM monotherapy: 15 mg/kg/day for 21 days.   
• Combination SSG 20mg/kg/day and PM 15 mg/kg/day for 17 days 
 
3. Randomisation 
Restricted block randomization was performed for the three arms per site within 
each country. Block sizes of 15 were used. Opaque envelopes were numbered 
sequentially and then sealed.  The process was carried out at the DNDi Trial Co-
ordinating centre at KEMRI, Nairobi where a copy of the randomisation schedule 
is kept securely. 
 
4. Primary Endpoint 
Parasitology at 6 months follow up: measured by visualization of parasites in 
tissue samples (spleen, lymph node or bone marrow) on microscopy. 
 




5.1.1 End of Treatment Parasitology 
Parasitology at end of treatment: measured by visualization of parasites in tissue 
samples (spleen, lymph node or bone marrow) on microscopy. 
 
The tissue sample is taken on the day following the last day of treatment: 
• SSG: Day 31 
• PM: Day 22 
• Combination: Day 18  
 
5.1.2 Parasitology at 3 months follow-up 
Follow up at 3 months is optional, dependent on investigator concerns following 
discharge and seasonal access to remote communities. 
 
Patients who attend for follow up are examined for clinical symptoms of VL and 
classed as clinically well or clinically unwell.  Parasitology, measured by 
visualization of parasites in tissue samples (spleen, lymph node or bone marrow) 
on microscopy, is performed in patients who are clinically unwell. 
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5.2 Safety 
 
5.2.1. Adverse events (AEs) and Serious adverse events 
(SAEs) 
Recorded by spontaneous recording and active examination and questioning.  
AEs will be coded according to MEDRA version 10.0 
 
5.2.2. ECG and Audiometry 
Recorded at specified assessment times (see Section 10) and categorised as 
Normal or Abnormal by site investigators at assessment times. 
 
5.3. Biological Parameters 
The following parameters were measured at specified assessment times, 
according to schedule specified in the next section. 
 
• Temperature: (˚Celsius) 
• Spleen size: (centimetres (cm) by palpation below left costal margin in 
the line of growth) 
• Liver size: (cm by palpation below right costal margin in the mid-clavicular 
line) 
• Weight: (kg) 
• Haemoglobin: (g/dl) 
• Platelet Count: (x 103/µl) 
• White Cell Count: (x 103/µl) 
• Heart Rate: (beats per minute) 
• Systolic Blood Pressure: (mm Hg) 
• Diastolic Blood Pressure: (mm Hg) 
• Total Bilirubin: (mg/dl) 
• BUN: (mg/dl) 
• Creatinine: (mg/dl) 
• AST: (U/L) 
• ALT: (U/L) 
• Albumin: (gm/dl) 
• Amylase: (micromol/L) 
 
6. Patient Assessment Schedule  
Table 1 below shows patient assessment schedule for efficacy, ECG and 
Audiometry and biological markers parameters by day of treatment and follow-
up at three and six months. 
 
Table 1 Patient Assessment Schedule  
Assessments Day of treatment Follow-up 




Efficacy: Parasitology ‡ 9    9 9  9 
ECG and Audiometry║ 9  9  9 9 9 
Biological Markers § 9 9 9 9 9 9 9 
*  SSG only 
†  End of treatment is on Day 31 for SSG, Day 22 for Paromomycin and day 18 for 
Combination  
‡  Only measured at 3 months if patient clinically unwell 
║ ECG and audiometry also carried out on Day 7 and Day 21 at KEMRI and Kassab, 
Audiometry not done at Um el Kehr 
§  Temperature, Spleen size, Liver Size, Weight, Haemoglobin, Platelets,White cell count, 
heart Rate, Systolic and Diastolic blood pressure, bilirubin, BUN, Creatinine, ALT, AST 
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7. Analysis Definitions 
 
7.1 Primary Efficacy Analysis 
Treatment success, or Definitive Cure (DC), is defined as  
• Absence of parasites on microscopy slide at 6 months, provided no rescue 
medication was given during treatment or follow up period. 
 
Treatment failure is defined as 
• receipt of rescue medication at any point in the trial 
• parasites visualized on a microscopy slide at 6 months in patients who 
have not received rescue medication during treatment or follow up period 
 
The efficacy in each arm will be the proportion of treatment successes. The 
treatment effect will be calculated as the difference in efficacy between SSG and 
PM arms and SSG and Combination at 6 months follow-up. 
 
If any of 6 months parasitology data are missing (only likely in the case of 
death, loss to follow up or withdrawal of consent) efficacy analyses will be 
carried out in three ways; 
• Complete case analysis: excluding patients with missing data from 
estimation of efficacy in each arm 
• Last parasitology carried forward: Patients with missing efficacy data will 
have their last parasitology results carried forward (Table 2). 
• Worst case analysis: Patients with missing efficacy data will be allocated 
efficacy results based on their ‘worst-case’ scenario i.e. treatment failure. 
 
Table 2 shows possible scenarios at 6 month parasitology result based on last 
parasitological measurements carried forward.  
 









1 Parasitological measurements taken at 3 
months: parasites visualised 
Positive Failure 
2 Parasitological measurements taken at 3 
months: parasites not visualised 
Negative Success 
3 Patient attended for 3 month visit: 
Parasitological measurements not taken 
but parasites visualised at end of 
treatment 
Positive Failure 
4 Patient attended for 3 month visit: 
Parasitological measurements not taken 
but parasites not visualised at end of 
treatment 
Negative Success 
5 Last seen at end of treatment: parasites 
visualised 
Positive Failure 
6 Last seen at end of treatment: parasites 
not visualised 
Negative Success 
*  receipt of rescue medication prior to 6 months follow-up visit is considered a treatment 
failure 
 
If a patient withdraws full consent at any time in the trial period, data collection, 
for the purposes of the trial, ceases and any primary or secondary outcome data 
beyond this point will be missing. 
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Patients whose baseline characteristics meet exclusion criteria (as additional 
protocol violations) will be included in the analyses. 
 
7.2 Secondary Efficacy Analysis 
Treatment success, or Test of Cure (TOC), is defined as:  
• Absence of parasites on microscopy slide at end of treatment provided no 
rescue medication was given during treatment period. 
 
Slow response is defined as:  
• Presence of parasites on microscopy slide at end of treatment, with a 
value of at least 2 log values lower than the baseline measurement and no 
rescue medication given during treatment period. 
 
Treatment failure is defined as 
• receipt of rescue medication during treatment period or following 
cessation of study treatment 
 
The treatment effect will be calculated as the difference in efficacy between SSG 
and PM arms and SSG and Combination at end of treatment. 
 
If any end of treatment parasitology data are missing (only likely to be due to 
withdrawal of consent) efficacy analyses will be carried out in two ways; 
• complete case analysis: excluding patients with missing data from 
estimation of efficacy in each arm 
• worst case analysis: patients with missing efficacy data will be allocated 
efficacy results based on their ‘worst-case’ scenario i.e. treatment failure. 
 
If a patient withdraws full consent at any time in the trial period, data collection, 
for the purposes of the trial, ceases and any primary or secondary outcome data 
beyond this point will be missing. 
 
Patients whose baseline characteristics meet exclusion criteria (as additional 
protocol violations) will be included in the analyses. 
 
Analyses assume that end of treatment time points are comparable, by definition 
of the treatment regimens.   
 
7.3 Analysis of ECG, Audiometry Biological Marker and AE Data  
 
Data collected during treatment will be analysed according to treatment 
allocation, using data from two groups of patients; 
• Patients completing treatment period and patients withdrawn from 
treatment up until the point of withdrawal 
• Patients completing treatment period and patients withdrawn from 
treatment up until the end of treatment
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8. LEAP 0104A Analysis 
 
8.1 Participant Flow  
 







Parasitological testing not possible n =
VL parasite negative n = 
Of VL parasite positive:
Refused consent n =
Age < 4 or  > 60 n = 
VL treatment within 6 months n = 
Concomitant condition n = 
Pregnant or lactating n =  




n  =  
SSG
n  =  
 


















Died n = 
Treatment stopped 
(lack of response) n = 
Treatment stopped 
(SAE)  n = 
Withdrew consent n = 
Died n = 
Treatment stopped 
(lack of response) n = 
Treatment stopped 
(SAE)  n = 
Withdrew consent n =
Died n = 
Treatment stopped 
(lack of response) n = 
Treatment stopped 
(SAE)  n = 
Withdrew consent n =
 


















Died n = 
Loss to follow up  n = 
Withdrew consent n =
Died n = 
Loss to follow up  n = 
Withdrew consent n =
Died n = 
Loss to follow up  n = 
Withdrew consent n =
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8.2 Baseline Characteristics  
 
Table 3 Baseline Demographic characteristics 
Demographics, n (%) SSG 
N =  
PM 







mean (SD)      
4 – 14     
Age (years) ‡ 
≥ 15     
  
Female     Sex 
Male    
  
Kenya    
Um El Kher    
Kassab    
Gondar    
Randomised  at 
Centre 
Arba Minch    
  
*  p-value from ANOVA for age comparison and chi-squared test for sex and categorical age 
comparisons, across all arms 
†  p-value from t-test for age comparison and chi-squared test for sex and categorical age 
comparisons, between SSG and PM 




Table 4 Baseline Biological Markers  
 SSG 
N =  
PM 
N =  
Comb 




mean (SD)      Temperature 
(°C)  median (IQR)      
mean (SD)      Heart Rate, 
(beats/min) median (IQR)      
mean (SD)      Spleen Size 
(cm) median (IQR)      
mean (SD)      Liver Size 
(cm) median (IQR)      
Severely underweight: 
<60% 
   








   




   
  
*  p-value from ANOVA for comparison of mean values, Kruskall-Wallis where median values 
are given and chi-squared test for categorical data comparisons. 
†  p-value from t-test for comparison of means and chi-squared test for sex and categorical 
age comparisons, between SSG and PM 
‡  Children classified as aged 4 to 14 years and adults, 15 years and above.  
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Table 5 Baseline Laboratory parameters  
Laboratory parameters*  SSG 




N =  
p-value† p-value‡ 
6+     
5+     
4+     
3+     
2+     
Parasite Count  
(log scale) 
1+     
 
mean (SD)      Haemoglobin (g/dl) 
median (IQR)      
mean (SD)      White-cell Count 
(x103/µL) median (IQR)      
mean (SD)      Platelets (x103/µL) 
median (IQR)      
mean (SD)      AST, (U/L) 
median (IQR)      
mean (SD)      ALT, (U/L) 
median (IQR)      
mean (SD)      Bilirubin, (mg/dl) 
median (IQR)      
mean (SD)      BUN, (mg/dl) 
median (IQR)      
mean (SD)      Creatinine 
(mg/dl) median (IQR)      
mean (SD)      Amylase, 
(micromol/L) median (IQR)      
mean (SD)      Alkaline Phosphatase, 
(U/L) median (IQR)      
Positive, n (%)     
Negative, n (%)     
HIV 
Not tested n (%)     
 
*  Measurements were not done at all the sites; WBC not measured at Um El Kher, Alkaline 
Phosphatase not measured at Kassab, Albumin only measured at Kenya and Kassab, 
Serum amylase only measured at Arba Minch. 
†  p-value from ANOVA for comparison of mean values, Kruskall-Wallis where median values 
are given and chi-squared test for categorical data comparisons. 
‡  p-value from t-test for comparison of means and chi-squared test for sex and  categorical 
 age comparisons, between SSG and PM 
 
Table 6 Baseline clinical characteristics     







Normal      
Abnormal      
Audiometry‡ 
Not done      
Normal    
Abnormal    
ECG‡ 
Not done    
  
Malaria prior to treatment      
Pneumonia      
Otitis Media      
*  p-value from chi-squared test across all arms 
†  p-value from chi-squared test between SSG and PM 
‡  Abnormal readings considered to be clinically significant 
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Table 7 Baseline Symptoms  
Symptom, n (%) 
  
SSG 
N =  
PM  
N =  
Comb  
N =  
p-value* p-value† 
Fever      
Headache      
Fatigue      
Epistaxis      
Abdominal pains      
Abdominal swellings      
Swelling of legs      
Cough      
Breathlessness      
Night Sweats      
Loss of appetite      
Weight loss      
Diarrhoea      
Skin lesions      
* p-value from chi-squared test across all arms 
† p-value from chi-squared test between SSG and PM 
 
 
8.3 Deviations from Protocol: Exclusion criteria at baseline 
 
If any patients are found not to have met inclusion and/or exclusion criteria at 
recruitment, a summary of the criteria will be given here.  
 
Table 8 Summary of patients that did not meet protocol entry 
criteria 
Entry Criteria, n SSG 
N =  
PM  
N =  
Comb  
N =  
Patients aged < 4 or > 60 years    
Patients not diagnosed with VL    
Patients that received anti-leishmanial drug in the last 6 
months 
   
Patients with malnutrition    
Patients with haemoglobin < 5gm/dl    
Patients with WBC < 1 x 10³/mm    
Patients with platelets < 40,000/mm    
Patients with liver function tests more than 3 times ULN    
Patients with creatinine outside the normal range for age &
gender 
   
Patients with pre-existing clinical hearing loss    
Patients with history of cardiac arrhythmia or an abnormal ECG    
Patients suffering from a concomitant severe infection     
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8.4 Primary Efficacy Analysis: Overall 
 
Table 9 Definitive Cure Analysis 1: Complete Case Analysis   
Estimation SSG 
N =  
PM  
N =  
Comb  
N =   
Treatment Efficacy at 6 months, n (%)    
Test of difference across arms: p-value*  
Difference between SSG & PM (95% CI)   
Difference between SSG & Combination (95% CI)  
Test of difference across centres, after adjustment 
for treatment : p-value* 
 
*  p-value from likelihood ratio test, comparing models with and without variable being 
tested. 
 
Table 10 Definitive Cure Analysis 2: Last parasitology carried forward 
Estimation SSG 
N =  
PM  
N =  
Comb  
N =   
Treatment efficacy at 6 months, n (%)    
Test of difference across arms: p-value*  
Difference between SSG & PM (95% CI)   
Difference between SSG & Combination (95% CI)  
Test of difference across centres, after adjustment 
for treatment: p-value* 
 




Table 11 Definitive Cure Analysis 3 – Worst-case analysis   
Estimation SSG 
N =  
PM  
N =  
Comb  
N =   
Parasite free at 6 months, n (%)    
Test of difference across arms: p-value*  
Difference between SSG & PM (95% CI)   
Difference between SSG & Combination (95% CI)  
Test of difference across centres, after adjustment 
for treatment: p-value* 
 
*  p-value from likelihood ratio test, comparing models with and without variable  being 
tested. 
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8.4.1   Primary Efficacy Analysis: By centre 
 
If the LRT p-value following comparison of models with and without centre ≤ 
0.05, by-centre efficacy analyses will be presented. 
 
Table 12 Primary Efficacy Analysis: By Centre 
Site Numbers randomised and 
treatment successes  
SSG 
N =  
PM  
N =  
Comb  
N =   
p-value*† p-value*║ 
Randomised      
DC: complete case      
DC: parasitology carried forward      
Um El 
Kher 
DC: worst case      
Randomised      
DC: complete case      
DC: parasitology carried forward      
Kassab 
DC: worst case      
Randomised      
DC: complete case      
DC: parasitology carried forward      
Kenya 
DC: worst case      
Randomised      
DC: complete case      
DC: parasitology carried forward      
Gondar 
DC: worst case      
Randomised      
DC: complete case      
DC: parasitology carried forward      
Arba 
Minch 
DC: worst case      
DC: complete case      
DC: parasitology carried forward      
p-
value*‡ 
DC: worst case      
*  p-value from chi-squared test or Fisher’s exact test if justified 
†  comparison across arms by site 
║  comparison between SSG and PM by site 
‡  comparison across sites by arm 
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8.5 Secondary Efficacy Parasitology Analysis 
 
Table 13 Test of Cure Analysis 1: Complete Case Analysis 
Estimation SSG 
N =  
PM  
N =  
Comb  
N =   
Treatment Success at end of treatment, n (%)    
Test of difference across arms: p-value*  
Difference between SSG & PM (95% CI)   
Difference between SSG & Combination (95% CI)  
Test of difference across centres, after adjustment 
for treatment: p-value* 
 
*  p-value from likelihood ratio test, comparing models with and without variable being 
tested. 
 
Table 14 Test of Cure Analysis 2: Worst Case Analysis 
Estimation SSG 
N =  
PM  
N =  
Comb  
N =   
Treatment Success at end of treatment, n (%)    
Test of difference across arms: p-value*  
Difference between SSG & PM (95% CI)   
Difference between SSG & Combination (95% CI)  
Test of difference across centres, after adjustment 
for treatment: p-value* 
 
*  p-value from likelihood ratio test, comparing models with and without variable being 
tested. 
 
8.5.1 Secondary Efficacy Parasitology Analysis 
 
If the LRT p-value following comparison of models with and without centre ≤ 
0.05, by-centre efficacy analyses will be presented. 
 
Table 15 Secondary Efficacy Analysis: By Centre
Site Numbers randomised and 
treatment successes  
SSG 
N =  
PM  
N =  
Comb  
N =   
p-value* 
Randomised     
TOC: complete case     
Um El Kher 
TOC: worst case     
Randomised     
TOC: complete case     
Kassab 
TOC: worst case     
Randomised     
TOC: complete case     
Kenya 
 
TOC: worst case     
Randomised     
TOC: complete case     
Gondar 
 
TOC: worst case     
Randomised     
TOC: complete case     
Arba Minch 
 
TOC: worst case     
TOC: complete case     p-value* 
TOC: worst case     
*  p-value from chi-squared test or Fisher’s exact test if justified 
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8.6 Safety ECG and Audiometry Analysis 
Data coded as normal or abnormal on treatment assessment days will be 
summarised using the following proportions; 
• proportion of patients who have an abnormal reading on day 7 
• proportion of patients who have an abnormal reading on day 14 
• proportion of patients who have had an abnormal reading by day 14 
(abnormal reading on day 7, 14 or both) 
• proportion of patients who have had an abnormal reading by end of 
treatment (abnormal reading on day 7, 14, end of treatment or all) 
• proportion of patients who have an abnormal reading at end of treatment 
• proportion of patients who have an abnormal reading at end of treatment 
that has not returned to normal at 6 months  
 
The denominator for all proportion will the number of patients randomised to 
treatment who recorded normal at baseline.   
 
8.6.1 Safety Analysis: ECG 
Table 16 ECG 
Estimation SSG 
N =  
PM  
N =  
Comb  
N =   
Number of patients randomised     
Abnormal on day 7, n (%)    
Abnormal on day 14, n (%)    
Abnormal by day 14, n (%)    
Abnormal by end of treatment, n (%)    
Abnormal result at end of treatment, n (%)    
Abnormal result remaining at 6 months†, n (%)    
Test of Difference across all arms at end of treatment* 
If p ≤ 0.05, perform pairwise tests: 
Between SSG & PM (95% CI):  
Test of difference*  
Between SSG & Combination (95% CI):  
Test of difference*  
Test of Difference across all arms at 6 months * 
If p ≤ 0.01, perform pairwise tests: 
Between SSG & PM (95% CI):  
Test of difference*  
Between SSG & Combination (95% CI):  
Test of difference*  
*  p-value from chi-squared test 
†  abnormal result at end of treatment, not returning to normal by end of follow-up 
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8.6.2 Safety Analysis: Audiometry 
Table 17 Audiometry 
Estimation SSG 
N =  
PM  
N =  
Comb  
N =   
Abnormal on day 7, n (%)    
Abnormal on day 14, n (%)    
Abnormal by day 14, n (%)    
Abnormal by end of treatment, n (%)    
Abnormal result at end of treatment, n (%)    
Abnormal result remaining at 6 months†, n (%)    
Test of Difference across all arms in result at end of treatment* 
If p ≤ 0.05, perform pairwise tests: 
Between SSG & PM (95% CI):  
Test of difference*  
Between SSG & Combination (95% CI):  
Test of difference*  
Test of Difference across all arms at 6 months†* 
If p ≤ 0.01, perform pairwise tests: 
Between SSG & PM (95% CI):  
Test of difference*  
Between SSG & Combination (95% CI):  
Test of difference*  
*  p-value from chi-squared test 
†  abnormal result at end of treatment, not returning to normal by end of follow-up 
 
8.6.3 Urinalysis: Protein  
 
Table 18 Urinalysis: Protein  
Estimation SSG 
N =  
PM  
N =  
Comb  
N =   
Number of patients randomised     
Abnormal on day 7, n (%)    
Abnormal on day 14, n (%)    
Abnormal by day 14, n (%)    
Abnormal by end of treatment, n (%)    
Abnormal result at end of treatment, n (%)    
Test of Difference across all arms in result at end of treatment* 
If p ≤ 0.05, perform pairwise tests: 
Between SSG & PM (95% CI):  
Test of difference*  
Between SSG & Combination (95% CI):  
Test of difference*  
*  p-value from chi-squared test 
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8.6.4 Urinalysis: Blood  
Table 19 Urinalysis: Blood 
Estimation SSG 
N =  
PM  
N =  
Comb  
N =   
Number of patients randomised     
Abnormal on day 7, n (%)    
Abnormal on day 14, n (%)    
Abnormal by day 14, n (%)    
Abnormal by end of treatment, n (%)    
Abnormal result at end of treatment, n (%)    
Test of Difference across all arms in result at end of treatment* 
If p ≤ 0.05, perform pairwise tests: 
Between SSG & PM (95% CI):  
Test of difference*  
Between SSG & Combination (95% CI):  
Test of difference*  
* p-value from chi-squared test 
 
8.7 Secondary Efficacy Analysis: Biological Markers during 
Treatment 
Predicted changes during treatment are presented with corresponding 95% CIs 
along with results of overall statistical comparisons across all arms.  Pairwise 
results are only performed where there is some evidence of an overall 
difference. 
 
Mean differences in parameters between time points are also presented with 
corresponding 95% CIs.  ANCOVA tests for evidence of a difference between 
treatment arms also allow for adjustment for centre. 
 
All available data will be used in safety analyses. 
 







n       
Predicted change       
Weight gain 
(Kg) 
95% CI       
n       
Predicted change       
Temperature 
(°C) 
95% CI       
n       
Predicted change       
Heart Rate, 
(beats/min) 
95% CI       
n       
Predicted change       
Spleen Size 
(cm)  
95% CI       
n       
Predicted change       
Liver Size 
(cm) 
95% CI       
§  p-value from random effects regression modelling 
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Table 20 Difference in biological markers between baseline and Day 7 
 
Mean Difference (95% CI) p-value* Efficacy Marker 




Weight gain (Kg)       
Temperature (°C)       
Heart Rate, (beats/min)       
Spleen Size (cm)        
Liver Size (cm)        
Haemoglobin (g/dl)        
White-cell Count (x103/µL)        
Platelets (x103/µL)        
AST, (U/L)       
ALT, (U/L)       
Bilirubin, (mg/dl)       
BUN, (mg/dl)       
Creatinine (mg/dl)       
Amylase, (micromol/L)       
Alkaline Phosphatase (U/L)       
*  p-value from ANCOVA between arms in day 7 measurements, adjusting for baseline values 
 
Table 21 Difference in biological markers between Day 7 and Day 14 
 
Mean Difference (95% CI) p-value* Efficacy Marker 




Weight gain (Kg)       
Temperature (°C)       
Heart Rate, (beats/min)       
Spleen Size (cm)        
Liver Size (cm)        
Haemoglobin (g/dl)        
White-cell Count (x103/µL)        
Platelets (x103/µL)        
AST, (U/L)       
ALT, (U/L)       
Bilirubin, (mg/dl)       
BUN, (mg/dl)       
Creatinine (mg/dl)       
Amylase, (micromol/L)       
Alkaline Phosphatase (U/L)       
*  p-value from ANCOVA between arms in day 14 measurements, adjusting for day 7 values 
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Table 22 Difference in biological markers between Day 14 and End of 
treatment 
 
Mean Difference (95% CI) p-value* Efficacy Marker 




Weight gain (Kg)       
Temperature (°C)       
Heart Rate, (beats/min)       
Spleen Size (cm)        
Liver Size (cm)        
Haemoglobin (g/dl)        
White-cell Count (x103/µL)        
Platelets (x103/µL)        
AST, (U/L)       
ALT, (U/L)       
Bilirubin, (mg/dl)       
BUN, (mg/dl)       
Creatinine (mg/dl)       
Amylase, (micromol/L)       
Alkaline Phosphatase (U/L)       
*  P-value from ANCOVA between arms in end of treatment measurements (day 31 
for SSG, day 22 for PM, day 18 for Combination), adjusting for day 14 values 
 
 
8.8 Adverse Events  
Adverse events will be summarised separately during treatment and follow-up.  
Severity and relation to study drug will be considered and summaries of 
numbers of AEs experienced will be given according to Medra, version 10.0. 
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8.8.1 Summary Results during treatment 
 
Table 23 Adverse Event Rates during Treatment.   
 Total person-days on treatment
(T) & rate per arm* 
SSG vs PM  SSG vs Comb  
 SSG 
T =  
PM 
T =  
Comb 















Serious adverse event 
Any          
Adverse drug reaction§          
Unrelated to study drug||          
Non-Serious adverse event 
Any          
Adverse drug reaction§          
Unrelated to study drug||          
Mild          
Moderate           
Severe          
*  multiple AEs per patient treated as separate AEs so contributes to the person-days on treatment per arm. 
†  p-value from random effects poisson regression to show strength of evidence of correlation within patients 
‡  rate ratio adjusted for correlation between patients where there are multiple AEs per patient and evidence of correlation 
§  Recorded as possible, probable or unlikely relation to study drug 
||  Recorded as unrelated to study drug 
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8.8.2 Summary Results at 3 months follow-up 
Table 24 Adverse Events at 3 months follow-up 
Absolute risk* SSG vs PM SSG vs Comb Patients experiencing 














Any        
Adverse drug reaction§        
Unrelated to study drug||        
Mild        
Moderate         
Severe        
*  data are n (%) 
†  negative difference implies an absolute risk decrease for experimental treatment compared to SSG 
§  a non-serious adverse event recorded as probably, possibly or unlikely to be related to study drug  
||  a non-serious adverse event recorded as unrelated to study drug  
 
8.8.3 Summary Results at 6 months follow-up 
Table 25 Adverse Events at 6 months follow-up 
Absolute risk* SSG vs PM SSG vs Comb Patients experiencing 














Any        
Adverse drug reaction§        
Unrelated to study drug||        
Mild        
Moderate         
Severe        
*  data are n (%) 
†  negative difference implies an absolute risk decrease for experimental treatment compared to SSG 
§  a non-serious adverse event recorded as probably, possibly or unlikely to be related to study drug  
||  a non-serious adverse event recorded as unrelated to study drug  
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8.8.4 Summary of All Adverse Events during Treatment Period and Follow-up by treatment 
 
Table 26 All adverse events summarised by treatment 
SSG PM Comb Adverse Event  
Body system (Preferred term) Related* Not related† Related* Not related† Related* Not related† 





      
CARDIAC DISORDERS  
BRADYCARDIA 
CARDIAC FAILURE HIGH OUTPUT 
SINUS ARRHYTHMIA 
SINUS BRADYCARDIA 
      
EAR AND LABYRINTH DISORDERS 
EAR PAIN 
      
ENDOCRINE DISORDERS       




      
GASTROINTESTINAL DISORDERS 
ABDOMINAL DISTENSION  
ABDOMINAL PAIN  
ABDOMINAL PAIN LEFT 
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SSG PM Comb Adverse Event  
Body system (Preferred term) Related* Not related† Related* Not related† Related* Not related† 
GINGIVITIS 
MOUTH ULCERATION 
MUCOUS STOOLS  
NAUSEA 






GENERAL DISORDERS AND 
ADMINISTRATION SITE CONDITIONS  
CHILLS 
INJECTION SITE PAIN 
INJECTION SITE SWELLING 
PYREXIA 
TENDERNESS  
      
HEPATOBILIARY DISORDERS       
IMMUNE SYSTEM DISORDERS  
ALLERGY TO ARTHROPOD BITE  
      
      
      













INJECTION SITE CELLULITIS 
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SSG PM Comb Adverse Event  







OTITIS MEDIA ACUTE 
PARASITIC INFECTION INTESTINAL 
PERICARDITIS MYCOPLASMAL 
PNEUMONIA 




UPPER RESPIRATORY TRACT INFECTION 
URINARY TRACT INFECTION 
VARICELLA 
VISCERAL LEISHMANIASIS  
WOUND SEPSIS 




SKIN LACERATION  
WOUND  
      
INVESTIGATIONS 
ALANINE AMINOTRANSFERASE INCREASED 
ASPARTATE AMINOTRANSFERASE INCREASED 
BLOOD AMYLASE INCREASED 
BLOOD ALKALINE PHOSPHATASE INCREASED 
BLOOD CREATININE INCREASED 
ELECTROCARDIOGRAM CHANGE  
ELECTROCARDIOGRAM QT PROLONGED 
HEPATIC ENZYMES INCREASED 
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SSG PM Comb Adverse Event  
Body system (Preferred term) Related* Not related† Related* Not related† Related* Not related† 
HAEMAGLOBIN DECREASED 
LIVER FUNCTION TEST ABNORMAL 
PLATELET COUNT DECREASED 
PROTHROMBIN TIME PROLONGED 
TRANSAMINASES INCREASED 
WEIGHT DECREASED 
WHITE BLOOD CELLS URINE POSITIVE 
METABOLISM AND NUTRITION DISORDERS 
HYPOGLYCAEMIA 
      
MUSCULOSKELETAL AND CONNECTIVE 
TISSUE DISORDERS  
ARTHRALGIA  
BACK PAIN 
NECK PAIN  
      
NEOPLASMS BENIIGN, MALIGNANT AND 
UNSPECIFIED (INCL CYSTS AND POLYPS) 
      





      
PREGNANCY, PUERPERIUM AND 
PERINATAL CONDITIONS 
      
PSYCHIATRIC DISORDERS       




RENAL FAILURE ACUTE 
      
REPRODUCTIVE SYSTEM AND BREAST 
DISORDERS 
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SSG PM Comb Adverse Event  
Body system (Preferred term) Related* Not related† Related* Not related† Related* Not related† 






      








SKIN LESION  
SKIN ULCER 
SWELLING FACE 
      
SURGICAL AND MEDICAL PROCEDURES       
VASCULAR DISORDERS 
HYPERTENSION 
      
Data are n (%) of total patients.   
* Recorded as probably, possibly or unlikely to be related to study drug 
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8.8.5 Summary of All Adverse Events during Treatment Period and Follow-up by severity 
Table 27 All adverse events summarised by Severity  
 
Mild Moderate Severe Adverse Event  
Body system (Preferred term) Related* Not related† Related* Not related† Related* Not related† 





      
CARDIAC DISORDERS  
BRADYCARDIA 
CARDIAC FAILURE HIGH OUTPUT 
SINUS ARRHYTHMIA 
SINUS BRADYCARDIA 
      
EAR AND LABYRINTH DISORDERS 
EAR PAIN 
      
ENDOCRINE DISORDERS       




      
GASTROINTESTINAL DISORDERS 
ABDOMINAL DISTENSION  
ABDOMINAL PAIN  
ABDOMINAL PAIN LEFT 
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Mild Moderate Severe Adverse Event  
Body system (Preferred term) Related* Not related† Related* Not related† Related* Not related† 
GINGIVITIS 
MOUTH ULCERATION 
MUCOUS STOOLS  
NAUSEA 






GENERAL DISORDERS AND 
ADMINISTRATION SITE CONDITIONS  
CHILLS 
INJECTION SITE PAIN 
INJECTION SITE SWELLING 
PYREXIA 
TENDERNESS  
      
HEPATOBILIARY DISORDERS       
IMMUNE SYSTEM DISORDERS  
ALLERGY TO ARTHROPOD BITE  
      













INJECTION SITE CELLULITIS 
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Mild Moderate Severe Adverse Event  







OTITIS MEDIA ACUTE 
PARASITIC INFECTION INTESTINAL 
PERICARDITIS MYCOPLASMAL 
PNEUMONIA 




UPPER RESPIRATORY TRACT INFECTION 
URINARY TRACT INFECTION 
VARICELLA 
VISCERAL LEISHMANIASIS  
WOUND SEPSIS 
      
      




SKIN LACERATION  
WOUND  
      
INVESTIGATIONS 
ALANINE AMINOTRANSFERASE INCREASED 
ASPARTATE AMINOTRANSFERASE INCREASED 
BLOOD AMYLASE INCREASED 
BLOOD ALKALINE PHOSPHATASE INCREASED 
BLOOD CREATININE INCREASED 
ELECTROCARDIOGRAM CHANGE  
ELECTROCARDIOGRAM QT PROLONGED 
HEPATIC ENZYMES INCREASED 
      
LEAP 0104a Appendices
Page 243 of 756
LEAP 0104A SAP 4 Jun 08 Page 32 of 38 
Mild Moderate Severe Adverse Event  
Body system (Preferred term) Related* Not related† Related* Not related† Related* Not related† 
HAEMAGLOBIN DECREASED 
LIVER FUNCTION TEST ABNORMAL 
PLATELET COUNT DECREASED 
PROTHROMBIN TIME PROLONGED 
TRANSAMINASES INCREASED 
WEIGHT DECREASED 
WHITE BLOOD CELLS URINE POSITIVE 
METABOLISM AND NUTRITION DISORDERS 
HYPOGLYCAEMIA 
      
MUSCULOSKELETAL AND CONNECTIVE 
TISSUE DISORDERS  
ARTHRALGIA  
BACK PAIN 
NECK PAIN  
      
NEOPLASMS BENIIGN, MALIGNANT AND 
UNSPECIFIED (INCL CYSTS AND POLYPS) 
      




      
PREGNANCY, PUERPERIUM AND 
PERINATAL CONDITIONS 
      
PSYCHIATRIC DISORDERS       




RENAL FAILURE ACUTE 
      
REPRODUCTIVE SYSTEM AND BREAST 
DISORDERS 
      
RESPIRATORY, THORACIC AND 
MEDIASTINAL DISORDERS 
ASTHMA  
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Mild Moderate Severe Adverse Event  












SKIN LESION  
SKIN ULCER 
SWELLING FACE 
      
SURGICAL AND MEDICAL PROCEDURES       
VASCULAR DISORDERS 
HYPERTENSION 
      
Data are n (%) of total patients.   
* Recorded as probably, possibly or unlikely to be related to study drug 
† Recorded as unrelated to study drug 
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9. Subgroup Analyses 
 
9.1 Primary Efficacy Analysis:  HIV negative patients 
 
Few HIV positive patients are expected in the trial population.  However, if the 
overall prevalence of HIV in randomised patients is 10% or greater, the primary 
efficacy analysis will be repeated in HIV negative patients. 
 
Table 28 Definitive Cure Analysis 1: Complete Case Analysis   
Estimation SSG 
N =  
PM  
N =  
Comb  
N =   
Treatment Efficacy at 6 months, n (%)    
Test of difference across arms: p-value*  
Difference between SSG & PM (95% CI)   
Difference between SSG & Combination (95% CI)  
Test of difference across centres, after adjustment 
for treatment : p-value* 
 
*  p-value from likelihood ratio test, comparing models with and without variable being tested. 
 
Table 29 Definitive Cure Analysis 2: Last parasitology carried forward 
Estimation SSG 
N =  
PM  
N =  
Comb  
N =   
Treatment efficacy at 6 months, n (%)    
Test of difference across arms: p-value*  
Difference between SSG & PM (95% CI)   
Difference between SSG & Combination (95% CI)  
Test of difference across centres, after adjustment 
for treatment: p-value* 
 
*  p-value from likelihood ratio test, comparing models with and without variable being tested. 
 
 
Table 30 Definitive Cure Analysis 3 – Worst-case analysis   
Estimation SSG 
N =  
PM  
N =  
Comb  
N =   
Treatment efficacy at 6 months, n (%)    
Test of difference across arms: p-value*  
Difference between SSG & PM (95% CI)   
Difference between SSG & Combination (95% CI)  
Test of difference across centres, after adjustment 
for treatment: p-value* 
 
*  p-value from likelihood ratio test, comparing models with and without variable being tested. 
 
 
If the LRT p-value following comparison of models with and without centre ≤ 
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9.2 Efficacy Analysis:  HIV positive patients  
 
For patients testing HIV positive a summary of the response to treatment at 6 
Months follow-up will be completed, depending on the number of patients and 
their distribution between the groups.  If insufficient numbers or uneven 
distribution then the treatment allocation, parasitology results at end of treatment 
and follow up will be presented here grouped by treatment, along with indication 
of receipt of rescue medication and timing of receipt. 
Table 31 Definitive Cure Summary for HIV positive patients 
   Treatment efficacy at 6 months, n (%) SSG 
N =  
PM  
N =  
Comb  
N =   
Definitive Cure 1: Complete Case Analysis    
Definitive Cure Analysis 2: Last parasitology carried forward    
Definitive Cure Analysis 3: Worst-case analysis    
 
Parasitology Data for HIV positive patients by Treatment 
Parasitology result Patient 
Number 
Treatment 









 SSG Positive Not Done Negative Yes 
      
      
 
 
9.3 Efficacy Analysis:  Age 
Summary of   
 
Treatment efficacy at 6 months, n (%) SSG 
N =  
PM  
N =  
Comb  
N =   
Adults 
Definitive Cure 1: Complete Case Analysis    
Definitive Cure Analysis 2: Last parasitology carried forward    
Definitive Cure Analysis 3: Worst-case analysis    
Children 
Definitive Cure 1: Complete Case Analysis    
Definitive Cure Analysis 2: Last parasitology carried forward    
Definitive Cure Analysis 3: Worst-case analysis    
 
 
10. Statistical Methods 
 
10.1 Data Summary and Comparison 
 
Age will be summarised as a continuous variable and with the categories 
paediatric (4 to 14 years) and adult (15 and above).   
 
To classify nutritional status, weight-for-age values will be used in children and 
BMI in adults. 
 
For each child, the weight-for-age is calculated as observed weight ÷ expected 
median weight-for-age x 100, where the expected median weight-for-age is 
calculated as (2 x age in years) + 8 
 
LEAP 0104a Appendices
Page 247 of 756
LEAP 0104A SAP 4 Jun 08 Page 36 of 38 
Children are classified as normal if weight-for-age is > 80%; underweight if 60% 
≤ weight-for-age ≤ 80% and severely underweight if weight-for-age < 60%. 
 
For each adult, body mass index (BMI) is calculated as weight in kg ÷ height in 
metres squared.  Adults are classified as normal if 18.5 ≤ BMI ≤ 24.9; 
underweight if 16.0 ≤ BMI ≤ 18.4 and severely underweight if BMI < 16. 
 
Continuous data are to be summarised using mean and standard deviation (SD) if 
normally distributed and tested using t-tests or ANOVA where appropriate or 
using median and inter-quartile range (IQR) and non-parametric testing if not 
normally distributed.  Binary and categorical data will be summarised using 
proportions and compared using chi-squared tests. 
 
10.2 Parasitological Efficacy  
 
The unadjusted treatment difference will be calculated for all sites, comparing 
each treatment to SSG using a binomial regression model with an identity link to 
provide difference estimates for equivalence with two-sided 95% confidence 
intervals. 
 
Centre will then be added to the model as a covariate and the models with and 
without centre compared using the likelihood ratio test (LRT).  If the LRT p-value 
following comparison of models with and without centre, after adjustment for 
treatment, is ≤0.05 treatment effectiveness by centre will be tabulated (Federov 
2005). 
 
If deemed necessary, adjustments will be made for multiple comparisons using 
Bonferroni adjustment where the significance level would be divided by the 
number of comparisons, c. Evidence of a difference between two groups will be 
identified if p-value estimated ≤ specified cut-off (usually 0.05)/c.   
 
10.3 Biological Markers, ECG and Audiometry 
 
For repeated measurements made during treatment, change during treatment will 
be modelled including random intercept terms to allow for correlation within 
patient’s measurements, assuming an appropriate distribution for each marker.  
Models with and without random slope terms will be compared using the likelihood 
ratio test to test for variation in changes within treatment arms.  For pairwise 
comparisons, SSG will be the reference treatment.   
 
Where there is evidence of a difference during treatment and it is of interest to 
know between which time point changes occurred, a mean difference in 
parameter values between consecutive time points will be summarised for each 
parameter and tests carried out across arms using ANCOVA, adjusting for values 
at the earlier time point.  Evidence of variability in mean differences by centre will 
also be investigated this way.  
 
 10.4 Serious and Non-serious Adverse Events 
 
In addition to data listings provided in the full trial report, SAEs and AEs are 
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Relation to study drug is classified as not related where original recording 
indicates unrelated and classified as related where recording indicates a possible 
or probable or unlikely relation. 
 
For overall analysis of AEs during treatment, the AE rate will be calculated as the 
number of events divided by the person-days on treatment, for each arm and 
comparisons made across arms.  Rate ratios and corresponding 95% CIs will be 
estimated for PM versus SSG and Combination treatment versus SSG. For AEs 
occurring at 3 months and 6 months follow-up, the absolute risk of an AE or SAE 
will be calculated for each treatment arm as the number of patients experiencing 
at least one AE divided by the number of patients randomised, per arm.  Relative 
risks with corresponding 95% CIs will be estimated for PM versus SSG and 
Combination treatment versus SSG.  The absolute risk difference with 
corresponding 95% confidence intervals will also be provided for these two 
comparisons. These measures will be repeated within categories of relation to 
study drug and severity of event. 
 
When considering the occurrence of specific AEs, according to the MEDRA coding 
system, multiple AEs per patient will be considered as separate individual AEs.  
Evidence of correlation between individual patients will be assessed and if found, 
account will be taken of multiple AEs per patient in comparisons. 
 
11. Power: Efficacy Analysis 
 
If treatment efficacy in the reference arm, SSG, is expected to be 95%, 135 
patients per arm would provide around 80% power to show evidence of a 
difference in efficacy at the 5% level, if the efficacy of PM or Combination 
treatment is 85% or lower, based on a two-sided test. 
 
If the efficacy of SSG is lower at say 85%, 135 patients per arm would provide 
80% power to show evidence of a difference at the 5% level, if the efficacy of PM 
or Combination treatment is 70% or lower, based on a two-sided test. 
 
With 135 patients per arm, it will be possible to show, with around 80% power, 
that the efficacy of PM or Combination treatment is no more than 7% lower than 
the efficacy of SSG, if the efficacy of SSG is assumed to be 95%.  
 
Note that these estimations assume there are no missing data for definitive cure. 
 
Number needed per regimen for a two-sample, two-sided test between two 
proportions (Kirkwood & Sterne): 
















u = one-sided percentage point of the normal distribution corresponding to 100% 
- power, so, for power of 80%, u = 0.84 and for power of 90%, u = 1.28 
v = percentage point of the normal distribution corresponding to the significance, 
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1. Trial Objectives  
To compare the efficacy and safety of: 
o Sodium Stibogluconate (SSG) monotherapy 
o Paromomycin (PM) monotherapy  
o SSG and PM in a combination therapy (Comb) 
 
2. Study Design 
Multi-centre individually randomised controlled trial. 
2.1 Study Sites 
• Kenya:  
o KEMRI, Nairobi (Co-ordinating Centre) 
• Sudan:  
o Um El Kher (UeK) 
o Kassab 
• Ethiopia:  
o Gondar 
o Arba Minch 
 
 2.2 Inclusion Criteria 
• Patients for whom written informed consent has been signed by the patients 
themselves (if aged 18 years and over) or by parent(s) or legal guardian for 
patients under 18 years of age.  
• Patients aged between 4 and 60 years (inclusive). 
• Patients with clinical signs and symptoms of VL and diagnosis confirmed by 
visualization of parasites in tissue samples (spleen, lymph node or bone marrow) 
on microscopy. 
 
 2.3 Exclusion Criteria 
• Patients who have received any anti-leishmanial drug in the last 6 months. 
• Patients with a clinical contraindication to splenic/lymph node/ bone marrow 
aspirates. 
• Patients with severe protein and or caloric malnutrition (Kwashiokor or 
marasmus) 
• Patients with previous hypersensitivity reaction to SSG or aminoglycosides. 
• Patients suffering from a concomitant severe infection such as TB or any other 
serious underlying disease (cardiac, renal, hepatic) which would preclude 
evaluation of the patient’s response to study medication.  
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• Patients suffering from other conditions associated with splenomegaly such as 
schistosomiasis. 
• Patients with previous history of cardiac arrhythmia or an abnormal ECG 
• Patients who are pregnant or lactating. 
• Patients with haemoglobin < 5gm/dl.  
• Patients with WBC < 1 x 10³/mm 
• Patients with platelets < 40,000/mm 
• Patients with liver function tests more than three times the normal range  
• Patients with serum creatinine outside the normal range for age and gender. 
• Patients with pre-existing clinical hearing loss 
 
 2.4 HIV-status and VCT 
All patients were offered counselling and screening for HIV under a voluntary counselling 
and testing programme (VCT). This was either to be done at the same time as consent 
was obtained for inclusion in the trial or at a later date, according to hospital practice. A 
HIV positive result was not an exclusion criterion. 
 
 2.5 Dose Schedule 
Treatment was administered by IM or IV at the same time each day according to the 
following schedule for each regimen; 
• SSG monotherapy: 20mg/kg/day for 30 days, with a maximum daily dose of 
850mg (8.5ml) per patient except in Sudan where there was no maximum dose 
• PM monotherapy: 15 mg/kg/day for 21 days.   
• Combination SSG 20mg/kg/day and PM 15 mg/kg/day for 17 days 
 
3. Randomisation 
Restricted block randomization was performed for the three arms per site within each 
country. Block sizes of 15 were used. Opaque envelopes were numbered sequentially 
and then sealed.  The process was carried out at the DNDi Trial Co-ordination Centre, 
Nairobi, where a copy of the randomisation schedule is kept securely. 
 
4. Primary Endpoint 
Parasitology at 6 months follow up: measured by visualization of parasites in tissue 
samples (spleen, lymph node or bone marrow) on microscopy. 
 
5. Secondary Endpoints 
5.1 Efficacy 
5.1.1 End of Treatment Parasitology 
Parasitology at end of treatment: measured by visualization of parasites in tissue 
samples (spleen, lymph node or bone marrow) on microscopy. 
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The tissue sample was taken on the day following the last day of treatment: 
• SSG: Day 31 
• PM: Day 22 
• Combination: Day 18  
 
5.1.2 Parasitology at 3 months follow-up 
Follow up at 3 months was optional, dependent on investigator concerns following 
discharge post treatment and seasonal access to remote communities. 
Patients who attended follow up were examined for clinical symptoms of VL and 
classified as clinically well or clinically unwell.  Parasitology, measured by visualization of 
parasites in tissue samples (spleen, lymph node or bone marrow) on microscopy, was 
performed in patients who were deemed to be clinically unwell. 
 
5.2 Safety 
5.2.1 Serious adverse events (SAE) and non-serious Adverse events (AE) 
Data were collected through spontaneous recording and active examination and 
questioning. AEs were coded according to Medical Dictionary for Regulatory Activities, 
version 10.0. 
 
5.2.2 ECG and Audiometry 
Recorded at specified assessment times and categorised as Normal, Clinically 
Insignificant Abnormality or Clinically Significant Abnormality. 
 
5.2.3 Urinalysis: Blood and Protein 
Recorded at each assessment during treatment and at follow up.  Data values were 
categorised as Negative (indicating a Normal result) or Positive (indicating an 
Abnormality). 
 
5.3 Biological Parameters  
The following parameters were measured at specified assessment times, according to 
schedule specified in the next section. 
• Temperature: (˚Celsius) 
• Heart Rate: (beats per minute) 
• Spleen size: (centimetres, cm by palpation below left costal margin in the line of 
growth) 
• Liver size: (cm by palpation below right costal margin in the mid-clavicular line)  
• Weight: (kg) 
• Haemoglobin: (g/dl) 
• White Cell Count: (x 103/µl) 
• Platelet Count: (x 103/µl) 
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• Systolic Blood Pressure: (mm Hg) 
• Diastolic Blood Pressure: (mm Hg) 
• Total Bilirubin: (umol/L) 
• BUN: (mmol/L) 
• Creatinine: (umol/L) 
• AST: (U/L) 
• ALT: (U/L) 
• Amylase: (micromol/L) 
• Alkaline Phosphatase (U/L) 
 
6. Patient Assessment Schedule  
There was a pre-specified patient assessment schedule for efficacy, ECG and Audiometry 
and biological markers parameters by day of treatment and follow-up at three and six 
months (Table 1). 
Table 1 Patient Assessment Schedule  
Assessments Day of treatment Follow-up 




Efficacy: Parasitology ‡         
ECG and Audiometry║        
Biological Markers §        
*  SSG only 
†  End of treatment is Day 31 for SSG, Day 22 for Paromomycin and day 18 for Combination, assuming 
Day 1 is first day of treatment for all regimens  
‡  Measured at 3 months if patient clinically unwell 
║ ECG and audiometry also carried out on Day 7 and Day 21 in Kenya and Kassab, Audiometry not done 
in Um el Kher 
§  Temperature, Spleen size, Liver Size, Weight, Haemoglobin, Platelets, White cell count, Heart Rate, 
Systolic and Diastolic blood pressure, Bilirubin, BUN, Creatinine, ALT, AST, Amylase (Arba Minch only), 
Alkaline Phosphatase (excluding Kassab)   
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7. Analysis Definitions 
7.1 Primary Efficacy Analysis 
Treatment success, or Definitive Cure (DC), was defined as  
• Absence of parasites on microscopy slide at 6 months, provided no rescue 
medication was given during treatment or follow up period. 
Treatment failure was defined as 
• receipt of rescue medication at any point in the trial 
• parasites visualized on a microscopy slide at 6 months in patients who have not 
received rescue medication during treatment or follow up period 
The efficacy in each arm is the proportion, or percentage, of treatment successes. The 
treatment effect is the difference in efficacy between SSG and PM arms and SSG and 
Combination arms at 6 months follow-up. 
Where 6 months parasitology data were missing, efficacy analyses were carried out, 
within an Intention-to Treat framework, in three ways; 
• Complete case analysis (full analysis set): excluding patients with missing efficacy 
data from estimation of efficacy in each arm 
• Last parasitology carried forward: Patients with missing efficacy data will have 
their last parasitology results carried forward (Table 2). 
• Worst case analysis: Patients with missing efficacy data will be allocated efficacy 
results based on their ‘worst-case’ scenario i.e. treatment failure. 
 









1 Parasitological measurements taken at 3 months: 
parasites visualised 
Positive Failure 
2 Parasitological measurements taken at 3 months: 
parasites not visualised 
Negative Success 
3 Patient attended for 3 month visit: Parasitological 
measurements not taken but parasites visualised 
at end of treatment 
Positive Failure 
4 Patient attended for 3 month visit: Parasitological 
measurements not taken but parasites not 
visualised at end of treatment 
Negative Success 
5 Last seen at end of treatment: parasites visualised Positive Failure 
6 Last seen at end of treatment: parasites not 
visualised 
Negative Success 
*  receipt of rescue medication prior to 6 months follow-up visit is considered a treatment failure 
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If a patient withdrew full consent at any time in the trial period, data collection for the 
purposes of the trial ceased and any primary or secondary outcome data beyond this 
point were treated as missing. 
Patients with confirmed VL whose baseline characteristics met exclusion criteria (minor 
protocol violations) were included in all efficacy analyses. 
 
7.2 Secondary Efficacy Analysis  
7.2.1 Test of Cure 
Treatment success, or Test of Cure (TOC), was defined as:  
• absence of parasites on microscopy slide at end of treatment  
Treatment failure was defined as 
• receipt of rescue medication during treatment period or initial hospitalisation 
period 
The treatment effect is the difference in efficacy between SSG and PM arms and SSG and 
Combination arms, at the end of treatment. 
Missing parasitology data at the end of treatment arose if  
• a patient died prior to the end of the treatment period 
• a patient was withdrawn from study treatment  
• a parasitology exam should have been done but was not (investigator error) 
To take account of missing data, efficacy analyses were carried out, also within an 
Intention-to Treat framework, in two ways; 
• complete case analysis: excluding patients with missing data from estimation of 
efficacy in each arm 
• worst case analysis: patients with missing efficacy data will be allocated efficacy 
results based on their ‘worst-case’ scenario i.e. treatment failure. 
Analyses assume that end of treatment time points are comparable, by definition of the 
treatment regimens.   
 
7.2.2 Slow Response to Treatment 
Slow response to treatment was described as the number and percentage of patients, 
randomised per arm, in whom parasites were visualised at the end of treatment but not 
visualised at 6 months post end of treatment, with no administration of rescue 
medication. 
 
7.3 Safety Analysis 
7.3.1 ECG and Audiometry 
Recorded categories of ‘normal’ and ‘clinically insignificant abnormality’ were combined 
in the analysis to one category of normal.  A clinically significant abnormality indicated 
an abnormal result.   
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7.3.2 Urinalysis: Blood and Protein 
Recorded categories were positive and negative.  A positive reading was assumed to 
indicate an abnormal result and a negative reading a normal result. 
 
7.3.3 Serious and Non-Serious Adverse Events 
Treatment emergent adverse events were defined as adverse events with onset between 
day 1 of treatment and 30 days post end of treatment, inclusive. 
Serious adverse events were summarised and compared using proportions per arm. 
Non-serious adverse events were summarised and compared using rates, to take 
account of different time at risk due to different length of treatment periods. 
 
7.4 Biological Marker Data 
Each biological marker was treated as a separate outcome.  Data for each treatment 
assessment day were summarised and compared between subsequent time points.  
 
8. Statistical Methods 
8.1 Baseline Data  
At baseline, age was summarised as a continuous variable and within the categories; 
paediatric (4 to 14 years) and adult (15 and above).   
To classify nutritional status, weight-for-age values were used in children and BMI in 
adults.  For each child, the weight-for-age was calculated as (observed weight ÷ 
expected median weight-for-age) x 100, where the expected median weight-for-age is 
calculated as (2 x age in years) + 8. Children were classified as normal if weight-for-age 
was > 80%; underweight if 60% ≤ weight-for-age ≤ 80% and severely underweight if 
weight-for-age < 60%.  For each adult, body mass index (BMI) was calculated as weight 
in kg ÷ height in metres squared.  Adults were classified as normal if 18.5 ≤ BMI ≤ 24.9; 
underweight if 16.0 ≤ BMI ≤ 18.4 and severely underweight if BMI < 16. 
To present and compare baseline data, continuous data were summarised using mean 
and standard deviation (SD) if normally distributed and tested using t-tests or ANOVA 
where appropriate or using median and inter-quartile range (IQR) and non-parametric 
testing if not normally distributed.  Binary and categorical data were summarised using 
proportions and compared using chi-squared or Fishers test. 
 
8.2 Timing of Follow-up Data Collection 
Every effort was made to follow-up patients as close as possible to 3 months or 6 
months post end of treatment.  Where 
• the date of a patient follow-up falls between 1.5 and 4.5 months post end of 
treatment assessment (expected 3 months follow-up date ±45 days), data were 
treated as 3 months follow-up data (Figure 1).   
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• the date of a patient follow-up falls anywhere beyond 4.5 months post end of 
treatment assessment, data were treated as 6 months follow-up data (TOC date 
plus 135 days or more). 
 
Figure 1 Data Collection during Follow-up: Data Handling 
End of Treatment 1.5 months 3 months 4.5 months 6 months
Eligible for 6 months 
follow up analysis
Eligible for 3 months follow up analysis
 
 
8.3 Parasitological Efficacy  
The unadjusted treatment difference was calculated for all sites, comparing each of the 
test regimens (PM and Combination) to SSG, using a binomial regression model with an 
identity link to provide difference estimates for equivalence with two-sided 95% 
confidence intervals. 
Centre was added to the model as a covariate and the models with and without centre 
compared using the likelihood ratio test (LRT).  If the LRT p-value following comparison 
of models with and without centre, after adjustment for treatment was ≤0.05, treatment 
effectiveness by centre was tabulated (Federov 2005). 
 
8.4 Biological Markers, ECG, Audiometry and Urinalysis 
For biological measurements measured repeatedly during treatment and follow-up, the 
mean difference in parameter values between consecutive time points was calculated, 
within each randomisation arm, for each parameter. Tests for differences in the mean 
difference were carried out across arms using ANCOVA, adjusting for values at the 
earlier time point and centre.   
 
ECG data were analysed as binary data, where categories were normal (normal or 
clinically insignificant abnormality) and abnormal (clinically significant abnormality). 
Data were summarised using the following proportions, where the denominator in all 
cases in the number of patients randomised to treatment with normal result at baseline.   
• proportion of patients who had an abnormal reading on day 7 
• proportion of patients who had an abnormal reading on day 14 
• proportion of patients who had had an abnormal reading by day 14 (abnormal 
reading on day 7, 14 or both) 
• proportion of patients who had had an abnormal reading by end of treatment 
(abnormal reading on day 7, 14, end of treatment or all) 
• proportion of patients who had an abnormal reading at end of treatment 
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• proportion of patients who had an abnormal reading at end of treatment that had 
not returned to normal at 6 months  
Chi-squared tests were used to compare proportions across arms. 
Patients were not expected to have negative (normal) values for the urinalysis 
parameters, protein and blood, at baseline.  Patients who had urinalysis results at 
baseline were categorised based on recorded changes between baseline and end of 
treatment, into one of the following distinct groups, 
• Baseline negative, end of treatment negative 
• Baseline negative, end of treatment positive 
• Baseline positive, end of treatment positive 
• Baseline positive, end of treatment negative 
• Baseline negative, end of treatment missing 
• Baseline positive, end of treatment missing 
Comparisons were made across all treatment arms and between SSG and PM separately.   
Note that this analysis assumes that a negative reading indicates a normal result and 
positive reading indicates an abnormal result. 
 
8.5 Serious and Non-serious Adverse Events 
SAEs and AEs, classified according to Medra, version 10, were tabulated by treatment 
arm according to their corresponding System Organ Class and preferred terms. 
Relation to study drug was classified as not related where original recording indicated 
unrelated and classified as related where a recording indicated a possible or probable or 
unlikely relation. 
Treatment emergent adverse events were defined as those beginning at any time 
between the first day of treatment and 30 days after the expected end of treatment, as 
specified in the protocol.   
For the analysis of treatment emergent AEs, the AE rate was calculated as the number of 
events divided by the person-days at risk, for each arm and comparisons made across 
arms.  The person-time at risk for a single patient in each arm was defined as follows, 
• SSG: 30 days treatment + 30 days = 60 days,  
• PM: : 21 days treatment + 30 days = 51 days,  
• Combination: 17 days treatment + 30 days = 47 days.   
The total person-time at risk per arm is the product of the total number of patients and 
the person-time at risk corresponding to that arm.  The treatment emergent AE rate is 
the total number of AE per arm divided by the total person-time at risk per arm. 
 
Rate ratios and corresponding 95% CIs were estimated for PM versus SSG and 
Combination treatment versus SSG, using poisson regression, which also accounts for 
multiple AEs within patients.  After adjustment for treatment, models with and without 
centre were compared using the LRT to assess evidence of heterogeneity between study 
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centres and evidence for a treatment-centre interaction.  Where evidence of 
heterogeneity or interaction was found, by-centre effects were reported. 
 
9. Power and Sample Size 
If treatment efficacy in the reference arm, SSG, was expected to be 95%, 135 patients 
per arm would provide around 80% power to show evidence of a difference in efficacy at 
a 5% significance level, if the efficacy of PM or Combination treatment was 85% or 
lower, based on a two-sided test. 
If the efficacy of SSG was lower at say 85%, 135 patients per arm would provide 80% 
power to show evidence of a difference at a 5% significance level, if the efficacy of PM or 
Combination treatment was 70% or lower, based on a two-sided test. 
With 135 patients per arm, it would be possible to show, with around 80% power, that 
the efficacy of PM or Combination treatment was no more than 7% lower than the 
efficacy of SSG, if the efficacy of SSG was assumed to be 95%.  
Note that these estimations assume no missing data for definitive cure. 
Number needed per regimen for a two-sample, two-sided test between two proportions 
(Kirkwood & Sterne, 2003): 


















u = one-sided percentage point of the normal distribution corresponding to 100% - 
power, so, for power of 80%, u = 0.84 and for power of 90%, u = 1.28 
v = percentage point of the normal distribution corresponding to the significance, so, for 
significance of 5% and a two-sided percentage point v = 1.96. 
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10. Results 
10.1 Participant Flow  






VL parasite negative n = 221
VL parasite positive n = 300
Of VL parasite positive:
Refused consent n = 3
Age < 4 or  > 60 n = 9
VL treatment within 6 months n = 1
Concomitant condition n = 17
Pregnant or lactating n = 8 
Abnormal biological safety parameter n = 59
Malnutrition n = 8
Nomadic n = 4




n  =  135
SSG
n  = 135 
 
 















Died, no rescue n = 1
Treatment stopped, 
no rescue* n = 1
Treatment stopped & 
rescue given due to:
- SAE n = 2 (1 died)
-lack of response n = 1
Died, no rescue n = 0
Treatment stopped & 
rescue given due to:
- SAE n = 2
- lack of response n = 1
Died, no rescue n = 0
Treatment stopped & 
rescue given due to:
- SAE n = 1
- lack of response n = 0
LTFU = loss to follow-up
* Tuberculosis diagnosis day 14 of treatment, no rescue medication given, loss to follow-up
End of Trial:
n = 107
Death (VL) n = 0
Death (non VL) n = 1
Rescued n = 5
LTFU n = 17
Death (VL, post rescue)
n = 1
Death (non VL) n = 1
Rescued n = 42
LTFU n = 7
Death (VL) n = 0
Death (non VL) n = 1
Rescued n = 8





Complete-case n = 116
(8 rescued, 1 VL death) 
Complete-case n = 127
(45 rescued, 1 VL death) 
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10.2 Baseline Characteristics  
Table 3 Baseline Demographic characteristics 
Demographics, n (%) SSG 
N = 135 
PM 







Age (years) ‡ mean (SD) 16.7 (10.4) 17.8 (11.1) 16.1 (9.4) 0.385 0.397 
4 – 14  69 (51.1) 67 (49.6) 68 (50.4) 
0.992 0.903 
≥ 15  66 (48.9) 68 (50.4) 67 (49.6) 
Sex Female  34 (25.2) 31 (23.0) 34 (25.2) 
0.896 0.776 
Male 101 (74.8) 104 (77.0) 101 (74.8) 
Randomised  
at Centre 
Kenya 15 (11.1) 15 (11.1) 15 (11.1)   
Um El Kher 30 (22.2) 30 (22.2) 30 (22.2) 
Kassab 15 (11.1) 15 (11.1) 15 (11.1) 
Gondar 45 (33.3) 45 (33.3) 45 (33.3) 
Arba Minch 30 (22.2) 30 (22.2) 30 (22.2) 
*  p-value from ANOVA for age comparison and chi-squared or Fishers test for sex and categorical age 
comparisons, across all arms 
†  p-value from t-test for age comparison and chi-squared or Fisher’s test for sex and categorical age 
comparisons, between SSG and PM 
‡  Children classified as aged 4 to 14 years and adults, 15 years and above.  
 
There was little or no evidence of variation in baseline parameters across all three 
treatment arms or between SSG and PM arms (Tables 3 to 7). 
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Table 4 Baseline Biological Markers  






mean (SD) 37.9 (1.1) 38.0 (1.2) 38.0 (1.1) 0.727 0.579 
median (IQR) 37.7 (1.7) 38.0 (1.9) 38.0 (1.8) 0.626 0.443 
Heart Rate, 
(beats/min) 







median (IQR) 108 (20) 102 (24) 104 (23) 0.518 0.262 
Spleen Size 
(cm) 
mean (SD) 8.2 (4.3) 8.3 (4.9) 8.2 (4.5) 0.976 0.828 
median (IQR) 7 (5) 8 (6) 7 (7) 0.994 0.919 
Liver Size 
(cm) 
mean (SD) 2.9 (2.4) 2.9 (2.3) 3.0 (2.4) 0.921 0.872 
median (IQR) 3 (4) 3 (4) 3 (4.5) 0.914 0.698 
Systolic BP 
(mm Hg) 







median (IQR) 100 (10) 100 (20) 100 (10) 0.080 0.063 
Diastolic BP 
(mm Hg) 
mean (SD) 63.3 (9.3) 64.7 (9.5) 62.8 (8.9) 0.225 0.207 





17 (12.6) 17 (12.6) 28 (20.7) 0.262 0.685 
Underweight 61 (45.2) 67 (49.7) 56 (41.6) 
Normal 57 (42.2) 50 (37.0) 50 (37.0) 
Obese/overweight 0 (0) 0 (0) 1 (0.7) 
BP = Blood pressure 
*  p-value from ANOVA for comparison of mean values, Kruskall-Wallis where median values are given 
and chi-squared or Fishers test for categorical data comparisons. 
†  p-value from t-test for comparison of means and chi-squared or Fishers test for categorical data 
comparisons, between SSG and PM 
‡  Based on weight for age in children (4-14 years), defined as severely underweight if <60%, 
underweight: 60 - 80%, normal: >80%.  Based on BMI in adults (15-60 years) defined as severely 
underweight if < 16, underweight: 16.0 – 18.4, normal: 18.5 – 24.9.  Missing BMI value for 1 patient 
in the PM arm. 
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Table 5 Baseline Laboratory parameters  




Parasite Count  
(log scale) 






5+ 18 (13.3%) 21 (15.6%) 24 (17.8%) 
4+ 28 (20.7%) 27 (20.0%) 24 (17.8%) 
3+ 30 (22.2%) 19 (14.1%) 29 (21.5%) 
2+ 34 (25.2%) 32 (23.7%) 26 (19.3%) 
1+ 18 (13.3%) 25 (18.5%) 18 (13.3%) 
Haemoglobin (g/dl) mean (SD) 8.0 (1.8) 8.1 (1.9) 7.8 (2.0) 0.446 0.686 
median (IQR) 7.8 (2.3) 7.9 (2.4) 7.5 (2.5) 0.236 0.598 
White-cell Count 
(x103/µL) 
mean (SD) 2.7 (1.7) 2.6 (1.6) 2.4 (1.5) 0.443 0.714 
median (IQR) 2.3 (1.7) 2.1 (1.5) 2 (1.3) 0.368 0.939 
Platelets§ (x103/µL) mean (SD) 109.2 (54.7) 108 (88.4) 105.1 (49.9) 0.900 0.901 
median (IQR) 94 (61.0) 95.5 (59.5) 95.5 (55) 0.896 0.672 
AST||, (U/L) mean (SD) 50.5 (28.2) 50.5 (36.0) 49.9 (32.9) 0.986 0.992 
median (IQR) 46 (45.4) 42.3 (40.7) 44 (40) 0.823 0.576 
ALT, (U/L) mean (SD) 28.1 (17.7) 26.5 (19.9) 27.1 (19.7) 0.786 0.488 
median (IQR) 23.2 (18) 20.5 (16.3) 22 (19) 0.239 0.102 
Bilirubin¶, (umol/L) mean (SD) 11.2 (6.7) 11.2 (5.5) 11.4 (5.4) 0.953 0.957 
median (IQR) 9.6 (5.1) 9.9 (5.4) 10.3 (6.8) 0.732 0.771 
BUN**, (mmol/L) mean (SD) 7.2 (3.3) 7.3 (3.4) 7.6 (3.7) 0.712 0.998 
median (IQR) 6.2 (5.1) 6.3 (4.8) 6.5 (6.0) 0.851 0.912 
Creatinine 
(umol/L) 
mean (SD) 75.9 (24.9) 74.5 (25.1) 75.0 (25.5) 0.894 0.639 
median (IQR) 74.2 (44.7) 70.7 (42.7) 73.7 (47.6) 0.937 0.733 
Amylase††, 
(micromol/L) 
mean (SD) 82.1 (35.4) 87.8 (50.1) 69.6 (37.6) 0.313 0.668 
median (IQR) 76 (45.3) 82.1 (53.7) 66 (40.4) 0.324 0.934 
Alkaline 
Phosphatase, (U/L) 





median (IQR) 244 (205) 223 (172.5) 206 (173) 0.150 0.221 
Data are n (%) of number randomised to each arm for parasite count, other data summaries are 
mean (SD) of number of values indicated as being available for each measure 
*  Measurements were not done at all the sites; WBC not measured at Um El Kher, Alkaline Phosphatase 
not measured at Kassab, Serum amylase only measured at Arba Minch. 
†  p-value from ANOVA for comparison of mean values, Kruskall-Wallis where median values are given 
and chi-squared or Fishers test for categorical data comparisons. 
‡  p-value from t-test for comparison of means and chi-squared or Fishers test for sex and  categorical 
age comparisons, between SSG and PM 
§ Missing platelet values: SSG 2, PM 1, Comb 1 
|| Missing AST values: PM 1 
¶ Missing Bilirubin values: SSG 3, PM 3, Comb 2 
** Missing BUN values: SSG 22, PM 22, Comb 26 
†† Missing Amylase values: SSG 9, PM 6, Comb 6 
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Table 6 Baseline clinical characteristics     









Audiometry Normal 101 (74.8) 101 (74.8) 101 (74.8)   
Abnormal‡ 0 0 1 (0.7) 
Not done 34 (25.2) 34 (25.2) 33 (24.5) 
ECG 
 
Normal 134 (99.3) 135 (100) 134 (99.3)   
Abnormal‡ 0 0 1 (0.7) 
Not done 1 (0.7) 0 0 
Malaria prior to treatment 7 (5.2) 5 (3.7) 4 (3.0) 0.634 0.769 
Pneumonia 6 (4.4) 4 (3.0) 3 (2.2) 0.573 0.749 
Otitis Media 0 0 0   
 HIV Positive 4 (3.0) 6 (4.4) 6 (4.4)  
0.959 
 
0.812 Negative 87 (64.4) 86 (63.7) 88 (65.2) 
Not tested 44 (32.6) 43 (31.9) 41 (30.4) 
Data are n (%) 
*  p-value from chi-squared or Fishers test across all arms 
†  p-value from chi-squared of Fishers test between SSG and PM 
‡  Abnormal readings considered to be clinically significant; normal and clinically insignificant recordings 
grouped together.  A clinically significant abnormality in Audiometry data corresponds to clinical 
hearing loss. 
 
Table 7 Baseline Symptoms  
Symptom, n (%) 
  
SSG 
N =135  
PM  
N =135  
Comb  
N = 135 
p-value* p-value† 
Fever 133 (98.5) 133 (98.5) 131 (97.0) 0.600 1.000 
Headache 94 (69.6) 98 (72.6) 92 (68.2) 0.656 0.525 
Fatigue 109 (80.7) 102 (75.6) 108 (80) 0.530 0.303 
Epistaxis 46 (34.1) 51 (37.8) 47 (34.8) 0.797 0.526 
Abdominal pains 89 (65.9) 88 (65.2) 79 (58.5) 0.381 0.898 
Abdominal swellings 77 (57.0) 84 (62.2) 72 (53.3) 0.332 0.385 
Swelling of legs 27 (20.0) 20 (14.8) 18 (13.3) 0.293 0.261 
Cough 91 (67.4) 83 (61.5) 84 (62.2) 0.544 0.309 
Breathlessness 63 (46.7) 59 (43.7) 65 (48.2) 0.757 0.625 
Night Sweats 89 (65.9) 85 (62.9) 80 (59.3) 0.525 0.611 
Loss of appetite 93 (68.9) 91 (67.4) 94 (69.6) 0.923 0.794 
Weight loss 114 (84.4) 111 (82.2) 108 (80.0) 0.634 0.624 
Diarrhoea 34 (25.2) 31 (23.0) 40 (29.6) 0.445 0.669 
Skin lesions 6 (4.4) 7 (5.19) 5 (3.7) 0.840 0.776 
*  p-value from chi-squared test across all arms 
†  p-value from chi-squared test between SSG and PM 
 FINAL: Page 21 of 56 
05 August 2009 For Internal Use Only 
10.3 Deviations from Protocol:  
10.3.1 Exclusion criteria at baseline 
Table 8 Minor Protocol Violations at Baseline 
Entry Criteria, n SSG 
N = 135 
PM  
N = 135 
Comb  
N = 135 
Aged < 4 or > 60 years 0 0 0 
Not diagnosed with VL 0 0 0 
Received anti-leishmanial drug in the last 6 months 0 0 0 
Malnutrition* 17 (12.6) 17 (12.6) 28 (20.7) 
Haemoglobin < 5g/dl 0 1 (0.7) 3 (2.1) 
WBC < 1 x 10³/mm 0 0 0 
Platelets < 40,000/mm 0 1 (0.7) 0 
Liver function tests more than 3 times ULN 0 1 (0.7) 1 (0.7) 
Creatinine outside the normal range for age & gender 4 (3.0) 5 (3.7) 5 (3.7) 
Pre-existing clinical hearing loss† 0 0 1 (0.7) 
History of cardiac arrhythmia or an abnormal ECG‡ 0 0 1 (0.7) 
Concomitant severe infection  0 0 0 
Data are n (%) 
*  assessed as severely underweight using weight-for-age in 4-14 year olds and BMI in patients 15 years 
and above 
†  1 patient had moderate to moderately severe hearing loss in the right ear at baseline 
‡ clinically significant abnormality  
 
10.3.2 Non-Compliance to Treatment Regimen 
SSG Arm (30 day treatment period): 
• 1 patient received 14 days of treatment only  
• 1 patient received full 30 days but a gap of 1 day on day 18 of treatment  
• 1 patient received 14 days of treatment: once daily for 4 days, twice daily (half 
dose) for 10 days  
PM Arm (21 day treatment period): 
• 1 patient received 20 days of PM treatment and one day of SSG on day 2 
Combination Arm (17 days treatment period): 
• 1 patient received 11 days of Combination treatment: days 1 – 8, 14 – 16 
inclusive  
 
10.3.3 Timing of Final Assessment  
Outcome data were missing for 25 patients at 6 months as a result of early follow up. Of 
those, 20 patients were followed up once within the first 4.5 months after the end of 
treatment.  Follow-up data collected for these patients were handled as 3 months data.  
A further 2 patients were seen within 1.5 months of TOC and again within 4.5 months of 
TOC.  For these patients, data from the later visit was handled as 3 month follow-up 
data in analyses.  For the remaining 3 patients, data were collected within 1.5 months of 
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the expected 3 month follow-up data and again within 4.5 months after TOC.  Since the 
final data collection took place prior to 4.5 months post end of treatment, the 6 months 
outcome data were handled as missing data.   
For 18 patients, primary endpoint data were collected more than 1.5 months (45 days) 
after the expected date of 6 months follow-up (Table 9). 
Table 9 Timing of final assessment 
Final evaluation SSG 





Within 2 weeks of expected date 51 (46.4) 52 (52.5) 71 (58.7) 
>2 weeks to <1.5 months  53 (48.2) 39 (39.4) 46 (38.0) 
1.5 to 3 months after expected date 5 (4.5) 6 (6.1) 3 (2.5) 
>3 to 4 months after expected date 1 (0.9) 1 (1.0) 0 
>4 to 5 months after expected date 0 0 1 (0.8) 
>7 to 8 months after expected date 0 1 (1.0) 0 
Data are n (%) 
 
10.4 Primary Efficacy Analysis: Overall 
10.4.1 Data handling of 6 months data 
As described in the methods, in the complete-case analysis missing values were 
replaced as treatment failures if 
• Death occurred during initial hospitalisation period, regardless of whether rescue 
medication was administered 
• Death occurred during follow-up and rescue was administered previously 
• Patients were not seen at 6 months (LTFU) but rescue was administered 
previously 
• Any other scenario where parasitology data were not available at 6 months but 
rescue was administered previously 
Data remain missing  
• Where patients were LTFU with no record of receipt of rescue medication prior to 
loss,  
• In the case of three deaths that occurred during follow up, confirmed to be 
independent of VL and the study drug by the medical co-ordinator (one death per 
arm);  
1. Unknown cause  
2. Sepsis and Immune Reconstitution 
3. Pericarditis due to TB 
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10.4.2 Primary Efficacy Analysis 
Table 10 Definitive Cure Analysis 1: Complete Case Analysis   
Estimation SSG 
N = 116 
PM  
N = 127 
Comb  
N = 123 
Treatment Efficacy at 6 months, n (%) 107 (92.2) 81 (63.8) 110 (89.4) 
Difference between SSG & PM (95% CI)  28.5% (18.8 to 38.1) 
Difference between SSG & Combination (95% CI) 2.8% (-4.5 to 10.1) 
Test of difference across arms: p-value* < 0.001 
Test of difference across centres, after adjustment for 
treatment : p-value* 
0.001 
Test of difference between adult & paediatric† patients, 
after adjustment for treatment : p-value* 
0.454 
*  p-value from likelihood ratio test, comparing models with and without variable  
being tested. 
†  paediatric: 4 to 14 years, adult 15 – 60 years 
 
There was strong evidence of a difference in efficacy between PM and SSG arms; the 
efficacy of PM was approximately 30% lower than the efficacy of SSG overall, although 
the efficacy could be somewhere between 20% and 40% lower than SSG (Table 10).  
There was no evidence of a difference in overall efficacy between the Combination and 
SSG arms. The efficacy of the Combination treatment was around 3% lower than SSG 
but 95% confidence bounds around the difference in efficacy show that results regarding 
inferiority of Combination treatment, compared to SSG, were inconclusive. 
There was strong evidence of an overall difference in efficacy by treatment arm (p < 
0.001), due to the much lower efficacy in the PM arm. 
After taking into account treatment allocation, there was strong evidence of a difference 
in efficacy by centre (p = 0.001) but no evidence of a difference in efficacy by age (p = 
0.454) when considering adult patients compared to paediatric patients. 
 
In the LPCF analysis (Table 11), missing values for parasitology at 6 months were 
replaced by the parasitology result obtained during the previous parasitological 
examination.  One patient in the SSG arm was excluded from this analysis because 
parasitological data were not available for this patients at the end of treatment or during 
follow-up.  
 
Differences in results of the LPCF analysis and complete-case analysis were negligible. 
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Table 11 Definitive Cure Analysis 2: Last parasitology carried forward 
Estimation SSG† 
N = 134 
PM  
N = 135 
Comb  
N = 135  
Treatment efficacy at 6 months, n (%) 124 (92.5) 88 (65.2) 122 (90.4) 
Difference between SSG & PM (95% CI)  27.4% (18.2 to 36.5) 
Difference between SSG & Combination (95% CI) 2.2% (-4.5 to 8.8) 
Test of difference across arms: p-value* < 0.001 
Test of difference across centres, after adjustment for 
treatment: p-value* 
0.018 
Test of difference between adult & paediatric‡ patients, 
after adjustment for treatment : p-value* 
0.379 
*  p-value from likelihood ratio test, comparing models with and without variable  
being tested. 
†  Parasitology examination not performed at end of treatment, 3 or 6 months follow-up for one patient 
in the SSG arm. 
‡  paediatric: 4 to 14 years, adult 15 – 60 years 
 
Loss to follow up was substantially higher in the SSG arm so, in the worst case analysis, 
the efficacy of SSG is calculated as 79% rather than 93% (Table 12). 
In the worst case analysis, the efficacy of the combination treatment is estimated to be 
higher than in the SSG arm, although the absolute difference and corresponding 
confidence bounds around the difference in efficacy are very similar to results of the 
previous two analyses.  The lower estimate of efficacy in the SSG arm leads to a smaller 
estimated difference in efficacy between SSG and PM; around 20% overall, compared to 
30% in the previous two analyses.   
The worst case analysis also provides strong evidence of variability by centre, after 
adjustment for treatment received (p < 0.001) and no evidence of variability between 
age groups (p = 0.346). 
Table 12 Definitive Cure Analysis 3: Worst-case analysis   
Estimation SSG 
N = 135 
PM  
N =135  
Comb  
N = 135   
Parasite free at 6 months, n (%) 107 (79.3) 81 (60.0) 110 (81.5) 
Difference between SSG & PM (95% CI)  19.3% (8.5 to 30.0) 
Difference between SSG & Combination (95% CI) -2.2% (-11.7 to 7.2) 
Test of difference across arms: p-value* < 0.001 
Test of difference across centres, after adjustment for 
treatment: p-value* 
< 0.001 
Test of difference between adult & paediatric† 
patients, after adjustment for treatment : p-value* 
0.346 
*  p-value from likelihood ratio test, comparing models with and without variable  
being tested. 
†  paediatric: 4 to 14 years, adult 15 – 60 years 
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10.4.3 Primary Efficacy Analysis: By centre 
Table 13 DC: Complete Case Analysis: By Centre 
Site SSG PM Comb  p-value*† 
Um el Kher 14 / 17 
(82.3%) 
4 / 28 
(14.3%) 
18 / 20 
(90.0%) 
< 0.001 
Kassab 14 / 15 
(93.3%) 
7 / 15 
(46.7%) 
14 / 15 
(93.3%) 
0.003 
Kenya 15 / 15 
(100.0) 
12 / 15 
(80.0%) 




Gondar 37 / 40 
(92.5%) 
30 / 40 
(75.0%) 
39 / 43 
(90.7%) 
0.064 
Arba Minch 27 / 29 
(93.1%) 
28 / 29 
(96.6%) 
28 / 30 
(93.3%) 
1.000 
p-value*‡ 0.568 < 0.001 0.373  
*  p-value from Fisher’s exact test 
†  comparison across arms within sites 
‡  comparison across sites within arms 
 
In the complete-case analysis, there was strong evidence of a difference in PM efficacy 
across sites (p < 0.001) and also between all treatment regimens in Sudanese sites (p < 
0.01), due to much lower efficacy in the PM arm (Table 13). 
In Gondar, the efficacy of SSG and Combination treatments was around 90% but 
approximately 15% lower in PM arm with weak statistical evidence of a difference across 
all arms (p = 0.064).   
In Kenya, the efficacy of PM was around 20% lower than SSG and the efficacy of the 
combination treatment was almost 25% lower.  The small sample size in Kenya does not 
provide adequate power to detect statistical evidence of a difference and it is impossible 
to predict whether the results based on increased numbers of patients in Kenya would be 
more balanced. 
Similar efficacy was observed in all three arms in Arba Minch. 
LTFU at 6m was higher in Um el Kher with evidence of a difference in LTFU by arm 
(Fisher’s exact test p = 0.001).  
The LPCF analysis by-centre produced very similar results to the complete-case analysis 
(Table 14). 
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Table 14 DC: LPCF Analysis: By Centre 
Site SSG PM Comb p-value*† 
Um el Kher 25 / 29 
(89.2%) 
6 / 30 
(20.0) 
28 / 30 
(93.3%) 
< 0.001 
Kassab 14 / 15 
(93.3%) 
7 / 15 
(46.7%) 
14 / 15 
(93.3%) 
0.003 
Kenya 15 / 15 
(100%) 
12 / 15 
(80.0%) 
11 / 15 
(73.3%) 
0.134 
Gondar 42 / 45 
(93.3%) 
34 / 45 
(75.6%) 
41 / 45 
(91.1%) 
0.037 
Arba Minch 28 / 29 
(96.6%) 
29 / 30 
(96.7%) 
28 / 30 
(93.3%) 
1.000 
p-value*‡ 0.636 < 0.001 0.302  
*  p-value from Fisher’s exact test 
†  comparison across arms within sites 
‡  comparison across sites within arms 
 
In the worst-case analysis assuming treatment failure for all patients with missing 6 
months efficacy data in Um el Kher, substantially reduced efficacy estimates in the SSG 
and Combination arms.  Based on these reduced estimates, there was strong evidence of 
a difference in efficacy in SSG and Combination arms, across treatment centres, results 
not seen in previous by-centre analyses.   
Results of the worst case analysis, comparing efficacy across arms within each site were 
similar to complete-case and LPCF analyses (Table 15). 
 
Table 15 DC: Worst Case Analysis: By Centre 
Site SSG PM Comb  p-value*† 
Um el Kher 14 / 30 
(46.7%) 
4 / 30 
(13.3%) 
18 / 30 
(60.0%) 
0.001 
Kassab 14 / 15 
(93.3%) 
7 / 15 
(46.7%) 
14 / 15 
(93.3%) 
0.003 
Kenya 15 / 15 
(100%) 
12 / 15 
(80.0%) 
11 / 15 
(73.3%) 
0.134 
Gondar 37 / 45 
(82.2%) 
30 / 45 
(66.7%) 
39 / 45 
(86.7%) 
0.059 
Arba Minch 27 / 30 
(90.0%) 
28 / 30 
(93.3%) 
28 / 30 
(93.3%) 
1.000 
p-value*‡ < 0.001 < 0.001 0.007  
*  p-value from Fisher’s exact test 
†  comparison across arms within sites 
‡  comparison across sites within arms 
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10.5 Secondary Efficacy Parasitology Analysis 
10.5.1 Data Handling at Test of Cure 
In the complete-case analysis, missing efficacy data were replaced as treatment failures 
in the following cases, since these events could not be assumed to be independent of VL 
or the study drug; 
• Death during initial hospitalization period, before or after receipt of rescue  
• Stopping of study treatment due to SAE or lack of response to treatment 
Stopping treatment due to a protocol violation or, investigator error in not conducting 
parasitological exam were not assumed to indicate treatment failure. 
 
10.5.2 Secondary Efficacy Parasitology Analysis: All sites 
There was too little power to test for a difference by centre, after adjustment for 
treatment arm.  Given the strong evidence of a difference between centres in the 
primary analysis, a by-centre analysis was also carried out for the secondary end point. 
Table 16 Test of Cure Analysis 1: Complete Case Analysis 
Estimation SSG 
N = 134 
PM  
N =135  
Comb‡  
N = 133  
Treatment Efficacy at end of treatment, n (%) 123 (91.8) 91 (67.4) 121 (91.0) 
Difference between SSG & PM (95% CI)  24.4% (15.2 to 33.6%) 
Difference between SSG & Combination (95% CI) 0.8% (-5.9 to 7.5) 
Test of difference across arms: p-value* < 0.001 
Test of difference between adult & paediatric† 
patients, after adjustment for treatment : p-value* 
0.793 
*  p-value from likelihood ratio test, comparing models with and without variable  
being tested. 
†  paediatric: 4 to 14 years, adult 15 – 60 years 
‡ Treatment was stopped prematurely for 2 patients who did not subsequently receive rescue 
medication or undergo parasitological testing at end of treatment  
 
Comparing complete-case results at DC and TOC, efficacy in the SSG and Combination 
arms only differed by 1% (Tables 10 & 16).  In the PM arm, efficacy differed by 3%, so 
overall differences in efficacy and corresponding 95% CIs showed similar results for 
primary and secondary end points.   
 
Results from both the worst-case and complete-case analyses at TOC were very similar 
due to there being only 3 missing values (Tables 16 & 17).  
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Table 17 Test of Cure Analysis 2: Worst Case Analysis 
Estimation SSG 
N = 135 
PM  
N =135  
Comb  
N = 135 
Treatment Efficacy at end of treatment, n (%) 123 (91.1) 91 (67.4) 121 (89.6) 
Difference between SSG & PM (95% CI)  23.7% (14.5 to 33.0%) 
Difference between SSG & Combination (95% CI) 1.5% (-5.5 to 8.5) 
Test of difference across arms: p-value* < 0.001 
Test of difference between adult & paediatric† 
patients, after adjustment for treatment : p-value* 
0.678 
*  p-value from likelihood ratio test, comparing models with and without variable  
being tested. 
†  paediatric: 4 to 14 years, adult 15 – 60 years 
 
10.5.3 Secondary Efficacy Parasitology Analysis: By Centre 
The overall efficacy of each treatment regimen remained almost the same between TOC 
and DC in complete-case analyses.  In Kenya and Sudan there appeared to be more 
failures during follow-up in the PM arm and some variability in Combination treatment 
efficacy across sites.  Patient numbers by-centre were too small however to consider 
statistical evidence of potential differences. 
Table 18 TOC: Complete Case Analysis By-Centre
Site SSG PM Comb p-value*† 
Um el Kher 26 / 29 
(89.7%) 
10 / 30 
(33.3%) 
26 / 30 
(86.7%) 
< 0.001 
Kassab 14 / 15 
(93.3%) 
9 / 15 
(60.0%) 
12 / 15 
(80.0%) 
0.113 
Kenya 15 / 15 
(100%) 
13 / 15 
(86.7%) 
13 / 13 
(100%) 
0.319 
Gondar 40 / 45 
(88.9%) 
30 / 45 
(66.7%) 
40 / 45 
(88.9%) 
0.014 
Arba Minch 28 / 30 
(93.3%) 
29 / 30 
(96.7%) 
30 / 30 
(100%) 
0.770 
p-value*‡ 0.832 < 0.001 0.127  
*  p-value from chi-squared test or Fisher’s exact test if justified 
†  comparison across arms by site 
‡  comparison across sites by arm 
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Table 19 TOC: Worst Case Analysis By-Centre 
Site SSG PM Comb  p-value*† 
Um el Kher 26 / 30 
(86.7%) 
10 / 30 
(33.3%) 
26 / 30 
(86.7%) 
< 0.001 
Kassab 14 / 15 
(93.3%) 
9 / 15 
(60.0%) 
12 / 15 
(80.0%) 
0.113 
Kenya 15 / 15 
(100%) 
13 / 15 
(86.7%) 
13 / 15 
(86.7%) 
0.524 
Gondar 40 / 45 
(88.9%) 
30 / 45 
(66.7%) 
40 / 45 
(88.9%) 
0.014 
Arba Minch 28 / 30 
(93.3%) 
29 / 30 
(96.7%) 
30 / 30 
(100%) 
0.770 
p-value*‡ 0.713 < 0.001 0.122  
*  p-value from chi-squared test or Fisher’s exact test if justified 
†  comparison across arms by site 
║  comparison between SSG and PM by site 
‡  comparison across sites by arm 
 
10.5.4 Slow response to Treatment 
The proportion of slow responders was less than 5% in all three arms (Table 20).   
 
Table 20 Slow Response by treatment arm  
Efficacy Outcome SSG 
N = 116 
PM 
N = 127 
Comb* 
N = 121 
Treatment Responder† 104 (90.4) 75 (59.1) 105 (85.4) 
Slow Responder‡  3 (2.6) 6 (4.7) 5 (4.1) 
     
Log drop in parasite load 
from baseline to end of 
treatment in slow 
responders 
1 0 2 1 
2 0 2 2 
>2 3 2 2 
Data are n (%) 
* Two patients had missing values for parasitology at end of treatment 
† parasites not detected at end of treatment or at 6 months follow-up, no rescue administered 
‡ parasites detected at end of treatment, not detected at 6 months follow-up, no rescue 
administered 
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10.5.5 Rescue Medication Outcomes 
Table 21 Rescue Medication and Study Outcome by Treatment 
 SSG PM Comb Total 
Total number of patients rescued prior to 
end of trial* 
8 46 9 63 
     
Timing of 1st rescue treatment:     
 During treatment period 3 3 1 7 
 During follow-up, prior to 6m assessment 5 43 8 56 
     
Outcome Post Rescue:     
 Died*  1 1 0 2 
 No VL at end of trial†  3 15 5 23 
 VL at end of trial†  0 3 2 5 
 Loss to follow up at 6 months 4 26 2 32 
 Parasitology not done at 6 months‡ 0 1 0 1 
      
VL detected at end of trial, first rescue 
treatment administered at end of trial. 
0 0 4 4 
EOT = end of treatment: SSG day 31, PM day 22, Combination day 18 
* PM arm only: 46 rescued patients presented as 45 rescued patients and 1 VL death in participant 
flow diagram  
† VL measured as presence of parasites in tissue samples on microscopy 
‡ patient was seen at 6 months 
 
 
10.5.6 Follow-up at 3 months 
Overall, 278 (83.2%) of 333 patients alive and parasite negative at TOC were followed 
up at 3 months along with 34 (50.0%) of 65 surviving treatment failures at TOC.  
Relapses had occurred in approximately 9% of PM patients and less than 5% of each of 
the SSG and Combination patients (Table 22).   
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Table 22 Overall Results 3 months Post End of Treatment  
Follow up at 3 months  SSG 
N = 135 
PM 
N = 135 
Comb 
N = 135 
Deaths 3 (2.2) 1 (0.7) 1 (0.7) 
Patients not seen 23 (17.0) 33 (24.4) 31 (23.0) 
    
Patients seen: assumed to be clinically well* 78 (57.8) 61 (45.2) 72 (53.3) 
Patients seen: parasites not detected 27 (20.0) 24 (17.8) 25 (18.5) 
Patients seen: parasites detected 4 (3.0) 16 (11.9) 6 (4.4) 
    
Patients seen: parasites not detected at TOC 102 82 94 
Relapses† 2 7 4 
EOT = end of treatment 
* clinically well patients did not have parasitological examination.   
† Relapse: parasites not detected at TOC, parasites detected at 3 months 
 
10.6 Safety ECG and Audiometry Analysis 
10.6.1 Safety Analysis: ECG 
Table 23 Number of ECG Tests performed per centre 
Day Centre 
Gondar 
N = 135 
Arba Minch 
N = 90 
Kenya 
N = 45 
Um el Kher  
N = 90 
Kassab  
N = 45 
0 135 89 45 90 45 
7 91 46 45 1 45 
14 134 90 44 88 43 
21 30 16 15 0 14 
EOT 132 88 43 87 43 
90 84 45 42 11 0 
180 121 85 43 35 33 
EOT = End of Treatment 
 
Table 24 ECG Analysis during treatment and follow-up 
Estimation SSG PM  Comb    
Number of patients randomised & normal on day 0 134 135 134 
Abnormal on day 7, n (%) 1 (0.8) 1 (0.7) 1 (0.8) 
Abnormal on day 14, n (%) 2 (1.5) 1 (0.7) 0  
Abnormal by day 14, n (%) 3 (2.2) 2 (1.5) 1 (0.8) 
Abnormal by end of treatment, n (%) 4 (3.0) 3 (2.2) 1 (0.8) 
Abnormal result at end of treatment, n (%) 1 (0.8) 1 (0.7)  0  
Abnormal result remaining at 6 months*, n (%) 0 0 0 
*  abnormal result at end of treatment, not returning to normal by end of follow-up 
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Less than 1% of patients in each of the SSG and PM arms with normal ECG results at 
baseline had an abnormal result at the end of treatment (Table 24).  No patients with a 
normal baseline reading in the Combination arm had an abnormal result at end of 
treatment.   Tests were not conducted across arms due to the small numbers of 
abnormal results at end of treatment. 
 
10.6.2 Safety Analysis: Audiometry 
Table 25 Number of Audiometry examinations performed per centre 
Day Centre 
Gondar 
N = 135 
Arba Minch 
N = 90 
Kenya 
N = 45 
Um el Kher  
N = 90 
Kassab  
N = 45 
0 135 79 45 0 45 
7 91 35 45 0 45 
14 134 78 43 0 41 
21 30 14 15 0 14 
End of 
Treatment 
132 77 43 0 43 
90 86 38 40 0 0 
180 121 78 44 0 33 
One patient allocated to Combination treatment had moderate to moderately severe 
hearing loss in their right ear at baseline and throughout the study.  This was recorded 
earlier as a minor protocol violation. 
There were no clinically significant audiometric readings recorded during treatment or 
follow-up 
 
10.6.3 Urinalysis: Protein and Blood  
Comparisons were made across all treatment arms and between SSG and PM separately.  
In addition to comparisons across all categorisations, comparisons were made for 
patients who completed treatment and hence had urinalysis results at both baseline and 
end of treatment. 
Note that this analysis assumes that a negative reading indicates a normal result and 
positive, abnormal. 
There was no evidence of a difference in how urinalysis parameters changed during 
treatment, across arms, or between SSG and PM arms. 
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Table 26 Urinalysis: Protein  
Estimation SSG 
N = 135 
PM  
N =135  
Comb  
N =135   
Baseline negative, end of treatment negative 73 (54.1) 78 (57.8) 72 (53.3) 
Baseline negative, end of treatment positive 4 (3.0) 5 (3.7) 9 (6.7) 
Baseline positive, end of treatment positive 6 (4.4) 5 (3.7) 6 (4.4) 
Baseline positive, end of treatment negative 45 (33.3) 41 (30.4) 44 (32.6) 
Baseline negative, end of treatment missing 4 (3.0) 2 (1.5) 3 (2.2) 
Baseline positive, end of treatment missing 2 (1.5) 1 (0.7) 0 (0) 
Test of Difference across all arms * 0.892 
Test of Difference across all arms † 0.848 
Test of Difference between SSG & PM * 0.911 
Test of Difference between SSG & PM † 0.906 
Data are n (%) 
Data unavailable at both baseline and end of treatment for 5 patients; SSG 1, PM 3, Comb 1 
*  p-value from chi-squared or Fishers test across all categories 
†  p-value from chi-squared or Fishers test across patients with values at both baseline and end of 
treatment (1st four categories) 
Table 27 Urinalysis: Blood 
Estimation SSG 
N = 135 
PM  
N =135  
Comb  
N =135   
Baseline negative, end of treatment negative 102 (75.6) 96 (71.1) 102 (75.6) 
Baseline negative, end of treatment positive 4 (3.0) 5 (3.7) 6 (4.4) 
Baseline positive, end of treatment positive 10 (7.4) 16 (11.9) 8 (5.9) 
Baseline positive, end of treatment negative 11 (8.2) 12 (8.9) 13 (9.6) 
Baseline negative, end of treatment missing 6 (4.4) 1 (0.7) 3 (2.2) 
Baseline positive, end of treatment missing 0 (0) 2 (1.5) 0 (0) 
Test of Difference across all arms * 0.411 
Test of Difference across all arms † 0.718 
Test of Difference between SSG & PM * 0.209 
Test of Difference between SSG & PM † 0.622 
Data are n (%) 
Data unavailable at both baseline and end of treatment for 8 patients; SSG 2, PM 3, Comb 3 
*  p-value from chi-squared or Fishers test across all categories 
†  p-value from chi-squared or Fishers test across patients with values at both baseline and end of 
treatment (1st four categories) 
 
10.7 Secondary Efficacy Analysis: Biological Parameters during 
Treatment  
Mean differences in parameters between time points are also presented with 
corresponding 95% CIs.  ANCOVA tests for evidence of a difference between treatment 
arms adjust for baseline values and treatment centre. 
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All available data were used in this analysis.  Data collection ceased if a patient was 
withdrawn from treatment due to a serious adverse event.  It is important to note that 
other patients may have experienced an adverse event that led to a large change in one 
of the parameters included in this analysis, such values were not excluded. 
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Table 28 Difference in biological parameters between baseline and Day 7  
Efficacy Marker SSG  PM  Comb p-value* p-value† 
 N Mean Change (95% CI) N Mean Change (95% CI) N Mean Change (95% CI)   
Weight gain (Kg) 135 0.76 (0.51 to 1.01 ) 135 0.52 (0.27 to 0.77) 135 0.53 (0.27 to 0.79) 0.345 0.186 
Temperature (°C) 135 -1.30 (-1.53 to -1.08) 135 -0.91 (-1.11 to -0.70) 135 -1.42 (-1.64 to -1.20) <0.001 <0.001 
Heart Rate, (beats/min) 135 -7.71 (-10.29 to -5.13) 135 -3.67 (-6.26 to -1.09) 135 -5.17 (-7.53 to -2.81) 0.118 0.053 
Spleen Size (cm)  135 -1.55 (-1.86 to -1.25) 135 -0.97 (-1.28 to -0.66) 135 -1.51 (-1.81 to -1.20) 0.006 0.003 
Liver Size (cm)  135 -0.42 (-0.64 to -0.21) 135 -0.26 (-0.47 to -0.05) 135 -0.41 (-0.64 to -0.19) 0.450 0.214 
Systolic BP (mm Hg) 135 -1.41 (-3.99 to 0.23) 135 -2.33 (-3.99 to -0.68) 135 -1.07 (-2.64 to 0.49) 0.965 0.973 
Diastolic BP (mm Hg) 135 -0.22 (-1.74 to 1.30 135 -1.00 (-2.51 to 0.51) 135 -0.37 (-1.71 to 0.97) 0.902 0.958 
Haemoglobin (g/dl)  135 0.12 (-0.08 to 0.32) 135 0.03 (-0.18 to 0.23) 135 0.39 (0.22 to 0.57) 0.042 0.572 
White-cell Count (x103/µL)  105 0.24 (-0.04 to 0.53) 105 0.44 (-0.14 to 1.02) 105 0.30 (0.05 to 0.56) 0.746 0.601 
Platelets (x103/µL)  102 41.5 (28.8 to 54.2) 104 5.95 (-4.28 to 16.2) 104 38.4 (25.3 to 51.5) <0.001 <0.001 
AST, (U/L) 135 24.9 (16.9 to 33.0) 134 10.4 (4.9 to 15.9) 135 30.8 (21.7 to 39.8) 0.001 0.004 
ALT, (U/L) 135 23.7 (16.9 to 30.5) 135 8.8 (5.4 to 12.3) 135 24.5 (17.1 to 31.8) <0.001 <0.001 
Bilirubin, (umol/L) 132 -0.81 (-1.69 to 0.07) 131 0.09 (-0.93 to 1.11) 131 -1.48 (-2.30 to -0.65) 0.020 0.111 
BUN, (mmol/L) 104 -0.14 (-1.28 to 1.01) 107 0.05 (-0.30 to 0.41) 101 -0.54 (-1.24 to 0.16) 0.639 0.773 
Creatinine (umol/L) 135 -2.90 (-7.17 to 1.36) 135 0.19 (-2.97 to 3.36) 135 -1.82 (-6.29 to 2.64) 0.610 0.298 
Amylase, (micromol/L) 21 83.9 (30.97 to 136.83) 22 7.61 (-15.74 to 30.97) 23 71.87 (22.83 to 120.93) 0.002 0.009 
Alkaline Phosphatase (U/L) 120 193.18 (110.24 to 276.12) 120 44.7 (14.34 to 75.06) 120 156.13 (117.65 to 194.61) 0.002 0.004 
SD = standard deviation, BP = blood pressure 
A negative value indicates a decrease in day 7 values, on average, compared to baseline 
*  p-value from ANCOVA between arms in day 7 measurements, adjusting for baseline values and centre 
† p-value from ANCOVA between SSG and PM in day 7 measurements, adjusting for baseline values and centre 
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Table 29 Difference in biological parameters between Day 7 and Day 14 
Efficacy Marker SSG  PM  Comb p-value* p-value† 
 N Mean Change (95% CI) N Mean Change (95% CI) N Mean Change (95% CI)   
Weight gain (Kg) 134 0.35 (0.13 to 0.57) 133 0.47 (0.28 to 0.65) 133 0.34 (0.13 to 0.55) 0.637 0.424 
Temperature (°C) 134 -0.03 (-0.15 to -0.10) 133 -0.43 (-0.60 to -0.26) 133 0 (-0.10 to 0.10) 0.583 0.714 
Heart Rate, (beats/min) 134 -2.22 (-4.32 to -0.13) 133 -2.03 (-3.86 to -0.20) 133 -2.90 (-4.68 to -1.12) 0.731 0.515 
Spleen Size (cm)  134 -1.46 (-1.72 to -1.02) 133 -1.32 (-1.61 to -1.02) 133 -2.05 (-2.34 to -1.75) <0.001 0.121 
Liver Size (cm)  132 -0.42 (-0.65 to -0.19) 132 -0.47 (-0.66 to -0.29) 133 -0.82 (-1.08 to -0.57) 0.010 0.935 
Systolic BP (mm Hg) 134 1.68 (0.11 to 3.24) 133 -0.19 (-1.77 to 1.40) 133 2.86 (1.28 to 4.44) 0.235 0.238 
Diastolic BP (mm Hg) 134 0.93 (-0.60 to 2.47) 133 0.60 (-1.02 to 2.22) 133 2.56 (1.12 to 3.99) 0.265 0.911 
Haemoglobin (g/dl)  134 1.06 (0.88 to 1.23) 133 1.10 (0.89 to 1.32) 131 1.23 (1.04 to 1.42) 0.324 0.714 
White-cell Count (x103/µL)  104 0.49 (0.28 to 0.70) 104 0.62 (0.03 to 1.22) 101 0.85 (0.57 to 1.12) 0.386 0.213 
Platelets (x103/µL)  103 37.8 (22.3 to 53.4) 104 54.1 (43.6 to 64.6) 101 57.2 (45.2 to 69.1) 0.154 0.376 
AST, (U/L) 134 -14.1 (-23.1 to -5.13) 133 0.38 (-7.30 to 8.06) 131 -19.0 (-29.3 to -8.75) 0.459 0.322 
ALT, (U/L) 134 -5.75 (-12.8 to 1.29) 133 10.1 (5.16 to 15.0) 131 -5.05 (-12.9 to 2.82) 0.211 0.053 
Bilirubin, (umol/L) 134 -0.03 (-0.75 to 0.69) 131 -0.82 (-1.86 to 0.23) 129 0.23 (-0.56 to 1.02) 0.704 0.562 
BUN, (mmol/L) 106 0.25 (-0.18 to 0.68) 106 0.47 (0.10 to 0.83) 99 0.05 (-0.41 to 0.51) 0.239 0.300 
Creatinine (umol/L) 134 -0.50 (-2.81 to 1.80) 133 -1.08 (-3.24 to 1.08) 131 0.22 (-2.56 to 3.01) 0.924 0.991 
Amylase, (micromol/L) 22 45.8 (-13.1 to 104.6) 21 3.42 (-9.55 to 16.4) 21 -19.6 (-53.2 to 13.9) 0.092 0.771 
Alkaline Phosphatase (U/L) 120 -85.6 (-140.7 to -30.5) 118 50.1 (26.7 to 73.4) 119 -41.9 (-84.4 to 0.67) 0.024 0.005 
SD = standard deviation, BP = blood pressure  
A negative value indicates a decrease in day 14 values, on average, compared to day 7 
*  p-value from ANCOVA between arms in day 14 measurements, adjusting for day 7 values and centre 
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Table 30 Difference in biological parameters between Baseline and Day 14 
Efficacy Marker SSG  PM  Comb p-value* p-value† 
 N Mean Change (95% CI) N Mean Change (95% CI) N Mean Change (95% CI)   
Weight gain (Kg) 134 1.14 (0.85 to 1.42) 133 1.02 (0.75 to 1.30) 133 0.88 (0.56 to 1.21) 0.487 0.518 
Temperature (°C) 134 -1.34 (-1.56 to -1.11) 133 -1.37 (-1.58 to -1.16) 133 -1.41 (-1.62 to-1.20) 0.729 0.463 
Heart Rate, (beats/min) 134 -10.0 (-12.7 to -7.34) 133 -5.97 (-8.54 to -3.39) 133 -8.06 (-10.5 to -5.58) 0.161 0.063 
Spleen Size (cm)  134 -3.00 (-3.42 to -2.58) 133 -2.28 (-2.69 to -1.87) 133 -3.56 (-3.97 to -3.15) < 0.001 0.002 
Liver Size (cm)  133 -0.84 (-1.17 to -0.51) 132 -0.77 (-1.05 to -0.48) 133 -1.26 (-1.56 to 0.89) 0.033 0.537 
Systolic BP (mm Hg) 134 0.15 (-1.57 to 1.87) 133 -2.48 (-4.35 to -0.61) 133 1.92 (0.38 to 3.46) 0.019 0.208 
Diastolic BP (mm Hg) 134 0.56 (-1.18 to 2.30) 133 -0.41 (-2.22 to 1.40) 133 2.33 (0.58 to 4.09) 0.299 0.999 
Haemoglobin (g/dl)  134 1.18 (0.94 to 1.42) 133 1.16 (0.89 to 1.42) 131 1.61 (1.36 to 1.86) 0.034 0.958 
White-cell Count (x103/µL)  104 0.72 (0.40 to 1.05) 104 1.07 (0.81 to 1.32) 101  1.14 (0.81 to 1.47) 0.180 0.084 
Platelets (x103/µL)  102 78.5 (63.4 to 93.6) 103 59.9 (48.3 to 71.5) 100  94.5 (80.3 to 108.8) 0.002 0.047 
AST, (U/L) 134 11.0 (4.50 to 17.5) 132 10.3 (2.95 to 17.7) 131  10.5 (3.85 to 17.2) 0.985 0.879 
ALT, (U/L) 134  18.0 (12.3 to 23.7) 133  19.0 (14.1 to 23.9) 131 18.0 (13.0 to 22.9) 0.968 0.832 
Bilirubin, (umol/L) 131 -0.83 (-1.79 to 0.13) 129 -0.67 (-1.63 to 0.28) 129 -1.01 (-2.01 to -0.01) 0.942 0.935 
BUN, (mmol/L) 103 -0.38 (-0.89 to 0.13) 105  0.43 (-0.03 to 0.88) 100 -0.82 (-1.38 to -0.26) 0.002 0.012 
Creatinine (umol/L) 134  -4.95 (-8.05 to -1.85) 133  -0.88 (-4.17 to 2.41) 131 -2.79 (-6.29 to 0.70) 0.208 0.071 
Amylase, (micromol/L) 19 146.8 (32.3 to 261.4) 18 10.1 (-12.0 to 32.3) 19 52.7 (8.73 to 96.8) 0.025 0.201 
Alkaline Phosphatase (U/L) 120 107.5 (62.5 to 152.6) 118  97.0 (57.1 to 136.9) 119 111.4 (78.4 to 144.5) 0.719 0.569 
SD = standard deviation, BP = blood pressure 
A negative value indicates a decrease in day 14 values, on average, compared to baseline 
*  p-value from ANCOVA between arms in day 14 measurements, adjusting for baseline values and centre 
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Table 31 Difference in biological parameters between Day 14 and End of treatment 
Efficacy Marker SSG  PM  Comb p-value* p-value† 
 N Mean Change (95% CI) N Mean Change (95% CI) N Mean Change (95% CI)   
Weight gain (Kg) 131 0.99 (0.71 to 1.26) 132 0.72 (0.52 to 0.92) 132 0.36 (0.21 to 0.51) <0.001 0.118 
Temperature (°C) 131 -0.02 (-0.13 to 0.09) 132 -0.10 (-0.21 to 0.01) 132 0.03 (-0.05 to 0.11) 0.111 0.570 
Heart Rate, (beats/min) 130 -1.08 (-3.30 to 1.12) 132 -4.0 (-5.89 to -2.11) 132 -1.70 (-3.12 to -0.28) 0.112 0.099 
Spleen Size (cm)  131 -1.81 (-2.14 to -1.47) 132 -1.64 (-1.95 to -1.32) 132 -0.86 (-1.07 to -0.65) <0.001 0.059 
Liver Size (cm)  131 -0.63 (-0.87 to -0.39) 131 -0.65 (-0.87 to -0.44) 132 -0.30 (-0.46 to -0.15) 0.107 0.659 
Systolic BP (mm Hg) 131 1.64 (0.08 to 3.20) 132 3.26 (1.76 to 4.75) 132 0.72 (-0.88 to 2.32) 0.099 0.115 
Diastolic BP (mm Hg) 131 1.22 (-0.31 to 3.83) 132 2.12 (0.41 to 3.83) 132 -0.34 (-1.80 to 1.11) 0.103 0.185 
Haemoglobin (g/dl)  130 1.12 (0.89 to 1.35) 132 0.92 (0.68 to 1.15) 129 0.35 (0.20 to 0.50) <0.001 0.237 
White-cell Count (x103/µL)  101 1.46 (1.09 to 1.82) 103 0.88 (0.63 to 1.12) 100 1.29 (-0.61 to 3.19) 0.807 0.021 
Platelets (x103/µL)  101 23.87 (11.07 to 36.68) 103 31.31 (19.50 to 43.13) 99 21.51 (10.38 to 32.63) 0.858 0.614 
AST, (U/L) 130 -5.59 (-12.46 to 1.28) 132 -2.14 (-8.74 to 4.45) 130 -1.78 (-5.95 to 2.39) 0.471 0.367 
ALT, (U/L) 130 -10.1 (-15.4 to -4.78) 132 0.80 (-4.06 to 5.65) 130 -3.22 (-6.89 to 0.45) 0.001 <0.001 
Bilirubin, (umol/L) 129 0.15 (-0.52 to 0.83) 128 0.73 (0.05 to 1.42) 128 -0.34 (-1.02 to 0.34) 0.030 0.103 
BUN, (mmol/L) 101 0.91 (-0.68 to 2.50) 104 0.06 (-0.42 to 0.54) 101 -0.23 (-0.58 to 0.12) 0.256 0.321 
Creatinine (umol/L) 130 4.11 (-1.30 to 9.51) 132 1.36 (-1.59 to 4.31) 130 0.30 (-2.82 to 3.41) 0.361 0.618 
Amylase, (micromol/L) 24 -29.87 (-107.52 to 47.77) 22 1.33 (-11.36 to 14.02) 24 4.63 (-22.47 to 31.74) 0.297 0.055 
Alkaline Phosphatase (U/L) 116 -30.63 (-74.94 to 13.67) 117 -8.09 (-46.14 to 29.95) 118 -7.17 (-30.06 to 15.73) 0.914 0.824 
SD = standard deviation, BP = blood pressure  
A negative value indicates a decrease in end of treatment values, on average, compared to day 14 
*  p-value from ANCOVA between arms in end of treatment measurements, adjusting for day 14 values and centre 
† p-value from ANCOVA between SSG and PM in end of treatment measurements, adjusting for day 14 values and centre 
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Table 32 Difference in biological parameters between Baseline and End of treatment  
Efficacy Marker SSG  PM  Comb p-value* p-value† 
 N Mean Change (95% CI) N Mean Change (95% CI) N Mean Change (95% CI)   
Weight gain (Kg) 131 2.13 (1.79 to 2.47) 132 1.74 (1.42 to 2.07) 132 1.25 (0.92 to 1.58) 0.001 0.085 
Temperature (°C) 131 -1.37 (-1.58 to -1.17) 132 -1.45 (-1.66 to -1.25) 132 -1.39 (-1.60 to -1.18) 0.166 0.705 
Heart Rate, (beats/min) 130  -11.8 (-14.3 to -9.25) 132 -10.1 (-12.7 to -7.46) 132 -9.70 (-12.2 to -7.24) 0.547 0.995 
Spleen Size (cm)  131 -4.83 (-5.38 to -4.28) 132  -3.92 (-4.49 to -3.35) 132 -4.41 (-4.88 to -3.95) 0.001 0.001 
Liver Size (cm)  130  -1.52 (-1.90 to -1.15) 131 -1.43 (-1.80 to -1.05) 132 -1.53 (-1.91 to -1.15) 0.607 0.343 
Systolic BP (mm Hg) 131 1.56 (-0.31 to 3.44) 132 0.68 (-1.36 to 2.73) 132 2.58 (0.74 to 4.41) 0.784 0.810 
Diastolic BP (mm Hg) 131 1.64 (-0.18 to 3.46) 132 1.78 (0.01 to 3.55) 132 2.01 (0.41 to 3.61) 0.497 0.258 
Haemoglobin (g/dl)  130 2.33 (2.03 to 2.63) 132 2.10 (1.80 to 2.39) 131 1.96 (1.72 to 2.21) 0.042 0.339 
White-cell Count (x103/µL)  101 2.17 (1.67 to 2.66) 103 1.97 (1.65 to 2.29) 102 2.49 (0.61 to 4.37) 0.874 0.226 
Platelets (x103/µL)  99 103.3 (84.1 to 122.4) 102 92.6 (77.6 to 107.5) 100 118.4 (102.9 to 134.0) 0.084 0.360 
AST, (U/L) 130 4.19 (-2.96 to 11.3) 131 7.99 (0.63 to 15.3) 132 8.75 (2.12 to 15.4) 0.532 0.383 
ALT, (U/L) 130 7.82 (3.87 to 11.8) 132 19.9 (14.2 to 25.6) 132 14.6 (9.07 to 20.2) 0.004 0.001 
Bilirubin, (umol/L) 126 -0.80 (-1.93 to 0.33) 126  -0.18 (-1.11 to 0.76) 128 -1.42 (-2.33 to -0.52) 0.095 0.233 
BUN, (mmol/L) 98 0.55 (-1.18 to 2.28) 102 0.50 (-0.10 to 1.10) 101 -1.06 (-1.65 to -0.47) 0.103 0.974 
Creatinine (umol/L) 130 -1.24 (-6.44 to 3.95) 132 0.54 (-3.46 to 4.54) 132 -3.19 (-6.59 to 0.22) 0.360 0.712 
Amylase, (micromol/L) 20 133.5(22.3 to 244.6) 21 8.42 (-13.1 to 30.0) 19 58.7 (27.4 to 90.0) 0.026 0.027 
Alkaline Phosphatase (U/L) 116 75.5 (23.5 to 127.4) 117 90.2 (44.7 to 135.7) 118 106.4 (76.9 to 135.8) 0.793 0.578 
SD = standard deviation, BP = blood pressure 
A negative value indicates a decrease in end of treatment values, on average, compared to baseline 
*  p-value from ANCOVA between arms in end of treatment measurements, adjusting for baseline values and centre 
† p-value from ANCOVA between SSG and PM in end of treatment measurements, adjusting for baseline values and centre 
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Table 33 Summary: Comparison of mean changes in biological parameters  
Results for mean changes within and between arms Baseline to Day 7 Day 7 to 14 Baseline to Day 14 Day 14 to End of 
Treatment 
Significant reduction in all arms, on average 





Spleen Size  
(smaller for PM) 
Spleen Size 
Significant reduction in all arms, on average 






Heart Rate, Liver Size 
Liver Size 
Significant increase in all arms, on average 
Evidence of difference in increase between arms 
AST, ALT 
Alkaline Phosphatase 
 HB, Platelets Weight, HB 
Significant increase in all arms, on average 
No or little evidence of difference in increase between arms 
Weight Weight, Platelets 
HB, WBC 
Weight, WBC, AST, 
ALT, Alk. Phosphatase 
Platelets 
Significant increase in parameter at least one arm* 
Evidence of a difference in average change between arms 
Platelets, Amylase  
(SSG Comb) 
Alk. Phosphatase (PM) 
(between PM & SSG) 
  
Significant increase in parameter at least one arm* 





Amylase (SSG) WBC (SSG PM) 
Bilirubin (PM) 
Significant reduction in parameter at least one arm* 
Evidence of a difference in average change between arms 
 AST (SSG & Comb) Bilirubin (Comb) ALT (SSG) 
Significant reduction in parameter at least one arm* 
No or little evidence of a difference between arms 
Bilirubin (Comb)  Bilirubin (Comb) 
Creatinine (SSG) 
Heart Rate (PM 
Comb) 
No significant change in parameter in any arm 





 Temperature, AST, 
BUN, Creatinine, 
Alk. Phosphatase 
HB = Haemoglobin, WBC = White Blood Cell Count 
Significant changes (reduction or increase) in parameter, on average, within arms assumed where 95% CI around mean difference excludes zero. 
Due to amount of comparisons made, evidence of statistical significance of variation in mean change across arms was assumed where p < 0.01 
* arm in which increase or reductions occurs is given in parentheses 
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Table 34 Summary: Change from Baseline to End of Treatment 
Results for mean changes within and between arms Change from Baseline to End of 
Treatment 
Significant reduction in all arms, on average 
Evidence of difference in reduction between arms 
Spleen Size (smaller reduction PM) 
Significant reduction in all arms, on average 
No or little evidence of difference in reduction between arms 
Temperature, liver size 
Significant increase in all arms, on average 
Evidence of difference in increase between arms 
Weight, heart rate 
Significant increase in all arms, on average 
No or little evidence of difference in increase between arms 
Platelets, AST, ALT, Alkaline 
Phosphatase 
Significant increase in parameter at least one arm* 
Evidence of a difference in average change between arms 
 
Significant increase in parameter at least one arm* 
No or little evidence of a difference between arms 
HB (Comb), Bilirubin (PM, Comb), 
Amylase (SSG, Comb), WBC (Comb)  
Significant reduction in parameter at least one arm* 
Evidence of a difference in average change between arms 
 
Significant reduction in parameter at least one arm* 
No or little evidence of a difference between arms 
BUN (Comb) 
No significant change in parameter in any arm 
No evidence of a difference between arms 
Creatinine 
HB = Haemoglobin, WBC = White Blood Cell Count 
Significant changes (reduction or increase) in parameter, on average, within arms assumed where 95% CI 
around mean difference excludes zero. 
Due to amount of comparisons made, evidence of statistical significance from ANCOVA of variation in mean 
change across arms was assumed where p < 0.01 
* arm in which increase or reductions occurs is given in parentheses 
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10.8 Serious Adverse Events (SAEs) and Non-Serious Adverse Events (AEs) 
Table 35 Number of patients experiencing adverse events 
 SSG PM Comb Total 
Number Randomised 135 135 135 405 
Number of patients with SAE*:     
 Total 8 (5.9%) 5 (3.7%) 3 (2.2%) 16 
 Treatment Emergent† 7 (5.2%) 3 (2.2%) 3 (2.2%) 13 
 During Follow-up 1 (0.7%) 2 (1.4%) 0 (0) 3 
 Adverse drug reaction‡ 5 (3.7%) 3 (2.2%) 2 (1.4%) 10 
 Unrelated to study drug§ 3 (2.2%) 2 (1.4%) 1 (0.7%) 3 
     
Patients with at least one AE:      
 At any time 99 (73.3%) 77 (57.0%) 93 (68.9%) 269 
 Treatment Emergent† 90 (66.7%) 65 (48.2%) 75 (55.6%) 230 
 During Follow-up 35 (25.9%) 33 (24.4%) 42 (31.1%) 110 
SAE  = Serious Adverse Event, AE = Non-serious adverse event 
*  no patients experienced more than one SAE 
†  Treatment emergent defined as onset  being between day 1 of treatment and 30 days post end of 
treatment, inclusive.  AEs occurring during follow-up had onset recorded as between day 31 of trial 
and end of study. 
‡  Adverse drug reaction recorded as unlikely, possible or probable relation to study drug.   
§  Adverse drug reaction recorded as Not Related to study drug 
 
Table 36 Number of adverse events 
 Total SSG PM Comb 
Number of AE*:     
 Total 566 217 (38.3%) 168 (29.7%) 181 (32.0%) 
 Treatment Emergent 411 169 (41.1%) 112 (27.3%) 130 (31.6%) 
 During Follow-up 155 48 (31.0%) 56 (36.1%) 51 (32.9%) 
     
Number of AEs per patient:     
Median  1 1 1 
Range  0 - 8 0 - 8 0 – 6 
SAE = Serious Adverse Event, AE = Non-serious adverse event, IQR = Inter-quartile range 
*  not all patients experienced an AE whereas some patients experienced more than one AE 
 
After adjustment for centre using Poisson regression (Table 36), there was weak 
evidence of a lower rate of treatment emergent AE between PM and SSG (p=0.041), but 
no evidence of a difference in rates between Combination and SSG arms (p=0.876).  
Tere was strong evidence (p<0.001) of heterogeneity in the rate of treatment emergent 
AE between study centres, after adjustment for treatment allocation, and strong 
evidence of a treatment-centre interaction (p<0.001).  Rate ratios (RR) comparing PM to 
SSG and also Combination to SSG are presented by centre to demonstrate this (Table 
37).    
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Across centres, the rate of treatment emergent AE in the PM arm, compared to SSG, was 
approximately equivalent in Arba Minch.  In all other sites, the rate appeared to be lower 
but there was only weak statistical evidence to support this in Gondar. 
In all centres except Gondar, the rate of treatment emergent AE in the Combination arm, 
was also estimated to be lower compared to SSG, with strong statistical evidence of a 
reduced rate in Um el Kher.  In Gondar, the treatment emergent AE rate in the 
Combination arm was significantly higher than in the SSG arm (p=0.007), an opposite 
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10.8.1 Treatment Emergent AEs: Summary Results 
Table 37 Treatment Emergent Adverse Event Rate Ratios 
 Total person-days on 
treatment (T) * 
Number of events* PM vs SSG Comb vs SSG  
 SSG PM Comb SSG PM Comb Adjusted Rate Ratio 
(95% CI) 
p-value‡ Adjusted Rate 
Ratio† (95% CI) 
p-value‡ 
Non-Serious adverse event: Treatment Emergent 
All 8100 6885 6345 169 112 130 0.78 (0.61 to 0.99)† 0.041 0.98 (0.78 to 1.23)† 0.876 
Gondar 2700 2295 2115 62 35 77 0.66 (0.44 to 1.00) 0.053 1.59 (1.13 to 2.22) 0.007 
Arba Minch 1800 1530 1410 25 22 14 1.03 (0.58 to 1.84) 0.906 0.71 (0.37 to 1.38) 0.315 
Kenya 900 765 705 29 23 15 0.93 (0.54 to 1.61) 0.804 0.66 (0.35 to 1.23) 0.192 
Um el Kher 1800 1530 1410 36 24 11 0.78 (0.47 to 1.31) 0.357 0.39 (0.20 to 0.77) 0.006 
Kassab 900 765 705 17 8 13 0.55 (0.24 to 1.28) 0.168 0.98 (0.47 to 2.01) 0.948 
SSG is the reference arm used in all analyses.  Rate Ratio (RR) < 1 suggests a reduced rate compared to SSG; RR > 1 suggests an increased rate. 
Treatment emergent defined as beginning between day 1 of treatment and 30 days post end of treatment, inclusive. 
Patients recruited: Gondar 135, Arba Minch 90, Kenya 45, Um el Kher 90, Kassab 45 
*  some patients experienced more than 1 AE 
†  rate ratio adjusted for centre 
‡ Wald p-value from Poisson regression model   
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10.8.2 Serious Adverse Events: Listing 
Table 38 Serious Adverse Events, by treatment and relation to study drug 
System Organ Class and Preferred 
MedDRA Term 
SSG PM Comb Total 
NR ADR NR ADR NR ADR  
BLOOD AND LYMPHATIC DISORDERS 0 0 0 1 0 0 1 
 ANAEMIA 0 0 0 1 0 0 1 
CARDIAC DISORDERS 0 0 0 1 0 0 1 
 CARDIAC FAILURE HIGH OUTPUT 0 0 0 1 0 0 1 
GASTROINTESTINAL DISORDERS 1 1 0 0 0 0 2 
 PANCREATITIS 0 1 0 0 0 0 1 
 PERITONEAL HAEMORRHAGE 1 0 0 0 0 0 1 
GENERAL DISORDERS AND 
ADMINISTRATION SITE CONDITIONS 
1 0 1 0 0 0 2 
 DEATH 1 0 1 0 0 0 2 
INFECTIONS AND INFESTATIONS 0 1 1 0 1 0 3 
 ABDOMINAL SEPSIS 0 1 1 0 0 0 2 
 PERICARDITIS MYCOPLASMAL 0 0 0 0 1 0 1 
INVESTIGATIONS 0 1 0 1 0 1 3 
 BLOOD AMYLASE INCREASED 0 1 0 0 0 0 1 
 HEPATIC ENZYME INCREASED 0 0 0 0 0 1 1 
 PLATELET COUNT DECREASED 0 0 0 1 0 0 1 
RENAL AND URINARY DISORDERS 0 2 0 0 0 1 3 
 RENAL FAILURE 0 0 0 0 0 1 1 
 RENAL FAILURE ACUTE 0 2 0 0 0 0 2 
RESPIRATORY, THORACIC AND 
MEDIASTINAL DISORDERS 
1 0 0 0 0 0 1 
 EPISTAXIS 1 0 0 0 0 0 1 
NR = Not Related to study drug, as recorded by investigator 
ADR = Adverse drug reaction, recorded as Probable, Possible or Unlikely relation to study drug by investigator 
Total number of AE, by System Organ Class, highlighted in bold type 
 
Table 39 Deaths during Treatment and Follow-up 
Arm Time of 
death* 
Cause of death System Organ Class† Relation to 
Study Drug 
SSG 87 Not clearly known General disorders‡  Not related 
SSG 34 Acute renal failure Renal & urinary disorders Possible 
SSG 12 Acute renal failure Renal & urinary disorders Probable 
PM 154 Sepsis secondary to gastroenteritis General disorders‡  Not related 
PM 183 Sepsis & immune reconstitution Infections & infestations Not related 
Comb 88 Pericarditis due to TB Infections & infestations Not related 
*  time: trial day that death occurred, calculated assuming day 1 of trial is day 1 of treatment 
†  classified according to MedDRA, version 10.0 
‡  full description: General disorders and administrative site conditions 
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10.8.3 Non-Serious Treatment Emergent Adverse Events: Listing 
In the tables below, 
• NR = Not Related to study drug, as recorded by investigator, ADR = Adverse drug reaction, 
recorded as Probable, Possible or Unlikely relation to study drug by investigator 
• Data are number of AE, by relation to study drug and treatment [number of patients 
experiencing AE, by relation to study drug and treatment] 
• Totals are for each system organ class and preferred MedDRA term. Totals in bold type 
correspond to overall totals for each system organ class 
Table 40 Treatment Emergent Non- Serious AEs 
Non-Serious Adverse Events SSG PM Comb Total 
 NR ADR NR ADR NR ADR  
BLOOD AND LYMPHATIC DISORDERS 1 2 0 0 0 0 3 
 ANAEMIA 0 1 0 0 0 0 1 
 LYMPHADENITIS 1 0 0 0 0 0 1 
 THROMBOCYTOPENIA 0 1 0 0 0 0 1 
CARDIAC DISORDERS 0 0 0 0 0 0 0 
EAR AND LABYRINTH DISORDERS 0 0 1 0 0 0 1 
 DEAFNESS 0 0 0 0 0 0 0 
 EAR PAIN 0 0 1 0 0 0 1 
ENDOCRINE DISORDERS 1 0 0 0 0 0 1 
 HYPOGLYCAEMIA 1 0 0 0 0 0 1 
EYE DISORDERS 5 0 0 0 1 1 7 
 CONJUNCTIVITIS 2 0 0 0 1 1 4 
 CONJUNCTIVITIS ALLERGIC 1 0 0 0 0 0 1 
 CONJUNCTIVITIS INFECTIVE 1 0 0 0 0 0 1 
 EYE PAIN 1 0 0 0 0 0 1 
GASTROINTESTINAL DISORDERS 7 6 7 7 [6] 4 11 42 
 ABDOMINAL DISTENSION 0 1 0 0 0 0 1 
 ABDOMINAL PAIN 1 1 1 2 0 1 6 
 ABDOMINAL PAIN UPPER 0 1 0 0 1 0 2 
 ASCITES 0 0 1 0 0 0 1 
 CHEILOSIS 0 1 0 0 0 0 1 
 DIARRHOEA 1 0 3 1 1 1 7 
 DYSPEPSIA 1 0 0 1 1 3 6 
 GASTRITIS 0 0 0 1 0 1 2 
 GINGIVAL BLEEDING 0 1 0 0 0 0 1 
 GINGIVITIS 1 0 0 0 0 0 1 
 MOUTH ULCERATION 1 0 0 0 0 0 1 
 MUCOUS STOOLS 1 0 0 0 0 0 1 
 NAUSEA 0 1 0 0 0 0 1 
 ORAL SOFT TISSUE DISORDER 0 0 0 0 0 1 1 
 PERITONITIS 0 0 1 0 0 0 1 
 VOMITING 1 0 1 2 [1] 1 4 9 
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Non-Serious Adverse Events (cont.) SSG PM Comb Total 
 NR ADR NR ADR NR ADR  
GENERAL DISORDERS AND 
ADMINISTRATION SITE CONDITIONS 
4 13 3 20 [19] 0 35 75 [74] 
 CHEST PAIN 1 0 0 0 0 0 1 
 CHILLS 1 0 0 1 0 0 2 
 INJECTION SITE PAIN 0 12 1 16 0 34 63 
 INJECTION SITE SWELLING 0 0 0 0 0 1 1 
 PERIPHERAL OEDEMA 1 0 0 0 0 0 1 
 PYREXIA 0 1 2 2 [1] 0 0 5 
 SWELLING 1 0 0 0 0 0 1 
 TENDERNESS 0 0 0 1 0 0 1 
IMMUNE SYSTEM DISORDERS 1 0 0 0 0 0 1 
 ALLERGY TO ARTHROPOD BITE 1 0 0 0 0 0 1 
INFECTIONS AND INFESTATIONS 
46 [44] 14 25 8 20 8 
121 
[119] 
 AMOEBIASIS 1 0 1 1 1 0 4 
 AMOEBIC DYSENTERY 0 0 0 0 1 0 1 
 ASCARIASIS 0 0 2 0 0 0 2 
 CELLULITIS 1 0 0 0 0 1 2 
 CROUP INFECTIOUS 1 0 0 0 0 0 1 
 DYSENTRY 0 1 0 0 0 0 1 
 FUNGAL SKIN INFECTION 0 0 0 1 0 0 1 
 GASTROENTERITIS 0 1 1 2 1 0 5 
 GIARDIASIS 3 0 0 1 1 0 5 
 HERPES ZOSTER 1 0 0 0 0 0 1 
 HOOKWORM INFECTION 1 0 0 0 1 1 3 
 INJECTION SITE CELLULITIS 0 0 0 0 0 3 3 
 LARYNGITIS 1 0 0 0 0 0 1 
 MALARIA 11 [10] 0 10 0 5 0 26 
 MOLLUSCUM CONTAGIOSUM 0 0 0 0 1 0 1 
 NASOPHARYNGITIS 6 0 1 0 1 0 8 
 OTITIS MEDIA 2 0 1 1 0 1 5 
 OTITIS MEDIA ACUTE 1 0 1 0 0 0 2 
 PNEUMONIA 9 [8] 2 4 0 1 1 17 
 PNEUMONIA PRIMARY ATYPICAL 1 1 0 0 1 0 3 
 STRONGYLOIDIASIS 0 0 0 0 1 0 1 
 TAENIASIS 1 0 0 0 0 0 1 
 UPPER RESPIRATORY TRACT 
INFECTION 
2 0 1 0 4 0 7 
 URINARY TRACT INFECTION 3 4 3 1 1 0 12 
 VARICELLA 1 0 0 0 0 0 1 
 VISCERAL LEISHMANIASIS 0 5 0 1 0 1 7 
 FINAL: Page 48 of 56 
05 August 2009 For Internal Use Only 
 
Non-Serious Adverse Events (cont.) SSG PM Comb Total 
 NR ADR NR ADR NR ADR  
INJURY, POISONING AND 
PROCEDURAL 
1 0 2 0 0 0 3 
 CONTUSION 0 0 1 0 0 0 1 
 RADIUS FRACTURE 1 0 0 0 0 0 1 
 SCRATCH 0 0 1 0 0 0 1 
INVESTIGATIONS 
0 43 [42] 0 24 1 37 
105 
[104] 
 ALANINE AMINOTRANSFERASE 
INCREASED 
0 7 0 3 0 3 13 
 ASPARTATE AMINOTRANSFERASE 
INCREASED 
0 13 0 7 0 15 35 
 AUDIOGRAM ABNORMAL 0 0 0 1 0 1 2 
 BLOOD ALKALINE PHOSPHATASE 
INCREASED 
0 7 0 5 0 6 18 
 BLOOD AMYLASE INCREASED 0 4 0 0 0 2 6 
 BLOOD CREATININE INCREASED 0 1 0 3 0 1 5 
 ELECTROCARDIOGRAM CHANGE 0 1 0 0 0 0 1 
 ELECTROCARDIOGRAM QT PROLONGED 0 2 [1] 0 0 0 0 2 
 HEPATIC ENZYMES INCREASED 0 2 0 0 0 2 4 
 PLATELET COUNT DECREASED 0 1 0 0 0 1 2 
 TRANSAMINASES INCREASED 0 5 0 4 0 6 15 
 WEIGHT DECREASED 0 0 0 1 0 0 1 
 WHITE BLOOD CELLS URINE POSITIVE 0 0 0 0 1 0 1 
METABOLISM AND NUTRITION 
DISORDERS 
0 0 0 0 0 1 1 
 ANOREXIA 0 0 0 0 0 1 1 
MUSCULOSKELETAL AND CONNECTIVE 
TISSUE DISORDERS 
2 2 1 2 0 0 7 
 ARTHRALGIA 0 1 0 1 0 0 2 
 BACK PAIN 1 1 1 1 0 0 4 
 NECK PAIN 1 0 0 0 0 0 1 
NERVOUS SYSTEM DISORDORS 3 2 0 5 1 0 11 
 BURNING SENSATION 0 1 0 0 0 0 1 
 HEADACHE 3 1 0 4 1 0 9 
 NEUROPATHY PERIPHERAL 0 0 0 1 0 0 1 
PSYCHIATRIC DISORDERS 0 0 0 0 1 0 1 
 INSOMINIA 0 0 0 0 1 0 1 
RENAL AND URINARY DISORDERS 0 0 0 1 1 0 2 
 ALBUMINURIA 0 0 0 1 0 0 1 
 HAEMATURIA 0 0 0 0 1 0 1 
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Non-Serious Adverse Events 
(cont.) 
SSG PM Comb Total 
 NR ADR NR ADR NR ADR  
RESPIRATORY, THORACIC AND 
MEDIASTINAL DISORDERS 
3 [1] 7 [6] 1 2 0 6 [5] 19 [12] 
 ALLERGIC BRONCHITIS 0 1  0 0 0 0 1 
 ASTHMA 0 0 0 0 0 3 [2] 3 
 COUGH 0 0 1 0 0 1 2 
 EPISTAXIS 3 [1] 6 [5] 0 2 0 2 13 
SKIN AND SUBCUTANEOUS TISSUE 
DISORDERS 
0 6 1 1 2 0 10 
 ACNE 0 1 0 0 0 0 1 
 PRURITUS 0 1 0 0 0 0 1 
 RASH 0 2 0 1 0 0 3 
 RASH MACULO-PAPULAR 0 1 0 0 0 0 1 
 RASH PAPULAR 0 1 0 0 0 0 1 
 RASH VESICULAR 0 0 0 0 1 0 1 
 SKIN LESION 0 0 0 0 1 0 1 
 SWELLING FACE 0 0 1 0 0 0 1 
VASCULAR DISORDERS 0 0 0 1 0 0 1 
 HYPERTENSION 0 0 0 1 0 0 1 
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10.8.4 All Non-Serious Adverse Events: Listing 
 
Table 41 All Non- Serious AEs, by treatment and relation to study drug 
Non-Serious Adverse Events SSG PM Comb Total 
 NR ADR NR ADR NR ADR  
BLOOD AND LYMPHATIC 
DISORDERS 
2 2 1 1 0 0 6 
 ANAEMIA 0 1 0 0 0 0 1 
 EOSINOPHILIA 0 0 1 0 0 0 1 
 LEUKOCYTOSIS 0 0 0 1 0 0 1 
 LYMPHADENITIS 1 0 0 0 0 0 1 
 THROMBOCYTOPENIA 1 1 0 0 0 0 2 
CARDIAC DISORDERS 0 2 0 2 0 0 4 
 BRADYCARDIA 0 2 0 1 0 0 3 
 SINUS ARRHYTHMIA 0 0 0 1 0 0 1 
EAR AND LABYRINTH DISORDERS 0 0 1 0 0 1 2 
 DEAFNESS 0 0 0 0 0 1 0 
 EAR PAIN 0 0 1 0 0 0 0 
ENDOCRINE DISORDERS 1 0 0 0 0 0 1 
 HYPOGLYCAEMIA 1 0 0 0 0 0 1 
EYE DISORDERS 7 0 2 0 3 1 13 
 CONJUNCTIVITIS 4 0 2 0 3 1 10 
 CONJUNCTIVITIS ALLERGIC 1 0 0 0 0 0 1 
 CONJUNCTIVITIS INFECTIVE 1 0 0 0 0 0 1 
 EYE PAIN 1 0 0 0 0 0 1 
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Non-Serious Adverse Events 
(cont.) 
SSG PM Comb Total 
 NR ADR NR ADR NR ADR  
GASTROINTESTINAL DISORDERS 9 7 10 8 6 11 51 
 ABDOMINAL DISTENSION 0 1 0 0 0 0 1 
 ABDOMINAL PAIN 1 1 1 2 0 1 6 
 ABDOMINAL PAIN UPPER 2 1 0 0 1 0 4 
 ASCITES 0 0 1 0 0 0 1 
 CHEILOSIS 0 1 0 0 0 0 1 
 DENTAL CARIES 0 0 1 0 0 0 1 
 DIARRHOEA 1 0 3 1 1 1 7 
 DOUDENAL ULCER 0 0 1 0 0 0 1 
 DYSPEPSIA 1 1 0 2 3 3 10 
 GASTRITIS 0 0 0 1 0 1 2 
 GINGIVAL BLEEDING 0 1 0 0 0 0 1 
 GINGIVITIS 1 0 0 0 0 0 1 
 MOUTH ULCERATION 1 0 0 0 0 0 1 
 MUCOUS STOOLS 1 0 0 0 0 0 1 
 NAUSEA 0 1 0 0 0 0 1 
 ORAL SOFT TISSUE DISORDER 0 0 0 0 0 1 1 
 PERITONITIS 0 0 1 0 0 0 1 
 VARICES OESOPHAGEAL 0 0 1 0 0 0 1 
 VOMITING 1 0 1 2 1 4 9 
GENERAL DISORDERS AND 
ADMINISTRATION SITE 
CONDITIONS 
5 13 3 21 1 37 80 
 CHEST PAIN 1 0 0 0 0 0 1 
 CHILLS 1 0 0 1 0 0 2 
 INJECTION SITE PAIN 0 12 1 16 0 34 63 
 INJECTION SITE SWELLING 0 0 0 0 0 1 1 
 MALAISE 0 0 0 0 0 1 1 
 PERIPHERAL OEDEMA 1 0 0 0 0 0 1 
 PYREXIA 1 1 2 3 1 1 9 
 SWELLING 1 0 0 0 0 0 1 
 TENDERNESS 0 0 0 1 0 0 1 
IMMUNE SYSTEM DISORDERS 1 0 0 0 0 0 1 
 ALLERGY TO ARTHROPOD BITE 1 0 0 0 0 0 1 
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Non-Serious Adverse Events 
(cont.) 
SSG PM Comb Total 
 NR ADR NR ADR NR ADR  
INFECTIONS AND INFESTATIONS 58 29 40 10 32 15 184 
 ACARODERMATITIS 0 0 0 0 1 0 1 
 AMOEBIASIS 1 0 1 1 2 0 5 
 AMOEBIC DYSENTERY 0 0 1 0 1 0 2 
 ASCARIASIS 0 0 2 0 0 0 2 
 BODY TINEA 0 0 1 0 0 0 1 
 CELLULITIS 1 0 0 0 0 1 2 
 CHRONIC SINUSITIS 0 0 1 0 0 0 1 
 CROUP INFECTIOUS 1 0 0 0 0 0 1 
 DYSENTRY 0 1 2 0 0 0 3 
 EAR INFECTION 0 0 0 0 1 0 1 
 FUNGAL SKIN INFECTION 0 0 0 1 0 0 1 
 GASTROENTERITIS 0 1 1 2 1 0 5 
 GIARDIASIS 3 0 0 1 2 0 6 
 HERPES ZOSTER 1 0 0 0 0 0 1 
 HOOKWORM INFECTION 1 0 0 0 1 1 3 
 INFECTION PARASITIC 1 0 0 0 1 0 2 
 INJECTION SITE CELLULITIS 0 0 0 0 0 3 3 
 LARYNGITIS 1 0 0 0 0 0 1 
 MALARIA 15 0 13 0 8 0 36 
 MOLLUSCUM CONTAGIOSUM 0 0 0 0 1 0 1 
 NASOPHARYNGITIS 7 0 1 0 3 0 11 
 OTITIS MEDIA 3 0 2 1 0 1 7 
 OTITIS MEDIA ACUTE 1 0 1 0 0 0 2 
 PNEUMONIA 11 2 5 1 2 2 23 
 PNEUMONIA PRIMARY ATYPICAL 1 1 1 0 1 0 4 
 SEPSIS 0 0 1 0 0 0 1 
 STRONGYLOIDIASIS 0 0 0 0 1 0 1 
 TAENIASIS 1 0 0 0 0 0 1 
 TUBERCULOSIS 1 0 0 0 0 0 1 
 UPPER RESPIRATORY TRACT 
INFECTION 
4 0 2 0 5 0 11 
 URINARY TRACT INFECTION 3 4 4 2 1 0 14 
 VARICELLA 1 0 0 0 0 0 1 
 VISCERAL LEISHMANIASIS 0 20 0 1 0 7 28 
 WOUND SEPSIS 0 0 1 0 0 0 1 
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Non-Serious Adverse Events 
(cont.) 
SSG PM Comb Total 
 NR ADR NR ADR NR ADR  
INJURY, POISONING AND 
PROCEDURAL 
2 0 3 0 2 0 7 
 CONTUSION 1 0 1 0 1 0 3 
 LIMB INJURY 0 0 1 0 0 0 1 
 RADIUS FRACTURE 1 0 0 0 0 0 1 
 SCRATCH 0 0 1 0 0 0 1 
 SKIN LACERATION 0 0 0 0 1 0 1 
INVESTIGATIONS 2 48 4 40 5 47 146 
 ALANINE AMINOTRANSFERASE 
INCREASED 
1 7 1 8 1 4 22 
 ASPARTATE AMINOTRANSFERASE 
INCREASED 
0 14 2 11 1 17 45 
 AUDIOGRAM ABNORMAL 0 0 0 3 0 3 6 
 BLOOD ALKALINE PHOSPHATASE 
INCREASED 
0 7 1 6 0 8 22 
 BLOOD AMYLASE INCREASED 1 4 0 0 0 2 7 
 BLOOD CREATININE INCREASED 0 2 0 4 0 2 8 
 ELECTROCARDIOGRAM CHANGE 0 1 0 0 0 0 1 
 ELECTROCARDIOGRAM QT 
PROLONGED 
0 2 0 0 0 0 2 
 HAEMAGLOBIN DECREASED 0 1 0 0 1 0 2 
 HEPATIC ENZYMES INCREASED 0 2 0 0 0 2 4 
 PLATELET COUNT DECREASED 0 2 0 0 1 2 5 
 TRANSAMINASES INCREASED 0 5 0 7 0 6 18 
 WEIGHT DECREASED 0 0 0 1 0 0 1 
 WHITE BLOOD CELL DECREASED 0 1 0 0 0 1 2 
 WHITE BLOOD CELLS URINE 
POSITIVE 
0 0 0 0 1 0 1 
METABOLISM AND NUTRITION 
DISORDERS 
1 0 0 0 0 1 2 
 ANOREXIA 1 0 0 0 0 1 2 
MUSCULOSKELETAL AND 
CONNECTIVE TISSUE DISORDERS 
2 2 1 2 1 1 9 
 ARTHRALGIA 0 1 0 1 0 0 2 
 BACK PAIN 1 1 1 1 1 0 5 
 MUSCULOSKELETAL PAIN 0 0 0 0 0 1 1 
 NECK PAIN 1 0 0 0 0 0 1 
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Non-Serious Adverse Events 
(cont.) 
SSG PM Comb Total 
 NR ADR NR ADR NR ADR  
NERVOUS SYSTEM DISORDORS 4 2 1 5 2 0 14 
 BURNING SENSATION 0 1 0 0 0 0 1 
 HEADACHE 4 1 1 4 2 0 12 
 NEUROPATHY PERIPHERAL 0 0 0 1 0 0 1 
PSYCHIATRIC DISORDERS 0 0 0 0 1 0 1 
 INSOMINIA 0 0 0 0 1 0 1 
RENAL AND URINARY DISORDERS 0 0 1 4 1 0 6 
 ALBUMINURIA 0 0 0 1 0 0 1 
 HAEMATURIA 0 0 1 3 1 0 5 
RESPIRATORY, THORACIC AND 
MEDIASTINAL DISORDERS 
3 7 3 2 1 7 23 
 ALLERGIC BRONCHITIS 0 1 0 0 0 0 1 
 ASTHMA 0 0 1 0 0 3 4 
 COUGH 0 0 2 0 0 1 3 
 EPISTAXIS 3 6 0 2 1 3 15 
SKIN AND SUBCUTANEOUS TISSUE 
DISORDERS 
1 7 1 1 3 0 13 
 ACNE 0 1 0 0 1 0 2 
 PRURITUS 0 1 0 0 0 0 1 
 RASH 0 2 0 1 0 0 3 
 RASH MACULO-PAPULAR 0 1 0 0 0 0 1 
 RASH PAPULAR 0 1 0 0 0 0 1 
 RASH VESICULAR 0 0 0 0 1 0 1 
 SKIN LESION 0 1 0 0 1 0 2 
 SKIN ULCER 1 0 0 0 0 0 1 
 SWELLING FACE 0 0 1 0 0 0 1 
VASCULAR DISORDERS 0 0 0 1 1 0 2 
 HYPERTENSION 0 0 0 1 1 0 2 
 
 
10.9 Subgroup Analyses 
10.9.1 HIV positive patients 
The overall prevalence of HIV was 4.0% (16 / 405).  In adults, the prevalence was 6.5% 
(13 / 201) and in children, 1.5% (3 / 204).  Given the number of patients not tested, 
prevalence could be underestimated. 
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Table 42 Number of adults and children tested for HIV at each centre 
Centre Adults: 15 - 60 years Children: 4 to 14 
years 
Total 
 N Tested N Tested N Tested 
Gondar 94 91 41 39  135 130 
Arba Minch 47 47 43 43 90 90 
Kenya 20 0 25 0 45 0 
Um el Kher 22 12 68 0 90 12 
Kassab 18 18 27 27 45 45 
Total 201 168 (83.6%) 204 109 (53.4%)  405 277 (68.4%) 
 
Table 43 Parasitology Data for HIV positive patients by Treatment 
Parasitology result Rescue given: 




6 month follow-up: DC 
Result 
    
SSG 
Negative: TOC Success Not indicated Negative: DC Success No 
Negative: TOC Success Negative Negative: DC Success No 
Negative: TOC Success Negative Negative: DC Success No 
Missing: TOC Failure Not indicated Negative: DC Failure Yes: day 26 
PM 
Positive: TOC Failure Positive Died*: DC Failure Yes: day 138 
Positive: TOC Failure Not seen LTFU: DC Missing No 
Positive: TOC Failure Negative Died†: DC Missing No 
Negative: TOC Success Negative Negative: DC Success No 
Positive: TOC Failure Not seen LTFU: DC Failure Yes: day 22 
Positive: TOC Failure Positive Positive: DC Failure Yes: day 25 
Combination 
Negative: TOC Success Not indicated Negative: DC Success No 
Negative: TOC Success Not indicated Positive: DC Failure Yes: day 190 
Negative: TOC Success Negative Negative: DC Success No 
Positive: TOC Failure Positive Positive: DC Failure Yes: day 21 
Positive: TOC Failure Not seen Positive: DC Failure Yes: day 178‡ 
Negative: TOC Success Not indicated Negative: DC Success No 
Not indicated at 3 months = deemed clinically well by investigator 
Note that approximate trial day of 6m follow-up would be day 211 for SSG patients, day 202 for PM patients & 
day 198 for Combination patients; calculated as days on treatment plus one plus 180 days. 
TOC = Test of Cure, DC = Definitive Cure 
* Cause of death: Sepsis secondary to gastroenteritis 
† Cause of death: Sepsis & immune reconstitution 
‡ Rescue medication given outside the trial by MSF Holland: 15 days of SSG plus 6 doses of Ambisome.  
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10.9.2 Post Kala-azar Dermal Leishmaniasis 
In total, 28 patients developed PKDL during the trial; 20 patients allocated to SSG, 1 
allocated to PM and 7 allocated to Combination treatment. 
In the SSG patients who developed PKDL, Ambisome rescue medication was given to 2 
patients for the VL infection and SSG was administered during follow-up to treat the PKDL 
for an additional 2 patients.  The primary outcome at 6 months for the 2 patients receiving 
additional treatment with SSG was missing due to LTFU.  Both patients have 
parasitological data for 3 months follow-up and parasites were detected in one of the two 
patients. 
The PM patient who developed PKDL was given Ambisome during follow-up. 
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16.2.9 Documentation of laboratory methods and quality assurance procedures  
Appendix 18 Lab normal ranges  
Standard units  Lab Parameter 
KEMRI Khassb Gondar Arba Minch 
Haemoglobin 11-18g/dL 12-18g/dL 12-18g/dL 9.9-15.7g/dL 
WBC 4.5-10.5x103 /µL 4.6-10.2x109 /L 4.6-10.2x109 /L 2.6-10.3x109 /L 
Platelets 150-450x103 /µL 140-400x109 /L 140-400x109 /L 128-434x109 /L 
ALT / SGPT 0-43U/L <38U/L <41U/L <40U/L 
AST / SGOT 0-37U/L <40U/L <38U/L <37U/L 
Bilirubin (Total) 0-20µmol/L   <1mg/dl <1mg/dl 
Alkaline Phosphatase <270   <270U/L <645U/L 
Albumin 32-52g/L 3.5-5g/dL 2.8-4.8g/dL   
Total Protein 60-80g/L 6-8g/dL 4.6-8.7g/dL 6.7-8.7g/dL 
Prothrombin time   12-17s     
Creatinine 60-130µmol/L   0.5-1.2mg/dL 0.6-1.1mg/dl 
BUN 1.7-9.1mmol/L   4.7-23mg/dL   
Amylase         
Urea     15-45mg/dL 15-45 mg/dL 
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Appendix 19 List of trial site monitoring visits  
UM-EL-KHER 
Date of visit Type of visit Visited by Designation 
13th -20th November 2004 Initiation visit Shibru Berhanu Clinical Monitor 
13th -14th December 2004 Monitoring visit Shibru Berhanu Clinical Monitor 
23rd – 26th January 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
15th – 17th February 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
15th -16th March 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
11th -13th June 2005 Close out visits Shibru Berhanu Clinical Monitor 
28th -30th June 2005 Close out visits Shibru Berhanu Clinical Monitor 
KASSAB 
Date of visit Type of visit Visited by Designation 
22nd November 2004 Site Assessment visit Shibru Berhanu Clinical Monitor 
16th December 2004 Initiation visit Shibru Berhanu Clinical Monitor 
27th -28th January 2005 Initiation visit Shibru Berhanu Clinical Monitor 
18th February 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
18th March 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
17th -21st April 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
15th -16th May 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
9th -11th July 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
15th -18th September 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
18th -21st December 2005 Monitoring visit Rashid Juma Clinical Trial Manager 
11th -15th April 2006 Monitoring visit Rashid Juma Clinical Trial Manager 
19th-22 May 2006 Monitoring visit Robert Balikuddembe and 
Rashid Juma 
Clinical Monitor and 
Clinical Trial Manager 
12th -15th August 2006 Monitoring visit Robert Balikuddembe Clinical Monitor 




Date of visit Type of visit Visited by Designation 
29th -31st November 2004 Initiation visit Shibru Berhanu Clinical Monitor 
17th - 19th January 2005 Initiation visit Follow up Shibru Berhanu Clinical Monitor 
23rd -26th February 2005  Monitoring visit Shibru Berhanu Clinical Monitor 
4th -9th April 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
5th -11th May 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
2nd-7th June 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
18th -21st July 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
31st August – 1st Sept 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
11th -13th October 2005 Monitoring visit Shibru Berhanu Clinical Monitor 
26th -28th May 2006 Monitoring visit Robert Balikuddembe Clinical Monitor 
17th -19th August 2006 Monitoring visit Robert Balikuddembe Clinical Monitor 
24th – 26th October 2006 Initiation visit LEAP B Ahmed Bedru Clinical Monitor 
27th -30th November 2006 Monitoring visit Ahmed Bedru Clinical Monitor 
5th -9th February 2007 Monitoring visit Ahmed Bedru Clinical Monitor 
21st -24th March 2007 Monitoring visit Ahmed Bedru Clinical Monitor 
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ARBA MINCH 
Date of visit Type of visit Visited by Designation 
9th -10th December 2004 Initiation visit/ Monitoring 
visit 
Hilda O’Hara Clinical Monitor 
25th -28th January 2005 Monitoring visit Hilda O’Hara Clinical Monitor 
1st -3rd June 2005 Monitoring visit Hilda O’Hara Clinical Monitor 
4th -8th July 2005 Monitoring visit Hilda O’Hara Clinical Monitor 
29th -31st August 2005 Monitoring visit Hilda O’Hara Clinical Monitor 
10th -14th October 2005 Monitoring visit Hilda O’Hara Clinical Monitor 
26th Feb to 1st March 2006 Monitoring visit Hilda O’Hara Clinical Monitor 
18th -21st June 2006 Monitoring visit Hilda O’Hara Clinical Monitor 
13th -16th August 2006 Monitoring visit Hilda O’Hara Clinical Monitor 
22nd -26th January 2007 Monitoring visit Isaiah Mwangi Clinical Monitor 
26th Feb -2nd March 2007 Monitoring visit Isaiah Mwangi Clinical Monitor 
28th -30th March 2007 Monitoring visit Isaiah Mwangi and Moses 
Alobo 
Clinical Monitor and 
Clinical Trial Manager 
13th-15th May 2007 Monitoring visit Isaiah Mwangi Clinical Monitor 
10th -13th July2007 Monitoring visit Isaiah Mwangi Clinical Monitor 
18th -23rd September 2007 Monitoring visit Isaiah Mwangi Clinical Monitor 
3rd -5th December 2007 Monitoring visit LEAP A 
and Initiation visit for LEAP 
B 
Isaiah Mwangi and Sally 
Ellis 
Clinical Monitor and Project 
Coordinator 
19th -21st Mach 2008 Monitoring visit Isaiah Mwangi Clinical Monitor 
GONDAR 
Date of visit Type of visit Visited by Designation 
14th -16th December 2004 Initiation/ Monitoring visit Lydia Kivihya-Ndugga Clinical Monitor 
31st Jan – 4th Feb 2005 Initiation/ Monitoring visit Lydia Kivihya-Ndugga Clinical Monitor 
16th -19th May 2005 Initiation/ Monitoring visit Lydia Kivihya-Ndugga Clinical Monitor 
3rd-6th July 2005 Monitoring visit Lydia Kivihya-Ndugga Clinical Monitor 
1st -3rd August 2005 Monitoring visit Rashid Juma,  Clinical Trial Manager 
26th September – 5th 
October 2005 
Monitoring visit Sarah Nanzigu and Rashid 
Juma 
Clinical Monitor and 
Clinical Trial Manager 
20th -23rd December 2005 Monitoring visit Sarah Nanzigu Clinical Monitor 
24th -27th January 2006 Monitoring visit Sarah Nanzigu Clinical Monitor 
28th March -1st April 2006 Monitoring visit Sarah Nanzigu Clinical Monitor 
2nd -7th July 2006 Monitoring visit Sarah Nanzigu and Rashid 
Juma 
Clinical Monitor and 
Clinical Trial Manager 
9th -11th of October 2006 Monitoring visit Rashid Juma Clinical Monitor 
7th -9th of February 2007 Monitoring visit Sarah Nanzigu Clinical Monitor 
5th -9th March 2007 Monitoring visit Sarah Nanzigu Clinical Monitor 
8th -11th May 2007 Monitoring visit Isaiah Mwangi, Moses 
Alobo and Mona Elfakii 
Clinical Monitor, Clinical 
Trial Manager and Trainee 
Clinical Monitor 
2nd-5th July 2007 Monitoring visit Sarah Nanzigu Clinical Monitor 
5th -9th October 2007 Monitoring visit Isaiah Mwangi Clinical Monitor 
4th -5th December 2007 Monitoring visit Sarah Nanzigu and Moses 
Alobo  
Clinical Monitor and 
Clinical Trial Manager  
17th -19th March 2008 Monitoring visit Sarah Nanzigu Clinical Monitor 
1st -3rd May 2008 Monitoring visit Isaiah Mwangi and Mona 
Elfakii 
Clinical Monitor and 
Trainee Clinical Monitor 
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Appendix 20 List for GCP trainings and number of attendees 
TRAINING 
Course Date No of 
attendees 
Site 
GCP Introductory Course 28–29 Jul 04 5 Addis Ababa, Ethiopia 
GCP Training 28–29 Jul 04 17 Addis Ababa, Ethiopia 
GCP Introductory Course 30–31 Jul 04 47 Nairobi, Kenya 
GCP Training 26–27 Sep 04 23 Khartoum, Sudan 
Audiometry Training 6–7 Dec 04 8 Addis Ababa, Ethiopia 
Audiometry Training Dec 04 6 Kassab, Sudan 
Audiometry Training 11–12 Jan 05 10 Nairobi, Kenya 
GCP Introductory Course 1–2 June 05 13 Arba Minch, Ethiopia 
GCP Refresher Course 25–26 Jan 06 15 Gondar, Ethiopia 
Laboratory Safety and Refresher 
Parasitology Course 
20 Sep 06 14 
 
Nairobi, Kenya 
GCP & Trial Site Audit Preparation 
Training Course 
20 Sep 06 40 Nairobi, Kenya 
Audiometry Training 2–3 Nov 06  Khassab, Sudan 
Audiometry Training 9–10 Nov 06 2 KEMRI, Kenya 
Workshop on Ethics and Good Clinical 
Practice in Research in Africa 
16 March 2007 35 Hotel Africana, Kampala 
Uganda 
GCP Training Course 29 – 30 March 2007 22 Arba Minch Hospital, 
Ethiopia 
From Molecule to Medicine 24 – 25 May 2007 4 CTC Basel, Switzerland 
Pharmacovigilance Training Course 11 September 2007 27 The Royal Society of 
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16.1.10 Important publications referenced in the report 
Appendix 21 Sundar et al. 2007 
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The new england  
journal of medicine
established in 1812 june 21, 2007 vol. 356 no. 25
Injectable Paromomycin for Visceral Leishmaniasis in India
Shyam Sundar, M.D., T.K. Jha, M.D., Chandreshwar P. Thakur, M.D., Prabhat K. Sinha, M.D.,  
and Sujit K. Bhattacharya, M.D.*
A bs tr ac t
From the Institute of Medical Sciences, 
Banaras Hindu University, Varanasi, Ut-
tar Pradesh (S.S.); the Kala-azar Research 
Centre, Brahmpura, Muzaffarpur, Bihar 
(T.K.J.); Balaji Utthan Sansthan, Patna, 
Bihar (C.P.T.); and the Rajendra Memorial 
Research Institute of Medical Sciences, 
Patna, Bihar (P.K.S., S.K.B.) — all in India. 
Address reprint requests to Dr. Sundar at 
the Institute of Medical Sciences, Banaras 
Hindu University, Varanasi 221005, India, 
or at drshyamsundar@hotmail.com.
*Additional members of the Paromomycin 
for Visceral Leishmaniasis Study Teams 
are listed in the Appendix.
N Engl J Med 2007;356:2571-81.
Copyright © 2007 Massachusetts Medical Society. 
Background
Visceral leishmaniasis (kala-azar) affects large, rural, resource-poor populations in 
South Asia, Africa, and Brazil. Safe, effective, and affordable new therapies are needed. 
We conducted a randomized, controlled, phase 3 open-label study comparing paro-
momycin, an aminoglycoside, with amphotericin B, the present standard of care in 
Bihar, India.
Methods
In four treatment centers for visceral leishmaniasis, 667 patients between 5 and 55 
years of age who were negative for the human immunodeficiency virus and had para-
sitologically confirmed visceral leishmaniasis were randomly assigned in a 3:1 ratio 
to receive paromomycin (502 patients) at a dose of 11 mg per kilogram of body weight 
intramuscularly daily for 21 days or amphotericin B (165 patients) at a dose of 1 mg per 
kilogram intravenously every other day for 30 days. Final cure was assessed 6 months 
after the end of treatment; safety assessments included daily clinical evaluations and 
weekly laboratory and audiometric evaluations. Noninferiority testing was used to com-
pare 6-month cure rates, with a chosen margin of noninferiority of 10 percentage 
points.
Results
Paromomycin was shown to be noninferior to amphotericin B (final cure rate, 94.6% 
vs. 98.8%; difference, 4.2 percentage points; upper bound of the 97.5% confidence 
interval, 6.9; P<0.001). Mortality rates in the two groups were less than 1%. Adverse 
events, which were more common among patients receiving paromomycin than among 
those receiving amphotericin B (6% vs. 2%, P = 0.02), included transient elevation of 
aspartate aminotransferase levels (>3 times the upper limit of the normal range); 
transient reversible ototoxicity (2% vs. 0, P = 0.20); and injection-site pain (55% vs. 0, 
P<0.001); and in patients receiving amphotericin B, as compared with those receiving 
paromomycin, nephrotoxicity (4% vs. 0, P<0.001), fevers (57% vs. 3%), rigors (24% 
vs. 0, P<0.001), and vomiting (10% vs. <1%, P<0.001).
Conclusions
Paromomycin was shown to be noninferior to amphotericin B for the treatment of 
visceral leishmaniasis in India. (ClinicalTrials.gov number, NCT00216346.)
reserved. 
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Visceral leishmaniasis (kala-azar) is primarily a fatal vectorborne parasitic dis-ease characterized by fever, hepatospleno-
megaly, and pancytopenia. Most of the approxi-
mately 500,000 cases of visceral leishmaniasis 
reported worldwide affect the rural poor in India, 
Nepal, Bangladesh, Sudan, and Brazil.1 Treatment 
options for visceral leishmaniasis are limited. So-
dium stibogluconate, a historically effective and 
affordable pentavalent antimonial compound, is 
associated with fatal toxic effects,2-4 and in some 
regions its use has led to the development of re-
sistant strains of Leishmania donovani,5 with the re-
sult that fewer than 50% of treated patients are 
cured.2,6-8 In regions where antimony resistance is 
prevalent, intravenous amphotericin B (desoxycho-
late) (Fungizone, Sarabhai Piramel Pharmaceuti-
cals) is used, but it is expensive and may require 
weeks of hospitalization with intensive clinical 
and laboratory monitoring. Liposomal formula-
tions of amphotericin B (AmBisome, Gilead Sci-
ences), which require a shorter treatment course 
(5 days) and have fewer side effects, remain unaf-
fordable at nearly 30 times the cost of conventional 
formulations.9,10 Miltefosine (Impavido, Aeterna 
Zentaris), the first effective oral therapy for visceral 
leishmaniasis,11 is expensive,12 is potentially tera-
togenic, and has significant gastrointestinal side 
effects.11 Safe, effective, and affordable treatments 
for visceral leishmaniasis in regions where the dis-
ease is endemic are urgently needed, particularly in 
formulations that are compatible with rural set-
tings.
Because humans are the reservoir for visceral 
leishmaniasis in the Indian subcontinent, the in-
fection could be eliminated with widespread treat-
ment of patients and rigorous vector control1 (al-
though elimination may not be possible in regions 
where zoonotic visceral leishmaniasis is prevalent, 
such as Brazil). Paromomycin, an aminoglyco-
side antibiotic, has been shown to have a dose–
response efficacy in the treatment of visceral 
leishmaniasis when administered intramuscularly 
at a dose of 12, 16, or 20 mg of sulfate per kilo-
gram of body weight daily for 21 days.13,14 We 
present the results of a phase 3, multicenter, non-
inferiority clinical trial comparing the safety and 
efficacy of paromomycin and of amphotericin B 




This study was an open-label, prospective, random-
ized trial comparing paromomycin with ampho-
tericin B (Sarabhai Piramal Pharmaceuticals) (here-
after referred to as amphotericin) in which the 
primary end point was safety and the secondary 
end point was efficacy. The study was conducted 
between June 2003 and November 2004 in Bihar, 
India; all patients provided written informed con-
sent. The protocol was approved by the indepen-
dent ethics committee at each of the four partici-
pating centers, the Drug Controller General of 
India, and the Steering Committee on Research In-
volving Human Subjects of the World Health Orga-
nization. AmBisome was donated by Gilead Sci-
ences for use as rescue medication in the study, but 
the company had no role in the design of the study, 
the accrual or analysis of the data, or the prepara-
tion of the manuscript.
Study Medications
Paromomycin solution, 375 mg per milliliter (500 
mg per milliliter as paromomycin sulfate) (Phar-
mamed Parenterals), was administered by deep glu-
teal intramuscular injection at a dose of 11 mg per 
kilogram (15 mg per kilogram as the sulfate) daily 
for 21 days. Amphotericin was diluted in water and 
5% dextrose and, after an initial dose (to test for 
an allergic response), was infused intravenously for 
6 hours at a dose of 1 mg per kilogram every other 
day for 30 days (a total of 15 infusions). Liposomal 
amphotericin, infused intravenously at a dose of 
3 mg per kilogram daily for 5 days, was used as 
rescue medication in patients in whom the study 
treatment failed or relapse occurred.
Study Patients
Eligible subjects were between 5 and 55 years of age 
and had clinically suspected visceral leishmaniasis. 
Inclusion criteria were parasitologically positive 
splenic or bone marrow smear; negative serologic 
testing for the human immunodeficiency virus 
(HIV); hemoglobin level of at least 5.0 g per deci-
liter; white blood count greater than or equal to 
1×109 per liter; platelet count greater than or equal 
to 50×109 per liter; levels of aspartate aminotrans-
ferase, alanine aminotransferase, and alkaline 
phosphatase less than or equal to three times the 
reserved. 
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upper limit of the normal range; prothrombin time 
less than or equal to 5 seconds greater than that 
among control subjects; and serum creatinine and 
potassium levels within the normal limits. Exclu-
sion criteria were treatment for visceral leishmani-
asis during the 2 weeks before enrollment, a hear-
ing loss of 75 dB in frequencies 1 through 8 kHz, 
a history of vestibular or auditory dysfunction, prior 
treatment with amphotericin without response, al-
lergy or hypersensitivity to aminoglycosides, sig-
nificant proteinuria (≥2+ on strip testing), signifi-
cant coexisting diseases possibly affecting the 
response to the study treatment response, and preg-
nancy or lactation.
Study Procedures
Enrolled patients were randomly assigned to treat-
ment with paromomycin or amphotericin in a 3:1 
ratio in permuted blocks of four. A fraction of the 
patients in the paromomycin group were also ran-
domly assigned to a substudy in which pharmaco-
kinetic sampling was performed. All patients were 
hospitalized for the duration of the study treat-
ment; vital signs were assessed daily and adverse 
events were reported according to the Common 
Toxicity Criteria (CTC) of the National Cancer In-
stitute.15 Patients were monitored for hematologic 
variables, serum chemistry, body weight, and the 
size of the spleen and liver every week during treat-
ment, at the end of treatment, and at 6 months af-
ter the treatment ended. Audiometric testing was 
performed every week during treatment in all pa-
tients and repeated every 2 weeks and then month-
ly for up to 6 months after treatment ended in pa-
tients with ototoxicity. A sparse sampling design 
was used for the collection of pharmacokinetic 
samples. Splenic or bone marrow aspiration was 
performed at the end of treatment, at the 4-week 
follow-up in patients with few residual parasites at 
end of treatment, and in those who had a relapse 
of visceral leishmaniasis, during the 6-month fol-
low-up period. Patients who were not cured or who 




The safety end points were reported adverse events, 
protocol-defined nephrotoxicity (defined as an in-
crease in serum creatinine that was either double 
the baseline levels and more than 2.0 mg per deci-
liter [177 μmol per liter], or more than 2.5 mg per 
deciliter16,17) and ototoxicity (defined as a con-
firmed shift from baseline in audiometric thresh-
olds by either 25+ dB at one or more of the tested 
frequencies [1 to 12 kHz], or 20+ dB at two or more 
adjacent frequencies), laboratory evaluations, and 
vital signs. Patients with potential ototoxicity were 
reviewed by an audiometry expert who was un-
aware of the treatment assignments.
Efficacy
Parasite density was graded on a log scale by pa-
thologists who were also unaware of the treatment 
assignments. Final cure was defined as an initial 
cure (clinical improvement with no parasites at the 
end of treatment or parasite density of 1 at the end 
of treatment with no parasites on repeated smear 
1 month after the end of treatment) and no relapse 
during follow-up. Relapse was defined as suspect-
ed visceral leishmaniasis after an initial cure, fol-
lowed by a positive result on analysis of a specimen 
obtained by splenic or bone marrow aspiration. 
Treatment failure was defined as lack of an initial 
cure or occurrence of relapse. For pharmacokinetic 
sampling, plasma paromomycin levels were mea-
sured with the use of an assay validated by liquid 
chromatography–tandem mass spectrometry.
Statistical Analysis
Statistical analyses were performed with the use 
of SAS software, version 8.2, unless otherwise 
noted. Statistical tests included Student’s t-test, 
Fisher’s exact test, the chi-square test or the Coch-
ran–Mantel–Haenszel test, and general linear 
equations, generalized estimation equations, or 
linear mixed-effect models. All tests were two-
sided. Efficacy calculations were performed with 
the use of StatXact, version 7.0 (Cytel). Assuming a 
99% cure rate for amphotericin, 666 patients were 
needed in a 3:1 ratio to support a one-sided, non-
inferiority analysis without stratification and with 
80% power to detect a type I error rate of 5%. Pri-
mary efficacy was calculated as the proportion of 
patients achieving a final cure; an exact confidence 
interval for that proportion was computed; the ex-
act, one-sided, upper bound of the 97.5% confi-
dence interval for the difference in success prob-
abilities was compared with the use of δ = 0.10 
(the chosen margin for noninferiority). All P val-
ues except the value for noninferiority were two-
tailed. Pharmacokinetic analyses were performed 
with NONMEM software, version V, level 1.1 
(GloboMax).
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R esult s
Of 1114 patients who underwent screening, 667 
(60%) were enrolled (Fig. 1). One patient assigned 
to paromomycin died before administration of the 
study drug. Ninety-six percent of the patients re-
ceived the first dose of a study drug within 1 day 
after randomization. One patient assigned to par-
omomycin received a full course of amphotericin. 
Of the enrolled patients, 252 (38%) were pediatric 
patients, defined as 5 to 14 years of age, and 415 
were adult patients, defined as 15 to 55 years of age. 
In 10% of the patients, either visceral leishmani-
asis did not respond to previous treatment or re-
lapses of visceral leishmaniasis had occurred (Ta-
ble 1). The two study groups were balanced with 
respect to baseline characteristics.
Safety
Serious Adverse Events
Seven serious adverse events occurred, including 
four deaths (0.6%) and three events (0.4%) requir-
ing discontinuation of the study drug (Table 2). 
Of the four deaths, one occurred in a patient be-
fore the administration of paromomycin; a second 
death, deemed by the investigator as possibly re-
lated to paromomycin, occurred in a patient with 
suspected alcoholism who received only two dos-
es of the drug, after which aspartate aminotrans-
ferase levels increased to more than six times the 
upper limit of the normal range; a third death, 
deemed by the investigator to be unrelated to par-
omomycin, resulted from septicemia secondary to 
a thigh abscess after the patient had received 11 
doses of the drug (no obvious connection between 
the injection site and the abscess was found); and 
a fourth death resulted from gastroenteritis and 
diarrhea and was considered to be probably related 
to amphotericin. The three nonfatal serious adverse 
events included two in patients who had elevated 
levels of hepatic enzymes after 8 doses of paromo-
mycin (both patients required rescue medication), 
and one patient with bacterial pneumonia was 
treated with gatifloxacin after 10 doses of ampho-
tericin.
Five patients (1%) in the paromomycin group 
had other adverse events requiring drug discon-
tinuation: one patient had reversible ototoxicity 
and one had elevated levels of hepatic enzymes, 
and both required rescue therapy; three patients 
(one with elevated levels of hepatic enzymes, one 
with transient reversible ototoxicity, and one with 
injection-site pain) received eight or more doses of 
paromomycin and did not require rescue therapy. 
One patient (0.6%) in the amphotericin group dis-
continued the study drug after receiving eight 
doses because pulmonary tuberculosis developed.
Audiometric Testing
Audiometry data were available for a total of 589 
patients (442 in the paromomycin group and 147 in 
the amphotericin group). After review by an expert 
audiologist who was unaware of the treatment as-
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Figure 1. Disposition of the Patients.
One patient in the paromomycin group received a full course of amphoteri-
cin. Three patients in the paromomycin group who were not cured at the 
end of treatment received rescue medication. Relapse was defined as para-
sitologically confirmed visceral leishmaniasis at any time after an initial 
cure; the 22 patients who had a relapse were treated with rescue medica-
tion. The one patient lost to follow-up could not be located for the 6-month 
visit. One patient in the amphotericin group discontinued the study drug 
after receiving eight doses because pulmonary tuberculosis developed, but 
this patient was followed for the full 6 months.
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Age — yr 22.1±12.3 20.8±11.7
Age category — no. (%)†
Pediatric 188 (38) 64 (39)
Adult 313 (63) 101 (61)
Sex — no. (%)
Male 321 (64) 95 (58)
Female 180 (36) 70 (42)
Weight — kg 35.5±11.8 33.6±11.0
Height — cm 146.9±18.5 145.9±16.7
Body-mass index‡ 15.9±2.9 15.3±2.8
Pediatric 13.8±2.0 13.1±2.2
Adult 17.2±2.5 16.7±2.2
Visceral leishmaniasis — no. (%)
Newly diagnosed 449 (90) 150 (91)
Previously diagnosed without response to treatment§ 52 (10) 15 (9)
Parasite density¶
Median 2 2
Interquartile range 1–3 1–3
Palpable spleen size — cm below costal margin 6.6±3.8 6.8±4.0
Palpable liver size — cm below costal margin 2.1±1.2 2.1±1.3
Vital signs
Body temperature — °F 99.9±1.3 100.0±1.4
Heart rate — beats/min‖ 98.1±9.9 98.1±11.3
Respiratory rate — breaths/min‖ 21.9±2.6 22.0±2.9
Systolic blood pressure — mm Hg‖ 105.4±9.8 104.5±10.8
Laboratory values
White-cell count — ×10−3/mm3 3.1±1.4 3.2±1.5
Platelet count — ×10−3/mm3 120.4±60.8 117.1±54.6
Hemoglobin — g/dl 7.8±1.7 7.7±1.6
Serum alanine aminotransferase — U/liter‖ 40.5±25.6 41.1±26.2
Serum aspartate aminotransferase — U/liter‖ 44.1±22.0 45.1±22.5
Alkaline phosphatase — U/liter‖ 216.4±114 228.2±130
Total bilirubin — mg/dl‖ 0.6±0.2 0.6±0.2
Serum creatinine — mg/dl‖ 0.8±0.2 0.8±0.2
Blood urea nitrogen — mg/dl‖ 11.7±4.2 11.9±3.8
Albumin — g/dl 3.1±0.5 3.1±0.7
* Plus–minus values are means ±SD. To convert the values for bilirubin to micromoles per liter, multiply by 17.1 To con-
vert the values for creatinine to micromoles per liter, multiply by 88.4. To convert the values for urea nitrogen to milli-
moles per liter, multiply by 0.357. 
† The pediatric age group was defined as patients 5 to 14 years of age, and the adult age group was defined as those 15 
to 55 years of age.
‡ Body-mass index is the weight in kilograms divided by the square of the height in meters. The two groups were similar 
for all variables other than body-mass index (P = 0.02); the difference was not statistically significant after adjustment 
for age and study center (P = 0.06 for the comparison between the two groups among pediatric patients; P = 0.09 for the 
comparison between the two groups among adult patients). Values are adjusted for study center.
§ Patients in this category had received prior treatment for visceral leishmaniasis but remained symptomatic or had been 
considered cured but had become symptomatic. Among the patients in the paromomycin group who had received pre-
vious treatment, 47 received sodium stibogluconate, 4 received miltefosine, and 1 patient received both these drugs. 
Among the patients in the amphotericin group who had received previous treatment, 14 received sodium stibogluco-
nate and 1 received miltefosine.
¶ Density ranges from 0 to 6, with higher values indicating greater splenic parasite load.
‖ The safety substudy included 500 patients in the paromomycin group and 166 in the amphotericin group.
reserved. 
Downloaded from www.nejm.org on June 21, 2007 . Copyright © 2007 Massachusetts Medical Society. All rights
LEAP 0104a Appendices
Page 317 of 756
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 356;25 www.nejm.org june 21, 20072576
signments, seven patients (2%) in the paromomy-
cin group and none in the amphotericin group were 
found to have confirmed threshold shifts for proto-
col-specified ototoxicity (P = 0.20) (Table 2). In six 
patients, the threshold shifts were at high frequen-
cy above the hearing range, and in all seven patients 
the shift was transient, with levels returning to near 
baseline values during follow-up. No patient report-
ed hearing loss or vestibular dysfunction.
Renal Evaluation
None of the patients in the paromomycin group 
and seven patients (4%) in the amphotericin group 
had protocol-defined nephrotoxicity (P<0.001) (Ta-





(N = 166) P Value†
no. of patients (%)
Deaths‡ 2 (<1) 1 (1) 1.00
Nonfatal serious events§ 2 (<1) 1 (1) 1.00
Reported events
Any 299 (60) 111 (67) 0.12
CTC grade 3 or 4 11 (2) 11 (7) 0.01
Specific events¶
Injection-site pain 276 (55) 0 <0.001
Pyrexia 13 (3) 94 (57) <0.001
Rigors 0 39 (24) <0.001
Vomiting 3 (1) 16 (10) <0.001
Nephrotoxicity‖
Protocol-defined 0 7 (4) <0.001
Defined post hoc 4 (1) 42 (25) <0.001
Ototoxicity** 7 (1) 0 0.20
Liver-function values†† 
Aspartate aminotransferase >3× ULN 31 (6) 3 (2) 0.02
Aspartate aminotransferase >5× ULN 9 (2) 0 0.12
Alanine aminotransferase >3× ULN 10 (2) 1 (1) 0.31
Alanine aminotransferase >5× ULN‡‡ 4 (1) 0 0.58
* Plus–minus values are means ±SD. Patients may have had more than one adverse event. CTC denotes Common 
Toxicity Criteria, and ULN upper limit of the normal range.
† P values for the comparison between the two groups were calculated with the use of Fisher’s exact test.
‡ Of the deaths reported during the study, one occurred before the patient received a study drug, one was considered 
to be possibly related to paromomycin, one was considered to be probably related to amphotericin, and one was 
deemed by the investigator to be unrelated to paromomycin and resulted from septicemia secondary to a thigh ab-
scess (no obvious connection between the injection site and the abscess was found).
§ Of the patients who had elevated levels of hepatic enzymes, two were in the paromomycin group and one with bacte-
rial pneumonia was in the amphotericin group.
¶ Specific events were those with an incidence ≥5%.
‖ Protocol-defined nephrotoxicity included events for which the value was double the baseline value and greater than 
2.0 mg per deciliter, or greater than 2.5 mg per deciliter; nephrotoxic events defined post hoc were those with values 
greater than or equal to 1.4 mg per deciliter and represented an increase during the treatment period of 50% or more 
above the baseline serum creatinine level.
** Ototoxicity was defined as a confirmed shift from baseline audiometric thresholds ≥25 dB at one or more of the test-
ed frequencies (1 to 12 kHz), or as a confirmed threshold shift ≥20 dB at two or more adjacent frequencies.
†† Events with a CTC grade of 3 or 4 in the paromomycin group included increased aspartate aminotransferase levels 
(seven patients), increased alanine aminotransferase levels (three patients), diarrhea (one patient), abnormal audio-
gram (one patient), neutropenia (one patient), and decreased white-cell count (one patient). Events with a CTC grade 
of 3 or 4 in the amphotericin group included pyrexia (five patients), diarrhea (one patient), rigors (two patients), in-
creased levels of alkaline phosphatase (one patient), jaundice (one patient), and toxic neuropathy (one patient).
‡‡ All four patients also had aspartate aminotransferase levels greater than five times the upper limit of normal.
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ble 2). To ascertain potential renal dysfunction, we 
performed a post hoc analysis of creatinine eleva-
tion greater than or equal to 50% of the baseline 
levels and greater than or equal to 1.4 mg per deci-
liter during treatment. According to this definition, 
some renal dysfunction developed in 4 patients 
(1%) in the paromomycin group and in 42 patients 
(25%) in the amphotericin group (P<0.001). Mean 
changes from baseline to the end of treatment in 
levels of blood urea nitrogen and serum creatinine 
were significantly higher in the amphotericin group 
than in the paromomycin group (P<0.001 for both 
comparisons) (Table 3).
Other Adverse Events
Injection-site pain was the most frequently reported 
adverse event among patients receiving paromomy-
cin (55%); adverse events that were most frequent-
ly reported among patients receiving amphoteri-
cin were infusion reactions of fever, rigors, and 
vomiting (57%, 24%, and 10%, respectively) (P< 
0.001 for all comparisons) (Table 2). Injection-site 
pain in those receiving paromomycin was rarely 
associated with swelling (0.4%) and was generally 
reported as CTC grade 1 (grade 2, <2%); only one 
patient (<1%) treated with paromomycin discontin-
ued the study drug because of injection-site pain 
and swelling. CTC grades 3 and 4 events occurred 
less frequently in the paromomycin group than in 
the amphotericin group. In addition, use of con-
comitant medication was less common in the paro-
momycin group than in the amphotericin group 
(14% vs. 77%, P<0.001).
Other Laboratory Tests
Almost half the patients enrolled had elevated lev-
els of alanine aminotransferase or aspartate ami-
notransferase, consistent with hepatic involvement 
in 25 to 40% of patients with visceral leishmani-
asis.18-21 Aspartate aminotransferase levels high-
er than three times the upper limit of the normal 
range developed in 31 patients (6%) in the paromo-
mycin group, as compared with 3 patients (2%) in 
the amphotericin group (P = 0.02). In nine (2%) of 
these patients in the paromomycin group, as com-
pared with none in the amphotericin group, the 
increases in aspartate aminotransferase levels were 
greater than five times the upper limit of the nor-
mal range (P = 0.12) (Table 2); and five patients in 
the paromomycin group discontinued the study 
drug because of adverse events (reversible ototox-
icity, elevated levels of hepatic enzymes, and injec-
tion-site pain). Liver-function testing showed that 
levels returned to near baseline for all surviving 
patients.
Efficacy
During the treatment period, 12 patients discon-
tinued the study treatment. Of these, five remained 
cured at the 6-month follow-up visit. A total of 493 
patients in the paromomycin group and 164 in the 
amphotericin group had an initial cure at the end of 
treatment. One patient in the amphotericin group 
was lost to follow-up; all 22 patients who had re-
lapses were in the paromomycin group (Fig. 1).
Final cure rates 6 months after the end of treat-
ment were 95% (474 of 501) in the paromomycin 
group and 99% (163 of 165) in the amphotericin 
group; the difference in rates was 4.2 percentage 
points with an upper bound of the 97.5% confi-
dence interval of 6.9 percentage points, demon-
strating the noninferiority of paromomycin (Ta-
ble 4). This finding was consistent across all tested 
subgroups. Of 449 patients with newly diagnosed 
visceral leishmaniasis in the paromomycin group, 
423 (94%) were cured, and of the 52 patients with 
prior visceral leishmaniasis, 51 (98%) were cured.
Pharmacokinetic Analyses
Paromomycin was absorbed quickly after intra-
muscular injection, reaching peak plasma levels 
within 1 hour. During the 21 days of treatment, 
the mean (±SD) peak plasma levels of paromomy-
cin at 1 hour after injection ranged from 18.3 μg 
per milliliter (±8.86) to 20.5 μg per milliliter (±7.01) 
and the trough plasma levels at 24 hours after in-
jection ranged from 1.31 μg per milliliter (±4.16) 
to 4.53 μg per milliliter (±6.71). The plasma lev-
els on days 1, 8, 15, 21, and 22 were similar, and 
there was no evidence of drug accumulation or the 
induction of metabolism. No significant differenc-
es in the mean peak or trough plasma levels at 
day 21 were observed between pediatric and adult 
patients.
Discussion
Paromomycin (administered intramuscularly at a 
dose of 11 mg per kilogram daily for 21 days) was 
shown to be noninferior to and to have an adverse-
event profile similar to that of amphotericin (ad-
ministered intravenously at a dose of 1 mg per kilo-
gram every other day for 30 days) in the treatment 
of visceral leishmaniasis. On the basis of this study, 
paromomycin was approved by the Indian govern-
ment in August 2006 for the treatment of patients 
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with visceral leishmaniasis and is now available as 
a public health tool in a nationwide program to 
eliminate visceral leishmaniasis.
The overall cure rate of 95% with the use of 
paromomycin was similar in pediatric patients 
(96%), female patients (95%), and male patients 
(94%), and the difference in cure rates between 
patients treated with paromomycin or ampho-
tericin was consistently less than 10 percentage 
points. The cure rate among those whose disease 
had not responded to previous treatment with so-
dium stibogluconate or miltefosine or who had 
had a relapse was high (98%). This finding is im-
portant in Bihar, where the failure of sodium sti-
bogluconate therapy is due primarily to drug re-
sistance.2,6,7 Although experience with the use of 
paromomycin during pregnancy is limited, this 
drug may be used, when clinically indicated, in 
women of childbearing potential.22 Furthermore, 
paromomycin can be administered intramuscu-
larly according to body weight (milligrams per 
kilogram) to patients with visceral leishmaniasis 
who have normal renal function, including chil-
dren, without the need for therapeutic monitoring 
or dose adjustment.
The duration of treatment with paromomycin 
(daily for 21 days) is shorter than with ampho-
tericin (every other day for 30 days), sodium sti-
bogluconate (daily for 30 days), or miltefosine 
(daily for 28 days), though the visit burden may 
be higher. In this study, protocol-defined nephro-
toxicity did not develop in any of the patients 
treated with paromomycin. When more stringent 
definitions of potential renal dysfunction were ap-
Table 3. Mean (±SD) End-of-Treatment Values and Changes in Clinical Measures and in Liver-Function and Renal-Function Values.*
Variable At End of Treatment
Change from Baseline  










Heart rate (beats/min) 84.4±5.5 84.8±7.7 –13.7±12.2 –13.2±14.7 0.48¶
Respiratory rate (breaths/min) 20.4±2.8 20.6±4.3 –1.4±3.6 –1.4±5.1 0.55¶
Systolic blood pressure (mm Hg) 109.4±9.1 108.5±9.6 4.0±8.6 4.0±8.9 0.55¶
Alanine aminotransferase (U/liter) 48.3±30.7 32.2±18.5 7.8±35.6 –8.9±30.1 <0.001
Aspartate aminotransferase (U/liter) 52.2±35.9 33.0±16.8 8.2±39.2 –12.1±26.4 <0.001
Alkaline phosphatase (U/liter) 227.5±110 249.9±191 12.5±123 21.8±158 0.15
Total bilirubin (mg/dl) 0.6±0.3 0.6±0.2 –0.0±0.4 0.0±0.3 0.58
Serum creatinine (mg/dl) 0.7±0.2 1.0±0.4 –0.1±0.3 0.2±0.4 <0.001
Blood urea nitrogen (U/liter) 12.0±3.4 17.0±7.4 0.3±4.8 5.1±8.0 <0.001
Efficacy analysis‖
Temperature (°F) 97.5±0.8 97.6±1.0 –2.4±1.5 –2.4±1.7 0.10
Spleen size (cm below costal margin) 1.7±2.2 1.3±1.8 –4.8±2.6 –5.5±3.2 <0.001
Weight (kg) 37.0±12.1 35.1±11.1 1.5±2.6 1.5±1.5 0.94
Hemoglobin (g/dl) 9.6±1.5 8.4±1.3 1.7±1.3 0.7±1.5 <0.001
Platelet count (×10−3/mm3) 254.5±122 253.9±120 133.9±111 136.8±111 0.81
White-cell count (×10−3/mm3) 6.7±2.9 6.9±2.2 3.6±2.7 3.7±2.2 0.65
Albumin (g/dl) 3.5±0.6 3.5±0.7 0.4±0.7 0.4±0.8 0.94
* To convert the values for bilirubin to micromoles per liter, multiply by 17.1. To convert the values for creatinine to micromoles per liter, 
multiply by 88.4. To convert the values for urea nitrogen to millimoles per liter, multiply by 0.357.
† For baseline values, see Table 1.
‡ Analysis of variance was used to correlate laboratory values at the end of treatment with the baseline value in the model.
§ Patients in the safety analysis included 500 in the paromomycin group and 166 in the amphotericin group.
¶P values were calculated with the use of a mixed model in which heterogeneous variance and a first-order autocorrelation structure are as-
sumed.
‖ Patients in the efficacy analysis included 501 in the paromomycin group and 165 in the amphotericin group.
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plied, only 1% of the patients in the paromomycin 
group had renal dysfunction, as compared with 
25% of those in the amphotericin group. This rela-
tive absence of nephrotoxicity among patients with 
visceral leishmaniasis who were treated with paro-
momycin at a dose of 11 mg per kilogram is not 
surprising, since the patients included in the study 
were generally young and had normal renal func-
tion and since leishmania parasites do not typi-
cally invade the kidneys. Audiometric data showed 
transient reversible ototoxicity during treatment in 
seven patients in the paromomycin group (2%); no 
long-term clinical hearing loss or vestibular effects 
were reported. These findings may help to guide 
the safety monitoring required for large-scale 
medication use in India.
All the medications used to treat visceral leish-
maniasis (pentavalent antimonial compounds, 
pentamidine, amphotericin, liposomal amphoteri-
cin, sodium stibogluconate, and miltefosine) may 
be associated with a significant increase in levels 
of liver enzymes during treatment,11,19,23,24 which 
some think may be due to the killing of the para-
sites in the liver, rather than to direct medication-
induced hepatic toxic effects. Aminoglycosides 
used as parenteral antibiotics are rarely associated 
with increased levels of liver enzymes.25 Although 
the exact cause of the transient significant increase 
in levels of hepatic enzymes, which affected pa-
tients in the paromomycin group but not those in 
the amphotericin group in this study, is difficult 
to ascertain, the possibilities include faster de-
struction of the parasites in liver tissue in patients 
treated with paromomycin or an emerging toxicity 
of paromomycin treatment in this setting. Mon-
itoring of aspartate aminotransferase or alanine 
aminotransferase levels, or both, in a program to 
control visceral leishmaniasis will be an important 
consideration, especially in patients with preexist-
ing liver disease.
Limitations of the study include high variation 
at the study sites in reporting injection-site pain, 
ranging from 2% to 97%. The data collection was 
not standardized for this specific outcome. More-
over, the patients were followed for only 6 months, 
which is the standard for visceral leishmaniasis 
trials, because most relapses occur during this 
period.26 Although rare, post–kala-azar dermal 
leishmaniasis (PKDL) can occur years after treat-
ment27; long-term follow up for PKDL was beyond 
the scope of this study. Though the overall relapse 
rate among patients treated with paromomycin 
was acceptable (4%), for a program to eliminate 
visceral leishmaniasis to succeed, early detection 
and prompt treatment of relapses, as well as 
mechanisms to identify and treat patients with 
PKDL, are imperative. Combination chemotherapy 
must also be explored to reduce the risk of drug 
resistance over time.
It is currently critical to address the elimina-
tion of visceral leishmaniasis in the Indian sub-
continent, where the rates of HIV infection and 
HIV–visceral leishmaniasis coinfection are ris-
ing.28 Since patients with HIV who are coinfected 
with visceral leishmaniasis will probably have re-
lapse without lifelong antiretroviral therapy, they 








Upper Bound of  
97.5% CI for Difference*
no. cured/total no. (%) % %
Overall† 474/501 (94.6) 163/165 (98.8) 4.2 6.9
Age category — no. (%)‡
Pediatric 181/188 (96.3) 63/64 (98.4) 2.1 6.5
Adult 293/313 (93.6) 100/101 (99.0) 5.4 9.1
Sex
Male 303/321 (94.4) 95/95 (100) 5.6 8.9
Female 171/180 (95.0) 68/70 (97.1) 2.1 7.2
* The value was determined by a test of noninferiority (margin of noninferiority, 0.10). CI denotes confidence interval.
† This category includes all patients who underwent randomization and received at least one dose of a study drug.
‡ The pediatric age group was defined as patients 5 to 14 years of age, and the adult age group was defined as those 15 
to 55 years of age.
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may remain an infectious reservoir until proper 
HIV therapy can be deployed in a sustainable man-
ner. Furthermore, a significant proportion of the 
at-risk population may have subclinical leishma-
nia infection, contributing to transmission of vis-
ceral leishmaniasis.29 For widespread public health 
use, the intramuscular administration of paromo-
mycin is challenging; however, primary health-
center personnel have experience with intramus-
cular administration of sodium stibogluconate, 
and supervised dosing can limit the resistance due 
to noncompliance with the regimen.
In conclusion, paromomycin was shown to be 
noninferior to amphotericin, and, with the excep-
tion of mild injection-site pain and a transient in-
crease in values on liver-function testing, it has a 
reasonable safety profile. Paromomycin may be 
advantageous because of the shorter duration of 
its administration and its demonstrated safety and 
efficacy in pediatric patients and in patients in 
whom visceral leishmaniasis did not respond to 
previous treatment. The health care delivery sys-
tem in India is well suited to the intramuscular 
administration of paromomycin under directly 
observed therapy, and the local manufacture of 
paromomycin in India, potentially at a very low 
cost, makes this an approachable therapy in the 
setting of limited resources.
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16.2.1 Patient Visit Dates 
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Appendix 23: Listing of Patient Assessment/ Visit date
Centre Patient Treatment Assessment Date
Number Number Baseline Day 1 Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 1 PM 17-Jun-05 18-Jun-05 24-Jun-05 1-Jul-05 9-Jul-05 5-Oct-05 4-Jan-06
11 2 Combination 17-Jun-05 18-Jun-05 24-Jun-05 1-Jul-05 5-Jul-05 29-Sep-05 5-Jan-06
11 3 Combination 17-Jun-05 19-Jun-05 25-Jun-05 2-Jul-05 6-Jul-05 30-Sep-05 29-Dec-05
11 4 PM 27-Jun-05 30-Jun-05 6-Jul-05 13-Jul-05 21-Jul-05 31-Dec-05 27-Jan-06
11 5 PM 27-Jun-05 30-Jun-05 6-Jul-05 13-Jul-05 21-Jul-05 18-Oct-05 14-Feb-06
11 6 Combination 27-Jun-05 2-Jul-05 8-Jul-05 15-Jul-05 19-Jul-05 13-Oct-05 11-Jan-06
11 7 PM 29-Jun-05 2-Jul-05 8-Jul-05 15-Jul-05 23-Jul-05 20-Oct-05 18-Jan-06
11 8 SSG 29-Jun-05 2-Jul-05 8-Jul-05 15-Jul-05 25-Jul-05 1-Aug-05 30-Oct-05 30-Jan-06
11 9 SSG 29-Jun-05 3-Jul-05 9-Jul-05 16-Jul-05 25-Jul-05 2-Aug-05 1-Nov-05 30-Jan-06
11 10 SSG 29-Jun-05 3-Jul-05 9-Jul-05 16-Jul-05 25-Jul-05 2-Aug-05 1-Nov-05 30-Jan-06
11 11 Combination 1-Jul-05 5-Jul-05 11-Jul-05 18-Jul-05 22-Jul-05 20-Oct-05 20-Jan-06
11 12 Combination 29-Jun-05 8-Jul-05 14-Jul-05 21-Jul-05 27-Jul-05 25-Oct-05 6-Feb-06
11 13 SSG 7-Jul-05 12-Jul-05 18-Jul-05 25-Jul-05 1-Aug-05 11-Aug-05 9-Nov-05 6-Feb-06
11 14 SSG 7-Jul-05 12-Jul-05 18-Jul-05 25-Jul-05 1-Aug-05 11-Aug-05 11-Nov-05 16-Apr-06
11 15 PM 13-Jul-05 14-Jul-05 20-Jul-05 7-Nov-05 5-Apr-06
11 16 Combination 12-Jul-05 15-Jul-05 21-Jul-05 28-Jul-05 1-Aug-05 30-Oct-05 6-Feb-06
11 17 Combination 12-Jul-05 19-Jul-05 25-Jul-05 1-Aug-05 5-Aug-05 7-Nov-05 6-Feb-06
11 18 SSG 13-Aug-05 16-Aug-05 22-Aug-05 29-Aug-05 5-Sep-05 15-Sep-05 22-Dec-05 15-Mar-06
11 19 Combination 14-Aug-05 16-Aug-05 22-Aug-05 29-Aug-05 2-Sep-05 29-Nov-05 27-Feb-06
11 20 SSG 14-Aug-05 16-Aug-05 22-Aug-05 29-Aug-05 5-Sep-05 15-Sep-05 14-Dec-05 14-Mar-06
11 21 SSG 14-Aug-05 16-Aug-05 22-Aug-05 29-Aug-05 5-Sep-05 15-Sep-05 22-Dec-05 15-Mar-06
11 22 SSG 15-Aug-05 17-Aug-05 23-Aug-05 30-Aug-05 6-Sep-05 16-Sep-05 15-Dec-05 14-Apr-06
11 23 PM 18-Aug-05 20-Aug-05 26-Aug-05 2-Sep-05 10-Sep-05 11-Jan-06 31-May-06
11 24 PM 18-Aug-05 20-Aug-05 26-Aug-05 2-Sep-05 10-Sep-05 28-Nov-05 10-Feb-06
11 25 SSG 18-Aug-05 20-Aug-05 26-Aug-05 2-Sep-05 9-Sep-05 19-Sep-05 2-Jan-06 14-Apr-06
11 26 Combination 15-Aug-05 25-Aug-05 31-Aug-05 7-Sep-05 12-Sep-05 10-Nov-05 16-Apr-06
11 27 PM 16-Sep-05 19-Sep-05 25-Sep-05 2-Oct-05 10-Oct-05 23-Jan-06
11 28 Combination 16-Sep-05 21-Sep-05 27-Sep-05 4-Oct-05 8-Oct-05 4-Jan-06 4-Apr-06
11 29 PM 21-Sep-05 22-Sep-05 28-Sep-05 5-Oct-05 13-Oct-05 9-Jan-06 18-Apr-06
11 30 PM 20-Sep-05 22-Sep-05 28-Sep-05 5-Oct-05 13-Oct-05 2-Jan-06 14-Apr-06
11 31 SSG 20-Sep-05 23-Sep-05 29-Sep-05 6-Oct-05 13-Oct-05 23-Oct-05 2-Feb-06 5-Apr-06
11 32 Combination 20-Sep-05 24-Sep-05 30-Sep-05 7-Oct-05 11-Oct-05 9-Jan-06 3-Apr-06
11 33 SSG 23-Sep-05 25-Sep-05 1-Oct-05 8-Oct-05 15-Oct-05 25-Oct-05 23-Jan-06 16-Apr-06
11 34 PM 23-Sep-05 27-Sep-05 3-Oct-05 10-Oct-05 18-Oct-05 17-Jan-06 16-Apr-06
11 35 SSG 24-Sep-05 27-Sep-05 3-Oct-05 10-Oct-05 17-Oct-05 27-Oct-05 11-Jan-06 16-Apr-06
11 36 SSG 21-Sep-05 28-Sep-05 4-Oct-05 11-Oct-05 18-Oct-05 28-Oct-05 24-Jan-06 10-Jun-06
11 37 Combination 26-Sep-05 28-Sep-05 4-Oct-05 11-Oct-05 15-Oct-05 17-Jan-06 14-Apr-06
11 38 PM 13-Oct-05 19-Oct-05 25-Oct-05 1-Nov-05 9-Nov-05 15-Feb-06 30-May-06
11 39 PM 13-Oct-05 19-Oct-05 25-Oct-05 1-Nov-05 9-Nov-05 6-Mar-06 22-May-06
11 40 PM 13-Oct-05 20-Oct-05 26-Oct-05 2-Nov-05 14-Apr-06 23-May-06
11 41 Combination 13-Oct-05 20-Oct-05 26-Oct-05 2-Nov-05 6-Nov-05 13-Feb-06 31-May-06
11 42 Combination 13-Oct-05 21-Oct-05 27-Oct-05 3-Nov-05 7-Nov-05 6-Feb-06 7-Jun-06
11 43 SSG 24-Oct-05 28-Oct-05 3-Nov-05 10-Nov-05 17-Nov-05 27-Nov-05 22-Feb-06 23-May-06
11 44 PM 24-Oct-05 28-Oct-05 3-Nov-05 10-Nov-05 18-Nov-05 14-Feb-06 19-May-06
11 45 Combination 24-Oct-05 28-Oct-05 3-Nov-05 10-Nov-05 14-Nov-05 14-Feb-06 19-May-06
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Centre Patient Treatment Assessment Date
Number Number Baseline Day 1 Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 46 SSG 2-May-06 5-May-06 11-May-06 18-May-06 25-May-06 4-Jun-06 24-Oct-06 5-Dec-06
11 47 SSG 2-May-06 5-May-06 11-May-06 18-May-06 25-May-06 4-Jun-06
11 48 Combination 3-May-06 5-May-06 11-May-06 18-May-06 22-May-06 2-Jan-07
11 49 SSG 7-May-06 9-May-06 15-May-06 22-May-06 29-May-06 8-Jun-06 9-Oct-06 27-Feb-07
11 50 PM 16-May-06 18-May-06 24-May-06 31-May-06 8-Jun-06 6-Sep-06 11-Dec-06
11 51 Combination 18-May-06 20-May-06 26-May-06 2-Jun-06 6-Jun-06 7-Sep-06 2-Jan-07
11 52 PM 19-May-06 20-May-06 26-May-06 2-Jun-06 10-Jun-06 26-Sep-06 11-Jan-07
11 53 SSG 25-May-06 26-May-06 1-Jun-06 8-Jun-06 15-Jun-06 25-Jun-06 26-Sep-06 11-Dec-06
11 54 PM 25-May-06 27-May-06 2-Jun-06 9-Jun-06 17-Jun-06 28-Aug-06 1-Jan-07
11 55 PM 29-May-06 30-May-06 5-Jun-06 12-Jun-06 20-Jun-06 26-Sep-06 11-Dec-06
11 56 SSG 29-May-06 31-May-06 6-Jun-06 13-Jun-06 20-Jun-06 30-Jun-06 28-Sep-06 14-Dec-06
11 57 Combination 3-Jun-06 4-Jun-06 10-Jun-06 17-Jun-06 21-Jun-06 12-Sep-06 12-Dec-06
11 58 Combination 3-Jun-06 6-Jun-06 12-Jun-06 19-Jun-06 23-Jun-06 26-Sep-06 13-Dec-06
11 59 PM 12-Jun-06 13-Jun-06 19-Jun-06 26-Jun-06 4-Jul-06 3-Oct-06 2-Jan-07
11 60 Combination 12-Jun-06 13-Jun-06 19-Jun-06 26-Jun-06 30-Jun-06 28-Sep-06 18-Dec-06
11 61 PM 12-Jun-06 13-Jun-06 19-Jun-06 26-Jun-06 4-Jul-06 3-Oct-06 2-Jan-07
11 62 SSG 15-Jun-06 16-Jun-06 22-Jun-06 29-Jun-06 6-Jul-06 16-Jul-06 25-Oct-06 11-Jan-07
11 63 SSG 19-Jun-06 20-Jun-06 26-Jun-06 3-Jul-06 10-Jul-06 20-Jul-06 3-Oct-06 28-Dec-06
11 64 SSG 21-Jun-06 22-Jun-06 28-Jun-06 5-Jul-06 12-Jul-06 22-Jul-06 29-Sep-06 14-Dec-06
11 65 PM 22-Jun-06 23-Jun-06 29-Jun-06 6-Jul-06 14-Jul-06
11 66 Combination 19-Jun-06 23-Jun-06 29-Jun-06 6-Jul-06 10-Jul-06 26-Sep-06 11-Dec-06
11 67 PM 30-Jun-06 1-Jul-06 7-Jul-06 14-Jul-06 22-Jul-06 3-Oct-06 2-Jan-07
11 68 SSG 7-Jul-06 8-Jul-06 14-Jul-06 21-Jul-06 28-Jul-06 7-Aug-06 11-Oct-06 9-Jan-07
11 69 Combination 14-Jul-06 15-Jul-06 21-Jul-06 28-Jul-06 1-Aug-06 9-Oct-06 13-Dec-06
11 70 Combination 14-Jul-06 15-Jul-06 21-Jul-06 28-Jul-06 1-Aug-06 9-Oct-06 2-Jan-07
11 71 Combination 21-Jul-06 22-Jul-06 28-Jul-06 4-Aug-06 8-Aug-06 12-Oct-06 9-Jan-07
11 72 SSG 21-Jul-06 22-Jul-06 28-Jul-06 4-Aug-06 9-Nov-06 7-Feb-07
11 73 PM 24-Jul-06 25-Jul-06 31-Jul-06 7-Aug-06 15-Aug-06 24-Oct-06 2-Apr-07
11 74 PM 27-Jul-06 28-Jul-06 3-Aug-06 10-Aug-06 18-Aug-06 25-Oct-06 23-Jan-07
11 75 Combination 27-Jul-06 28-Jul-06 3-Aug-06 10-Aug-06 14-Aug-06 31-Oct-06 9-Jan-07
11 76 PM 30-Jul-06 31-Jul-06 6-Aug-06 13-Aug-06 21-Aug-06 30-Oct-06 29-Jan-07
11 77 PM 29-Jul-06 31-Jul-06 6-Aug-06 13-Aug-06 21-Aug-06 30-Oct-06 29-Jan-07
11 78 SSG 30-Jul-06 31-Jul-06 6-Aug-06 13-Aug-06 20-Aug-06 30-Aug-06 30-Oct-06 29-Jan-07
11 79 PM 30-Jul-06 31-Jul-06 6-Aug-06 13-Aug-06 21-Aug-06 30-Oct-06 30-Jan-07
11 80 PM 2-Aug-06 3-Aug-06 9-Aug-06 16-Aug-06 24-Aug-06 23-Nov-06 17-Mar-07
11 81 Combination 5-Aug-06 6-Aug-06 12-Aug-06 19-Aug-06 23-Aug-06 7-Nov-06 6-Feb-07
11 82 SSG 13-Aug-06 15-Aug-06 21-Aug-06 28-Aug-06 4-Sep-06 14-Sep-06 13-Nov-06 5-Feb-07
11 83 SSG 14-Aug-06 16-Aug-06 22-Aug-06 29-Aug-06 5-Sep-06 15-Sep-06 13-Nov-06 13-Feb-07
11 84 SSG 17-Aug-06 18-Aug-06 24-Aug-06 31-Aug-06 7-Sep-06 17-Sep-06 15-Nov-06 14-Feb-07
11 85 SSG 24-Aug-06 25-Aug-06 31-Aug-06 7-Sep-06 14-Sep-06 24-Sep-06 21-Nov-06
11 86 Combination 28-Aug-06 29-Aug-06 4-Sep-06 11-Sep-06 15-Sep-06 13-Nov-06 5-Feb-07
11 87 Combination 28-Aug-06 29-Aug-06 4-Sep-06 11-Sep-06 15-Sep-06 14-Nov-06 5-Feb-07
11 88 PM 28-Aug-06 29-Aug-06 4-Sep-06 11-Sep-06 19-Sep-06 21-Nov-06 27-Feb-07
11 89 Combination 31-Aug-06 2-Sep-06 8-Sep-06 15-Sep-06 19-Sep-06 17-Nov-06 15-Mar-07
11 90 Combination 1-Sep-06 2-Sep-06 8-Sep-06 15-Sep-06 19-Sep-06
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Centre Patient Treatment Assessment Date
Number Number Baseline Day 1 Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 91 PM 16-Dec-06 18-Dec-06 24-Dec-06 31-Dec-06 8-Jan-07 5-Mar-07 18-Jun-07
11 92 Combination 30-Dec-06 31-Dec-06 6-Jan-07 13-Jan-07 17-Jan-07 30-Mar-07 27-Jun-07
11 93 SSG 1-Jan-07 2-Jan-07 8-Jan-07 15-Jan-07 22-Jan-07 1-Feb-07 9-May-07 7-Aug-07
11 94 SSG 3-Jan-07 4-Jan-07 10-Jan-07 17-Jan-07 24-Jan-07 3-Feb-07 2-Apr-07 25-Jun-07
11 95 SSG 3-Jan-07 4-Jan-07 10-Jan-07 17-Jan-07 24-Jan-07 3-Feb-07 3-Apr-07 23-Jun-07
11 96 Combination 19-Jan-07 20-Jan-07 26-Jan-07 2-Feb-07 6-Feb-07 23-Apr-07 6-Sep-07
11 97 Combination 19-Jan-07 20-Jan-07 26-Jan-07 2-Feb-07 6-Feb-07 23-Apr-07 25-Jul-07
11 98 PM 23-Jan-07 24-Jan-07 30-Jan-07 6-Feb-07 14-Feb-07 25-Apr-07 26-Jul-07
11 99 SSG 25-Jan-07 26-Jan-07 1-Feb-07 8-Feb-07 15-Feb-07 25-Feb-07 30-Apr-07 30-Jul-07
11 100 PM 25-Jan-07 26-Jan-07 1-Feb-07 8-Feb-07 16-Feb-07
11 101 PM 2-Feb-07 3-Feb-07 9-Feb-07 16-Feb-07 24-Feb-07 24-May-07 6-Nov-07
11 102 Combination 2-Feb-07 3-Feb-07 9-Feb-07 16-Feb-07 20-Feb-07 1-May-07 30-Jul-07
11 103 Combination 6-Feb-07 7-Feb-07 13-Feb-07 20-Feb-07 24-Feb-07 7-May-07 10-Aug-07
11 104 PM 9-Feb-07 10-Feb-07 16-Feb-07 23-Feb-07 3-Mar-07 16-May-07 27-Aug-07
11 105 SSG 23-Feb-07 24-Feb-07 2-Mar-07 9-Mar-07 16-Mar-07 26-Mar-07 29-May-07 27-Aug-07
11 106 Combination 24-Feb-07 25-Feb-07 3-Mar-07 10-Mar-07 14-Mar-07 25-May-07 19-Aug-07
11 107 PM 24-Feb-07 25-Feb-07 3-Mar-07 10-Mar-07 18-Mar-07 29-May-07 28-Aug-07
11 108 PM 28-Feb-07 2-Mar-07 8-Mar-07 15-Mar-07 23-Mar-07 21-May-07 27-Aug-07
11 109 SSG 27-Feb-07 3-Mar-07 9-Mar-07 16-Mar-07 23-Mar-07 2-Apr-07 8-May-07 6-Aug-07
11 110 PM 2-Mar-07 3-Mar-07 9-Mar-07 16-Mar-07 24-Mar-07 29-May-07 27-Aug-07
11 111 Combination 23-Mar-07 24-Mar-07 30-Mar-07 6-Apr-07 10-Apr-07 22-Jun-07 24-Sep-07
11 112 Combination 23-Mar-07 24-Mar-07 30-Mar-07 6-Apr-07 10-Apr-07 30-Jul-07 24-Sep-07
11 113 SSG 23-Mar-07 28-Mar-07 3-Apr-07 10-Apr-07 17-Apr-07 27-Apr-07 29-Jun-07
11 114 SSG 28-Mar-07 30-Mar-07 5-Apr-07 12-Apr-07 19-Apr-07 29-Apr-07 2-Jul-07 5-Oct-07
11 115 Combination 30-Mar-07 31-Mar-07 6-Apr-07 13-Apr-07 17-Apr-07 7-Jul-07 21-Sep-07
11 116 SSG 30-Mar-07 31-Mar-07 6-Apr-07 13-Apr-07 20-Apr-07 30-Apr-07 31-Jul-07 1-Nov-07
11 117 PM 3-Apr-07 4-Apr-07 10-Apr-07 17-Apr-07 25-Apr-07 26-Jun-07
11 118 PM 18-Apr-07 19-Apr-07 25-Apr-07 2-May-07 10-May-07 6-Jul-07 19-Sep-07
11 119 SSG 20-Apr-07 21-Apr-07 27-Apr-07 4-May-07 11-May-07 21-May-07 24-Jul-07 29-Oct-07
11 120 Combination 20-Apr-07 21-Apr-07 27-Apr-07 4-May-07 8-May-07 23-Jul-07 29-Oct-07
11 121 Combination 20-Apr-07 21-Apr-07 27-Apr-07 4-May-07 8-May-07 23-Jul-07 29-Oct-07
11 122 SSG 20-Apr-07 21-Apr-07 27-Apr-07 4-May-07 11-May-07 21-May-07
11 123 SSG 27-Apr-07 28-Apr-07 4-May-07 11-May-07 18-May-07 28-May-07 30-Jul-07 19-Oct-07
11 124 SSG 20-May-07 21-May-07 27-May-07 3-Jun-07 10-Jun-07 20-Jun-07 7-Apr-08
11 125 SSG 23-May-07 24-May-07 30-May-07 6-Jun-07 13-Jun-07 23-Jun-07 20-Aug-07 19-Nov-07
11 126 Combination 26-May-07 28-May-07 3-Jun-07 10-Jun-07 14-Jun-07 10-Dec-07
11 127 PM 26-May-07 28-May-07 3-Jun-07 10-Jun-07 18-Jun-07 27-Aug-07 30-Oct-07
11 128 Combination 1-Jun-07 2-Jun-07 8-Jun-07 15-Jun-07 19-Jun-07 15-Aug-07 15-Nov-07
11 129 PM 6-Jun-07 7-Jun-07 13-Jun-07 20-Jun-07 28-Jun-07 17-Sep-07 21-Nov-07
11 130 Combination 7-Jun-07 9-Jun-07 15-Jun-07 22-Jun-07 26-Jun-07 17-Sep-07 19-Nov-07
11 131 PM 10-Jun-07 11-Jun-07 17-Jun-07 24-Jun-07 2-Jul-07 8-Oct-07 12-Dec-07
11 132 SSG 15-Jun-07 16-Jun-07 22-Jun-07 29-Jun-07 6-Jul-07 16-Jul-07 5-Sep-07 19-Dec-07
11 133 Combination 1-Jul-07 4-Jul-07 10-Jul-07 17-Jul-07 21-Jul-07 17-Oct-07 2-Jan-08
11 134 PM 10-Jul-07 11-Jul-07 17-Jul-07 24-Jul-07 1-Aug-07 9-Nov-07 8-Jan-08
11 135 PM 12-Jul-07 13-Jul-07 19-Jul-07 26-Jul-07 3-Aug-07 3-Oct-07 31-Dec-07
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12 241 Combination 28-Jun-05 29-Jun-05 5-Jul-05 12-Jul-05 16-Jul-05 9-Feb-06
12 242 SSG 28-Jun-05 29-Jun-05 5-Jul-05 12-Jul-05 19-Jul-05 29-Jul-05 24-Oct-05 9-Feb-06
12 243 PM 28-Jun-05 29-Jun-05 5-Jul-05 12-Jul-05 20-Jul-05 4-Nov-05 7-Aug-06
12 244 SSG 7-Jun-05 29-Jun-05 5-Jul-05 12-Jul-05 19-Jul-05 29-Jul-05 29-Oct-05 4-Apr-06
12 245 PM 16-Jul-05 20-Jul-05 25-Jul-05 1-Aug-05 9-Aug-05 18-Nov-05
12 246 PM 2-Aug-05 4-Aug-05 10-Aug-05 17-Aug-05 25-Aug-05 25-Nov-05
12 247 PM 12-Sep-05 28-Sep-05 4-Oct-05 11-Oct-05 19-Oct-05 18-Jan-06 17-Apr-06
12 248 PM 12-Sep-05 23-Sep-05 29-Sep-05 6-Oct-05 14-Oct-05 23-Jan-06 17-Apr-06
12 249 Combination 24-Oct-05 25-Oct-05 31-Oct-05 7-Nov-05 11-Nov-05 3-Mar-06 15-May-06
12 250 SSG 24-Oct-05 25-Oct-05 31-Oct-05 7-Nov-05 14-Nov-05 24-Nov-05 22-Feb-06 8-Jul-06
12 251 Combination 27-Oct-05 29-Oct-05 4-Nov-05 11-Nov-05 15-Nov-05 12-Feb-06 15-May-06
12 252 SSG 27-Oct-05 29-Oct-05 4-Nov-05 11-Nov-05 18-Nov-05 28-Nov-05 4-Apr-06 21-Jun-06
12 253 SSG 27-Oct-05 29-Oct-05 4-Nov-05 11-Nov-05 18-Nov-05 28-Nov-05 4-Apr-06 21-Jun-06
12 254 Combination 27-Oct-05 29-Oct-05 4-Nov-05 11-Nov-05 15-Nov-05 12-Feb-06 24-May-06
12 255 Combination 29-Oct-05 2-Nov-05 7-Nov-05 14-Nov-05 18-Nov-05 9-Mar-06 17-May-06
12 256 Combination 14-Nov-05 17-Nov-05 23-Nov-05 30-Nov-05 5-Dec-05 4-Mar-06 6-Jun-06
12 257 SSG 14-Nov-05 17-Nov-05 23-Nov-05 30-Nov-05 7-Dec-05 17-Dec-05 17-Apr-06 14-Jun-06
12 258 SSG 30-Nov-05 6-Dec-05 12-Dec-05 19-Dec-05 26-Dec-05 5-Jan-06 13-Jul-06
12 259 PM 26-Dec-05 31-Dec-05 6-Jan-06 13-Jan-06 23-Jan-06 8-May-06 27-Jul-06
12 260 PM 26-Dec-05 3-Jan-06 9-Jan-06 16-Jan-06 24-Jan-06 11-Jul-06
12 261 Combination 26-Dec-05 3-Jan-06 9-Jan-06 16-Jan-06 20-Jan-06 17-Apr-06 21-Jul-06
12 262 PM 26-Dec-05 3-Jan-06 9-Jan-06 16-Jan-06 23-Jan-06 22-Jun-06 27-Jul-06
12 263 SSG 20-Jan-06 26-Jan-06 1-Feb-06 9-Feb-06 15-Feb-06 25-Feb-06 29-May-06 25-Aug-06
12 264 Combination 7-Feb-06 15-Feb-06 21-Feb-06 28-Feb-06 4-Mar-06 16-Jun-06 1-Sep-06
12 265 SSG 8-Feb-06 15-Feb-06 21-Feb-06 28-Feb-06 7-Mar-06 15-Mar-06
12 266 PM 8-Feb-06 15-Feb-06 21-Feb-06 28-Feb-06 8-Mar-06 2-Jun-06 4-Oct-06
12 267 SSG 8-Feb-06 15-Feb-06 21-Feb-06 28-Feb-06 7-Mar-06 17-Mar-06 15-Jun-06 14-Sep-06
12 268 PM 6-Mar-06 10-Mar-06 16-Mar-06 23-Mar-06 31-Mar-06 29-Jun-06 26-Sep-06
12 269 Combination 13-Mar-06 16-Mar-06 22-Mar-06 29-Mar-06 2-Apr-06 6-Jul-06 13-Nov-06
12 270 Combination 13-Mar-06 16-Mar-06 22-Mar-06 29-Mar-06 4-Apr-06 9-Oct-06
12 271 SSG 27-Mar-06 31-Mar-06 6-Apr-06 13-Apr-06 20-Apr-06 30-Apr-06 31-Jul-06 31-Oct-06
12 272 PM 4-Apr-06 8-Apr-06 14-Apr-06 21-Apr-06 29-Apr-06 27-Jun-06 13-Nov-06
12 273 SSG 4-Apr-06 8-Apr-06 14-Apr-06 21-Apr-06 28-Apr-06 8-May-06 8-Aug-06 13-Nov-06
12 274 SSG 4-Apr-06 8-Apr-06 14-Apr-06 21-Apr-06 28-Apr-06 8-May-06 7-Aug-06 13-Nov-06
12 275 Combination 4-Apr-06 8-Apr-06 14-Apr-06 21-Apr-06 25-Apr-06 24-Jul-06 24-Oct-06
12 276 PM 4-Apr-06 8-Apr-06 14-Apr-06 21-Apr-06 29-Apr-06 19-Jul-06 29-Oct-06
12 277 Combination 17-Apr-06 21-Apr-06 27-Apr-06 4-May-06 8-May-06 4-Aug-06 13-Nov-06
12 278 SSG 17-Apr-06 21-Apr-06 27-Apr-06 4-May-06 11-May-06 21-May-06 17-Aug-06
12 279 PM 17-Apr-06 21-Apr-06 27-Apr-06 4-May-06 12-May-06 9-Aug-06 13-Nov-06
12 280 SSG 17-Apr-06 21-Apr-06 27-Apr-06 4-May-06 21-May-06 21-May-06 25-Aug-06 21-Nov-06
12 281 Combination 17-Apr-06 21-Apr-06 27-Apr-06 4-May-06 8-May-06 7-Aug-06 21-Dec-06
12 282 PM 27-Apr-06 28-Apr-06 4-May-06 11-May-06 19-May-06 25-Aug-06 18-Dec-06
12 283 PM 10-May-06 11-May-06 17-May-06 24-May-06 1-Jun-06 25-Aug-06 29-Dec-06
12 284 Combination 18-May-06 20-May-06 26-May-06 2-Jun-06 6-Jun-06 4-Sep-06 5-Dec-06
12 285 Combination 18-May-06 20-May-06 26-May-06 2-Jun-06 6-Jun-06 4-Sep-06 5-Dec-06
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12 286 PM 21-Dec-06 2-Jan-07 8-Jan-07 15-Jan-07 23-Jan-07 30-Apr-07 4-Sep-07
12 287 SSG 21-Dec-06 2-Jan-07 8-Jan-07 15-Jan-07 22-Jan-07 1-Feb-07 16-Jun-07 7-Aug-07
12 288 Combination 26-Dec-06 2-Jan-07 8-Jan-07 15-Jan-07 19-Jan-07 20-Apr-07 24-Jul-07
12 289 Combination 26-Dec-06 2-Jan-07 8-Jan-07 15-Jan-07 19-Jan-07 30-Apr-07 3-Sep-07
12 290 SSG 4-Jan-07 6-Jan-07 12-Jan-07 19-Jan-07 26-Jan-07 5-Feb-07 5-Sep-07
12 291 SSG 8-Jan-07 11-Jan-07 17-Jan-07 24-Jan-07 31-Jan-07 10-Feb-07 30-Apr-07 3-Sep-07
12 292 PM 15-Jan-07 18-Jan-07 24-Jan-07 31-Jan-07 7-Feb-07 21-Aug-07
12 293 SSG 22-Jan-07 24-Jan-07 30-Jan-07 6-Feb-07 13-Feb-07 23-Feb-07 5-Sep-07
12 294 Combination 19-Feb-07 22-Feb-07 28-Feb-07 7-Mar-07 11-Mar-07 11-Jun-07 7-Sep-07
12 295 Combination 11-Mar-07 16-Mar-07 22-Mar-07 29-Mar-07 2-Apr-07 20-Sep-07
12 296 PM 4-Apr-07 12-Apr-07 18-Apr-07 25-Apr-07 3-May-07 31-Jul-07 30-Oct-07
12 297 SSG 4-Apr-07 12-Apr-07 18-Apr-07 25-Apr-07
12 298 PM 16-Apr-07 21-Apr-07 27-Apr-07 4-May-07 14-May-07 8-Aug-07 9-Nov-07
12 299 Combination 1-Jun-07 5-Jun-07 11-Jun-07 18-Jun-07 22-Jun-07 31-Dec-07
12 300 PM 1-Jun-07 5-Jun-07 11-Jun-07 18-Jun-07 26-Jun-07 25-Sep-07 24-Dec-07
12 301 SSG 2-Jun-07 5-Jun-07 11-Jun-07 18-Jun-07 25-Jun-07 5-Jul-07 8-Oct-07 4-Feb-08
12 302 SSG 2-Jun-07 5-Jun-07 11-Jun-07 18-Jun-07 25-Jun-07 5-Jul-07 1-Oct-07 26-Dec-07
12 303 PM 2-Jun-07 5-Jun-07 11-Jun-07 18-Jun-07 26-Jun-07 1-Oct-07 26-Dec-07
12 304 Combination 2-Jun-07 5-Jun-07 11-Jun-07 18-Jun-07 22-Jun-07 1-Oct-07 26-Dec-07
12 305 PM 2-Jun-07 5-Jun-07 11-Jun-07 18-Jun-07 26-Jun-07 1-Oct-07 26-Dec-07
12 306 Combination 2-Jun-07 5-Jun-07 11-Jun-07 18-Jun-07 22-Jun-07 1-Oct-07 26-Dec-07
12 307 Combination 13-Jun-07 15-Jun-07 21-Jun-07 28-Jun-07 2-Jul-07 1-Oct-07 26-Dec-07
12 308 PM 13-Jun-07 15-Jun-07 21-Jun-07 28-Jun-07 6-Jul-07 8-Oct-07 26-Dec-07
12 309 PM 16-Jun-07 16-Jun-07 22-Jun-07 29-Jun-07 7-Jul-07 1-Oct-07 26-Dec-07
12 310 SSG 16-Jun-07 16-Jun-07 22-Jun-07 29-Jun-07 6-Jul-07 16-Jul-07 18-Oct-07 4-Feb-08
12 311 SSG 4-Jul-07 5-Jul-07 11-Jul-07 18-Jul-07 25-Jul-07 6-Aug-07 1-Nov-07 11-Mar-08
12 312 Combination 10-Jul-07 12-Jul-07 18-Jul-07 25-Jul-07 30-Jul-07 27-Oct-07 19-Mar-08
12 313 PM 31-Jul-07 2-Aug-07 8-Aug-07 15-Aug-07 23-Aug-07 22-Nov-07 21-Feb-08
12 314 SSG 31-Jul-07 7-Aug-07 13-Aug-07 20-Aug-07 27-Aug-07 6-Sep-07 4-Dec-07 4-Mar-08
12 315 Combination 20-Aug-07 29-Aug-07 4-Sep-07 11-Sep-07 17-Sep-07 8-Jan-08 11-Aug-08
12 316 SSG 20-Aug-07 29-Aug-07 4-Sep-07 11-Sep-07 25-Sep-07 28-Dec-07 1-Apr-08
12 317 SSG 21-Aug-07 29-Aug-07 4-Sep-07 11-Sep-07 18-Sep-07 28-Sep-07 22-Apr-08
12 318 Combination 27-Aug-07 28-Aug-07 4-Sep-07 11-Sep-07 17-Sep-07 17-Dec-07 15-Mar-08
12 319 Combination 27-Aug-07 28-Aug-07 4-Sep-07 11-Sep-07 17-Sep-07 20-Dec-07 14-Mar-08
12 320 Combination 4-Sep-07 6-Sep-07 12-Sep-07 19-Sep-07 23-Sep-07 24-Dec-07 19-Mar-08
12 321 Combination 4-Sep-07 6-Sep-07 12-Sep-07 19-Sep-07 23-Sep-07 24-Dec-07 24-Mar-08
12 322 PM 11-Sep-07 13-Sep-07 19-Sep-07 26-Sep-07 4-Oct-07 16-Jan-08 19-Apr-08
12 323 SSG 18-Sep-07 20-Sep-07 26-Sep-07 3-Oct-07 10-Oct-07 20-Oct-07 18-Jan-08 16-Apr-08
12 324 SSG 18-Sep-07 20-Sep-07 26-Sep-07 3-Oct-07 10-Oct-07 20-Oct-07 18-Jan-08 16-Apr-08
12 325 PM 18-Sep-07 27-Sep-07 3-Oct-07 10-Oct-07 18-Oct-07 15-Jan-08 16-Apr-08
12 326 PM 2-Oct-07 3-Oct-07 9-Oct-07 16-Oct-07 24-Oct-07 23-Jan-08 19-Apr-08
12 327 Combination 2-Oct-07 3-Oct-07 9-Oct-07 16-Oct-07 20-Oct-07 18-Jan-08 16-Apr-08
12 328 PM 3-Oct-07 5-Oct-07 11-Oct-07 18-Oct-07 26-Oct-07 24-Jan-08 14-Apr-08
12 329 SSG 8-Oct-07 10-Oct-07 16-Oct-07 23-Oct-07 30-Oct-07 9-Nov-07 5-Feb-08 6-May-08
12 330 PM 8-Oct-07 10-Oct-07 16-Oct-07 23-Oct-07 31-Oct-07 4-Feb-08 6-May-08
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23 361 Combination 19-Jan-05 20-Jan-05 26-Jan-05 2-Feb-05 6-Feb-05 5-May-05 10-Aug-05
23 362 PM 18-Jan-05 20-Jan-05 26-Jan-05 2-Feb-05 10-Feb-05 10-May-05 16-Aug-05
23 363 PM 18-Jan-05 20-Jan-05 27-Jan-05 2-Feb-05 10-Feb-05 5-May-05 10-Aug-05
23 364 Combination 18-Jan-05 20-Jan-05 26-Jan-05 2-Feb-05 8-Feb-05 27-Apr-05 19-Aug-05
23 365 SSG 18-Jan-05 20-Jan-05 27-Jan-05 2-Feb-05 10-Feb-05 10-Feb-05 20-May-05 30-Aug-05
23 366 Combination 27-Jan-05 1-Feb-05 7-Feb-05 14-Feb-05 18-Feb-05 20-May-05 19-Aug-05
23 367 SSG 28-Jan-05 1-Feb-05 8-Feb-05 14-Feb-05 22-Feb-05 3-Mar-05 8-Jun-05 23-Sep-05
23 368 PM 27-Jan-05 1-Feb-05 7-Feb-05 14-Feb-05 22-Feb-05 26-May-05 5-Sep-05
23 369 Combination 3-Feb-05 4-Feb-05 10-Feb-05 17-Feb-05 21-Feb-05 26-May-05 30-Aug-05
23 370 SSG 27-Jan-05 4-Feb-05 10-Feb-05 17-Feb-05 24-Feb-05 6-Mar-05 8-Jun-05 23-Sep-05
23 371 PM 2-Feb-05 4-Feb-05 10-Feb-05 17-Feb-05 25-Feb-05 26-May-05 6-Sep-05
23 372 PM 9-Feb-05 11-Feb-05 17-Feb-05 24-Feb-05 4-Mar-05 6-Jun-05 9-Sep-05
23 373 SSG 16-Feb-05 18-Feb-05 24-Feb-05 3-Mar-05 10-Mar-05 21-Mar-05 6-Jul-05 24-Oct-05
23 374 SSG 17-Feb-05 24-Feb-05 2-Mar-05 9-Mar-05 16-Mar-05 28-Mar-05 27-Jun-05 29-Sep-05
23 375 Combination 23-Feb-05 25-Feb-05 3-Mar-05 10-Mar-05 14-Mar-05 15-Jun-05 23-Sep-05
23 376 SSG 24-Feb-05 1-Mar-05 7-Mar-05 14-Mar-05 21-Mar-05 31-Mar-05 29-Jun-05 28-Sep-05
23 377 Combination 7-Mar-05 9-Mar-05 17-Mar-05 23-Sep-05
23 378 Combination 7-Mar-05 9-Mar-05 15-Mar-05 22-Mar-05 26-Mar-05 6-Jul-05 23-Sep-05
23 379 PM 23-Feb-05 10-Mar-05 17-Mar-05 23-Mar-05 31-Mar-05 30-Sep-05
23 380 SSG 8-Mar-05 15-Mar-05 21-Mar-05 28-Mar-05 4-Apr-05 14-Apr-05 19-Jul-05 13-Oct-05
23 381 PM 14-Mar-05 15-Mar-05 21-Mar-05 28-Mar-05 5-Apr-05 12-Jul-05 16-Nov-05
23 382 Combination 17-Mar-05 18-Mar-05 24-Mar-05 31-Mar-05 4-Apr-05 12-Jul-05 29-Sep-05
23 383 PM 23-Mar-05 5-Apr-05 11-Apr-05 18-Apr-05 26-Apr-05 29-Sep-05 24-Oct-05
23 384 SSG 23-Mar-05 5-Apr-05 11-Apr-05 18-Apr-05 25-Apr-05 5-May-05 28-Sep-05 16-Nov-05
23 385 SSG 23-Mar-05 7-Apr-05 13-Apr-05 20-Apr-05 27-Apr-05 7-May-05 10-Aug-05 11-Nov-05
23 386 Combination 14-Apr-05 19-Apr-05 25-Apr-05 11-May-05 16-May-05 19-Aug-05 11-Nov-05
23 387 Combination 14-Apr-05 19-Apr-05 25-Apr-05 2-May-05 6-May-05 10-Aug-05 11-Nov-05
23 388 PM 14-Apr-05 19-Apr-05 25-Apr-05 4-May-05 10-May-05 28-Sep-05 2-Dec-05
23 389 SSG 14-Apr-05 20-Apr-05 26-Apr-05 4-May-05 10-May-05 20-May-05 6-Sep-05 9-Dec-05
23 390 PM 14-Apr-05 20-Apr-05 26-Apr-05 3-May-05 11-May-05 10-Aug-05 2-Dec-05
23 391 Combination 21-Apr-05 22-Apr-05 28-Apr-05 5-May-05 9-May-05 19-Aug-05 16-Nov-05
23 392 Combination 21-Apr-05 22-Apr-05 28-Apr-05 5-May-05 22-Jul-05 29-Sep-05
23 393 SSG 20-Apr-05 22-Apr-05 28-Apr-05 5-May-05 12-May-05 22-May-05 19-Aug-05 16-Nov-05
23 394 PM 14-Apr-05 26-Apr-05 2-May-05 9-May-05 17-May-05 19-Aug-05 16-Nov-05
23 395 PM 28-Apr-05 29-Apr-05 5-May-05 13-May-05 20-May-05 1-Jul-05 14-Dec-05
23 396 SSG 10-May-05 13-May-05 19-May-05 26-May-05 2-Jun-05 12-Jun-05 16-Sep-05 14-Dec-05
23 397 SSG 10-May-05 18-May-05 19-May-05 26-May-05 2-Jun-05 12-Jun-05 16-Sep-05 14-Dec-05
23 398 Combination 13-May-05 18-May-05 24-May-05 31-May-05 6-Jun-05 30-Sep-05 14-Dec-05
23 399 PM 12-May-05 18-May-05 24-May-05 31-May-05 8-Jun-05 14-Oct-05 14-Dec-05
23 400 PM 2-Jun-05 3-Jun-05 9-Jun-05 16-Jun-05 24-Jun-05 14-Oct-05 12-Jan-06
23 401 Combination 30-May-05 3-Jun-05 9-Jun-05 16-Jun-05 20-Jun-05 19-Sep-05 20-Dec-05
23 402 Combination 30-May-05 3-Jun-05 9-Jun-05 16-Jun-05 20-Jun-05 23-Sep-05 20-Dec-05
23 403 SSG 30-May-05 4-Jun-05 10-Jun-05 17-Jun-05 24-Jun-05 4-Jul-05 30-Sep-05 12-Jan-06
23 404 SSG 30-May-05 4-Jun-05 10-Jun-05 17-Jun-05 24-Jun-05 4-Jul-05 12-Jan-06
23 405 PM 9-Jun-05 10-Jun-05 16-Jun-05 24-Jun-05 1-Jul-05 29-Sep-05 5-Jan-06
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34 451 Combination 16-Nov-04 17-Nov-04 23-Nov-04 30-Nov-04 4-Dec-04 3-Jun-05
34 452 PM 16-Nov-04 17-Nov-04 23-Nov-04 30-Nov-04 8-Dec-04
34 453 PM 17-Nov-04 18-Nov-04 24-Nov-04 1-Dec-04 9-Dec-04
34 454 Combination 18-Nov-04 21-Nov-04 27-Nov-04 4-Dec-04 8-Dec-04 7-Jun-05
34 455 PM 18-Nov-04 19-Nov-04 25-Nov-04 2-Dec-04 10-Dec-04
34 456 SSG 18-Nov-04 19-Nov-04 25-Nov-04 2-Dec-04 9-Dec-04 19-Dec-04 25-Feb-05
34 457 Combination 18-Nov-04 19-Nov-04 25-Nov-04 2-Dec-04 6-Dec-04
34 458 PM 19-Nov-04 20-Nov-04 26-Nov-04 3-Dec-04 11-Dec-04 16-Jan-05
34 459 Combination 20-Nov-04 20-Nov-04 26-Nov-04 3-Dec-04 7-Dec-04 7-Jan-05 3-Jun-05
34 460 PM 22-Nov-04 24-Nov-04 30-Nov-04 7-Dec-04 15-Dec-04
34 461 SSG 24-Nov-04 26-Nov-04 2-Dec-04 9-Dec-04
34 462 SSG 24-Nov-04 25-Nov-04 1-Dec-04 8-Dec-04 15-Dec-04 25-Dec-04 7-Jun-05
34 463 Combination 25-Nov-04 27-Nov-04 3-Dec-04 10-Dec-04 14-Dec-04 16-Jun-05
34 464 SSG 26-Nov-04 27-Nov-04 3-Dec-04 10-Dec-04 17-Dec-04 27-Dec-04 2-Jun-05
34 465 SSG 27-Nov-04 29-Nov-04 5-Dec-04 12-Dec-04 19-Dec-04 29-Dec-04 3-Jun-05
34 466 Combination 27-Nov-04 30-Nov-04 6-Dec-04 13-Dec-04 17-Dec-04
34 467 PM 28-Nov-04 29-Nov-04 5-Dec-04 12-Dec-04 20-Dec-04 5-Feb-05
34 468 Combination 28-Nov-04 29-Nov-04 5-Dec-04 12-Dec-04 16-Dec-04 4-Jun-05
34 469 SSG 28-Nov-04 29-Nov-04 5-Dec-04 12-Dec-04 19-Dec-04 29-Dec-04 10-Jun-05
34 470 Combination 29-Nov-04 29-Nov-04 5-Dec-04 12-Dec-04 16-Dec-04 7-Jun-05
34 471 PM 29-Nov-04 29-Nov-04 5-Dec-04 12-Dec-04 20-Dec-04
34 472 SSG 1-Dec-04 1-Dec-04 7-Dec-04 14-Dec-04 21-Dec-04 31-Dec-04 9-Jun-05
34 473 PM 1-Dec-04 3-Dec-04 9-Dec-04 16-Dec-04 24-Dec-04
34 474 Combination 3-Dec-04 4-Dec-04 10-Dec-04 17-Dec-04 21-Dec-04 1-Jun-05
34 475 PM 4-Dec-04 5-Dec-04 11-Dec-04 18-Dec-04 26-Dec-04
34 476 PM 4-Dec-04 5-Dec-04 11-Dec-04 18-Dec-04 26-Dec-04 10-Jan-05
34 477 SSG 6-Dec-04 6-Dec-04 12-Dec-04 19-Dec-04 26-Dec-04 5-Jan-05 5-Jun-05
34 478 Combination 6-Dec-04 7-Dec-04 13-Dec-04 20-Dec-04 24-Dec-04 5-Jun-05
34 479 SSG 8-Dec-04 8-Dec-04 14-Dec-04 21-Dec-04 28-Dec-04 7-Jan-05 1-Jun-05
34 480 SSG 8-Dec-04 9-Dec-04 15-Dec-04 22-Dec-04 29-Dec-04 8-Jan-05 13-Jun-05
34 481 Combination 9-Dec-04 9-Dec-04 15-Dec-04 22-Dec-04 26-Dec-04 3-Jun-05
34 482 Combination 9-Dec-04 10-Dec-04 16-Dec-04 23-Dec-04 27-Dec-04 5-Jun-05
34 483 PM 9-Dec-04 10-Dec-04 16-Dec-04 23-Dec-04 31-Dec-04 31-May-05
34 484 PM 10-Dec-04 12-Dec-04 18-Dec-04
34 485 Combination 10-Dec-04 12-Dec-04 18-Dec-04 25-Dec-04 29-Dec-04 6-Jun-05
34 486 Combination 11-Dec-04 13-Dec-04 19-Dec-04 26-Dec-04 30-Dec-04 7-Jun-05
34 487 SSG 12-Dec-04 13-Dec-04 19-Dec-04 26-Dec-04 2-Jan-05 12-Jan-05 2-Jun-05
34 488 SSG 13-Dec-04 14-Dec-04 20-Dec-04 27-Dec-04 3-Jan-05 13-Jan-05 17-Feb-05 7-Jun-05
34 489 SSG 15-Dec-04 16-Dec-04 22-Dec-04 29-Dec-04 5-Jan-05 15-Jan-05 3-Jun-05
34 490 PM 16-Dec-04 16-Dec-04 22-Dec-04 29-Dec-04 6-Jan-05 15-Jun-05
34 491 PM 16-Dec-04 17-Dec-04 23-Dec-04 30-Dec-04 7-Jan-05
34 492 PM 16-Dec-04 19-Dec-04 25-Dec-04 1-Jan-05 9-Jan-05 2-Jun-05
34 493 SSG 16-Dec-04 17-Dec-04 23-Dec-04 30-Dec-04 6-Jan-05 16-Jan-05
34 494 Combination 17-Dec-04 17-Dec-04 23-Dec-04 30-Dec-04 3-Jan-05 3-Jun-05
34 495 SSG 17-Dec-04 18-Dec-04 24-Dec-04 31-Dec-04 7-Jan-05 17-Jan-05 2-Jun-05
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Centre Patient Treatment Assessment Date
Number Number Baseline Day 1 Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
34 496 SSG 18-Dec-04 19-Dec-04 25-Dec-04 1-Jan-05 8-Jan-05 18-Jan-05 2-Jun-05
34 497 PM 20-Dec-04 21-Dec-04 27-Dec-04 3-Jan-05 11-Jan-05 12-Feb-05
34 498 SSG 20-Dec-04 21-Dec-04 27-Dec-04 3-Jan-05 10-Jan-05 20-Jan-05 6-Jun-05
34 499 Combination 20-Dec-04 21-Dec-04 27-Dec-04 3-Jan-05 7-Jan-05 6-Jun-05
34 500 PM 20-Dec-04 22-Dec-04 28-Dec-04 4-Jan-05 12-Jan-05 7-Jun-05
34 501 Combination 21-Dec-04 22-Dec-04 28-Dec-04 4-Jan-05 8-Jan-05 8-Jun-05
34 502 Combination 22-Dec-04 23-Dec-04 29-Dec-04 5-Jan-05 9-Jan-05 8-Jun-05
34 503 PM 24-Dec-04 25-Dec-04 31-Dec-04 7-Jan-05 15-Jan-05
34 504 Combination 26-Dec-04 27-Dec-04 2-Jan-05 9-Jan-05 13-Jan-05
34 505 SSG 27-Dec-04 28-Dec-04 3-Jan-05 10-Jan-05 17-Jan-05 27-Jan-05 1-Jun-05
34 506 SSG 30-Dec-04 31-Dec-04 6-Jan-05 13-Jan-05 20-Jan-05 30-Jan-05 10-Jun-05
34 507 SSG 30-Dec-04 31-Dec-04 6-Jan-05 13-Jan-05 20-Jan-05 30-Jan-05 31-May-05
34 508 PM 30-Dec-04 31-Dec-04 6-Jan-05 13-Jan-05 21-Jan-05
34 509 PM 31-Dec-04 2-Jan-05 8-Jan-05 15-Jan-05 23-Jan-05
34 510 Combination 31-Dec-04 1-Jan-05 7-Jan-05 14-Jan-05 18-Jan-05 13-Jun-05
34 511 Combination 31-Dec-04 1-Jan-05 7-Jan-05 14-Jan-05 18-Jan-05 10-Jun-05
34 512 PM 1-Jan-05 2-Jan-05 8-Jan-05 15-Jan-05 23-Jan-05
34 513 Combination 2-Jan-05 3-Jan-05 9-Jan-05 16-Jan-05 20-Jan-05 28-Feb-05 31-May-05
34 514 SSG 3-Jan-05 4-Jan-05 10-Jan-05 17-Jan-05 24-Jan-05 3-Feb-05 7-Jun-05
34 515 SSG 4-Jan-05 5-Jan-05 11-Jan-05 18-Jan-05 25-Jan-05 4-Feb-05 13-May-05
34 516 PM 5-Jan-05 6-Jan-05 12-Jan-05 19-Jan-05 27-Jan-05 6-Jun-05
34 517 PM 5-Jan-05 6-Jan-05 12-Jan-05 19-Jan-05 27-Jan-05
34 518 SSG 6-Jan-05 9-Jan-05 14-Jan-05 21-Jan-05 29-Jan-05 8-Feb-05 3-Jun-05
34 519 PM 6-Jan-05 7-Jan-05 13-Jan-05 20-Jan-05 28-Jan-05 3-Apr-05
34 520 SSG 10-Jan-05 11-Jan-05 17-Jan-05 24-Jan-05 31-Jan-05 10-Feb-05 5-Jun-05
34 521 PM 10-Jan-05 11-Jan-05 17-Jan-05 24-Jan-05 1-Feb-05
34 522 Combination 10-Jan-05 11-Jan-05 17-Jan-05 24-Jan-05 28-Jan-05
34 523 SSG 12-Jan-05 14-Jan-05 20-Jan-05 27-Jan-05 3-Feb-05 13-Feb-05 1-Jun-05
34 524 Combination 12-Jan-05 13-Jan-05 19-Jan-05 26-Jan-05 30-Jan-05 5-Jun-05
34 525 Combination 12-Jan-05 13-Jan-05 19-Jan-05 26-Jan-05 30-Jan-05 9-Jun-05
34 526 SSG 13-Jan-05 14-Jan-05 20-Jan-05 27-Jan-05 3-Feb-05 13-Feb-05 4-Jun-05
34 527 Combination 14-Jan-05 15-Jan-05 21-Jan-05 28-Jan-05 1-Feb-05 31-May-05
34 528 PM 16-Jan-05 17-Jan-05 23-Jan-05 30-Jan-05 7-Feb-05
34 529 Combination 17-Jan-05 18-Jan-05 24-Jan-05 31-Jan-05 4-Feb-05 14-Jun-05
34 530 Combination 19-Jan-05 20-Jan-05 26-Jan-05 2-Feb-05 6-Feb-05 14-Jun-05
34 531 SSG 20-Jan-05 21-Jan-05 27-Jan-05 3-Feb-05 10-Feb-05 20-Feb-05
34 532 Combination 20-Jan-05 21-Jan-05 27-Jan-05 3-Feb-05 7-Feb-05 3-Jun-05
34 533 SSG 22-Jan-05 23-Jan-05 29-Jan-05 5-Feb-05 12-Feb-05 22-Feb-05 9-Jun-05
34 534 PM 23-Jan-05 24-Jan-05 30-Jan-05 6-Feb-05 14-Feb-05
34 535 PM 23-Jan-05 24-Jan-05 30-Jan-05 6-Feb-05 14-Feb-05 25-Mar-05
34 536 PM 24-Jan-05 25-Jan-05 31-Jan-05 7-Feb-05 15-Feb-05 6-May-06
34 537 SSG 24-Jan-05 25-Jan-05 31-Jan-05 7-Feb-05 15-Feb-05 24-Feb-05 31-May-05
34 538 PM 24-Jan-05 26-Jan-05 1-Feb-05 8-Feb-05 16-Feb-05
34 539 Combination 25-Jan-05 26-Jan-05 1-Feb-05 8-Feb-05 12-Feb-05 5-Jun-05
34 540 SSG 26-Jan-05 27-Jan-05 2-Feb-05 9-Feb-05 16-Feb-05 26-Feb-05 31-May-05
LEAP 0104a Appendices
Page 335 of 756
Appendix 23: Listing of Patient Assessment/ Visit date
Centre Patient Treatment Assessment Date
Number Number Baseline Day 1 Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
35 646 PM 26-Jan-05 28-Jan-05 3-Feb-05 10-Feb-05 18-Feb-05 5-Dec-05
35 647 PM 29-Jan-05 30-Jan-05 5-Feb-05 12-Feb-05 20-Feb-05 21-May-05 15-Aug-05
35 648 Combination 30-Jan-05 30-Jan-05 5-Feb-05 16-Feb-05 21-May-05 25-Aug-05
35 649 Combination 29-Jan-05 30-Jan-05 5-Feb-05 16-Feb-05 18-May-05 12-Sep-05
35 650 SSG 30-Jan-05 30-Jan-05 5-Feb-05 12-Feb-05 19-Feb-05 1-Mar-05 6-Jun-05 12-Sep-05
35 651 SSG 30-Jan-05 30-Jan-05 5-Feb-05 12-Feb-05 19-Feb-05 1-Mar-05 9-Jun-05 14-Sep-05
35 652 PM 31-Jan-05 1-Feb-05 7-Feb-05 14-Feb-05 22-Feb-05 15-Aug-05
35 653 Combination 2-Feb-05 3-Feb-05 9-Feb-05 16-Feb-05 20-Feb-05 24-May-05 25-Aug-05
35 654 SSG 2-Feb-05 3-Feb-05 9-Feb-05 16-Feb-05 23-Feb-05 5-Mar-05 9-Jun-05 19-Sep-05
35 655 Combination 2-Feb-05 3-Feb-05 9-Feb-05 16-Feb-05 20-Feb-05 23-May-05 25-Aug-05
35 656 SSG 1-Feb-05 3-Feb-05 9-Feb-05 16-Feb-05 23-Feb-05 5-Mar-05 6-Jun-05 6-Oct-05
35 657 PM 7-Feb-05 8-Feb-05 14-Feb-05 21-Feb-05 1-Mar-05 9-Jun-05 14-Sep-05
35 658 Combination 7-Feb-05 8-Feb-05 14-Feb-05 21-Feb-05 25-Feb-05 21-May-05 25-Aug-05
35 659 SSG 7-Feb-05 8-Feb-05 14-Feb-05 21-Feb-05 28-Feb-05 10-Mar-05 5-Jun-05 25-Oct-05
35 660 PM 5-Feb-05 10-Feb-05 16-Feb-05 23-Feb-05 3-Mar-05 9-Jun-05 15-Sep-05
35 661 Combination 15-Feb-05 16-Feb-05 22-Feb-05 1-Mar-05 5-Mar-05 9-Jun-05 24-Sep-05
35 662 PM 19-Feb-05 20-Feb-05 26-Feb-05 5-Mar-05 12-Mar-05 9-Jun-05 17-Sep-05
35 663 SSG 19-Feb-05 20-Feb-05 26-Feb-05 5-Mar-05 12-Mar-05 22-Mar-05 22-Jun-05 22-Sep-05
35 664 Combination 19-Feb-05 20-Feb-05 26-Feb-05 10-Oct-05
35 665 SSG 22-Feb-05 23-Feb-05 1-Mar-05 8-Mar-05 15-Mar-05 25-Mar-05 28-Jun-05 25-Oct-05
35 666 SSG 25-Feb-05 26-Feb-05 4-Mar-05 11-Mar-05 18-Mar-05 28-Mar-05 27-Jun-05 25-Sep-05
35 667 Combination 27-Feb-05 28-Feb-05 6-Mar-05 13-Mar-05 17-Mar-05 5-Jun-05 20-Oct-05
35 668 PM 27-Feb-05 28-Feb-05 6-Mar-05 13-Mar-05 21-Mar-05 25-Sep-05
35 669 PM 28-Feb-05 28-Feb-05 6-Mar-05 13-Mar-05 21-Mar-05
35 670 SSG 2-Mar-05 3-Mar-05 9-Mar-05 16-Mar-05 23-Mar-05 2-Apr-05 4-Jul-05 12-Oct-05
35 671 PM 10-Mar-05 11-Mar-05 17-Mar-05 24-Mar-05 1-Apr-05
35 672 Combination 10-Mar-05 11-Mar-05 17-Mar-05 24-Mar-05 28-Mar-05 20-Oct-05
35 673 SSG 10-Mar-05 11-Mar-05 17-Mar-05 24-Mar-05 31-Mar-05 10-Apr-05 15-Jul-05 16-Oct-05
35 674 Combination 12-Mar-05 13-Mar-05 19-Mar-05 26-Mar-05 30-Mar-05 10-Jul-05 20-Oct-05
35 675 PM 13-Mar-05 14-Mar-05 20-Mar-05 27-Mar-05 4-Apr-05 7-Dec-05
35 676 PM 19-Mar-05 20-Mar-05 26-Mar-05 2-Apr-05 10-Apr-05 18-Jul-05 20-Oct-05
35 677 SSG 19-Mar-05 20-Mar-05 26-Mar-05
35 678 Combination 20-Mar-05 22-Mar-05 28-Mar-05 4-Apr-05 8-Apr-05 7-Jul-05 25-Oct-05
35 679 SSG 20-Mar-05 22-Mar-05 28-Mar-05 4-Apr-05 11-Apr-05 21-Apr-05 24-Jul-05 25-Oct-05
35 680 Combination 20-Mar-05 22-Mar-05 28-Mar-05 4-Apr-05 8-Apr-05 10-Jul-05 12-Oct-05
35 681 Combination 21-Mar-05 22-Mar-05 28-Mar-05 4-Apr-05 8-Apr-05 7-Jul-05 20-Oct-05
35 682 PM 21-Mar-05 22-Mar-05 28-Mar-05 4-Apr-05 12-Apr-05 19-Oct-05
35 683 Combination 21-Mar-05 22-Mar-05 28-Mar-05 4-Apr-05 8-Apr-05 29-Oct-05
35 684 SSG 8-Apr-05 9-Apr-05 15-Apr-05 22-Apr-05 29-Apr-05 9-May-05 20-Aug-05 29-Oct-05
35 685 PM 8-Apr-05 9-Apr-05 15-Apr-05 22-Apr-05 30-Apr-05 2-Aug-05 29-Oct-05
35 686 PM 8-Apr-05 13-Apr-05 19-Apr-05 26-Apr-05 4-May-05 7-Aug-05 26-Oct-05
35 687 SSG 12-Apr-05 13-Apr-05 19-Apr-05 26-Apr-05 3-May-05 13-May-05 20-Aug-05 29-Oct-05
35 688 PM 15-Apr-05 16-Apr-05 22-Apr-05 29-Apr-05 7-May-05 18-Aug-05 25-Oct-05
35 689 Combination 15-Apr-05 16-Apr-05 22-Apr-05 29-Apr-05 3-May-05 3-Aug-05 26-Oct-05
35 690 SSG 15-Apr-05 16-Apr-05 22-Apr-05 29-Apr-05 6-May-05 16-May-05 22-Aug-05 29-Oct-05
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16.3 PATIENT DATA LISTINGS  
16.3.1 Discontinued patients  
Appendix 24 Listing of discontinued patients 
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Centre Patient Treatment Treatment Date of Days on Reason for no Serious adverse event / Comment
Number Number Start date End date last visit Treatment 6 month follow-up
11 27 PM 19-Sep-05 21 Other DEATH
11 47 SSG 5-May-06 30 Other DEATH
11 65 PM 23-Jun-06 21 Lost to follow-up
11 85 SSG 25-Aug-06 30 Lost to follow-up
11 90 Combination 2-Sep-06 17 Lost to follow-up
11 100 PM 26-Jan-07 21 Lost to follow-up
11 113 SSG 28-Mar-07 30 Lost to follow-up
11 117 PM 4-Apr-07 21 Lost to follow-up
11 122 SSG 21-Apr-07 30 Lost to follow-up
12 245 PM 20-Jul-05 21 Lost to follow-up
12 265 SSG 15-Feb-06 13-Mar-06 27 ACUTE RENAL FAILURE
12 278 SSG 21-Apr-06 30 Lost to follow-up
12 297 SSG 12-Apr-07 25-Apr-07 14 Lost to follow-up PANCREATITIS
34 452 PM 17-Nov-04 7-Dec-04 7-Dec-04 21 Comment: Treatment failure, received rescue
34 453 PM 18-Nov-04 8-Dec-04 8-Dec-04 21 Comment: Treatment failure, received rescue
34 455 PM 19-Nov-04 9-Dec-04 9-Dec-04 21 Comment: Treatment failure, received rescue
34 456 SSG 19-Nov-04 30 Comment: Treatment failure, received rescue
34 457 Combination 19-Nov-04 17 Lost to follow-up
34 458 PM 20-Nov-04 21 Comment: Treatment failure, received rescue
34 460 PM 24-Nov-04 14-Dec-04 14-Dec-04 21 Comment: Treatment failure, received rescue
34 461 SSG 26-Nov-04 10-Dec-04 10-Dec-04 4 EXTENSIVE EPISTAXIS
34 466 Combination 30-Nov-04 17-Dec-04 17-Dec-04 17 Comment: Treatment failure, received rescue
34 467 PM 29-Nov-04 21 Comment: Treatment failure, received rescue
34 471 PM 29-Nov-04 19-Dec-04 19-Dec-04 21 Comment: Treatment failure, received rescue
34 473 PM 3-Dec-04 23-Dec-04 24-Dec-04 20 Comment: Treatment failure, received rescue
34 475 PM 5-Dec-04 25-Dec-04 25-Dec-04 21 Comment: Treatment failure, received rescue
34 476 PM 5-Dec-04 26-Dec-04 26-Dec-04 21 Comment: Treatment failure, received rescue
34 484 PM 12-Dec-04 18-Dec-04 18-Dec-04 7 Comment: Treatment failure, received rescue
34 491 PM 17-Dec-04 6-Jan-05 7-Jan-05 21 Comment: Treatment failure, received rescue
34 493 SSG 17-Dec-04 30 Comment: lost to follow-up
34 497 PM 21-Dec-04 21 Comment: Treatment failure, received rescue
34 503 PM 25-Dec-04 14-Jan-05 14-Jan-05 21 Comment: Treatment failure, received rescue
34 504 Combination 27-Dec-04 12-Jan-05 13-Jan-05 17 Comment: Treatment failure, received rescue
34 508 PM 31-Dec-04 20-Jan-05 21-Jan-05 21 Comment: Treatment failure, received rescue
34 509 PM 2-Jan-05 22-Jan-05 23-Jan-05 21 Comment: Treatment failure, received rescue
34 512 PM 2-Jan-05 23-Jan-05 24-Jan-05 21 Comment: Treatment failure, received rescue
34 515 SSG 5-Jan-05 30 Comment: lost to follow-up
34 517 PM 6-Jan-05 26-Jan-05 27-Jan-05 21 Comment: Treatment failure, received rescue
34 519 PM 7-Jan-05 21 Comment: Treatment failure, received rescue
34 521 PM 11-Jan-05 31-Jan-05 31-Jan-05 21 Comment: Treatment failure, received rescue
34 522 Combination 11-Jan-05 17 SUSPECTEDTB PERICARDITIS
34 528 PM 17-Jan-05 6-Feb-05 7-Feb-05 21 Comment: Treatment failure, received rescue
34 531 SSG 21-Jan-05 19-Feb-05 20-Feb-05 30 Comment: Treatment failure, received rescue
34 534 PM 24-Jan-05 14-Feb-05 14-Feb-05 21 THREATENED ANAEMIC HEART FAILURE
34 535 PM 24-Jan-05 21 Comment: Treatment failure, received rescue
34 538 PM 26-Jan-05 15-Feb-05 16-Feb-05 21 Comment: Treatment failure, received rescue
35 669 PM 28-Feb-05 20-Mar-05 21-Mar-05 21 Lost to follow-up
35 677 SSG 20-Mar-05 26-Mar-05 31-Mar-05 7 ACUTE RENAL FAILURE
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16.3.2 Protocol deviations  
Appendix 25 Listing of protocol deviations 
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Appendix 26: Listing of Missing Laboratory parameters
Centre Patients Treatment Day of Assessment Missing
Number Number Assessment
11 1 PM Day 7 BUN
11 1 PM Day 7 Bilirubin
11 2 Combination Day 7 BUN
11 2 Combination Day 7 Bilirubin
11 3 Combination Day 7 BUN
11 3 Combination Day 7 Bilirubin
11 3 Combination EOT Platelet count
11 3 Combination EOT Haemaglobin
11 4 PM Baseline BUN
11 4 PM Baseline Bilirubin
11 5 PM Baseline BUN
11 5 PM Baseline Bilirubin
11 6 Combination Baseline BUN
11 6 Combination Baseline Bilirubin
11 7 PM Baseline BUN
11 7 PM Baseline Bilirubin
11 8 SSG Baseline BUN
11 8 SSG Baseline Bilirubin
11 9 SSG Baseline BUN
11 9 SSG Baseline Bilirubin
11 10 SSG Baseline BUN
11 10 SSG Baseline Bilirubin
11 12 Combination Baseline BUN
11 12 Combination Baseline Bilirubin
11 15 PM Day 14 Creatinine
11 15 PM Day 14 BUN
11 15 PM Day 14 Bilirubin
11 15 PM Day 14 Alkaline Phosphatase
11 15 PM Day 14 Aspartate Aminotransferase
11 15 PM Day 14 Alanine Aminotransferase
11 15 PM Day 14 Haemaglobin
11 15 PM Day 14 White Blood Cell Count
11 15 PM Day 14 Platelet count
11 15 PM EOT Creatinine
11 15 PM EOT BUN
11 15 PM EOT Bilirubin
11 15 PM EOT Alkaline Phosphatase
11 15 PM EOT Aspartate Aminotransferase
11 15 PM EOT Alanine Aminotransferase
11 15 PM EOT Platelet count
11 15 PM EOT Haemaglobin
11 15 PM EOT White Blood Cell Count
11 18 SSG Day 7 Platelet count
11 40 PM EOT Creatinine
11 40 PM EOT BUN
11 40 PM EOT Bilirubin
11 40 PM EOT Alkaline Phosphatase
11 40 PM EOT Aspartate Aminotransferase
11 40 PM EOT Alanine Aminotransferase
11 40 PM EOT Platelet count
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11 40 PM EOT Haemaglobin
11 40 PM EOT White Blood Cell Count
11 65 PM 6 mon FU Creatinine
11 65 PM 6 mon FU BUN
11 65 PM 6 mon FU Bilirubin
11 65 PM 6 mon FU Alkaline Phosphatase
11 65 PM 6 mon FU Aspartate Aminotransferase
11 65 PM 6 mon FU Alanine Aminotransferase
11 65 PM 6 mon FU Platelet count
11 65 PM 6 mon FU Haemaglobin
11 65 PM 6 mon FU White Blood Cell Count
11 72 SSG Day 7 BUN
11 72 SSG EOT Creatinine
11 72 SSG EOT BUN
11 72 SSG EOT Bilirubin
11 72 SSG EOT Alkaline Phosphatase
11 72 SSG EOT Aspartate Aminotransferase
11 72 SSG EOT Alanine Aminotransferase
11 72 SSG EOT Platelet count
11 72 SSG EOT Haemaglobin
11 72 SSG EOT White Blood Cell Count
11 85 SSG 6 mon FU Creatinine
11 85 SSG 6 mon FU BUN
11 85 SSG 6 mon FU Bilirubin
11 85 SSG 6 mon FU Alkaline Phosphatase
11 85 SSG 6 mon FU Aspartate Aminotransferase
11 85 SSG 6 mon FU Alanine Aminotransferase
11 85 SSG 6 mon FU Platelet count
11 85 SSG 6 mon FU Haemaglobin
11 85 SSG 6 mon FU White Blood Cell Count
11 90 Combination 6 mon FU Creatinine
11 90 Combination 6 mon FU BUN
11 90 Combination 6 mon FU Bilirubin
11 90 Combination 6 mon FU Alkaline Phosphatase
11 90 Combination 6 mon FU Aspartate Aminotransferase
11 90 Combination 6 mon FU Alanine Aminotransferase
11 90 Combination 6 mon FU Platelet count
11 90 Combination 6 mon FU Haemaglobin
11 90 Combination 6 mon FU White Blood Cell Count
11 96 Combination 6 mon FU Bilirubin
11 100 PM 6 mon FU Creatinine
11 100 PM 6 mon FU BUN
11 100 PM 6 mon FU Bilirubin
11 100 PM 6 mon FU Alkaline Phosphatase
11 100 PM 6 mon FU Aspartate Aminotransferase
11 100 PM 6 mon FU Alanine Aminotransferase
11 100 PM 6 mon FU Platelet count
11 100 PM 6 mon FU Haemaglobin
11 100 PM 6 mon FU White Blood Cell Count
11 113 SSG 6 mon FU Creatinine
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11 113 SSG 6 mon FU BUN
11 113 SSG 6 mon FU Bilirubin
11 113 SSG 6 mon FU Alkaline Phosphatase
11 113 SSG 6 mon FU Aspartate Aminotransferase
11 113 SSG 6 mon FU Alanine Aminotransferase
11 113 SSG 6 mon FU Platelet count
11 113 SSG 6 mon FU Haemaglobin
11 113 SSG 6 mon FU White Blood Cell Count
11 117 PM 6 mon FU Creatinine
11 117 PM 6 mon FU BUN
11 117 PM 6 mon FU Bilirubin
11 117 PM 6 mon FU Alkaline Phosphatase
11 117 PM 6 mon FU Aspartate Aminotransferase
11 117 PM 6 mon FU Alanine Aminotransferase
11 117 PM 6 mon FU Platelet count
11 117 PM 6 mon FU Haemaglobin
11 117 PM 6 mon FU White Blood Cell Count
11 122 SSG 6 mon FU Creatinine
11 122 SSG 6 mon FU BUN
11 122 SSG 6 mon FU Bilirubin
11 122 SSG 6 mon FU Alkaline Phosphatase
11 122 SSG 6 mon FU Aspartate Aminotransferase
11 122 SSG 6 mon FU Alanine Aminotransferase
11 122 SSG 6 mon FU Platelet count
11 122 SSG 6 mon FU Haemaglobin
11 122 SSG 6 mon FU White Blood Cell Count
12 241 Combination Baseline Platelet count
12 241 Combination Baseline Amylase
12 242 SSG Baseline Platelet count
12 242 SSG Baseline Amylase
12 243 PM 6 mon FU Amylase
12 243 PM Baseline Platelet count
12 243 PM Baseline Amylase
12 243 PM EOT Amylase
12 244 SSG Baseline Platelet count
12 244 SSG Baseline Amylase
12 245 PM 6 mon FU Creatinine
12 245 PM 6 mon FU BUN
12 245 PM 6 mon FU Bilirubin
12 245 PM 6 mon FU Alkaline Phosphatase
12 245 PM 6 mon FU Aspartate Aminotransferase
12 245 PM 6 mon FU Alanine Aminotransferase
12 245 PM 6 mon FU Platelet count
12 245 PM 6 mon FU Amylase
12 245 PM 6 mon FU Total Protein
12 245 PM 6 mon FU Haemaglobin
12 245 PM 6 mon FU White Blood Cell Count
12 246 PM Day 14 Total Protein
12 247 PM 6 mon FU Amylase
12 247 PM Day 7 Total Protein
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12 248 PM 6 mon FU Amylase
12 248 PM Day 14 Total Protein
12 248 PM Day 7 Total Protein
12 248 PM EOT Total Protein
12 250 SSG 6 mon FU Amylase
12 252 SSG 6 mon FU Amylase
12 253 SSG 6 mon FU Amylase
12 256 Combination 6 mon FU Amylase
12 257 SSG 6 mon FU Amylase
12 258 SSG 6 mon FU Amylase
12 259 PM 6 mon FU Amylase
12 259 PM EOT Total Protein
12 260 PM 6 mon FU Amylase
12 260 PM Day 14 Amylase
12 261 Combination 6 mon FU Amylase
12 262 PM 6 mon FU Amylase
12 262 PM Baseline Total Protein
12 263 SSG 6 mon FU Amylase
12 264 Combination 6 mon FU Amylase
12 264 Combination Baseline Amylase
12 264 Combination Day 7 Total Protein
12 265 SSG Day 7 Total Protein
12 265 SSG EOT Total Protein
12 266 PM Day 7 Total Protein
12 267 SSG 6 mon FU Amylase
12 267 SSG 6 mon FU Total Protein
12 267 SSG Day 7 Total Protein
12 270 Combination Baseline Total Protein
12 271 SSG 6 mon FU Amylase
12 271 SSG 6 mon FU Total Protein
12 271 SSG Baseline Amylase
12 271 SSG Day 14 Amylase
12 271 SSG Day 7 Total Protein
12 271 SSG Day 7 Amylase
12 271 SSG EOT Amylase
12 272 PM Baseline Amylase
12 272 PM Day 14 Amylase
12 272 PM Day 7 Amylase
12 272 PM EOT Amylase
12 272 PM EOT Total Protein
12 273 SSG Baseline Amylase
12 273 SSG Day 14 Amylase
12 273 SSG Day 7 Amylase
12 274 SSG Baseline Amylase
12 274 SSG Day 14 Amylase
12 274 SSG Day 7 Amylase
12 275 Combination 6 mon FU Amylase
12 275 Combination Baseline Amylase
12 275 Combination Day 14 Amylase
12 275 Combination Day 7 Amylase
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12 275 Combination EOT Amylase
12 276 PM 6 mon FU Amylase
12 276 PM Day 14 Amylase
12 276 PM Day 7 Amylase
12 276 PM EOT Amylase
12 277 Combination Baseline Amylase
12 277 Combination Day 7 Amylase
12 278 SSG 6 mon FU Creatinine
12 278 SSG 6 mon FU BUN
12 278 SSG 6 mon FU Bilirubin
12 278 SSG 6 mon FU Alkaline Phosphatase
12 278 SSG 6 mon FU Aspartate Aminotransferase
12 278 SSG 6 mon FU Alanine Aminotransferase
12 278 SSG 6 mon FU Platelet count
12 278 SSG 6 mon FU Amylase
12 278 SSG 6 mon FU Total Protein
12 278 SSG 6 mon FU Haemaglobin
12 278 SSG 6 mon FU White Blood Cell Count
12 278 SSG Baseline Amylase
12 278 SSG Day 7 Amylase
12 279 PM Baseline Amylase
12 279 PM Day 14 Total Protein
12 279 PM Day 7 Amylase
12 280 SSG 6 mon FU Creatinine
12 280 SSG 6 mon FU BUN
12 280 SSG 6 mon FU Amylase
12 280 SSG 6 mon FU Total Protein
12 280 SSG Baseline Amylase
12 280 SSG Day 7 Amylase
12 281 Combination 6 mon FU Creatinine
12 281 Combination 6 mon FU BUN
12 281 Combination 6 mon FU Amylase
12 281 Combination 6 mon FU Total Protein
12 281 Combination Baseline Amylase
12 281 Combination Day 7 Amylase
12 282 PM 6 mon FU Creatinine
12 282 PM 6 mon FU BUN
12 282 PM 6 mon FU Amylase
12 282 PM 6 mon FU Total Protein
12 282 PM Baseline Amylase
12 282 PM Day 14 Bilirubin
12 283 PM 6 mon FU Amylase
12 283 PM 6 mon FU Total Protein
12 283 PM EOT Amylase
12 284 Combination 6 mon FU Creatinine
12 284 Combination 6 mon FU BUN
12 284 Combination 6 mon FU Alkaline Phosphatase
12 284 Combination 6 mon FU Amylase
12 284 Combination 6 mon FU Total Protein
12 284 Combination Day 14 Amylase
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12 284 Combination Day 7 Amylase
12 284 Combination EOT Amylase
12 285 Combination 6 mon FU Creatinine
12 285 Combination 6 mon FU BUN
12 285 Combination 6 mon FU Amylase
12 285 Combination 6 mon FU Total Protein
12 285 Combination Day 14 Amylase
12 285 Combination EOT Amylase
12 286 PM 6 mon FU Amylase
12 286 PM Baseline Amylase
12 287 SSG Baseline Amylase
12 294 Combination 6 mon FU Amylase
12 297 SSG 6 mon FU Creatinine
12 297 SSG 6 mon FU BUN
12 297 SSG 6 mon FU Bilirubin
12 297 SSG 6 mon FU Alkaline Phosphatase
12 297 SSG 6 mon FU Aspartate Aminotransferase
12 297 SSG 6 mon FU Alanine Aminotransferase
12 297 SSG 6 mon FU Platelet count
12 297 SSG 6 mon FU Amylase
12 297 SSG 6 mon FU Haemaglobin
12 297 SSG 6 mon FU White Blood Cell Count
12 297 SSG EOT Creatinine
12 297 SSG EOT BUN
12 297 SSG EOT Bilirubin
12 297 SSG EOT Alkaline Phosphatase
12 297 SSG EOT Aspartate Aminotransferase
12 297 SSG EOT Alanine Aminotransferase
12 297 SSG EOT Platelet count
12 297 SSG EOT Amylase
12 297 SSG EOT Haemaglobin
12 297 SSG EOT White Blood Cell Count
12 299 Combination Day 14 Amylase
12 299 Combination EOT Amylase
12 300 PM Day 14 Amylase
12 300 PM EOT Bilirubin
12 301 SSG Day 14 Amylase
12 302 SSG Day 14 Amylase
12 303 PM Day 14 Amylase
12 304 Combination Day 14 Amylase
12 304 Combination EOT Amylase
12 305 PM Day 14 Amylase
12 306 Combination Day 14 Amylase
12 306 Combination EOT Amylase
12 307 Combination Baseline Amylase
12 307 Combination Day 7 Amylase
12 308 PM Baseline Amylase
12 308 PM Day 7 Amylase
12 309 PM Baseline Amylase
12 309 PM Day 7 Amylase
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12 310 SSG Baseline Amylase
12 310 SSG Day 7 Amylase
12 316 SSG EOT Creatinine
12 316 SSG EOT BUN
12 316 SSG EOT Bilirubin
12 316 SSG EOT Alkaline Phosphatase
12 316 SSG EOT Aspartate Aminotransferase
12 316 SSG EOT Alanine Aminotransferase
12 316 SSG EOT Platelet count
12 316 SSG EOT Haemaglobin
12 316 SSG EOT White Blood Cell Count
23 377 Combination Day 14 Creatinine
23 377 Combination Day 14 BUN
23 377 Combination Day 14 Albumin
23 377 Combination Day 14 Globulin
23 377 Combination Day 14 Bilirubin
23 377 Combination Day 14 Alkaline Phosphatase
23 377 Combination Day 14 Aspartate Aminotransferase
23 377 Combination Day 14 Alanine Aminotransferase
23 377 Combination Day 14 Haemaglobin
23 377 Combination Day 14 White Blood Cell Count
23 377 Combination Day 14 Platelet count
23 377 Combination EOT Creatinine
23 377 Combination EOT BUN
23 377 Combination EOT Albumin
23 377 Combination EOT Globulin
23 377 Combination EOT Bilirubin
23 377 Combination EOT Alkaline Phosphatase
23 377 Combination EOT Aspartate Aminotransferase
23 377 Combination EOT Alanine Aminotransferase
23 377 Combination EOT Platelet count
23 377 Combination EOT Haemaglobin
23 377 Combination EOT White Blood Cell Count
23 379 PM Baseline Aspartate Aminotransferase
23 392 Combination EOT Creatinine
23 392 Combination EOT BUN
23 392 Combination EOT Albumin
23 392 Combination EOT Globulin
23 392 Combination EOT Bilirubin
23 392 Combination EOT Alkaline Phosphatase
23 392 Combination EOT Aspartate Aminotransferase
23 392 Combination EOT Alanine Aminotransferase
23 392 Combination EOT Platelet count
23 392 Combination EOT Haemaglobin
23 392 Combination EOT White Blood Cell Count
34 461 SSG EOT Creatinine
34 461 SSG EOT Bilirubin
34 461 SSG EOT Alkaline Phosphatase
34 461 SSG EOT Aspartate Aminotransferase
34 461 SSG EOT Alanine Aminotransferase
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34 461 SSG EOT Haemaglobin
34 484 PM Day 14 Creatinine
34 484 PM Day 14 Bilirubin
34 484 PM Day 14 Alkaline Phosphatase
34 484 PM Day 14 Aspartate Aminotransferase
34 484 PM Day 14 Alanine Aminotransferase
34 484 PM Day 14 Haemaglobin
34 484 PM EOT Creatinine
34 484 PM EOT Bilirubin
34 484 PM EOT Alkaline Phosphatase
34 484 PM EOT Aspartate Aminotransferase
34 484 PM EOT Alanine Aminotransferase
34 484 PM EOT Haemaglobin
34 492 PM EOT Bilirubin
34 502 Combination EOT Bilirubin
34 506 SSG EOT Bilirubin
34 512 PM EOT Bilirubin
34 525 Combination EOT Bilirubin
35 646 PM 6 mon FU Prothrombin time
35 647 PM 6 mon FU Prothrombin time
35 648 Combination Day 14 Creatinine
35 648 Combination Day 14 BUN
35 648 Combination Day 14 Albumin
35 648 Combination Day 14 Bilirubin
35 648 Combination Day 14 Aspartate Aminotransferase
35 648 Combination Day 14 Alanine Aminotransferase
35 648 Combination Day 14 Prothrombin time
35 648 Combination Day 14 Platelet count
35 648 Combination Day 14 Total Protein
35 648 Combination Day 14 Haemaglobin
35 648 Combination Day 14 White Blood Cell Count
35 649 Combination Day 14 Creatinine
35 649 Combination Day 14 BUN
35 649 Combination Day 14 Albumin
35 649 Combination Day 14 Bilirubin
35 649 Combination Day 14 Aspartate Aminotransferase
35 649 Combination Day 14 Alanine Aminotransferase
35 649 Combination Day 14 Prothrombin time
35 649 Combination Day 14 Platelet count
35 649 Combination Day 14 Total Protein
35 649 Combination Day 14 Haemaglobin
35 649 Combination Day 14 White Blood Cell Count
35 652 PM 6 mon FU Prothrombin time
35 654 SSG Day 7 Total Protein
35 661 Combination Day 14 Albumin
35 662 PM 6 mon FU Prothrombin time
35 662 PM Day 7 Albumin
35 664 Combination Day 14 Creatinine
35 664 Combination 6 mon FU Prothrombin time
35 664 Combination Day 14 BUN
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35 664 Combination Day 14 Albumin
35 664 Combination Day 14 Bilirubin
35 664 Combination Day 14 Aspartate Aminotransferase
35 664 Combination Day 14 Alanine Aminotransferase
35 664 Combination Day 14 Prothrombin time
35 664 Combination Day 14 Platelet count
35 664 Combination Day 14 Total Protein
35 664 Combination Day 14 Haemaglobin
35 664 Combination Day 14 White Blood Cell Count
35 664 Combination EOT Creatinine
35 664 Combination EOT BUN
35 664 Combination EOT Albumin
35 664 Combination EOT Bilirubin
35 664 Combination EOT Aspartate Aminotransferase
35 664 Combination EOT Alanine Aminotransferase
35 664 Combination EOT Prothrombin time
35 664 Combination EOT Platelet count
35 664 Combination EOT Total Protein
35 664 Combination EOT Haemaglobin
35 664 Combination EOT White Blood Cell Count
35 665 SSG Baseline Prothrombin time
35 669 PM 6 mon FU Creatinine
35 669 PM 6 mon FU BUN
35 669 PM 6 mon FU Albumin
35 669 PM 6 mon FU Bilirubin
35 669 PM 6 mon FU Aspartate Aminotransferase
35 669 PM 6 mon FU Alanine Aminotransferase
35 669 PM 6 mon FU Prothrombin time
35 669 PM 6 mon FU Platelet count
35 669 PM 6 mon FU Total Protein
35 669 PM 6 mon FU Haemaglobin
35 669 PM 6 mon FU White Blood Cell Count
35 671 PM 6 mon FU Prothrombin time
35 675 PM 6 mon FU Prothrombin time
35 679 SSG EOT Albumin
35 682 PM 6 mon FU Prothrombin time
35 684 SSG Day 7 Total Protein
35 686 PM 6 mon FU Prothrombin time
35 689 Combination 6 mon FU Prothrombin time
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16.3.3 Patients excluded from the efficacy analysis 
Not applicable. 
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16.3.4 Demographic data  
Appendix 26 Individual patient demographic data  
 
Appendix 27 Individual Baseline VL symptoms 
 
Appendix 28 Individual Height and Weight 
 
Appendix 29 Individual Heart rate and Axiliary temperature 
 
Appendix 30 Individual Systolic and Diastolic Blood pressure 
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Centre Patient Date of Age Sex HIV Date of Treatment
Number Number Bith status Admission
11 1 30 Male negative 17-Jun-05 PM
11 2 19 Male negative 17-Jun-05 Combination
11 3 20 Male negative 18-Jun-05 Combination
11 4 19 Male negative 27-Jun-05 PM
11 5 10 Female negative 27-Jun-05 PM
11 6 10 Female negative 27-Jun-05 Combination
11 7 45 Female negative 28-Jun-05 PM
11 8 28 Male negative 28-Jun-05 SSG
11 9 20 Male negative 2-Jul-05 SSG
11 10 17 Male negative 2-Jul-05 SSG
11 11 12 Male not tested 30-Jun-05 Combination
11 12 18 Male negative 29-Jun-05 Combination
11 13 40 Female negative 5-Jul-05 SSG
11 14 7 Male negative 6-Jul-05 SSG
11 15 20 Male negative 8-Jul-05 PM
11 16 35 Female negative 6-Jul-05 Combination
11 17 40 Male negative 6-Jul-05 Combination
11 18 34 Male negative 12-Aug-05 SSG
11 19 33 Male negative 13-Aug-05 Combination
11 20 7 Male negative 13-Aug-05 SSG
11 21 28 Male negative 13-Aug-05 SSG
11 22 11 Male negative 14-Aug-05 SSG
11 23 10 Male negative 17-Aug-05 PM
11 24 7 Female negative 17-Aug-05 PM
11 25 10 Female negative 17-Aug-05 SSG
11 26 8 Female negative 14-Aug-05 Combination
11 27 31 Male positive 16-Sep-05 PM
11 28 13 Male positive 16-Sep-05 Combination
11 29 25 Male not tested 17-Sep-05 PM
11 30 6 Female negative 19-Sep-05 PM
11 31 40 Female negative 19-Sep-05 SSG
11 32 22 Female negative 19-Sep-05 Combination
11 33 25 Male negative 22-Sep-05 SSG
11 34 55 Male negative 23-Sep-05 PM
11 35 18 Male negative 23-Sep-05 SSG
11 36 20 Male negative 19-Sep-05 SSG
11 37 40 Male not tested 24-Sep-05 Combination
11 38 47 Male negative 12-Oct-05 PM
11 39 6 Male negative 12-Oct-05 PM
11 40 8 Female negative 12-Oct-05 PM
11 41 5 Male negative 12-Oct-05 Combination
11 42 30 Male negative 12-Oct-05 Combination
11 43 15 Male negative 23-Oct-05 SSG
11 44 16 Male negative 23-Oct-05 PM
11 45 16 Male negative 23-Oct-05 Combination
11 46 6 Female negative 2-May-06 SSG
11 47 20 Male negative 2-May-06 SSG
11 48 15 Male negative 3-May-06 Combination
11 49 7 Male negative 6-May-06 SSG
11 50 20 Male negative 16-May-06 PM
11 51 15 Male negative 17-May-06 Combination
11 52 11 Male negative 17-May-06 PM
11 53 26 Male negative 24-May-06 SSG
11 54 24 Male positive 25-May-06 PM
LEAP 0104a Appendices
Page 351 of 756
Appendix 26: Patient Demographics
Centre Patient Date of Age Sex HIV Date of Treatment
Number Number Bith status Admission
11 55 27 Male negative 26-May-06 PM
11 56 13 Female negative 26-May-06 SSG
11 57 27 Male negative 2-Jun-06 Combination
11 58 12 Male negative 3-Jun-06 Combination
11 59 12 Male negative 9-Jun-06 PM
11 60 32 Male negative 9-Jun-06 Combination
11 61 27 Male negative 9-Jun-06 PM
11 62 6 Male negative 12-Jun-06 SSG
11 63 32 Male negative 16-Jun-06 SSG
11 64 26 Male negative 17-Jun-06 SSG
11 65 5 Male negative 19-Jun-06 PM
11 66 17 Female negative 16-Jun-06 Combination
11 67 11 Male negative 28-Jun-06 PM
11 68 9 Male negative 5-Jul-06 SSG
11 69 18 Male negative 12-Jul-06 Combination
11 70 20 Male negative 12-Jul-06 Combination
11 71 33 Male positive 19-Jul-06 Combination
11 72 23 Male positive 20-Jul-06 SSG
11 73 23 Male positive 21-Jul-06 PM
11 74 34 Male negative 26-Jul-06 PM
11 75 25 Male negative 26-Jul-06 Combination
11 76 23 Male negative 26-Jul-06 PM
11 77 10 Male negative 28-Jul-06 PM
11 78 30 Male positive 28-Jul-06 SSG
11 79 5 Male negative 28-Jul-06 PM
11 80 9 Female negative 31-Jul-06 PM
11 81 25 Male negative 3-Aug-06 Combination
11 82 15 Male negative 11-Aug-06 SSG
11 83 22 Male negative 14-Aug-06 SSG
11 84 15 Male negative 11-Aug-06 SSG
11 85 20 Male negative 23-Aug-06 SSG
11 86 5 Male negative 24-Aug-06 Combination
11 87 18 Male positive 24-Aug-06 Combination
11 88 25 Male negative 24-Aug-06 PM
11 89 24 Male negative 23-Aug-06 Combination
11 90 10 Male negative 29-Aug-06 Combination
11 91 35 Male negative 14-Dec-06 PM
11 92 7 Male negative 21-Dec-06 Combination
11 93 26 Male negative 29-Dec-06 SSG
11 94 5 Female negative 1-Jan-07 SSG
11 95 6 Male negative 1-Jan-07 SSG
11 96 12 Male positive 17-Jan-07 Combination
11 97 19 Male negative 18-Jan-07 Combination
11 98 20 Male negative 22-Jan-07 PM
11 99 19 Male negative 24-Jan-07 SSG
11 100 36 Male positive 25-Jan-07 PM
11 101 22 Male negative 1-Feb-07 PM
11 102 22 Male negative 1-Feb-07 Combination
11 103 28 Male negative 31-Jan-07 Combination
11 104 13 Female negative 6-Feb-07 PM
11 105 18 Male positive 19-Feb-07 SSG
11 106 18 Male negative 23-Feb-07 Combination
11 107 21 Male negative 23-Feb-07 PM
11 108 25 Male negative 28-Feb-07 PM
LEAP 0104a Appendices
Page 352 of 756
Appendix 26: Patient Demographics
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Number Number Bith status Admission
11 109 19 Male negative 26-Feb-07 SSG
11 110 6 Female negative 1-Mar-07 PM
11 111 19 Male negative 15-Mar-07 Combination
11 112 28 Male negative 22-Mar-07 Combination
11 113 18 Male negative 22-Mar-07 SSG
11 114 25 Male negative 20-Mar-07 SSG
11 115 12 Male negative 28-Mar-07 Combination
11 116 23 Male negative 28-Mar-07 SSG
11 117 22 Male negative 28-Mar-07 PM
11 118 25 Male negative 11-Apr-07 PM
11 119 26 Male negative 17-Apr-07 SSG
11 120 17 Male negative 18-Apr-07 Combination
11 121 6 Male negative 18-Apr-07 Combination
11 122 20 Male negative 18-Apr-07 SSG
11 123 14 Male not tested 25-Apr-07 SSG
11 124 30 Male not tested 18-May-07 SSG
11 125 22 Male negative 22-May-07 SSG
11 126 23 Male positive 23-May-07 Combination
11 127 14 Female negative 25-May-07 PM
11 128 30 Male positive 30-May-07 Combination
11 129 31 Male negative 4-Jun-07 PM
11 130 25 Male negative 6-Jun-07 Combination
11 131 6 Male negative 8-Jun-07 PM
11 132 20 Male negative 11-Jun-07 SSG
11 133 20 Male negative 29-Jun-07 Combination
11 134 23 Male negative 9-Jul-07 PM
11 135 17 Male negative 11-Jul-07 PM
12 241 20 Male negative 7-Jun-05 Combination
12 242 7 Male negative 7-Jun-05 SSG
12 243 10 Male negative 7-Jun-05 PM
12 244 20 Male negative 7-Jun-05 SSG
12 245 36 Male negative 15-Jul-05 PM
12 246 40 Male positive 3-Aug-05 PM
12 247 11 Male negative 9-Sep-05 PM
12 248 28 Male negative 9-Sep-05 PM
12 249 16 Male negative 22-Oct-05 Combination
12 250 15 Male negative 22-Oct-05 SSG
12 251 18 Male negative 26-Oct-05 Combination
12 252 14 Male positive 26-Oct-05 SSG
12 253 9 Male negative 26-Oct-05 SSG
12 254 8 Male negative 27-Oct-05 Combination
12 255 14 Male negative 29-Oct-05 Combination
12 256 35 Female negative 14-Nov-05 Combination
12 257 15 Male negative 14-Nov-05 SSG
12 258 10 Male negative 29-Nov-05 SSG
12 259 20 Male negative 23-Dec-05 PM
12 260 16 Male negative 23-Dec-05 PM
12 261 13 Male negative 24-Dec-05 Combination
12 262 10 Male negative 23-Dec-05 PM
12 263 17 Female negative 22-Jan-06 SSG
12 264 9 Male negative 8-Feb-06 Combination
12 265 5 Female negative 8-Feb-06 SSG
12 266 32 Male negative 8-Feb-06 PM
12 267 30 Female negative 8-Feb-06 SSG
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12 268 28 Male negative 4-Mar-06 PM
12 269 18 Male negative 13-Mar-06 Combination
12 270 10 Male negative 13-Mar-06 Combination
12 271 28 Male negative 27-Mar-06 SSG
12 272 44 Male negative 24-Mar-06 PM
12 273 13 Female negative 27-Mar-06 SSG
12 274 10 Female negative 4-Apr-06 SSG
12 275 16 Female negative 4-Apr-06 Combination
12 276 10 Male negative 4-Apr-06 PM
12 277 18 Male negative 17-Apr-06 Combination
12 278 25 Male negative 17-Apr-06 SSG
12 279 41 Male negative 17-Apr-06 PM
12 280 5 Male negative 17-Apr-06 SSG
12 281 16 Male negative 17-Apr-06 Combination
12 282 8 Male negative 26-Apr-06 PM
12 283 25 Male negative 10-May-06 PM
12 284 9 Female negative 17-May-06 Combination
12 285 17 Male negative 17-May-06 Combination
12 286 12 Male negative 21-Dec-06 PM
12 287 10 Male negative 21-Dec-06 SSG
12 288 6 Male negative 26-Dec-06 Combination
12 289 40 Male negative 26-Dec-06 Combination
12 290 10 Female negative 4-Jan-07 SSG
12 291 45 Male negative 8-Jan-07 SSG
12 292 30 Male negative 14-Jan-07 PM
12 293 13 Male negative 21-Jan-07 SSG
12 294 5 Female negative 13-Feb-07 Combination
12 295 10 Male negative 9-Mar-07 Combination
12 296 12 Male negative 3-Apr-07 PM
12 297 29 Male negative 3-Apr-07 SSG
12 298 12 Male negative 16-Apr-07 PM
12 299 30 Male negative 1-Jun-07 Combination
12 300 20 Female negative 1-Jun-07 PM
12 301 25 Male negative 2-Jun-07 SSG
12 302 4 Male negative 2-Jun-07 SSG
12 303 25 Female negative 2-Jun-07 PM
12 304 17 Male negative 2-Jun-07 Combination
12 305 6 Male negative 2-Jun-07 PM
12 306 5 Male negative 2-Jun-07 Combination
12 307 39 Male negative 12-Jun-07 Combination
12 308 31 Male negative 12-Jun-07 PM
12 309 18 Male negative 15-Jun-07 PM
12 310 13 Female negative 15-Jun-07 SSG
12 311 12 Male negative 3-Jul-07 SSG
12 312 20 Female negative 9-Jul-07 Combination
12 313 25 Male negative 31-Jul-07 PM
12 314 18 Male negative 31-Jul-07 SSG
12 315 10 Male negative 19-Aug-07 Combination
12 316 36 Male negative 19-Aug-07 SSG
12 317 4 Male negative 21-Aug-07 SSG
12 318 8 Male negative 26-Aug-07 Combination
12 319 8 Male negative 26-Aug-07 Combination
12 320 8 Male negative 3-Sep-07 Combination
12 321 8 Male negative 3-Sep-07 Combination
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12 322 16 Female negative 10-Sep-07 PM
12 323 32 Male negative 18-Sep-07 SSG
12 324 30 Male negative 18-Sep-07 SSG
12 325 22 Male negative 18-Sep-07 PM
12 326 25 Male negative 2-Oct-07 PM
12 327 14 Male negative 2-Oct-07 Combination
12 328 14 Male negative 3-Oct-07 PM
12 329 6 Male negative 8-Oct-07 SSG
12 330 11 Male negative 8-Oct-07 PM
23 361 15-Jun-97 8 Male not tested 17-Jan-05 Combination
23 362 15-Jun-91 14 Male not tested 17-Jan-05 PM
23 363 15-Jun-00 5 Female not tested 16-Jan-05 PM
23 364 15-Jun-93 12 Female not tested 16-Jan-05 Combination
23 365 15-Jun-90 15 Male not tested 16-Jan-05 SSG
23 366 15-Jun-93 12 Male not tested 26-Jan-05 Combination
23 367 15-Jun-85 20 Male not tested 26-Jan-05 SSG
23 368 15-Jun-89 16 Female not tested 26-Jan-05 PM
23 369 15-Jun-93 12 Male not tested 26-Jan-05 Combination
23 370 15-Jun-97 8 Male not tested 26-Jan-05 SSG
23 371 15-Jun-91 14 Female not tested 1-Feb-05 PM
23 372 15-Jun-80 25 Male not tested 9-Feb-05 PM
23 373 21 Male not tested 16-Feb-05 SSG
23 374 15-Jun-81 24 Female not tested 16-Feb-05 SSG
23 375 15-Jun-93 12 Male not tested 23-Feb-05 Combination
23 376 15-Jun-89 16 Female not tested 22-Feb-05 SSG
23 377 15-Jun-65 40 Female not tested 6-Mar-05 Combination
23 378 15-Jun-98 7 Male not tested 6-Mar-05 Combination
23 379 15-Jun-00 5 Male not tested 23-Feb-05 PM
23 380 15-Jun-98 7 Female not tested 6-Mar-05 SSG
23 381 15-Jun-92 13 Male not tested 7-Mar-05 PM
23 382 15-Jun-90 15 Male not tested 15-Mar-05 Combination
23 383 15-Jun-75 30 Male not tested 22-Mar-05 PM
23 384 15-Jun-92 13 Male not tested 22-Mar-05 SSG
23 385 15-Jun-91 14 Male not tested 23-Mar-05 SSG
23 386 15-Jun-92 13 Female not tested 13-Apr-05 Combination
23 387 15-Jun-90 15 Female not tested 13-Apr-05 Combination
23 388 15-Jun-90 15 Male not tested 13-Apr-05 PM
23 389 15-Jun-93 12 Male not tested 13-Apr-05 SSG
23 390 15-Jun-85 20 Male not tested 13-Apr-05 PM
23 391 15-Jun-93 12 Female not tested 19-Apr-05 Combination
23 392 15-Jun-98 7 Male not tested 19-Apr-05 Combination
23 393 15-Jun-93 12 Male not tested 19-Apr-05 SSG
23 394 15-Jun-96 9 Male not tested 13-Apr-05 PM
23 395 15-Jun-63 42 Male not tested 27-Apr-05 PM
23 396 15-Jun-89 16 Male not tested 9-May-05 SSG
23 397 15-Jun-91 14 Female not tested 9-May-05 SSG
23 398 15-Jun-97 8 Male not tested 12-May-05 Combination
23 399 15-Jun-99 6 Male not tested 12-May-05 PM
23 400 15-Jun-99 6 Female not tested 12-May-05 PM
23 401 15-Jun-65 40 Male not tested 29-May-05 Combination
23 402 15-Jun-90 15 Male not tested 29-May-05 Combination
23 403 15-Jun-83 22 Male not tested 29-May-05 SSG
23 404 15-Jun-89 16 Male not tested 29-May-05 SSG
23 405 15-Jun-89 16 Male not tested 29-May-05 PM
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34 451 6 Female not tested 16-Nov-04 Combination
34 452 15 Male not tested 16-Nov-04 PM
34 453 4 Male not tested 17-Nov-04 PM
34 454 5 Female not tested 18-Nov-04 Combination
34 455 11 Male not tested 18-Nov-04 PM
34 456 8 Female not tested 18-Nov-04 SSG
34 457 25 Male negative 18-Nov-04 Combination
34 458 12 Female not tested 19-Nov-04 PM
34 459 9 Female not tested 20-Nov-04 Combination
34 460 4 Male not tested 22-Nov-04 PM
34 461 50 Male not tested 24-Nov-04 SSG
34 462 4 Female not tested 24-Nov-04 SSG
34 463 4 Male not tested 25-Nov-04 Combination
34 464 22 Male not tested 26-Nov-04 SSG
34 465 25 Female negative 27-Nov-04 SSG
34 466 10 Female not tested 27-Nov-04 Combination
34 467 14 Male not tested 28-Nov-04 PM
34 468 25 Female negative 28-Nov-04 Combination
34 469 11 Female not tested 28-Nov-04 SSG
34 470 4 Female not tested 29-Nov-04 Combination
34 471 13 Male not tested 29-Nov-04 PM
34 472 4 Male not tested 1-Dec-04 SSG
34 473 5 Male not tested 1-Dec-04 PM
34 474 10 Male not tested 3-Dec-04 Combination
34 475 9 Male not tested 4-Dec-04 PM
34 476 10 Female not tested 4-Dec-04 PM
34 477 8 Female not tested 6-Dec-04 SSG
34 478 5 Female not tested 6-Dec-04 Combination
34 479 4 Male not tested 8-Dec-04 SSG
34 480 12 Male not tested 8-Dec-04 SSG
34 481 15 Male not tested 9-Dec-04 Combination
34 482 18 Male negative 9-Dec-04 Combination
34 483 24 Male not tested 9-Dec-04 PM
34 484 5 Male not tested 10-Dec-04 PM
34 485 5 Female not tested 10-Dec-04 Combination
34 486 12 Male not tested 11-Dec-04 Combination
34 487 12 Male not tested 12-Dec-04 SSG
34 488 7 Male not tested 13-Dec-04 SSG
34 489 11 Male not tested 15-Dec-04 SSG
34 490 9 Female not tested 16-Dec-04 PM
34 491 50 Male positive 16-Dec-04 PM
34 492 39 Male negative 16-Dec-04 PM
34 493 12 Female not tested 17-Dec-04 SSG
34 494 30 Male negative 17-Dec-04 Combination
34 495 6 Female not tested 17-Dec-04 SSG
34 496 35 Male not tested 18-Dec-04 SSG
34 497 22 Male not tested 20-Dec-04 PM
34 498 10 Female not tested 20-Dec-04 SSG
34 499 12 Male not tested 20-Dec-04 Combination
34 500 14 Male not tested 20-Dec-04 PM
34 501 9 Male not tested 21-Dec-04 Combination
34 502 12 Female not tested 22-Dec-04 Combination
34 503 11 Male not tested 24-Dec-04 PM
34 504 8 Female not tested 26-Dec-04 Combination
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34 505 40 Male negative 27-Dec-04 SSG
34 506 8 Male not tested 30-Dec-04 SSG
34 507 6 Male not tested 30-Dec-04 SSG
34 508 4 Male not tested 31-Dec-04 PM
34 509 20 Female negative 31-Dec-04 PM
34 510 8 Male not tested 31-Dec-04 Combination
34 511 6 Male not tested 1-Jan-05 Combination
34 512 6 Female not tested 1-Jan-05 PM
34 513 10 Male not tested 2-Jan-05 Combination
34 514 7 Male not tested 3-Jan-05 SSG
34 515 10 Male not tested 5-Jan-05 SSG
34 516 15 Male not tested 6-Jan-05 PM
34 517 12 Male not tested 6-Jan-05 PM
34 518 4 Male not tested 6-Jan-05 SSG
34 519 8 Female not tested 6-Jan-05 PM
34 520 19 Male negative 10-Jan-05 SSG
34 521 5 Male not tested 10-Jan-05 PM
34 522 36 Male negative 11-Jan-05 Combination
34 523 11 Male not tested 12-Jan-05 SSG
34 524 15 Male not tested 12-Jan-05 Combination
34 525 8 Male not tested 12-Jan-05 Combination
34 526 5 Male not tested 13-Jan-05 SSG
34 527 19 Female not tested 14-Jan-05 Combination
34 528 6 Male not tested 16-Jan-05 PM
34 529 5 Female not tested 18-Jan-05 Combination
34 530 22 Male negative 19-Jan-05 Combination
34 531 5 Male not tested 20-Jan-05 SSG
34 532 4 Male not tested 20-Jan-05 Combination
34 533 10 Male not tested 22-Jan-05 SSG
34 534 7 Male not tested 23-Jan-05 PM
34 535 11 Female not tested 23-Jan-05 PM
34 536 12 Male not tested 25-Jan-05 PM
34 537 4 Female not tested 25-Jan-05 SSG
34 538 6 Male not tested 25-Jan-05 PM
34 539 6 Male not tested 25-Jan-05 Combination
34 540 11 Female not tested 26-Jan-05 SSG
35 646 16 Male negative 26-Jan-05 PM
35 647 23 Male negative 29-Jan-05 PM
35 648 5 Male negative 29-Jan-05 Combination
35 649 13 Female negative 29-Jan-05 Combination
35 650 6 Male negative 29-Jan-05 SSG
35 651 5 Male negative 29-Jan-05 SSG
35 652 8 Female negative 31-Jan-05 PM
35 653 6 Female negative 1-Feb-05 Combination
35 654 5 Female negative 31-Jan-05 SSG
35 655 11 Male negative 1-Feb-05 Combination
35 656 8 Female negative 3-Feb-05 SSG
35 657 10 Female negative 7-Feb-05 PM
35 658 15 Male negative 6-Feb-05 Combination
35 659 6 Male negative 7-Feb-05 SSG
35 660 32 Male negative 6-Feb-05 PM
35 661 27 Male negative 14-Feb-05 Combination
35 662 25 Male negative 19-Feb-05 PM
35 663 48 Male negative 19-Feb-05 SSG
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35 664 37 Female negative 19-Feb-05 Combination
35 665 13 Male negative 22-Feb-05 SSG
35 666 12 Female negative 25-Feb-05 SSG
35 667 13 Female negative 26-Feb-05 Combination
35 668 17 Female negative 26-Feb-05 PM
35 669 9 Female negative 27-Feb-05 PM
35 670 10 Male negative 1-Mar-05 SSG
35 671 9 Female negative 10-Mar-05 PM
35 672 8 Male negative 10-Mar-05 Combination
35 673 11 Female negative 10-Mar-05 SSG
35 674 9 Female negative 11-Mar-05 Combination
35 675 8 Female negative 13-Mar-05 PM
35 676 8 Female negative 19-Mar-05 PM
35 677 37 Male negative 19-Mar-05 SSG
35 678 15 Male negative 20-Mar-05 Combination
35 679 45 Female negative 20-Mar-05 SSG
35 680 11 Male negative 21-Mar-05 Combination
35 681 16 Male negative 21-Mar-05 Combination
35 682 8 Female negative 21-Mar-05 PM
35 683 12 Female negative 21-Mar-05 Combination
35 684 15 Female negative 8-Apr-05 SSG
35 685 14 Male negative 8-Apr-05 PM
35 686 28 Male negative 8-Apr-05 PM
35 687 21 Female negative 13-Apr-05 SSG
35 688 17 Male negative 14-Apr-05 PM
35 689 18 Female negative 14-Apr-05 Combination
35 690 10 Male negative 14-Mar-05 SSG
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11 1 Yes No Yes Yes No No No Yes
11 2 Yes Yes Yes No No No No No
11 3 Yes Yes Yes No No No No Yes
11 4 Yes Yes Yes No No Yes No Yes
11 5 Yes Yes Yes No No Yes No No
11 6 Yes Yes No Yes Yes Yes No Yes
11 7 Yes No Yes No Yes Yes No Yes
11 8 Yes No Yes Yes Yes Yes No Yes
11 9 Yes Yes Yes No Yes No No No
11 10 Yes Yes No No Yes No No Yes
11 11 Yes No Yes No Yes No No No
11 12 Yes Yes Yes No No Yes No Yes
11 13 Yes Yes Yes No Yes No No Yes
11 14 Yes Yes Yes No No Yes No Yes
11 15 Yes Yes No No Yes No No
11 16 Yes No Yes Yes No No No Yes
11 17 Yes No No Yes No No No Yes
11 18 Yes No Yes Yes Yes Yes No No
11 19 Yes Yes Yes Yes No Yes No No
11 20 Yes Yes Yes No Yes No No No
11 21 Yes Yes Yes No No Yes No No
11 22 Yes Yes Yes No No Yes No Yes
11 23 Yes Yes Yes No Yes Yes No No
11 24 Yes No Yes No Yes Yes No No
11 25 Yes Yes Yes No Yes Yes No No
11 26 Yes No Yes No Yes Yes No No
11 27 Yes No Yes Yes No No Yes No
11 28 Yes Yes Yes No Yes Yes No No
11 29 Yes Yes Yes No Yes Yes No No
11 30 Yes Yes Yes No Yes Yes No No
11 31 Yes Yes Yes No Yes Yes Yes Yes
11 32 Yes Yes Yes No Yes No No No
11 33 Yes Yes Yes No No Yes No No
11 34 Yes No Yes No Yes Yes No No
11 35 No No Yes No Yes Yes No No
11 36 Yes Yes Yes No No No Yes No
11 37 Yes No Yes Yes No No No No
11 38 Yes Yes Yes No No Yes No No
11 39 Yes No No No Yes Yes No No
11 40 Yes Yes Yes No Yes Yes No No
11 41 Yes Yes Yes No Yes Yes No Yes
11 42 Yes Yes Yes No Yes Yes No Yes
11 43 Yes Yes Yes Yes Yes No No No
11 44 Yes Yes Yes Yes Yes Yes No No
11 45 Yes Yes Yes No Yes Yes No No
11 46 Yes Yes No Yes Yes No No Yes
11 47 Yes Yes Yes Yes No No No Yes
11 48 Yes Yes Yes No Yes Yes No Yes
11 49 Yes Yes Yes No Yes Yes Yes Yes
11 50 Yes No Yes Yes No Yes Yes Yes
11 51 Yes Yes Yes Yes No No Yes No
11 52 Yes Yes Yes Yes Yes Yes No Yes
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11 53 Yes No Yes No Yes Yes No Yes
11 54 Yes Yes Yes Yes Yes Yes No No
11 55 Yes Yes Yes Yes Yes Yes Yes No
11 56 Yes Yes Yes Yes Yes Yes Yes Yes
11 57 Yes No Yes No No Yes No Yes
11 58 Yes Yes Yes No Yes Yes No No
11 59 Yes Yes Yes No No Yes Yes Yes
11 60 Yes Yes Yes Yes Yes Yes Yes Yes
11 61 Yes Yes Yes Yes Yes Yes Yes Yes
11 62 Yes No Yes No No Yes No Yes
11 63 Yes No Yes No Yes Yes No No
11 64 Yes Yes Yes No Yes Yes No Yes
11 65 Yes Yes Yes No Yes Yes No Yes
11 66 Yes Yes Yes No No Yes Yes Yes
11 67 Yes Yes Yes No Yes Yes No Yes
11 68 Yes Yes Yes Yes No Yes Yes Yes
11 69 Yes Yes Yes Yes Yes Yes Yes Yes
11 70 Yes No Yes Yes Yes Yes Yes Yes
11 71 Yes Yes Yes Yes Yes Yes No No
11 72 Yes Yes Yes Yes No No No Yes
11 73 Yes Yes Yes Yes No Yes No No
11 74 Yes Yes Yes No Yes Yes No Yes
11 75 Yes No Yes No Yes No No Yes
11 76 Yes Yes Yes No Yes Yes No Yes
11 77 Yes Yes Yes Yes Yes Yes No Yes
11 78 Yes No Yes Yes No Yes No Yes
11 79 Yes Yes Yes No Yes Yes No Yes
11 80 Yes Yes Yes No Yes Yes No Yes
11 81 Yes No Yes Yes Yes Yes Yes Yes
11 82 Yes No Yes No Yes Yes Yes Yes
11 83 Yes No Yes No Yes Yes Yes Yes
11 84 Yes Yes Yes Yes Yes Yes Yes Yes
11 85 Yes Yes Yes Yes Yes Yes No Yes
11 86 Yes Yes Yes Yes Yes Yes Yes Yes
11 87 Yes No Yes No Yes Yes No Yes
11 88 Yes No Yes Yes No No No Yes
11 89 Yes Yes Yes Yes Yes Yes Yes Yes
11 90 Yes No Yes No No No No Yes
11 91 Yes Yes Yes Yes No Yes Yes Yes
11 92 Yes No Yes No Yes No Yes Yes
11 93 Yes Yes Yes No Yes Yes No No
11 94 Yes Yes Yes No Yes Yes No Yes
11 95 Yes Yes Yes No Yes No No Yes
11 96 Yes No Yes No Yes Yes Yes Yes
11 97 Yes Yes Yes No Yes Yes Yes Yes
11 98 Yes Yes Yes Yes Yes Yes Yes Yes
11 99 Yes Yes Yes No No Yes No No
11 100 Yes No Yes No No No No No
11 101 Yes Yes Yes Yes Yes Yes No Yes
11 102 Yes Yes Yes Yes No Yes Yes Yes
11 103 Yes No Yes No Yes Yes No Yes
11 104 Yes Yes Yes Yes Yes Yes Yes Yes
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11 105 Yes No Yes No No Yes Yes Yes
11 106 Yes Yes Yes No No Yes No No
11 107 Yes Yes No Yes No Yes No Yes
11 108 Yes No Yes Yes Yes Yes Yes Yes
11 109 Yes No Yes No No Yes Yes Yes
11 110 Yes Yes Yes No Yes Yes No No
11 111 Yes No Yes Yes Yes No Yes Yes
11 112 Yes No Yes No No Yes No Yes
11 113 Yes Yes Yes Yes Yes Yes Yes Yes
11 114 Yes Yes Yes No Yes Yes Yes Yes
11 115 Yes Yes Yes Yes No Yes No Yes
11 116 Yes No Yes Yes No Yes No Yes
11 117 Yes Yes Yes Yes Yes Yes No Yes
11 118 No No Yes No Yes Yes No Yes
11 119 Yes No Yes No No No No Yes
11 120 Yes Yes Yes No No No No No
11 121 Yes Yes Yes No Yes Yes No Yes
11 122 Yes Yes Yes No No Yes Yes Yes
11 123 Yes No Yes Yes Yes No Yes Yes
11 124 Yes Yes Yes No Yes No No Yes
11 125 Yes Yes Yes Yes Yes Yes Yes Yes
11 126 Yes Yes Yes Yes Yes Yes Yes Yes
11 127 Yes Yes Yes No Yes No No Yes
11 128 Yes Yes Yes Yes Yes Yes No No
11 129 Yes No Yes Yes No No No Yes
11 130 Yes Yes Yes Yes No No Yes Yes
11 131 Yes No Yes No No No No No
11 132 Yes No Yes No No No Yes Yes
11 133 Yes Yes Yes Yes Yes Yes No Yes
11 134 Yes No Yes Yes No No Yes Yes
11 135 Yes Yes Yes Yes Yes No No Yes
12 241 Yes Yes Yes No Yes Yes No Yes
12 242 Yes Yes Yes No No Yes No No
12 243 Yes Yes Yes Yes Yes Yes No Yes
12 244 Yes Yes Yes No Yes Yes No Yes
12 245 Yes Yes Yes Yes Yes Yes No Yes
12 246 Yes Yes Yes No Yes Yes Yes No
12 247 Yes Yes Yes Yes Yes Yes No Yes
12 248 Yes Yes Yes Yes Yes Yes Yes No
12 249 Yes Yes Yes Yes Yes Yes No Yes
12 250 Yes Yes Yes No No No No No
12 251 No Yes Yes No No No No Yes
12 252 Yes No Yes Yes Yes No No Yes
12 253 Yes Yes Yes No Yes Yes No Yes
12 254 Yes Yes Yes No No No No No
12 255 Yes Yes Yes No No No No No
12 256 Yes Yes Yes Yes No No No Yes
12 257 Yes Yes Yes Yes No Yes No Yes
12 258 Yes Yes Yes Yes No Yes Yes No
12 259 Yes Yes Yes No Yes Yes No Yes
12 260 Yes No Yes Yes Yes Yes No No
12 261 Yes No Yes No Yes Yes No Yes
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12 262 Yes No Yes No Yes Yes No No
12 263 Yes Yes Yes Yes Yes Yes No Yes
12 264 Yes Yes Yes No Yes Yes Yes Yes
12 265 Yes Yes Yes No Yes Yes No No
12 266 Yes Yes Yes No Yes Yes No Yes
12 267 Yes Yes Yes No No Yes No Yes
12 268 Yes Yes Yes Yes No No No Yes
12 269 Yes No Yes No Yes Yes No No
12 270 No No Yes No Yes Yes No No
12 271 Yes Yes Yes No Yes Yes No Yes
12 272 Yes No Yes No Yes Yes No Yes
12 273 Yes Yes Yes Yes Yes Yes No Yes
12 274 Yes Yes Yes No No No No Yes
12 275 Yes Yes Yes Yes Yes Yes No No
12 276 Yes Yes Yes No Yes Yes No Yes
12 277 Yes Yes Yes Yes Yes Yes No Yes
12 278 Yes Yes Yes Yes Yes Yes No Yes
12 279 Yes Yes Yes No Yes Yes No No
12 280 Yes No Yes No Yes Yes Yes Yes
12 281 Yes Yes Yes No No No No Yes
12 282 Yes Yes Yes No Yes Yes No Yes
12 283 Yes Yes Yes No Yes Yes No Yes
12 284 Yes Yes Yes No Yes No No Yes
12 285 Yes Yes Yes Yes Yes No No Yes
12 286 Yes Yes Yes No No Yes Yes Yes
12 287 Yes Yes Yes Yes Yes Yes Yes Yes
12 288 Yes Yes Yes No Yes Yes No No
12 289 Yes Yes Yes No Yes Yes No Yes
12 290 Yes Yes Yes No Yes Yes No Yes
12 291 No No Yes No Yes Yes No No
12 292 Yes Yes Yes Yes Yes Yes No Yes
12 293 Yes Yes Yes No Yes Yes No Yes
12 294 Yes Yes Yes No Yes Yes No Yes
12 295 Yes Yes Yes No Yes Yes No No
12 296 Yes Yes Yes No Yes Yes Yes No
12 297 Yes Yes Yes No Yes Yes No No
12 298 Yes Yes Yes No Yes No No No
12 299 Yes Yes Yes Yes Yes Yes No Yes
12 300 Yes Yes Yes No Yes Yes No Yes
12 301 Yes No Yes No No Yes Yes No
12 302 Yes No Yes No No Yes No Yes
12 303 Yes No Yes No No Yes No Yes
12 304 Yes No Yes No Yes Yes No Yes
12 305 Yes No Yes No No Yes No Yes
12 306 Yes No Yes No Yes Yes No Yes
12 307 Yes Yes Yes No Yes Yes No Yes
12 308 Yes Yes Yes Yes Yes Yes Yes Yes
12 309 Yes Yes Yes Yes Yes Yes No No
12 310 Yes Yes Yes No Yes Yes Yes Yes
12 311 Yes Yes Yes Yes Yes Yes Yes Yes
12 312 Yes Yes Yes Yes Yes Yes No Yes
12 313 Yes Yes Yes No Yes Yes No Yes
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12 314 Yes Yes Yes No Yes Yes No Yes
12 315 Yes Yes Yes Yes Yes Yes Yes Yes
12 316 Yes Yes Yes Yes Yes Yes No Yes
12 317 Yes Yes Yes No Yes Yes Yes Yes
12 318 Yes Yes Yes No Yes Yes No Yes
12 319 Yes Yes Yes Yes Yes Yes No Yes
12 320 Yes Yes Yes Yes No No No No
12 321 Yes Yes Yes Yes Yes Yes No Yes
12 322 Yes Yes Yes No Yes Yes Yes No
12 323 Yes Yes Yes Yes Yes Yes No No
12 324 Yes Yes Yes No Yes Yes No Yes
12 325 Yes Yes Yes No Yes Yes No Yes
12 326 Yes Yes Yes Yes Yes Yes No Yes
12 327 Yes No Yes No Yes Yes No Yes
12 328 Yes Yes Yes Yes Yes Yes No Yes
12 329 Yes Yes Yes No Yes Yes No Yes
12 330 Yes Yes Yes Yes Yes Yes No Yes
23 361 No No No Yes No Yes No Yes
23 362 No No No Yes No Yes No Yes
23 363 Yes Yes No No Yes Yes Yes Yes
23 364 No Yes No Yes Yes Yes No No
23 365 Yes Yes Yes No Yes Yes No No
23 366 Yes Yes Yes Yes Yes Yes No Yes
23 367 Yes Yes Yes Yes Yes Yes Yes Yes
23 368 Yes Yes No No Yes Yes No Yes
23 369 Yes Yes Yes Yes No Yes No Yes
23 370 Yes Yes Yes No Yes Yes No Yes
23 371 Yes Yes No Yes Yes Yes Yes Yes
23 372 Yes Yes Yes No Yes Yes No No
23 373 Yes No No No Yes Yes No No
23 374 Yes Yes Yes Yes Yes Yes Yes No
23 375 Yes Yes Yes No Yes Yes No Yes
23 376 Yes Yes No Yes Yes No No Yes
23 377 Yes Yes No No Yes Yes No No
23 378 Yes No No No Yes Yes No No
23 379 Yes Yes Yes No Yes Yes No No
23 380 Yes Yes No Yes Yes Yes Yes No
23 381 Yes No No No Yes Yes No No
23 382 Yes No No No No Yes No Yes
23 383 Yes Yes No Yes Yes Yes Yes Yes
23 384 Yes Yes No Yes Yes Yes No No
23 385 Yes Yes No Yes Yes Yes No Yes
23 386 Yes Yes Yes Yes Yes Yes No Yes
23 387 Yes Yes Yes No Yes Yes No Yes
23 388 Yes Yes Yes No Yes No No Yes
23 389 Yes Yes Yes No Yes Yes No Yes
23 390 Yes Yes Yes No No Yes No Yes
23 391 Yes Yes Yes Yes No Yes No Yes
23 392 Yes Yes Yes No Yes Yes No Yes
23 393 Yes Yes Yes No No No No No
23 394 Yes Yes No Yes Yes Yes No Yes
23 395 Yes Yes Yes No Yes Yes No No
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23 396 Yes Yes Yes Yes Yes Yes No Yes
23 397 Yes Yes Yes Yes Yes Yes No Yes
23 398 Yes Yes No Yes Yes Yes Yes Yes
23 399 Yes Yes No Yes Yes Yes No No
23 400 Yes Yes No Yes Yes Yes Yes Yes
23 401 Yes Yes Yes No Yes Yes No Yes
23 402 Yes Yes Yes Yes Yes Yes No No
23 403 Yes Yes Yes Yes No Yes No Yes
23 404 Yes Yes Yes No Yes Yes Yes Yes
23 405 Yes Yes Yes Yes Yes Yes No Yes
34 451 Yes No No No No No No No
34 452 Yes No No Yes No No No No
34 453 Yes No No No No No No Yes
34 454 Yes No No No No No No Yes
34 455 Yes Yes No No No No No No
34 456 Yes Yes No No No No No No
34 457 Yes No No No No No No No
34 458 Yes Yes Yes No No No No No
34 459 Yes Yes No No Yes No No Yes
34 460 Yes Yes Yes No Yes No No Yes
34 461 Yes No Yes Yes No No No Yes
34 462 Yes Yes No Yes Yes No No Yes
34 463 Yes No Yes No Yes No No Yes
34 464 Yes Yes Yes No Yes No No Yes
34 465 Yes Yes Yes No Yes No No Yes
34 466 Yes No No Yes Yes No No No
34 467 Yes Yes Yes Yes Yes No No Yes
34 468 Yes Yes Yes No No No No No
34 469 Yes No Yes No No No No Yes
34 470 Yes No No No No No No Yes
34 471 Yes Yes Yes No Yes No No Yes
34 472 Yes Yes No No No No No Yes
34 473 Yes Yes No No No No No Yes
34 474 Yes Yes No Yes Yes No No No
34 475 Yes Yes No Yes Yes No No No
34 476 Yes Yes No Yes Yes No No No
34 477 Yes Yes No No Yes No No Yes
34 478 Yes Yes No No No No No Yes
34 479 Yes No No No Yes No No No
34 480 Yes Yes No No Yes No No Yes
34 481 Yes No Yes No No No No No
34 482 Yes Yes No No Yes No No Yes
34 483 Yes Yes No No No No No No
34 484 Yes No No No No No No No
34 485 Yes No No Yes Yes No No No
34 486 Yes Yes Yes No Yes No No Yes
34 487 Yes Yes Yes Yes Yes No No Yes
34 488 Yes Yes No No Yes No No No
34 489 Yes No No No Yes No No No
34 490 Yes Yes No No No No No Yes
34 491 Yes No No No Yes Yes No Yes
34 492 Yes Yes No No Yes No No No
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34 493 Yes No Yes No Yes No No No
34 494 Yes Yes Yes No No No No Yes
34 495 Yes Yes No No No No No Yes
34 496 Yes Yes No No No No No No
34 497 Yes Yes Yes No No No No Yes
34 498 Yes Yes Yes Yes No No No Yes
34 499 Yes Yes Yes No No No No No
34 500 Yes Yes Yes Yes No No No No
34 501 Yes No No No No No No No
34 502 Yes Yes No No No No No No
34 503 Yes Yes Yes No No No No No
34 504 Yes Yes No No Yes No No No
34 505 Yes Yes Yes No No No No Yes
34 506 Yes Yes No Yes Yes No No No
34 507 Yes No No No No No No No
34 508 Yes No No No Yes No No No
34 509 Yes No No No Yes No No Yes
34 510 Yes Yes Yes No No No No No
34 511 Yes No Yes No No No No Yes
34 512 Yes Yes No No Yes No No No
34 513 Yes Yes Yes No No No No Yes
34 514 Yes No No No No No No Yes
34 515 Yes Yes No No Yes No No No
34 516 Yes Yes Yes No No No No No
34 517 Yes No No No No No No Yes
34 518 Yes No Yes No No No No Yes
34 519 Yes No No No Yes No No Yes
34 520 Yes Yes Yes No No No No Yes
34 521 Yes Yes No No No No No Yes
34 522 Yes No No No Yes No No Yes
34 523 Yes No Yes No No No No Yes
34 524 Yes Yes Yes No No No No No
34 525 Yes Yes Yes No No No No Yes
34 526 Yes No No No Yes No No Yes
34 527 Yes No Yes No No No No No
34 528 Yes Yes Yes No No No No Yes
34 529 Yes No Yes No Yes No No Yes
34 530 Yes Yes Yes Yes No No No Yes
34 531 Yes No Yes No Yes No No Yes
34 532 Yes Yes No No No No No No
34 533 Yes Yes Yes No No No No No
34 534 Yes Yes No No No No No Yes
34 535 Yes No No No No No No Yes
34 536 Yes Yes No No Yes No No No
34 537 Yes No No No Yes No No No
34 538 Yes No No No No No No Yes
34 539 Yes Yes No No No No No No
34 540 Yes Yes Yes No Yes No No No
35 646 Yes Yes Yes Yes Yes Yes No Yes
35 647 Yes Yes Yes No Yes No No Yes
35 648 Yes Yes No No No Yes No Yes
35 649 Yes Yes No No No Yes No No
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35 650 Yes No No No No Yes No No
35 651 Yes No Yes No Yes Yes No No
35 652 Yes Yes Yes No Yes No No No
35 653 Yes No Yes No Yes No No No
35 654 Yes Yes Yes Yes Yes Yes No No
35 655 Yes Yes Yes No Yes No No No
35 656 Yes No Yes No No No No No
35 657 Yes Yes Yes Yes Yes Yes No Yes
35 658 Yes Yes Yes Yes Yes No No Yes
35 659 Yes No Yes Yes Yes No No Yes
35 660 Yes No Yes No No No No Yes
35 661 Yes No Yes No Yes No No No
35 662 Yes Yes Yes Yes Yes No No Yes
35 663 Yes Yes Yes No Yes No No Yes
35 664 Yes Yes Yes No No No No Yes
35 665 Yes No Yes No No No No No
35 666 Yes No No Yes No No No Yes
35 667 Yes Yes Yes Yes Yes No No Yes
35 668 Yes Yes Yes No Yes Yes No Yes
35 669 Yes Yes Yes No No No No No
35 670 Yes Yes Yes Yes No No No Yes
35 671 Yes Yes Yes Yes No Yes No Yes
35 672 Yes No Yes Yes No Yes No No
35 673 Yes Yes Yes Yes Yes No No Yes
35 674 Yes Yes Yes No No No No No
35 675 Yes No No No No No No No
35 676 Yes Yes Yes No Yes No No No
35 677 Yes Yes Yes Yes Yes Yes No Yes
35 678 Yes No No No No No No No
35 679 Yes Yes Yes No Yes No No Yes
35 680 Yes Yes Yes Yes Yes Yes No Yes
35 681 Yes Yes Yes No No No No No
35 682 Yes No Yes No No Yes No Yes
35 683 Yes Yes Yes No No No No Yes
35 684 Yes No No No Yes Yes No No
35 685 Yes No Yes No No No No No
35 686 Yes No Yes Yes Yes No No Yes
35 687 Yes Yes Yes No Yes Yes No Yes
35 688 Yes Yes Yes Yes No No No No
35 689 Yes No Yes No No No No No
35 690 Yes No Yes Yes Yes No No Yes
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11 7 URINARY TRACT INFECTION
11 14 BR. ASTHMA
11 15 T. VERSICOLOR
11 16 BRONCHIAL ASTHMA
11 18 NON - ULCER DYSPEPSIA
11 25 HOOK WORM
11 31 TYPE - 2DM
11 40 P.FALCIPARNE MALARIA
11 43 TINEA VERSICOLOR
11 46 T.FACIES
11 49 STRONGLOIDIASIS
11 55 HYPOPIGMENTED SKIN (T. VERSICOLOR)
11 55 DYSPEPSIA
11 57 COMMUNITY ACQUIRED PNEUMONIA
11 68 SCLERITIES




11 97 ACUTE GASTROENTERITIS






11 124 IP (AMOEBIASIS)
11 124 CELLULITIS
11 126 HERPES ZOSTER
11 127 DYSPEPSIA
11 135 T.VERSICOLOR
12 264 URINARY TRACT INFE









12 325 TINIA ALBA
23 369 ABDOMINAL WOUND
23 369 BRONCH PNEUMONIA
23 370 HEMATURIA
23 370 BIL. B/PNEUMONIA
23 371 ASCARIS LUMBRICOIDES
23 371 DENTAL CARIES
23 374 B. PNEUMONIA
23 376 PROLONGED PROTHROMBIN TIME
23 376 TINEA CAPITIS
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23 379 PNEUMONIA
23 380 ENTAMEBA HISTOLYTICA
23 380 ENTAMEBA COLI
23 380 GIADIA LAMBLIA
23 381 TINEA CAPITIS
23 381 A. HISTOLYTICA CYSTS
23 383 B.PNEUMONIA
23 384 PNEUMONIA
23 385 PROLONGED PROTHROMBIN TIME
23 385 PROTEINURIA
23 385 PNEUMONIA
23 394 MICROSCOPIC HAEMATURIA
23 394 PNEUMONIA
23 394 SEVERE ANAEMIA
23 397 BASAL PNEUMONITIS
23 400 ANAEMIA
23 400 PNEUMONIA
23 403 DENTAL CARIES
23 405 ATYPICAL PNEUMONIA
34 454 PNEUMONIA
34 456 HEPATITIS B (DISCOVERED 25.11.04)
34 460 OTITIS MEDIA
34 461 SUSPECTED TB




34 474 FIRST DEGREE AV BLOCK - BINIGN CONDITION
34 486 PNEUMONIA
34 490 FIRST DEGREE AV BLOCK - BINIGN CONDITION
34 492 MUCOID DIARREA
34 492 SUPERFICIAL FUNGEAL SKIN INFECTION (ABDOMINAL+ EPIGASTRIC)
34 492 SUSPECTED DYSENTRY
34 496 RIGHT VENTRICULAR CONDUCTION DELAY - BINIGN CONDITION
34 500 MALARIA
34 509 URINARY TRACT INFECTION
34 518 MALARIA
34 523 MALARIA (P. FALCIPARUM)
34 534 MALARIA
34 536 RBBB-RIGHT BUNDLE BRANCH BLOCK - BIGIGN CONDITION
34 537 RIGHT VENTRICULAR CONDUCTION DELAY - BINIGN CONDITION
34 538 WATERY DIARRHOEA
34 539 MALARIA
35 659 BRONCHOPNEUMONIA
35 660 CYSTIC CHANGES IN THE RIGHT LUNG
35 660 TINEA VERSICOLOR
35 686 BRONCHO-PNEUMONIA
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11 1 PM 1.72 48 51 52 52 56 58
11 2 Combination 1.68 52 52 52 54 61 58
11 3 Combination 1.72 42 44 41 41 54 54
11 4 PM 1.65 45 49 48 49 49 49
11 5 PM 1.24 20 21 22 21 23 22
11 6 Combination 1.3 25 28 28 28 30 27
11 7 PM 1.58 47 48 46 46 50 51
11 8 SSG 1.72 50 53 52 52 53 53 54
11 9 SSG 1.69 52 52 53 51 51 52 52
11 10 SSG 1.52 37 37 38 36 36 38 39
11 11 Combination 1.26 21 21 20 20 20 20
11 12 Combination 1.7 56 55 52 52 53 55
11 13 SSG 1.59 47 45 46 46 46 49 46
11 14 SSG 1.17 20 20 20 21 20 20 21
11 15 PM 1.65 47 45 49 50
11 16 Combination 1.49 45 45 46 46 50 46
11 17 Combination 1.71 58 57 59 59 58 56
11 18 SSG 1.72 52 52 52 52 52 50 55
11 19 Combination 1.71 53 53 52 51 56 53
11 20 SSG 1.21 22 24 23 23 22 24 25
11 21 SSG 1.65 48 50 50 50 50 50 50
11 22 SSG 1.29 24 23 23 23 25 25 25
11 23 PM 1.29 26 25 25 26 26 26
11 24 PM 1.1 18 16 16 17 17 18
11 25 SSG 1.2 20 17 18 19 20 20 21
11 26 Combination 1.21 20 20 20 20 20 20
11 27 PM 1.64 46 46 44 42 41
11 28 Combination 1.4 29 29 28 29 31 32
11 29 PM 1.6 42 42 43 43 45 45
11 30 PM 1.03 15 14 15 14 15 17
11 31 SSG 1.56 39 40 38 40 42 50 48
11 32 Combination 1.54 38 38 38 39 50 50
11 33 SSG 1.74 55 56 58 59 59 59 56
11 34 PM 1.59 49 49 50 49 51 49
11 35 SSG 1.5 47 47 47 49 48 50 46
11 36 SSG 1.69 43 45 45 49 47 51 56
11 37 Combination 1.7 59 57 57 57 68 69
11 38 PM 1.76 48 48 49 51 53 54
11 39 PM 1.12 18 18 18 19 18 19
11 40 PM 1.18 16 18 17 21 21
11 41 Combination 1.01 17 17 17 17 18 19
11 42 Combination 1.71 53 54 55 56 58 58
11 43 SSG 1.51 44 44 44 45 46 45 45
11 44 PM 1.61 45 46 47 49 48 47
11 45 Combination 1.57 50 51 52 52 52 52
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11 46 SSG 0.95 16 15 16 16 16 16 16
11 47 SSG 1.67 44 44 45 47 49
11 48 Combination 1.6 40 41 42 42 50
11 49 SSG 1.1 16 17 18 20 20 21 21
11 50 PM 1.73 55 55 56 55 62 64
11 51 Combination 1.43 32 33 32 33 38 38
11 52 PM 1.3 24 25 25 26 26 25
11 53 SSG 1.73 46 47 47 47 48 50 51
11 54 PM 1.64 46 47 48 48 54 52
11 55 PM 1.6 46 46 48 47 55 56
11 56 SSG 1.44 33 31 32 33 34 36 35
11 57 Combination 1.2 47 45 46 48 56 57
11 58 Combination 1.22 22 24 24 24 24 25
11 59 PM 1.27 23 22 23 24 25 26
11 60 Combination 1.72 50 49 49 49 53 51
11 61 PM 1.66 47 48 48 49 52 52
11 62 SSG 1.09 16 17 16 16 17 18 20
11 63 SSG 1.69 59 60 60 62 62 61 61
11 64 SSG 1.62 49 50 47 48 48 52 59
11 65 PM 0.93 14 15 15 15
11 66 Combination 1.5 34 32 31 31 47 51
11 67 PM 1.31 22 24 23 24 24 25
11 68 SSG 1.17 21 19 19 19 21 21 22
11 69 Combination 1.65 41 43 43 42 42 42
11 70 Combination 1.65 49 48 48 48 55 55
11 71 Combination 1.78 46 48 48 47 50 49
11 72 SSG 1.72 50 48 49 51 50
11 73 PM 1.6 48 48 49 48 55 54
11 74 PM 1.68 49 48 49 49 56 54
11 75 Combination 1.7 52 53 53 53 54 57
11 76 PM 1.62 45 45 45 46 50 50
11 77 PM 1.27 20 20 22 23 23 24
11 78 SSG 1.63 46 48 50 50 52 49 53
11 79 PM 0.99 12 13 13 15 14 15
11 80 PM 1.19 22 21 22 23 23 25
11 81 Combination 1.74 53 53 55 54 55 62
11 82 SSG 1.32 25 28 27 26 28 29 29
11 83 SSG 1.67 40 39 40 39 40 47 54
11 84 SSG 1.28 19 23 23 24 24 23 25
11 85 SSG 1.52 42 42 43 43 44 50
11 86 Combination 0.9 11 13 13 13 14 16
11 87 Combination 1.53 35 37 38 38 40 43
11 88 PM 1.6 53 52 53 55 57 58
11 89 Combination 1.76 59 59 55 57 65 68
11 90 Combination 1 14 17 16 17
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11 91 PM 1.62 52 53 53 54 55 55
11 92 Combination 1.19 16 17 17 18 20 20
11 93 SSG 1.7 46 45 45 46 50 52 51
11 94 SSG 0.9 14 15 14 15 14 15 16
11 95 SSG 0.98 15 15 16 17 17 16 16
11 96 Combination 1.14 17 19 20 20 21 21
11 97 Combination 1.62 37 38 41 43 49 50
11 98 PM 1.7 35 35 34 33 45 48
11 99 SSG 1.56 38 38 39 38 39 42 44
11 100 PM 1.68 44 45 45 46
11 101 PM 1.68 44 43 43 45 50 46
11 102 Combination 1.7 51 51 51 51 60 57
11 103 Combination 1.8 51 50 51 51 57 61
11 104 PM 1.4 30 29 29 30 33 32
11 105 SSG 1.6 36 36 38 39 40 46 51
11 106 Combination 1.74 50 49 50 49 58 60
11 107 PM 1.64 47 48 49 50 59 55
11 108 PM 1.65 46 47 48 50 55 57
11 109 SSG 1.63 47 47 48 49 48 56 55
11 110 PM 1.06 15 15 14 15 17 19
11 111 Combination 1.68 47 49 51 52 58 59
11 112 Combination 1.6 46 44 47 47 50 50
11 113 SSG 1.62 46 44 46 47 47 54
11 114 SSG 1.62 51 51 51 52 51 56 56
11 115 Combination 1.36 26 28 28 28 34 32
11 116 SSG 1.64 48 47 47 48 51 54 54
11 117 PM 1.8 54 52 53 52 58
11 118 PM 1.59 47 49 50 52 54 57
11 119 SSG 1.66 45 47 49 50 52 54 51
11 120 Combination 1.71 46 47 48 48 51 50
11 121 Combination 1.07 15 15 15 15 16 15
11 122 SSG 1.68 49 52 50 52 53
11 123 SSG 1.6 45 45 46 48 49 48 48
11 124 SSG 1.74 55 58 63 61 56 64
11 125 SSG 1.81 51 52 50 52 54 56 63
11 126 Combination 1.69 52 52 52 52 57
11 127 PM 1.51 27 28 29 30 33 32
11 128 Combination 1.8 52 53 51 50 57 54
11 129 PM 1.58 40 39 40 42 48 46
11 130 Combination 1.72 47 44 45 45 54 52
11 131 PM 1.08 17 17 18 18 17 18
11 132 SSG 1.68 50 49 51 50 51 55 54
11 133 Combination 1.8 48 48 48 49 59 54
11 134 PM 1.7 53 51 52 52 57 63
11 135 PM 1.62 47 48 48 50 51 51
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12 241 Combination 1.55 42 44.5 44 45 55
12 242 SSG 1.2 20 21 22 21 21 23 23
12 243 PM 1.18 22 22 25 26 28.5 29
12 244 SSG 1.67 53 56 55 56 56 57 57
12 245 PM 43 43 43 44 45
12 246 PM 1.87 47 49 49 49 48
12 247 PM 1.33 24 26 25 26.3 30 30
12 248 PM 1.87 53.5 55 55 55 60 38
12 249 Combination 1.54 35 35 34 34 38 39
12 250 SSG 1.56 37 35.5 38 36 37 41.5 43
12 251 Combination 1.71 46 46 46 46 52 52
12 252 SSG 1.63 34 38 40 41 40 43 46
12 253 SSG 1.4 25 27 27 27 29 30 31
12 254 Combination 1.22 20 20 20 22 24 27
12 255 Combination 1.54 37 38 37 37 40 40
12 256 Combination 1.5 40 40 40 40 46 48
12 257 SSG 1.58 42 43 42 43 45 47 48
12 258 SSG 1.31 24 25 25 25 26 28
12 259 PM 1.8 58 60 60 65 64 64
12 260 PM 1.48 37 39 39 39 40
12 261 Combination 1.4 35 35 36 36 38 39
12 262 PM 1.26 22 25 26 26 27 27
12 263 SSG 1.62 45 47 48 48 50 54 51
12 264 Combination 1.29 24 25 24 24 25 26
12 265 SSG 1.02 15 15 15 16 15
12 266 PM 1.64 59 60 62 64 60 60
12 267 SSG 1.68 57 57 58 57 56 52 61
12 268 PM 1.71 60 60 62 64 66 67
12 269 Combination 1.55 41 40 42 43 50 50
12 270 Combination 1.24 22 23 22 23 25
12 271 SSG 1.72 59 57 57 55 54 66 65
12 272 PM 0.88 11 12 12 12.5 13 14.5
12 273 SSG 1.32 26 26.5 26 28 28 28 29
12 274 SSG 1.27 23 24 24 25 25 25 27
12 275 Combination 1.56 38 39 38 38 41 43
12 276 PM 1.25 20 21.5 22 24 24 26
12 277 Combination 1.64 44 45 45 46 48 52
12 278 SSG 1.64 45 46 45 47 49 57
12 279 PM 1.72 44 46 48 49 56 61
12 280 SSG 0.9 12 13 14 15 16 16.5 17.5
12 281 Combination 1.66 45 46 45 45 48 52
12 282 PM 1.2 18 20 20 21 22 24
12 283 PM 1.64 54 55 56 56 57 56
12 284 Combination 1.12 14 16 16 16 18 20
12 285 Combination 1.64 38 38 41 42 44 52
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12 286 PM 1.45 31 32 32 32 35 36
12 287 SSG 1.39 26 28 28 29 29 31 31
12 288 Combination 1.2 22 22 22 22 24 25
12 289 Combination 1.62 50 50 51 51.5 55 57
12 290 SSG 1.385 26 28 28 30 28 32
12 291 SSG 1.6 48 50 50 51 52 55 56
12 292 PM 1.74 50 50 50 50 63
12 293 SSG 1.4 30 30 30 30 30 35
12 294 Combination 1.08 19 18 18 19 20 22
12 295 Combination 1.4 25 25 27 27 32
12 296 PM 1.26 23 24 24 24 24 25
12 297 SSG 1.56 47 47 47
12 298 PM 1.33 27 26 27 27 28 28
12 299 Combination 1.86 56 56 55 57 65
12 300 PM 1.62 45 44 44 46 49 48
12 301 SSG 1.7 45 45 44.5 45 46 52 52
12 302 SSG 0.92 13 13 14 15 15 18 19
12 303 PM 1.6 40 40 40 41 46 48
12 304 Combination 1.63 42 44 42 43 51 50
12 305 PM 0.99 14 14 14 15 16 17
12 306 Combination 1 15 14 14.5 14.5 16 16
12 307 Combination 1.76 61 62 65 66 68 74
12 308 PM 1.85 57 56 57.5 58 62 63
12 309 PM 1.75 53 53 53 53 58 59
12 310 SSG 1.41 30 30 30 31 32 34 36
12 311 SSG 1.27 27 28 27 28 28 33 31
12 312 Combination 1.62 48 48 50 50 56 62
12 313 PM 1.75 58 58 59 60 66 67
12 314 SSG 1.78 46 48 46 47 49 51 55
12 315 Combination 1.14 18 20 22 21 21 21
12 316 SSG 1.73 54 56 53 54 61 60
12 317 SSG 0.95 13 14 14 14 14 14
12 318 Combination 1.15 16 17 16 17 19 20
12 319 Combination 1.28 23 24 24 24 26 26
12 320 Combination 1.23 22 22 22 22 23 24
12 321 Combination 1.16 21 21 21 21 22 24
12 322 PM 1.55 40 39 39 41 45 44
12 323 SSG 1.8 58 59 59 61 61 62 61
12 324 SSG 1.84 61 63 62 65 65 68 70
12 325 PM 1.74 55 58 60 60 62 60
12 326 PM 1.74 45 46 45 48 58 62
12 327 Combination 1.42 30 33 33 32 34 34
12 328 PM 1.43 29 28 30 28 30 30
12 329 SSG 1.02 14 15 15 15 15 16 16
12 330 PM 1.3 26 29 29 29 33 27
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23 361 Combination 1.2 17 18 19 20 19 20
23 362 PM 1.2 39 39 38 40 38 40
23 363 PM 1.1 18 17 17 18 18 18
23 364 Combination 1.31 23 23 23 24 24 25
23 365 SSG 1.6 41 42 42 42 45 41 46
23 366 Combination 1.41 28 30 31 31 26 30
23 367 SSG 1.64 44 43 44 44 45 58 50
23 368 PM 1.54 48 51 50 51 57 61
23 369 Combination 1.47 26 26 27 28 31 32
23 370 SSG 1.18 18 19 19 20 20 18 20
23 371 PM 1.43 38 37 37 38 38 41
23 372 PM 1.72 55 55 57 59 58 58
23 373 SSG 1.64 40 41 43 44 46 45 46
23 374 SSG 1.51 39 40 39 40 41 43 42
23 375 Combination 1.37 23 25 26 27 26 26
23 376 SSG 1.56 36 37 38 38 39 41 42
23 377 Combination 1.58 46 48 54
23 378 Combination 1.16 17 17 18 18 17 20
23 379 PM 1.17 18 20 20 20 19 21
23 380 SSG 1.15 16 17 17 18 18 18 18
23 381 PM 1.37 29 29 30 33 31 32
23 382 Combination 1.67 40 40 41 42 45 45
23 383 PM 1.68 42 44 46 49 49 50
23 384 SSG 1.47 32 34 35 35 35 34 34
23 385 SSG 1.5 28 31 32 31 31 31 32
23 386 Combination 1.55 30 32 33 33 34 35
23 387 Combination 1.69 43 44 45 45 45 48
23 388 PM 1.47 26 28 29 30 30 30
23 389 SSG 1.38 29 30 31 32 33 33 31
23 390 PM 1.72 45 45 47 48 49 50
23 391 Combination 1.45 30 30 31 32 30 30
23 392 Combination 1.15 18 18 18 18 19
23 393 SSG 1.34 23 24 26 26 28 25 26
23 394 PM 1.24 19 20 22 22 22 22
23 395 PM 1.69 54 54 56 58 59 56
23 396 SSG 1.67 51 52 53 53 55 55 55
23 397 SSG 1.56 30 32 34 35 37 36 35
23 398 Combination 1.24 20 21 22 22 24 23
23 399 PM 1.17 20 21 21 23 21 22
23 400 PM 1.21 19 19 18 20 19 21
23 401 Combination 1.72 55 57 56 57 56 55
23 402 Combination 1.6 43 44 43 44 47 47
23 403 SSG 1.7 45 46 43 45 46 50 52
23 404 SSG 1.64 45 47 48 50 52 50
23 405 PM 1.52 39 39 41 42 41 43
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34 451 Combination 1.16 16 18 18 18 21
34 452 PM 1.44 28 28 29 29
34 453 PM 1 15 14 16 16
34 454 Combination 0.96 12 12 12 12 14
34 455 PM 1.31 21 24 23 23
34 456 SSG 1.2 20 22 22 23 24 23
34 457 Combination 1.72 48 55 55 56
34 458 PM 1.36 24 26 25 27 27
34 459 Combination 1.38 24 25 24 26 27 27
34 460 PM 0.96 12 12 13 13
34 461 SSG 1.74 55 60 59
34 462 SSG 0.95 11 12 12 12 13 13
34 463 Combination 0.89 10 11 11 12 13
34 464 SSG 1.77 52 54 54 54 54 58
34 465 SSG 1.73 51 56 56 56 56 55
34 466 Combination 1.19 20 21 21 22
34 467 PM 1.52 30 32 32 32 30
34 468 Combination 1.61 46 48 49 49 51
34 469 SSG 1.4 25 26 27 26 27 28
34 470 Combination 0.98 14 14 16 16 15
34 471 PM 1.42 29 30 31 32
34 472 SSG 0.94 13 14 14 15 14 14
34 473 PM 1.03 16 16 15 15
34 474 Combination 1.31 24 26 26 27
34 475 PM 1.19 19 19 19 19
34 476 PM 1.31 26 27 27 28 27
34 477 SSG 1.24 18 18 19 19 18 17
34 478 Combination 0.9 10 11 12 12 12
34 479 SSG 0.91 10 11 12 12 11 12
34 480 SSG 1.46 28 29 30 30 30 31
34 481 Combination 1.34 23 23 25 25 29
34 482 Combination 1.68 55 57 56 56 63
34 483 PM 1.87 57 57 55 56 55
34 484 PM 1.07 15 13
34 485 Combination 1.12 15 15 16 19 17
34 486 Combination 1.44 32 33 34 33 37
34 487 SSG 1.65 37 41 40 41 41 47
34 488 SSG 1.29 20 22 21 23 23 23 23
34 489 SSG 1.48 26 27 27 26 27 29
34 490 PM 1.28 19 20 20 20 23
34 491 PM 1.71 50 53 51 51
34 492 PM 1.91 66 76 75 72 74
34 493 SSG 1.52 33 36 33 33 36 36
34 494 Combination 1.76 58 49 49 51 62
34 495 SSG 1.12 15 17 16 16 17 17
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34 496 SSG 1.73 63 63 63 62 65 66
34 497 PM 1.66 49 49 50 50 52
34 498 SSG 1.47 32 31 34 34 34 35
34 499 Combination 1.31 26 26 28 27 27
34 500 PM 1.55 34 34 36 39 37
34 501 Combination 1.32 22 23 24 24 26
34 502 Combination 1.47 35 34 34 35 39
34 503 PM 1.37 25 23 23 25
34 504 Combination 1.1 16 15 17 17
34 505 SSG 1.56 52 54 57 58 57 59
34 506 SSG 1.25 18 19 19 19 20 21
34 507 SSG 1.09 15 17 18 17 18 18
34 508 PM 0.98 14 13 14 14
34 509 PM 1.89 55 58 61 61
34 510 Combination 1.22 19 20 22 23 22
34 511 Combination 1.08 16 16 18 17 17
34 512 PM 1.06 14 15 16 16
34 513 Combination 1.22 21 23 24 21 25 26
34 514 SSG 1.21 21 22 24 24 23 25
34 515 SSG 1.28 24 24 26 26 26 26
34 516 PM 1.63 44 44 45 44 46
34 517 PM 1.39 27 28 27 28
34 518 SSG 0.96 14 16 14 15 15 16
34 519 PM 1.31 20 22 22 22 20
34 520 SSG 1.67 53 52 51 52 52 65
34 521 PM 1.1 16 17 16 17
34 522 Combination 1.64 48 51 53 53
34 523 SSG 1.31 23 22 24 24 24 27
34 524 Combination 1.47 33 34 33 34 35
34 525 Combination 1.22 22 22 22 23 22
34 526 SSG 1.02 13 13 13 14 13 13
34 527 Combination 1.65 47 46 44 45 56
34 528 PM 1.16 19 19 19 19
34 529 Combination 1.05 13 15 15 15 15
34 530 Combination 1.76 53 55 57 57 62
34 531 SSG 0.98 13 14 15 16 15
34 532 Combination 0.95 12 13 13 13 14
34 533 SSG 1.45 28 29 29 29 31 33
34 534 PM 1.09 14 14 13 14
34 535 PM 1.36 28 27 28 29 28
34 536 PM 1.34 25 25 26 27 30
34 537 SSG 0.97 11 12 12 13 13 13
34 538 PM 1.15 17 18 18 18
34 539 Combination 1.3 21 21 22 21 19
34 540 SSG 1.43 29 30 30 32 31 35
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35 646 PM 1.58 32 32 34 36 46
35 647 PM 1.83 61 61 65 65 63 65
35 648 Combination 1 15 15 15 15 16 18
35 649 Combination 1.45 29 32 32 32 35 37
35 650 SSG 1.04 15 15 16 16 16 16 17
35 651 SSG 1.09 16 16 16 17 17 20 22
35 652 PM 1.25 20 20 20 21 21
35 653 Combination 1.12 15 15 15 15 17 17
35 654 SSG 1.01 13 13 13 13 14 13 15
35 655 Combination 1.43 29 29 29 29 31 35
35 656 SSG 1.36 22 22 22 22 23 25 28
35 657 PM 1.28 22 22 23 26 30 31
35 658 Combination 1.61 36 37 39 39 43 46
35 659 SSG 1.08 16 16 17 16 16 20 22
35 660 PM 1.76 52 52 53 53 55 56
35 661 Combination 1.75 50 50 50 53 55 59
35 662 PM 1.82 61 61 62 61 58 63
35 663 SSG 1.75 57 57 58 58 58 60 60
35 664 Combination 1.71 73 70 70
35 665 SSG 1.41 24 25 27 28 28 30 30
35 666 SSG 1.47 33 33 35 36 37 36 39
35 667 Combination 1.38 23 25 25 26 28 30
35 668 PM 1.5 42 40 40 42 49
35 669 PM 1.47 29 29 30 31
35 670 SSG 1.34 22 22 25 25 26 27 28
35 671 PM 1.22 18 18 19 17 20
35 672 Combination 1.28 23 23 23 24 26
35 673 SSG 1.64 26 28 27 28 28 30 30
35 674 Combination 1.25 20 20 20 21 25 30
35 675 PM 1.43 24 24 25 26 24
35 676 PM 1.24 18 18 17 17 18 21
35 677 SSG 1.8 61 57
35 678 Combination 1.54 31 30 32 33 35 37
35 679 SSG 1.47 32 32 32 32 34 38 38
35 680 Combination 1.33 22 22 24 25 28 30
35 681 Combination 1.62 46 46 48 48 47 47
35 682 PM 1.27 15 16 15 16 16
35 683 Combination 1.32 30 31 30 31 32
35 684 SSG 1.58 49 47 47 47 45 50 51
35 685 PM 1.59 37 37 38 40 40 42
35 686 PM 1.65 47 47 48 48 50 53
35 687 SSG 1.6 49 49 50 51 51 51 53
35 688 PM 1.65 39 41 41 43 47 46
35 689 Combination 1.64 42 42 43 43 55 58
35 690 SSG 1.43 21 22 25 26 26 28 30
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Centre Patient Treatment Heart rate (Beats per minute)
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
11 1 PM 84 100 104 100 100 84
11 2 Combination 94 88 88 84 84 82
11 3 Combination 88 80 88 90 78 78
11 4 PM 91 80 96 80 64 64
11 5 PM 83 116 84 80 90 82
11 6 Combination 104 116 108 108 88 78
11 7 PM 78 100 90 88 80 80
11 8 SSG 82 80 60 80 72 68 58
11 9 SSG 70 68 76 68 84 96 64
11 10 SSG 80 74 86 76 78 80 64
11 11 Combination 88 124 130 112 112 108
11 12 Combination 75 104 84 76 74 65
11 13 SSG 80 100 84 76 80 65 67
11 14 SSG 96 112 108 116 112 108 112
11 15 PM 100 124 80 76
11 16 Combination 88 74 90 88 80 82
11 17 Combination 80 80 68 84 78 64
11 18 SSG 72 68 80 92 86 70 68
11 19 Combination 74 88 94 102 80 74
11 20 SSG 90 94 76 104 80 80 82
11 21 SSG 74 74 64 104 70 54 60
11 22 SSG 140 104 98 90 90 92 74
11 23 PM 74 86 92 96 67 66
11 24 PM 120 123 120 104 96 100
11 25 SSG 110 70 84 96 90 96 88
11 26 Combination 100 94 104 108 78 94
11 27 PM 96 90 88 94 116
11 28 Combination 80 88 84 86 84 60
11 29 PM 92 84 90 84 78 80
11 30 PM 120 120 108 100 110 94
11 31 SSG 98 90 76 94 90 80 84
11 32 Combination 100 98 94 78 88 90
11 33 SSG 80 88 64 62 70 66 66
11 34 PM 68 74 72 72 60 54
11 35 SSG 88 96 94 94 100 78 78
11 36 SSG 108 100 88 84 102 68 60
11 37 Combination 100 116 100 94 67 70
11 38 PM 84 80 90 80 64 88
11 39 PM 100 110 96 96 96 94
11 40 PM 110 120 120 102 84
11 41 Combination 86 100 96 98 100 110
11 42 Combination 88 80 96 96 68 57
11 43 SSG 100 100 90 108 84 100 54
11 44 PM 80 80 70 70 70 78
11 45 Combination 88 84 94 84 80 76
11 46 SSG 100 80 70 88 88 92 80
11 47 SSG 120 96 84 94 80
11 48 Combination 100 86 92 95 80
11 49 SSG 108 93 80 78 86 90 88
11 50 PM 94 104 102 84 80 74
11 51 Combination 106 104 108 98 88 94
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Centre Patient Treatment Heart rate (Beats per minute)
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
11 52 PM 102 92 88 84 80 74
11 53 SSG 120 100 80 88 86 72 84
11 54 PM 102 84 86 80 80 80
11 55 PM 96 109 80 90 64 68
11 56 SSG 120 100 96 94 92 63 74
11 57 Combination 120 100 94 100 78 82
11 58 Combination 106 108 90 100 102 94
11 59 PM 112 100 116 112 100 88
11 60 Combination 104 90 100 86 60 84
11 61 PM 116 99 100 96 96 88
11 62 SSG 108 100 120 100 84 94 80
11 63 SSG 94 94 80 80 76 80 72
11 64 SSG 96 120 90 80 94 64 68
11 65 PM 120 100 105 92
11 66 Combination 120 108 98 96 98 80
11 67 PM 112 68 80 98 84 80
11 68 SSG 140 100 98 80 82 85 90
11 69 Combination 80 84 80 78 86 80
11 70 Combination 100 94 84 70 80 74
11 71 Combination 80 82 80 86 80 100
11 72 SSG 104 100 110 80 68
11 73 PM 100 82 82 68 84 72
11 74 PM 69 80 76 76 72 80
11 75 Combination 114 100 100 84 84 80
11 76 PM 96 98 84 86 64 72
11 77 PM 88 82 92 94 80 84
11 78 SSG 96 78 80 84 80 78 82
11 79 PM 108 98 96 86 96 92
11 80 PM 120 84 88 100 80 76
11 81 Combination 94 96 90 80 96 76
11 82 SSG 108 84 100 96 106 84 100
11 83 SSG 108 100 100 100 96 102 80
11 84 SSG 88 80 98 86 100 90 72
11 85 SSG 120 114 90 98 96 80
11 86 Combination 110 102 106 98 90 100
11 87 Combination 108 86 90 98 88 92
11 88 PM 124 96 83 90 70 64
11 89 Combination 104 96 90 98 100 90
11 90 Combination 120 98 88 97
11 91 PM 102 92 84 82 82 78
11 92 Combination 80 96 84 80 90 84
11 93 SSG 110 100 104 92 96 82 82
11 94 SSG 112 88 80 100 94 108 98
11 95 SSG 94 82 84 94 100 80 84
11 96 Combination 108 98 80 86 90 60
11 97 Combination 110 92 88 96 80 62
11 98 PM 120 116 110 100 104 72
11 99 SSG 104 100 96 80 80 92 78
11 100 PM 106 96 96 92
11 101 PM 94 80 80 98 84 76
11 102 Combination 104 100 80 94 74 82
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 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
11 103 Combination 106 100 84 96 78 64
11 104 PM 112 108 104 100 82 78
11 105 SSG 120 100 112 104 112 78 70
11 106 Combination 100 84 84 84 68 64
11 107 PM 70 84 104 92 72 66
11 108 PM 96 94 90 88 82 80
11 109 SSG 112 98 88 96 112 92 68
11 110 PM 112 126 108 124 80 86
11 111 Combination 100 82 86 82 72 68
11 112 Combination 80 120 98 86 60 64
11 113 SSG 106 82 80 92 88 80
11 114 SSG 110 82 62 88 98 76 82
11 115 Combination 126 100 92 86 80 86
11 116 SSG 120 92 94 80 100 72 86
11 117 PM 88 80 84 98 70
11 118 PM 96 110 100 98 100 78
11 119 SSG 112 120 124 100 96 80 70
11 120 Combination 102 92 100 96 88 88
11 121 Combination 116 106 100 102 112 90
11 122 SSG 72 80 86 90 90
11 123 SSG 108 98 84 104 96 90 86
11 124 SSG 126 96 82 102 104 80
11 125 SSG 116 80 76 94 112 64 68
11 126 Combination 68 88 86 80 92
11 127 PM 106 118 116 96 102 82
11 128 Combination 100 108 90 86 88 96
11 129 PM 110 108 88 92 80 76
11 130 Combination 92 104 110 96 100 76
11 131 PM 126 120 86 120 100 86
11 132 SSG 120 80 76 80 96 78 80
11 133 Combination 130 120 112 98 78 64
11 134 PM 100 104 106 94 100 80
11 135 PM 104 86 86 86 86 70
12 241 Combination 84 92 80 76 78
12 242 SSG 90 96 88 84 88 88 86
12 243 PM 104 102 92 88 76 76
12 244 SSG 84 92 76 80 84 86 76
12 245 PM 100 80 80 80 96
12 246 PM 88 82 88 80 90
12 247 PM 104 96 80 100 89 88
12 248 PM 80 64 68 68 89 64
12 249 Combination 76 80 92 104 100 72
12 250 SSG 96 80 80 88 80 74 87
12 251 Combination 104 80 84 92 78 80
12 252 SSG 84 76 84 80 100 80 82
12 253 SSG 100 96 96 90 80 90 90
12 254 Combination 96 100 100 100 92 80
12 255 Combination 76 80 88 88 88 88
12 256 Combination 104 90 94 100 76 76
12 257 SSG 90 100 94 90 96 70 86
12 258 SSG 82 94 88 84 80 82
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Centre Patient Treatment Heart rate (Beats per minute)
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
12 259 PM 80 87 92 74 72 68
12 260 PM 84 88 92 80 76
12 261 Combination 100 80 92 80 84 82
12 262 PM 104 94 96 96 84 96
12 263 SSG 88 84 96 90 92 80 74
12 264 Combination 84 98 90 96 92 80
12 265 SSG 100 100 100 90 88
12 266 PM 76 72 80 80 72 68
12 267 SSG 80 80 76 76 60 76 84
12 268 PM 80 82 80 82 68 78
12 269 Combination 92 84 84 80 68 82
12 270 Combination 100 108 80 80 68
12 271 SSG 96 80 72 92 68 48 70
12 272 PM 96 100 100 90 104 98
12 273 SSG 88 76 88 76 90 66 80
12 274 SSG 80 96 96 80 90 68 72
12 275 Combination 84 92 84 80 64 70
12 276 PM 84 92 88 100 88 92
12 277 Combination 100 92 82 80 82 60
12 278 SSG 84 98 94 92 90 68
12 279 PM 84 90 90 96 72 68
12 280 SSG 96 110 110 100 100 108 104
12 281 Combination 92 96 92 88 80 76
12 282 PM 92 92 86 86 92 84
12 283 PM 92 60 76 64 64 60
12 284 Combination 112 120 100 120 100 96
12 285 Combination 96 90 84 80 74 89
12 286 PM 88 100 108 100 88 80
12 287 SSG 96 128 100 100 120 89 84
12 288 Combination 120 108 96 100 88 80
12 289 Combination 88 96 80 80 76 72
12 290 SSG 72 106 104 104 92 88
12 291 SSG 108 88 82 82 82 84 80
12 292 PM 100 100 92 84 82
12 293 SSG 120 100 96 100 100 88
12 294 Combination 112 100 92 90 104 90
12 295 Combination 104 76 108 100 72
12 296 PM 120 90 92 84 84 90
12 297 SSG 92 96 92
12 298 PM 104 96 96 82 88 80
12 299 Combination 92 80 100 86 60
12 300 PM 76 84 60 64 68 88
12 301 SSG 84 84 100 82 86 72 76
12 302 SSG 116 112 100 100 100 100 104
12 303 PM 112 100 100 98 64 80
12 304 Combination 92 88 80 80 80 72
12 305 PM 112 108 100 80 104 108
12 306 Combination 100 112 100 80 108 104
12 307 Combination 88 86 82 76 68 72
12 308 PM 100 80 80 76 72 64
12 309 PM 108 88 82 80 80 84
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12 310 SSG 112 108 96 86 86 86 76
12 311 SSG 96 96 96 88 92 90 92
12 312 Combination 112 88 90 88 64 76
12 313 PM 100 80 80 80 68 64
12 314 SSG 92 80 72 80 68 76 60
12 315 Combination 112 112 108 108 86 92
12 316 SSG 64 64 84 60 52
12 317 SSG 108 104 120 108 104 92
12 318 Combination 132 108 116 112 108 108
12 319 Combination 128 108 100 100 100 80
12 320 Combination 104 92 100 90 96 80
12 321 Combination 116 100 108 100 72 68
12 322 PM 88 88 80 84 82 84
12 323 SSG 72 60 60 68 76 60 60
12 324 SSG 76 76 78 72 76 68 80
12 325 PM 68 60 60 76 76 66
12 326 PM 100 96 88 76 100 76
12 327 Combination 104 92 92 88 84 82
12 328 PM 120 104 100 88 88 76
12 329 SSG 128 118 100 108 104 106 94
12 330 PM 112 84 84 88 86 80
23 361 Combination 112 108 96 96 102 80
23 362 PM 74 112 96 84 100 100
23 363 PM 144 107 96 100 100 104
23 364 Combination 120 104 96 100 112 100
23 365 SSG 104 92 84 84 98 88 84
23 366 Combination 106 102 106 92 84 86
23 367 SSG 100 100 112 84 96 80 78
23 368 PM 80 100 96 86 86 84
23 369 Combination 80 84 104 108 94 80
23 370 SSG 104 100 104 112 104 100 96
23 371 PM 100 104 100 96 108 80
23 372 PM 76 80 80 76 96 86
23 373 SSG 88 98 78 88 84 84 52
23 374 SSG 108 108 102 100 84 102 100
23 375 Combination 116 100 96 96 100 92
23 376 SSG 94 140 80 88 96 94 78
23 377 Combination 92 98 76
23 378 Combination 128 112 104 104 96 104
23 379 PM 132 108 102 102 105 94
23 380 SSG 120 112 100 104 104 96 114
23 381 PM 104 100 104 94 108 100
23 382 Combination 120 100 86 80 104 96
23 383 PM 88 120 102 88 92 88
23 384 SSG 100 96 96 100 86 98 80
23 385 SSG 98 104 96 102 98 100 100
23 386 Combination 100 100 100 98 100 96
23 387 Combination 98 98 96 100 104 96
23 388 PM 80 98 110 100 88 100
23 389 SSG 120 102 100 100 96 80 88
23 390 PM 100 92 88 98 96 92
LEAP 0104a Appendices
Page 382 of 756
Appendix 30: Individual Heart rate and Axiliary temperature listing
Centre Patient Treatment Heart rate (Beats per minute)
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
23 391 Combination 100 104 96 104 108 80
23 392 Combination 120 120 105 100 110
23 393 SSG 110 122 100 100 94 104 78
23 394 PM 126 100 118 104 100 104
23 395 PM 105 100 100 84 80 84
23 396 SSG 98 96 94 88 86 80 84
23 397 SSG 98 104 112 96 94 80 90
23 398 Combination 104 120 108 98 88 88
23 399 PM 120 120 118 100 112 96
23 400 PM 120 104 104 96 120 102
23 401 Combination 84 84 84 96 82 80
23 402 Combination 108 96 100 98 88 88
23 403 SSG 116 96 90 90 96 64 84
23 404 SSG 80 76 76 96 94 80
23 405 PM 80 98 96 98 92 80
34 451 Combination 120 120 104 108 92
34 452 PM 104 120 112 96
34 453 PM 128 120 120 104
34 454 Combination 136 120 124 108 128
34 455 PM 120 112 120 96
34 456 SSG 128 124 120 120 120 122
34 457 Combination 112 104 104 92
34 458 PM 140 136 124 116 128
34 459 Combination 100 100 104 104 71 80
34 460 PM 112 108 104 104
34 461 SSG 96 108 120
34 462 SSG 140 124 128 120 120 120
34 463 Combination 140 88 108 108 132
34 464 SSG 100 112 104 96 89 61
34 465 SSG 112 100 88 96 124 88
34 466 Combination 112 96 92 77
34 467 PM 100 100 112 96 139
34 468 Combination 92 88 88 88 80
34 469 SSG 120 100 120 120 100 88
34 470 Combination 140 128 120 120 130
34 471 PM 104 120 120 100
34 472 SSG 120 112 112 120 108 96
34 473 PM 124 108 112 104
34 474 Combination 112 104 92 88 96
34 475 PM 128 116 114 116
34 476 PM 88 92 95 96 101
34 477 SSG 112 96 96 120 108 104
34 478 Combination 124 120 120 100 88
34 479 SSG 132 108 100 108 96 88
34 480 SSG 104 104 108 100 92 92
34 481 Combination 100 96 100 100 82
34 482 Combination 96 92 72 71 55
34 483 PM 92 92 88 92 88
34 484 PM 120 124
34 485 Combination 116 116 116 108 81
34 486 Combination 112 92 96 100 110
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34 487 SSG 112 96 88 120 76 79
34 488 SSG 108 100 94 100 104 100 96
34 489 SSG 100 100 112 92 80 80
34 490 PM 120 100 124 108 90
34 491 PM 112 96 96 96
34 492 PM 88 76 76 88 75
34 493 SSG 108 96 100 96 96 88
34 494 Combination 98 92 88 88 70
34 495 SSG 142 100 120 108 104 78
34 496 SSG 104 82 100 100 96 79
34 497 PM 92 88 88 72 78
34 498 SSG 112 124 116 92 92 99
34 499 Combination 112 108 106 111 88
34 500 PM 92 88 78 82 72
34 501 Combination 120 112 86 86 70
34 502 Combination 120 92 89 96 82
34 503 PM 112 104 105 94
34 504 Combination 92 92 100 89
34 505 SSG 128 108 89 92 83 72
34 506 SSG 108 92 109 96 96 82
34 507 SSG 120 116 112 104 100 80
34 508 PM 128 132 112 120
34 509 PM 148 124 117 102
34 510 Combination 108 108 108 105 88
34 511 Combination 100 104 102 92 92
34 512 PM 112 136 145 109
34 513 Combination 120 104 112 108 100 96
34 514 SSG 128 108 115 104 89 91
34 515 SSG 112 96 92 92 83 80
34 516 PM 76 88 80 76 70
34 517 PM 112 92 96 75
34 518 SSG 128 120 112 96 97 120
34 519 PM 112 124 96 92 100
34 520 SSG 114 96 104 88 85 78
34 521 PM 136 124 117 115
34 522 Combination 120 120 106 106
34 523 SSG 118 120 106 100 93 96
34 524 Combination 96 96 107 96 78
34 525 Combination 137 128 125 112 96
34 526 SSG 120 112 125 100 109 111
34 527 Combination 140 112 114 120 96
34 528 PM 120 120 112 89
34 529 Combination 112 96 91 101 100
34 530 Combination 88 100 77 80 67
34 531 SSG 128 112 112 96 104
34 532 Combination 120 120 115 115 100
34 533 SSG 96 88 87 88 82 72
34 534 PM 112 128 117 149
34 535 PM 131 112 141 113 146
34 536 PM 104 92 74 66 75
34 537 SSG 158 142 150 140 147 100
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34 538 PM 157 132 130 121
34 539 Combination 87 92 101 94 92
34 540 SSG 125 92 103 108 92 80
35 646 PM 104 84 92 94 72
35 647 PM 98 110 106 94 82 86
35 648 Combination 80 104 108 110 94 82
35 649 Combination 110 88 92 84 90 84
35 650 SSG 120 100 108 105 104 106 92
35 651 SSG 108 110 100 110 98 104 98
35 652 PM 112 104 100 106 114
35 653 Combination 90 106 100 90 88 104
35 654 SSG 115 100 112 118 120 110 96
35 655 Combination 115 118 104 112 92 88
35 656 SSG 118 92 100 94 112 74 80
35 657 PM 140 96 104 100 82 84
35 658 Combination 88 90 78 100 108 100
35 659 SSG 115 118 104 98 110 104 100
35 660 PM 76 78 92 90 78 70
35 661 Combination 116 90 92 98 74 78
35 662 PM 95 84 90 96 86 82
35 663 SSG 96 76 88 68 88 76 76
35 664 Combination 102 84 92
35 665 SSG 104 96 94 96 94 78 92
35 666 SSG 114 102 86 80 90 84 92
35 667 Combination 110 92 104 108 82 78
35 668 PM 94 102 80 80 78
35 669 PM 112 100 100 104
35 670 SSG 112 92 90 94 98 80 74
35 671 PM 122 106 108 104 112
35 672 Combination 120 108 88 84 82
35 673 SSG 104 100 108 106 98 90 80
35 674 Combination 118 106 100 100 76 80
35 675 PM 100 118 96 108 116
35 676 PM 110 94 118 102 92 102
35 677 SSG 104 108
35 678 Combination 128 104 88 96 82 74
35 679 SSG 120 85 84 80 88 74 86
35 680 Combination 104 112 108 100 84 78
35 681 Combination 112 88 76 90 84 78
35 682 PM 104 112 118 118 104
35 683 Combination 102 104 114 100 78
35 684 SSG 98 100 104 96 92 78 70
35 685 PM 96 108 98 88 78 84
35 686 PM 88 94 102 100 78 80
35 687 SSG 108 74 92 88 92 72 82
35 688 PM 128 112 106 86 88 72
35 689 Combination 128 90 96 88 76 82
35 690 SSG 120 100 108 104 108 92 88
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Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
37 37 37 35.9 37.2 36.4
37 36.7 36.5 36.5 37 36.4
38 36.8 36.7 35.7 36.8 36.4
37.4 37 36.6 36.8 36.7 36.9
36.5 37.8 36.8 36.6 36 36.8
37.5 37.5 37.1 37.4 37.5 36.7
36.9 37.2 37.3 37.1 36.7 36.3
37.5 37.2 35.9 37.3 36.4 37.2 37.1
37.2 36.5 37 36.6 35.1 36.4 36.7
37.2 36.2 37.3 36.1 35.9 36.5 36.7
36.9 36.8 37.6 36.9 36.9 37.1
36.9 37.8 36 36.6 36.9 36.1
36.5 36.7 37.1 37 36.1 36.9 37
36.5 36.4 36.7 36.5 36 36.7 36.5
37.9 37.4 36.3 37.1
37.2 36.4 36.8 36.5 36.5 36.4
36.8 36.5 36.4 35.8 36.7 36.3
36.8 36.5 36.1 36.5 36.1 36.4 36.1
36.9 36.6 37.1 37.6 36.7 36.8
37.5 37.3 36.7 37 36.8 37.4 37
36.9 36.7 36.3 37 36.7 36 36
37.1 36.5 36 36 36.3 36.6 36.4
37.1 36.6 36.3 37 36.8 36
36.7 36.2 36.3 36 36.8 36.3
38.1 35.5 36.5 36.8 36.6 36.5 36.6
37.2 36.7 36.5 36.5 36.7 36.5
37.4 37 35.6 36.4 38.6
36.9 37 36.7 37.5 36.6 36.4
37.7 36.8 36.8 36.7 36.4 36
37 36.7 36 36.9 36.4 36.7
37.3 37.2 35.7 36.5 36.2 36.6 36.5
37.3 35.9 36.4 36.4 36.4 36
36.6 36.6 36.8 37 36.9 37.3 37
37.4 36.7 36.4 36.6 36.5 36.3
36.7 36.5 37.2 36.9 36.6 37 36
38.4 35.9 36.6 37 37.4 36.8 36.6
38.3 36.1 36.1 36.5 36.6 36.3
36.6 36 36.8 36.3 36.9 36
36.6 36.2 37.1 36.8 36.9 36.3
40 40 36.7 37.2 36.7
37.5 37.4 36.8 37.2 37.1 36.4
38.6 36.5 37.1 37.2 36.9 36.6
37.7 36.6 36.4 37.1 36.6 37 36.1
37.8 36.6 37 36.5 36.4 37
37.6 36.8 37 36.9 36.7 37.1
37 36.8 36.2 36.4 36.6 36.7 36.2
39.3 36.2 36.3 36.9 36.4
37.5 37.2 37.1 37.8 37
40.3 36.1 36.8 37.3 36.8 37 36.8
38.2 38.5 37.5 36.2 36.4 36.4
39.3 37.2 37.4 37 36.8 36.5
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Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
37.3 37 36.6 36.8 36.1 36
38.4 37 36.4 36.9 36.6 36.2 36.6
37.8 37.3 36.8 36.8 36.7 36.4
37.4 37.3 36 36.5 36.5 36.4
37.8 36.2 36.5 36.7 37 36.2 36.4
39.9 36 37.4 36.6 36.8 36.4
37 36.8 36.8 37 36.8 37
38.9 38.3 37 37.3 36.1 36.4
40.2 36 36.1 36.6 36.1 36.4
37.9 37.5 36.7 36.5 36.2 36.8
37.9 36.5 37.3 36 36 36.1 36.5
37.7 36.6 36.9 36.6 36.5 36.6 36.8
39.6 39 36 36.5 36 36.2 36
37.5 36.3 36.6 36.5
38.9 36.3 36.4 36 36.8 36.1
39.5 36.8 36 36.5 36.8 36.1
39.6 36.6 36.2 36 36 36.4 36.8
38.8 36.8 36.5 36.2 37.1 36.9
38.3 36 36.2 36.2 37 36.1
36.6 36 36 36 35.9 36.4
38.1 37.6 39 36.4 36
39.3 37 36.1 36.5 36.3 36.4
39.5 36.4 36.5 36 36.8 36.4
38.2 36.9 36.9 36.5 36.4 36.7
38.3 36.8 36.7 36.4 36.4 36.8
38.9 36.2 36.9 36 36.6 37.1
40 37 36.9 36.7 36.5 36.7 36.6
39.6 38 36.6 36.6 36.4 36
39.9 36 36.1 36.3 36.2 36
38.4 36.3 36.4 36.2 36.7 36.4
39.6 36.3 36.8 36.8 37 37.1 37
39 36.7 36.1 36 36 37 37
36.8 36.9 37 37 36.8 36.2 37
38.2 37 36.6 36.7 36.8 37
39.5 37 36.4 36.8 36.4 37.2
38.8 36.6 37 36.3 36.1 36.4
39.2 36.8 36.5 37 36.5 36
38.6 36.4 36.8 37.1 36.6 36.6
38.8 36.8 36.8 36.7
38 36 36 36 37.2 36.1
37.5 36.6 36 36.4 37.2 36.8
37.1 36 36.3 36.2 36.4 36.6 36.4
38.6 36.4 36 36.2 36.6 37.1 36.9
38.1 36.1 36.3 36 36.4 36.5 36.8
39.8 36.8 36.1 36.8 37 36.5
39.6 37.2 36.4 37 36 36.3
40.3 38.9 38.8 37.5 36.9 36
41 36.8 36 36 35.9 35.8 35.4
38 36.2 36.5 36.9
38 37 36.3 36.5 36 36.2
40.9 36.8 36.4 36.2 36.3 36.1
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Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
38.8 36.6 36.8 37 36.2 36.5
38.2 38.8 36.3 36.7 36.4 36.5
38.8 36.5 36.5 35.9 36.6 36.1 36.3
39.8 36.6 36.4 36.4 36 36
39.8 36.2 37 36.8 37.2 36.3
38.1 36.2 36.4 36.2 36.4 36.8
38 35.4 36.2 36 36 36.7 36.4
39 36.8 36.3 36.1 36.3 36.3
38.8 36.5 37 36.8 37.1 36.6
36.8 38 36 36.2 36.1 35.1
37.8 36 36.8 36.8 36.5 36.4
38.3 36.2 36.1 36.9 36.7 36.4 37.1
39 36.5 36 36.3 36.5 36.3
39.6 36.4 35.5 36 36 36.8 37
38.2 36.1 36.4 36.4 36.2
37 36.9 37 36.8 37.1 36
38 35.8 36.5 36.7 37.1 36.4 36.6
39.4 36.1 36.5 36.6 36 36.3
39.1 36.4 36.4 36.6 36.2 36.9
38.8 35.7 36.4 36.9 36.6
39.4 36 36.1 36.7 36.2 36.3 36.5
39.9 36.7 35.6 36.5 37 37
39.5 35.6 35.9 36.7 36.5 36.7 36.1
36 35.8 36.5 36.5 37
39 38.3 37.1 36.5 36.7 36.2
39.9 37.8 37.6 37.9 36.9 36.8
39.2 40.1 36.4 36.5 36.6 36.5
38.8 36.8 37.1 36.5 36.8 36.3
40.3 38.8 36.6 37 36.7 36.7
39.4 36 36.1 36.6 36.8 36.2 36.9
39.2 36.5 36.5 36.8 36.4 36
37.9 37.5 37.4 36.6 36.6 36.5
37.8 36.3 36.2 37.8 36.7 36.2
37 36 37.3 36.6 37
36.8 36.4 36.8 36.5 36.8 36.8 37.3
38 36.5 37 36.3 36.8 36.2
36.8 37 36.8 36.6 36.7 36.4 36
37 36.1 36 36.2 37.2
36 36 36 36.2 36.8
37.8 36.5 36.8 38 36.8 36.6
36.5 36 36.5 36.5 37 37
36 36.5 37 37 37.4 36.5
36.2 37 36.6 37.2 36.5 36.5 37
36.9 36.8 36.8 37.5 36.5 36.7
37.8 36.2 37 37 36 36 36.7
37.2 37 37 36.5 36.8 36.2 36
37 37 37.2 37.1 36.8 36.5
37 37.8 37.6 36.8 36.2 36.8
36.8 36.5 36 36 36 36.5
37.4 36.3 37 36.5 36.8 36.8 36.8
36.5 37.2 36 36 36 36
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Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
37 37 36.2 36 37 36
37 36 36.4 36.2 36
38 36 36.4 36.8 36.2 36.8
36.4 36 36 36 36.8 37.1
36.6 36.8 37.3 37.1 37.4 37 36.5
37 36.3 36.8 36.2 37 36.6
37.1 37 36.6 37 36.5
37.1 36.3 36.5 36 36.8 36.6
36.4 36 36.4 36.4 37 36.5 36.8
37 37.3 36.8 37 36.2 36.8
38 36.5 36 36.7 36.4 36.2
36.4 37.2 36.5 36 36.5
37.3 37 36.6 39.8 36 36 36
39 36.2 36.3 36.4 36.8 36.8
36.1 36.5 36.1 37 36 36.6 36.6
36.8 37.1 37.1 37 36 36.2 36.4
36.6 36.6 36.2 36.1 36.5 36.2
36.2 36.6 36.5 36 37.1 36.8
38.4 37 37 36.8 36 36.2
36.6 37 36.4 36.5 37.1 36.4
36 37 36.8 36.6 36.7 35.8
36.4 37.1 37.1 37.1 36.5 36.8 37.4
37.4 37.3 36.5 36.5 36.8 36.4
36.4 37 36.7 37.2 37 36.2
38 36 36.7 36.1 36.2 36.5
37.1 37.5 37.4 36.5 36.6 36.5
37 37.2 36.8 37 36.9 37.1
37 35.5 36.5 36.4 36.7 36.8
37.6 36.6 36 37 37 37 36.6
37.1 35 37.3 37.6 36.5 36.7
37 37 36.5 36.8 36.4 37
37.2 37.4 36.8 37 36.8 37
37.1 37 36 36.8 37.1 36.6 36.5
37.8 37 38 36 37
37.4 37.2 37.3 37 36.7 36.5
37.4 37.2 37.2 37 37 36.8
38 36.4 37 37 37
37 37.3 36.5 37 37 36.5
37 36.6 36.2
38.4 37.3 37.3 37 37 36.8
37 35.8 37 36 35.8
37.2 37.1 36.3 36.5 36.6 36.8
37 36.8 36.3 36 36.7 36.2 36.9
37.3 37 38 37 36.8 37 36.3
38.8 36.6 36 36 36.5 36.3
37.1 37 36.2 36.8 36.6 36.2
37.5 36.5 37 36.2 36.6 36
36 36.5 36 36.2 37.2 36.6
38.8 36.8 36.2 36.8 36.8 36.2
37 36.5 37 36.5 37.2 36.5
38.2 36 36.6 36.8 36.5 36.5
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Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
36.5 36.7 36.8 37 37.3 37 35.5
36.9 37 36.4 36.1 37 36.8 37.2
37.6 36.5 36.5 37 35.8 36.5
36.2 36.3 36.5 36.5 36.5 36.3
37 36 36.8 36.1 36.5 36.3 36.5
37.3 36.8 37.2 36.8 37 37.7
36.7 36.5 36.6 36.5 36.5 36.7
36.8 36.7 37 36 36.8 36.6
38.2 37 36.3 36.2 36.4 36.9
38.2 36.2 37 36.4 37 36.2
36.5 36.4 36.5 36.8 36.4 36.3
36.8 37 37.3 36.8 36.5 36.2
37 36.5 36 36 36.5 36.8
37.2 36.1 36 36.8 36.4 36.5 36.6
37 36.7 36.5 36.6 36.5 36.4 36.5
36.8 36 36.2 36.6 36.8 36.5
38 38.5 35.4 36 36.9 36.3
39.4 36.6 36.6 36.8 36.8 36.7
40 36.5 37 35.6 37 37
38.3 37 37.8 36.7 37 37.3 37
38.2 36.4 36.3 36.3 36.8 37.6
37.6 36.4 36.4 36 37 36.6
36.8 36.8 36 36 36.4 36.8
38 37 36.6 36 36.4 36.7
37.3 36 36.4 36.4 37.6 36.4
36 36 36.2 36.6 36.4 36.6 36.4
38.2 36.4 36.4 36.4 36.2 36.6
37.4 36.2 36.2 36 36.2 36.4 36.5
37 36.2 36.4 36.8 36.8 36.4
36 36.2 36.2 36.3 36.2 36.8
37.2 36.2 36.7 37 36.2 36.6 36.5
37.8 36 36.4 36.4 36.8 36
37 37 36.4 36 36.8 36.4
36.6 36.6 36.8 36.2 36 36.6 36.6
39 36.2 36.6 36.4 36.4 36.8 36.8
38 36.2 36.2 36 36 36
36.6 38.4 36.2 36.2 36.2 36.4 35.6
36.8 36.6 36.4
38 36.6 37 36.8 37 37.4
37.6 36.2 36.2 36.4 36.5 36.4
37 36 36.4 36.4 36.8 36.2 36.5
36.4 36.7 36.4 36.4 37 36.5
37 36.4 36.6 36.4 36 36
36.6 36.6 36.2 36.4 36.6 36.8
36.8 36 36 36.4 36.6 36.6 36.5
36.8 36.4 36.2 36.6 36 36.8 36.4
39 36.6 36.4 37 36.6 36.6
36.4 37 36.8 36.4 36.8 36.8
35.8 36.6 36.4 36.4 36.8 36.8
37 37.2 36.8 36.6 36.6 36 36.4
37.4 36.4 36.4 36 36.8 36.8
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Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
37 37 36.2 37.2 36.4 36.4
37 36.6 36.4 36.4 36.8
36.2 36.4 36.4 36.6 36.2 36.4 37.2
39.4 36.4 36.4 36.2 36.4 36.4
37.8 36 36.4 36 36.4 36.6
37.8 36.6 36.6 36.4 37 36.2 36.2
38 36.2 36.8 36.8 36.8 36.6 36.6
36.8 36.2 36.8 37 36.4 36
37.8 36.6 36.8 36.4 35.6 36.3
38.6 36.8 36.6 36.6 36.6 36.8
36.7 36.6 37 36.4 36.6 37.2
37.5 36.6 36.4 37 36.6 36.6
37 36.3 37.2 36.6 36.4 36.2 37
36.8 36.2 36.2 36.4 36.2 36.4
36 36.4 36.4 36 36.4 36.2
39.4 36.8 37.1 36.6 37.1
39.4 38.4 35.7 36.4
39.2 38.4 36.7 36.6
39.9 36.6 36.8 36.2 36.8
39.3 39.7 39.2 36.1
39.9 37.8 36.9 36.1 36.8 37.1
39.9 36.7 36.8 36.7
39.8 39.1 37.5 37.5 38.1
38.6 35.8 36.4 37 36.5
38.1 36.2 36.1 36.4
37.2 37.9 35
39.3 36.3 34.8 36.8 37.2 37.3
39.6 36.2 36.1 36.8 36.8
38.3 37.8 35.9 36.7 34.1 36
39.4 36.3 36.6 36.8 37.3 37
36.6 36.7 36.7 35.8
38.2 36.1 37.7 36.4 39.3
38.1 36.4 36.6 36.9 36.7
39.7 37.7 38.5 37.1 36.9 36.5
40.1 37.1 37 36.6 36.5
38.4 38.4 37.8 37.2
37.1 36.4 36.8 36.8 36.7 36.5
40.2 36.8 37 36.7
37.8 36.8 36.2 36.1 37
38.7 38.1 36.9 37.8
38.1 38.2 37.3 37.6 38
39.1 36.5 36.6 38.8 36.7 37.5
38.6 36.2 36.9 37 36.9
38.9 35.5 36.9 36.8 36.8 36.7
36.5 36.4 37 36.7 36.6 36.7
37.5 36.4 37.1 37 37.2
37.9 35.8 36.2 35 36.1
38.6 37.4 36.2 36.9 37.9
36.7 39.4
39.6 37.7 37.4 37.3 36.1
38.5 36.6 37.1 36.4 36.4
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Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
39.4 36.3 36.3 38.8 36.7 37.1
37.7 36.9 37 36.8 36.7 37.1 37.1
37.6 36.1 36.7 36.6 37 36.7
36.7 35.9 37.8 36.9 36.5
38.1 38.1 36.6 36.8
36.6 36.9 36.7 36.9 36.9
38.8 36.2 37.3 36.3 36.6 37.4
38.1 36 36 36.6 36
40.4 36.4 37.1 36.2 36.2 37.2
39.8 36.2 36.2 36.7 36.7 36.9
39.5 36.8 36.5 36.1 35.9
38.1 37.1 36.8 36.5 36.9 36.5
38.8 36.7 36.7 36.4 37
38.2 36.5 36.7 36.7 36.9
40.6 35.9 36.8 37 36.9
39.6 36.2 36.5 36.8 36.7
40 37.5 37.5 37
36.5 36.6 37.2 36.8
39.3 36.9 36.9 36.9 36.7 36.7
38.1 35.8 37 36.4 36.7 36.7
39.8 34.7 36 37 36.9 37.3
39.3 39.4 36 36.7
40.2 36.6 36.6 35.5
39.9 36.8 37.2 37.3 36.7
36.5 37.3 36.8 36.6 36.8
37.3 39.3 38 37.7
38.4 37 36.6 36.4 36.5 37.2
38.7 37 36.5 36.9 36.6 36.7
38.4 36.5 36.7 36.7 36.7 36.2
34.9 36.7 36.9 35.6 36.5
37.3 38.6 37.2 35.5
38.2 36.8 38 36.7 37 37.3
38.4 39.4 37.5 36.9 39.4
40.2 36.9 36.9 36.3 36.7 37.1
38.9 37.1 36.7 37.1
37.1 36.1 35.9 36.7
37.7 37.2 36.9 36.8 37 36.8
37.8 37 37 36.7 36.7
37.4 37.1 36.8 37.3 36.8
39.7 36.6 37 37 36.4 36.9
38.2 36.3 36.7 36.9 37.5
37.9 36.5 36.9 36.5
38.1 36.6 37.1 37.2 37.2
37.7 36.6 36.6 36.2 35.8
38.6 37.6 37.4 36.7 36.9
38.8 37.2 36.8 37.2 37.5
37.9 36.8 36.7 36.1 36.1 36.2
39.8 39.2 36 37.2
37.8 36.7 38 36.8 38
39.8 36.7 36.9 36.9 36.7
39.4 37.2 36.9 37.4 37.2 37.6
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Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
40.3 38.5 37.2 36.9
37 37.2 36.8 36.6 36.5
39.1 36.9 36.5 36.8 37.2 36.7
39 36.5 36 36.2 36.2
39.1 37.6 36.4 36 35.6 35.6
36.8 36 36 37 36.1 36.4
38.5 35.5 35.6 36 35.7 37
36.7 35.7 35.8 36 36.2 36 36.5
37.4 36 35.5 36.2 36.3 36.2 37
38.8 37.5 36.1 36.5 37.2
38.8 37.2 36 36.1 36.2 36.6
36 36.1 36 35.7 35.6 36.5 35.2
39 35.7 35.8 35.9 36 36.2
37 36.7 36.4 35.8 36.5 36 35.5
38 36.1 36.2 36 35.9 36.5
39.2 35.6 35.7 36 35.7 36.7
37.5 37.7 37.5 35.5 36.9 36.4 36.8
36.4 36.5 36 35.8 35 36.5
38.5 35.5 36 36.7 35.5 36.4
38 38.5 35.5 35.8 35.5 37.5
38.5 35.4 36 36.5 36.5 36.4 36.8
39 35.2 35.2
39.4 36.5 36.4 36.7 36.4 36 35.7
37.6 35.6 36.1 36 35.9 37 36
39 36.3 36.4 36.1 36.5 36.5
39 36 35.9 36 35.6
39 36.4 36.8 37.4
38.7 36.4 36.2 35.5 36.6 35.4 36
38.8 36.5 36.2 36.3 35.6
38.3 36 36.2 36.1 35.7
37.8 36.2 36.1 36.5 36.3 35.6 36.5
38.4 38.3 36.3 36.6 37 36
38.2 38.4 35.5 36.7 36.5
38.6 38.6 36.6 36.8 36.2 36.6
37.9 37.4
38.1 36.5 35.3 35.8 36.6 37
38.5 36.4 35 35.8 36 37 36.7
36.3 36.1 35.3 36.1 36.5 36
39.9 35.5 36.1 36 36.1 35.8
38.5 37.1 36 36.5 37.2
38.1 35.8 35.6 35.9 36.4
38.5 37.6 36.6 35.8 35.9 36.5 36.3
36.1 37.2 36 36 36.4 35.7
37.1 36.1 36 36 35.8 36.2
38.6 36.1 36.8 37.3 35.7 35.8 36
37.2 36.2 36.5 36.2 36 36.6
38.4 36 36 37 37.1 36
38.3 36.7 36 36.5 37.3 36.4 36.1
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Appendix 31: Individual Systolic and Diastolic Blood Pressure Listing
Centre Patient Treatment Systolic Blood Pressure (mmHg)
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
11 1 PM 100 100 100 100 100 110
11 2 Combination 100 100 100 100 120 110
11 3 Combination 100 100 100 110 110 120
11 4 PM 110 110 100 120 90 120
11 5 PM 100 120 120 125 100 120
11 6 Combination 100 100 110 100 100 100
11 7 PM 100 110 100 100 90 120
11 8 SSG 100 100 100 110 80 100 100
11 9 SSG 120 100 110 100 110 100 110
11 10 SSG 100 90 100 90 90 100 100
11 11 Combination 110 100 100 105 105 100
11 12 Combination 120 120 100 100 100 100
11 13 SSG 100 105 80 80 80 100 90
11 14 SSG 100 95 100 100 100 100 90
11 15 PM 120 110 100 110
11 16 Combination 100 90 90 90 110 100
11 17 Combination 90 80 90 110 100 100
11 18 SSG 100 100 100 100 100 90 90
11 19 Combination 100 100 110 100 100 110
11 20 SSG 80 90 90 90 90 110 90
11 21 SSG 120 110 120 90 120 120 100
11 22 SSG 100 100 90 100 90 100 80
11 23 PM 90 80 90 90 100 100
11 24 PM 90 100 90 100 100 100
11 25 SSG 100 80 80 90 90 100 100
11 26 Combination 110 100 110 100 100 100
11 27 PM 100 100 100 100 80
11 28 Combination 110 90 90 90 90 100
11 29 PM 110 90 90 110 100 90
11 30 PM 110 90 80 100 100 100
11 31 SSG 100 100 80 90 100 100 80
11 32 Combination 100 90 100 90 110 100
11 33 SSG 110 120 120 110 120 120 120
11 34 PM 110 110 100 100 110 110
11 35 SSG 100 110 90 110 110 100 90
11 36 SSG 100 110 100 100 110 110 120
11 37 Combination 110 110 120 100 140 140
11 38 PM 120 100 110 100 90 80
11 39 PM 100 100 110 110 90 100
11 40 PM 100 100 110 110 100
11 41 Combination 100 100 110 100 100 100
11 42 Combination 110 100 120 120 100 110
11 43 SSG 100 100 100 100 100 100 100
11 44 PM 100 100 100 100 100 90
11 45 Combination 100 110 100 100 100 90
11 46 SSG 100 100 90 100 100 110 90
11 47 SSG 100 80 90 90 100
11 48 Combination 100 90 80 90 100
11 49 SSG 100 80 90 90 90 90 100
11 50 PM 100 100 100 100 100 100
11 51 Combination 110 90 120 100 100 100
11 52 PM 100 90 100 110 90 100
11 53 SSG 100 90 100 100 110 100 100
11 54 PM 80 90 80 90 90 100
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Appendix 31: Individual Systolic and Diastolic Blood Pressure Listing
Centre Patient Treatment Systolic Blood Pressure (mmHg)
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
11 55 PM 90 100 90 90 100 110
11 56 SSG 110 90 100 100 100 100 90
11 57 Combination 100 80 90 110 100 110
11 58 Combination 100 110 100 100 90 100
11 59 PM 110 100 110 140 140 110
11 60 Combination 100 90 100 90 100 100
11 61 PM 100 100 90 100 100 110
11 62 SSG 100 90 110 100 110 100 110
11 63 SSG 100 100 100 90 100 110 120
11 64 SSG 80 80 90 80 80 100 100
11 65 PM 90 100 100 90
11 66 Combination 100 100 80 80 80 90
11 67 PM 110 100 90 100 110 100
11 68 SSG 100 90 90 100 100 90 80
11 69 Combination 90 80 100 100 110 110
11 70 Combination 110 90 100 110 120 100
11 71 Combination 80 90 90 90 100 90
11 72 SSG 110 100 110 110 120
11 73 PM 90 100 100 110 100 120
11 74 PM 90 90 100 100 100 100
11 75 Combination 100 100 110 120 110 110
11 76 PM 80 90 110 90 110 100
11 77 PM 100 80 80 100 100 100
11 78 SSG 80 100 100 110 100 100 100
11 79 PM 100 100 90 80 90 100
11 80 PM 100 100 100 90 90 90
11 81 Combination 100 100 100 110 110 90
11 82 SSG 90 100 110 100 100 100 100
11 83 SSG 90 100 90 100 100 90 110
11 84 SSG 80 90 90 100 100 100 100
11 85 SSG 90 90 90 100 100 90
11 86 Combination 70 80 80 90 90 100
11 87 Combination 80 80 80 100 90 120
11 88 PM 110 100 90 100 110 100
11 89 Combination 110 110 100 100 120 120
11 90 Combination 90 70 90 80
11 91 PM 100 100 90 100 100 100
11 92 Combination 80 90 90 100 90 90
11 93 SSG 90 80 100 100 110 90 120
11 94 SSG 100 80 90 100 100 100 100
11 95 SSG 90 100 90 90 100 80 80
11 96 Combination 110 90 100 110 110 100
11 97 Combination 90 80 110 100 110 100
11 98 PM 90 100 80 90 90 80
11 99 SSG 90 80 100 90 90 80 80
11 100 PM 80 80 90 100
11 101 PM 100 100 120 110 100 100
11 102 Combination 90 80 90 100 100 80
11 103 Combination 100 100 100 120 110 100
11 104 PM 110 120 100 110 100 100
11 105 SSG 100 100 100 100 100 90 100
11 106 Combination 100 100 110 90 120 110
11 107 PM 100 110 100 100 90 100
11 108 PM 100 100 80 100 100 100
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Appendix 31: Individual Systolic and Diastolic Blood Pressure Listing
Centre Patient Treatment Systolic Blood Pressure (mmHg)
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
11 109 SSG 100 110 110 90 100 120 100
11 110 PM 90 70 90 80 80 80
11 111 Combination 80 100 80 100 110 110
11 112 Combination 80 90 80 110 100 80
11 113 SSG 90 90 90 100 100 100
11 114 SSG 110 100 110 100 120 110 100
11 115 Combination 100 100 110 110 130 110
11 116 SSG 100 90 100 100 100 100 110
11 117 PM 120 120 100 110 120
11 118 PM 100 100 110 120 100 110
11 119 SSG 100 100 110 100 100 110 100
11 120 Combination 120 100 120 110 100 110
11 121 Combination 100 90 90 100 80 90
11 122 SSG 90 70 90 90 80
11 123 SSG 90 90 100 100 110 100 100
11 124 SSG 100 100 100 100 90 100
11 125 SSG 100 90 90 100 120 110 110
11 126 Combination 90 90 90 100 90
11 127 PM 100 80 100 100 100 100
11 128 Combination 100 90 90 80 100 100
11 129 PM 100 100 90 100 100 110
11 130 Combination 90 80 90 100 100 110
11 131 PM 90 90 80 90 90 100
11 132 SSG 90 100 110 90 100 100 100
11 133 Combination 100 100 100 100 110 100
11 134 PM 100 100 100 110 110 100
11 135 PM 100 90 100 100 100 100
12 241 Combination 100 100 110 100 120
12 242 SSG 90 90 90 80 90 90 90
12 243 PM 90 80 90 90 100 90
12 244 SSG 100 100 100 100 120 120 120
12 245 PM 100 90 90 110 100
12 246 PM 100 110 110 120 120
12 247 PM 100 90 100 100 100 90
12 248 PM 110 90 100 100 120 110
12 249 Combination 90 90 80 90 100 90
12 250 SSG 90 90 90 90 100 110 100
12 251 Combination 120 110 100 100 100 90
12 252 SSG 100 100 100 110 110 110 110
12 253 SSG 100 90 100 90 100 100 100
12 254 Combination 80 80 80 80 80 90
12 255 Combination 110 100 100 120 110 100
12 256 Combination 80 90 100 100 110 110
12 257 SSG 90 100 100 100 100 100 100
12 258 SSG 80 90 90 90 100 100
12 259 PM 120 100 100 100 110 110
12 260 PM 120 100 100 110 110
12 261 Combination 100 100 100 90 110 110
12 262 PM 100 100 90 90 90 80
12 263 SSG 100 90 100 100 100 100 100
12 264 Combination 90 100 100 100 90 90
12 265 SSG 80 90 80 90 70
12 266 PM 100 100 105 120 110 100
12 267 SSG 90 90 90 90 90 110 100
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Appendix 31: Individual Systolic and Diastolic Blood Pressure Listing
Centre Patient Treatment Systolic Blood Pressure (mmHg)
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
12 268 PM 100 100 110 110 100 110
12 269 Combination 90 100 100 110 120 110
12 270 Combination 100 90 80 80 90
12 271 SSG 100 105 110 110 90 110 110
12 272 PM 90 80 90 90 90 80
12 273 SSG 90 80 80 90 90 90 100
12 274 SSG 90 80 80 100 90 90 90
12 275 Combination 90 100 90 90 90 100
12 276 PM 90 90 90 100 90 90
12 277 Combination 100 100 100 100 110 110
12 278 SSG 90 90 100 100 100 110
12 279 PM 80 80 90 90 110 100
12 280 SSG 70 80 80 90 90 80 90
12 281 Combination 100 100 100 100 100 100
12 282 PM 70 90 90 90 90 90
12 283 PM 110 90 100 100 100 110
12 284 Combination 70 70 80 80 80 80
12 285 Combination 90 90 100 100 100 100
12 286 PM 100 90 100 90 90 90
12 287 SSG 110 100 100 100 90 100 100
12 288 Combination 100 100 100 90 90 90
12 289 Combination 120 110 120 120 100 130
12 290 SSG 100 90 80 90 90 90
12 291 SSG 100 90 110 100 100 100 100
12 292 PM 80 70 80 90 120
12 293 SSG 90 80 100 100 100 90
12 294 Combination 80 80 90 90 90 90
12 295 Combination 80 80 100 80 90
12 296 PM 100 90 90 90 90 100
12 297 SSG 90 100 90
12 298 PM 100 90 100 90 100 110
12 299 Combination 90 80 90 100 90
12 300 PM 100 100 100 100 110 100
12 301 SSG 100 110 100 100 100 110 110
12 302 SSG 80 80 70 80 80 90 80
12 303 PM 120 110 100 110 120 130
12 304 Combination 90 100 100 80 100 100
12 305 PM 70 70 70 60 80 70
12 306 Combination 80 80 80 80 80 80
12 307 Combination 100 100 110 110 100 120
12 308 PM 120 90 90 90 120 110
12 309 PM 100 90 100 100 100 110
12 310 SSG 100 90 90 90 90 90 100
12 311 SSG 70 80 80 90 80 90 80
12 312 Combination 100 90 90 90 100 110
12 313 PM 100 100 90 100 100 100
12 314 SSG 90 100 90 100 90 120 110
12 315 Combination 80 90 100 100 90 100
12 316 SSG 110 120 100 100 100 90
12 317 SSG 60 80 90 90 90 70
12 318 Combination 100 80 100 80 100 80
12 319 Combination 100 90 90 100 100 80
12 320 Combination 80 80 80 80 100 80
12 321 Combination 90 90 100 90 90 80
LEAP 0104a Appendices
Page 397 of 756
Appendix 31: Individual Systolic and Diastolic Blood Pressure Listing
Centre Patient Treatment Systolic Blood Pressure (mmHg)
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
12 322 PM 100 90 90 90 100 100
12 323 SSG 110 100 100 100 110 110 110
12 324 SSG 100 100 100 110 100 120 120
12 325 PM 110 90 100 120 100 100
12 326 PM 90 100 100 100 120 120
12 327 Combination 100 100 100 90 90 90
12 328 PM 100 100 100 100 100 100
12 329 SSG 90 90 90 100 90 90 80
12 330 PM 100 90 100 100 100 60
23 361 Combination 90 100 100 90 100 100
23 362 PM 110 110 100 120 110 100
23 363 PM 100 100 100 90 100 100
23 364 Combination 110 110 90 110 100 100
23 365 SSG 110 100 120 110 110 110 100
23 366 Combination 90 100 100 100 100 100
23 367 SSG 90 120 110 110 120 110 100
23 368 PM 100 100 100 100 120 100
23 369 Combination 90 100 100 100 80 90
23 370 SSG 90 90 100 100 90 90 80
23 371 PM 100 100 110 110 100 90
23 372 PM 110 120 110 120 100 120
23 373 SSG 110 110 100 100 110 110 100
23 374 SSG 110 90 100 100 100 110 100
23 375 Combination 100 100 100 100 100 100
23 376 SSG 110 100 100 100 100 100 90
23 377 Combination 100 110 100
23 378 Combination 90 90 100 90 90 100
23 379 PM 100 90 90 100 90 100
23 380 SSG 90 90 100 90 90 90 90
23 381 PM 90 100 100 100 100 100
23 382 Combination 100 100 100 100 90 100
23 383 PM 110 110 100 110 110 100
23 384 SSG 100 100 100 100 100 100 100
23 385 SSG 120 100 100 100 100 90 100
23 386 Combination 110 110 100 90 100 110
23 387 Combination 100 90 100 100 100 100
23 388 PM 90 90 100 110 100 90
23 389 SSG 100 100 100 100 100 90 110
23 390 PM 100 110 110 110 110 110
23 391 Combination 90 100 100 100 110 100
23 392 Combination 90 90 100 90 100
23 393 SSG 100 100 100 90 100 100 100
23 394 PM 100 100 100 100 100 100
23 395 PM 120 110 110 110 105 120
23 396 SSG 110 100 110 110 100 110 100
23 397 SSG 100 100 110 90 110 100 100
23 398 Combination 90 90 90 90 90 90
23 399 PM 90 90 90 100 100 100
23 400 PM 100 90 90 90 100 90
23 401 Combination 100 110 110 110 110 110
23 402 Combination 100 110 100 110 100 100
23 403 SSG 100 100 110 110 100 110 120
23 404 SSG 100 100 110 110 110 110
23 405 PM 100 100 100 100 100 100
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Appendix 31: Individual Systolic and Diastolic Blood Pressure Listing
Centre Patient Treatment Systolic Blood Pressure (mmHg)
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
34 451 Combination 100 100 110 110 110
34 452 PM 100 100 120 120
34 453 PM 105 110 110 110
34 454 Combination 90 90 90 90 90
34 455 PM 110 120 110 90
34 456 SSG 95 95 95 110 120 90
34 457 Combination 120 120 120 120
34 458 PM 100 110 110 110 110
34 459 Combination 100 110 110 100 100 100
34 460 PM 110 120 110 110
34 461 SSG 100 130 130
34 462 SSG 90 90 85 90 90 90
34 463 Combination 90 90 90 90 90
34 464 SSG 120 120 120 120 120 120
34 465 SSG 110 120 120 120 120 120
34 466 Combination 90 90 90 90
34 467 PM 90 100 110 120 100
34 468 Combination 120 120 120 120 110
34 469 SSG 110 100 110 100 110 110
34 470 Combination 105 120 120 120 100
34 471 PM 120 120 110 120
34 472 SSG 100 100 100 100 80 90
34 473 PM 95 90 80 80
34 474 Combination 100 100 100 110 100
34 475 PM 110 100 100 110
34 476 PM 110 110 110 120 100
34 477 SSG 110 100 100 110 100 110
34 478 Combination 90 90 100 110 80
34 479 SSG 90 90 100 90 80 80
34 480 SSG 100 100 110 110 110 110
34 481 Combination 100 100 110 120 110
34 482 Combination 120 120 120 120 110
34 483 PM 120 120 110 120 120
34 484 PM 90 90
34 485 Combination 100 80 110 100 90
34 486 Combination 110 110 120 110 110
34 487 SSG 110 120 120 120 120 110
34 488 SSG 110 100 95 90 90 90 100
34 489 SSG 110 100 80 80 90 110
34 490 PM 100 100 85 90 110
34 491 PM 100 90 100 110
34 492 PM 100 110 110 120 120
34 493 SSG 100 100 100 90 95 90
34 494 Combination 110 120 120 120 120
34 495 SSG 100 100 90 85 85 90
34 496 SSG 120 110 110 120 120 110
34 497 PM 100 100 100 100 100
34 498 SSG 90 100 100 110 110 100
34 499 Combination 80 80 90 90 100
34 500 PM 100 110 100 100 110
34 501 Combination 100 80 90 90 90
34 502 Combination 110 110 100 110 110
34 503 PM 120 80 90 90
34 504 Combination 100 100 100 100
LEAP 0104a Appendices
Page 399 of 756
Appendix 31: Individual Systolic and Diastolic Blood Pressure Listing
Centre Patient Treatment Systolic Blood Pressure (mmHg)
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
34 505 SSG 120 120 120 120 120 120
34 506 SSG 80 80 80 90 90 90
34 507 SSG 100 90 90 100 100 100
34 508 PM 85 90 90 100
34 509 PM 120 120 120 120
34 510 Combination 90 90 90 90 90
34 511 Combination 80 90 90 90 90
34 512 PM 80 90 90 90
34 513 Combination 100 100 100 90 90 100
34 514 SSG 90 90 90 90 90 110
34 515 SSG 90 90 90 90 90 90
34 516 PM 120 120 120 110 110
34 517 PM 90 90 100 90
34 518 SSG 100 90 90 90 90 90
34 519 PM 100 95 90 80 90
34 520 SSG 120 120 110 120 110 120
34 521 PM 90 80 80 80
34 522 Combination 110 120 120 120
34 523 SSG 90 90 90 90 90 100
34 524 Combination 110 110 110 110 100
34 525 Combination 100 110 100 110 100
34 526 SSG 100 90 90 80 80 80
34 527 Combination 110 110 110 110 120
34 528 PM 90 90 90 90
34 529 Combination 80 80 80 80 80
34 530 Combination 110 110 110 110 110
34 531 SSG 90 90 85 90 90
34 532 Combination 90 100 90 100 100
34 533 SSG 100 90 100 100 90 100
34 534 PM 90 80 70 70
34 535 PM 100 100 90 100 100
34 536 PM 90 80 80 70 85
34 537 SSG 90 90 80 80 90 100
34 538 PM 100 100 90 80
34 539 Combination 90 90 90 90 90
34 540 SSG 100 110 100 100 110 120
35 646 PM 105 105 100 100 110
35 647 PM 100 100 110 120 110 120
35 648 Combination 80 75 80 80 80 95
35 649 Combination 100 105 95 100 100 100
35 650 SSG 90 90 80 80 80 90 100
35 651 SSG 95 90 90 90 90 80 95
35 652 PM 90 95 90 90 90
35 653 Combination 90 80 90 90 100 90
35 654 SSG 80 80 80 85 85 90 90
35 655 Combination 100 90 95 110 100 100
35 656 SSG 80 80 75 95 90 110 100
35 657 PM 100 90 100 100 90 100
35 658 Combination 90 100 100 110 110 110
35 659 SSG 70 60 90 90 90 90 90
35 660 PM 110 110 110 120 120 120
35 661 Combination 110 110 120 120 110 120
35 662 PM 110 100 115 120 120 110
35 663 SSG 120 110 130 110 120 120 120
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Appendix 31: Individual Systolic and Diastolic Blood Pressure Listing
Centre Patient Treatment Systolic Blood Pressure (mmHg)
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
35 664 Combination 130 100 120
35 665 SSG 100 100 110 110 100 100 100
35 666 SSG 110 110 110 100 110 100 100
35 667 Combination 90 100 110 110 110 100
35 668 PM 105 100 100 90 110
35 669 PM 90 100 80 100
35 670 SSG 85 80 80 80 95 110 110
35 671 PM 80 85 85 80 90
35 672 Combination 90 80 85 90 100
35 673 SSG 100 110 115 110 110 105 100
35 674 Combination 80 80 80 90 90 90
35 675 PM 110 110 105 100 90
35 676 PM 100 100 80 90 80 80
35 677 SSG 110 125
35 678 Combination 110 120 120 110 110 105
35 679 SSG 95 90 90 90 110 120 120
35 680 Combination 90 80 90 80 90 95
35 681 Combination 100 100 100 100 110 110
35 682 PM 80 80 90 90 100
35 683 Combination 100 120 110 110 100
35 684 SSG 120 110 110 110 120 120 120
35 685 PM 90 100 100 110 110 100
35 686 PM 120 110 110 110 120 120
35 687 SSG 105 100 105 100 100 110 120
35 688 PM 120 110 100 100 105 110
35 689 Combination 90 100 105 110 110 110
35 690 SSG 80 90 90 100 100 100 100
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Diastolic Blood Pressure (mmHg)
Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
80 70 70 70 60 70
80 70 70 80 80 70
70 70 70 80 80 80
60 60 70 70 60 60
80 70 70 70 70 80
60 60 60 60 70 60
70 70 70 60 60 60
70 70 60 70 60 60 60
80 70 80 60 80 70 80
70 50 60 60 60 60 60
80 70 70 65 65 70
70 70 60 60 70 70
70 65 50 50 60 70 60
80 60 70 70 60 60 60
70 70 70 70
70 60 60 60 70 60
60 60 70 70 70 60
80 70 70 70 70 50 60
60 60 70 60 70 70
60 60 60 60 60 80 70
60 80 80 60 80 80 80
70 70 60 70 50 60 60
60 70 60 70 70 70
60 70 70 70 60 70
70 60 60 60 60 60 60
80 60 70 60 70 80
70 70 80 70 40
70 60 60 60 60 60
60 70 60 70 60 70
70 50 60 60 60 60
60 70 70 70 70 60 80
60 60 70 60 80 60
80 70 80 80 80 80 80
70 70 60 60 70 60
60 70 60 60 70 60 60
60 70 60 60 60 70 80
80 80 80 90 100 100
80 70 60 60 50 60
70 70 60 70 60 60
80 70 70 80 70
70 60 70 60 60 70
70 70 80 70 70 70
70 70 70 70 70 70 60
70 60 70 60 60 80
60 80 60 70 70 70
80 70 50 60 70 70 60
70 50 50 60 60
70 60 50 50 70
50 50 60 50 60 70 60
70 60 70 70 70 60
60 60 80 50 60 70
70 60 70 70 70 70
60 50 60 60 70 60 60
60 50 60 50 50 60
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Diastolic Blood Pressure (mmHg)
Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
60 50 60 50 70 60
70 50 60 70 60 70 60
60 50 50 70 60 60
70 70 50 60 60 60
70 50 70 100 70 70
60 50 60 60 60 60
60 50 60 60 70 70
70 50 70 70 70 60 70
60 60 60 60 60 70 70
60 50 60 60 60 60 70
60 60 60 60
70 60 40 50 60 60
70 70 60 80 80 70
60 50 50 60 70 70 60
60 60 70 60 70 70
70 60 70 70 70 70
50 70 70 70 60 50
70 70 80 70 80
50 60 60 70 60 80
60 60 60 70 70 60
60 60 70 80 60 60
40 60 70 60 80 70
60 60 60 70 70 60
40 60 60 70 70 60 70
70 60 60 60 50 60
60 60 60 70 60 60
70 70 90 80 70 70
50 60 75 60 60 70 60
50 60 60 60 70 70 70
50 60 60 60 60 70 60
70 60 60 70 70 60
50 60 60 60 60 60
60 60 60 60 60 80
60 70 60 60 80 70
70 60 60 60 80 80
60 60 70 50
70 60 60 60 70 60
40 50 60 60 60 60
60 60 60 60 70 60 80
60 60 50 70 60 60 60
70 60 60 60 60 60 50
60 60 60 60 60 60
60 60 70 60 80 70
50 60 60 50 70 60
50 60 60 50 60 60 60
60 60 60 60
60 80 80 80 70 80
50 50 50 70 70 60
70 70 60 90 70 80
70 70 60 70 70 70
60 60 70 70 70 60 60
60 50 60 50 70 70
60 60 80 70 60 70
70 60 60 70 60 60
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Diastolic Blood Pressure (mmHg)
Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
60 70 70 60 60 80 60
50 50 50 60 50 60
50 60 60 60 80 70
60 50 60 80 60 60
60 60 50 60 70 60
70 60 80 60 60 70 80
60 80 80 70 80 80
60 60 60 60 70 70 70
60 80 70 70 80
60 70 70 80 60 70
60 60 70 60 60 80 60
60 60 70 60 60 70
60 60 60 70 60 50
50 50 60 60 50
50 60 70 80 70 60 70
60 50 90 70 60 60
60 60 60 60 70 70 80
60 60 50 60 60
60 50 60 60 60 70
60 60 50 50 70 70
70 70 60 70 60 80
60 60 70 60 80 70
60 50 60 60 60 60
60 60 80 60 80 70 60
60 60 70 60 70 60
40 50 70 70 80 60
60 60 60 70 80 70
60 70 80 70 80
60 60 60 60 70 60 60
60 60 70 70 60 60
60 60 60 80 80 70 80
60 60 70 70 70
70 70 70 80 80
60 60 60 70 70 60
60 70 70 70 80 80
60 60 60 60 60 60
60 70 60 60 60 60 60
80 80 70 80 60 60
70 60 70 80 70 70 60
60 60 60 60 80 60 70
50 50 50 50 50 60
80 70 60 80 60 60
60 60 70 70 60 70
60 70 80 80 60 60 60
50 60 60 60 80 60
70 80 60 60 70 70
80 60 60 60 60
70 60 60 60 80 80
60 60 60 60 60 50
70 70 60 60 70 60 60
60 60 70 60 60 60
50 60 50 50 40
70 60 70 70 60 70
70 50 60 60 60 70 60
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Diastolic Blood Pressure (mmHg)
Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
60 60 70 70 70 70
60 60 70 70 70 70
70 50 40 50 60
60 60 60 70 60 80 70
50 50 60 60 50 50
60 60 50 60 70 60 60
60 50 50 60 60 60 60
60 70 60 60 60 60
60 60 60 70 60 65
60 60 70 80 60 80
60 60 70 70 70 70
50 50 60 60 80 70
40 50 50 50 50 40 60
70 70 70 70 60 60
40 60 60 60 50 60
70 70 60 60 70 70
50 50 40 50 50 45
60 60 70 70 70 70
80 60 70 60 60 60
70 80 70 70 60 60 60
70 60 60 60 60 60
70 60 80 80 70 80
80 60 60 60 60 60
60 60 70 60 60 60 70
50 50 50 60 70
60 60 70 60 60 70
50 40 60 50 60 60
50 40 60 60 60
60 60 60 60 60 60
60 70 60
80 70 70 70 70 70
70 60 60 60 70
60 70 60 60 70 60
60 80 70 70 70 80 70
40 50 50 50 50 60 40
80 70 70 70 80 80
60 80 80 70 70 70
30 40 50 50 40 40
50 40 60 50 40 50
80 70 70 70 70 70
80 60 60 60 80 80
70 60 60 60 70 60
70 70 60 60 60 60 70
50 50 60 60 50 60 50
60 60 60 60 60 80
60 60 60 60 70 70
60 60 50 60 60 80 70
40 50 70 70 50 70
60 80 60 60 50 60
30 40 50 60 60 40
60 50 70 50 60 40
60 60 50 60 60 50
50 50 60 50 50 60
60 60 60 60 50 50
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Diastolic Blood Pressure (mmHg)
Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
70 60 70 60 60 60
60 60 60 60 60 60 70
70 60 60 60 60 80 80
60 60 60 80 70 70
50 50 60 60 80 70
70 70 70 60 60 60
70 60 60 80 70 60
50 50 50 60 60 60 50
70 50 70 60 60 30
50 60 60 60 60 60
80 70 60 80 70 60
70 60 60 60 60 60
70 70 60 70 60 60
80 60 60 70 70 70 60
60 60 70 60 70 60
60 70 70 60 80 70 60
60 70 60 60 60 60
50 60 60 60 50 50
60 60 60 60 60 60 50
60 60 70 70 60 50
70 70 70 70 60 70
80 70 60 60 70 60 60
60 60 60 60 60 60 70
60 60 60 60 60 60
60 60 60 60 70 60 60
70 60 60
50 60 60 60 60 70
60 60 60 60 60 50
60 60 60 60 60 60 60
60 60 60 60 60 60
60 60 60 60 60 60
60 70 60 70 70 60
60 60 70 60 60 60 60
70 60 60 60 60 60 60
70 60 60 60 60 70
70 60 60 60 70 70
60 60 50 60 70 60
70 60 70 60 60 50 60
60 70 70 60 70 70
60 60 60 60 60 60
60 50 60 60 60
60 60 60 60 60 60 70
60 70 60 60 60 60
80 60 70 70 70 70
70 60 60 70 60 70 70
60 60 60 60 60 60 60
50 50 60 60 60 70
60 50 50 60 60 60
60 60 60 60 60 50
60 60 70 60 60 70
70 70 70 70 70 70
60 60 60 60 60 70 60
60 60 60 70 60 70
60 60 60 60 70 60
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Diastolic Blood Pressure (mmHg)
Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
60 60 75 70 70
60 65 80 80
60 70 70 70
60 60 60 60 65
60 80 80 60
55 60 60 70 80 60
70 75 80 80
60 75 15 80 70
65 70 65 60 60 70
70 80 70 70
70 80 80
60 70 60 60 70 60
50 60 60 55 70
80 70 80 80 80 80
70 80 80 80 80 80
60 60 60 60
70 70 80 80 60
80 80 80 80 80
80 80 70 80 80 70
70 80 80 80 70
80 70 80 80
60 60 60 60 50 60
60 50 50 60
60 60 60 70 70
70 60 60 80
80 80 80 80 70
60 60 70 70 60 70
60 60 70 70 60
55 60 70 60 60 50
60 70 80 80 70 70
70 70 70 70 70
80 80 80 80 70
80 80 80 80 70
60 60
60 50 70 60 60
70 80 80 80 70
70 70 80 80 80 80
65 80 60 60 60 60 70
70 80 60 60 60 70
65 70 60 60 80
70 70 70 70
70 70 70 70 80
70 70 70 60 60 60
70 80 80 80 70
70 80 60 60 60 60
70 70 70 80 80 80
70 70 70 70 70
70 70 70 70 70 70
60 60 60 60 70
80 80 60 80 70
70 60 60 60 60
70 80 70 70 70
70 60 60 60
80 70 70 70
LEAP 0104a Appendices


























































Diastolic Blood Pressure (mmHg)
Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
80 80 80 80 80 80
60 60 60 60 60 50
60 60 60 60 60 60
60 60 60 60
80 80 80 80
60 60 60 60 60
60 60 60 60 60
60 60 60 60
60 60 60 60 60 60
70 70 70 70 70 75
60 60 60 60 60 60
80 80 80 70 70
70 60 70 60
70 60 60 60 60 60
70 70 60 60 60
80 80 70 80 70 80
60 60 60 60
80 80 80 80
60 60 60 60 60 70
80 70 80 80 70
70 70 70 70 60
60 60 60 60 60 60
70 70 70 70 70
60 60 60 60
60 60 60 60 60
70 70 70 70 70
60 60 60 60 60
60 60 60 65 60
70 60 70 70 60 70
60 50 50 50
70 70 60 70 70
60 60 60 50 60
70 60 60 60 60 70
80 70 60 60
60 60 60 60 60
80 80 70 70 80 70
65 55 60 70 75
50 50 60 80 70 80
50 50 50 50 55 50
60 55 50 60 65 55
60 55 50 50 40 50 50
70 70 65 70 65 60 60
70 65 75 60 65
50 60 50 60 65 50
60 60 60 65 65 60 60
50 50 60 60 60 60
60 65 65 70 65 60 60
70 75 70 70 60 60
60 70 80 80 75 80
50 55 60 55 60 65 60
70 80 80 70 80 75
60 60 70 65 80 70
65 65 75 80 70 70
70 70 80 60 75 85 85
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Diastolic Blood Pressure (mmHg)
Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
80 70 70
80 70 80 70 65 70 60
60 60 80 70 80 70 65
50 70 60 60 70 70
65 70 80 60 70
60 60 60 60
70 60 60 55 60 60 65
50 65 60 60 60
60 60 60 70 70
60 70 70 60 70 70 70
50 50 55 70 65 70
80 70 60 80 60
60 65 65 60 50 50
60 80
70 70 80 70 70 70
60 60 60 60 70 70 65
60 65 70 60 70 70
60 80 80 60 70 75
55 60 70 60 60
70 80 80 80 70
70 70 70 60 80 70 80
70 60 65 70 65 65
80 80 75 80 80 80
65 60 60 70 60 70 80
60 60 60 70 70 70
50 60 60 60 75 80
50 50 50 75 70 70 65
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16.2.6 Compliance and/or drug concentration data  
Appendix 32: Listing of Daily Paromomycin Treatment  
Appendix 33: Listing of Daily SSG Treatment  
Appendix 34: Listing of Daily Combination Treatment (Paromomycin) 
Appendix 35: Listing of Daily Combination Treatment (SSG) 
Appendix 36: Listing of Rescue medication 
Appendix 37: Listing of concomitant medications  
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Appendix 32: Individual listing of Paromomycin total daily dose. 
Centre Patient Paromomycin mg/day (Dose 15mg/kg/day)
Number Number D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17 D18 D19 D20 D21
11 1 720 720 720 720 720 720 720 720 720 720 720 720 765 765 765 765 765 765 765 765 765
11 4 675 675 675 675 675 675 675 735 735 735 735 735 735 735 720 720 720 720 720 720 720
11 5 300 300 300 300 300 300 300 315 315 315 315 315 315 315 330 330 330 330 330 330 330
11 7 705 705 705 705 705 705 705 720 720 720 720 720 720 720 690 690 690 690 690 690 690
11 15 705 705 705 705 705 705 705
11 23 390 390 390 390 390 390 390 375 375 375 375 375 375 375 375 375 375 375 375 375 375
11 24 270 270 270 270 270 270 270 240 240 240 240 240 240 240 240 240 240 240 240 240 240
11 27 690 690 690 690 690 690 690 690 690 690 690 690 690 690 690 690 690 690 690 690 690
11 29 630 630 630 630 630 630 630 630 630 630 630 630 630 630 645 645 645 645 645 645 645
11 30 225 225 225 225 225 225 225 210 210 210 210 210 210 210 225 225 225 225 225 225 225
11 34 735 735 735 735 735 735 735 735 735 735 735 735 735 735 735 735 735 735 735 735 735
11 38 720 720 720 720 720 720 720 720 720 720 720 720 720 720 735 735 735 735 735 735 735
11 39 270 270 270 270 270 270 270 270 270 270 270 270 270 270 270 270 270 270 270 270 270
11 40 240 240 240 240 240 240 240 240 270 270 270 270 270 270 255
11 44 675 675 675 675 675 675 675 690 690 690 690 690 690 690 705 705 705 705 705 705 705
11 50 825 825 825 825 825 825 825 825 825 825 825 825 825 825 840 840 840 840 840 840 840
11 52 360 360 360 360 360 360 360 375 375 375 375 375 375 375 375 375 375 375 375 375 375
11 54 690 690 690 690 690 690 690 705 705 705 705 705 705 705 720 720 720 720 720 720 720
11 55 690 690 690 690 690 690 690 690 690 690 690 690 690 690 720 720 720 720 720 720 720
11 59 345 345 345 345 345 345 345 330 330 330 330 330 330 330 345 345 345 345 345 345 345
11 61 705 705 705 705 705 705 705 720 720 720 720 720 720 720 720 720 720 720 720 720 720
11 65 210 210 210 210 210 210 210 225 225 225 225 225 225 225 225 225 225 225 225 225 225
11 67 330 330 330 330 330 330 330 360 360 360 360 360 360 360 345 345 345 345 345 345 345
11 73 720 720 720 720 720 720 720 720 720 720 720 720 720 720 735 735 735 735 735 735 735
11 74 735 735 735 735 735 735 735 720 720 720 720 720 720 720 735 735 735 735 735 735 735
11 76 675 675 675 675 675 675 675 675 675 675 675 675 675 675 675 675 675 675 675 675 675
11 77 300 300 300 300 300 300 300 300 300 300 300 300 300 300 330 330 330 330 330 330 330
11 79 180 180 180 180 180 180 180 195 195 195 195 195 195 195 195 195 195 195 195 195 195
11 80 330 330 330 330 330 330 330 315 315 315 315 315 315 315 330 330 330 330 330 330 330
11 88 795 795 795 795 795 795 795 780 780 780 780 780 780 780 795 795 795 795 795 795 795
11 91 780 780 780 780 780 780 780 795 795 795 795 795 795 795 795 795 795 795 795 795 795
11 98 525 525 525 525 525 525 525 525 525 525 525 525 525 525 510 510 510 510 510 510 510
11 100 660 660 660 660 660 660 660 675 675 675 675 675 675 675 675 675 675 675 675 675 675
11 101 660 660 660 660 660 660 660 645 645 645 645 645 645 645 645 645 645 645 645 645 645
11 104 450 450 450 450 450 450 450 435 435 435 435 435 435 435 435 435 435 435 435 435 435
11 107 705 705 705 705 705 705 705 720 720 720 720 720 720 720 735 735 735 735 735 735 735
11 108 690 690 690 690 690 690 690 705 705 705 705 705 705 705 720 720 720 720 720 720 720
11 110 225 225 225 225 225 225 225 225 225 225 225 225 225 225 210 210 210 210 210 210 210
11 117 810 810 810 810 810 810 810 810 810 810 780 780 780 780 795 795 795 795 795 795 795
11 118 705 705 705 705 705 705 705 735 735 735 735 735 735 735 750 750 750 750 750 750 750
11 127 405 405 405 405 405 405 405 420 420 420 420 420 420 420 420 420 420 420 420 420 420
11 129 600 600 600 600 600 600 600 585 585 585 585 585 585 585 600 600 600 600 600 600 600
11 131 255 255 255 255 255 255 255 255 255 255 255 255 255 255 270 270 270 270 270 270 270
11 134 795 795 795 795 795 795 795 765 765 765 765 765 765 765 780 780 780 780 780 780 780
11 135 705 705 705 705 705 705 705 720 720 720 720 720 720 720 720 720 720 720 720 720 720
12 243 330 330 330 330 330 330 330 330 330 330 330 330 330 330 375 375 375 375 375 375 375
12 245 645 645 645 645 645 645 645 645 645 645 645 645 645 645 645 645 645 645 645 645 645
12 246 690 690 690 690 690 690 690 735 735 735 735 735 735 735 735 735 735 735 735 735 735
12 247 360 360 360 360 360 360 360 390 390 390 390 390 390 390 375 375 375 375 375 375 375
12 248 803 803 803 803 803 803 825 825 825 825 825 825 825 825 825 825 825 825 825 825 825
12 259 870 870 870 870 870 870 870 900 900 900 900 900 900 900 900 900 900 900 900 900 900
12 260 555 555 555 555 555 555 555 585 585 585 585 585 585 585 585 585 585 585 585 585 585
12 262 345 345 345 345 345 345 375 375 375 375 375 375 375 375 375 375 375 375 375 375 375
12 266 885 885 885 885 885 885 885 900 900 900 900 900 900 900 900 900 900 900 900 900 900
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Appendix 32: Individual listing of Paromomycin total daily dose. 
Centre Patient Paromomycin mg/day (Dose 15mg/kg/day)
Number Number D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17 D18 D19 D20 D21
12 268 900 900 900 900 900 900 900 900 900 900 900 900 900 900 930 930 930 930 930 930 930
12 272 165 165 165 165 165 165 165 180 180 180 180 180 180 180 180 180 180 180 180 180 180
12 276 300 300 300 300 300 300 300 323 323 323 323 323 323 323 330 330 330 330 330 330 330
12 279 660 660 660 660 660 660 660 690 690 690 690 690 690 690 720 720 720 720 720 720 720
12 282 270 270 270 270 270 270 270 300 300 300 300 300 300 300 300 300 300 300 300 300 300
12 283 810 810 810 810 810 810 810 825 825 825 825 825 825 825 840 840 840 840 840 840 840
12 286 465 465 465 465 465 465 465 480 480 480 480 480 480 480 480 480 480 480 480 480 480
12 292 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750
12 296 345 345 345 345 345 345 345 360 360 360 360 360 360 360 360 360 360 360 360 360 360
12 298 405 405 405 405 405 405 405 390 390 390 390 390 390 390 405 405 405 405 405 405 405
12 300 675 675 675 675 675 675 660 660 660 660 660 660 660 660 660 660 660 660 660 660 660
12 303 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600
12 305 210 210 210 210 210 210 210 210 210 210 210 210 210 210 210 210 210 210 210 210 210
12 308 855 855 855 855 855 855 855 840 840 840 840 840 840 840 863 863 863 863 863 863 863
12 309 795 795 795 795 795 795 795 795 795 795 795 795 795 795 795 795 795 795 795 795 795
12 313 870 870 870 870 870 870 870 870 870 870 870 870 870 870 885 885 885 885 885 885 885
12 322 600 600 600 600 600 600 600 585 585 585 585 585 585 585 585 585 585 585 585 585 855
12 325 825 825 825 825 825 825 825 870 870 870 870 870 870 870 900 900 900 900 900 900 900
12 326 675 675 675 675 675 675 675 690 690 690 690 690 690 690 675 675 675 675 675 675 675
12 328 435 435 435 435 435 435 435 420 420 420 420 420 420 420 420 420 420 420 420 420 420
12 330 390 390 390 390 390 390 390 435 435 435 435 435 435 435 435 435 435 435 435 435 435
23 362 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600
23 363 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
23 368 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750
23 371 550 550 550 550 550 550 550 550 550 550 550 550 550 550 550 550 550 550 550 550 550
23 372 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
23 379 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
23 381 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450
23 383 650 650 650 650 650 650 650 650 650 650 650 650 650 700 700 700 700 700 700 700 700
23 388 400 400 400 400 400 400 400 400 400 400 400 400 400 450 450 450 450 450 450 450 450
23 390 700 700 700 700 700 700 700 700 700 700 700 700 700 700 700 700 700 700 700 700 700
23 394 300 300 300 300 300 300 300 300 300 300 300 300 300 325 325 325 325 325 325 325 325
23 395 800 800 800 800 800 800 800 800 800 800 800 850 850 850 850 850 850 850 850 850 850
23 399 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
23 400 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
23 405 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600
34 452 400 400 400 400 400 400 400 400 400 400 400 400 400 400 450 450 450 450 450 450 450
34 453 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
34 455 300 300 300 300 300 300 300 350 350 350 350 350 350 350 350 350 350 350 350 350 350
34 458 350 350 350 350 350 350 350 400 400 400 400 400 400 400 400 400 400 400 400 400 400
34 460 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200
34 467 450 450 450 450 450 450 450 500 500 500 500 500 500 500 500 500 500 500 500 500 500
34 471 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450
34 473 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
34 475 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
34 476 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400
34 483 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
34 484 200 200 200 200 200 200 200
34 490 250 250 250 250 250 250 250 300 300 300 300 300 300 300 300 300 300 300 300 300 300
34 491 750 750 750 750 750 750 750 800 800 800 800 800 800 800 750 750 750 750 750 750 750
34 492 1000 1000 1000 1000 1000 1000 1000 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150 1150
34 497 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750
34 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 550 550 550 550 550 550 550
34 503 400 400 400 400 400 400 400 350 350 350 350 350 350 350 350 350 350 350 350 350 350
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Appendix 32: Individual listing of Paromomycin total daily dose. 
Centre Patient Paromomycin mg/day (Dose 15mg/kg/day)
Number Number D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17 D18 D19 D20 D21
34 508 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200
34 509 850 850 850 850 850 850 850 850 850 850 850 850 850 850 900 900 900 900 900 900 900
34 512 200 200 200 200 200 200 200 250 250 250 250 250 250 250 250 250 250 250 250 250 250
34 516 650 650 650 650 650 650 650 650 650 650 650 650 650 650 700 700 700 700 700 700 700
34 517 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400
34 519 300 300 300 300 300 300 300 350 350 350 350 350 350 350 350 350 350 350 350 350 350
34 521 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
34 528 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
34 534 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200
34 535 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400
34 536 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400
34 538 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
35 646 480 480 480 480 480 480 480 480 480 480 480 480 480 510 510 510 510 510 510 510 510
35 647 915 915 915 915 915 915 915 915 915 915 915 915 915 975 975 975 975 975 975 975 975
35 652 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
35 657 330 330 330 330 330 330 330 330 330 330 330 330 330 345 345 345 345 345 345 345 345
35 660 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800
35 662 900 900 900 900 900 900 900 900 900 900 900 900 900 900 930 930 930 930 930 930 930
35 668 630 630 630 630 630 630 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600
35 669 435 435 435 435 435 435 435 435 435 435 435 435 435 450 450 450 450 450 450 450 450
35 671 270 270 270 270 270 270 270 270 270 270 270 270 270 285 285 285 285 285 285 285 285
35 675 360 360 360 360 360 360 360 360 360 360 360 360 360 375 375 375 375 375 375 375 375
35 676 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
35 682 225 225 225 225 225 225 225 240 240 240 240 240 240 225 225 225 225 225 225 225 225
35 685 555 555 555 555 555 555 555 555 555 555 555 555 555 570 570 570 570 570 570 570 570
35 686 400 400 400 400 400 400 400 400 400 400 400 400 400 520 520 520 520 520 520 520 520
35 688 585 585 585 585 585 585 615 615 615 615 615 615 615 615 615 615 615 615 615 615 615
LEAP 0104a Appendices
Page 413 of 756
Appendix 33: Individual  Listing of SSG total daily dose 
Centre Patient Sodium Stibogluconate mg/day (Dose 20mg/kg/day)
Number Number D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15
11 8 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 9 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 10 740 740 740 740 740 740 740 740 740 740 740 740 740 740 760
11 13 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 14 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400
11 18 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 20 440 440 440 440 440 440 440 480 480 480 480 480 480 480 480
11 21 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 22 480 480 480 480 480 480 480 460 460 460 460 460 460 460 460
11 25 400 400 400 400 400 400 400 340 340 340 340 340 340 340 360
11 31 780 780 780 780 780 780 780 800 800 800 800 800 800 800 760
11 33 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 35 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 36 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 43 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 46 320 320 320 320 320 320 320 320 320 320 320 320 320 320 320
11 47 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 49 320 320 320 320 320 320 320 320 320 320 320 320 320 320 320
11 53 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 56 660 660 660 660 660 660 660 620 620 620 620 620 620 620 640
11 62 320 320 320 320 320 320 320 340 340 340 340 340 340 340 320
11 63 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 64 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 68 420 420 420 420 420 420 420 380 380 380 380 380 380 380 380
11 72 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 78 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 82 500 500 500 500 500 500 500 500 500 500 500 500 500 500 540
11 83 800 800 800 800 800 800 800 780 780 780 780 780 780 780 800
11 84 380 380 380 380 380 380 380 460 460 460 460 460 460 460 460
11 85 840 840 840 840 840 840 840 840 840 840 840 840 840 840 850
11 93 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 94 280 280 280 280 280 280 280 300 300 300 300 300 300 300 280
11 95 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
11 99 760 760 760 760 760 760 760 760 760 760 760 760 760 760 780
11 105 720 720 720 720 720 720 720 720 720 720 720 720 720 720 760
11 109 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 113 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 114 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 116 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
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Sodium Stibogluconate mg/day (Dose 20mg/kg/day)
D16 D17 D18 D19 D20 D21 D22 D23 D24 D25 D26 D27 D28 D29 D30
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
760 760 760 760 760 760 760 760 720 720 720 720 720 720 720
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
400 400 400 400 400 400 420 420 420 420 420 420 420 420 420
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
460 460 460 460 460 460 460 460 460 460 460 460 460 460 460
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
460 460 460 460 460 460 460 460 460 460 460 460 460 460 460
360 360 360 360 360 360 380 380 380 380 380 380 380 380 380
760 760 760 760 760 760 800 800 800 800 800 800 800 800 800
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
320 320 320 320 320 320 320 320 320 320 320 320 320 320 320
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
320 320 320 320 320 320 320 320 320 320 320 320 320 320 320
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
640 640 640 640 640 640 660 660 660 660 660 660 660 660 660
320 320 320 320 320 320 320 320 320 320 320 320 320 320 320
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
380 380 380 380 380 380 380 380 380 380 380 380 380 380 380
850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
540 540 540 540 540 540 520 520 520 520 520 520 520 520 520
800 800 800 800 800 800 780 780 780 780 780 780 780 780 780
460 460 460 460 460 460 480 480 480 480 480 480 480 480 480
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
280 280 280 280 280 280 300 300 300 300 300 300 300 300 300
300 300 300 300 300 300 340 340 340 340 340 340 340 340 340
780 780 780 780 780 780 760 760 760 760 760 760 760 760 760
760 760 760 760 760 760 780 780 780 780 780 780 780 780 780
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
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Appendix 33: Individual  Listing of SSG total daily dose 
Centre Patient Sodium Stibogluconate mg/day (Dose 20mg/kg/day)
Number Number D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15
11 119 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 122 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 123 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 124 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 125 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 132 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 242 400 400 400 400 400 400 400 420 420 420 420 420 420 420 440
12 244 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 250 740 740 740 740 740 740 740 710 710 710 710 710 710 710 760
12 252 680 680 680 680 680 680 680 760 760 760 760 760 760 760 800
12 253 500 500 500 500 500 500 500 540 540 540 540 540 540 540 540
12 257 840 840 840 840 840 840 840 850 850 850 850 850 850 850 850
12 258 480 480 480 480 480 480 480 500 500 500 500 500 500 500 500
12 263 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 265 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
12 267 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 271 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 273 520 520 520 520 520 520 520 530 530 530 530 530 530 530 520
12 274 460 460 460 460 460 460 460 480 480 480 480 480 480 480 480
12 278 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 280 240 240 240 240 240 240 240 260 260 260 260 260 260 260 280
12 287 520 520 520 520 520 520 520 560 560 560 560 560 560 560 560
12 290 520 520 520 520 520 520 520 560 560 560 560 560 560 560 560
12 291 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 293 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600
12 297 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 301 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 302 260 260 260 260 260 260 260 280 280 280 280 280 280 280 280
12 310 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600
12 311 540 540 540 540 540 540 540 560 560 560 560 560 560 560 560
12 314 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 316 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 317 260 260 260 260 260 260 260 280 280 280 280 280 280 280 280
12 323 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 324 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 329 280 280 280 280 280 280 280 300 300 300 300 300 300 300 300
23 365 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
23 367 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
23 370 370 370 370 370 370 370 370 370 370 370 370 370 370 370 370
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Sodium Stibogluconate mg/day (Dose 20mg/kg/day)
D16 D17 D18 D19 D20 D21 D22 D23 D24 D25 D26 D27 D28 D29 D30
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
440 440 440 440 440 440 420 420 420 420 420 420 420 420 420
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
760 760 760 760 760 760 720 720 720 720 720 720 720 720 720
800 800 800 800 800 800 820 820 820 820 820 820 820 820 820
540 540 540 540 540 540 540 540 540 540 540 540 540 540 540
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
500 500 500 500 500 500 500 500 500 500 500 500 500 500 500
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
300 300 300 300 300 300 320 320 320 320 320 320
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
520 520 520 520 520 560 560 560 560 560 560 560 560 560 560
480 480 480 480 480 480 500 500 500 500 500 500 500 500 500
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
280 280 280 280 280 280 300 300 300 300 300 300 300 300 300
560 560 560 560 560 560 580 580 580 580 580 580 580 580 580
560 560 560 560 560 560 600 600 600 600 600 600 600 600 600
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
600 600 600 600 600 600 600 600 600 600 600 600 600 600 600
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
280 280 280 280 280 280 280 280 280 280 280 280 280 280 280
600 600 600 600 600 600 620 620 620 620 620 620 620 620 620
560 560 560 560 560 560 560 560 560 560 560 560 560 560 560
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
280 280 280 280 280 280 280 280 280 280 280 280 280 280 280
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
370 370 370 370 370 400 400 400 400 400 400 400 400 400 400
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Appendix 33: Individual  Listing of SSG total daily dose 
Centre Patient Sodium Stibogluconate mg/day (Dose 20mg/kg/day)
Number Number D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15
23 373 840 840 840 840 840 840 840 840 840 840 840 840 840 840 840
23 374 780 780 780 780 780 780 780 780 780 780 780 780 780 780 780
23 376 740 740 740 740 740 740 740 740 740 740 740 740 740 760 760
23 380 320 320 320 320 320 320 320 320 320 320 320 320 320 340 340
23 384 700 700 700 700 700 700 700 700 700 700 700 700 700 700 700
23 385 630 630 630 630 630 630 630 630 630 630 630 630 630 640 640
23 389 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600
23 393 460 460 460 460 460 460 460 460 460 460 460 460 460 510 510
23 396 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
23 397 540 540 540 540 540 540 640 640 640 640 640 640 640 690 690
23 403 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
23 404 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
34 456 400 400 400 400 400 400 400 440 440 440 440 440 440 440 440
34 461 1100 1100 1100 1100
34 462 230 230 230 230 230 230 230 240 240 240 240 240 240 240 240
34 464 1040 1040 1040 1040 1040 1040 1040 1080 1080 1080 1080 1080 1080 1080 1080
34 465 1020 1020 1020 1020 1020 1020 1020 1120 1120 1120 1120 1120 1120 1120 1120
34 469 500 500 500 500 500 500 500 520 520 520 520 520 520 520 540
34 472 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260
34 477 360 360 360 360 360 360 360 360 360 360 360 360 360 360 380
34 479 200 200 200 200 200 200 200 220 220 220 220 220 220 220 240
34 480 550 550 550 550 550 550 550 570 570 570 570 570 570 570 600
34 487 740 740 740 740 740 740 740 820 820 820 820 820 820 820 800
34 488 400 400 400 400 400 400 400 440 440 440 440 440 440 440 420
34 489 520 520 520 520 520 520 520 540 540 540 540 540 540 540 540
34 493 660 660 660 660 660 660 660 720 720 720 720 720 720 720 660
34 495 300 300 300 300 300 300 300 330 330 330 330 330 330 330 320
34 496 1260 1260 1260 1260 1260 1260 1260 1260 1260 1260 1260 1260 1260 1260 1260
34 498 640 640 640 640 640 640 640 620 620 620 620 620 620 620 680
34 505 1040 1040 1040 1040 1040 1040 1040 1080 1080 1080 1080 1080 1080 1080 1130
34 506 360 360 360 360 360 360 360 380 380 380 380 380 380 380 370
34 507 300 300 300 300 300 300 300 340 340 340 340 340 340 340 360
34 514 420 420 420 420 420 420 420 440 440 440 440 440 440 440 470
34 515 470 470 470 470 470 470 470 480 480 480 480 480 480 480 520
34 518 280 280 280 280 280 280 280 320 320 320 320 320 320 320 280
34 520 1050 1050 1050 1050 1050 1050 1050 1040 1040 1040 1040 1040 1040 1040 1020
34 523 460 460 460 460 460 460 460 440 440 440 440 440 440 440 470
34 526 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260
34 531 260 260 260 260 260 260 260 280 280 280 280 280 280 280 300
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Sodium Stibogluconate mg/day (Dose 20mg/kg/day)
D16 D17 D18 D19 D20 D21 D22 D23 D24 D25 D26 D27 D28 D29 D30
840 840 840 840 840 840 850 850 850 850 850 850 850 850 850
780 780 780 780 780 800 800 800 800 800 800 800 800 800 800
760 760 760 760 760 760 760 760 760 760 760 760 760 760 760
340 340 340 340 340 360 360 360 360 360 360 360 360 360 360
700 700 700 700 700 700 700 700 700 700 700 700 700 700 700
640 640 640 640 640 640 640 640 640 640 640 640 640 640 640
600 600 600 600 600 650 650 650 650 650 650 650 650 650 650
510 510 510 510 510 520 520 520 520 520 520 520 520 520 520
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
690 690 690 690 690 690 690 690 690 690 690 690 690 690 690
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
440 440 440 440 440 440 460 460 460 460 460 460 460 460 460
240 240 240 240 240 240 240 240 240 240 240 240 240 240 240
1080 1080 1080 1080 1080 1080 1080 1080 1080 1080 1080 1080 1080 1080 1080
1120 1120 1120 1120 1120 1120 1120 1120 1120 1120 1120 1120 1120 1120 1120
540 540 540 540 540 540 540 540 540 520 520 520 520 520 520
260 260 260 260 260 260 290 290 290 290 290 290 290 290 290
380 380 380 380 380 380 380 380 380 380 380 380 380 380 380
240 240 240 240 240 240 240 240 240 240 240 240 240 240 240
600 600 600 600 600 600 600 600 600 600 600 600 600 600 600
800 800 800 800 800 800 820 820 820 820 820 820 820 820 820
420 420 420 420 420 420 460 460 460 460 460 460 460 460 460
540 540 540 540 540 540 520 520 520 520 520 520 520 520 520
660 660 660 660 660 660 660 660 660 660 660 660 660 660 660
320 320 320 320 320 320 320 320 320 320 320 320 320 320 320
1260 1260 1260 1260 1260 1260 1240 1240 1240 1240 1240 1240 1240 1240 1240
680 680 680 680 680 680 680 680 680 680 680 680 680 680 680
1130 1130 1130 1130 1130 1130 1160 1160 1160 1160 1160 1160 1160 1160 1160
370 370 370 370 370 370 370 370 370 370 370 370 370 370 370
360 360 360 360 360 360 340 340 340 340 340 340 340 340 340
470 470 470 470 470 470 470 470 470 470 470 470 470 470 470
520 520 520 520 520 520 520 520 520 520 520 520 520 520 520
280 280 300 280 280 280 280 300 300 300 300 300 300 300 300
1020 1020 1020 1020 1020 1020 1040 1040 1040 1040 1040 1040 1040 1040 1040
470 470 470 470 470 470 480 480 480 480 480 480 480 480 480
260 260 260 260 260 260 270 270 270 270 270 270 270 270 270
300 300 300 300 300 300 320 320 320 320 320 320 320 320 320
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Appendix 33: Individual  Listing of SSG total daily dose 
Centre Patient Sodium Stibogluconate mg/day (Dose 20mg/kg/day)
Number Number D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15
34 533 560 560 560 560 560 560 560 570 570 570 570 570 570 570 580
34 537 220 220 220 220 220 220 220 240 240 240 240 240 240 240 240
34 540 580 580 580 580 580 580 580 600 600 600 600 600 600 600 600
35 650 300 300 300 300 300 300 300 300 300 300 300 300 300 320 320
35 651 320 320 320 320 320 320 320 320 320 320 320 320 320 320 320
35 654 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260
35 656 440 440 440 440 440 440 440 440 440 440 440 440 440 440 440
35 659 320 320 320 320 320 320 320 320 320 320 320 320 320 340 340
35 663 1140 1140 1140 1140 1140 1140 1140 1140 1140 1140 1140 1140 1140 1140 1160
35 665 480 480 480 480 480 480 500 500 500 500 500 500 500 500 500
35 666 660 660 660 660 660 660 660 660 660 660 660 660 660 710 710
35 670 440 440 440 440 440 440 440 440 440 440 440 440 440 500 500
35 673 520 520 520 520 520 520 560 560 560 560 560 560 560 540 540
35 677 1220 1220 1220 1220 1220 1220 1140
35 679 640 640 640 640 640 640 640 640 640 640 640 640 640 640 640
35 684 980 980 980 980 980 980 940 940 940 940 940 940 940 940 940
35 687 980 980 980 980 980 980 980 980 980 980 980 980 980 1000 1000
35 690 420 420 420 420 420 420 440 440 440 440 440 440 440 500 500
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Sodium Stibogluconate mg/day (Dose 20mg/kg/day)
D16 D17 D18 D19 D20 D21 D22 D23 D24 D25 D26 D27 D28 D29 D30
580 580 580 580 580 580 580 580 580 580 580 580 580 580 580
240 240 240 240 240 240 240 250 250 250 250 250 250 250 250
600 600 600 600 600 600 630 630 630 630 630 630 630 630 630
320 320 320 320 320 320 320 320 320 320 320 320 320 320 320
320 320 320 320 320 340 340 340 340 340 340 340 340 340 340
260 260 260 260 260 260 260 260 260 260 260 260 260 260 260
440 440 440 440 440 440 440 440 440 440 440 440 440 440 440
340 340 340 340 340 320 320 320 320 320 320 320 320 320 320
1160 1160 1160 1160 1160 1160 1140 1140 1140 1140 1140 1140 1140 1140 1140
500 500 500 500 500 560 560 560 560 560 560 560 560 560 560
710 710 710 710 710 720 720 720 720 720 720 720 720 720 720
500 500 500 500 500 500 500 500 500 500 500 500 500 500 500
540 540 540 540 540 560 560 560 560 560 560 560 560 560 560
640 640 640 640 640 640 640 640 640 640 640 640 640 640 640
940 940 940 940 940 940 940 940 940 940 940 940 940 940 940
1000 1000 1000 1000 1000 1020 1020 1020 1020 1020 1020 1020 1020 1020 1020
500 500 500 500 500 520 520 520 520 520 520 520 520 520 520
LEAP 0104a Appendices
Page 421 of 756
Appendix 34: Individual Listing for Combination patients of Paromomycin total daily dose 
Centre Patient Combination, Paromomycin mg/day (Dose 15mg/kg/day)
Number Number D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17
11 2 788 788 788 788 788 788 788 788 788 788 788 788 788 788 788 788 788
11 3 630 630 630 630 630 630 630 630 630 630 630 660 660 660 630 630 630
11 6 275 275 275 275 275 375 375 420 420 420 420 420 420 420 420 420 420
11 11 315 315 315 315 315 315 315 315 315 315 315 315 315 315 300 300 300
11 12 840 840 840 840 840 840 840 825 825 825 825 825 825 825 780 780 780
11 16 675 675 675 675 675 675 675 675 675 675 675 675 675 675 690 690 690
11 17 870 870 870 870 870 870 870 855 855 855 855 855 855 855 885 885 885
11 19 795 795 795 795 795 795 795 795 795 795 795 795 795 795 780 780 780
11 26 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
11 28 435 435 435 435 435 435 435 435 435 435 435 435 435 435 420 420 420
11 32 570 570 570 570 570 570 570 570 570 570 570 570 570 570 570 570 570
11 37 885 885 885 885 885 885 885 855 855 855 855 855 855 855 855 855 855
11 41 235 235 235 235 235 235 235 235 235 235 235 235 235 235 235 235 235
11 42 795 795 795 795 795 795 795 795 810 810 810 810 810 810 810 810 810
11 45 750 750 750 750 750 750 750 765 765 765 765 765 765 765 780 780 780
11 48 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 630 630
11 51 480 480 480 480 480 480 480 495 495 495 495 495 495 495 480 480 680
11 57 705 705 705 705 705 705 705 675 675 675 675 675 675 675 675 675 675
11 58 330 330 330 330 330 330 330 360 360 360 360 360 360 360 360 360 360
11 60 750 750 750 750 750 750 750 735 735 735 735 735 735 735 735 735 735
11 66 510 510 510 510 510 510 510 480 480 480 480 480 480 480 465 465 465
11 69 615 615 615 615 615 615 615 645 645 645 645 645 645 645 645 645 645
11 70 735 735 735 735 735 735 735 720 720 720 720 720 720 720 720 720 720
11 71 690 690 690 690 690 690 690 720 720 720 720 720 720 720 720 720 720
11 75 780 780 780 780 780 780 780 795 795 795 795 795 795 795 795 795 795
11 81 795 795 795 795 795 795 795 795 795 795 795 795 795 795 825 825 825
11 86 165 165 165 165 165 165 165 195 195 195 195 195 195 195 195 195 195
11 87 525 525 525 525 525 525 525 555 555 555 555 555 555 555 570 570 570
11 89 885 885 885 885 885 885 885 885 885 885 885 885 885 885 825 825 825
11 90 210 210 210 210 210 210 210 255 255 255 255 355 355 255 240 240 240
11 92 240 240 240 240 240 240 240 255 255 255 255 255 255 255 255 255 255
11 96 255 255 255 255 255 255 255 255 255 255 255 255 255 255 300 300 300
11 97 555 555 555 555 555 555 555 570 570 570 570 570 570 570 615 615 615
11 102 765 765 765 765 765 765 765 765 765 765 765 765 765 765 765 765 765
11 103 765 765 765 765 765 765 765 750 750 750 750 750 750 750 765 765 765
11 106 750 750 750 750 750 750 750 735 735 735 735 735 735 735 750 750 750
11 111 705 705 705 705 705 705 705 705 735 735 735 735 735 735 765 765 765
11 112 690 690 690 690 690 690 690 660 660 660 660 660 660 660 705 705 705
11 115 390 390 390 390 390 390 390 420 420 420 420 420 420 420 420 420 420
11 120 690 690 690 690 690 690 690 705 705 705 705 705 705 705 720 720 720
11 121 225 225 225 225 225 225 225 225 225 225 225 225 225 225 225 225 225
11 126 780 780 780 780 780 780 780 780 780 780 780 780 780 780 780 780 780
11 128 780 780 780 780 780 780 780 795 795 795 795 795 795 795 765 765 765
11 130 705 705 705 705 705 705 705 660 660 660 660 660 660 660 675 675 675
11 133 720 720 720 720 720 720 720 720 720 720 720 720 720 720 720 720 720
12 241 630 630 630 630 630 630 630 660 660 660 660 660 660 660 660 660 660
12 249 525 525 525 525 525 525 525 525 525 525 525 525 525 525 490 490 490
12 251 690 690 690 690 690 690 690 690 690 690 690 690 690 690 690 690 690
12 254 300 300 300 300 300 300 300 285 285 285 285 285 285 285 300 300 300
12 255 570 570 570 570 570 570 570 555 555 555 555 555 555 555 555 555 555
12 256 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600
12 261 525 525 525 525 525 525 525 525 525 525 525 525 525 525 525 525 525
12 264 360 360 360 360 360 360 360 375 375 375 375 375 375 375 375 375 375
12 269 615 615 615 615 615 615 615 600 600 600 600 600 600 600 630 630 630
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Appendix 34: Individual Listing for Combination patients of Paromomycin total daily dose 
Centre Patient Combination, Paromomycin mg/day (Dose 15mg/kg/day)
Number Number D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17
12 270 330 330 330 330 330 330 330 345 345 345 345 345 345 345 345 345 345
12 275 570 570 570 570 570 570 570 585 585 585 585 585 585 585 570 570 570
12 277 660 660 660 660 660 660 660 675 675 675 675 675 675 675 675 675 675
12 281 675 675 675 675 675 675 675 690 690 690 690 690 690 690 675 675 675
12 284 210 210 210 210 210 210 210 240 240 240 240 240 240 240 240 240 240
12 285 570 570 570 570 570 570 570 570 570 570 570 570 570 570 615 615 615
12 288 330 330 330 330 330 330 330 330 330 330 330 330 330 330 330 330 330
12 289 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750 750
12 294 380 285 285 285 285 285 285 270 270 270 270 270 270 270 285 285 285
12 295 375 375 375 375 375 375 375 375 375 375 375 375 375 405 405 405 405
12 299 840 840 840 840 840 840 840 840 840 840 840 840 840 840 840 840 840
12 304 630 630 630 630 630 630 630 645 645 645 645 645 645 645 645 645 645
12 306 225 225 225 225 225 225 225 210 210 260 210 210 210 210 210 210 210
12 307 915 915 915 915 915 915 915 900 900 900 900 900 900 900 975 975 975
12 312 720 720 720 720 720 720 720 720 720 720 720 720 720 720 750 750 750
12 315 270 270 270 270 270 270 270 300 300 300 300 300 300 300 330 330 330
12 318 240 240 240 240 240 240 240 255 255 255 255 255 255 255 240 240 240
12 319 345 345 345 345 345 345 345 360 360 360 360 360 360 360 360 360 360
12 320 330 330 330 330 330 330 330 330 330 330 330 330 330 330 330 330 330
12 321 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315 315
12 327 450 450 450 450 450 450 450 480 480 480 480 480 480 480 495 495 495
23 361 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
23 364 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350
23 366 400 400 400 400 400 400 400 400 400 400 400 400 400 450 450 450 450
23 369 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400
23 375 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350
23 377 700 700 700 700 700 700 700 700 700
23 378 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
23 382 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600
23 386 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500
23 387 650 650 650 650 650 650 650 650 650 650 650 650 650 650 650 650 650
23 391 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450
23 392 250 250 250 250 250 250 250 250 250 250 250
23 398 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
23 401 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
23 402 650 650 650 650 650 650 650 650 650 650 650 650 650 650 650 650 650
34 451 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
34 454 150 150 150 150 150 150 150 200 200 200 200 200 200 200 200 200 200
34 457 700 700 700 700 700 700 700 800 800 800 800 800 800 800 800 800 800
34 459 350 350 350 350 350 350 350 400 400 400 400 400 400 400 350 350 350
34 463 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150 150
34 466 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
34 468 700 700 700 700 700 700 700 700 700 700 700 700 700 700 750 750 750
34 470 200 200 200 200 200 200 200 200 200 200 200 200 200 200 250 250 250
34 474 350 350 350 350 350 350 350 350 350 350 350 350 350 350 400 400 400
34 478 150 150 150 150 150 150 150 150 150 150 150 150 150 150 200 200 200
34 481 350 350 350 350 350 350 350 350 350 350 350 350 350 350 400 400 400
34 482 800 800 800 800 800 800 800 850 850 850 850 850 850 850 850 850 850
34 485 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
34 486 450 450 450 450 450 450 450 500 500 500 500 500 500 500 500 500 500
34 494 850 850 850 850 850 850 850 750 750 750 750 750 750 750 750 750 750
34 499 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400
34 501 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350
34 502 550 550 550 550 550 550 550 500 500 500 500 500 500 500 500 500 500
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Appendix 34: Individual Listing for Combination patients of Paromomycin total daily dose 
Centre Patient Combination, Paromomycin mg/day (Dose 15mg/kg/day)
Number Number D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17
34 504 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
34 510 300 300 300 300 300 300 300 300 300 300 300 300 300 300 350 350 350
34 511 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250 250
34 513 300 300 300 300 300 300 300 350 350 350 350 350 350 350 350 350 350
34 522 700 700 700 700 700 700 700 750 750 750 750 750 750 750 800 800 800
34 524 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500
34 525 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350
34 527 700 700 700 700 700 700 700 700 700 700 700 700 700 700 650 650 650
34 529 200 200 200 200 200 200 200 250 250 250 250 250 250 250 250 250 250
34 530 800 800 800 800 800 800 800 850 850 850 850 850 850 850 850 850 850
34 532 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200 200
34 539 300 300 300 300 300 300 300 300 300 300 300 300 300 300 350 350 350
35 648 225 225 225 225 225 225 225 225 225 225 225 225 225 225 225 225 225
35 649 435 435 435 435 435 435 480 480 480 480 480 480 480 480 480 480 480
35 653 225 225 225 225 225 225 225 225 225 225 225 225 225 225 225 225 225
35 655 435 435 435 435 435 435 435 435 435 435 435 435 435 435 435 435 435
35 658 550 550 550 550 550 550 555 555 555 555 555 555 555 585 585 585 585
35 661 750 750 750 750 750 750 750 750 750 750 750 750 750 750 765 765 765
35 664 1095 1095 1095 1095 1095 1095 1050
35 667 345 345 345 345 345 345 345 375 375 375 375 375 375 375 375 375 375
35 672 345 345 345 345 345 345 345 345 345 345 345 345 345 345 345 345 345
35 674 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
35 678 465 465 465 465 465 465 465 465 465 465 465 465 465 480 480 480 480
35 680 330 330 330 330 330 330 330 330 330 330 330 330 330 360 360 360 360
35 681 690 690 690 690 690 690 690 690 690 690 690 690 690 720 720 720 720
35 683 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450
35 689 630 630 630 630 630 630 630 630 630 630 630 630 630 645 645 645 645
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Appendix 35: Individual listing for combination patients for SSG total daily dose
Centre Patient Combination, SSG mg/day (Dose 20mg/kg/day)
Number Number D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17
11 2 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 3 840 840 840 840 840 840 840 840 840 840 840 840 840 840 840 840 840
11 6 500 500 500 500 500 500 500 560 560 560 560 560 560 560 560 560 560
11 11 420 420 420 420 420 420 420 420 420 420 420 420 420 420 400 400 400
11 12 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 16 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 17 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 19 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 26 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400
11 28 580 580 580 580 580 580 580 580 580 580 580 580 580 580 560 560 560
11 32 760 760 760 760 760 760 760 760 760 760 760 760 760 760 760 760 760
11 37 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 41 340 340 340 340 340 340 340 340 340 340 340 340 340 340 340 340 340
11 42 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 45 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 48 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 840 840
11 51 640 640 640 640 640 640 640 660 660 660 660 660 660 660 640 640 640
11 57 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 58 440 440 440 440 440 440 440 480 480 480 480 480 480 480 480 480 480
11 60 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 66 680 680 680 680 680 680 680 640 640 640 640 640 640 640 620 620 620
11 69 820 820 820 820 820 820 820 850 850 850 850 850 850 850 850 850 850
11 70 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 71 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 75 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 81 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 86 220 220 220 220 220 220 220 260 260 260 260 260 260 260 260 260 260
11 87 700 700 700 700 700 700 700 740 740 740 740 740 740 740 760 760 760
11 89 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 90 280 280 280 280 280 280 280 340 340 340 340 340 340 340 320 320 320
11 92 320 320 320 320 320 320 320 340 340 340 340 340 340 340 340 340 340
11 96 340 340 340 340 340 340 340 340 340 340 340 340 340 340 400 400 400
11 97 740 740 740 740 740 740 740 760 760 760 760 760 760 760 820 820 820
11 102 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 103 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 106 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 111 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 112 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 115 520 520 520 520 520 520 520 560 560 560 560 560 560 560 560 560 560
11 120 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 121 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
11 126 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 128 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 130 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
11 133 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 241 840 840 840 840 840 840 840 850 850 850 850 850 850 850 850 850 850
12 249 700 700 700 700 700 700 700 700 700 700 700 700 700 700 660 660 660
12 251 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 254 400 400 400 400 400 400 400 380 380 380 380 380 380 380 400 400 400
12 255 760 760 760 760 760 760 760 740 740 740 740 740 740 740 740 740 740
12 256 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800
12 261 700 700 700 700 700 700 700 700 700 700 700 700 700 700 700 700 700
12 264 480 480 480 480 480 480 480 500 500 500 500 500 500 500 500 500 500
12 269 820 820 820 820 820 820 820 800 800 800 800 800 800 800 840 840 840
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Appendix 35: Individual listing for combination patients for SSG total daily dose
Centre Patient Combination, SSG mg/day (Dose 20mg/kg/day)
Number Number D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17
12 270 440 440 440 440 440 440 440 460 460 460 460 460 460 460 460 460 460
12 275 760 760 760 760 760 760 760 780 780 780 780 780 780 780 760 760 760
12 277 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 281 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 284 280 280 280 280 280 280 280 320 320 320 320 320 320 320 320 320 320
12 285 760 760 760 760 760 760 760 760 760 760 760 760 760 760 820 820 820
12 288 440 440 440 440 440 440 440 440 440 440 440 440 440 440 440 440 440
12 289 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 294 285 380 380 380 380 380 380 360 360 360 360 360 360 360 380 380 380
12 295 500 500 500 500 500 500 500 500 500 500 500 500 500 540 540 540 540
12 299 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 304 840 840 840 840 840 840 840 850 850 850 850 850 850 850 850 850 850
12 306 300 300 300 300 300 300 300 280 280 280 280 280 280 280 290 290 290
12 307 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
12 312 850 850 850 850 850 850 850 850 850 850 85 850 850 850 850 850 850
12 315 360 360 360 360 360 360 360 400 400 400 400 400 400 400 440 440 440
12 318 320 320 320 320 320 320 320 340 340 340 340 340 340 340 320 320 320
12 319 460 460 460 460 460 460 460 480 480 480 480 480 480 480 480 480 480
12 320 440 440 440 440 440 440 440 440 440 440 440 440 440 440 440 440 440
12 321 420 420 420 420 420 420 420 420 420 420 420 420 420 420 420 420 420
12 327 600 600 600 600 600 600 600 640 640 640 640 640 640 640 660 660 660
23 361 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350 350
23 364 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450 450
23 366 560 560 560 560 560 560 560 560 560 560 560 560 560 600 600 600 600
23 369 540 540 540 540 540 540 540 540 540 540 540 540 540 540 540 540 540
23 375 460 460 460 460 460 460 460 460 460 460 460 460 460 460 460 460 460
23 377 850 850 850 850 850 850 850 850 850
23 378 340 340 340 340 340 340 340 340 340 340 340 340 340 340 340 340 340
23 382 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800
23 386 620 620 620 620 620 620 620 620 640 640 640 640 640 660 660 660 660
23 387 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
23 391 580 580 580 580 580 580 580 580 580 580 580 580 580 620 620 620 620
23 392 340 340 340 340 340 340 340 340 360 360 360
23 398 430 430 430 430 430 430 430 430 430 430 430 430 430 430 430 430 430
23 401 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
23 402 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850 850
34 451 320 320 320 320 320 320 320 360 360 360 360 360 360 360 350 350 350
34 454 230 230 230 230 230 230 230 240 240 240 240 240 240 240 240 240 240
34 457 960 960 960 960 960 960 960 1100 1100 1100 1100 1100 1100 1100 1100 1100 1100
34 459 480 480 480 480 480 480 480 500 500 500 500 500 500 500 480 480 480
34 463 210 210 210 210 210 210 210 210 210 210 210 210 210 210 210 220 220
34 466 400 400 400 400 400 400 400 420 420 420 420 420 420 420 420 420 420
34 468 920 920 920 920 920 920 920 960 960 960 960 960 960 960 980 980 980
34 470 280 280 280 280 280 280 280 280 280 280 280 280 280 280 320 320 320
34 474 480 480 480 480 480 480 480 510 510 510 510 510 510 510 520 520 520
34 478 200 200 200 200 200 200 200 220 220 220 220 220 220 220 240 240 240
34 481 460 460 460 460 460 460 460 460 460 460 460 460 460 460 500 500 500
34 482 1100 1100 1100 1100 1100 1100 1100 1130 1130 1130 1130 1130 1130 1130 1120 1120 1120
34 485 300 300 300 300 300 300 300 300 300 300 300 300 300 300 320 320 320
34 486 640 640 640 640 640 640 640 660 660 660 660 660 660 660 680 680 680
34 494 1160 1160 1160 1160 1160 1160 1160 980 980 980 980 980 980 980 980 980 980
34 499 520 520 520 520 520 520 520 520 520 520 520 520 520 520 560 560 560
34 501 440 440 440 440 440 440 440 460 460 460 460 460 460 460 480 480 480
34 502 700 700 700 700 700 700 700 680 680 680 680 680 680 680 680 680 680
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Appendix 35: Individual listing for combination patients for SSG total daily dose
Centre Patient Combination, SSG mg/day (Dose 20mg/kg/day)
Number Number D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17
34 504 320 320 320 320 320 320 320 300 300 300 300 300 300 300 340 340 340
34 510 380 380 380 380 380 380 380 400 400 400 400 400 400 400 440 440 440
34 511 320 320 320 320 320 320 320 320 320 320 320 320 320 320 360 360 360
34 513 420 420 420 420 420 420 420 460 460 460 460 460 460 460 480 480 480
34 522 960 960 960 960 960 960 960 1020 1020 1020 1020 1020 1020 1020 1050 1050 1050
34 524 660 660 660 660 660 660 660 680 680 680 680 680 680 680 660 660 660
34 525 440 440 440 440 440 440 440 440 440 440 440 440 440 440 440 440 440
34 527 940 940 940 940 940 940 940 920 920 920 920 920 920 920 880 880 880
34 529 260 260 260 260 260 260 260 300 300 300 300 300 300 300 300 300 300
34 530 1060 1060 1060 1060 1060 1060 1060 1100 1100 1100 1100 1100 1100 1100 1130 1130 1130
34 532 240 240 240 240 240 240 240 240 260 260 260 260 260 260 260 260 260
34 539 420 420 420 420 420 420 420 420 420 420 420 420 420 420 440 440 440
35 648 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
35 649 580 580 580 580 580 580 640 640 640 640 640 640 640 640 640 640 640
35 653 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300
35 655 580 580 580 580 580 580 580 580 580 580 580 580 580 580 580 580 580
35 658 720 720 720 720 720 720 740 740 740 740 740 740 740 780 780 780 780
35 661 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 1020 1020 1020
35 664 1460 1460 1460 1460 1460 1460 1400
35 667 460 460 460 460 460 460 460 500 500 500 500 500 500 500 500 500 500
35 672 460 460 460 460 460 460 460 460 460 460 460 460 460 460 460 460 460
35 674 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400 400
35 678 620 620 620 620 620 620 620 620 620 620 620 620 620 640 640 640 640
35 680 440 440 440 440 440 440 440 440 440 440 440 440 440 480 480 480 480
35 681 920 920 920 920 920 920 920 920 920 920 920 920 920 960 960 960 960
35 683 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600
35 689 840 840 840 840 840 840 840 840 840 840 840 840 840 860 860 860 860
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Appendix 36: Rescue Medication (Ambisome)
Centre Patient Treatment Treatment Rescue Medication - Ambisome
 Number Number Start date Dose Frequency Start date End Date
11 7 PM 2-Jul-05 150MG 26-Oct-05 31-Oct-05
11 10 SSG 3-Jul-05 110 6-Sep-05 15-Sep-05
11 10 SSG 3-Jul-05 110 MG 6-Sep-05 7-Sep-05
11 10 SSG 3-Jul-05 110 MG 8-Sep-05 11-Sep-05
11 15 PM 14-Jul-05 140MG 29-Jul-05 8-Aug-05
11 21 SSG 16-Aug-05 147MG 15-Oct-05 20-Oct-05
11 21 SSG 16-Aug-05 147MG 15-Oct-05 20-Oct-05
11 27 PM 19-Sep-05 123MG 3-Feb-06 12-Feb-06
11 34 PM 27-Sep-05 150MG 25-Nov-05 11-Dec-05
11 40 PM 20-Oct-05 47.5MG 12-Nov-05 25-Nov-05
11 50 PM 18-May-06 165 MG 17-Jun-06 26-Jun-06
11 50 PM 18-May-06 165 MG 8-Jun-06 18-Jun-06
11 54 PM 27-May-06 147 MG 20-Jun-06 29-Jun-06
11 54 PM 27-May-06 153 MG 27-Sep-06 6-Oct-06
11 54 PM 27-May-06 156 MG 30-Dec-06 8-Jan-07
11 55 PM 30-May-06 141 MG 21-Jun-06 30-Jun-06
11 55 PM 30-May-06 141 MG 21-Jun-06 30-Jun-06
11 71 Combination 22-Jul-06 141 11-Aug-06 20-Aug-06
11 71 Combination 22-Jul-06 150 MG 30-Dec-06 8-Jan-07
11 71 Combination 22-Jul-06 150 MG 30-Dec-06 9-Jan-07
11 72 SSG 22-Jul-06 141 MG 16-Aug-06 25-Aug-06
11 75 Combination 28-Jul-06 180 MG 30-Dec-06 8-Jan-07
11 91 PM 18-Dec-06 165 MG O.D 5-Mar-07 14-Mar-07
11 91 PM 18-Dec-06 162 MG O.D 26-Jun-07 5-Jul-07
11 104 PM 10-Feb-07 90 MG OD 5-Mar-07 14-Mar-07
11 126 Combination 28-May-07 SSG 15MG 21-Nov-07 7-Dec-07
11 126 Combination 28-May-07 6 DOSES 21-Nov-07 26-Nov-07
11 128 Combination 2-Jun-07 AMBISOME 8-Dec-07 17-Dec-07
12 245 PM 20-Jul-05 150MG OD 25-Nov-05 4-Dec-05
12 284 Combination 20-May-06 60MG DAILY 7-Dec-06 11-Dec-06
12 284 Combination 20-May-06 60MG /DAY 16-Dec-06 16-Dec-06
12 297 SSG 12-Apr-07 144MG DAILY 4-May-07 8-May-07
12 297 SSG 12-Apr-07 144MG ONCE 13-May-07
12 315 Combination 29-Aug-07 63MG DAILY 11-Jan-08 20-Jan-08
23 364 Combination 20-Jan-05 48MG OD 28-Apr-05 4-May-05
23 378 Combination 9-Mar-05 34.4 OD 7-Jul-05 13-Jul-05
23 379 PM 10-Mar-05 38MG O.D 30-Jun-05 6-Jul-05
23 395 PM 29-Apr-05 120MG OD 26-May-05 1-Jun-05
23 398 Combination 18-May-05 48MG OD 15-Dec-05 21-Dec-05
23 400 PM 3-Jun-05 40 MG O.D 25-Jun-05 1-Jul-05
23 401 Combination 3-Jun-05 112MG OD 21-Sep-05 27-Sep-05
34 452 PM 17-Nov-04 145 MG ONCE 8-Dec-04
34 452 PM 17-Nov-04 145 MG ONCE 9-Dec-04
34 452 PM 17-Nov-04 145 MG 10-Dec-04
34 452 PM 17-Nov-04 145 MG 12-Dec-04
34 452 PM 17-Nov-04 145 MG 17-Dec-04
34 452 PM 17-Nov-04 145 MG 22-Dec-04
34 453 PM 18-Nov-04 80 MG ONCE 9-Dec-04
34 453 PM 18-Nov-04 80 MG ONCE 10-Dec-04
34 453 PM 18-Nov-04 80 MG 11-Dec-04
34 453 PM 18-Nov-04 80 MG 13-Dec-04
34 453 PM 18-Nov-04 90 MG 18-Dec-04
34 453 PM 18-Nov-04 90 MG 23-Dec-04
34 455 PM 19-Nov-04 112.5 MG ONCE 10-Dec-04
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34 455 PM 19-Nov-04 112.5 MG ONCE 11-Dec-04
34 455 PM 19-Nov-04 112.5 MG 12-Dec-04
34 455 PM 19-Nov-04 112.5 MG 14-Dec-04
34 455 PM 19-Nov-04 120 MG 19-Dec-04
34 456 SSG 19-Nov-04 115 MG ONCE 27-Jan-05
34 456 SSG 19-Nov-04 115 MG 28-Jan-05
34 456 SSG 19-Nov-04 115 MG 29-Jan-05
34 456 SSG 19-Nov-04 115 MG 31-Jan-05
34 456 SSG 19-Nov-04 115 MG 5-Feb-05
34 456 SSG 19-Nov-04 115 MG
34 458 PM 20-Nov-04 135 MG ONCE 16-Jan-05
34 458 PM 20-Nov-04 135 MG 17-Jan-05
34 458 PM 20-Nov-04 135 MG 18-Jan-05
34 458 PM 20-Nov-04 135 MG 20-Jan-05
34 458 PM 20-Nov-04 135 MG 25-Jan-05
34 458 PM 20-Nov-04 135 MG
34 460 PM 24-Nov-04 65 MG ONCE 15-Dec-04
34 460 PM 24-Nov-04 65 MG ONCE 16-Dec-04
34 460 PM 24-Nov-04 65 MG 17-Dec-04
34 460 PM 24-Nov-04 65 MG 19-Dec-04
34 460 PM 24-Nov-04 75 MG 24-Dec-04
34 460 PM 24-Nov-04 75 MG 29-Dec-04
34 466 Combination 30-Nov-04 110 MG ONCE 18-Dec-04
34 466 Combination 30-Nov-04 110 MG ONCE 19-Dec-04
34 466 Combination 30-Nov-04 110 MG 20-Dec-04
34 466 Combination 30-Nov-04 110 MG 22-Dec-04
34 466 Combination 30-Nov-04 110 MG 27-Dec-04
34 466 Combination 30-Nov-04 100 MG 1-Jan-05
34 467 PM 29-Nov-04 150 MG ONCE 5-Feb-05
34 467 PM 29-Nov-04 150 MG 6-Feb-05
34 467 PM 29-Nov-04 150 MG 7-Feb-05
34 467 PM 29-Nov-04 150 MG 9-Feb-05
34 467 PM 29-Nov-04 150 MG 14-Feb-05
34 467 PM 29-Nov-04 150 MG
34 471 PM 29-Nov-04 160 MG ONCE 20-Dec-04
34 471 PM 29-Nov-04 160 MG ONCE 21-Dec-04
34 471 PM 29-Nov-04 160 MG 22-Dec-04
34 471 PM 29-Nov-04 160 MG 24-Dec-04
34 471 PM 29-Nov-04 160 MG 29-Dec-04
34 471 PM 29-Nov-04 160 MG 3-Jan-05
34 473 PM 3-Dec-04 75 MG ONCE 24-Dec-04
34 473 PM 3-Dec-04 75 MG ONCE 25-Dec-04
34 473 PM 3-Dec-04 75 MG 26-Dec-04
34 473 PM 3-Dec-04 75 MG 28-Dec-04
34 473 PM 3-Dec-04 75 MG 2-Jan-05
34 473 PM 3-Dec-04 75 MG 7-Jan-05
34 475 PM 5-Dec-04 90 MG ONCE 26-Dec-04
34 475 PM 5-Dec-04 90 MG ONCE 27-Dec-04
34 475 PM 5-Dec-04 90 MG 28-Dec-04
34 475 PM 5-Dec-04 90 MG 30-Dec-04
34 475 PM 5-Dec-04 90 MG 4-Jan-05
34 475 PM 5-Dec-04 100 MG 9-Jan-05
34 476 PM 5-Dec-04 135 MG ONCE 10-Jan-05
34 476 PM 5-Dec-04 135 MG ONCE 11-Jan-05
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34 476 PM 5-Dec-04 135 MG 12-Jan-05
34 476 PM 5-Dec-04 135 MG 14-Jan-05
34 476 PM 5-Dec-04 135 MG 19-Jan-05
34 476 PM 5-Dec-04 135 MG 24-Jan-05
34 476 PM 5-Dec-04 135 MG ONCE 10-Jan-05
34 476 PM 5-Dec-04 135 MG 11-Jan-05
34 476 PM 5-Dec-04 135 MG 12-Jan-05
34 476 PM 5-Dec-04 135 MG 14-Jan-05
34 476 PM 5-Dec-04 135 MG 19-Jan-05
34 476 PM 5-Dec-04 135 MG
34 484 PM 12-Dec-04 65 MG ONCE 19-Dec-04
34 484 PM 12-Dec-04 65 MG ONCE 20-Dec-04
34 484 PM 12-Dec-04 65 MG 21-Dec-04
34 484 PM 12-Dec-04 70 MG 23-Dec-04
34 484 PM 12-Dec-04 70 MG 28-Dec-04
34 484 PM 12-Dec-04 70 MG 2-Jan-05
34 491 PM 17-Dec-04 255 MG ONCE 7-Jan-05
34 491 PM 17-Dec-04 255 MG ONCE 8-Jan-05
34 491 PM 17-Dec-04 255 MG 9-Jan-05
34 491 PM 17-Dec-04 255 MG 11-Jan-05
34 491 PM 17-Dec-04 255 MG 16-Jan-05
34 491 PM 17-Dec-04 255 MG 21-Jan-05
34 497 PM 21-Dec-04 260 MG ONCE 12-Feb-05
34 497 PM 21-Dec-04 260 MG 13-Feb-05
34 497 PM 21-Dec-04 260 MG 14-Feb-05
34 497 PM 21-Dec-04 260 MG 16-Feb-05
34 497 PM 21-Dec-04 260 MG 21-Feb-05
34 497 PM 21-Dec-04 260 MG
34 503 PM 25-Dec-04 125 MG ONCE 16-Jan-05
34 503 PM 25-Dec-04 125 MG ONCE 17-Jan-05
34 503 PM 25-Dec-04 125 MG 18-Jan-05
34 503 PM 25-Dec-04 125 MG 20-Jan-05
34 503 PM 25-Dec-04 125 MG 25-Jan-05
34 503 PM 25-Dec-04 125 MG 30-Jan-05
34 504 Combination 27-Dec-04 85 MG ONCE 13-Jan-05
34 504 Combination 27-Dec-04 85 MG ONCE 14-Jan-05
34 504 Combination 27-Dec-04 85 MG 15-Jan-05
34 504 Combination 27-Dec-04 85 MG 17-Jan-05
34 504 Combination 27-Dec-04 85 MG 22-Jan-05
34 504 Combination 27-Dec-04 85 MG 27-Jan-05
34 508 PM 31-Dec-04 70 MG ONCE 21-Jan-05
34 508 PM 31-Dec-04 70 MG ONCE 22-Jan-05
34 508 PM 31-Dec-04 70 MG 23-Jan-05
34 508 PM 31-Dec-04 70 MG 25-Jan-05
34 508 PM 31-Dec-04 70 MG 30-Jan-05
34 508 PM 31-Dec-04 70 MG 4-Feb-05
34 509 PM 2-Jan-05 300 MG ONCE 23-Jan-05
34 509 PM 2-Jan-05 300 MG ONCE 24-Jan-05
34 509 PM 2-Jan-05 300 MG 25-Jan-05
34 509 PM 2-Jan-05 300 MG 27-Jan-05
34 509 PM 2-Jan-05 300 MG 1-Feb-05
34 509 PM 2-Jan-05 300 MG 6-Feb-05
34 512 PM 2-Jan-05 80 MG ONCE 24-Jan-05
34 512 PM 2-Jan-05 80 MG ONCE 25-Jan-05
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34 512 PM 2-Jan-05 80 MG 26-Jan-05
34 512 PM 2-Jan-05 80 MG 28-Jan-05
34 512 PM 2-Jan-05 80 MG 2-Feb-05
34 512 PM 2-Jan-05 80 MG 7-Feb-05
34 517 PM 6-Jan-05 140 MG ONCE 28-Jan-05
34 517 PM 6-Jan-05 140 MG ONCE 29-Jan-05
34 517 PM 6-Jan-05 140 MG 30-Jan-05
34 517 PM 6-Jan-05 140 MG 1-Feb-05
34 517 PM 6-Jan-05 140 MG 6-Feb-05
34 517 PM 6-Jan-05 140 MG 11-Feb-05
34 519 PM 7-Jan-05 100 MG ONCE DAILY 3-Apr-05
34 519 PM 7-Jan-05 100 MG 4-Apr-05
34 519 PM 7-Jan-05 100 MG 5-Apr-05
34 519 PM 7-Jan-05 100 MG 7-Apr-05
34 519 PM 7-Jan-05 100 MG 12-Apr-05
34 519 PM 7-Jan-05 100 MG
34 521 PM 11-Jan-05 85 MG ONCE 2-Feb-05
34 521 PM 11-Jan-05 85 MG ONCE 3-Feb-05
34 521 PM 11-Jan-05 85 MG 4-Feb-05
34 521 PM 11-Jan-05 85 MG 6-Feb-05
34 521 PM 11-Jan-05 85 MG 11-Feb-05
34 521 PM 11-Jan-05 85 MG 16-Feb-05
34 528 PM 17-Jan-05 95 MG ONCE 11-Mar-05
34 528 PM 17-Jan-05 95 MG ONCE 12-Mar-05
34 528 PM 17-Jan-05 95 MG 13-Mar-05
34 528 PM 17-Jan-05 95 MG 15-Mar-05
34 531 SSG 21-Jan-05 75 MG ONCE 20-Feb-05
34 531 SSG 21-Jan-05 75 MG ONCE 21-Feb-05
34 531 SSG 21-Jan-05 75 MG 22-Feb-05
34 531 SSG 21-Jan-05 75 MG 24-Feb-05
34 531 SSG 21-Jan-05 75 MG 1-Mar-05
34 531 SSG 21-Jan-05 80 MG 6-Mar-05 6-Mar-05
34 534 PM 24-Jan-05 67.5 MG ONCE 15-Feb-05
34 534 PM 24-Jan-05 67.5 MG ONCE 16-Feb-05
34 534 PM 24-Jan-05 67.5 MG 17-Feb-05
34 534 PM 24-Jan-05 67.5 MG 19-Feb-05
34 534 PM 24-Jan-05 67.5 MG 24-Feb-05
34 534 PM 24-Jan-05 75 MG 1-Mar-05 1-Mar-05
34 535 PM 24-Jan-05 140 MG ONCE DAILY 25-Mar-05
34 535 PM 24-Jan-05 140 MG 26-Mar-05
34 535 PM 24-Jan-05 140 MG 27-Mar-05
34 535 PM 24-Jan-05 140 MG 29-Mar-05
34 535 PM 24-Jan-05 140 MG 3-Apr-05
34 535 PM 24-Jan-05 140 MG
34 538 PM 26-Jan-05 87.5 MG ONCE 16-Feb-05
34 538 PM 26-Jan-05 87.5 MG ONCE 17-Feb-05
34 538 PM 26-Jan-05 87.5 MG 18-Feb-05
34 538 PM 26-Jan-05 87.5 MG 20-Feb-05
34 538 PM 26-Jan-05 87.5 MG 25-Feb-05
34 538 PM 26-Jan-05 85 MG 2-Mar-05 2-Mar-05
35 646 PM 28-Jan-05 100 MG 6-Jul-05 15-Jul-05
35 647 PM 30-Jan-05 3MG/KG/D 28-Mar-05 6-Apr-05
35 647 PM 30-Jan-05 175 MG 28-Mar-05 6-Apr-05
35 652 PM 1-Feb-05 60 MG 22-Mar-05 31-Mar-05
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35 662 PM 20-Feb-05 3 MG/KG/DAY 12-Apr-05 21-Apr-05
35 662 PM 20-Feb-05 150 MG 12-Apr-05 21-Apr-05
35 664 Combination 20-Feb-05 3 MG/KG 15-Mar-05 19-Mar-05
35 669 PM 28-Feb-05 3 MG/KG 22-Mar-05 31-Mar-05
35 671 PM 11-Mar-05 50 MG 1-May-05 9-May-05
35 675 PM 14-Mar-05 75 MG 4-Jun-05 13-Jun-05
35 677 SSG 20-Mar-05 3 MG/KG 28-Mar-05 29-Mar-05
35 682 PM 22-Mar-05 50 MG 5-Jul-05 14-Jul-05
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11 3 Combination 19-Jun-05 CIMITHIDINE DYSPEPSIA 2-Jul-05 7-Jul-05
11 3 Combination 19-Jun-05 ORS ACUTE GASTROENTERITIS 7-Jul-05 8-Jul-05
11 5 PM 30-Jun-05 VIT A XEROPHTHALMIA 6-Jul-05 19-Jul-05
11 5 PM 30-Jun-05 DIPYRON FEVER & CHILLINESS 8-Jul-05 8-Jul-05
11 5 PM 30-Jun-05 METOCLOPRAMID VOMITING 8-Jul-05 8-Jul-05
11 7 PM 2-Jul-05 NORFLOXECILLIN UTI 29-Jun-05 11-Jul-05
11 7 PM 2-Jul-05 40% GLUCOSE HYPOGLUCOMIA 8-Jul-05 8-Jul-05
11 7 PM 2-Jul-05 1000CC N\S HYPOGLYCOMIA FOR 
DEXTROSE INFUSION
8-Jul-05 8-Jul-05
11 7 PM 2-Jul-05 PARACETAMOL INJ. SITE PAIN 13-Jul-05 17-Jul-05
11 7 PM 2-Jul-05 DIPYRON INJ. SITE PAIN 18-Jul-05 18-Jul-05
11 7 PM 2-Jul-05 SALBUTAMOL BRONCHIAL ATHMA 25-Oct-05
11 7 PM 2-Jul-05 COUGH SYRUP BRONCHIAL ATHMA 25-Oct-05
11 7 PM 2-Jul-05 NORFLOXACLINE UTI (URINARY TRACT 
INFECTION)
23-Jan-06 29-Jan-06
11 9 SSG 3-Jul-05 AL(OH)3 OR MALOX DYSPEPSIA 6-Jul-05
11 9 SSG 3-Jul-05 MALOX SYRUP DYSPEPSIA 31-Jan-06
11 9 SSG 3-Jul-05 CIMITIDIN DYSPEPSIA 31-Jan-06 11-Feb-06
11 10 SSG 3-Jul-05 QUININ MALARIA 17-Jul-05 19-Jul-05
11 10 SSG 3-Jul-05 FANSIDAR MALARIA 19-Jul-05 19-Jul-05
11 10 SSG 3-Jul-05 PARACETAMOL FEVER 17-Jul-05 19-Jul-05
11 10 SSG 3-Jul-05 PARAC HEADACHE 29-Jul-05 29-Jul-05
11 12 Combination 8-Jul-05 QUININE MALARIA (P.F) 14-Jul-05 20-Jul-05
11 12 Combination 8-Jul-05 PARACETAMOL HEADACHE 6-Feb-06
11 14 SSG 12-Jul-05 METRONIDAZOLE GIARDIASIS 3-Aug-05 8-Aug-05
11 14 SSG 12-Jul-05 AMOXACILLINE PNEUMONIA 10-Aug-05
11 14 SSG 12-Jul-05 SALBUTAMOL B. ASTHMA 19-Jul-05 3-Aug-05
11 14 SSG 12-Jul-05 EPHEDRINE B. ASTHMA 19-Jul-05 3-Aug-05
11 15 PM 14-Jul-05 CLOTTRIMAZOLE 
CREAM
T.VERSICOLOR 13-Jul-05
11 15 PM 14-Jul-05 MALOX SYRUP PUD 20-Jul-05
11 16 Combination 15-Jul-05 THEOPHEDRIN BR. ASTHMA 14-Jul-05 28-Jul-05
11 16 Combination 15-Jul-05 SALBUT. BR. ASTHMA 14-Jul-05 28-Jul-05
11 16 Combination 15-Jul-05 MALOX SYRUP PUD 12-Jul-05
11 16 Combination 15-Jul-05 NORFLOX UTI 29-Jul-05 4-Aug-05
11 16 Combination 15-Jul-05 VERMOX HOOK WORM 29-Jul-05 31-Jul-05
11 16 Combination 15-Jul-05 ALOH3 DYSPEPSIA 31-Oct-05 4-Nov-05
11 16 Combination 15-Jul-05 CIMITIDIN DYSPEPSIA 6-Feb-06 20-Feb-06
11 16 Combination 15-Jul-05 NORFLOXACIN DYSPEPSIA 6-Feb-06 13-Feb-06
11 16 Combination 15-Jul-05 MALOX DYSPEPSIA 6-Feb-06
11 17 Combination 19-Jul-05 ALBENDAZOLE INTESTINAL PARASITOSIS 24-Jul-05 27-Jul-05
11 17 Combination 19-Jul-05 HYOCINE ABDOMINAL CRAMP 24-Jul-05
11 18 SSG 16-Aug-05 CIMITEDIN NUD 20-Aug-05
11 18 SSG 16-Aug-05 MEBADIZOLE HOOK WORM INFECTION 2-Sep-05
11 18 SSG 16-Aug-05 AMOXACILIN COMMUNITY ACQUIRED 
PNEUMONIA
23-Dec-05 2-Jan-06
11 19 Combination 16-Aug-05 CIMITIDIN DSPEPSIA 29-Aug-05
11 19 Combination 16-Aug-05 CIMITIDIN DYSPEPSIA 29-Nov-05 13-Dec-05
11 19 Combination 16-Aug-05 CHLOROQUINE TROPICAL SPELNOMEGALY 
SYNDROM
29-Nov-05 28-Jan-06
11 19 Combination 16-Aug-05 METRONIDAZOLE E.HISTOLOTICA 27-Feb-06 8-Mar-06
11 20 SSG 16-Aug-05 AMOXACCLLINE PNEUMONIA 9-Sep-05 16-Sep-05
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11 22 SSG 17-Aug-05 DYPRON CHILLS 18-Aug-05
11 22 SSG 17-Aug-05 PARACETAMOL CHILLS 18-Aug-05
11 25 SSG 20-Aug-05 MEBENDAZLE HOOK WORM 18-Aug-05 21-Aug-05
11 25 SSG 20-Aug-05 PARACITAMOLE FEVER 21-Aug-05 23-Aug-05
11 25 SSG 20-Aug-05 MEBENDAZOLE ABDOMINAL DISTENSION 4-Jan-06 6-Jan-06
11 27 PM 19-Sep-05 NORFLOXACILLIN ACUTE GASTRO ENTERITIS 22-Sep-05 26-Sep-05
11 27 PM 19-Sep-05 DICLOFENAC PAIN AT INJECTION SITE 2-Oct-05
11 27 PM 19-Sep-05 ORS ACUTE GASTRO ENTERITIS 21-Sep-05 23-Sep-05
11 27 PM 19-Sep-05 CEFTRAXONE SEPSIS OF GI 20-Jan-06 27-Jan-06
11 27 PM 19-Sep-05 40% DEXTROSE HYPOGLYCEMIA 20-Jan-06 23-Jan-06
11 27 PM 19-Sep-05 ORS SHOCK 20-Jan-06 28-Jan-06
11 27 PM 19-Sep-05 NORMAL SALINE MAINTENANCE 20-Jan-06 24-Jan-06
11 27 PM 19-Sep-05 CO-TRIMOZAXOLE PCP PROPHOLAXIS 12-Feb-06 18-Feb-06
11 29 PM 22-Sep-05 PARACETAMOL HEADACHE 27-Sep-05 27-Sep-05
11 31 SSG 23-Sep-05 GLIBEN CLAMIDE TYPE II DM 3-Feb-06 4-Mar-06
11 31 SSG 23-Sep-05 REGULAR INSULIN TYPE 1 DM 7-Apr-06 7-Apr-06
11 31 SSG 23-Sep-05 LENTE INSULIN TYPE 1 DM 8-Apr-06 14-Apr-06
11 31 SSG 23-Sep-05 LENTE INSULIN TYPE 1 DM 14-Apr-06 19-Apr-06
11 31 SSG 23-Sep-05 LENTE INSULIN TYPE 1 DM 20-Apr-06 24-Apr-06
11 31 SSG 23-Sep-05 LENTE INSULIN TYPE 1 DM 24-Apr-06 3-May-06
11 31 SSG 23-Sep-05 LENTE INSULIN TYPE 1 DM 3-May-06 10-May-06
11 31 SSG 23-Sep-05 LENTE INSULIN TYPE 1 DM 10-May-06
11 33 SSG 25-Sep-05 PARACETAMOL HEADACHE 4-Oct-05 4-Oct-05
11 37 Combination 28-Sep-05 HYDROCHLORTHIAZID
E
HYPERTENSIVE 14-Apr-06
11 38 PM 19-Oct-05 PARCITAMOLE HEADACHE 1-Nov-05 5-Nov-05
11 38 PM 19-Oct-05 OMPEROZOLE PEPTIC ULCER DISEASE 30-May-06 5-Jun-06
11 38 PM 19-Oct-05 CLARITHROMCIN PEPTIC ULCER DISEASE 30-May-06 5-Jun-06
11 38 PM 19-Oct-05 AMOXACILLIN PEPTIC ULCER DISEASE 30-May-06 5-Jun-06
11 40 PM 20-Oct-05 COARTEM P.FALCIPAREN MALARIA 18-Oct-05 21-Oct-05
11 40 PM 20-Oct-05 PARACETAMOL HEADACHE 23-Oct-05 23-Oct-05
11 40 PM 20-Oct-05 DYPRONE FEVER 18-Oct-05 18-Oct-05
11 41 Combination 20-Oct-05 COARTEM MALARIA 22-Oct-05 25-Oct-05
11 41 Combination 20-Oct-05 CHLOROQUINE MALARIA 22-Oct-05 25-Oct-05
11 41 Combination 20-Oct-05 DIPZLRONE MALARIA 22-Oct-05 25-Oct-05
11 42 Combination 21-Oct-05 QUININE MALARIA 7-Nov-05 14-Nov-05
11 43 SSG 28-Oct-05 CLOTRIMAZOLE TINEA VERSICOLAR 27-Oct-05
11 43 SSG 28-Oct-05 CO-TRIMOXAZOLE PYURIA (UTI) 3-Nov-05 7-Nov-05
11 45 Combination 28-Oct-05 ALBENDAZOLE INTESTINAL PARASITOSIS 19-May-06 21-May-06
11 46 SSG 5-May-06 METRONIDAZOLE GIADIACYST 10-May-06 16-May-06
11 46 SSG 5-May-06 CLOTRIMAZOLE T. FACIES 16-May-06
11 48 Combination 5-May-06 PARACETAMOLE HEADACHE 11-May-06 11-May-06
11 49 SSG 9-May-06 ALBENDAZOLE STRONGYIODSIS 10-May-06 12-May-06
11 52 PM 20-May-06 PARACETAMOL FEVER 22-May-06 22-May-06
11 54 PM 27-May-06 METRONDAZOLE E-HISTOLOTICA CYST 23-Jun-06 2-Jul-06
11 54 PM 27-May-06 CO-TRIMOXAZOLE PROFLAXIS 29-Jun-06
11 54 PM 27-May-06 METRONDAZOLE AMOEBIASIS 23-Jun-06 2-Jul-06
11 54 PM 27-May-06 STAVUDINE HIV 7-Jul-06
11 54 PM 27-May-06 LAMUVIDINE HIV 7-Jul-06
11 54 PM 27-May-06 NEVIRAPINE HIV 7-Jul-06
11 54 PM 27-May-06 CETRIMOXAZOLE PCP PROPHYLAXIS 29-Jun-06
11 54 PM 27-May-06 COARTEM MALARIA 18-Dec-06 20-Dec-06
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11 54 PM 27-May-06 CHLOROQUINE MALARIA 18-Dec-06 20-Dec-06
11 54 PM 27-May-06 AMOXACILLINE DENTAL CARIES 25-Dec-06 1-Jan-07
11 54 PM 27-May-06 IBUPROFEN DENTAL CARIES 25-Dec-06 29-Dec-06
11 55 PM 30-May-06 CLOTRIMAZOLE 
CREAM
T. VERSICOLOR 2-Jun-06 20-Jun-06
11 55 PM 30-May-06 CIMITIDIN DYSPEPSIA 2-Jun-06 12-Jun-06
11 57 Combination 4-Jun-06 AMOXACELLINE CAP (COMMUNITY ACQUIRED 
PNEUMONIA)
6-Jun-06 13-Jun-06
11 57 Combination 4-Jun-06 MALOX SYRUP DYSPEPSIA 10-Jun-06
11 57 Combination 4-Jun-06 CLOTRIMAZOLE T. VERSICOLOR 10-Jun-06
11 58 Combination 6-Jun-06 PARACETAMOL PAIN AT INJECTION SITE 20-Jun-06 20-Jun-06
11 59 PM 13-Jun-06 ALDOMET HYPERTENSION 8-Jul-06 11-Jul-06
11 59 PM 13-Jun-06 ALDOMET HYPERTENSION 29-Aug-06
11 59 PM 13-Jun-06 ALDOMET HYPERTENSION 29-Aug-06
11 66 Combination 23-Jun-06 NORFLOXACILLIN URINARY TRACT INFECTION 23-Jun-06 30-Jun-06
11 69 Combination 15-Jul-06 TINIDAZOLE GIARDIASIS 31-Oct-06 31-Oct-06
11 70 Combination 15-Jul-06 PARACETAMOLE INJECTION SITE PAIN 28-Jul-06 28-Jul-06
11 70 Combination 15-Jul-06 BENZYL BENZOATE SCABIES 9-Oct-06 12-Oct-06
11 71 Combination 22-Jul-06 MALLOX DYSPEPSIA 1-Aug-06
11 71 Combination 22-Jul-06 CIMETIDINE DYSPEPSIA 1-Aug-06 10-Aug-06
11 71 Combination 22-Jul-06 ORS DIARRHEA 29-Jul-06 4-Aug-06
11 71 Combination 22-Jul-06 STAVUDIN HIV 19-Jul-05
11 71 Combination 22-Jul-06 LAMVUDIN HIV 19-Jul-05
11 71 Combination 22-Jul-06 EFV HIV 19-Jul-05
11 71 Combination 22-Jul-06 CO-TRIMOXOZOL PCP PROPHYLAXIS 19-Jul-05
11 71 Combination 22-Jul-06 METRONIDAZOLE AMOEBIASIS 21-Aug-06 31-Aug-06
11 71 Combination 22-Jul-06 MALLOX PUD 4-Jan-06
11 71 Combination 22-Jul-06 MULTIVITAMIN EASYFATIGABILITY 4-Jan-06 14-Jan-06
11 72 SSG 22-Jul-06 MALOX SYRUP DYSPEPSIA 21-Jul-06 15-Aug-06
11 72 SSG 22-Jul-06 MULTI-VITAMIN LOSS OF APPITITE 27-Jul-06 5-Aug-06
11 72 SSG 22-Jul-06 DNS MAINTENANCE 1-Aug-06 5-Aug-06
11 72 SSG 22-Jul-06 DEXTROSE HEPATITIS 1-Aug-06 1-Aug-06
11 72 SSG 22-Jul-06 VITAMIN B.COMPLEX HEPATITIS (DRUG INDUCED) 1-Aug-06 5-Aug-06
11 72 SSG 22-Jul-06 CEFTRIAXONE SEPSIS OF GI FOCUS 5-Aug-06
11 72 SSG 22-Jul-06 ORS FOR ONGOING 
REPLACEMENT
5-Aug-06 7-Aug-06
11 72 SSG 22-Jul-06 GENTAMYCIN SEPSIS OF GI FOCUS 6-Aug-06
11 72 SSG 22-Jul-06 STAVUDIN HIV 31-Jul-06
11 72 SSG 22-Jul-06 LAMUVIDIN HIV 31-Jul-06
11 72 SSG 22-Jul-06 NEVIRAPINE HIV 31-Jul-06
11 72 SSG 22-Jul-06 CO-TRIMOXOZOL PCP PROPHYLAXIS 31-Jul-06
11 75 Combination 28-Jul-06 CIPROFLOXACLIN ABDOMINAL CRAMP 10-Aug-06 16-Aug-06
11 76 PM 31-Jul-06 MALOX SYRUP DYSPEPSIA 30-Jul-06 21-Aug-06
11 79 PM 31-Jul-06 MULTI-VITAMIN LOSS OF APPETITE 3-Aug-06 13-Aug-06
11 79 PM 31-Jul-06 ORS ACUTE GASTROENTIRITIS 5-Aug-06 6-Aug-06
11 79 PM 31-Jul-06 NS NORMAL SALINE ACUTE GASTROENTIRITIS 5-Aug-06 6-Aug-06
11 83 SSG 16-Aug-06 CIPROFLOXACELINE ACUTE GASTRO INTERITIS 22-Aug-06 29-Aug-06
11 84 SSG 18-Aug-06 DOXYCYCLINE PNEUMONIA 17-Sep-06 24-Sep-06
11 85 SSG 25-Aug-06 MALLOX DYSPEPSIA 21-Nov-06 5-Dec-06
11 85 SSG 25-Aug-06 RAMTIDINE DYSPEPSIA 21-Nov-06 5-Dec-06
11 88 PM 29-Aug-06 DOXYCYCLINE PNEMONIA 21-Nov-06 30-Nov-06
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11 89 Combination 2-Sep-06 DOXYCYCLINE ATYPICAL PNEUMONIA 17-Nov-06 27-Nov-06
11 91 PM 18-Dec-06 MALOX DYSPEPSIA 24-Apr-07 3-Jul-07
11 91 PM 18-Dec-06 CIMETIDINE DYSPEPSIA 24-Apr-07 8-May-07
11 97 Combination 20-Jan-07 CIPROFLOXACILIN ACUTE GASTROENTERITIES 21-Jan-07 27-Jan-07
11 98 PM 24-Jan-07 CLOTRIMAZOLE 
CREAM
T. VERSICOLOR 23-Jan-07 10-Mar-07
11 98 PM 24-Jan-07 CIPROFLOXACILIN UTI URINARY TRACT INFE 8-Feb-07 15-Feb-07
11 100 PM 26-Jan-07 MALOX SYRUP DYSPEPSIA 12-Feb-07 28-Feb-07
11 103 Combination 7-Feb-07 MULTIVITAMIN LOSS OF APPETITE 2-Feb-07 12-Feb-07
11 106 Combination 25-Feb-07 PARACETAMOLE FEVER 24-Feb-07 26-Feb-07
11 108 PM 2-Mar-07 CHLOROQUINE VIVAX MALARIA 23-Mar-07 25-Mar-07
11 109 SSG 3-Mar-07 MALOX DYSPEPSIA 4-Mar-07 2-Apr-07
11 109 SSG 3-Mar-07 TINIDAZOL INTESTINAL PARACITE 29-Mar-07 29-Mar-07
11 109 SSG 3-Mar-07 MEBENDAZOL INTESTINAL PARACITE 29-Mar-07 1-Apr-07
11 109 SSG 3-Mar-07 DOXYCYCLINE ATYPICAL PNEUMONIA 31-Mar-07 9-Apr-07
11 113 SSG 28-Mar-07 NICLOSAMIDE INTESTINAL PARACITOSIS 3-Apr-07 3-Apr-07
11 113 SSG 28-Mar-07 AMOXACILLINE URTI 20-Apr-07 27-Apr-07
11 114 SSG 30-Mar-07 CLOTRIMAZOLE 
CREAM
T.VERSICOLOR 2-Apr-07 30-Apr-07
11 116 SSG 31-Mar-07 ACYCLOVIR HERPES ZOSTER 30-Apr-07 5-May-07
11 117 PM 4-Apr-07 CIPROFLOXACIN UTI 15-Apr-07 22-Apr-07
11 117 PM 4-Apr-07 NEUROBION PERIPHERAL NEUROPATHY 23-Apr-07 3-May-07
11 122 SSG 21-Apr-07 CLOXACILLINE PYOGENIC LYMPHADENOITIS 4-May-07 11-May-07
11 122 SSG 21-Apr-07 CHLORAMPHENICOL PYOGENIC LYMPHADENITIS 8-May-07 19-May-07
11 123 SSG 28-Apr-07 CLOXACILLIN CELLULITIS 18-May-07 25-May-07
11 124 SSG 21-May-07 M. VITAMIN LOSS OF APPETITE 20-May-07 31-May-07
11 124 SSG 21-May-07 TINIDAZOLE AMOEBIASIS 22-May-07 22-May-07
11 124 SSG 21-May-07 CLOXACILLIN CELLULITIS 25-May-07 4-Jun-07
11 124 SSG 21-May-07 CHLORAMPHENCOL CELLULITIS 25-May-07 4-Jun-07
11 124 SSG 21-May-07 ACYCLOVIR CHICKENPOX 18-Jun-07
11 124 SSG 21-May-07 CLOXACILLIN IMPETIGENIZED CHICKENPOX 18-Jun-07
11 126 Combination 28-May-07 ACYCLOVIR HERPES ZOSTER 29-May-07 5-Jun-07
11 126 Combination 28-May-07 DICLOFENAC NEUROPATHIC PAIN 29-May-07 5-Jun-07
11 126 Combination 28-May-07 CO-TRIMOXAZOLE CO-TRIZOXAZOLE 
PROPHYLAXIS
10-Jun-07
11 126 Combination 28-May-07 AMITRYPITLIN NEUROPATHIC PAIN 25-Jun-07 3-Jul-07
11 126 Combination 28-May-07 OMEPEVOZOLE DYSPEPSIA 13-Dec-07 27-Dec-07
11 126 Combination 28-May-07 STAVUDINE HIV 23-Jun-07
11 126 Combination 28-May-07 LAMUVIDINE HIV 23-Jun-07
11 126 Combination 28-May-07 EFAVIVENZ HIV 23-Jun-07
11 128 Combination 2-Jun-07 CO-TRIMOXAZOLE CO-TRIMOXAZOLE 
PROPHYLAXIS
10-Jun-07
11 132 SSG 16-Jun-07 ANTIMALARIA MALARIA 19-Nov-07 21-Nov-07
11 135 PM 13-Jul-07 CLOTRIMAZOLE 
CREAM
T.VERSICOLOR 12-Jul-07
12 241 Combination 29-Jun-05 AMOXACILLIN CELLULITIS 13-Jul-05 18-Jul-05
12 241 Combination 29-Jun-05 PARACETAMOL INJECTION SITE PAIN 13-Jul-05 18-Jul-05
12 242 SSG 29-Jun-05 AMPICILLIN UTI 18-Jul-05 22-Jul-05
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12 242 SSG 29-Jun-05 ORS VOMITING 17-Jul-05 18-Jul-05
12 242 SSG 29-Jun-05 TTC EYE OINTMENT BACTERIAL CONJECTIVITIS 24-Oct-05 29-Oct-05
12 242 SSG 29-Jun-05 CLOXACILLIN INFECTED SKIN LESION 9-Feb-06 16-Feb-06
12 244 SSG 29-Jun-05 METRONIDAZOLE GIARDIASIS 8-Jul-05 12-Jul-05
12 244 SSG 29-Jun-05 ALBENDAZOLE STROGLOIDIASIS 8-Jul-05 10-Jul-05
12 244 SSG 29-Jun-05 COTRIMOXAZOLE UTI 20-Jul-05 24-Jul-05
12 244 SSG 29-Jun-05 METRONIDAZOLE GIARDIASIS 30-Oct-05 4-Nov-05
12 244 SSG 29-Jun-05 AMP LEG ULCER 4-Apr-06 20-Apr-06
12 244 SSG 29-Jun-05 TTC EYE OINT CONJUCTIVITIS 4-Apr-06 11-Apr-06
12 245 PM 20-Jul-05 DOXYCYCLINE PNEUMONIA 28-Nov-05 5-Dec-05
12 245 PM 20-Jul-05 PARACETAMOL PNEUMONIA 28-Nov-05 5-Dec-05
12 246 PM 4-Aug-05 ORS AGE 21-Aug-05 23-Aug-05
12 246 PM 4-Aug-05 PARACITAMOL HEADACHE BACK PAI 24-Aug-05 25-Aug-05
12 246 PM 4-Aug-05 ORS CHRONIC DIARRHEA 21-Aug-05 25-Aug-05
12 246 PM 4-Aug-05 COTRIMOXAZOLE DYSENTRY 4-Nov-05 11-Nov-05
12 246 PM 4-Aug-05 KETOCOMAZOLE TINIA CORPORIS 4-Nov-05 19-Nov-05
12 246 PM 4-Aug-05 WHITE FIELD TINIA CORPORIS 4-Nov-05 11-Nov-05
12 247 PM 28-Sep-05 PCM INJECTION SITE PAIN 10-Oct-05 13-Oct-05
12 247 PM 28-Sep-05 AMOX PNEUMONIA 19-Oct-05 22-Oct-05
12 249 Combination 25-Oct-05 PCM FEVER 25-Oct-05 25-Oct-05
12 249 Combination 25-Oct-05 DICLOPLEN FEVER 25-Oct-05 25-Oct-05
12 249 Combination 25-Oct-05 DIPYRON FEVER 25-Oct-05 25-Oct-05
12 249 Combination 25-Oct-05 AMOX PNEUMONIA 4-Mar-06 8-Mar-06
12 249 Combination 25-Oct-05 PCM PNEUMONIA 4-Mar-06 4-Mar-06
12 249 Combination 25-Oct-05 ERYTHROMYCIN PNEUMONIA 8-Mar-06 22-Mar-06
12 249 Combination 25-Oct-05 COTRIMOX PNEUMONIA 8-Mar-06 22-Mar-06
12 250 SSG 25-Oct-05 AMOX OTITIS MEDIA 17-Nov-05 22-Nov-05
12 251 Combination 29-Oct-05 AMOXACILLIN OTITIS MEDIA 11-Nov-05 15-Nov-05
12 253 SSG 29-Oct-05 PARACITAMOL COMMON COLD 9-Nov-05 10-Nov-05
12 254 Combination 29-Oct-05 PARACITAMOL PAIN ON INJECTION SITE 11-Nov-05 12-Nov-05
12 261 Combination 3-Jan-06 PCM INJECT PAIN 16-Jan-06 20-Jan-06
12 264 Combination 15-Feb-06 COARTEM P.FALCIPARUM 7-Feb-06 10-Feb-06
12 264 Combination 15-Feb-06 METRONIDA GIARDIASIS 7-Feb-06 14-Feb-06
12 264 Combination 15-Feb-06 PARACETAMOL INJECTION SITE PAIN 4-Mar-06 8-Mar-06
12 265 SSG 15-Feb-06 AMOXACILLIN 1 SUPERINFECTED 
CHILLOSIS
25-Feb-06 4-Mar-06
12 265 SSG 15-Feb-06 AMOXACILLIN 2 UTI 25-Feb-06 4-Mar-06
12 265 SSG 15-Feb-06 PARACITAMOL FEVER 25-Feb-06 28-Feb-06
12 265 SSG 15-Feb-06 CLOXACILLIN HOSPITAL ACQUIRED PNEU 13-Mar-06 15-Mar-06
12 265 SSG 15-Feb-06 CEFTRIAXONE HAP + SEPSIS 14-Mar-06 20-Mar-06
12 265 SSG 15-Feb-06 LASIX ACUTE RENAL FAILURE 14-Mar-06
12 265 SSG 15-Feb-06 BLOOD TRANSFUSION SEVERE ANEEMIA + 
BLEEDING
18-Mar-06
12 271 SSG 31-Mar-06 PARACITAMOL FEVER 21-Apr-06 22-Apr-06
12 276 PM 8-Apr-06 METRONIDAZOL GIARDIASIS 4-Apr-06 11-Apr-06
12 283 PM 11-May-06 METRINIDAZOLE AMEBIASIS 10-May-06 17-May-06
12 284 Combination 20-May-06 ADRENALIN EPISTAXIS 9-Dec-06 10-Dec-06
12 295 Combination 16-Mar-07 MEBANDAZO HOOKWORM 11-Mar-07 14-Mar-07
12 295 Combination 16-Mar-07 METRINDAZO GIARDIASIS 19-Mar-07 24-Mar-07
12 303 PM 5-Jun-07 TETRACYCLINE CONJUCTIVITIS 1-Oct-07 5-Oct-07
12 307 Combination 15-Jun-07 MAGNISIUM 
TRISILICATE
GASTRITIS 22-Jun-07 26-Jun-07
12 307 Combination 15-Jun-07 PARACITAMOL SHOULDER PAIN 1-Oct-07 4-Oct-07
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12 308 PM 15-Jun-07 ANTIACID 
SUSPENSION
GASTRITIS 18-Jun-07 22-Jun-07
12 308 PM 15-Jun-07 ERYTHROMYCIN PNEUMONIA 10-Oct-07 20-Oct-07
12 308 PM 15-Jun-07 AMOXACILLIN CHRONIC SINUSITIS 27-Dec-07 2-Jan-08
12 310 SSG 16-Jun-07 PARACETAMOL INJECTION SITE PAIN 6-Jul-07 9-Jul-07
12 321 Combination 6-Sep-07 PARACITAMOL INJECTION SITE PAIN 12-Sep-07 21-Sep-07
12 321 Combination 6-Sep-07 METRONIDAZOL GIARDIASIS 19-Sep-07 24-Sep-07
12 322 PM 13-Sep-07 METRONIDAZOLE GIARDIASIS 25-Sep-07 1-Oct-07
12 322 PM 13-Sep-07 METRONIDAZOLE AMEOBIASIS 25-Sep-07 1-Oct-07
12 324 SSG 20-Sep-07 METRONIDAZOLE AMOEBIASIS 4-Oct-07 11-Oct-07
12 325 PM 27-Sep-07 TINIDAZOLE GIARDIASIS 18-Sep-07 18-Sep-07
12 325 PM 27-Sep-07 KETOCOMAZOLE TINIA ALBA 3-Oct-07 13-Oct-07
12 326 PM 3-Oct-07 MEBENDAZOLE ASCARIASIS 9-Oct-07 11-Oct-07
12 326 PM 3-Oct-07 AMOXACILIN OTITIS MEDIA 13-Oct-07 17-Oct-07
12 329 SSG 10-Oct-07 AMOXACILLIN OTITIS MEDIA 18-Oct-07 23-Oct-07
23 362 PM 20-Jan-05 BENZYL-PENICILLIN LOBAR PNEUMONIA 26-Jan-05 1-Feb-05
23 364 Combination 20-Jan-05 PARACETAMOL FEVER 27-Apr-05 1-May-05
23 364 Combination 20-Jan-05 BROZEDEX COUGH 27-Apr-05 4-May-05
23 366 Combination 1-Feb-05 TETRACYCLINE 
OINTMENT
CONJUNCTIVITIS (BILATERAL) 19-Aug-05
23 367 SSG 1-Feb-05 CRYSTALLINE 
PENICILLIN
PNEUMONIA 26-Feb-05 28-Feb-05
23 367 SSG 1-Feb-05 GENTAMYCIN PNEUMONIA 26-Feb-05 26-Feb-05
23 367 SSG 1-Feb-05 PARACETAMOL PNEUMONIA 26-Feb-05 2-Mar-05
23 367 SSG 1-Feb-05 CIPROFLOXACIN PNEUMONIA 27-Feb-05 5-Mar-05
23 367 SSG 1-Feb-05 GENTIN VIOLET HERPETIC MOUTH ULCER 3-Mar-05 3-Mar-05
23 367 SSG 1-Feb-05 CRYSTALLINE 
PENICILLIN
PNEUMONIA 9-Feb-05 14-Feb-05
23 367 SSG 1-Feb-05 MAKDEX EYE DROPS ALLERGIC CONJUCTIVITIS 8-Jun-05 13-Jun-05
23 367 SSG 1-Feb-05 FLOXAPEN OTITIS MEDIA 7-Mar-05 12-Mar-05
23 367 SSG 1-Feb-05 CATEFLAM OTITIS MEDIA 7-Mar-05 12-Mar-05
23 369 Combination 4-Feb-05 CRYSTAL PEN. BRONCHO PNEUMONIA 28-Jan-05 3-Feb-05
23 369 Combination 4-Feb-05 GENTAMICIN BRONCHO PNEUMONIA 28-Jan-05 2-Feb-05
23 370 SSG 4-Feb-05 CRYTALLIN PENICILLIN B/PNEUMONIA 28-Jan-05 2-Feb-05
23 371 PM 4-Feb-05 PARACETAMOL ABDOMINAL PAIN 4-Feb-05 14-Feb-05
23 371 PM 4-Feb-05 CRYSTALLINE 
PENICILLIN
PERITONITIS 6-Feb-05 9-Feb-05
23 371 PM 4-Feb-05 MEBENDAZOLE ASCARIS INFECTION 7-Feb-05 9-Feb-05
23 371 PM 4-Feb-05 VITAMIN K ASCITES ? BLEEDING 7-Feb-05 9-Feb-05
23 371 PM 4-Feb-05 FLAGYL PERITONITIS 7-Feb-05 14-Feb-05
23 371 PM 4-Feb-05 AUGUMENTIN U.T.I (URINARY TRACT 
INFECTION)
21-Feb-05 28-Feb-05
23 371 PM 4-Feb-05 BROZEDEX URTI 5-Sep-05 10-Sep-05
23 371 PM 4-Feb-05 CLAVULIN URTI 7-Sep-05 14-Sep-05
23 371 PM 4-Feb-05 DUCOLAX ?CONSTIPESLIN 14-Sep-05 15-Sep-05
23 374 SSG 24-Feb-05 PARACETAMOL FEVER 19-Feb-05 23-Feb-05
23 374 SSG 24-Feb-05 BENZYL PENICILLIN B. PNEUMONIA 19-Feb-05 24-Feb-05
23 374 SSG 24-Feb-05 NITROFUNATON UTI 7-Mar-05 13-Mar-05
23 374 SSG 24-Feb-05 VIT K BLEEDING GUMS 12-Mar-05 14-Mar-05
23 374 SSG 24-Feb-05 PARACETAMOL NECK PAINS 17-Mar-05 20-Mar-05
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23 375 Combination 25-Feb-05 PARACETAMOL EYE PAIN 11-Mar-05 13-Mar-05
23 376 SSG 1-Mar-05 VIT. K. PROLONGED PROTHROMBIN 
TIME
23-Feb-05 26-Feb-05
23 376 SSG 1-Mar-05 PARACETAMOL FEVER HEADACHE JOINT 
PAINS
7-Mar-05 9-Mar-05
23 376 SSG 1-Mar-05 TETRACYCLINE EYE 
OINTMENT
CONJUCTIVITIS 28-Mar-05 31-Mar-05
23 377 Combination 9-Mar-05 PARACETAMOL 1 GM 13-Mar-05 14-Mar-05
23 378 Combination 9-Mar-05 CEFTRIAXONE BIL PNEUMONIA 7-Jul-05 11-Jul-05
23 379 PM 10-Mar-05 ERYTHROMYCIN PNEUMONIA 1-Mar-05 7-Mar-05
23 379 PM 10-Mar-05 AMPICLOX SEPTIC WOUND 30-Sep-05 7-Oct-05
23 379 PM 10-Mar-05 PARACETAMOL SEPTIC WOUND 30-Sep-05 7-Oct-05
23 379 PM 10-Mar-05 BETADINE SEPTIC WOUND 30-Sep-05 7-Oct-05
23 380 SSG 15-Mar-05 ALBENDAZOLE DE-WORMING 10-Mar-05 10-Mar-05
23 380 SSG 15-Mar-05 FLAGYL AMOEBIASIS GIARDIASIS 10-Mar-05 14-Mar-05
23 381 PM 15-Mar-05 ALBENDAZOLE TABS GENERAL DEWORMING 10-Mar-05 10-Mar-05
23 381 PM 15-Mar-05 MEBENDAZOLE TABS A HISTOLYTICA CYSTS 10-Mar-05 15-Mar-05
23 381 PM 15-Mar-05 ENHANCIN PNEUMONIA 13-Jul-05 22-Jul-05
23 381 PM 15-Mar-05 NIZORAL TINEA CAPITIS 19-Jul-05 22-Jul-05
23 381 PM 15-Mar-05 ENHANCIN PNEUMONIA 13-Jul-05 21-Jul-05
23 381 PM 15-Mar-05 NIZORAL TINEA CAPITIS 19-Jul-05 2-Aug-05
23 382 Combination 18-Mar-05 CRYSTALLINE 
PENICILLIN
U.R.T.I (UPPER RESP. TRACT 
INFECTION)
21-Mar-04 23-Mar-04
23 382 Combination 18-Mar-05 AMOXIL URTI 23-Mar-04 29-Mar-04
23 382 Combination 18-Mar-05 ASCORIL URTI 25-Mar-04 29-Mar-04
23 382 Combination 18-Mar-05 PARACETAMOL CELLULITIS RIGHT BUTTOCK 3-Apr-05 7-Apr-05
23 382 Combination 18-Mar-05 SUPRAPEN CELLULITIS RT. BUTTOCK 4-Apr-05 7-Apr-05
23 383 PM 5-Apr-05 XPEN B. PNEUMONIA 27-Mar-05 31-Mar-05
23 383 PM 5-Apr-05 CLAVULIN B. PNEUMONIA 1-Apr-05 4-Apr-05
23 383 PM 5-Apr-05 PANADOL B. PNEUMONIA 29-Mar-05 5-Apr-05
23 383 PM 5-Apr-05 CERUMOL EAR WAX 1-Apr-05 4-Apr-05
23 383 PM 5-Apr-05 PANADOL GLUTEAL TENDERNESS 20-Apr-05 25-Apr-05
23 384 SSG 5-Apr-05 AMOXYCILLIN CAPS PNEUMONIA 28-Mar-05 3-Apr-05
23 384 SSG 5-Apr-05 POP LT RADIAL 28-Apr-05
23 384 SSG 5-Apr-05 CLAVULIN PNEUMONIA 17-Nov-05 24-Nov-05
23 384 SSG 5-Apr-05 ASCORIL WHEEZING 17-Nov-05 24-Nov-05
23 385 SSG 7-Apr-05 VITAMIN K PROLONGED PROTHROMBIN 
TIME
24-Mar-05 26-Mar-05
23 385 SSG 7-Apr-05 VIT K PROLONGED PROTHROMBIN 
TIME
29-Mar-05 31-Mar-05
23 385 SSG 7-Apr-05 AMOXIL PNEUMONIA 1-Apr-05 5-Apr-05
23 385 SSG 7-Apr-05 CEFITRIAXONE PNEUMONIA 15-Apr-05 20-Apr-05
23 392 Combination 22-Apr-05 XPEN PNEUMONIA 25-Apr-05 29-Apr-05
23 392 Combination 22-Apr-05 PIRITON ALLERGIC SKIN REACTION 12-May-05 25-May-05
23 392 Combination 22-Apr-05 BETADINE ALLERGIC SKIN REACTION 19-May-05 27-May-05
23 392 Combination 22-Apr-05 BETADINE BRUISES ON BOTH LEGS 22-Jul-05 29-Jul-05
23 394 PM 26-Apr-05 CRYSTALLINE 
PENICILLIN
PNEUMONIA 19-Apr-05 19-Apr-05
23 394 PM 26-Apr-05 AUGUMENTIN PNEUMONIA 19-Apr-05 26-Apr-05
23 394 PM 26-Apr-05 ALBENDAZOLE POSSIBLE HELMINTHS 19-Apr-05 19-Apr-05
23 394 PM 26-Apr-05 BUSCOPAN ABDOMINAL PAIN 30-Apr-05 1-May-05
23 395 PM 29-Apr-05 PARACETAMOL HEADACHE & FEVER 15-May-05 17-May-05
LEAP 0104a Appendices
Page 439 of 756
Appendix 37: Concomitant medication
Centre Patient Treatment Treatment Concomitant Diagnosis Start date End date
 Number Number start date Medication
23 396 SSG 13-May-05 AMOXYCILLIN CAPS ACUTE OTITIS MEDIA 20-May-05 27-May-05
23 396 SSG 13-May-05 PARACETAMOL TABS ACUTE OTITIS MEDIA 20-May-05 27-May-05
23 397 SSG 18-May-05 (CEPHOGRAM) 
CETRIAXONE
BASAL PNEUMONITIS 13-May-05 18-May-05
23 397 SSG 18-May-05 PARACETAMOL BASAL PNEUMONITIS 13-May-05 15-May-05
23 397 SSG 18-May-05 VIT K NOT KNOWN 13-May-05 16-May-05
23 399 PM 18-May-05 TETRACYCLINE CONJUCTIVITIS 14-Oct-05 21-Oct-05
23 399 PM 18-May-05 TETANUS TOXOID WOUND RT TOE 14-Oct-05 14-Oct-05
23 400 PM 3-Jun-05 CRYSTALLINE 
PENICILLIN
PNEUMONIA 14-May-05 24-May-05
23 400 PM 3-Jun-05 PANADOL PNEUMONIA 14-May-05 23-May-05
23 400 PM 3-Jun-05 MUCO SLOVAN PNEUMONIA 20-May-05 30-May-05
23 400 PM 3-Jun-05 BLOOD ANAEMIA 25-May-05 26-May-05
23 400 PM 3-Jun-05 CEFTRIOXONE PNEUMONIA 23-May-05 30-May-05
23 401 Combination 3-Jun-05 PARACETAMOL FEVER 8-Sep-05 14-Sep-05
23 401 Combination 3-Jun-05 LASIX TO COVER TRANSFUSION 15-Sep-05 15-Sep-05
23 401 Combination 3-Jun-05 FANSIDAR TO COVER TRANSFUSION 15-Sep-05 15-Sep-05
23 401 Combination 3-Jun-05 LASIX TRANSFUSION 15-Sep-05 15-Sep-05
23 401 Combination 3-Jun-05 FANSIDER TRANSFUSION 15-Sep-05 15-Sep-05
23 403 SSG 4-Jun-05 BETADINE MOUTH 
WASH
DENTAL CARIES & GINGIVITIS 9-Jun-05 29-Jun-05
23 403 SSG 4-Jun-05 PIRITON PAPULAR RASH 23-Jun-05 26-Jun-05
23 405 PM 10-Jun-05 ERYTHROMYCIN ATYPICAL PNEUMONIA 4-Jun-05 8-Jun-05
34 451 Combination 17-Nov-04 MEASLES VACC. PROPHYLAXIS 17-Nov-04
34 451 Combination 17-Nov-04 MEASLES VACC. PROPHYLAXIS 4-Dec-04
34 451 Combination 17-Nov-04 VITAMIN A SUPPLEMENTARY 17-Nov-04
34 451 Combination 17-Nov-04 MULTI VIT SUPPLEMENTARY 17-Nov-04 3-Dec-04
34 451 Combination 17-Nov-04 FOLIC ACID ANAEMIA 17-Nov-04 3-Dec-04
34 451 Combination 17-Nov-04 FERROUS SULFATE ANAEMIA 17-Nov-04 3-Dec-04
34 451 Combination 17-Nov-04 PARACETAMOL FEVER 17-Nov-04 19-Nov-04
34 452 PM 17-Nov-04 MEASLES VACC PROPHYLAXIS 17-Nov-04
34 452 PM 17-Nov-04 MEASLES VACC. PROPHYLAXIS 7-Dec-04
34 452 PM 17-Nov-04 VITAMIN A SUPPLEMENTARY 17-Nov-04
34 452 PM 17-Nov-04 FOLIC ACID ANAEMIA 17-Nov-04 7-Dec-04
34 452 PM 17-Nov-04 FERROUS SULFATE ANAEMIA 17-Nov-04 7-Dec-04
34 452 PM 17-Nov-04 MULTI VITS SUPPLEMENTARY 17-Nov-04 7-Dec-04
34 452 PM 17-Nov-04 PARACETAMOL FEVER 16-Nov-04 17-Nov-04
34 453 PM 18-Nov-04 PARACETAMOL FEVER 18-Nov-04 24-Nov-04
34 453 PM 18-Nov-04 FOLIC ACID ANAEMIA 18-Nov-04 17-Jan-05
34 453 PM 18-Nov-04 FERROUS SULFATE ANAEMIA 18-Nov-04 17-Jan-05
34 453 PM 18-Nov-04 MULTI VITS SUPPLEMENTARY 18-Nov-04 17-Jan-05
34 453 PM 18-Nov-04 SULFADOXINE MALARIA 21-Nov-04
34 453 PM 18-Nov-04 PYRIMETHAMINE MALARIA 21-Nov-04
34 453 PM 18-Nov-04 ARTEMETHER MALARIA 22-Nov-04 25-Nov-04
34 453 PM 18-Nov-04 ARTESUNATE MALARIA 26-Nov-04 27-Nov-04
34 454 Combination 21-Nov-04 MEASLES VACC. PROPHYLAXIS 19-Nov-04
34 454 Combination 21-Nov-04 MEASLES VACC. PROPHYLAXIS 8-Dec-04
34 454 Combination 21-Nov-04 VITAMIN A SUPPLEMENTARY 18-Nov-04
34 454 Combination 21-Nov-04 FOLIC ACID ANAEMIA 18-Nov-04 8-Dec-04
34 454 Combination 21-Nov-04 FERROUS SULFATE ANAEMIA 18-Nov-04 8-Dec-04
34 454 Combination 21-Nov-04 MULTI VITS ANAEMIA 18-Nov-04 8-Dec-04
34 454 Combination 21-Nov-04 PARACETAMOL FEVER 18-Nov-04 22-Nov-04
34 454 Combination 21-Nov-04 AMOXICILLIN PNEUMONIA 18-Nov-04 22-Nov-04
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34 455 PM 19-Nov-04 MEASLES VACC. PROPHYLAXIS 19-Nov-04
34 455 PM 19-Nov-04 MEASLES VACC. PROPHYLAXIS 9-Dec-04
34 455 PM 19-Nov-04 VITAMIN A SUPPLEMENTARY 18-Nov-04
34 455 PM 19-Nov-04 FOLIC ACID ANAEMIA 18-Nov-04 1-Jan-05
34 455 PM 19-Nov-04 FERROUS SULFATE ANAEMIA 18-Nov-04 1-Jan-05
34 455 PM 19-Nov-04 MULTI VITS SUPPLEMENTARY 18-Nov-04 1-Jan-05
34 455 PM 19-Nov-04 PARACETAMOL FEVER 18-Nov-04 29-Nov-04
34 455 PM 19-Nov-04 ARTESUNATE MALARIA 25-Nov-04 27-Nov-04
34 455 PM 19-Nov-04 SULFADOXINE 25-Nov-04
34 455 PM 19-Nov-04 PYRIMETHAMINE 25-Nov-04
34 455 PM 19-Nov-04 QUININE 28-Nov-04 4-Dec-04
34 456 SSG 19-Nov-04 MEASLES VACC. PROPHYLAXIS 18-Nov-04
34 456 SSG 19-Nov-04 MEASLES VACC. PROPHYLAXIS 16-Dec-04
34 456 SSG 19-Nov-04 VITAMIN A SUPPLEMENTARY 18-Nov-04
34 456 SSG 19-Nov-04 FOLIC ACID ANAEMIA 18-Nov-04 17-Dec-04
34 456 SSG 19-Nov-04 FERROUS SULFATE ANAEMIA 18-Nov-04 17-Dec-04
34 456 SSG 19-Nov-04 MULTI VITS SUPPLEMENTARY 18-Nov-04 17-Dec-04
34 456 SSG 19-Nov-04 PARACETAMOL FEVER 18-Nov-04 24-Nov-04
34 457 Combination 19-Nov-04 VITAMIN A SUPPLEMENTARY 18-Nov-04
34 457 Combination 19-Nov-04 FOLIC ACID ANAEMIA 18-Nov-04 5-Dec-04
34 457 Combination 19-Nov-04 FERROUS SULPHATE ANAEMIA 18-Nov-04 5-Dec-04
34 457 Combination 19-Nov-04 PARACETAMOL FEVER 18-Nov-04 21-Nov-04
34 457 Combination 19-Nov-04 DEXTROSE 5% DEHYDRATION 18-Nov-04
34 457 Combination 19-Nov-04 MULTI VIT SUPPLEMENTARY 18-Nov-04 5-Dec-04
34 458 PM 20-Nov-04 MEASLES VACC. PROPHYLAXIS 20-Nov-04
34 458 PM 20-Nov-04 MEASLES VACC. PROPHYLAXIS 12-Dec-04
34 458 PM 20-Nov-04 VITAMIN A SUPPLEMENTARY 19-Nov-04
34 458 PM 20-Nov-04 FOLIC ACID ANAEMIA 19-Nov-04 11-Dec-04
34 458 PM 20-Nov-04 FERROUS SULPHATE ANAEMIA 19-Nov-04 11-Dec-04
34 458 PM 20-Nov-04 PARACETAMOL FEVER 19-Nov-04 20-Nov-04
34 458 PM 20-Nov-04 MULTI VITAMIN SUPPLEMENTARY 19-Nov-04 11-Dec-04
34 458 PM 20-Nov-04 ARTESUNATE MALARIA 26-Nov-04 28-Nov-04
34 458 PM 20-Nov-04 SULFADOXINE 26-Nov-04
34 458 PM 20-Nov-04 PYRIMETHAMINE 26-Nov-04
34 459 Combination 20-Nov-04 MEASLES VACC PROPHYLAXIS 20-Nov-04
34 459 Combination 20-Nov-04 MEASLES VACC PROPHYLAXIS 7-Dec-04
34 459 Combination 20-Nov-04 VITAMIN A SUPPLEMENTARY 20-Nov-04
34 459 Combination 20-Nov-04 FOLIC ACID ANAEMIA 20-Nov-04 6-Dec-04
34 459 Combination 20-Nov-04 FERROUS SULFATE ANAEMIA 20-Nov-04 6-Dec-04
34 459 Combination 20-Nov-04 MULTI VITS SUPPLEMENTARY 20-Nov-04 6-Dec-04
34 459 Combination 20-Nov-04 PARACETAMOL FEVER 20-Nov-04 22-Nov-04
34 460 PM 24-Nov-04 MEASLES VACC. PROPHYLAXIS 23-Nov-04
34 460 PM 24-Nov-04 PARACETAMOL FEVER 22-Nov-04 24-Nov-04
34 460 PM 24-Nov-04 MULTI VITS SUPPLEMENTARY 22-Nov-04 12-Jan-05
34 460 PM 24-Nov-04 FOLIC ACID ANAEMIA 22-Nov-04 12-Jan-05
34 460 PM 24-Nov-04 FERROUS SULFATE ANAEMIA 22-Nov-04 12-Jan-05
34 460 PM 24-Nov-04 MEASLES VACC PROPHYLAXIS 14-Dec-04
34 460 PM 24-Nov-04 VITAMIN A SUPPLEMENTARY 22-Nov-04
34 460 PM 24-Nov-04 AMOXICILLIN OTITIS MEDIA 22-Nov-04 26-Nov-04
34 461 SSG 26-Nov-04 VITAMIN A SUPPLEMENTARY 24-Nov-04
34 461 SSG 26-Nov-04 FOLIC ACID ANAEMIA 24-Nov-04 10-Dec-04
34 461 SSG 26-Nov-04 FERROUS SULPHATE ANAEMIA 24-Nov-04 10-Dec-04
34 461 SSG 26-Nov-04 MULTI VITS SUPPLEMENTARY 24-Nov-04 10-Dec-04
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34 461 SSG 26-Nov-04 CEFTRIAXONE PNEUMONIA 24-Nov-04 2-Dec-04
34 461 SSG 26-Nov-04 PARACETAMOL CHEST PAIN 25-Nov-04 27-Nov-04
34 461 SSG 26-Nov-04 GELATINE 
POLYSUCCINATE 4%
EPISTAXIS 28-Nov-04
34 461 SSG 26-Nov-04 VITAMIN K EPISTAXIS 28-Nov-04 29-Nov-04
34 461 SSG 26-Nov-04 SALBUTAMOL 29-Nov-04
34 461 SSG 26-Nov-04 BLOOD TRANSFUSION 30-Nov-04
34 461 SSG 26-Nov-04 BLOOD TRANSFUSION 10-Dec-04
34 461 SSG 26-Nov-04 CIPROFLOXACINE 3-Dec-04 9-Dec-04
34 461 SSG 26-Nov-04 SPIRONOLACTON 9-Dec-04 10-Dec-04
34 461 SSG 26-Nov-04 HYDROCORTISON 9-Dec-04
34 461 SSG 26-Nov-04 ETHAMBUTOL 9-Dec-04
34 461 SSG 26-Nov-04 RIFANPICINE 9-Dec-04
34 461 SSG 26-Nov-04 ISOMIAZIOLE 9-Dec-04
34 461 SSG 26-Nov-04 PYRAZINAMIDE 9-Dec-04
34 462 SSG 25-Nov-04 MEASLES VACC. PROPHYLAXIS 25-Nov-04
34 462 SSG 25-Nov-04 MEASLES VACC. PROPHYLAXIS 24-Dec-04
34 462 SSG 25-Nov-04 PARACETAMOL FEVER 25-Nov-04 27-Nov-04
34 462 SSG 25-Nov-04 VITAMIN A SUPPLEMENTARY 25-Nov-04
34 462 SSG 25-Nov-04 FOLIC ACID ANAEMIA 25-Nov-04 24-Dec-04
34 462 SSG 25-Nov-04 FERROUS SULPHATE ANAEMIA 25-Nov-04 24-Dec-04
34 462 SSG 25-Nov-04 MULTI VITS SUPPLEMENTARY 25-Nov-04 24-Dec-04
34 463 Combination 27-Nov-04 VITAMIN A SUPPLEMENTARY 25-Nov-04
34 463 Combination 27-Nov-04 FOLIC ACID ANAEMIA 25-Nov-04 14-Dec-04
34 463 Combination 27-Nov-04 FERROUS SULFATE ANAEMIA 25-Nov-04 14-Dec-04
34 463 Combination 27-Nov-04 MULTI VITS SUPPLEMENTARY 25-Nov-04 14-Dec-04
34 463 Combination 27-Nov-04 PARACETAMOL FEVER 25-Nov-04 28-Nov-04
34 463 Combination 27-Nov-04 TETRACYCLIN EYE 
OINTMENT
CONJUNCTIVITIS 27-Nov-04 29-Nov-04
34 463 Combination 27-Nov-04 MEASLES VACC. PROPHYLAXIS 28-Nov-04
34 463 Combination 27-Nov-04 MEASLES VACC. PROPHYLAXIS 14-Dec-04
34 464 SSG 27-Nov-04 VITAMIN A SUPPLEMENTARY 26-Nov-04
34 464 SSG 27-Nov-04 FOLIC ACID ANAEMIA 26-Nov-04 26-Dec-04
34 464 SSG 27-Nov-04 FERROUS SULPHATE ANAEMIA 26-Nov-04 26-Dec-04
34 464 SSG 27-Nov-04 MULTI VITS SUPPLEMENTARY 26-Nov-04 26-Dec-04
34 464 SSG 27-Nov-04 PARACETAMOL FEVER 26-Nov-04 28-Nov-04
34 465 SSG 29-Nov-04 VITAMIN A SUPPLEMENTARY 27-Nov-04
34 465 SSG 29-Nov-04 FOLIC ACID ANAEMIA 27-Nov-04 27-Dec-04
34 465 SSG 29-Nov-04 FERROUS SULFATE ANAEMIA 27-Nov-04 27-Dec-04
34 465 SSG 29-Nov-04 MULTI VITS SUPPLEMENTARY 27-Nov-04 27-Dec-04
34 465 SSG 29-Nov-04 PARACETAMOL FEVER 1-Dec-04
34 465 SSG 29-Nov-04 CEFTRIAXONE PNEUMONIA 27-Nov-04 1-Dec-04
34 465 SSG 29-Nov-04 TETRACYCLINE EYE 
OINTMENT
CONJUNCTIVITIS 25-Dec-04 27-Dec-04
34 466 Combination 30-Nov-04 VITAMIN A SUPPLEMENTARY 28-Nov-04
34 466 Combination 30-Nov-04 FOLIC ACID ANAEMIA 4-Dec-04 15-Jan-05
34 466 Combination 30-Nov-04 FERROUS SULFATE ANAEMIA 28-Nov-04 15-Jan-05
34 466 Combination 30-Nov-04 MULTI VITS SUPPLEMENTARY 28-Nov-04 15-Jan-05
34 466 Combination 30-Nov-04 ARTESUNATE MALARIA 28-Nov-04 30-Nov-04
34 466 Combination 30-Nov-04 SULFADOXINE MALARIA 28-Nov-04
34 466 Combination 30-Nov-04 PYRIMETHAMINE MALARIA 28-Nov-04
34 466 Combination 30-Nov-04 PARACETAMOL FEVER 28-Nov-04 29-Nov-04
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34 467 PM 29-Nov-04 VITAMIN A SUPPLEMENTARY 29-Nov-04
34 467 PM 29-Nov-04 FOLIC ACID ANAEMIA 29-Nov-04 19-Dec-04
34 467 PM 29-Nov-04 FERROUS SULFATE ANAEMIA 29-Nov-04 19-Dec-04
34 467 PM 29-Nov-04 PARACETAMOL FEVER 28-Nov-04 19-Dec-04
34 467 PM 29-Nov-04 MEASLES VACCINE PROPHYLAXIS 29-Nov-04
34 467 PM 29-Nov-04 ARTESUNATE MALARIA 8-Dec-04 10-Dec-04
34 467 PM 29-Nov-04 SULFADOXINE MALARIA 8-Dec-04
34 467 PM 29-Nov-04 PYRIMETHAMINE MALARIA 8-Dec-04
34 467 PM 29-Nov-04 MEASLES VACC. 19-Dec-04
34 468 Combination 29-Nov-04 VITAMIN A SUPPLEMENTARY 29-Nov-04
34 468 Combination 29-Nov-04 FOLIC ACID ANAEMIA 29-Nov-04 15-Dec-04
34 468 Combination 29-Nov-04 FERROUS SULFATE ANAEMIA 29-Nov-04 15-Dec-04
34 468 Combination 29-Nov-04 MULTI VITS SUPPLEMENTARY 29-Nov-04 15-Dec-04
34 468 Combination 29-Nov-04 PARACETAMOL FEVER 28-Nov-04 30-Nov-04
34 469 SSG 29-Nov-04 VITAMIN A SUPPLEMENTARY 29-Nov-04
34 469 SSG 29-Nov-04 FOLIC ACID ANAEMIA 29-Nov-04 27-Dec-04
34 469 SSG 29-Nov-04 FERROUS SULPHATE ANAEMIA 29-Nov-04 27-Dec-04
34 469 SSG 29-Nov-04 MULTI VITS SUPPLEMENTARY 29-Nov-04 27-Dec-04
34 469 SSG 29-Nov-04 PARACETAMOL FEVER 28-Nov-04 3-Dec-04
34 469 SSG 29-Nov-04 MEASLES VACCINE PROPHYLAXIS 3-Dec-04
34 469 SSG 29-Nov-04 ARTESUNATE MALARIA 9-Dec-04 11-Dec-04
34 469 SSG 29-Nov-04 SULFADOXINE MALARIA 9-Dec-04
34 469 SSG 29-Nov-04 PYRIMETHAMINE 9-Dec-04
34 470 Combination 29-Nov-04 VITAMIN A SUPPLEMENTARY 29-Nov-04
34 470 Combination 29-Nov-04 FOLIC ACID ANAEMIA 29-Nov-04 15-Dec-04
34 470 Combination 29-Nov-04 FERROUS SULPHATE ANAEMIA 29-Nov-04 15-Dec-04
34 470 Combination 29-Nov-04 MULTI VITS SUPPLEMENTARY 29-Nov-04 15-Dec-04
34 470 Combination 29-Nov-04 PARACETAMOL FEVER 29-Nov-04 4-Dec-04
34 470 Combination 29-Nov-04 MEASLES VACCINE PROPHYLAXIS 29-Nov-04
34 470 Combination 29-Nov-04 MEASLES VACCINE PROPHYLAXIS 17-Dec-04
34 471 PM 29-Nov-04 VITAMIN A SUPPLEMENTARY 29-Nov-04
34 471 PM 29-Nov-04 FOLIC ACID ANAEMIA 29-Nov-04 18-Jan-05
34 471 PM 29-Nov-04 FERROUS SULFATE ANAEMIA 29-Nov-04 18-Jan-05
34 471 PM 29-Nov-04 MULTI VITS SUPPLEMENTARY 29-Nov-04 18-Jan-05
34 471 PM 29-Nov-04 PARACETAMOL FEVER 29-Nov-04 30-Nov-04
34 471 PM 29-Nov-04 MEASLES VACCINE PROPHYLAXIS 3-Dec-04
34 471 PM 29-Nov-04 ARTESUNATE MALARIA 5-Dec-04 7-Dec-04
34 471 PM 29-Nov-04 SULFADOXINE MALARIA 5-Dec-04
34 471 PM 29-Nov-04 PYRIMETHAMINE 5-Dec-04
34 471 PM 29-Nov-04 MEASLES VACC. 19-Dec-04
34 472 SSG 1-Dec-04 VITAMIN A SUPPLEMENTARY 1-Dec-04
34 472 SSG 1-Dec-04 FOLIC ACID ANAEMIA 1-Dec-04 29-Dec-04
34 472 SSG 1-Dec-04 FERROUS SULPHATE ANAEMIA 1-Dec-04 29-Dec-04
34 472 SSG 1-Dec-04 MULTI VITS SUPPLEMENTARY 1-Dec-04 29-Dec-04
34 472 SSG 1-Dec-04 PARACETAMOL FEVER 1-Dec-04 2-Dec-04
34 472 SSG 1-Dec-04 MEASLES VACCINE PROPHYLAXIS 4-Dec-04
34 472 SSG 1-Dec-04 MEASLES VACC. PROPHYLAXIS 30-Dec-04
34 473 PM 3-Dec-04 VITAMIN A SUPPLEMENTARY 1-Dec-04
34 473 PM 3-Dec-04 FOLIC ACID ANAEMIA 1-Dec-04 22-Jan-05
34 473 PM 3-Dec-04 FERROUS SULPHATE ANAEMIA 1-Dec-04 22-Jan-05
34 473 PM 3-Dec-04 MULTI VITS SUPPLEMENTARY 1-Dec-04 22-Jan-05
34 473 PM 3-Dec-04 PARACETAMOL FEVER 1-Dec-04 2-Dec-04
34 473 PM 3-Dec-04 MEASLES VACC. PROPHYLAXIS 5-Dec-04
34 473 PM 3-Dec-04 MEASLES VACC. PROPHYLAXIS 24-Dec-04
34 474 Combination 4-Dec-04 MEASLES VACC. PROPHYLAXIS 4-Dec-04
34 474 Combination 4-Dec-04 VITAMIN A SUPPLEMENTARY 4-Dec-04
34 474 Combination 4-Dec-04 FOLIC ACID ANAEMIA 4-Dec-04 21-Dec-04
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34 474 Combination 4-Dec-04 FERROUS SULFATE ANAEMIA 4-Dec-04 21-Dec-04
34 474 Combination 4-Dec-04 MULTI VITS SUPPLEMENTARY 4-Dec-04 21-Dec-04
34 474 Combination 4-Dec-04 MEASLES VACC. PROPHYLAXIS 21-Dec-04
34 475 PM 5-Dec-04 VITAMIN A SUPPLEMENTARY 4-Dec-04
34 475 PM 5-Dec-04 FOLIC ACID ANAEMIA 4-Dec-04 25-Dec-04
34 475 PM 5-Dec-04 FERROUS SULFATE ANAEMIA 4-Dec-04 25-Dec-04
34 475 PM 5-Dec-04 MULTI VITS SUPPLEMENTARY 4-Dec-04 25-Dec-04
34 475 PM 5-Dec-04 PARACETAMOL FEVER 4-Dec-04
34 475 PM 5-Dec-04 MEASLES VACC. PROPHYLAXIS 5-Dec-04
34 475 PM 5-Dec-04 MEASLES VACC. PROPHYLAXIS 25-Dec-04
34 476 PM 5-Dec-04 VITAMIN A SUPPLEMENTARY 4-Dec-04
34 476 PM 5-Dec-04 FOLIC ACID ANAEMIA 4-Dec-04 25-Dec-04
34 476 PM 5-Dec-04 FERROUS SULFATE ANAEMIA 4-Dec-04 25-Dec-04
34 476 PM 5-Dec-04 MULTI VITS SUPPLEMENTARY 4-Dec-04 25-Dec-04
34 476 PM 5-Dec-04 PARACETAMOL FEVER 4-Dec-04
34 476 PM 5-Dec-04 MEASLES VACC. PROPHYLAXIS 5-Dec-04
34 476 PM 5-Dec-04 MEASLES VACC. PROPHYLAXIS 25-Dec-04
34 477 SSG 6-Dec-04 VITAMIN A SUPPLEMENTARY 6-Dec-04
34 477 SSG 6-Dec-04 FOLIC ACID ANAEMIA 6-Dec-04 4-Jan-05
34 477 SSG 6-Dec-04 FERROUS SULPHATE ANAEMIA 6-Dec-04 4-Jan-05
34 477 SSG 6-Dec-04 MULTI VITS SUPPLEMENTARY 6-Dec-04 4-Jan-05
34 477 SSG 6-Dec-04 PARACETAMOL FEVER 6-Dec-04 7-Dec-04
34 477 SSG 6-Dec-04 MEASLES VACC. PROPHYLAXIS 6-Dec-04
34 477 SSG 6-Dec-04 ARTESUNATE MALARIA 26-Dec-04 28-Dec-04
34 477 SSG 6-Dec-04 PYRIMETHAMINE MALARIA 26-Dec-04
34 477 SSG 6-Dec-04 SULFADOXINE 26-Dec-04
34 477 SSG 6-Dec-04 ARTESUNATE MALARIA 5-Jun-05 7-Jun-05
34 477 SSG 6-Dec-04 SULFADOXINE MALARIA 5-Jun-05
34 477 SSG 6-Dec-04 PYRIMETHAMINE MALARIA 5-Jun-05
34 477 SSG 6-Dec-04 PARACETAMOL FEVER 5-Jun-05
34 478 Combination 7-Dec-04 VITAMIN A SUPPLEMENTARY 6-Dec-04
34 478 Combination 7-Dec-04 FERROUS SULFATE ANAEMIA 6-Dec-04 23-Dec-04
34 478 Combination 7-Dec-04 FOLIC ACID ANAEMIA 6-Dec-04 23-Dec-04
34 478 Combination 7-Dec-04 MULTI VITS SUPPLEMENTARY 6-Dec-04 23-Dec-04
34 478 Combination 7-Dec-04 PARACETAMOL FEVER 6-Dec-04 7-Dec-04
34 478 Combination 7-Dec-04 MEASLES VACC. PROPHYLAXIS 7-Dec-04
34 478 Combination 7-Dec-04 MEASLES VACC. PROPHYLAXIS 23-Dec-04
34 479 SSG 8-Dec-04 MEASLES VACC. PROPHYLAXIS 7-Dec-04
34 479 SSG 8-Dec-04 VITAMIN A SUPPLEMENTARY 8-Dec-04
34 479 SSG 8-Dec-04 FOLIC ACID ANAEMIA 8-Dec-04 6-Jan-05
34 479 SSG 8-Dec-04 FERROUS SULPHATE ANAEMIA 8-Dec-04 6-Jan-05
34 479 SSG 8-Dec-04 PARACETAMOL FEVER 8-Dec-04 10-Dec-04
34 479 SSG 8-Dec-04 MULTI VITS SUPPLEMENTARY 8-Dec-04 6-Jan-05
34 480 SSG 9-Dec-04 VITAMIN A SUPPLEMENTARY 9-Dec-04
34 480 SSG 9-Dec-04 MEASLES VACC. PROPHYLAXIS 9-Dec-04
34 480 SSG 9-Dec-04 FOLIC ACID ANAEMIA 9-Dec-04 7-Jan-05
34 480 SSG 9-Dec-04 FERROUS SULPHATE ANAEMIA 9-Dec-04 7-Jan-05
34 480 SSG 9-Dec-04 MULTI VITS SUPPLEMENTARY 9-Dec-04 7-Jan-05
34 480 SSG 9-Dec-04 MEASLES VACC. PROPHYLAXIS 7-Jan-05
34 481 Combination 9-Dec-04 MEASLES VACC. PROPHYLAXIS 9-Dec-04
34 481 Combination 9-Dec-04 FOLIC ACID ANAEMIA 9-Dec-04 25-Dec-04
34 481 Combination 9-Dec-04 FERROUS SULPHATE ANAEMIA 9-Dec-04 25-Dec-04
34 481 Combination 9-Dec-04 VITAMIN A SUPPLEMENTARY 9-Dec-04
34 481 Combination 9-Dec-04 MULTI VITAMIN SUPPLEMENTARY 9-Dec-04 25-Dec-04
34 481 Combination 9-Dec-04 PARACETAMOL FEVER 9-Dec-04
34 481 Combination 9-Dec-04 MEASLES VACC. PROPHYLAXIS 25-Dec-04
34 482 Combination 10-Dec-04 VITAMIN A SUPPLEMENTARY 10-Dec-04
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34 482 Combination 10-Dec-04 FOLIC ACID SUPPLEMENTARY 10-Dec-04 26-Dec-04
34 482 Combination 10-Dec-04 FERROUS SULPHATE SUPPLEMENTARY 10-Dec-04 26-Dec-04
34 482 Combination 10-Dec-04 MULTI VITS SUPPLEMENTARY 10-Dec-04 26-Dec-04
34 482 Combination 10-Dec-04 PARACETAMOL FEVER 9-Dec-04 10-Dec-04
34 482 Combination 10-Dec-04 ARTESUNATE MALARIA 14-Mar-05 16-Mar-05
34 482 Combination 10-Dec-04 SULFADOXINE MALARIA 14-Mar-05
34 482 Combination 10-Dec-04 PYRIMETHAMINE MALARIA 14-Mar-05
34 482 Combination 10-Dec-04 PARACETAMOL FEVER 14-Mar-05
34 483 PM 10-Dec-04 VITAMIN A SUPPLEMENTARY 10-Dec-04
34 483 PM 10-Dec-04 FOLIC ACID SUPPLEMENTARY 10-Dec-04 29-Dec-04
34 483 PM 10-Dec-04 FERROUS SULPHATE SUPPLEMENTARY 10-Dec-04 29-Dec-04
34 483 PM 10-Dec-04 MULTI VITS SUPPLEMENTARY 10-Dec-04 29-Dec-04
34 483 PM 10-Dec-04 PARACETAMOL FEVER 9-Dec-04 13-Dec-04
34 483 PM 10-Dec-04 AMOXICILLIN PNEUMONIA 13-Dec-04 19-Dec-04
34 484 PM 12-Dec-04 VITAMIN A SUPPLEMENTARY 11-Dec-04
34 484 PM 12-Dec-04 MULTI VITS SUPPLEMENTARY 11-Dec-04 16-Jan-05
34 484 PM 12-Dec-04 FOLIC ACID ANAEMIA 11-Dec-04 16-Jan-05
34 484 PM 12-Dec-04 FERROUS SULPHATE ANAEMIA 11-Dec-04 16-Jan-05
34 484 PM 12-Dec-04 PARACETAMOL FEVER 11-Dec-04 18-Dec-04
34 484 PM 12-Dec-04 MEASLES VACC PROPHYLAXIS 13-Dec-04
34 485 Combination 12-Dec-04 VITAMIN A PROPHYLAXIS 11-Dec-04
34 485 Combination 12-Dec-04 FERROUS SULPHATE ANAEMIA 11-Dec-04 28-Dec-04
34 485 Combination 12-Dec-04 FOLIC ACID ANAEMIA 11-Dec-04 28-Dec-04
34 485 Combination 12-Dec-04 MULTI VIT SUPPLEMENTARY 11-Dec-04 28-Dec-04
34 485 Combination 12-Dec-04 PARACETAMOL FEVER 11-Dec-04 15-Dec-04
34 485 Combination 12-Dec-04 MEASLES VACC. PROPHYLAXIS 16-Dec-04
34 485 Combination 12-Dec-04 MEASLES VACC. PROPHYLAXIS 28-Dec-04
34 485 Combination 12-Dec-04 ARTESUNATE MALARIA 1-May-05 3-May-05
34 485 Combination 12-Dec-04 SULFADOXINE MALARIA 1-May-05
34 485 Combination 12-Dec-04 PYRIMETHAMINE MALARIA 1-May-05
34 485 Combination 12-Dec-04 PARACETAMOL FEVER 1-May-05 3-May-05
34 486 Combination 13-Dec-04 VITAMIN A SUPPLEMENTARY 11-Dec-04
34 486 Combination 13-Dec-04 AMOXICILLIN PNEUMONIA 11-Dec-04 15-Dec-04
34 486 Combination 13-Dec-04 FERROUS SULPHATE ANAEMIA 11-Dec-04 29-Dec-04
34 486 Combination 13-Dec-04 FOLIC ACID ANAEMIA 11-Dec-04 29-Dec-04
34 486 Combination 13-Dec-04 MULTI VIT SUPPLEMENTARY 11-Dec-04 29-Dec-04
34 486 Combination 13-Dec-04 PARACETAMOL FEVER 11-Dec-04 12-Dec-04
34 486 Combination 13-Dec-04 MEASLES VACC. PROPHYLAXIS 13-Dec-04
34 486 Combination 13-Dec-04 MEASLES VACC. PROPHYLAXIS 30-Dec-04
34 487 SSG 13-Dec-04 PARACETAMOL FEVER 13-Dec-04 14-Dec-04
34 487 SSG 13-Dec-04 MEASLES VACC. PROPHYLAXIS 18-Dec-04
34 487 SSG 13-Dec-04 VITAMIN A SUPPLEMENTARY 13-Dec-04
34 487 SSG 13-Dec-04 FOLIC ACID ANAEMIA 13-Dec-04 12-Jan-05
34 487 SSG 13-Dec-04 FERROUS SULFATE ANAEMIA 13-Dec-04 12-Jan-05
34 487 SSG 13-Dec-04 MULTI VITS SUPPLEMENTARY 13-Dec-04 12-Jan-05
34 487 SSG 13-Dec-04 PYRIMETHAMINE MALARIA 2-Jan-05
34 487 SSG 13-Dec-04 SULFADOXINE MALARIA 2-Jan-05
34 487 SSG 13-Dec-04 ARTESUNATE 2-Jan-05 4-Jan-05
34 487 SSG 13-Dec-04 MEASLES VACC. 12-Jan-05
34 488 SSG 14-Dec-04 MEASLES VACC. PROPHYLAXIS 18-Dec-04
34 488 SSG 14-Dec-04 VITAMIN A SUPPLEMENTARY 13-Dec-04
34 488 SSG 14-Dec-04 FOLIC ACID ANAEMIA 13-Dec-04 12-Jan-05
34 488 SSG 14-Dec-04 FERROUS SULFATE ANAEMIA 13-Dec-04 12-Jan-05
34 488 SSG 14-Dec-04 MULTI VITS SUPPLEMENTARY 13-Dec-04 12-Jan-05
34 488 SSG 14-Dec-04 PARACETAMOL FEVER 13-Dec-04
34 488 SSG 14-Dec-04 MEASLES VACC PROPHYLAXIS 13-Jan-05
34 489 SSG 16-Dec-04 MEASLES VACC. PROPHYLAXIS 16-Dec-04
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34 489 SSG 16-Dec-04 VITAMIN A SUPPLEMENTARY 16-Dec-04
34 489 SSG 16-Dec-04 FOLIC ACID ANAEMIA 16-Dec-04 14-Jan-05
34 489 SSG 16-Dec-04 FERROUS SULPHATE ANAEMIA 16-Dec-04 14-Jan-05
34 489 SSG 16-Dec-04 PARACETAMOL FEVER 16-Dec-04
34 489 SSG 16-Dec-04 MULTI VITS SUPPLEMENTARY 16-Dec-04 14-Jan-05
34 489 SSG 16-Dec-04 MEASLES VACC PROPHYLAXIS 13-Jan-05
34 490 PM 16-Dec-04 VITAMIN A PROPHYLAXIS 16-Dec-04
34 490 PM 16-Dec-04 FOLIC ACID ANAEMIA 16-Dec-04 5-Jan-05
34 490 PM 16-Dec-04 FERROUS SULFATE ANAEMIA 16-Dec-04 5-Jan-05
34 490 PM 16-Dec-04 MULTI VITS SUPPLEMENTARY 16-Dec-04 5-Jan-05
34 490 PM 16-Dec-04 PARACETAMOL FEVER 16-Dec-04
34 490 PM 16-Dec-04 MEASLES VACC. PROPHYLAXIS 17-Dec-04
34 490 PM 16-Dec-04 MEASLES VACC. PROPHYLAXIS 7-Jan-05
34 491 PM 17-Dec-04 VITAMIN A SUPPLEMENTARY 16-Dec-04
34 491 PM 17-Dec-04 FOLIC ACID ANAEMIA 16-Dec-04 7-Jan-05
34 491 PM 17-Dec-04 FERROUS SULPHATE ANAEMIA 16-Dec-04 7-Jan-05
34 491 PM 17-Dec-04 MULTI VITS SUPPLEMENTARY 16-Dec-04 7-Jan-05
34 491 PM 17-Dec-04 PARACETAMOL FEVER 16-Dec-04
34 491 PM 17-Dec-04 SULFAMETHOXAZOLE PROPHYLAXIS 24-Dec-04
34 491 PM 17-Dec-04 TRIMETHOPRIM PROPHYLAXIS 24-Dec-04
34 492 PM 19-Dec-04 VITAMIN A PROPHYLAXIS 16-Dec-04
34 492 PM 19-Dec-04 TINIDAZOL MUCOID DIARRHEA 16-Dec-04 18-Dec-04
34 492 PM 19-Dec-04 FOLIC ACID SUPPLEMENTARY 16-Dec-04 9-Jan-05
34 492 PM 19-Dec-04 FERROUS SULFATE SUPPLEMENTARY 16-Dec-04 9-Jan-05
34 492 PM 19-Dec-04 MULTI VITS SUPPLEMENTARY 16-Dec-04 9-Jan-05
34 492 PM 19-Dec-04 RINGER LACFELE DEHYDRATION 16-Dec-04
34 492 PM 19-Dec-04 HYOSCINE 
BUTYLBROMIDE
ABDOMINAL PAIN 16-Dec-04 18-Dec-04
34 492 PM 19-Dec-04 CIPROFLOXACIN SUSPECTED DYSENTRY 17-Dec-04 21-Dec-04
34 492 PM 19-Dec-04 BENZOIC ACID 18-Dec-04 25-Dec-04
34 492 PM 19-Dec-04 SALICYLIC ACID 18-Dec-04 25-Dec-04
34 492 PM 19-Dec-04 METRONIDAZOL AMOEBIASIS 30-Mar-05 5-Apr-05
34 492 PM 19-Dec-04 CIPROFLOXACIN DYSENTRY 6-Apr-05 11-Apr-05
34 493 SSG 17-Dec-04 MEASLES VACC. PROPHYLAXIS 17-Dec-04
34 493 SSG 17-Dec-04 VITAMIN A SUPPLEMENTARY 17-Dec-04
34 493 SSG 17-Dec-04 FOLIC ACID ANAEMIA 17-Dec-04 15-Jan-05
34 493 SSG 17-Dec-04 FERROUS SULFATE ANAEMIA 17-Dec-04 15-Jan-05
34 493 SSG 17-Dec-04 MULTI VITS SUPPLEMENTARY 17-Dec-04 15-Jan-05
34 493 SSG 17-Dec-04 PARACETAMOL FEVER 17-Dec-04 19-Dec-04
34 493 SSG 17-Dec-04 GLUCOSE HYPOGLYCEMIA 17-Dec-04
34 493 SSG 17-Dec-04 ARTESUNATE MALARIA 1-Jan-05 3-Jan-05
34 493 SSG 17-Dec-04 SULFADOXINE 1-Jan-05
34 493 SSG 17-Dec-04 PYRIMETHAMINE 1-Jan-05
34 493 SSG 17-Dec-04 MEASLES VACC. 13-Jan-05
34 493 SSG 17-Dec-04 SSG PKDL WITH MUCOSAL 
INVOLVEMENT
12-Apr-05 18-May-05
34 494 Combination 17-Dec-04 VITAMIN A PROPHYLAXIS 17-Dec-04
34 494 Combination 17-Dec-04 FOLIC ACID ANAEMIA 17-Dec-04 3-Jan-05
34 494 Combination 17-Dec-04 FERROUS SULFATE ANAEMIA 17-Dec-04 3-Jan-05
34 494 Combination 17-Dec-04 MULTI VITS SUPPLEMENTARY 17-Dec-04 3-Jan-05
34 494 Combination 17-Dec-04 PARACETAMOL HEADACHE 17-Dec-04
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34 495 SSG 18-Dec-04 VITAMIN A SUPPLEMENTARY 17-Dec-04
34 495 SSG 18-Dec-04 FOLIC ACID ANAEMIA 17-Dec-04 17-Jan-05
34 495 SSG 18-Dec-04 FERROUS SULFATE ANAEMIA 17-Dec-04 17-Jan-05
34 495 SSG 18-Dec-04 MULTI VITS SUPPLEMENTARY 17-Dec-04 17-Jan-05
34 495 SSG 18-Dec-04 PARACETAMOL FEVER 17-Dec-04 18-Dec-05
34 495 SSG 18-Dec-04 MEASLES VACC. PROPHYLAXIS 18-Dec-04
34 495 SSG 18-Dec-04 PROMETHAZINE ALLERGIC REACTION 24-Dec-04
34 495 SSG 18-Dec-04 MEASLES VACC PROPHYLAXIS 13-Jan-05
34 496 SSG 19-Dec-04 VITAMIN A SUPPLEMENTARY 18-Dec-04
34 496 SSG 19-Dec-04 FOLIC ACID ANAEMIA 18-Dec-04 18-Jan-05
34 496 SSG 19-Dec-04 FERROUS SULFATE ANAEMIA 18-Dec-04 18-Jan-05
34 496 SSG 19-Dec-04 MULTI VITS SUPPLEMENTARY 18-Dec-04 18-Jan-05
34 496 SSG 19-Dec-04 PARACETAMOL FEVER 18-Dec-04 20-Dec-04
34 497 PM 21-Dec-04 VITAMIN A PROPHYLAXIS 21-Dec-04
34 497 PM 21-Dec-04 FOLIC ACID ANAEMIA 21-Dec-04 11-Jan-05
34 497 PM 21-Dec-04 FERROUS SULPHATE ANAEMIA 21-Dec-04 11-Jan-05
34 497 PM 21-Dec-04 MULTI VITS SUPPLEMENTARY 21-Dec-04 11-Jan-05
34 497 PM 21-Dec-04 PARACETAMOL FEVER 20-Dec-04 22-Dec-04
34 498 SSG 21-Dec-04 MEASLES VACC. PROPHYLAXIS 21-Dec-04
34 498 SSG 21-Dec-04 PARACETAMOL FEVER 20-Dec-04 21-Dec-04
34 498 SSG 21-Dec-04 VITAMIN A SUPPLEMENTARY 21-Dec-04
34 498 SSG 21-Dec-04 FOLIC ACID ANAEMIA 21-Dec-04 20-Jan-05
34 498 SSG 21-Dec-04 FERROUS SULPHATE ANAEMIA 21-Dec-04 20-Jan-05
34 498 SSG 21-Dec-04 MULTI VITS SUPPLEMENTARY 21-Dec-04 20-Jan-05
34 498 SSG 21-Dec-04 AMOXICILLIN PNEUMONIA 18-Jan-05 20-Jan-05
34 498 SSG 21-Dec-04 MEASLES VACC PROPHYLAXIS 20-Jan-05
34 499 Combination 21-Dec-04 MEASLES VACC PROPHYLAXIS 21-Dec-04
34 499 Combination 21-Dec-04 VITAMIN A SUPPLEMENTARY 21-Dec-04
34 499 Combination 21-Dec-04 MULTI VITS SUPPLEMENTARY 21-Dec-04 6-Jan-05
34 499 Combination 21-Dec-04 FOLIC ACID ANAEMIA 21-Dec-04 6-Jan-05
34 499 Combination 21-Dec-04 FERROUS SULFATE ANAEMIA 21-Dec-04 6-Jan-05
34 499 Combination 21-Dec-04 PARACETAMOL FEVER 20-Dec-04 21-Dec-04
34 499 Combination 21-Dec-04 GENTIAN VIOLET MUCOSAL LESION IN MOUTH 30-Dec-04 3-Jan-05
34 499 Combination 21-Dec-04 MEASLES VACC PROPHYLAXIS 6-Jan-05
34 500 PM 22-Dec-04 MEASLES VACC. PROPHYLAXIS 21-Dec-04
34 500 PM 22-Dec-04 VITAMIN A SUPPLEMENTARY 21-Dec-04
34 500 PM 22-Dec-04 MULTI VITS SUPPLEMENTARY 21-Dec-04 11-Jan-05
34 500 PM 22-Dec-04 FOLIC ACID ANAEMIA 22-Dec-04 11-Jan-05
34 500 PM 22-Dec-04 FERROUS SULFATE ANAEMIA 27-Dec-04 11-Jan-05
34 500 PM 22-Dec-04 PARACETAMOL FEVER 20-Dec-04
34 500 PM 22-Dec-04 ARTESUNATE MALARIA 20-Dec-04 22-Dec-04
34 500 PM 22-Dec-04 PYRIMETHAMINE MALARIA 20-Dec-04
34 500 PM 22-Dec-04 SALFADOXINE 20-Dec-04
34 500 PM 22-Dec-04 MEASLES VACC 11-Jan-05
34 501 Combination 22-Dec-04 MEASLES VACC. PROPHYLAXIS 22-Dec-04
34 501 Combination 22-Dec-04 VITAMIN A SUPPLEMENTARY 21-Dec-04
34 501 Combination 22-Dec-04 FOLIC ACID ANAEMIA 21-Dec-04 7-Jan-05
34 501 Combination 22-Dec-04 FERROUS SULFATE ANAEMIA 21-Dec-04 7-Jan-05
34 501 Combination 22-Dec-04 MULTI VITS ANAEMIA 21-Dec-04 7-Jan-05
34 501 Combination 22-Dec-04 PARACETAMOL FEVER 21-Dec-04 23-Dec-04
34 501 Combination 22-Dec-04 MEASLES VACC PROPHYLAXIS 8-Jan-05
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34 502 Combination 23-Dec-04 MEASLES VACC. PROPHYLAXIS 22-Dec-04
34 502 Combination 23-Dec-04 VITAMIN A SUPPLEMENTARY 22-Dec-04
34 502 Combination 23-Dec-04 FOLIC ACID ANAEMIA 22-Dec-04 9-Jan-05
34 502 Combination 23-Dec-04 FERROUS SULFATE ANAEMIA 22-Dec-04 9-Jan-05
34 502 Combination 23-Dec-04 MULTI VITS SUPPLEMENTARY 22-Dec-04 9-Jan-05
34 502 Combination 23-Dec-04 PARACETAMOL FEVER 22-Dec-04 24-Dec-04
34 502 Combination 23-Dec-04 MEASLES VACC PROPHYLAXIS 8-Jan-05
34 503 PM 25-Dec-04 MEASLES VACC. PROPHYLAXIS 25-Dec-04
34 503 PM 25-Dec-04 VITAMIN A SUPPLEMENTARY 24-Dec-04
34 503 PM 25-Dec-04 MULTI VITS SUPPLEMENTARY 24-Dec-04 15-Jan-05
34 503 PM 25-Dec-04 FOLIC ACID ANAEMIA 24-Dec-04 15-Jan-05
34 503 PM 25-Dec-04 FERROUS SULFATE ANAEMIA 24-Dec-04 15-Jan-05
34 503 PM 25-Dec-04 PARACETAMOL FEVER 24-Dec-04 25-Dec-04
34 503 PM 25-Dec-04 MEASLES VACC PROPHYLAXIS 15-Jan-05
34 504 Combination 27-Dec-04 MEASLES VACC. PROPHYLAXIS 27-Dec-04
34 504 Combination 27-Dec-04 VITAMIN A SUPPLEMENTARY 26-Dec-04
34 504 Combination 27-Dec-04 FOLIC ACID ANAEMIA 26-Dec-04
34 504 Combination 27-Dec-04 FERROUS SULFATE ANAEMIA 26-Dec-04
34 504 Combination 27-Dec-04 MULTI VITS SUPPLEMENTARY 26-Dec-04
34 504 Combination 27-Dec-04 PARACETAMOL FEVER 27-Dec-04
34 504 Combination 27-Dec-04 MEASLES VACC PROPHYLAXIS 12-Jan-05
34 505 SSG 28-Dec-04 VITAMIN A SUPPLEMENTARY 27-Dec-04
34 505 SSG 28-Dec-04 FOLIC ACID ANAEMIA 27-Dec-04 27-Jan-05
34 505 SSG 28-Dec-04 FERROUS SULFATE ANAEMIA 27-Dec-04 27-Jan-05
34 505 SSG 28-Dec-04 MULTI VITS SUPPLEMENTARY 27-Dec-04 27-Jan-05
34 505 SSG 28-Dec-04 CIPROFLOXACIN UTI 3-Jan-05 10-Jan-05
34 505 SSG 28-Dec-04 PARACETAMOL FEVER 27-Dec-04 28-Dec-04
34 506 SSG 31-Dec-04 VITAMIN A SUPPLEMENTARY 30-Dec-04
34 506 SSG 31-Dec-04 FOLIC ACID ANAEMIA 30-Dec-04 29-Jan-05
34 506 SSG 31-Dec-04 FERROUS SULFATE ANAEMIA 30-Dec-04 29-Jan-05
34 506 SSG 31-Dec-04 MULTI VITS SUPPLEMENTARY 30-Dec-04 29-Jan-05
34 506 SSG 31-Dec-04 PARACETAMOL FEVER 30-Dec-04 1-Jan-05
34 506 SSG 31-Dec-04 MEASLES VACC. PROPHYLAXIS 3-Jan-05
34 506 SSG 31-Dec-04 MEASLES VACC PROPHYLAXIS 29-Jan-05
34 507 SSG 31-Dec-04 VITAMIN A SUPPLEMENTARY 30-Dec-04
34 507 SSG 31-Dec-04 FOLIC ACID ANAEMIA 30-Dec-04 30-Jan-05
34 507 SSG 31-Dec-04 FERROUS SULFATE ANAEMIA 30-Dec-04 30-Jan-05
34 507 SSG 31-Dec-04 MULTI VITS SUPPLEMENTARY 30-Dec-04 30-Jan-05
34 507 SSG 31-Dec-04 PARACETAMOL FEVER 30-Dec-04 4-Jan-05
34 507 SSG 31-Dec-04 MEASLES VACC. PROPHYLAXIS 6-Jan-05
34 507 SSG 31-Dec-04 SULFADOXINE MALARIA 15-Jan-05
34 507 SSG 31-Dec-04 PYRIMETHAMINE MALARIA 15-Jan-05
34 507 SSG 31-Dec-04 ARTESUNATE 15-Jan-05 17-Jan-05
34 507 SSG 31-Dec-04 MEASLES VACC. 29-Jan-05
34 508 PM 31-Dec-04 VITAMIN A SUPPLEMENTARY 31-Dec-04
34 508 PM 31-Dec-04 PARACETAMOL FEVER 31-Dec-04 4-Jan-05
34 508 PM 31-Dec-04 FOLIC ACID ANAEMIA 31-Dec-04
34 508 PM 31-Dec-04 FERROUS SULFATE ANAEMIA 31-Dec-04
34 508 PM 31-Dec-04 MULTI VITS SUPPLEMENTARY 31-Dec-04
34 508 PM 31-Dec-04 MEASLES VACC. PROPHYLAXIS 31-Dec-04
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34 508 PM 31-Dec-04 MEASLES VACC PROPHYLAXIS 21-Jan-05
34 509 PM 2-Jan-05 VITAMIN A SUPPLEMENTARY 31-Dec-04
34 509 PM 2-Jan-05 FOLIC ACID ANAEMIA 31-Dec-04
34 509 PM 2-Jan-05 FERROUS SULFATE ANAEMIA 1-Jan-05
34 509 PM 2-Jan-05 MULTI VITS SUPPLEMENTARY 31-Dec-04
34 509 PM 2-Jan-05 CIPROFLOXACIN UTI 31-Dec-04 8-Jan-05
34 509 PM 2-Jan-05 PARACETAMOL FEVER 31-Dec-04 1-Jan-05
34 510 Combination 1-Jan-05 MEASLES VACC. PROPHYLAXIS 9-Jan-05
34 510 Combination 1-Jan-05 VITAMIN A SUPPLEMENTARY 31-Dec-04
34 510 Combination 1-Jan-05 FOLIC ACID ANAEMIA 31-Dec-04 18-Jan-05
34 510 Combination 1-Jan-05 FERROUS SULFATE ANAEMIA 31-Dec-04 18-Jan-05
34 510 Combination 1-Jan-05 MULTI VITS SUPPLEMENTARY 31-Dec-04 18-Jan-05
34 510 Combination 1-Jan-05 PARACETAMOL FEVER 31-Dec-04 1-Jan-05
34 510 Combination 1-Jan-05 ARTESUNATE MALARIA 3-Jan-05 5-Jan-05
34 510 Combination 1-Jan-05 SULFADOXINE MALARIA 3-Jan-05
34 510 Combination 1-Jan-05 PYRIMETHAMINE 3-Jan-05
34 511 Combination 1-Jan-05 VITAMIN A SUPPLEMENTARY 1-Jan-05
34 511 Combination 1-Jan-05 FOLIC ACID ANAEMIA 1-Jan-05 18-Jan-05
34 511 Combination 1-Jan-05 FERROUS SULFATE ANAEMIA 1-Jan-05 18-Jan-05
34 511 Combination 1-Jan-05 MULTI VITS SUPPLEMENTARY 1-Jan-05 18-Jan-05
34 511 Combination 1-Jan-05 PARACETAMOL FEVER 1-Jan-05
34 511 Combination 1-Jan-05 MEASLES VACC. PROPHYLAXIS 3-Jan-05
34 511 Combination 1-Jan-05 MEASLES VACC. PROPHYLAXIS 17-Jan-05
34 511 Combination 1-Jan-05 ARTESUNATE MALARIA 11-Jan-05 13-Jan-05
34 511 Combination 1-Jan-05 SULFADOXINE 11-Jan-05
34 511 Combination 1-Jan-05 PYRIMETHAMINE 11-Jan-05
34 512 PM 2-Jan-05 VITAMIN A SUPPLEMENTARY 2-Jan-05
34 512 PM 2-Jan-05 FOLIC ACID ANAEMIA 2-Jan-05
34 512 PM 2-Jan-05 FERROUS SULFATE ANAEMIA 2-Jan-05
34 512 PM 2-Jan-05 MULTI VITS SUPPLEMENTARY 2-Jan-05
34 512 PM 2-Jan-05 PARACETAMOL FEVER 2-Jan-05 3-Jan-05
34 512 PM 2-Jan-05 MEASLES VACC. PROPHYLAXIS 1-Jan-05
34 512 PM 2-Jan-05 ARTESUNATE MALARIA 8-Jan-05 10-Jan-05
34 512 PM 2-Jan-05 SULFADOXINE MALARIA 8-Jan-05
34 512 PM 2-Jan-05 PYRIMETHAMINE 8-Jan-05
34 512 PM 2-Jan-05 MEASLES VACC. 23-Jan-05
34 513 Combination 3-Jan-05 MEASLES VACC. PROPHYLAXIS 6-Jan-05
34 513 Combination 3-Jan-05 VITAMIN A SUPPLEMENTARY 2-Jan-05
34 513 Combination 3-Jan-05 FOLIC ACID ANAEMIA 2-Jan-05 20-Jan-05
34 513 Combination 3-Jan-05 FERROUS SULFATE ANAEMIA 2-Jan-05 20-Jan-05
34 513 Combination 3-Jan-05 MULTI VITS SUPPLEMENTARY 2-Jan-05 20-Jan-05
34 513 Combination 3-Jan-05 PARACETAMOL FEVER 2-Jan-05 3-Jan-05
34 513 Combination 3-Jan-05 METRONIDAZOL ACUTE WATERY DIARRHOEA 7-Jan-05 13-Jan-05
34 513 Combination 3-Jan-05 GENTIAN VIOLET SUPERFICIAL SKIN LESION 15-Jan-05 19-Jan-05
34 513 Combination 3-Jan-05 MEASLES VACC 19-Jan-05
34 514 SSG 4-Jan-05 MEASLES VACC. PROPHYLAXIS 6-Jan-05
34 514 SSG 4-Jan-05 VITAMIN A SUPPLEMENTARY 3-Jan-05
34 514 SSG 4-Jan-05 FOLIC ACID ANAEMIA 3-Jan-05 2-Feb-05
34 514 SSG 4-Jan-05 FERROUS SULFATE ANAEMIA 3-Jan-05 2-Feb-05
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34 514 SSG 4-Jan-05 MULTI VITS SUPPLEMENTARY 3-Jan-05 2-Feb-05
34 514 SSG 4-Jan-05 PARACETAMOL FEVER 3-Jan-05 4-Jan-05
34 514 SSG 4-Jan-05 MEASLES VACC PROPHYLAXIS 2-Feb-05
34 514 SSG 4-Jan-05 AMOXICILLIN PNEUMONIA 29-Jan-05 2-Feb-05
34 515 SSG 5-Jan-05 MEASLES VACC. PROPHYLAXIS 5-Jan-05
34 515 SSG 5-Jan-05 VITAMIN A SUPPLEMENTARY 5-Jan-05
34 515 SSG 5-Jan-05 PARACETAMOL FEVER 5-Jan-05
34 515 SSG 5-Jan-05 FOLIC ACID ANAEMIA 5-Jan-05 3-Feb-05
34 515 SSG 5-Jan-05 FERROUS SULFATE ANAEMIA 5-Jan-05 3-Feb-05
34 515 SSG 5-Jan-05 MULTI VITS SUPPLEMENTARY 5-Jan-05 3-Feb-05
34 515 SSG 5-Jan-05 MEASLES VACC. PROPHYLAXIS 3-Feb-05
34 515 SSG 5-Jan-05 ARTESUNATE MALARIA 13-May-05 15-May-05
34 515 SSG 5-Jan-05 SULFADOXINE MALARIA 13-May-05
34 515 SSG 5-Jan-05 PYRIMETHAMINE MALARIA 13-May-05
34 515 SSG 5-Jan-05 PARACETAMOL FEVER 13-May-05
34 515 SSG 5-Jan-05 SSG PKDL II 14-May-05
34 516 PM 6-Jan-05 VITAMIN A SUPPLEMENTARY 6-Jan-05
34 516 PM 6-Jan-05 FOLIC ACID ANAEMIA 6-Jan-05 26-Jan-05
34 516 PM 6-Jan-05 FERROUS SULFATE ANAEMIA 6-Jan-05 26-Jan-05
34 516 PM 6-Jan-05 MULTI VITS SUPPLEMENTARY 6-Jan-05 26-Jan-05
34 516 PM 6-Jan-05 MEASLES VACC. PROPHYLAXIS 6-Jan-05
34 516 PM 6-Jan-05 PARACETAMOL FEVER 10-Jan-05
34 516 PM 6-Jan-05 BENZOIC ACID SUPERFICIAL FUNGAL SKIN 
INFECTION
19-Jan-05 26-Jan-05
34 516 PM 6-Jan-05 SALICYLIC ACID SUPERFICIAL FUNGAL SKIN 
INFECTION
19-Jan-05 26-Jan-05
34 516 PM 6-Jan-05 ALUMINIUM 
HYDROXIDE
24-Jan-05
34 516 PM 6-Jan-05 MEASLES VACC. 27-Jan-05
34 517 PM 6-Jan-05 VITAMIN A SUPPLEMENTARY 6-Jan-05
34 517 PM 6-Jan-05 FOLIC ACID ANAEMIA 6-Jan-05 26-Jan-05
34 517 PM 6-Jan-05 FERROUS SULFATE ANAEMIA 6-Jan-05 26-Jan-05
34 517 PM 6-Jan-05 MULTI VITS SUPPLEMENTARY 6-Jan-05 26-Jan-05
34 517 PM 6-Jan-05 MEASLES VACC. PROPHYLAXIS 7-Jan-05
34 517 PM 6-Jan-05 PARACETAMOL FEVER 18-Jan-05
34 518 SSG 9-Jan-05 MEASLES VACC. PROPHYLAXIS 7-Jan-05
34 518 SSG 9-Jan-05 VITAMIN A SUPPLEMENTARY 7-Jan-05
34 518 SSG 9-Jan-05 MULTI VITS SUPPLEMENTARY 6-Jan-05 8-Feb-05
34 518 SSG 9-Jan-05 FOLIC ACID ANAEMIA 15-Jan-05 8-Feb-05
34 518 SSG 9-Jan-05 FERROUS SULFATE ANAEMIA 15-Jan-05 8-Feb-05
34 518 SSG 9-Jan-05 PARACETAMOL FEVER 6-Jan-05 8-Jan-05
34 518 SSG 9-Jan-05 ARTESUNATE MALARIA 6-Jan-05 8-Jan-05
34 518 SSG 9-Jan-05 SULFADOXINE MALARIA 6-Jan-05
34 518 SSG 9-Jan-05 PYRIMETHAMINE 6-Jan-05
34 518 SSG 9-Jan-05 ARTEMETHER 11-Jan-05 13-Jan-05
34 518 SSG 9-Jan-05 LUMEFANTRINE 11-Jan-05 13-Jan-05
34 518 SSG 9-Jan-05 QUININE 19-Jan-05 24-Jan-05
34 518 SSG 9-Jan-05 CEFTRIAXONE 18-Jan-05 22-Jan-05
34 518 SSG 9-Jan-05 MEASLES VACC 7-Feb-05
34 519 PM 7-Jan-05 MEASLES VACC. PROPHYLAXIS 8-Jan-05
34 519 PM 7-Jan-05 VITAMIN A SUPPLEMENTARY 6-Jan-05
34 519 PM 7-Jan-05 FOLIC ACID SUPPLEMENTARY 6-Jan-05 27-Jan-05
34 519 PM 7-Jan-05 FERROUS SULFATE SUPPLEMENTARY 6-Jan-05 27-Jan-05
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34 519 PM 7-Jan-05 MULTI VITS SUPPLEMENTARY 6-Jan-05 27-Jan-05
34 519 PM 7-Jan-05 PARACETAMOL FEVER 6-Jan-05 13-Jan-05
34 519 PM 7-Jan-05 ARTESUNATE MALARIA 13-Jan-05 15-Jan-05
34 519 PM 7-Jan-05 SULFADOXINE MALARIA 13-Jan-05
34 519 PM 7-Jan-05 PYRIMETHAMINE 13-Jan-05
34 519 PM 7-Jan-05 ARTESUNATE MALARIA 22-Mar-05 25-Mar-05
34 519 PM 7-Jan-05 PARACETAMOL FEVER 22-Mar-05 25-Mar-05
34 519 PM 7-Jan-05 SULFADOXINE MALARIA 22-Mar-05
34 519 PM 7-Jan-05 PYRIMETHAMINE MALARIA 22-Mar-05
34 520 SSG 11-Jan-05 VITAMIN A SUPPLEMENTARY 10-Jan-05
34 520 SSG 11-Jan-05 FOLIC ACID ANAEMIA 10-Jan-05 8-Feb-05
34 520 SSG 11-Jan-05 FERROUS SULFATE ANAEMIA 10-Jan-05 8-Feb-05
34 520 SSG 11-Jan-05 MULTI VITS SUPPLEMENTARY 10-Jan-05 8-Feb-05
34 520 SSG 11-Jan-05 PARACETAMOL FEVER 10-Jan-05 13-Jan-05
34 520 SSG 11-Jan-05 TINIDAZOLE ACUTE WATERY DIARRHOEA 17-Jan-05 19-Jan-05
34 520 SSG 11-Jan-05 METRONIDAZOL MUCOID STOOL 23-Jan-05 29-Jan-05
34 520 SSG 11-Jan-05 SULFADOXINE MALARIA 15-May-05
34 520 SSG 11-Jan-05 PYRIMETHAMINE MALARIA 15-May-05
34 520 SSG 11-Jan-05 CHLOROQUINE MALARIA 15-May-05
34 521 PM 11-Jan-05 MEASLES VACC. PROPHYLAXIS 11-Jan-05
34 521 PM 11-Jan-05 VITAMIN A SUPPLEMENTARY 10-Jan-05
34 521 PM 11-Jan-05 FOLIC ACID ANAEMIA 10-Jan-05 31-Jan-05
34 521 PM 11-Jan-05 FERROUS SULFATE ANAEMIA 10-Jan-05 31-Jan-05
34 521 PM 11-Jan-05 MULTI VITS SUPPLEMENTARY 10-Jan-05 31-Jan-05
34 521 PM 11-Jan-05 PARACETAMOL FEVER 10-Jan-05 11-Jan-05
34 521 PM 11-Jan-05 ARTESUNATE MALARIA 20-Jan-05 22-Jan-05
34 521 PM 11-Jan-05 SULFADOXINE MALARIA 20-Jan-05
34 521 PM 11-Jan-05 PYRIMETHAMINE 20-Jan-05
34 522 Combination 11-Jan-05 FERROUS SULFATE ANAEMIA 11-Jan-05 27-Jan-05
34 522 Combination 11-Jan-05 FOLIC ACID ANAEMIA 11-Jan-05 27-Jan-05
34 522 Combination 11-Jan-05 MULTI VITS SUPPLEMENTARY 11-Jan-05 27-Jan-05
34 522 Combination 11-Jan-05 VITAMIN A SUPPLEMENTARY 11-Jan-05
34 522 Combination 11-Jan-05 SALBUTAMOL ASTHMA 19-Jan-05 21-Jan-05
34 522 Combination 11-Jan-05 SALBUTAMOL ASTHMA 24-Jan-05 27-Jan-05
34 522 Combination 11-Jan-05 HYDROCORTISON ASTHMA 18-Jan-05
34 523 SSG 14-Jan-05 MEASLES VACC. PROPHYLAXIS 12-Jan-05
34 523 SSG 14-Jan-05 SULFADOXINE MALARIA 12-Jan-05
34 523 SSG 14-Jan-05 PYRIMETHAMINE MALARIA 12-Jan-05
34 523 SSG 14-Jan-05 ARTESUNATE MALARIA 12-Jan-05 14-Jan-05
34 523 SSG 14-Jan-05 PARACETAMOL FEVER 12-Jan-05
34 523 SSG 14-Jan-05 VITAMIN A SUPPLEMENTARY 12-Jan-05
34 523 SSG 14-Jan-05 MULTI VITS SUPPLEMENTARY 12-Jan-05 12-Feb-05
34 523 SSG 14-Jan-05 FOLIC ACID ANAEMIA 16-Jan-05 12-Feb-05
34 523 SSG 14-Jan-05 FERROUS SULFATE 16-Jan-05 12-Feb-05
34 523 SSG 14-Jan-05 MEASLES VACC. 8-Feb-05
34 524 Combination 13-Jan-05 MEASLES VACC. PROPHYLAXIS 13-Jan-05
34 524 Combination 13-Jan-05 VITAMIN A SUPPLEMENTARY 12-Jan-05
34 524 Combination 13-Jan-05 PARACETAMOL FEVER 12-Jan-05 13-Jan-05
34 524 Combination 13-Jan-05 FOLIC ACID ANAEMIA 12-Jan-05 30-Jan-05
34 524 Combination 13-Jan-05 FERROUS SULFATE ANAEMIA 12-Jan-05 30-Jan-05
34 524 Combination 13-Jan-05 MULTI VITS SUPPLEMENTARY 12-Jan-05 30-Jan-05
34 524 Combination 13-Jan-05 MEASLES VACC PROPHYLAXIS 29-Jan-05
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34 525 Combination 13-Jan-05 MEASLES VACC. PROPHYLAXIS 13-Jan-05
34 525 Combination 13-Jan-05 VITAMIN A SUPPLEMENTARY 13-Jan-05
34 525 Combination 13-Jan-05 FOLIC ACID ANAEMIA 13-Jan-05 30-Jan-05
34 525 Combination 13-Jan-05 FERROUS SULFATE ANAEMIA 13-Jan-05 30-Jan-05
34 525 Combination 13-Jan-05 MULTI VITS SUPPLEMENTARY 13-Jan-05 30-Jan-05
34 525 Combination 13-Jan-05 PARACETAMOL FEVER 13-Jan-05
34 525 Combination 13-Jan-05 MEASLES VACC PROPHYLAXIS 29-Jan-05
34 526 SSG 14-Jan-05 MEASLES VACC PROPHYLAXIS 13-Jan-05
34 526 SSG 14-Jan-05 PARACETAMOL FEVER 13-Jan-05 17-Jan-05
34 526 SSG 14-Jan-05 VITAMIN A SUPPLEMENTARY 13-Jan-05
34 526 SSG 14-Jan-05 MULTI VITS SUPPLEMENTARY 13-Jan-05 12-Feb-05
34 526 SSG 14-Jan-05 FOLIC ACID ANAEMIA 13-Jan-05 16-Jan-05
34 526 SSG 14-Jan-05 FERROUS SULFATE ANAEMIA 13-Jan-05 16-Jan-05
34 526 SSG 14-Jan-05 SULFADOXINE MALARIA 16-Jan-05
34 526 SSG 14-Jan-05 PYRIMETHAMINE MALARIA 16-Jan-05
34 526 SSG 14-Jan-05 ARTESUNATE 16-Jan-05 18-Jan-05
34 526 SSG 14-Jan-05 MEASLES VACC 12-Feb-05
34 526 SSG 14-Jan-05 BENZYL PENICILLIN BACTERIAL INFECTION 15-Apr-05 16-Apr-05
34 526 SSG 14-Jan-05 AMPICILLIN SYRUP BACTERIAL INFECTION 17-Apr-05 22-Apr-05
34 527 Combination 15-Jan-05 VITAMIN A SUPPLEMENTARY 14-Jan-05
34 527 Combination 15-Jan-05 FOLIC ACID ANAEMIA 14-Jan-05
34 527 Combination 15-Jan-05 FERROUS SULFATE ANAEMIA 14-Jan-05
34 527 Combination 15-Jan-05 MULTI VITS SUPPLEMENTARY 14-Jan-05
34 527 Combination 15-Jan-05 PARACETAMOL FEVER 14-Jan-05 15-Jan-05
34 527 Combination 15-Jan-05 PROMETHAZINE NAUSEA + VOMITING 17-Jan-05
34 528 PM 17-Jan-05 MEASLES VACC. PROPHYLAXIS 17-Jan-05
34 528 PM 17-Jan-05 VITAMIN A SUPPLEMENTARY 16-Jan-05
34 528 PM 17-Jan-05 MULTI VITS SUPPLEMENTARY 16-Jan-05 6-Feb-05
34 528 PM 17-Jan-05 FOLIC ACID ANAEMIA 16-Jan-05 6-Feb-05
34 528 PM 17-Jan-05 FERROUS SULFATE ANAEMIA 16-Jan-05 6-Feb-05
34 528 PM 17-Jan-05 PARACETAMOL FEVER 16-Jan-05 17-Jan-05
34 529 Combination 18-Jan-05 MEASLES VACC. PROPHYLAXIS 18-Jan-05
34 529 Combination 18-Jan-05 PARACETAMOL FEVER 18-Jan-05 19-Jan-05
34 529 Combination 18-Jan-05 VITAMIN A SUPPLEMENTARY 18-Jan-05
34 529 Combination 18-Jan-05 FOLIC ACID ANAEMIA 18-Jan-05 4-Feb-05
34 529 Combination 18-Jan-05 FERROUS SULFATE ANAEMIA 18-Jan-05 4-Feb-05
34 529 Combination 18-Jan-05 MULTI VITS SUPPLEMENTARY 18-Jan-05 4-Feb-05
34 529 Combination 18-Jan-05 MEASLES VACC PROPHYLAXIS 3-Feb-05
34 530 Combination 20-Jan-05 VITAMIN A SUPPLEMENTARY 19-Jan-05
34 530 Combination 20-Jan-05 MULTI VITS SUPPLEMENTARY 19-Jan-05 6-Feb-05
34 530 Combination 20-Jan-05 FOLIC ACID ANAEMIA 19-Jan-05 6-Feb-05
34 530 Combination 20-Jan-05 FERROUS SULFATE ANAEMIA 19-Jan-05 6-Feb-05
34 530 Combination 20-Jan-05 PARACETAMOL FEVER 19-Jan-05 20-Jan-05
34 530 Combination 20-Jan-05 AMOXICILLIN EAR INFECTION 14-Apr-05 19-Apr-05
34 531 SSG 21-Jan-05 MEASLES VACC PROPHYLAXIS 21-Jan-05
34 531 SSG 21-Jan-05 VITAMIN A SUPPLEMENTARY 20-Jan-05
34 531 SSG 21-Jan-05 FOLIC ACID ANAEMIA 20-Jan-05 19-Feb-05
34 531 SSG 21-Jan-05 FERROUS SULFATE ANAEMIA 20-Jan-05 19-Feb-05
34 531 SSG 21-Jan-05 MULTI VITS SUPPLEMENTARY 20-Jan-05 19-Feb-05
34 531 SSG 21-Jan-05 PARACETAMOL FEVER 20-Jan-05 21-Jan-05
34 531 SSG 21-Jan-05 MEASLES VACC PROPHYLAXIS 19-Feb-05
34 532 Combination 21-Jan-05 MEASLES VACC. PROPHYLAXIS 21-Jan-05
34 532 Combination 21-Jan-05 VITAMIN A SUPPLEMENTARY 20-Jan-05
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34 532 Combination 21-Jan-05 MULTI VITS SUPPLEMENTARY 20-Jan-05 6-Feb-05
34 532 Combination 21-Jan-05 FOLIC ACID ANAEMIA 20-Jan-05 6-Feb-05
34 532 Combination 21-Jan-05 FERROUS SULFATE ANAEMIA 20-Jan-05 6-Feb-05
34 532 Combination 21-Jan-05 PARACETAMOL FEVER 20-Jan-05 21-Jan-05
34 533 SSG 23-Jan-05 MEASLES VACC PROPHYLAXIS 23-Jan-05
34 533 SSG 23-Jan-05 VITAMIN A SUPPLEMENTARY 22-Jan-05
34 533 SSG 23-Jan-05 FOLIC ACID ANAEMIA 22-Jan-05 22-Feb-05
34 533 SSG 23-Jan-05 FERROUS SULFATE ANAEMIA 22-Jan-05 22-Feb-05
34 533 SSG 23-Jan-05 MULTI VITS SUPPLEMENTARY 22-Jan-05 22-Feb-05
34 533 SSG 23-Jan-05 PARACETAMOL FEVER 22-Jan-05 23-Jan-05
34 534 PM 24-Jan-05 MEASLES VACC PROPHYLAXIS 24-Jan-05
34 534 PM 24-Jan-05 ARTESUNATE MALARIA 23-Jan-05
34 534 PM 24-Jan-05 PARACETAMOL FEVER 23-Jan-05 24-Jan-05
34 534 PM 24-Jan-05 VITAMIN A SUPPLEMENTARY 23-Jan-05
34 534 PM 24-Jan-05 FOLIC ACID ANAEMIA 23-Jan-05 14-Feb-05
34 534 PM 24-Jan-05 FERROUS SULFATE ANAEMIA 23-Jan-05 14-Feb-05
34 534 PM 24-Jan-05 MULTI VITS SUPPLEMENTARY 23-Jan-05 14-Feb-05
34 534 PM 24-Jan-05 CEFTRIAXONE PNEUMONIA 30-Jan-05 3-Feb-05
34 534 PM 24-Jan-05 MEASLES VACC 14-Feb-05
34 535 PM 24-Jan-05 MEASLES VACC PROPHYLAXIS 24-Jan-05
34 535 PM 24-Jan-05 VITAMIN A SUPPLEMENTARY 23-Jan-05
34 535 PM 24-Jan-05 FOLIC ACID ANAEMIA 23-Jan-05 14-Feb-05
34 535 PM 24-Jan-05 FERROUS SULFATE ANAEMIA 23-Jan-05 14-Feb-05
34 535 PM 24-Jan-05 MULTI VITS SUPPLEMENTARY 23-Jan-05 14-Feb-05
34 535 PM 24-Jan-05 PARACETAMOL FEVER 23-Jan-05 24-Jan-05
34 535 PM 24-Jan-05 TINIDAZOLE ACUTE WATERY DIARRHOE 6-Feb-05 8-Feb-05
34 535 PM 24-Jan-05 MEASLES VACC PROPHYLAXIS 14-Feb-05
34 536 PM 25-Jan-05 MEASLES VACC. PROPHYLAXIS 25-Jan-05
34 536 PM 25-Jan-05 VITAMIN A SUPPLEMENTARY 25-Jan-05
34 536 PM 25-Jan-05 FOLIC ACID ANAEMIA 25-Jan-05 15-Feb-05
34 536 PM 25-Jan-05 FERROUS SULFATE ANAEMIA 25-Jan-05 15-Feb-05
34 536 PM 25-Jan-05 MULTI VITS SUPPLEMENTARY 25-Jan-05 15-Feb-05
34 536 PM 25-Jan-05 PARACETAMOL FEVER 25-Jan-05
34 536 PM 25-Jan-05 MEASLES VACC PROPHYLAXIS 14-Feb-05
34 536 PM 25-Jan-05 PARACETAMOL HEADACHE 5-May-05 6-May-05
34 537 SSG 25-Jan-05 MEASLES VACC. PROPHYLAXIS 25-Jan-05
34 537 SSG 25-Jan-05 VITAMIN A SUPPLEMENTARY 25-Jan-05
34 537 SSG 25-Jan-05 FOLIC ACID ANAEMIA 25-Jan-05 24-Feb-05
34 537 SSG 25-Jan-05 FERROUS SULFATE ANAEMIA 25-Jan-05 24-Feb-05
34 537 SSG 25-Jan-05 MULTI VITS SUPPLEMENTARY 25-Jan-05 24-Feb-05
34 537 SSG 25-Jan-05 PARACETAMOL FEVER 25-Jan-05
34 538 PM 26-Jan-05 MEASLES VACC PROPHYLAXIS 26-Jan-05
34 538 PM 26-Jan-05 VITAMIN A SUPPLEMENTARY 25-Jan-05
34 538 PM 26-Jan-05 FOLIC ACID ANAEMIA 25-Jan-05 16-Feb-05
34 538 PM 26-Jan-05 FERROUS SULFATE ANAEMIA 25-Jan-05 16-Feb-05
34 538 PM 26-Jan-05 MULTI VITS SUPPLEMENTARY 25-Jan-05 16-Feb-05
34 538 PM 26-Jan-05 PARACETAMOL FEVER 25-Jan-05 26-Jan-05
34 538 PM 26-Jan-05 TINIDAZOL WATERY DIARRHOEA 25-Jan-05 27-Jan-05
34 538 PM 26-Jan-05 AMOXICILLIN MUCOSAL INFECTION OF THE 
NOSE
31-Jan-05 4-Feb-05
34 538 PM 26-Jan-05 MEASLES VACC 15-Feb-05
34 539 Combination 26-Jan-05 MEASLES VACC. PROPHYLAXIS 26-Jan-05
34 539 Combination 26-Jan-05 VITAMIN A SUPPLEMENTARY 25-Jan-05
34 539 Combination 26-Jan-05 MULTI VITS SUPPLEMENTARY 25-Jan-05 12-Feb-05
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34 539 Combination 26-Jan-05 FOLIC ACID ANAEMIA 25-Jan-05 12-Feb-05
34 539 Combination 26-Jan-05 FERROUS SULFATE ANAEMIA 25-Jan-05 12-Feb-05
34 539 Combination 26-Jan-05 PARACETAMOL FEVER 25-Jan-05 26-Jan-05
34 539 Combination 26-Jan-05 ARTESUNATE MALARIA 25-Jan-05
34 539 Combination 26-Jan-05 MEASLES VACC PROPHYLAXIS 11-Feb-05
34 539 Combination 26-Jan-05 CHLOROQUINE MALARIA 2-Jun-05 7-Jun-05
34 539 Combination 26-Jan-05 VITAMIN B COMPL ? 2-Jun-05 7-Jun-05
34 539 Combination 26-Jan-05 CHLORPHENIRAMINE ? 2-Jun-05 7-Jun-05
34 540 SSG 27-Jan-05 MEASLES VACC PROPHYLAXIS 2-Feb-05
34 540 SSG 27-Jan-05 VITAMIN A SUPPLEMENTARY 26-Jan-05
34 540 SSG 27-Jan-05 MULTI VITS SUPPLEMENTARY 26-Jan-05 25-Feb-05
34 540 SSG 27-Jan-05 FOLIC ACID ANAEMIA 26-Jan-05 25-Feb-05
34 540 SSG 27-Jan-05 FERROUS SULFATE ANAEMIA 26-Jan-05 25-Feb-05
34 540 SSG 27-Jan-05 PARACETAMOL FEVER 26-Jan-05 28-Jan-05
34 540 SSG 27-Jan-05 ALUMINIUM 
HYDROXIDE
EPIGASTRIC PAIN 29-Jan-05 30-Jan-05
34 540 SSG 27-Jan-05 AMOXICILLIN PNEUMONIA 9-Feb-05 15-Feb-05
35 646 PM 28-Jan-05 PARACETAMOL HIGH-GRADE FEVER 29-Jan-05 29-Jan-05
35 646 PM 28-Jan-05 AMPICLOX CAPS SUPPURATIVE OTITIS MEDIA 3-Feb-05 12-Feb-05
35 647 PM 30-Jan-05 PARACETAMOL FEVER 31-Jan-05 1-Feb-05
35 647 PM 30-Jan-05 PARACETAMOL FEVER 1-Feb-05 2-Feb-05
35 647 PM 30-Jan-05 COTRIMOXAZOLE UTI 20-Mar-05 24-Mar-05
35 648 Combination 30-Jan-05 SALBUTAMOL ASTHMATIC ATTACK 8-Feb-05 8-Feb-05
35 648 Combination 30-Jan-05 SALBUTAMOL ASTHMATIC ATTACK 8-Feb-05 16-Feb-05
35 651 SSG 30-Jan-05 CHLOROQUINE SUSP. MALARIA 18-Feb-05 21-Feb-05
35 651 SSG 30-Jan-05 PARACETAMOL FEVER 18-Feb-05 18-Feb-05
35 652 PM 1-Feb-05 PARACETAMOL FEVER 1-Feb-05 1-Feb-05
35 652 PM 1-Feb-05 PARACETAMOL FEVER 5-Feb-05 6-Feb-05
35 652 PM 1-Feb-05 AMOXYCILLIN SUSP. ACUTE OTITIS MEDIA 7-Feb-05 16-Feb-05
35 652 PM 1-Feb-05 PARACETAMOL FEVER EARACHE 7-Feb-05 8-Feb-05
35 654 SSG 3-Feb-05 TETRACYCLINE 
OINTMENT
PURULENT CONJUNCTIVITIS 21-Feb-05 25-Feb-05
35 655 Combination 3-Feb-05 PARACETAMOL FEVER 4-Feb-05 4-Feb-05
35 656 SSG 3-Feb-05 PARACETAMOL FEVER 4-Feb-05 4-Feb-05
35 656 SSG 3-Feb-05 PARACETAMOL FEVER 5-Feb-05 5-Feb-05
35 658 Combination 8-Feb-05 TINIDAZOLE AMOEBIC DYSENTRY 17-Feb-05 17-Feb-05
35 659 SSG 8-Feb-05 BENZYL PENICILLIN BRONCHO-PNEUMONIA 9-Feb-05 11-Feb-05
35 659 SSG 8-Feb-05 PARACETAMOL PNEUMONIA WITH HIGH 
GRADE FEVER
9-Feb-05 10-Feb-05
35 659 SSG 8-Feb-05 AMOXYCILLIN PNEUMONIA CONTINUATION 11-Feb-05 15-Feb-05
35 662 PM 20-Feb-05 CHLOROQUINE UNCOMPLICATED MALARIA 21-Feb-05 23-Feb-05
35 662 PM 20-Feb-05 PARACETAMOL UNCOMPLICATED MALARIA 21-Feb-05 21-Feb-05
35 663 SSG 20-Feb-05 CEPHALEXIN PNEUMONIA 23-Feb-05 27-Feb-05
35 664 Combination 20-Feb-05 ANTACID HEART BURN 21-Feb-05 23-Feb-05
35 676 PM 20-Mar-05 PARACETAMOLE HIGH GRADE FEVER 22-Mar-05 23-Mar-05
35 677 SSG 20-Mar-05 ANTACID HEART BURN 27-Mar-05 29-Mar-05
35 677 SSG 20-Mar-05 PARACETAMOL FEVER 27-Mar-05 27-Mar-05
35 681 Combination 22-Mar-05 CRYSTALLINE PNEUMONIA 27-Mar-05 28-Mar-05
35 681 Combination 22-Mar-05 ERYTHROMYCIN TABS PNEUMONIA 28-Mar-05 1-Apr-05
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35 684 SSG 9-Apr-05 PARACETAMOLE UN-COMPLICATED MALARIA 5-May-05 6-May-05
35 684 SSG 9-Apr-05 PYRIDOXINE UN-COMPLICATED MALARIA 5-May-05 5-May-05
35 684 SSG 9-Apr-05 CHLOROQUINE UN-COMPLICATED MALARIA 5-May-05 7-May-05
35 687 SSG 13-Apr-05 CHLORPHENERAMINE 
MALEATE
ALLERGIC BRONCHITIS 16-Apr-05 19-Apr-05
35 687 SSG 13-Apr-05 CEPHALEXINE UTI 5-May-05 11-May-05
35 688 PM 16-Apr-05 CHLOROQUINE MALARIA 15-Sep-05 18-Sep-05
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Appendix 38: Listing of individual efficacy data – Clinical Response and Parasitology 
 
Appendix 39: Listing of individual efficacy data – Spleen size and liver size 
 
Appendix 40: Listing of individual efficacy data – Clinical Characteristics, cervical 
lymphadenopathy and axiliary lymphadenopathy 
 
Appendix 41: Listing of individual efficacy data – Clinical Characteristics, inguinal 
lymphadenopathy and muscle wasting 
 
Appendix 42: Listing of individual efficacy data – Clinical Characteristics, mucosal pallor 
and jaundice 
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11 1 PM Stable Improving Partial Partial Partial
11 2 Combination Improving Improving Partial Partial Partial
11 3 Combination Improving Improving Partial Partial Partial
11 4 PM Improving Improving Partial Partial Complete
11 5 PM Stable Stable Partial Partial Complete
11 6 Combination Stable Improving Partial Partial Partial
11 7 PM Stable Stable Partial Partial Partial
11 8 SSG Improving Improving Improving Partial Partial Partial
11 9 SSG Stable Stable Stable Partial Partial Partial
11 10 SSG Improving Improving Improving Partial Complete Complete
11 11 Combination Stable Stable Partial Partial Partial
11 12 Combination Stable Deteriorating Partial Complete Complete
11 13 SSG Stable Stable Stable Partial Partial Complete
11 14 SSG Stable Stable Improving Partial Partial Partial
11 15 PM Deteriorating Partial Partial
11 16 Combination Stable Stable Complete Complete Complete
11 17 Combination Stable Stable Partial Partial Partial
11 18 SSG Stable Improving Improving Partial Partial Partial
11 19 Combination Improving Improving Partial Partial Partial
11 20 SSG Improving Improving Improving Partial Partial Partial
11 21 SSG Stable Stable Stable Partial Partial Partial
11 22 SSG Improving Improving Improving Partial Complete Complete
11 23 PM Improving Improving Partial Partial Partial
11 24 PM Stable Stable Partial Partial Partial
11 25 SSG Improving Improving Improving Partial Partial Complete
11 26 Combination Stable Stable Partial Partial Partial
11 27 PM Improving Improving Partial Partial
11 28 Combination Stable Stable Partial Partial Partial
11 29 PM Improving Stable Partial Partial Partial
11 30 PM Improving Improving Partial Partial Partial
11 31 SSG Stable Improving Improving Partial Partial Partial
11 32 Combination Improving Improving Complete Complete Complete
11 33 SSG Stable Improving Improving Complete Complete Complete
11 34 PM Improving Improving Partial Partial Partial
11 35 SSG Stable Stable Stable Partial Partial Partial
11 36 SSG Improving Improving Improving Partial Partial Complete
11 37 Combination Improving Improving Complete Complete Complete
11 38 PM Stable Stable Partial Partial Partial
11 39 PM Improving Improving Partial Partial Partial
11 40 PM Stable Improving Partial Partial
11 41 Combination Stable Improving Partial Partial Complete
11 42 Combination Improving Improving Complete Complete Complete
11 43 SSG Improving Improving Stable Partial Partial Partial
11 44 PM Improving Improving Partial Partial Complete
11 45 Combination Improving Improving Partial Partial Complete
11 46 SSG Stable Improving Improving Partial Partial Complete
11 47 SSG Improving Improving Improving Partial
11 48 Combination Improving Improving Partial Complete
11 49 SSG Improving Improving Improving Partial Complete Complete
11 50 PM Stable Stable Partial Partial Partial
11 51 Combination Improving Improving Partial Complete Complete
11 52 PM Stable Stable Partial Partial Partial
11 53 SSG Improving Improving Improving Partial Complete Complete
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11 54 PM Improving Improving Partial Partial Partial
11 55 PM Stable Stable Partial Complete Complete
11 56 SSG Improving Improving Improving Partial Partial Partial
11 57 Combination Improving Improving Partial Partial Partial
11 58 Combination Stable Improving Partial Complete Complete
11 59 PM Stable Improving Partial Partial Complete
11 60 Combination Improving Improving Partial Partial Partial
11 61 PM Stable Improving Partial Partial Partial
11 62 SSG Improving Improving Improving Partial Partial Partial
11 63 SSG Improving Improving Improving Partial Partial Partial
11 64 SSG Stable Improving Improving Partial Partial Partial
11 65 PM Improving Improving Partial
11 66 Combination Improving Improving Partial Complete Complete
11 67 PM Improving Improving Partial Partial Complete
11 68 SSG Improving Improving Improving Partial Partial Partial
11 69 Combination Improving Improving Partial Partial Partial
11 70 Combination Improving Improving Partial Complete Complete
11 71 Combination Stable Stable Partial Partial Partial
11 72 SSG Stable Stable Partial Partial
11 73 PM Improving Improving Partial Partial Partial
11 74 PM Improving Improving Complete Complete Complete
11 75 Combination Improving Improving Partial Partial Partial
11 76 PM Improving Improving Partial Complete Complete
11 77 PM Improving Improving Partial Partial Partial
11 78 SSG Improving Improving Improving Partial Partial Partial
11 79 PM Stable Improving Partial Partial Partial
11 80 PM Improving Improving Partial Partial Partial
11 81 Combination Improving Improving Partial Partial Partial
11 82 SSG Improving Improving Improving Partial Partial Partial
11 83 SSG Improving Improving Improving Partial Complete Complete
11 84 SSG Improving Improving Improving Partial Complete Complete
11 85 SSG Improving Improving Improving Partial Partial
11 86 Combination Improving Improving Complete Complete Complete
11 87 Combination Improving Improving Partial Partial Partial
11 88 PM Improving Improving Partial Complete Complete
11 89 Combination Improving Improving Partial Partial Complete
11 90 Combination Improving Improving Partial
11 91 PM Improving Improving Partial Partial Partial
11 92 Combination Improving Improving Partial Partial Complete
11 93 SSG Improving Improving Improving Partial Complete Complete
11 94 SSG Improving Improving Improving Partial Partial Partial
11 95 SSG Improving Improving Improving Partial Partial Complete
11 96 Combination Improving Improving Partial Complete Complete
11 97 Combination Improving Improving Partial Partial Complete
11 98 PM Stable Stable Partial Partial Complete
11 99 SSG Improving Improving Improving Partial Partial Complete
11 100 PM Improving Improving Partial
11 101 PM Improving Improving Partial Partial Partial
11 102 Combination Improving Improving Partial Complete Complete
11 103 Combination Improving Improving Partial Complete Complete
11 104 PM Stable Improving Partial Partial Partial
11 105 SSG Improving Improving Improving Partial Partial Partial
11 106 Combination Improving Improving Complete Complete Complete
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11 107 PM Improving Improving Partial Partial Partial
11 108 PM Improving Improving Complete Complete Complete
11 109 SSG Improving Improving Improving Partial Partial Partial
11 110 PM Improving Improving Partial Partial Partial
11 111 Combination Improving Improving Complete Complete Complete
11 112 Combination Stable Improving Partial Complete Complete
11 113 SSG Improving Improving Improving Partial Partial
11 114 SSG Improving Improving Improving Partial Partial Complete
11 115 Combination Improving Improving Partial Complete Complete
11 116 SSG Improving Improving Improving Partial Complete Complete
11 117 PM Improving Improving Partial Partial
11 118 PM Stable Improving Partial Partial Partial
11 119 SSG Improving Improving Improving Partial Partial Partial
11 120 Combination Improving Improving Partial Complete Complete
11 121 Combination Improving Improving Partial Complete Complete
11 122 SSG Improving Improving Improving Partial
11 123 SSG Improving Improving Improving Partial Partial Partial
11 124 SSG Improving Improving Improving Partial Complete
11 125 SSG Improving Improving Improving Complete Complete Complete
11 126 Combination Stable Stable Partial Partial
11 127 PM Stable Improving Partial Partial Partial
11 128 Combination Stable Stable Partial Partial Partial
11 129 PM Stable Improving Partial Complete Complete
11 130 Combination Improving Improving Complete Complete Complete
11 131 PM Stable Improving Partial Complete Complete
11 132 SSG Improving Improving Improving Partial Complete Partial
11 133 Combination Improving Improving Partial Complete Complete
11 134 PM Stable Improving Partial Partial Partial
11 135 PM Improving Improving Partial Partial Complete
12 241 Combination Improving Improving Complete Complete
12 242 SSG Improving Improving Improving Complete Partial Complete
12 243 PM Improving Improving Partial Complete Complete
12 244 SSG Improving Improving Stable Partial Partial Complete
12 245 PM Improving Improving Partial Partial
12 246 PM Improving Stable Complete Partial
12 247 PM Improving Improving Partial Complete Complete
12 248 PM Improving Improving Complete Complete Complete
12 249 Combination Stable Stable Partial Partial Complete
12 250 SSG Improving Improving Improving Complete Partial Complete
12 251 Combination Stable Improving Partial Complete Complete
12 252 SSG Improving Improving Improving Complete Complete Complete
12 253 SSG Stable Improving Improving Partial Complete Complete
12 254 Combination Improving Stable Partial Partial Complete
12 255 Combination Improving Improving Complete Complete Complete
12 256 Combination Improving Improving Complete Complete Complete
12 257 SSG Improving Improving Improving Partial Partial Complete
12 258 SSG Improving Improving Improving Partial Complete
12 259 PM Improving Improving Complete Complete Complete
12 260 PM Improving Improving Complete Complete
12 261 Combination Improving Improving Partial Complete Complete
12 262 PM Improving Improving Complete Complete Complete
12 263 SSG Stable Stable Stable Complete Complete Complete
12 264 Combination Improving Improving Partial Partial Complete
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12 265 SSG Improving Stable Improving
12 266 PM Improving Improving Partial Partial Complete
12 267 SSG Improving Improving Improving Complete Complete Complete
12 268 PM Stable Stable Partial Complete Partial
12 269 Combination Improving Improving Partial Complete Complete
12 270 Combination Improving Improving Partial Complete
12 271 SSG Improving Improving Improving Complete Complete Complete
12 272 PM Improving Improving Complete Complete Complete
12 273 SSG Improving Improving Improving Complete Complete Complete
12 274 SSG Improving Improving Improving Complete Complete Complete
12 275 Combination Stable Improving Partial Complete Complete
12 276 PM Improving Improving Complete Complete Complete
12 277 Combination Improving Improving Partial Complete Complete
12 278 SSG Stable Improving Improving Partial Complete
12 279 PM Improving Improving Complete Complete Complete
12 280 SSG Improving Improving Improving Partial Complete Complete
12 281 Combination Stable Improving Partial Complete Complete
12 282 PM Stable Improving Partial Complete Complete
12 283 PM Improving Improving Complete Complete Complete
12 284 Combination Improving Improving Complete Partial Partial
12 285 Combination Stable Improving Partial Complete Complete
12 286 PM Stable Improving Partial Complete Complete
12 287 SSG Improving Stable Improving Partial Complete Complete
12 288 Combination Improving Improving Complete Complete Complete
12 289 Combination Improving Improving Complete Complete Complete
12 290 SSG Stable Improving Improving Complete Complete
12 291 SSG Stable Stable Improving Partial Complete Complete
12 292 PM Improving Improving Complete Complete
12 293 SSG Improving Improving Improving Complete Complete
12 294 Combination Stable Improving Partial Partial Complete
12 295 Combination Improving Improving Complete Complete
12 296 PM Improving Improving Complete Complete Complete
12 297 SSG Stable Stable
12 298 PM Improving Improving Complete Complete Complete
12 299 Combination Stable Improving Partial Complete
12 300 PM Improving Improving Complete Complete Complete
12 301 SSG Improving Improving Improving Complete Complete Complete
12 302 SSG Stable Improving Improving Partial Partial Complete
12 303 PM Stable Improving Partial Partial
12 304 Combination Improving Improving Complete Complete Complete
12 305 PM Improving Improving Complete Partial Complete
12 306 Combination Improving Improving Partial Partial Partial
12 307 Combination Improving Improving Partial Complete Complete
12 308 PM Improving Improving Partial Partial Complete
12 309 PM Stable Improving Partial Complete Complete
12 310 SSG Improving Improving Improving Partial Complete Complete
12 311 SSG Stable Stable Improving Complete Partial Complete
12 312 Combination Improving Improving Partial Complete Complete
12 313 PM Stable Improving Complete Complete Complete
12 314 SSG Improving Improving Improving Partial Complete Complete
12 315 Combination Improving Improving Partial Partial Complete
12 316 SSG Improving Improving Partial Complete Complete
12 317 SSG Improving Improving Improving Partial Complete
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12 318 Combination Improving Improving Partial Partial Complete
12 319 Combination Improving Improving Complete Complete Complete
12 320 Combination Improving Improving Partial Partial Complete
12 321 Combination Improving Improving Partial Partial Partial
12 322 PM Improving Improving Partial Partial Complete
12 323 SSG Improving Improving Improving Complete Complete Complete
12 324 SSG Improving Improving Improving Partial Complete Complete
12 325 PM Improving Improving Partial Complete Complete
12 326 PM Stable Improving Partial Partial Complete
12 327 Combination Improving Improving Complete Complete Complete
12 328 PM Stable Improving Partial Complete Complete
12 329 SSG Improving Stable Improving Partial Complete Partial
12 330 PM Improving Improving Partial Partial Partial
23 361 Combination Improving Improving Partial Partial Complete
23 362 PM Stable Improving Complete Complete Complete
23 363 PM Improving Improving Partial Complete Complete
23 364 Combination Stable Improving Complete Complete
23 365 SSG Improving Improving Improving Complete Complete Complete
23 366 Combination Improving Improving Partial Complete Complete
23 367 SSG Improving Improving Improving Partial Complete Complete
23 368 PM Stable Improving Partial Complete Complete
23 369 Combination Stable Stable Partial Complete Partial
23 370 SSG Improving Improving Improving Partial Complete Complete
23 371 PM Stable Stable Partial Partial Partial
23 372 PM Improving Stable Partial Complete Complete
23 373 SSG Improving Improving Improving Partial Complete Partial
23 374 SSG Stable Improving Improving Complete Complete Complete
23 375 Combination Improving Improving Partial Complete Complete
23 376 SSG Improving Stable Improving Partial Complete Complete
23 377 Combination Improving Complete
23 378 Combination Improving Improving Partial Partial Complete
23 379 PM Improving Improving Partial Complete
23 380 SSG Stable Improving Improving Complete Complete Complete
23 381 PM Improving Improving Partial Partial Complete
23 382 Combination Improving Improving Partial Complete Complete
23 383 PM Stable Improving Complete Complete Complete
23 384 SSG Stable Stable Stable Partial Complete Complete
23 385 SSG Improving Improving Improving Partial Partial Complete
23 386 Combination Stable Improving Complete Complete Complete
23 387 Combination Stable Stable Partial Complete Complete
23 388 PM Improving Improving Partial Partial Complete
23 389 SSG Improving Improving Improving Complete Complete Complete
23 390 PM Improving Improving Partial Complete Complete
23 391 Combination Improving Improving Partial Partial Complete
23 392 Combination Stable Improving Complete Complete
23 393 SSG Improving Improving Improving Partial Complete Complete
23 394 PM Improving Improving Partial Complete Complete
23 395 PM Improving Improving Complete Complete Complete
23 396 SSG Improving Improving Improving Partial Complete Complete
23 397 SSG Improving Improving Improving Partial Complete Complete
23 398 Combination Improving Improving Complete Complete Partial
23 399 PM Improving Improving Partial Complete Complete
23 400 PM Improving Improving Partial Complete Partial
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Centre Patient Treatment Clinical Response to treatment
 Number Number Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
23 401 Combination Stable Improving Complete Partial Partial
23 402 Combination Improving Improving Partial Complete Complete
23 403 SSG Improving Improving Improving Partial Complete Complete
23 404 SSG Stable Improving Improving Complete Complete
23 405 PM Improving Improving Partial Complete Complete
34 451 Combination Improving Improving Partial Complete
34 452 PM Improving Improving Partial
34 453 PM Stable Improving Partial
34 454 Combination Improving Improving Complete Complete
34 455 PM Stable Stable Partial
34 456 SSG Stable Improving Improving Complete Partial
34 457 Combination Improving Improving Partial
34 458 PM Stable Improving Partial Partial
34 459 Combination Improving Improving Partial Complete Complete
34 460 PM Improving Improving Complete
34 461 SSG Deteriorating Deteriorating
34 462 SSG Improving Improving Improving Complete Complete
34 463 Combination Improving Improving Complete Complete
34 464 SSG Stable Improving Improving Partial Complete
34 465 SSG Improving Improving Improving Partial Complete
34 466 Combination Improving Improving Partial
34 467 PM Stable Improving Partial Partial
34 468 Combination Improving Improving Complete Complete
34 469 SSG Improving Stable Improving Partial Complete
34 470 Combination Improving Improving Partial Partial
34 471 PM Stable Improving Partial
34 472 SSG Improving Improving Improving Partial Complete
34 473 PM Improving Improving Partial
34 474 Combination Improving Improving Complete Complete
34 475 PM Improving Improving Partial
34 476 PM Improving Improving Partial Partial
34 477 SSG Improving Improving Stable Partial Partial
34 478 Combination Improving Improving Partial Complete
34 479 SSG Improving Improving Improving Partial Complete
34 480 SSG Improving Improving Improving Complete Complete
34 481 Combination Improving Improving Complete Complete
34 482 Combination Improving Improving Partial Complete
34 483 PM Improving Improving Complete Complete
34 484 PM Deteriorating
34 485 Combination Improving Improving Partial Complete
34 486 Combination Improving Improving Partial Complete
34 487 SSG Improving Improving Improving Complete Complete
34 488 SSG Improving Improving Improving Partial Partial Partial
34 489 SSG Improving Improving Improving Partial Complete
34 490 PM Stable Improving Partial Complete
34 491 PM Stable Improving Partial
34 492 PM Improving Improving Partial Complete
34 493 SSG Improving Improving Improving Complete Partial
34 494 Combination Improving Improving Partial Complete
34 495 SSG Improving Improving Improving Complete Complete
34 496 SSG Improving Improving Improving Partial Complete
34 497 PM Improving Improving Partial Partial
34 498 SSG Improving Improving Improving Complete Complete
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 Number Number Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
34 499 Combination Improving Improving Partial Complete
34 500 PM Improving Improving Partial Complete
34 501 Combination Improving Improving Partial Complete
34 502 Combination Improving Improving Partial Complete
34 503 PM Improving Improving Partial
34 504 Combination Improving Improving Partial
34 505 SSG Improving Improving Improving Complete Complete
34 506 SSG Improving Improving Improving Partial Complete
34 507 SSG Improving Improving Improving Complete Complete
34 508 PM Stable Improving Complete
34 509 PM Improving Improving Complete
34 510 Combination Improving Improving Complete Complete
34 511 Combination Improving Improving Partial Partial
34 512 PM Stable Improving Partial
34 513 Combination Improving Improving Partial Partial Complete
34 514 SSG Improving Improving Improving Partial Complete
34 515 SSG Improving Improving Improving Complete Partial
34 516 PM Improving Improving Partial Partial
34 517 PM Stable Improving Partial
34 518 SSG Improving Improving Improving Partial Partial
34 519 PM Stable Improving Partial Partial
34 520 SSG Improving Improving Improving Partial Complete
34 521 PM Improving Improving Partial
34 522 Combination Improving Improving Partial
34 523 SSG Improving Improving Improving Complete Complete
34 524 Combination Improving Improving Complete Complete
34 525 Combination Improving Improving Partial Complete
34 526 SSG Improving Improving Improving Complete Partial
34 527 Combination Improving Improving Complete Complete
34 528 PM Improving Improving Partial
34 529 Combination Improving Improving Complete Complete
34 530 Combination Improving Improving Partial Partial
34 531 SSG Improving Improving Improving Partial
34 532 Combination Improving Improving Partial Complete
34 533 SSG Improving Improving Improving Partial Partial
34 534 PM Stable Improving Partial
34 535 PM Improving Improving Partial Partial
34 536 PM Improving Improving Partial Complete
34 537 SSG Improving Improving Improving Partial Complete
34 538 PM Stable Improving Partial
34 539 Combination Improving Improving Complete Partial
34 540 SSG Improving Improving Improving Partial Partial
35 646 PM Improving Improving Partial Complete
35 647 PM Improving Improving Partial Complete Complete
35 648 Combination Improving Improving Partial Complete Complete
35 649 Combination Improving Improving Partial Complete Complete
35 650 SSG Improving Improving Improving Partial Complete Complete
35 651 SSG Improving Improving Improving Partial Complete Complete
35 652 PM Stable Improving Partial Complete
35 653 Combination Improving Improving Partial Complete Complete
35 654 SSG Improving Improving Improving Partial Complete Complete
35 655 Combination Improving Improving Partial Complete Complete
35 656 SSG Improving Improving Improving Partial Complete Complete
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Centre Patient Treatment Clinical Response to treatment
 Number Number Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
35 657 PM Improving Improving Partial Complete Complete
35 658 Combination Improving Improving Partial Complete Complete
35 659 SSG Stable Improving Improving Partial Complete Complete
35 660 PM Improving Improving Partial Complete Complete
35 661 Combination Improving Improving Partial Complete Complete
35 662 PM Stable Improving Partial Complete Complete
35 663 SSG Improving Improving Improving Partial Partial Partial
35 664 Combination Improving Complete
35 665 SSG Improving Improving Improving Partial Complete Complete
35 666 SSG Improving Improving Improving Partial Complete Complete
35 667 Combination Improving Improving Partial Complete Complete
35 668 PM Improving Improving Partial Complete
35 669 PM Improving Improving Partial
35 670 SSG Improving Improving Improving Partial Complete Complete
35 671 PM Improving Improving Partial Complete
35 672 Combination Improving Improving Partial Partial
35 673 SSG Improving Improving Improving Partial Complete Complete
35 674 Combination Stable Improving Partial Complete Complete
35 675 PM Stable Improving Partial Complete
35 676 PM Stable Improving Partial Partial Complete
35 677 SSG Stable
35 678 Combination Improving Improving Partial Complete Complete
35 679 SSG Improving Improving Improving Partial Complete Complete
35 680 Combination Improving Improving Partial Complete Complete
35 681 Combination Improving Improving Partial Complete Complete
35 682 PM Improving Improving Partial Complete
35 683 Combination Improving Improving Partial Complete
35 684 SSG Stable Improving Improving Partial Complete Complete
35 685 PM Stable Improving Partial Complete Complete
35 686 PM Improving Improving Partial Complete Complete
35 687 SSG Improving Improving Improving Partial Complete Complete
35 688 PM Improving Improving Partial Complete Complete
35 689 Combination Improving Improving Partial Complete Complete
35 690 SSG Improving Improving Improving Partial Complete Complete
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Appendix 39: Individual Patient Listing of Spleen and Liver size
Centre Patient Spleen size (cm)
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 1 PM 5 5 5 5 4.5 5
11 2 Combination 9 9 6 5 4 7
11 3 Combination 10 8 4 4 0.5 0.5
11 4 PM 5 5 5 3.5 2 0
11 5 PM 3 3 4 3.5 2.5 0
11 6 Combination 14 13 10 6 5 2.5
11 7 PM 9 8 7 5 7 6
11 8 SSG 4 5 4 2 1.5 1.5 2
11 9 SSG 5 5 5 5 4.5 3 4
11 10 SSG 5 5 4 3 2.5 0 0
11 11 Combination 4 3.5 3 3 0 0
11 12 Combination 5 3.5 4 3 0 0
11 13 SSG 8 7.5 6 6 6 2 0
11 14 SSG 9 5.5 4 7 6 4 3
11 15 PM 8 5.5 5.5 5
11 16 Combination 0 0 0 0 0 0
11 17 Combination 5.5 5.5 4 4 7 5
11 18 SSG 9 9 8 7.5 6 5.5 5
11 19 Combination 15 14 12 11.5 14 11
11 20 SSG 9 7 7 7 7 5.5 5
11 21 SSG 11 9 8 9.5 7 3 3
11 22 SSG 6 6 3 2 2 0 0
11 23 PM 10 10 7 5 2 3
11 24 PM 8 7 6 5 5 5
11 25 SSG 9 6.5 6 5 3.5 2.5 0
11 26 Combination 6 3 3 3 2 2
11 27 PM 7 7 5.5 5.5 6
11 28 Combination 10 9 7 6 4 3
11 29 PM 6 5 4 4 4 2
11 30 PM 6 5.5 5 4 2.5 1
11 31 SSG 6.5 5 5 3 5 2.5 1
11 32 Combination 6 0.5 0 0 0 0
11 33 SSG 7 4 2 2 0 0 0
11 34 PM 10 10 9 8 5 4.5
11 35 SSG 13 13 10 10 10 9 8
11 36 SSG 3 3 4 5 5 2 0
11 37 Combination 4.5 3 0 0 0 0
11 38 PM 5 5 6 6 3 3
11 39 PM 13 11 10 6 5 1
11 40 PM 8 6 5.5 2 1
11 41 Combination 6 4 3 3 1 0
11 42 Combination 3 0.5 0 0 0 0
11 43 SSG 6 6 5.5 5.5 5.5 4 1
11 44 PM 10 6 5 3 2 0
11 45 Combination 4 2.5 2 2 2 0
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Centre Patient Spleen size (cm)
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 46 SSG 6 6 4 3 2.5 0 0
11 47 SSG 7 5 3 3 3
11 48 Combination 6.5 6.5 4 3 2
11 49 SSG 4 3 3 2 2.5 0 0
11 50 PM 14 12 10 4 3 2
11 51 Combination 6 6 4 4.5 0 0
11 52 PM 11 10 7.5 6.5 4 5
11 53 SSG 6 6 5 3 3 0 0
11 54 PM 6 5 4 1 3 5
11 55 PM 5 5 4 3 0 0
11 56 SSG 7 8 6 6 5 3 2
11 57 Combination 8 7 4 4 4.5 4
11 58 Combination 7 6 5 3.5 0 0
11 59 PM 4 4 3.5 1 1 0
11 60 Combination 7 5 4 3.5 3 2
11 61 PM 7 7 4 3 2.5 2
11 62 SSG 8 6 5 4 4 2.5 1.5
11 63 SSG 6 5 4 3.5 3 3 3
11 64 SSG 6.5 5 5 4 4 2.5 2
11 65 PM 6 8 8 4
11 66 Combination 4.5 4 2.5 2.5 0 0
11 67 PM 4 4 4 2.5 2 0
11 68 SSG 5 5 4 3 3 3 2
11 69 Combination 8 7.5 5 5 5 4
11 70 Combination 6 5 3 3 0 1
11 71 Combination 8 8 8 8 6 13
11 72 SSG 7 6 6 2.5 3
11 73 PM 9 7 7 5 4 2
11 74 PM 3 2 0 0 0 0
11 75 Combination 7 8 6 5 4 5
11 76 PM 4 4 3 3 0 0
11 77 PM 5.5 5 3.5 3 3.5 2.5
11 78 SSG 6 5 5 3 4 3.5 3
11 79 PM 4 4 3.5 3 3.5 3
11 80 PM 9.5 7 6 5 2 2
11 81 Combination 8 7 5 5 5 3
11 82 SSG 8 4.5 6 5 3.5 1.5 1
11 83 SSG 4 4 3.5 4 3.5 0 0
11 84 SSG 4 3 2 3 2 0 0
11 85 SSG 7 5 5 6 3.5 2
11 86 Combination 3 2 0 0 0 0
11 87 Combination 5 5 5 4 2.5 1
11 88 PM 2.5 1 1 1 0 0
11 89 Combination 6 5 5 4.5 4 0
11 90 Combination 7 5 3.5 3.5
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Centre Patient Spleen size (cm)
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 91 PM 6 5 4 2.5 3 4
11 92 Combination 5 5 5 5 2 0
11 93 SSG 4.5 3 2 3 1.5 0 0
11 94 SSG 9 8 5 4 3 2.5 2.5
11 95 SSG 3.5 1 2 2 1 0 0
11 96 Combination 4 3.5 3.5 3.5 0 0
11 97 Combination 6.5 5 4 3 3 0
11 98 PM 4 3.5 3 2 2.5 0
11 99 SSG 6.5 5.5 4.5 3.5 3 1.5 0
11 100 PM 6.5 5 4.5 4.5
11 101 PM 5 5 3.5 3.5 2.5 2
11 102 Combination 7.5 6 3.5 3.5 0 0
11 103 Combination 5 3.5 2.5 2 0 0
11 104 PM 5 4 4 4 2 2
11 105 SSG 8 6 6 6 6 4 2.5
11 106 Combination 4 2 0 0 0 0
11 107 PM 8 4 3 3 2.5 2
11 108 PM 7 5 3 0 0 0
11 109 SSG 6.5 5 4 4 4 2 1.5
11 110 PM 6 6 6 5 3.5 2
11 111 Combination 4 4 0 0 0 0
11 112 Combination 7 4.5 3 2.5 0 0
11 113 SSG 6.5 6.5 4.5 4 4 2.5
11 114 SSG 4 3.5 3 3 3 2 0
11 115 Combination 5.5 5 4 3 0 0
11 116 SSG 5 4.5 3 3 2.5 0 0
11 117 PM 7 4.5 4 2.5 2
11 118 PM 4 4 3.5 3 2.5 2
11 119 SSG 6 4.5 4 4 4 2.5 2.5
11 120 Combination 7 3 2 2 0 0
11 121 Combination 3.5 4.5 3 2.5 0 0
11 122 SSG 4.5 4 4 3.5 3
11 123 SSG 4.5 4.5 4.5 4 3.5 3 2
11 124 SSG 4 3.5 3 2.5 2.5 0
11 125 SSG 4.5 3 3 2.5 0 0 0
11 126 Combination 4 3 2.5 2.5 5
11 127 PM 6 3.5 3 3 1.5 1.5
11 128 Combination 4.5 3 2.5 2.5 2 6
11 129 PM 3.5 3.5 3.5 2.5 0 0
11 130 Combination 3.5 3 1 0 0 0
11 131 PM 4 4 3 3 0 0
11 132 SSG 5 3 3 2.5 2 0 4
11 133 Combination 7.5 7.5 5 4 0 0
11 134 PM 6.5 6.5 5 5 5 5
11 135 PM 4 3 3 2 1 0
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Centre Patient Spleen size (cm)
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
12 241 Combination 8 4 3 3 0
12 242 SSG 8 9 4 1.5 0.5 0 0
12 243 PM 7 7 7 5.5 0 0
12 244 SSG 11 7 7 6 6 3 2
12 245 PM 12 8 8 5.5 8
12 246 PM 3 0.5 0 0 0
12 247 PM 12.5 10 10 10 1 0
12 248 PM 8.5 7 6 4 0 0
12 249 Combination 15 15 15 12 5 11
12 250 SSG 12 10 9 8 6 4 2
12 251 Combination 12 8 4 3 0 0
12 252 SSG 8 3 1.5 0 0 0 0
12 253 SSG 8 5 4 3 2 0 0
12 254 Combination 9 8 8 6 3 0
12 255 Combination 10 7 5 3 0 0
12 256 Combination 6 5 3 3 0 0
12 257 SSG 16 10 8 8 7 1 0
12 258 SSG 9 7 6 5 4 0
12 259 PM 8 7 5 0 0 0
12 260 PM 4 4 2 0 0
12 261 Combination 9 9 7 6 0 0
12 262 PM 7 6 5 3 0 0
12 263 SSG 7 5 3 1 0 0 0
12 264 Combination 10 8 9 9 3 2
12 265 SSG 14 13 11 9 13
12 266 PM 12 10 10 9 5 4
12 267 SSG 2 1 0 0 0 0 0
12 268 PM 11 10 8 4 0 4
12 269 Combination 12 10 9 7 1 0
12 270 Combination 7 6 4 2.5 0
12 271 SSG 9 7 4 3 3 0 0
12 272 PM 5 4.5 3.5 3 0.5 0
12 273 SSG 9 7 5 4 3 0 0
12 274 SSG 4 3 2 2 1 0 0
12 275 Combination 12 11 10 10 3 3
12 276 PM 12 10 7 5 4 2
12 277 Combination 12 8 6 4 0 0
12 278 SSG 8 5 3 2 1 0
12 279 PM 13 11 8 6 2 0
12 280 SSG 15 12 8 6 4 0 2
12 281 Combination 6 5 4 3 0 0
12 282 PM 13 10 6 6 2 2
12 283 PM 4 3 2 0 0 0
12 284 Combination 10 8 7 6 3 6
12 285 Combination 8 5 0 0 0 0
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Centre Patient Spleen size (cm)
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
12 286 PM 18 17.5 10 8 2 1
12 287 SSG 10 8.5 8 6 3 0 0
12 288 Combination 13 12 8 6 0 0
12 289 Combination 12.5 12 8 4 0 3
12 290 SSG 14 13 10 6 2 0
12 291 SSG 9 7 5 5 4 0 3
12 292 PM 16 15 14 13 0
12 293 SSG 8 7 6 5 3 0
12 294 Combination 8 8 6 5 4 0
12 295 Combination 8 0 0 0 0
12 296 PM 8 4 2 0 0 0
12 297 SSG 4 1 0
12 298 PM 7 6 5 3 0 0
12 299 Combination 14 13.5 10 7 0
12 300 PM 10 9.5 7 1 5 0
12 301 SSG 10 3 1 1 0 0 0
12 302 SSG 15 15 14 10 6 2 0
12 303 PM 25 25 18 15 1 3
12 304 Combination 13 6 5 3 0 0
12 305 PM 13 13 10 8 3 0
12 306 Combination 20 18 15 10 2 4
12 307 Combination 17 10 10 8 0 0
12 308 PM 20 13 10 6 3 0
12 309 PM 11.5 10.5 6 3 0 0
12 310 SSG 13 12 8 6 4 0 0
12 311 SSG 16 10 10 8 5 2 0
12 312 Combination 22 18 10 7 0 0
12 313 PM 18 14 10 0 0 0
12 314 SSG 14 12 4 5 3 0 0
12 315 Combination 16 18 17 11 11 0
12 316 SSG 18 10 6 3 0 0
12 317 SSG 12 11 10 7 6 0
12 318 Combination 10 5 3 3 0 0
12 319 Combination 7 7 2 0 0 0
12 320 Combination 13 6 4 3 0 0
12 321 Combination 20 15 15 10 3 7
12 322 PM 18 8 8 4 2 0
12 323 SSG 6 5 4 3 0 0 0
12 324 SSG 10 12 10 8 6 2 0
12 325 PM 9 10 8 3 0 0
12 326 PM 10 10 4 4 7 0
12 327 Combination 2 0 0 0 0 0
12 328 PM 8 11 6 3 0 0
12 329 SSG 9 7 8 6 3 0 2
12 330 PM 9 6 5 4 4 3
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Centre Patient Spleen size (cm)
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
23 361 Combination 17 14.5 12.5 12 1.5 0
23 362 PM 15.5 13 12 7 0 0
23 363 PM 8 9.5 7 3.5 0 0
23 364 Combination 18 17 11.5 11 16 3
23 365 SSG 11.5 9.5 6.5 3 0 0 0
23 366 Combination 15.5 15 9 9 0 0
23 367 SSG 18 18 17 12 11 0 0
23 368 PM 19 16 10.5 9 0 0
23 369 Combination 15 15 10 9 0 5
23 370 SSG 10.5 10 3.5 3 3 0 0
23 371 PM 22.5 22 22.5 16 6.5 4
23 372 PM 8 6 5.5 3 0 0
23 373 SSG 13.5 14 9.5 8 6 0 6
23 374 SSG 8.5 8.5 5.5 4.5 0 0 0
23 375 Combination 8 6.5 3.5 1 0 0
23 376 SSG 13 9 5 4.5 1 0 0
23 377 Combination 13 11 0
23 378 Combination 6 6 6 6.5 9.5 1
23 379 PM 12 11 9 8 10 0
23 380 SSG 8 7.5 7.5 4 4 0 0
23 381 PM 14.5 14 10.5 4 6 0
23 382 Combination 15 14 12 9 5 0
23 383 PM 11.5 11 8 5 0 0
23 384 SSG 13 13 10 10 9 0 0
23 385 SSG 16 15 13 13 12.5 1.5 0
23 386 Combination 15 15 8 5 0 0
23 387 Combination 15 16 16 14 1 0
23 388 PM 9 9 6 5 5 0
23 389 SSG 20 16 14 11.5 10 0 0
23 390 PM 13.5 12 10 9 1 0
23 391 Combination 16 13 8 9 0.5 0
23 392 Combination 11 8 6 0 0
23 393 SSG 7 7 4.5 4.5 4.5 0 0
23 394 PM 11 11 10.5 7 0 0
23 395 PM 10 7 3.5 0 0 0
23 396 SSG 23 20 17 15 13 1 0
23 397 SSG 18 13 11 10 9 0 0
23 398 Combination 16 14.5 12 10 5.5 16
23 399 PM 18 21 17 14 12.5 9
23 400 PM 19 20 16.5 16 7 4
23 401 Combination 10.5 11 7.5 7 20 19
23 402 Combination 15 14.5 10 10 0 0
23 403 SSG 14 9.5 9 7 6 0 0
23 404 SSG 16 8 7 5 1 0
23 405 PM 20 13 13 13 3 0
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Centre Patient Spleen size (cm)
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
34 451 Combination 6 4 2.5 2 0
34 452 PM 5 5 5 5
34 453 PM 6.5 6 5 4
34 454 Combination 3 3 1 0 0
34 455 PM 8 5 5 5
34 456 SSG 4.5 2.5 1 0 0 3
34 457 Combination 6 4 1 0
34 458 PM 6.5 6.5 6 6 10
34 459 Combination 3.5 3.5 1 0 0 0
34 460 PM 3 2 1 0
34 461 SSG 10 8.5 8.5
34 462 SSG 2 1 1 0 0 0
34 463 Combination 3 2 0 0 0
34 464 SSG 13 13 12 11 7 0
34 465 SSG 10 8 5 5 5 0
34 466 Combination 3 1 0 0
34 467 PM 10 9 7 4 10
34 468 Combination 0 0 0 0 0
34 469 SSG 9 9 6 5 3 0
34 470 Combination 9 6 4 3 4
34 471 PM 4 2 0 4
34 472 SSG 1 1 0 0 0 0
34 473 PM 4.5 3 3 3
34 474 Combination 4 3 1 0 0
34 475 PM 14.5 14 13 10
34 476 PM 14 13 13 12 12.5
34 477 SSG 7 4 2 3 4 4
34 478 Combination 11 8 3 2 0
34 479 SSG 2 2 0 0 0 0
34 480 SSG 2 2 0 0 0 0
34 481 Combination 3 2 0 0 0
34 482 Combination 10 6 0 0 0
34 483 PM 0 0 0 0 0
34 484 PM 5 5
34 485 Combination 0 0 0 0 0
34 486 Combination 14 10 6 5 0
34 487 SSG 3 3 0 0 0 0
34 488 SSG 14 10 6 6 6 3 3
34 489 SSG 6.5 6 6 5 2 0
34 490 PM 14 8 13 11 0
34 491 PM 17 15 13.5 11
34 492 PM 0.5 0 0 0 0
34 493 SSG 7 5 3 3 0 4
34 494 Combination 6 2 0 0 0
34 495 SSG 2 0 0 0 0 0
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Centre Patient Spleen size (cm)
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
34 496 SSG 6 4 2 0 0 0
34 497 PM 8 13 13 12 18
34 498 SSG 0 0 0 0 0 0
34 499 Combination 9 7 4 4 0
34 500 PM 0 2 3 1 0
34 501 Combination 4 3.5 1 0 0
34 502 Combination 9 8 6 2 0
34 503 PM 3 5 2 0
34 504 Combination 5 2 0 0
34 505 SSG 2 1 0 0 0 0
34 506 SSG 3 2 1 0 0 0
34 507 SSG 3 3 3 0 0 0
34 508 PM 3 2.5 2.5 0
34 509 PM 6 5 2 0
34 510 Combination 0 0 0 0 0
34 511 Combination 5 4.5 4.5 4 3
34 512 PM 6 5 5 3
34 513 Combination 7 6 3 2.5 0.5 0
34 514 SSG 7 7 3 2.5 2.5 0
34 515 SSG 6 2 2 2 0 4
34 516 PM 6 5 6 5 4
34 517 PM 8 7 7 5
34 518 SSG 11 12 14 11 8 4
34 519 PM 2 0 0 2 3
34 520 SSG 5 5 3 2 2 0
34 521 PM 4 4 3 2
34 522 Combination 7 7 5 3
34 523 SSG 8 3.5 1 0 0 0
34 524 Combination 2 0 0 0 0
34 525 Combination 5 0 1 0 0
34 526 SSG 2 2 2 0 0 0
34 527 Combination 4 0 0 0 0
34 528 PM 9 10 11 8
34 529 Combination 5 3 2 0 0
34 530 Combination 8 8 7 5 1
34 531 SSG 6 7 6 6 3.5
34 532 Combination 4 6 4 3 0
34 533 SSG 7 7 5 5 4 2
34 534 PM 6 5 3 0
34 535 PM 4 3 3 2 6
34 536 PM 0 0 0 0 0
34 537 SSG 2 1 0 0 0 0
34 538 PM 8 9 8 8
34 539 Combination 4 2 0 0 4
34 540 SSG 6 5 5 5 3 3
LEAP 0104a Appendices
Page 480 of 756
Appendix 39: Individual Patient Listing of Spleen and Liver size
Centre Patient Spleen size (cm)
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
35 646 PM 4 4 2 0 0
35 647 PM 6 6 4 4 0 0
35 648 Combination 8 6 1 1 0 0
35 649 Combination 12 10 7 7 0 0
35 650 SSG 6 4 2 2 0 0 0
35 651 SSG 5 4 3 3 3 0 0
35 652 PM 6 5 5 5 0
35 653 Combination 8 8 6 4 0 0
35 654 SSG 8 4 4 4 2 0 0
35 655 Combination 7 3 0 0 0 0
35 656 SSG 9 6 5 4 0 0 0
35 657 PM 12 12 12 8 2 0
35 658 Combination 7 5 2 2 0 0
35 659 SSG 10 10 10 7 6 0 0
35 660 PM 0 0 0 0 0 0
35 661 Combination 4 4 1 0 0 0
35 662 PM 8 8 2 0 0 0
35 663 SSG 13 13 8 8 6 2 2
35 664 Combination 6 6 0
35 665 SSG 9 6 6 2 0 0 0
35 666 SSG 7 4 2 0 0 0 0
35 667 Combination 2 2 0 0 0 0
35 668 PM 8 8 6 1 0
35 669 PM 9 9 9 9
35 670 SSG 4 4 2 2 0 0 0
35 671 PM 13 13 9 9 0
35 672 Combination 12 12 10 7 2
35 673 SSG 10 8 4 4 4 0 0
35 674 Combination 9 9 6 6 0 0
35 675 PM 0 0 0 0 0
35 676 PM 8 7 7 7 2 0
35 677 SSG 14 12
35 678 Combination 12 12 8 8 0 0
35 679 SSG 6 4 4 2 3 0 0
35 680 Combination 13 13 7 6 0 0
35 681 Combination 4 4 0 0 0 0
35 682 PM 4 4 3 0 0
35 683 Combination 9 9 5 4 0
35 684 SSG 8 8 8 4 4 0 0
35 685 PM 4 4 4 2 0 0
35 686 PM 10 8 4 4 0 0
35 687 SSG 18 14 8 8 8 0 0
35 688 PM 8 5 2 0 0 0
35 689 Combination 12 6 4 4 0 0
35 690 SSG 7 2 0 0 0 0 0
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
6 4 3 0 0 0
0 0 5 5 3 3
0 0 0 0 0 0
3 3 0 0 0 0
3 2 3 2 0 0
3.5 4 3 2 0 0
10 8 5 0 0 0
3.5 0 0 0 0 0 0
5 0 0 0 0 0 0
4 4 0 0 0 0 0
6.5 5.5 4.5 5 3 4
0 0 0 0 0 0
3 2 0 0 0 0 0
6 3.5 3 3 2 3 2
0 1.5 0 0
0 0 0 0 0 0
3 3 3 3 4.5 4
4 4 3 3 3 0 0
0 0 0 0 4 3
0 0 0 0 0 0 0
0 0 0 0 0 0 0
2 2 2 2 0 0 0
7 6 7 6 0 0
3 2 2 0 0 0
0 0 0 0 0 0 0
5 4 2 2 0 0
6 4.5 5 5 4
0 0 0 0 0 0
0 0 0 0 0 0
4 3 3 3 0 0
3 4 4 2 3 2 0
6 3.5 0 0 0 0
0 0 0 0 0 0 0
5 5 4 3 4 3
0 0 3 4 3 0 0
0 0 4 4 3.5 2 0
4 4 0 0 0 0
3 3 4 3 0 4
6 6 4.5 3 1 0
0 4 0 0 0
0 0 0 0 0 0
4 2 0 0 0 0
5 2 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
6 3 3 3 2 1.5 0
0 0 0 0 0
0 0 0 0 0
6 3 0 0 0 0 0
3 3 3 0 0 0
4 5 2 2 0 0
5 5 6 4 3 3
0 0 0 0 0 0 0
4 3 2 0 0 4
0 0 0 0 0 0
6 5 2 2 2 0 0
3 3 3 3 1.5 0
0 0 0 0 0 0
4 3.5 3 2 3 3
2 0 0 0 0 0
3 4 3 2 0 0
8 7 7 7 6 4 0
0 0 0 0 0 0 0
4.5 3 3 3 0 0 0
8 6 6 3
0 0 0 0 0 0
3.5 3 2 0 0 0
3 4 2 0 0 0 0
4 4 3 3 2 2
4 4 2 2 0 0
5 3 3 4 3 5
4 3 3 0 0
4 2 0 0 0 0
0 0 0 0 0 0
6 4 3 1 2 0
2 2 0 0 0 0
4 4 2 0 0 0
4 2 0 0 0 0 0
0 0 0 0 0 0
5 7 5 2.5 3 0
0 0 0 0 0 0
3 3 3 3 4 3 0
2 3 2 2 1.5 0 0
0 0 0 3 3 0 0
6 7 7 9 6 4
2 3 0 0 0 0
2 3 3 2 0 0
0 0 0 0 0 0
5 5 5 5 5 0
0 0 0 0
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
2 3 2 2 0 0
3 3 3 2.5 0 0
2 2 0 0 0 0 0
4 5 3 3 2 0 0
3.5 3 3 3 3 2 0
6 3 3 3 0 0
3 3 3 3 0 0
4 2.5 2 0 0 0
3 3 3 2.5 1.5 0 0
4 3 3 3
4 4 3 3.5 2 0
4.5 3 0 0 0 0
4 3 2 0 0 0
6 6 5 4 1 0
4 4 4 4 4 2 1
0 0 0 0 0 0
4 3 0 0 0 0
4 3 0 0 0 0
3 3 3 3 3 0 0
4.5 4.5 4 4 2 2
2 3 0 0 0 0
4.5 4.5 2 0 0 0
7 6 4.5 3 3 3
2 2 0 0 0 0 0
6 4 2 2 0 0
2.5 0 0 0 0 0 0
4 2 0 0 0
3 1 0 0 0 0
4 3 2 2 2 0 0
4.5 2.5 0 0 0 0
2 2.5 2.5 2 0 0
4 1.5 1 0 0
4 4 3 3 3 2 0
2 2 0 0 0 0
4 2.5 2 1.5 0 0 0
2 2 2 1.5 4
3 3 2 2 1 0
2 2.5 1 0 0 2
2 2 2 2 0 0
0 0 0 0 0 0
3 3 2 2 0 0
4.5 2.5 2 1.5 0 0 0
2 2 0 0 0 0
3.5 3.5 2 2 2 2
3.5 2 2 0 0 0
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
2 2 0.5 0.5 0
4 3 3 0.5 0.5 0 0
0.5 3 3 3 0 0
4 6 4 8 7 4.5 0
4 7 7 6 8
3 0.5 0 0 0
3 2.5 5 5 0 0
1 0.5 0.5 0 0 0
10 10 9 7 3 0
8 8 9 9 6 7 2
3 3 0 0 0 0
0 0 0 0 0 0 0
3 3 4 0 1 0 2
1 2 2 3 0 0
0 0 0 0 0 0
0 0 0 0 0 0
4 2 2 1 1 0 0
10 10 6 6 3 0
2 2 0 0 0 0
2 2 0 0 0
8 7 4 3 0 0
5 5 4 0 0 0
2 2 0 0 0 0 0
0 0 3 5 2 0
0 2 2 3 6
2 1 3 6 2 0
0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
3 0 0 0 0
0 0 0 0 0
0 0 0 0 0 0
3 2 2 2 3 0 0
0 0 0 0 0 0
5 3 0 0 0 0
5 4 3 2 2 0
5 3 2 1 0 0
4 2 0 0 0 0
2 0 0 0 3 0
5 3 0 0 0 0 0
3 0 0 0 0 0
2 2 2 2 0 0
0 0 0 0 0 0
3 2 0 0 2 1
3 1 0 0 0 0
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
4 2 2 1 0 0
7.5 6 4 2 0 0 0
0 0 0 0.5 0 0
0 2 1 1 0 2
0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0
0.5 0 0 0 0 0
0 4 2 2 3 0
2 0 0 0 0
3 1 0 0 0 0
5 0 2
0 0 0 0 2 0
0 0 0 0 0
0 0 2 0 4 0
0 0 0 0 0 0 0
6 7 7 5 3 2 0
3 2 3 3 0 0
8 7 1 0 0 0
2 3 4 4 3 0
6 5 4 4 1 0
5 10 7 4 0 0
8.5 4 2 0 0 0
0 0 0 0 0 0
2 2 0 0 0 0 0
3 2 1 0 0 1 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0
2 6 2 0 0 0
0 0 0 0 0 0
8 8 6 5 4 0
0 0 0 0 0 0
0 0 0 0 0 0
4 4 2 0 0 0
4 2 1 0 0 0
0 0 3 0 0 0
1 0 0 0 0 0 0
0 0 0 4 4 0 0
4 2 0 1 0 0
5 4 4 4 4 0
4 4 0 0 0 0
0 0 0 0 0 0
3 3 2 0 0 0 0
5 3 3 1 2 0
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
0 0 0 0 0 0
0 0 0 0 0 0
1 1 0 0
4 4 3.5 3 0 4
0 0 0 0 0 0 0
11 11.5 4 4 0 0
3 3 3 3 2 0 0
0 0 0 0 0 0
2 2 3 3 0 0
0 0 0 0 0 0 0
8 7 7 3 0 0
3 1 0 0 0 0
0 0 0 0 0 0 1
6.5 6 3.5 1.5 0 0 0
4 4 4 3.5 0 0
2 2 1 1 0 0 0
7.5 5 0
2 2 2 2 3 0
3 1.5 0 0 1.5 0
1 1 0 0 0 0 0
4 4 2 0 2 0
3 3 3 0 0 0
0 0 0 0 0 0
3.5 2 1.5 1 1 0 0
5 6 3.5 2 2 0 0
3 1.5 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
10.5 8 5 4 4 1.5 0
4.5 4 4 4 0 0
4 4 4 4 0 0
5 5 4 0 0
2.5 2.5 2.5 2.5 2.5 0 0
5 5 5 2 0 0
5 4 2 2 0 0
5 3 3 3 2 0 0
3 3 3 2 2 0 0
2 1 1 1 1 2
5 5 5 5 0 0
3 3 2.5 1 0 0
2 1 1 0 2 0
3 3 2 2 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
5 5 4 3 0
0.5 0 0 0
2 1 0 0
4 4 3 3 0
0 0 0 0
4 5 5 3 2 4
0 0 0 0
2 2 2 3 3
0 0 0 0 0 0
0 0 0 0
1 4 9
5 5 3.5 3.5 2 1
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
1 0 0 0
0 0 0 0 5
0 0 0 0 0
2 0 0 0 0 0
6 5 5 2 4
5 4 4 3
4 2 0 0 0 0
5 3 3 3
0 0 0 0 0
4 4 4 5
5 5 4.5 7 8
0 0 0 0 0 0
4 3 2 0 2
3 3 2 3 3 0
0 0 0 0 0 0
5 3 3 1 0
8 5 0 0 0
0 0 0 0 0
0 2
7 5 4 2 4
4 2 2 0 0
0 0 0 0 0 0
3 3 3 3 3 2 0
3 2 5.5 3.5 1 0
8 5 5 5 0
5 5 4 4
0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0
4 2 4 2.5 1 1
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
0 0 0 0 0 0
3 3 3 1 5
0 0 0 0 0 0
5 4.5 4 4 0
0 4 4 2.5 0
3 3 3 3 0
6 4 2 1.5 0
2.5 4 3 3
3 2 2 2
2 2 2 1 0 0
5 4 3 2 1.5 0
2 5 5 2 3.5 4
4 4 4 2
0 3 2 0
3 3 3 2 0
0 0 0 0 0
5 6 6 4
3 3 2.5 2.5 2.5 2.5
4 4 4 4 4 2
2.5 1 0 2 2 0
0 0 0 0 0
5 4 3.5 2
5 5 6 6 5 5
0 2 2 2 2
0 0 0 0 0 0
4 3 3 3
5 5 4 9
4 2.5 2.5 2 1 0
2 1 0 0 0
6 1.5 2 0 0
0 0 3 2 0 0
5 4 3 2 0
3 6 5.5 5
4 4 3 3 1
2 3 3 2 0
2.5 6 6 4 2
3 5 3 2 3
3 3 2 2 1 0
2 2 2 4
3 2 2 2 4
4 3 2 0 0
4 3 3 3 1 0
5 5 4 3
3 1 0 0 0
4 4 2 2 0 0
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
4 4 4 4 0
4 4 4 4 0 0
4 4 2 2 0 0
6 4 3 3 0 0
4 4 4 2 2 0 0
3 3 2 2 2 0 0
4 4 3 3 0
5 5 4 4 0 0
5 4 4 4 4 0 0
2 2 2 2 0 0
4 4 4 2 2 0 0
5 5 5 3 0 0
4 4 4 2 0 0
5 4 4 2 2 0 0
0 0 0 0 0 0
2 2 2 2 0 0
4 4 2 0 0 0
4 4 2 2 2 0 0
2 2 0
2 2 2 2 0 0 0
2 2 2 0 0 0 0
2 2 2 2 0 0
2 2 2 0 0
1 1 1 1
0 0 0 0 0 0 0
4 4 3 2 0
6 6 6 6 0
3 2 2 2 0 0 0
3 3 3 3 0 0
2 2 2 0 0
6 7 6 6 2 0
4 4
4 4 3 3 0 0
2 2 0 0 0 0 0
5 5 5 4 0 0
0 0 0 0 0 0
5 4 4 0 0
4 3 0 0 0
0 0 0 0 0 0 0
0 0 0 0 0 0
7 6 2 0 0 0
7 6 6 6 6 0 0
4 2 0 0 0 0
8 2 2 2 0 0
5 5 4 4 4 0 0
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Appendix 40: Individual listing of clinical characteristic, cervical and axiliary Lymphadenopathy
Centre Patient Cervical lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 1 PM Absent Absent Absent Absent Absent Absent
11 2 Combination Absent Absent Absent Absent Absent Absent
11 3 Combination Absent Absent Absent Absent Absent Absent
11 4 PM Absent Absent Absent Absent Absent Absent
11 5 PM Absent Absent Absent Absent Absent Absent
11 6 Combination Absent Absent Absent Absent Absent Absent
11 7 PM Absent Absent Absent Absent Absent Absent
11 8 SSG Absent Absent Absent Absent Absent Absent Absent
11 9 SSG Absent Absent Absent Absent Absent Absent Absent
11 10 SSG Absent Absent Absent Absent Absent Absent Absent
11 11 Combination Absent Absent Absent Absent Absent Absent
11 12 Combination Absent Absent Absent Absent Absent Absent
11 13 SSG Absent Absent Absent Absent Absent Absent Absent
11 14 SSG Absent Absent Absent Absent Absent Absent Absent
11 15 PM Absent Absent Absent Absent
11 16 Combination Absent Absent Absent Absent Absent Absent
11 17 Combination Absent Absent Absent Absent Absent Absent
11 18 SSG Absent Absent Absent Absent Absent Absent Absent
11 19 Combination Absent Absent Absent Absent Absent Absent
11 20 SSG Absent Absent Absent Absent Absent Absent Absent
11 21 SSG Absent Absent Absent Absent Absent Absent Absent
11 22 SSG Absent Absent Absent Absent Absent Absent Absent
11 23 PM Absent Absent Absent Absent Absent Absent
11 24 PM Absent Absent Absent Absent Absent Absent
11 25 SSG Absent Absent Absent Absent Absent Absent Absent
11 26 Combination Absent Absent Absent Absent Absent Absent
11 27 PM Absent Absent Absent Absent Absent
11 28 Combination Absent Absent Absent Absent Absent Absent
11 29 PM Absent Absent Absent Absent Absent Absent
11 30 PM Absent Absent Absent Absent Absent Absent
11 31 SSG Absent Absent Absent Absent Absent Absent Absent
11 32 Combination Absent Absent Absent Absent Absent Absent
11 33 SSG Absent Absent Absent Absent Absent Absent Absent
11 34 PM Absent Absent Absent Absent Absent Absent
11 35 SSG Absent Absent Absent Absent Absent Absent Absent
11 36 SSG Absent Absent Absent Absent Absent Absent Absent
11 37 Combination Absent Absent Absent Absent Absent Absent
11 38 PM Absent Absent Absent Absent Absent Absent
11 39 PM Absent Absent Absent Absent Absent Absent
11 40 PM Absent Absent Absent Absent Absent
11 41 Combination Absent Absent Absent Absent Absent Absent
11 42 Combination Absent Absent Absent Absent Absent Absent
11 43 SSG Absent Absent Absent Absent Absent Absent Absent
11 44 PM Absent Absent Absent Absent Absent Absent
11 45 Combination Absent Absent Absent Absent Absent Absent
11 46 SSG Absent Absent Absent Absent Absent Absent Absent
11 47 SSG Absent Absent Absent Absent Absent
11 48 Combination Absent Absent Absent Absent Absent
11 49 SSG Absent Absent Absent Absent Absent Absent Absent
11 50 PM Absent Absent Absent Absent Absent Absent
11 51 Combination Absent Absent Absent Absent Absent Absent
11 52 PM Present Absent Absent Absent Absent Absent
11 53 SSG Absent Absent Absent Absent Absent Absent Absent
11 54 PM Absent Absent Absent Absent Absent Absent
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Appendix 40: Individual listing of clinical characteristic, cervical and axiliary Lymphadenopathy
Centre Patient Cervical lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 55 PM Absent Absent Absent Absent Absent Absent
11 56 SSG Absent Absent Absent Absent Absent Absent Absent
11 57 Combination Absent Absent Absent Absent Absent Absent
11 58 Combination Absent Absent Absent Absent Absent Absent
11 59 PM Absent Absent Absent Absent Absent Absent
11 60 Combination Absent Absent Absent Absent Absent Absent
11 61 PM Absent Absent Absent Absent Absent Absent
11 62 SSG Absent Absent Absent Absent Absent Absent Absent
11 63 SSG Absent Absent Absent Absent Absent Absent Absent
11 64 SSG Absent Absent Absent Absent Absent Absent Absent
11 65 PM Absent Absent Absent Absent
11 66 Combination Absent Absent Absent Absent Absent Absent
11 67 PM Absent Absent Absent Absent Absent Absent
11 68 SSG Present Absent Absent Absent Absent Absent Absent
11 69 Combination Present Absent Absent Absent Absent Absent
11 70 Combination Absent Absent Absent Absent Absent Absent
11 71 Combination Absent Absent Absent Absent Absent Absent
11 72 SSG Absent Absent Absent Absent Absent
11 73 PM Absent Absent Absent Absent Absent Absent
11 74 PM Absent Absent Absent Absent Absent Absent
11 75 Combination Absent Absent Absent Absent Absent Absent
11 76 PM Absent Absent Absent Absent Absent Absent
11 77 PM Absent Absent Absent Absent Absent Absent
11 78 SSG Absent Absent Absent Absent Absent Absent Absent
11 79 PM Absent Absent Absent Absent Absent Absent
11 80 PM Absent Absent Absent Absent Absent Absent
11 81 Combination Absent Absent Absent Absent Absent Absent
11 82 SSG Absent Absent Absent Absent Absent Absent Absent
11 83 SSG Absent Absent Absent Absent Absent Absent Absent
11 84 SSG Absent Absent Absent Absent Absent Absent Absent
11 85 SSG Absent Absent Absent Absent Absent Absent
11 86 Combination Absent Absent Absent Absent Absent Absent
11 87 Combination Absent Absent Absent Absent Absent Absent
11 88 PM Absent Absent Absent Absent Absent Absent
11 89 Combination Absent Absent Absent Absent Absent Absent
11 90 Combination Absent Absent Absent Absent
11 91 PM Absent Absent Absent Absent Absent Absent
11 92 Combination Absent Absent Absent Absent Absent Absent
11 93 SSG Absent Absent Absent Absent Absent Absent Absent
11 94 SSG Absent Absent Absent Absent Absent Absent Absent
11 95 SSG Absent Absent Absent Absent Absent Absent Absent
11 96 Combination Absent Absent Absent Absent Absent Absent
11 97 Combination Absent Absent Absent Absent Absent Absent
11 98 PM Absent Absent Absent Absent Absent Absent
11 99 SSG Absent Absent Absent Absent Absent Absent Absent
11 100 PM Absent Absent Absent Absent
11 101 PM Absent Absent Absent Absent Absent Absent
11 102 Combination Absent Absent Absent Absent Absent Absent
11 103 Combination Absent Absent Absent Absent Absent Absent
11 104 PM Absent Absent Absent Absent Absent Absent
11 105 SSG Absent Absent Absent Absent Absent Absent Absent
11 106 Combination Absent Absent Absent Absent Absent Absent
11 107 PM Absent Absent Absent Absent Absent Absent
11 108 PM Absent Absent Absent Absent Absent Absent
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Appendix 40: Individual listing of clinical characteristic, cervical and axiliary Lymphadenopathy
Centre Patient Cervical lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 109 SSG Absent Absent Absent Absent Absent Absent Absent
11 110 PM Absent Absent Absent Absent Absent Absent
11 111 Combination Absent Absent Absent Absent Absent Absent
11 112 Combination Absent Absent Absent Absent Absent Absent
11 113 SSG Absent Absent Absent Absent Absent Absent
11 114 SSG Absent Absent Absent Absent Absent Absent Absent
11 115 Combination Absent Absent Absent Absent Absent Absent
11 116 SSG Absent Absent Absent Absent Absent Absent Absent
11 117 PM Absent Absent Absent Absent Absent
11 118 PM Absent Absent Absent Absent Absent Absent
11 119 SSG Absent Absent Absent Absent Absent Absent Absent
11 120 Combination Absent Absent Absent Absent Absent Absent
11 121 Combination Absent Absent Absent Absent Absent Absent
11 122 SSG Absent Absent Absent Absent Absent
11 123 SSG Absent Absent Absent Absent Absent Absent Absent
11 124 SSG Absent Absent Absent Absent Absent Absent
11 125 SSG Absent Absent Absent Absent Absent Absent Absent
11 126 Combination Absent Absent Absent Absent Absent
11 127 PM Absent Absent Absent Absent Absent Absent
11 128 Combination Absent Absent Absent Absent Absent Absent
11 129 PM Absent Absent Absent Absent Absent Absent
11 130 Combination Absent Absent Absent Absent Absent Absent
11 131 PM Absent Absent Absent Absent Absent Absent
11 132 SSG Absent Absent Absent Absent Absent Absent Absent
11 133 Combination Absent Absent Absent Absent Absent Absent
11 134 PM Absent Absent Absent Absent Absent Absent
11 135 PM Absent Absent Absent Absent Absent Absent
12 241 Combination Absent Absent Absent Absent Absent
12 242 SSG Absent Absent Absent Absent Absent Absent Absent
12 243 PM Absent Absent Absent Absent Absent Absent
12 244 SSG Absent Absent Absent Absent Absent Absent Absent
12 245 PM Absent Absent Absent Absent Absent
12 246 PM Absent Absent Absent Absent Absent
12 247 PM Present Present Present Present Absent Absent
12 248 PM Absent Absent Absent Absent Absent Absent
12 249 Combination Present Absent Absent Absent Absent Absent
12 250 SSG Absent Present Present Absent Absent Absent Absent
12 251 Combination Present Absent Absent Absent Absent Absent
12 252 SSG Present Absent Absent Absent Absent Absent Absent
12 253 SSG Present Absent Absent Absent Absent Absent Absent
12 254 Combination Absent Absent Absent Absent Absent Absent
12 255 Combination Absent Absent Absent Absent Absent Absent
12 256 Combination Absent Absent Absent Absent Absent Absent
12 257 SSG Absent Absent Absent Absent Absent Absent Absent
12 258 SSG Absent Absent Absent Absent Absent Absent
12 259 PM Absent Absent Absent Absent Absent Absent
12 260 PM Absent Absent Absent Absent Absent
12 261 Combination Present Absent Absent Absent Absent Absent
12 262 PM Absent Absent Absent Absent Absent Absent
12 263 SSG Absent Absent Absent Absent Absent Absent Absent
12 264 Combination Absent Absent Absent Absent Absent Absent
12 265 SSG Absent Absent Absent Absent Absent
12 266 PM Absent Absent Absent Absent Absent Absent
12 267 SSG Absent Absent Absent Absent Absent Absent Absent
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Appendix 40: Individual listing of clinical characteristic, cervical and axiliary Lymphadenopathy
Centre Patient Cervical lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
12 268 PM Absent Absent Absent Absent Absent Absent
12 269 Combination Absent Absent Absent Absent Absent Absent
12 270 Combination Absent Absent Absent Absent Absent
12 271 SSG Absent Absent Absent Absent Absent Absent Absent
12 272 PM Absent Absent Absent Absent Present Absent
12 273 SSG Absent Absent Absent Absent Absent Absent Absent
12 274 SSG Present Absent Absent Absent Absent Absent Absent
12 275 Combination Absent Absent Absent Absent Absent Absent
12 276 PM Absent Absent Absent Absent Absent Absent
12 277 Combination Absent Absent Absent Absent Absent Absent
12 278 SSG Absent Absent Absent Absent Absent Absent
12 279 PM Absent Absent Absent Absent Absent Absent
12 280 SSG Absent Absent Absent Absent Absent Absent Absent
12 281 Combination Absent Absent Absent Absent Absent Absent
12 282 PM Absent Absent Absent Absent Absent Absent
12 283 PM Absent Absent Absent Absent Absent Absent
12 284 Combination Absent Absent Absent Absent Absent Absent
12 285 Combination Absent Absent Absent Absent Absent Absent
12 286 PM Absent Absent Absent Absent Absent Absent
12 287 SSG Absent Absent Absent Absent Absent Absent Absent
12 288 Combination Absent Absent Absent Absent Absent Absent
12 289 Combination Absent Absent Absent Absent Absent Absent
12 290 SSG Absent Absent Absent Absent Absent Absent
12 291 SSG Absent Absent Absent Absent Absent Absent Absent
12 292 PM Absent Absent Absent Absent Absent
12 293 SSG Absent Absent Absent Absent Absent Absent
12 294 Combination Absent Absent Absent Absent Absent Absent
12 295 Combination Absent Absent Absent Absent Absent
12 296 PM Absent Absent Absent Absent Absent Absent
12 297 SSG Present Absent Absent
12 298 PM Absent Absent Absent Absent Absent Absent
12 299 Combination Absent Absent Absent Absent Absent
12 300 PM Absent Absent Absent Absent Absent Absent
12 301 SSG Absent Absent Absent Absent Absent Absent Absent
12 302 SSG Absent Absent Absent Absent Absent Absent Absent
12 303 PM Absent Absent Absent Absent Absent Absent
12 304 Combination Absent Absent Absent Absent Absent Absent
12 305 PM Present Present Absent Absent Absent Absent
12 306 Combination Absent Absent Absent Absent Absent Absent
12 307 Combination Absent Absent Absent Absent Absent Absent
12 308 PM Absent Absent Absent Absent Absent Absent
12 309 PM Absent Absent Absent Absent Absent Absent
12 310 SSG Absent Absent Absent Absent Absent Absent Absent
12 311 SSG Absent Absent Absent Absent Absent Absent Absent
12 312 Combination Absent Absent Absent Absent Absent Absent
12 313 PM Absent Absent Absent Absent Absent Absent
12 314 SSG Absent Absent Absent Absent Absent Absent Absent
12 315 Combination Absent Absent Absent Absent Absent Absent
12 316 SSG Absent Absent Absent Absent Absent Absent
12 317 SSG Absent Absent Absent Absent Absent Absent
12 318 Combination Absent Absent Absent Absent Absent Absent
12 319 Combination Absent Absent Absent Absent Absent Absent
12 320 Combination Absent Absent Absent Absent Absent Absent
12 321 Combination Absent Absent Absent Absent Absent Absent
LEAP 0104a Appendices
Page 494 of 756
Appendix 40: Individual listing of clinical characteristic, cervical and axiliary Lymphadenopathy
Centre Patient Cervical lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
12 322 PM Absent Absent Absent Absent Absent Absent
12 323 SSG Absent Absent Absent Absent Absent Absent Absent
12 324 SSG Absent Absent Absent Absent Absent Absent Absent
12 325 PM Absent Absent Absent Absent Absent Absent
12 326 PM Absent Absent Absent Absent Absent Absent
12 327 Combination Absent Absent Absent Absent Absent Absent
12 328 PM Absent Absent Absent Absent Absent Absent
12 329 SSG Absent Absent Absent Absent Absent Absent Absent
12 330 PM Absent Absent Absent Absent Absent Absent
23 361 Combination Absent Absent Absent Absent Absent Absent
23 362 PM Absent Absent Absent Absent Absent Absent
23 363 PM Absent Absent Absent Absent Absent Absent
23 364 Combination Absent Absent Absent Absent Absent Absent
23 365 SSG Absent Absent Absent Absent Absent Absent Absent
23 366 Combination Absent Absent Absent Absent Absent Absent
23 367 SSG Absent Absent Absent Absent Absent Absent Absent
23 368 PM Absent Absent Absent Absent Absent Absent
23 369 Combination Absent Absent Absent Absent Absent Absent
23 370 SSG Absent Absent Absent Absent Absent Absent Absent
23 371 PM Absent Absent Absent Absent Present Absent
23 372 PM Absent Absent Absent Absent Absent Absent
23 373 SSG Absent Absent Absent Absent Absent Absent Absent
23 374 SSG Absent Absent Absent Absent Absent Absent Absent
23 375 Combination Absent Absent Absent Absent Absent Absent
23 376 SSG Absent Absent Absent Absent Absent Absent Absent
23 377 Combination Absent Absent Absent
23 378 Combination Present Present Present Present Absent Absent
23 379 PM Absent Absent Absent Absent Absent Absent
23 380 SSG Absent Absent Absent Absent Absent Absent Absent
23 381 PM Absent Absent Absent Absent Absent Absent
23 382 Combination Absent Absent Absent Absent Absent Absent
23 383 PM Absent Absent Absent Absent Absent Absent
23 384 SSG Absent Absent Absent Absent Absent Absent Absent
23 385 SSG Present Absent Absent Present Present Present Absent
23 386 Combination Absent Absent Absent Absent Absent Absent
23 387 Combination Absent Absent Absent Absent Absent Absent
23 388 PM Absent Absent Absent Absent Absent Absent
23 389 SSG Present Present Present Absent Absent Absent Absent
23 390 PM Absent Absent Absent Absent Absent Absent
23 391 Combination Absent Absent Absent Absent Present Absent
23 392 Combination Present Absent Present Absent Absent
23 393 SSG Absent Absent Absent Absent Absent Absent Absent
23 394 PM Absent Absent Absent Absent Absent Absent
23 395 PM Absent Absent Absent Absent Absent Absent
23 396 SSG Absent Absent Absent Absent Absent Absent Absent
23 397 SSG Absent Absent Absent Absent Absent Absent Absent
23 398 Combination Absent Absent Absent Absent Absent Absent
23 399 PM Absent Absent Absent Absent Absent Absent
23 400 PM Absent Absent Absent Absent Absent Absent
23 401 Combination Absent Absent Absent Absent Absent Absent
23 402 Combination Absent Absent Absent Absent Absent Absent
23 403 SSG Absent Absent Absent Absent Absent Absent Absent
23 404 SSG Absent Absent Absent Absent Absent Absent
23 405 PM Absent Absent Absent Absent Absent Absent
LEAP 0104a Appendices
Page 495 of 756
Appendix 40: Individual listing of clinical characteristic, cervical and axiliary Lymphadenopathy
Centre Patient Cervical lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
34 451 Combination Absent Absent Absent Absent Absent
34 452 PM Absent Absent Absent Absent
34 453 PM Absent Absent Absent Absent
34 454 Combination Absent Absent Absent Absent Absent
34 455 PM Absent Absent Absent Absent
34 456 SSG Absent Absent Absent Absent Absent Absent
34 457 Combination Absent Absent Absent Absent
34 458 PM Absent Absent Absent Absent Absent
34 459 Combination Absent Absent Absent Absent Absent Absent
34 460 PM Absent Absent Absent Absent
34 461 SSG Absent Absent Absent
34 462 SSG Absent Absent Absent Absent Absent Present
34 463 Combination Present Present Present Absent Absent
34 464 SSG Absent Absent Absent Absent Absent Absent
34 465 SSG Absent Absent Absent Absent Absent Absent
34 466 Combination Absent Absent Absent Absent
34 467 PM Absent Absent Absent Absent Absent
34 468 Combination Absent Absent Absent Absent Absent
34 469 SSG Absent Absent Absent Absent Absent Absent
34 470 Combination Absent Absent Absent Absent Absent
34 471 PM Absent Absent Absent Absent
34 472 SSG Absent Absent Absent Absent Absent Absent
34 473 PM Absent Absent Absent Absent
34 474 Combination Absent Absent Absent Absent Absent
34 475 PM Absent Absent Absent Absent
34 476 PM Absent Absent Absent Absent Present
34 477 SSG Absent Absent Absent Absent Absent Absent
34 478 Combination Absent Absent Absent Absent Absent
34 479 SSG Absent Absent Absent Absent Absent Absent
34 480 SSG Absent Absent Absent Absent Absent Absent
34 481 Combination Absent Absent Absent Absent Present
34 482 Combination Absent Absent Absent Absent Absent
34 483 PM Absent Absent Absent Absent Absent
34 484 PM Absent Absent
34 485 Combination Absent Absent Absent Absent Absent
34 486 Combination Absent Absent Absent Absent Absent
34 487 SSG Absent Absent Absent Absent Absent Absent
34 488 SSG Absent Absent Absent Absent Absent Absent Present
34 489 SSG Absent Absent Absent Absent Absent Absent
34 490 PM Absent Absent Absent Absent Absent
34 491 PM Absent Absent Absent Absent
34 492 PM Absent Absent Absent Absent Absent
34 493 SSG Absent Absent Absent Absent Absent Absent
34 494 Combination Absent Absent Absent Absent Absent
34 495 SSG Absent Absent Absent Absent Absent Present
34 496 SSG Absent Absent Absent Absent Absent Absent
34 497 PM Absent Absent Absent Absent Absent
34 498 SSG Absent Absent Absent Absent Absent Present
34 499 Combination Absent Absent Absent Absent Absent
34 500 PM Absent Absent Absent Absent Absent
34 501 Combination Absent Absent Absent Absent Absent
34 502 Combination Absent Absent Absent Absent Absent
34 503 PM Absent Absent Absent Absent
34 504 Combination Absent Absent Absent Absent
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Appendix 40: Individual listing of clinical characteristic, cervical and axiliary Lymphadenopathy
Centre Patient Cervical lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
34 505 SSG Absent Absent Absent Absent Absent Absent
34 506 SSG Absent Absent Absent Absent Absent Present
34 507 SSG Absent Absent Present Absent Absent Absent
34 508 PM Absent Absent Absent Absent
34 509 PM Absent Absent Absent Absent
34 510 Combination Absent Absent Absent Absent Absent
34 511 Combination Absent Absent Absent Absent Present
34 512 PM Absent Absent Absent Absent
34 513 Combination Absent Absent Absent Absent Absent Absent
34 514 SSG Absent Absent Absent Absent Absent Absent
34 515 SSG Absent Absent Absent Absent Absent Absent
34 516 PM Absent Absent Absent Absent Absent
34 517 PM Absent Absent Absent Absent
34 518 SSG Absent Absent Absent Absent Absent Absent
34 519 PM Absent Absent Absent Absent Absent
34 520 SSG Absent Absent Absent Absent Absent Absent
34 521 PM Absent Absent Absent Absent
34 522 Combination Absent Absent Absent Absent
34 523 SSG Absent Absent Absent Absent Absent Absent
34 524 Combination Absent Absent Absent Absent Absent
34 525 Combination Absent Absent Absent Absent Present
34 526 SSG Absent Absent Absent Absent Absent Present
34 527 Combination Absent Absent Absent Absent Absent
34 528 PM Absent Absent Absent Absent
34 529 Combination Absent Absent Absent Absent Absent
34 530 Combination Absent Absent Absent Absent Absent
34 531 SSG Absent Absent Absent Absent Absent
34 532 Combination Absent Absent Absent Absent Absent
34 533 SSG Absent Absent Absent Absent Absent Absent
34 534 PM Absent Absent Absent Absent
34 535 PM Absent Absent Absent Absent Absent
34 536 PM Absent Absent Absent Absent Absent
34 537 SSG Absent Absent Absent Absent Absent Absent
34 538 PM Absent Absent Absent Absent
34 539 Combination Absent Absent Absent Absent Absent
34 540 SSG Absent Absent Absent Absent Absent Absent
35 646 PM Absent Absent Absent Absent Absent
35 647 PM Absent Absent Absent Absent Absent Absent
35 648 Combination Present Present Absent Absent Absent Absent
35 649 Combination Absent Absent Absent Absent Absent Absent
35 650 SSG Absent Absent Absent Absent Absent Absent Absent
35 651 SSG Absent Absent Absent Absent Absent Absent Absent
35 652 PM Present Present Present Present Absent
35 653 Combination Present Present Present Present Absent Absent
35 654 SSG Absent Absent Absent Absent Absent Absent Absent
35 655 Combination Present Present Present Present Absent Absent
35 656 SSG Present Absent Absent Absent Absent Absent Absent
35 657 PM Present Present Present Present Absent Absent
35 658 Combination Absent Absent Absent Absent Absent Absent
35 659 SSG Present Present Present Present Present Absent Absent
35 660 PM Absent Absent Absent Absent Absent Absent
35 661 Combination Absent Absent Absent Absent Absent Absent
35 662 PM Absent Absent Absent Absent Absent Absent
35 663 SSG Absent Absent Absent Absent Absent Absent Absent
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Appendix 40: Individual listing of clinical characteristic, cervical and axiliary Lymphadenopathy
Centre Patient Cervical lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
35 664 Combination Absent Absent Absent
35 665 SSG Present Present Present Present Absent Absent Absent
35 666 SSG Absent Absent Absent Absent Absent Absent Absent
35 667 Combination Absent Absent Absent Absent Absent Absent
35 668 PM Absent Absent Absent Absent Absent
35 669 PM Absent Absent Absent Absent
35 670 SSG Absent Absent Absent Absent Absent Absent Absent
35 671 PM Absent Absent Absent Absent Absent
35 672 Combination Absent Absent Absent Absent Absent
35 673 SSG Absent Absent Absent Absent Absent Absent Absent
35 674 Combination Absent Absent Absent Absent Absent Absent
35 675 PM Absent Absent Absent Absent Absent
35 676 PM Absent Absent Absent Absent Absent Absent
35 677 SSG Absent Absent
35 678 Combination Absent Absent Absent Absent Absent Absent
35 679 SSG Absent Absent Absent Absent Absent Absent Absent
35 680 Combination Absent Absent Absent Absent Absent Absent
35 681 Combination Absent Absent Absent Absent Absent Absent
35 682 PM Absent Absent Absent Absent Absent
35 683 Combination Absent Absent Absent Absent Absent
35 684 SSG Absent Absent Absent Absent Absent Absent Absent
35 685 PM Absent Absent Absent Absent Absent Absent
35 686 PM Absent Absent Absent Absent Absent Absent
35 687 SSG Absent Absent Absent Absent Absent Absent Absent
35 688 PM Absent Absent Absent Absent Absent Absent
35 689 Combination Absent Absent Absent Absent Absent Absent
35 690 SSG Absent Absent Absent Absent Absent Absent Absent
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Present Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Present Present Present Present Present Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Present Present Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Present Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Absent Present Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Present Present Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
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Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Absent Absent Present Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
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Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Present Present Present Present Present Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Present Present Present Present Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Present Absent Absent Absent Absent
Absent Present Present Present Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Present Present Present Absent Absent
Present Present Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Present Present
Present Present Present Absent Present Absent
Absent Absent Absent Absent Absent Present
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Absent Absent
Absent Absent Absent Absent Present Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Present
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Present Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Present Absent
Absent Present Absent Absent Present Present
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent Absent Present Absent
Present Present Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent
Present Absent Absent Absent Present Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
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Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Present Absent Absent Present Present Present Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Present Absent
Present Present Present Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
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Appendix 41:  Individual listing of clinical characteristics, inguinal lyphadenopathy and muscle wasting
Centre Patient Inguinal lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 1 PM Absent Absent Absent Absent Absent Absent
11 2 Combination Absent Absent Absent Absent Absent Absent
11 3 Combination Absent Absent Absent Absent Absent Absent
11 4 PM Present Absent Absent Absent Absent Absent
11 5 PM Absent Absent Absent Absent Absent Absent
11 6 Combination Absent Absent Absent Absent Absent Absent
11 7 PM Absent Absent Absent Absent Absent Absent
11 8 SSG Absent Absent Absent Absent Absent Absent Absent
11 9 SSG Absent Absent Absent Absent Absent Absent Absent
11 10 SSG Absent Absent Absent Absent Absent Absent Absent
11 11 Combination Absent Absent Absent Absent Absent Absent
11 12 Combination Present Present Present Present Absent Absent
11 13 SSG Absent Absent Absent Present Absent Absent Absent
11 14 SSG Absent Absent Absent Absent Absent Absent Absent
11 15 PM Absent Absent Absent Absent
11 16 Combination Absent Absent Absent Present Absent Absent
11 17 Combination Absent Absent Absent Absent Absent Absent
11 18 SSG Absent Absent Absent Absent Absent Absent Absent
11 19 Combination Absent Absent Absent Absent Absent Absent
11 20 SSG Absent Absent Absent Absent Absent Absent Absent
11 21 SSG Absent Absent Absent Absent Absent Absent Absent
11 22 SSG Absent Absent Absent Absent Absent Absent Absent
11 23 PM Absent Absent Absent Absent Absent Absent
11 24 PM Absent Absent Absent Absent Absent Absent
11 25 SSG Absent Absent Absent Absent Absent Absent Absent
11 26 Combination Absent Absent Absent Absent Absent Absent
11 27 PM Present Absent Absent Absent Absent
11 28 Combination Absent Absent Absent Absent Absent Absent
11 29 PM Absent Absent Absent Absent Absent Absent
11 30 PM Absent Absent Absent Absent Absent Absent
11 31 SSG Absent Absent Absent Absent Absent Absent Absent
11 32 Combination Absent Absent Absent Absent Absent Absent
11 33 SSG Absent Absent Absent Absent Absent Absent Absent
11 34 PM Absent Absent Absent Absent Absent Absent
11 35 SSG Absent Absent Absent Absent Absent Absent Absent
11 36 SSG Absent Absent Absent Absent Absent Absent Absent
11 37 Combination Absent Absent Absent Absent Absent Absent
11 38 PM Present Absent Absent Absent Absent Absent
11 39 PM Absent Absent Absent Absent Absent Absent
11 40 PM Absent Absent Absent Absent Absent
11 41 Combination Absent Absent Absent Absent Absent Absent
11 42 Combination Present Absent Absent Absent Absent Absent
11 43 SSG Absent Absent Absent Absent Absent Absent Absent
11 44 PM Absent Absent Absent Absent Absent Absent
11 45 Combination Absent Absent Absent Absent Absent Absent
11 46 SSG Absent Absent Absent Absent Absent Absent Absent
11 47 SSG Absent Absent Absent Absent Absent
11 48 Combination Absent Absent Absent Absent Absent
11 49 SSG Absent Absent Absent Absent Absent Absent Absent
11 50 PM Absent Absent Absent Absent Absent Absent
11 51 Combination Absent Absent Absent Absent Absent Absent
11 52 PM Absent Absent Absent Absent Absent Absent
11 53 SSG Absent Absent Absent Absent Absent Absent Absent
11 54 PM Absent Absent Absent Absent Absent Absent
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Appendix 41:  Individual listing of clinical characteristics, inguinal lyphadenopathy and muscle wasting
Centre Patient Inguinal lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 55 PM Absent Absent Absent Absent Absent Absent
11 56 SSG Absent Absent Absent Absent Absent Absent Absent
11 57 Combination Absent Absent Absent Absent Absent Absent
11 58 Combination Absent Absent Absent Absent Absent Absent
11 59 PM Absent Absent Absent Absent Absent Absent
11 60 Combination Absent Absent Absent Absent Absent Absent
11 61 PM Absent Absent Absent Absent Absent Absent
11 62 SSG Absent Absent Absent Absent Absent Absent Absent
11 63 SSG Absent Absent Absent Absent Absent Absent Absent
11 64 SSG Absent Absent Absent Absent Absent Absent Absent
11 65 PM Absent Absent Absent Absent
11 66 Combination Absent Absent Absent Absent Absent Absent
11 67 PM Absent Absent Absent Absent Absent Absent
11 68 SSG Absent Absent Absent Absent Absent Absent Absent
11 69 Combination Absent Absent Absent Absent Absent Absent
11 70 Combination Absent Absent Absent Absent Absent Absent
11 71 Combination Absent Absent Absent Absent Absent Absent
11 72 SSG Absent Absent Absent Absent Absent
11 73 PM Absent Absent Absent Absent Absent Absent
11 74 PM Absent Absent Absent Absent Absent Absent
11 75 Combination Absent Absent Absent Absent Absent Absent
11 76 PM Absent Absent Absent Absent Absent Absent
11 77 PM Absent Absent Absent Absent Absent Absent
11 78 SSG Absent Absent Absent Absent Absent Absent Absent
11 79 PM Absent Absent Absent Absent Absent Absent
11 80 PM Absent Absent Absent Absent Absent Absent
11 81 Combination Absent Absent Absent Absent Absent Absent
11 82 SSG Absent Absent Absent Absent Absent Absent Absent
11 83 SSG Absent Absent Absent Absent Absent Absent Absent
11 84 SSG Absent Absent Absent Absent Absent Absent Absent
11 85 SSG Absent Absent Absent Absent Absent Absent
11 86 Combination Absent Absent Absent Absent Absent Absent
11 87 Combination Absent Absent Absent Absent Absent Absent
11 88 PM Absent Absent Absent Absent Absent Absent
11 89 Combination Absent Absent Absent Absent Absent Absent
11 90 Combination Absent Absent Absent Absent
11 91 PM Absent Absent Absent Absent Absent Absent
11 92 Combination Absent Absent Absent Absent Absent Absent
11 93 SSG Absent Absent Absent Absent Absent Absent Absent
11 94 SSG Absent Absent Absent Absent Absent Absent Absent
11 95 SSG Absent Absent Absent Absent Absent Absent Absent
11 96 Combination Absent Absent Absent Absent Absent Absent
11 97 Combination Present Absent Absent Absent Absent Absent
11 98 PM Absent Absent Absent Absent Absent Absent
11 99 SSG Present Absent Absent Absent Absent Absent Absent
11 100 PM Absent Absent Absent Absent
11 101 PM Absent Absent Absent Absent Absent Absent
11 102 Combination Absent Absent Absent Absent Absent Absent
11 103 Combination Absent Absent Absent Absent Absent Absent
11 104 PM Absent Absent Absent Absent Absent Absent
11 105 SSG Absent Absent Absent Absent Absent Absent Absent
11 106 Combination Absent Absent Absent Absent Absent Absent
11 107 PM Absent Absent Absent Absent Absent Absent
11 108 PM Absent Absent Absent Absent Absent Absent
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Appendix 41:  Individual listing of clinical characteristics, inguinal lyphadenopathy and muscle wasting
Centre Patient Inguinal lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 109 SSG Absent Absent Absent Absent Absent Absent Absent
11 110 PM Absent Absent Absent Absent Absent Absent
11 111 Combination Absent Absent Absent Absent Absent Absent
11 112 Combination Absent Absent Absent Absent Absent Absent
11 113 SSG Absent Absent Absent Absent Absent Absent
11 114 SSG Absent Absent Absent Absent Absent Absent Absent
11 115 Combination Absent Absent Absent Absent Absent Absent
11 116 SSG Absent Absent Absent Absent Absent Absent Absent
11 117 PM Absent Absent Absent Absent Absent
11 118 PM Absent Absent Absent Absent Absent Absent
11 119 SSG Present Absent Absent Absent Absent Absent Absent
11 120 Combination Absent Absent Absent Absent Absent Absent
11 121 Combination Absent Absent Absent Absent Absent Absent
11 122 SSG Present Absent Absent Absent Absent
11 123 SSG Absent Absent Absent Absent Absent Absent Absent
11 124 SSG Absent Absent Absent Absent Absent Absent
11 125 SSG Absent Absent Absent Absent Absent Absent Absent
11 126 Combination Absent Absent Absent Absent Absent
11 127 PM Absent Absent Absent Absent Absent Absent
11 128 Combination Absent Absent Absent Absent Absent Absent
11 129 PM Absent Absent Absent Absent Absent Absent
11 130 Combination Absent Absent Absent Absent Absent Absent
11 131 PM Absent Absent Absent Absent Absent Absent
11 132 SSG Absent Absent Absent Absent Absent Absent Absent
11 133 Combination Absent Absent Absent Absent Absent Absent
11 134 PM Absent Absent Absent Absent Absent Absent
11 135 PM Absent Absent Absent Absent Absent Absent
12 241 Combination Absent Absent Absent Absent Absent
12 242 SSG Present Present Absent Absent Absent Absent Present
12 243 PM Absent Absent Absent Absent Absent Absent
12 244 SSG Present Absent Absent Absent Absent Absent Absent
12 245 PM Present Present Present Present Absent
12 246 PM Absent Absent Absent Absent Absent
12 247 PM Present Present Present Present Absent Absent
12 248 PM Absent Absent Absent Absent Absent Absent
12 249 Combination Present Absent Absent Absent Absent Absent
12 250 SSG Absent Present Absent Absent Absent Absent Absent
12 251 Combination Present Present Present Present Absent Absent
12 252 SSG Present Present Absent Absent Absent Absent Absent
12 253 SSG Absent Absent Absent Absent Absent Absent Absent
12 254 Combination Present Present Present Present Absent Absent
12 255 Combination Absent Absent Absent Absent Absent Absent
12 256 Combination Absent Absent Absent Absent Absent Absent
12 257 SSG Present Present Absent Absent Absent Absent Absent
12 258 SSG Absent Absent Absent Absent Absent Absent
12 259 PM Absent Absent Absent Absent Absent Absent
12 260 PM Absent Absent Absent Absent Absent
12 261 Combination Absent Absent Absent Absent Absent Present
12 262 PM Absent Absent Absent Absent Absent Absent
12 263 SSG Absent Absent Absent Absent Absent Absent Absent
12 264 Combination Absent Absent Absent Absent Absent Absent
12 265 SSG Absent Absent Absent Absent Absent
12 266 PM Absent Absent Absent Absent Absent Absent
12 267 SSG Absent Absent Absent Absent Absent Absent Absent
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Appendix 41:  Individual listing of clinical characteristics, inguinal lyphadenopathy and muscle wasting
Centre Patient Inguinal lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
12 268 PM Absent Absent Absent Absent Absent Absent
12 269 Combination Absent Absent Absent Absent Absent Absent
12 270 Combination Absent Absent Absent Absent Absent
12 271 SSG Absent Absent Absent Absent Absent Absent Absent
12 272 PM Absent Absent Absent Absent Absent Absent
12 273 SSG Present Present Absent Absent Absent Absent Absent
12 274 SSG Absent Absent Absent Absent Absent Absent Absent
12 275 Combination Present Absent Absent Absent Absent Absent
12 276 PM Absent Absent Absent Absent Absent Absent
12 277 Combination Present Present Present Present Absent Absent
12 278 SSG Absent Absent Absent Absent Absent Absent
12 279 PM Absent Absent Absent Absent Absent Absent
12 280 SSG Absent Absent Absent Absent Absent Absent Absent
12 281 Combination Absent Absent Absent Absent Absent Absent
12 282 PM Absent Absent Absent Absent Absent Absent
12 283 PM Absent Absent Absent Absent Absent Absent
12 284 Combination Absent Absent Absent Absent Absent Absent
12 285 Combination Present Present Present Present Absent Absent
12 286 PM Absent Absent Absent Absent Absent Present
12 287 SSG Absent Absent Absent Absent Absent Absent Absent
12 288 Combination Absent Absent Absent Absent Absent Absent
12 289 Combination Absent Absent Absent Absent Absent Absent
12 290 SSG Absent Absent Absent Absent Absent Absent
12 291 SSG Absent Absent Absent Absent Absent Absent Absent
12 292 PM Absent Absent Absent Absent Absent
12 293 SSG Absent Absent Absent Absent Absent Absent
12 294 Combination Absent Absent Absent Absent Absent Absent
12 295 Combination Absent Absent Absent Absent Absent
12 296 PM Absent Present Present Present Absent Absent
12 297 SSG Present Absent Absent
12 298 PM Absent Absent Absent Absent Present Absent
12 299 Combination Absent Absent Absent Absent Absent
12 300 PM Absent Absent Absent Absent Absent Absent
12 301 SSG Absent Absent Absent Absent Absent Absent Absent
12 302 SSG Absent Absent Absent Absent Absent Absent Absent
12 303 PM Absent Absent Absent Absent Absent Absent
12 304 Combination Absent Absent Absent Absent Absent Present
12 305 PM Absent Absent Absent Absent Absent Absent
12 306 Combination Absent Absent Absent Absent Absent Present
12 307 Combination Absent Absent Absent Absent Absent Absent
12 308 PM Absent Absent Absent Absent Absent Absent
12 309 PM Absent Absent Absent Absent Absent Absent
12 310 SSG Absent Absent Absent Absent Absent Absent Absent
12 311 SSG Absent Absent Absent Absent Absent Absent Absent
12 312 Combination Absent Absent Absent Absent Absent Absent
12 313 PM Absent Absent Absent Absent Absent Absent
12 314 SSG Absent Absent Absent Absent Absent Absent Absent
12 315 Combination Absent Absent Absent Absent Absent Absent
12 316 SSG Absent Absent Absent Absent Absent Absent
12 317 SSG Absent Absent Absent Absent Absent Absent
12 318 Combination Absent Absent Absent Present Present Absent
12 319 Combination Present Absent Absent Absent Absent Absent
12 320 Combination Absent Absent Absent Absent Present Absent
12 321 Combination Absent Absent Absent Absent Present Present
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Appendix 41:  Individual listing of clinical characteristics, inguinal lyphadenopathy and muscle wasting
Centre Patient Inguinal lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
12 322 PM Absent Absent Absent Absent Absent Absent
12 323 SSG Absent Absent Present Absent Absent Absent Absent
12 324 SSG Present Present Present Present Present Absent Absent
12 325 PM Present Present Present Absent Absent Absent
12 326 PM Present Present Present Present Absent Absent
12 327 Combination Absent Absent Present Absent Absent Absent
12 328 PM Absent Absent Absent Absent Absent Absent
12 329 SSG Absent Absent Absent Absent Absent Absent Absent
12 330 PM Absent Absent Absent Absent Absent Absent
23 361 Combination Absent Absent Absent Absent Present Absent
23 362 PM Absent Absent Absent Absent Absent Absent
23 363 PM Absent Absent Absent Absent Present Absent
23 364 Combination Absent Absent Absent Absent Absent Absent
23 365 SSG Absent Absent Absent Absent Absent Absent Absent
23 366 Combination Absent Absent Absent Absent Absent Absent
23 367 SSG Absent Absent Absent Absent Absent Absent Absent
23 368 PM Absent Absent Absent Absent Absent Absent
23 369 Combination Absent Absent Absent Absent Absent Absent
23 370 SSG Absent Absent Absent Absent Absent Absent Absent
23 371 PM Absent Absent Absent Absent Absent Absent
23 372 PM Present Absent Absent Absent Absent Absent
23 373 SSG Absent Absent Absent Absent Absent Absent Absent
23 374 SSG Absent Absent Absent Absent Absent Absent Absent
23 375 Combination Absent Absent Absent Absent Absent Absent
23 376 SSG Absent Absent Absent Absent Absent Absent Absent
23 377 Combination Absent Absent Absent
23 378 Combination Absent Absent Absent Absent Absent Absent
23 379 PM Absent Absent Absent Absent Absent Absent
23 380 SSG Absent Absent Absent Absent Absent Absent Absent
23 381 PM Absent Absent Absent Absent Absent Absent
23 382 Combination Present Present Absent Absent Absent Absent
23 383 PM Absent Absent Absent Absent Absent Absent
23 384 SSG Absent Absent Absent Absent Absent Absent Absent
23 385 SSG Present Absent Absent Present Present Present Absent
23 386 Combination Absent Absent Absent Absent Absent Absent
23 387 Combination Absent Absent Absent Absent Absent Absent
23 388 PM Absent Absent Absent Absent Absent Absent
23 389 SSG Present Present Present Present Present Absent Absent
23 390 PM Absent Absent Absent Absent Absent Absent
23 391 Combination Absent Absent Absent Absent Absent Absent
23 392 Combination Present Present Absent Absent Absent
23 393 SSG Present Present Present Present Absent Absent Absent
23 394 PM Absent Absent Absent Absent Absent Absent
23 395 PM Absent Present Absent Absent Absent Absent
23 396 SSG Absent Absent Absent Absent Absent Absent Absent
23 397 SSG Absent Absent Absent Absent Absent Absent Absent
23 398 Combination Absent Absent Absent Absent Absent Absent
23 399 PM Absent Absent Absent Absent Absent Absent
23 400 PM Absent Absent Absent Absent Absent Absent
23 401 Combination Absent Absent Absent Absent Absent Absent
23 402 Combination Absent Absent Absent Absent Absent Absent
23 403 SSG Absent Absent Absent Absent Absent Absent Absent
23 404 SSG Absent Absent Absent Absent Absent Absent
23 405 PM Absent Absent Absent Absent Absent Absent
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Appendix 41:  Individual listing of clinical characteristics, inguinal lyphadenopathy and muscle wasting
Centre Patient Inguinal lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
34 451 Combination Present Present Present Present Present
34 452 PM Present Present Present Present
34 453 PM Present Present Present Present
34 454 Combination Present Present Present Present Present
34 455 PM Present Present Present Present
34 456 SSG Present Present Present Present Present Present
34 457 Combination Present Present Present Present
34 458 PM Present Present Present Present Present
34 459 Combination Present Present Present Present Present Present
34 460 PM Present Present Present Present
34 461 SSG Present Present Present
34 462 SSG Present Present Present Present Present Present
34 463 Combination Present Present Present Present Present
34 464 SSG Present Present Present Present Present Present
34 465 SSG Present Present Present Present Present Present
34 466 Combination Present Present Present Present
34 467 PM Present Present Present Present Present
34 468 Combination Present Present Present Present Present
34 469 SSG Present Present Present Present Present Present
34 470 Combination Present Present Present Present Present
34 471 PM Present Present Present Present
34 472 SSG Present Present Present Present Present Present
34 473 PM Present Present Present Present
34 474 Combination Present Present Present Present Present
34 475 PM Present Present Present Present
34 476 PM Present Present Present Present Present
34 477 SSG Present Present Present Present Present Present
34 478 Combination Present Present Present Present Present
34 479 SSG Present Present Absent Absent Absent Present
34 480 SSG Present Present Present Present Present Present
34 481 Combination Present Present Present Present Present
34 482 Combination Present Present Present Present Present
34 483 PM Present Present Present Present Present
34 484 PM Present Present
34 485 Combination Present Present Present Present Present
34 486 Combination Present Present Present Present Present
34 487 SSG Present Present Present Present Present Present
34 488 SSG Present Present Present Present Present Present Present
34 489 SSG Present Present Present Present Present Present
34 490 PM Present Present Present Present Present
34 491 PM Present Present Present Present
34 492 PM Present Present Present Present Present
34 493 SSG Present Present Present Present Present Present
34 494 Combination Present Present Present Present Present
34 495 SSG Present Present Present Present Present Present
34 496 SSG Present Present Present Present Present Present
34 497 PM Present Present Present Present Present
34 498 SSG Present Present Present Present Present Present
34 499 Combination Present Present Present Present Present
34 500 PM Present Present Present Present Present
34 501 Combination Present Present Present Present Present
34 502 Combination Present Present Present Present Present
34 503 PM Present Present Present Present
34 504 Combination Present Present Present Present
LEAP 0104a Appendices
Page 512 of 756
Appendix 41:  Individual listing of clinical characteristics, inguinal lyphadenopathy and muscle wasting
Centre Patient Inguinal lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
34 505 SSG Present Present Present Present Present Present
34 506 SSG Present Present Present Present Present Present
34 507 SSG Present Present Present Present Present Present
34 508 PM Present Present Present Present
34 509 PM Present Present Present Present
34 510 Combination Present Present Present Present Present
34 511 Combination Present Present Present Present Present
34 512 PM Present Present Present Present
34 513 Combination Present Present Present Present Present Present
34 514 SSG Present Present Present Present Present Present
34 515 SSG Present Present Present Present Present Present
34 516 PM Present Present Present Present Present
34 517 PM Present Present Present Present
34 518 SSG Present Present Present Present Present Present
34 519 PM Present Present Present Present Present
34 520 SSG Present Present Present Present Present Present
34 521 PM Present Present Present Present
34 522 Combination Present Present Present Present
34 523 SSG Present Present Present Present Present Present
34 524 Combination Present Present Present Present Present
34 525 Combination Present Present Present Present Present
34 526 SSG Present Present Present Present Present Present
34 527 Combination Present Present Present Present Absent
34 528 PM Present Present Present Present
34 529 Combination Present Present Present Present Present
34 530 Combination Present Present Present Present Present
34 531 SSG Present Present Present Present Present
34 532 Combination Present Present Present Present Present
34 533 SSG Present Present Present Present Present Present
34 534 PM Present Present Present Present
34 535 PM Present Present Present Present Present
34 536 PM Present Present Present Present Present
34 537 SSG Present Present Present Present Present Present
34 538 PM Present Present Present Present
34 539 Combination Present Present Present Present Present
34 540 SSG Present Present Present Present Present Present
35 646 PM Present Present Present Present Absent
35 647 PM Present Present Present Present Absent Absent
35 648 Combination Present Present Present Present Present Absent
35 649 Combination Present Present Present Present Present Absent
35 650 SSG Present Present Present Present Present Absent Absent
35 651 SSG Present Present Present Present Present Absent Absent
35 652 PM Present Present Present Present Absent
35 653 Combination Present Present Present Present Absent Absent
35 654 SSG Present Present Present Present Present Present Absent
35 655 Combination Present Present Present Present Present Absent
35 656 SSG Absent Present Present Present Present Absent Absent
35 657 PM Present Present Present Present Present Absent
35 658 Combination Present Present Present Present Present Absent
35 659 SSG Present Present Present Present Present Absent Absent
35 660 PM Present Present Present Present Absent Absent
35 661 Combination Present Present Present Present Absent Absent
35 662 PM Present Present Present Present Present Absent
35 663 SSG Absent Absent Absent Present Present Absent Absent
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Appendix 41:  Individual listing of clinical characteristics, inguinal lyphadenopathy and muscle wasting
Centre Patient Inguinal lymphadenopathy
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
35 664 Combination Absent Absent Absent
35 665 SSG Present Present Present Present Present Absent Absent
35 666 SSG Present Present Present Present Present Absent Absent
35 667 Combination Present Present Present Present Absent Absent
35 668 PM Present Present Present Present Absent
35 669 PM Present Present Present Present
35 670 SSG Present Present Present Present Present Absent Absent
35 671 PM Present Present Present Present Absent
35 672 Combination Present Present Present Present Absent
35 673 SSG Present Present Present Present Present Absent Absent
35 674 Combination Present Present Present Present Absent Absent
35 675 PM Present Present Present Present Absent
35 676 PM Present Present Present Present Absent Absent
35 677 SSG Present Present
35 678 Combination Present Present Present Present Absent Absent
35 679 SSG Present Present Present Present Present Absent Absent
35 680 Combination Present Present Present Present Absent Absent
35 681 Combination Present Present Present Present Absent Absent
35 682 PM Present Present Present Present Absent
35 683 Combination Present Present Present Present Absent
35 684 SSG Present Present Present Present Present Absent Absent
35 685 PM Present Present Present Present Absent Absent
35 686 PM Present Present Present Present Absent Absent
35 687 SSG Present Present Present Present Present Absent Absent
35 688 PM Present Present Present Present Absent Absent
35 689 Combination Present Present Present Present Absent Absent
35 690 SSG Present Present Present Present Present Absent Absent
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Present Absent
Absent Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Present Present Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Absent Absent Present
Present Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Present Present Absent Absent Absent
Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent Absent Absent Absent
Present Present Present Absent Absent Absent Absent
Present Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent
Present Present Present Present Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Present Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Present Present Present Present Absent Absent
Present Present Present Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
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Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent
Present Present Present Present Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent Absent
Present Present Present Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent
Present Present Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent
Present Present Present Absent Absent Absent
Present Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
LEAP 0104a Appendices



























































Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent Absent Absent
Present Present Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Present Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent
Present Absent Absent Absent
Present Present Present
Present Absent Absent Absent Absent Absent
Present Present Present Absent Absent
Present Present Present Present Present Absent
Present Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Present Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Present Present Present Present
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Present Present Present Absent Absent Absent
Present Present Absent Absent Absent Absent
Present Present Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent
Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Present Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent
Present Present Present Present Absent
Present Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent
LEAP 0104a Appendices



























































Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Present Absent Absent Absent
Absent Absent Absent Absent Absent
Present Present Absent Absent Absent
Present Present Present Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Absent
Present Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Present
Present Absent Absent Absent Absent
Absent Absent Absent Absent
Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Present
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Present Present Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Present Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Absent Absent Absent Absent
Present Present Present Absent Absent Absent Absent
Present Present Absent Absent Absent Absent Absent
Present Present Present Present Absent
Present Present Present Present Absent Absent
Present Present Present Present Absent Absent Absent
Present Present Present Present Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Present Present Present Present Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Absent Absent Absent Absent
Present Present Present Present Absent Absent
Present Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Present Present Present Absent Absent Absent Absent
LEAP 0104a Appendices
































Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent
Present Present Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Present Present Present Absent Absent Absent Absent
Present Present Absent Absent Absent
Present Present Present Present Absent
Present Present Absent Absent Absent Absent Absent
Present Present Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Present Present Present Present Absent Absent
Absent Present
Present Present Present Present Absent Absent
Present Present Present Present Present Absent Absent
Present Present Present Present Absent Absent
Present Present Present Present Absent Absent
Present Present Present Present Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Present Present Present Absent Absent Absent
Present Present Present Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Present Present Present Present Absent Absent
Present Present Present Present Absent Absent
Present Present Present Absent Absent Absent Absent
LEAP 0104a Appendices
Page 522 of 756
Appendix 42: Individual Listing of clinical characteristic, Mucosal pallor and Jaundice
Centre Patient Mucosal Pallor
 number number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 1 PM Present Absent Absent Absent Absent Absent
11 2 Combination Absent Absent Absent Absent Absent Absent
11 3 Combination Present Present Absent Absent Absent Absent
11 4 PM Present Present Absent Absent Absent Absent
11 5 PM Absent Absent Absent Absent Absent Absent
11 6 Combination Present Present Present Present Present Absent
11 7 PM Absent Absent Absent Absent Absent Absent
11 8 SSG Present Present Present Absent Absent Absent Absent
11 9 SSG Absent Present Absent Absent Absent Absent Absent
11 10 SSG Absent Absent Absent Absent Absent Present Absent
11 11 Combination Absent Absent Absent Absent Absent Absent
11 12 Combination Absent Absent Absent Absent Absent Absent
11 13 SSG Present Present Present Present Absent Present Absent
11 14 SSG Absent Absent Absent Absent Absent Absent Absent
11 15 PM Present Present Absent Absent
11 16 Combination Absent Absent Absent Absent Absent Absent
11 17 Combination Present Absent Absent Absent Absent Absent
11 18 SSG Absent Present Present Absent Absent Absent Absent
11 19 Combination Present Present Present Present Absent Absent
11 20 SSG Present Present Present Present Present Absent Absent
11 21 SSG Present Present Present Present Present Absent Absent
11 22 SSG Present Present Present Present Present Absent Absent
11 23 PM Absent Absent Absent Absent Absent Absent
11 24 PM Absent Absent Absent Absent Absent Absent
11 25 SSG Absent Present Present Absent Absent Absent Absent
11 26 Combination Absent Absent Absent Absent Absent Absent
11 27 PM Present Present Present Present Present
11 28 Combination Present Present Absent Absent Absent Absent
11 29 PM Present Present Present Absent Absent Absent
11 30 PM Present Present Absent Absent Absent Absent
11 31 SSG Present Present Present Absent Absent Absent Absent
11 32 Combination Absent Present Absent Absent Absent Absent
11 33 SSG Present Present Absent Absent Absent Absent Absent
11 34 PM Present Present Absent Absent Absent Absent
11 35 SSG Absent Absent Absent Absent Absent Absent Absent
11 36 SSG Present Present Present Present Absent Absent Absent
11 37 Combination Present Present Absent Absent Absent Absent
11 38 PM Absent Absent Present Absent Absent Absent
11 39 PM Present Present Absent Absent Absent Absent
11 40 PM Present Present Present Absent Absent
11 41 Combination Present Absent Absent Absent Absent Absent
11 42 Combination Absent Absent Absent Absent Absent Absent
11 43 SSG Present Present Present Present Present Absent Absent
11 44 PM Absent Absent Absent Absent Absent Absent
11 45 Combination Absent Absent Absent Absent Absent Absent
11 46 SSG Absent Absent Absent Absent Absent Absent Absent
11 47 SSG Present Present Present Absent Absent
11 48 Combination Present Present Absent Absent Absent
11 49 SSG Present Present Absent Absent Absent Absent Absent
11 50 PM Present Absent Absent Absent Absent Absent
11 51 Combination Present Present Absent Absent Absent Absent
11 52 PM Present Present Present Present Absent Absent
11 53 SSG Present Present Present Present Absent Absent Absent
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Appendix 42: Individual Listing of clinical characteristic, Mucosal pallor and Jaundice
Centre Patient Mucosal Pallor
 number number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 54 PM Absent Absent Absent Absent Absent Absent
11 55 PM Present Present Present Present Absent Absent
11 56 SSG Present Present Absent Present Present Absent Absent
11 57 Combination Present Present Present Present Absent Absent
11 58 Combination Present Present Present Present Absent Absent
11 59 PM Present Present Present Absent Absent Absent
11 60 Combination Present Present Present Present Absent Absent
11 61 PM Present Present Present Present Absent Absent
11 62 SSG Present Present Present Present Present Absent Absent
11 63 SSG Present Absent Absent Absent Absent Absent Absent
11 64 SSG Present Present Present Present Present Absent Absent
11 65 PM Present Present Present Present
11 66 Combination Present Present Present Present Absent Absent
11 67 PM Present Present Present Absent Absent Absent
11 68 SSG Present Present Present Present Absent Absent Absent
11 69 Combination Present Present Present Present Absent Absent
11 70 Combination Present Present Present Present Absent Absent
11 71 Combination Present Present Present Present Present Absent
11 72 SSG Present Present Present Absent Absent
11 73 PM Present Present Absent Absent Absent Absent
11 74 PM Absent Absent Absent Absent Absent Absent
11 75 Combination Present Present Present Present Absent Absent
11 76 PM Present Present Absent Absent Absent Absent
11 77 PM Present Present Present Absent Absent Absent
11 78 SSG Present Present Present Absent Absent Absent Absent
11 79 PM Present Present Present Present Absent Absent
11 80 PM Present Present Absent Absent Absent Absent
11 81 Combination Present Present Present Present Absent Absent
11 82 SSG Present Present Present Present Absent Absent Absent
11 83 SSG Present Present Present Present Absent Absent Absent
11 84 SSG Present Present Present Absent Absent Absent Absent
11 85 SSG Present Present Present Absent Absent Absent
11 86 Combination Present Present Absent Absent Absent Absent
11 87 Combination Present Present Absent Absent Absent Absent
11 88 PM Present Absent Absent Absent Absent Absent
11 89 Combination Present Present Present Absent Absent Absent
11 90 Combination Present Absent Absent Absent
11 91 PM Present Present Present Absent Absent Present
11 92 Combination Present Present Present Absent Absent Absent
11 93 SSG Present Present Present Absent Absent Absent Absent
11 94 SSG Present Present Absent Absent Absent Absent Absent
11 95 SSG Absent Absent Absent Absent Absent Absent Absent
11 96 Combination Present Present Present Present Absent Absent
11 97 Combination Present Present Present Absent Absent Absent
11 98 PM Present Present Present Present Absent Absent
11 99 SSG Present Present Present Present Absent Absent Absent
11 100 PM Present Present Present Present
11 101 PM Present Present Present Absent Absent Absent
11 102 Combination Present Present Present Present Absent Absent
11 103 Combination Present Present Absent Absent Absent Absent
11 104 PM Present Present Present Present Absent Absent
11 105 SSG Present Present Present Present Absent Absent Absent
11 106 Combination Present Present Present Present Absent Absent
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Appendix 42: Individual Listing of clinical characteristic, Mucosal pallor and Jaundice
Centre Patient Mucosal Pallor
 number number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 107 PM Present Present Present Absent Absent Absent
11 108 PM Present Present Present Absent Absent Absent
11 109 SSG Present Present Present Absent Absent Absent Absent
11 110 PM Present Present Present Present Absent Absent
11 111 Combination Present Present Absent Absent Absent Absent
11 112 Combination Present Present Present Absent Absent Absent
11 113 SSG Present Present Absent Present Absent Absent
11 114 SSG Present Present Absent Absent Absent Absent Absent
11 115 Combination Present Present Absent Absent Absent Absent
11 116 SSG Present Present Absent Absent Absent Absent Absent
11 117 PM Present Present Absent Absent Absent
11 118 PM Present Present Absent Absent Absent Absent
11 119 SSG Present Present Present Absent Absent Absent Absent
11 120 Combination Present Present Present Absent Absent Absent
11 121 Combination Present Present Present Absent Absent Absent
11 122 SSG Present Present Present Absent Absent
11 123 SSG Present Present Absent Absent Absent Absent Absent
11 124 SSG Present Present Present Present Present Absent
11 125 SSG Present Present Absent Absent Absent Absent Absent
11 126 Combination Present Present Present Present Absent
11 127 PM Present Present Absent Absent Absent Absent
11 128 Combination Present Present Present Present Absent Absent
11 129 PM Present Present Present Absent Absent Absent
11 130 Combination Present Present Absent Absent Absent Absent
11 131 PM Present Present Absent Absent Absent Absent
11 132 SSG Present Present Absent Absent Absent Absent Absent
11 133 Combination Present Present Present Absent Absent Absent
11 134 PM Present Present Present Present Absent Absent
11 135 PM Present Present Present Present Absent Absent
12 241 Combination Present Present Present Present Absent
12 242 SSG Present Present Absent Absent Absent Absent Absent
12 243 PM Present Present Absent Absent Absent Absent
12 244 SSG Absent Absent Absent Absent Absent Absent Absent
12 245 PM Present Present Present Present Present
12 246 PM Present Absent Absent Absent Absent
12 247 PM Present Present Absent Absent Absent Absent
12 248 PM Present Present Present Absent Absent Absent
12 249 Combination Present Present Present Present Present Absent
12 250 SSG Present Present Present Present Absent Absent Absent
12 251 Combination Present Absent Absent Absent Absent Absent
12 252 SSG Present Absent Absent Absent Absent Absent Absent
12 253 SSG Present Absent Absent Absent Absent Absent Absent
12 254 Combination Present Present Absent Absent Absent Absent
12 255 Combination Present Present Present Absent Absent Absent
12 256 Combination Present Present Present Absent Absent Absent
12 257 SSG Present Absent Absent Absent Absent Absent Absent
12 258 SSG Present Present Present Absent Absent Absent
12 259 PM Absent Absent Absent Absent Absent Absent
12 260 PM Present Present Present Absent Absent
12 261 Combination Present Present Present Present Absent Absent
12 262 PM Absent Absent Absent Absent Absent Absent
12 263 SSG Absent Absent Absent Absent Absent Absent Absent
12 264 Combination Absent Absent Absent Absent Absent Absent
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Appendix 42: Individual Listing of clinical characteristic, Mucosal pallor and Jaundice
Centre Patient Mucosal Pallor
 number number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
12 265 SSG Absent Absent Absent Present Present
12 266 PM Absent Absent Present Present Absent Absent
12 267 SSG Absent Absent Absent Absent Absent Absent Absent
12 268 PM Present Absent Absent Absent Absent Absent
12 269 Combination Absent Present Present Absent Absent Absent
12 270 Combination Absent Present Present Present Absent
12 271 SSG Present Present Present Present Absent Absent Absent
12 272 PM Absent Present Present Present Absent Absent
12 273 SSG Present Present Absent Absent Absent Absent Absent
12 274 SSG Present Present Present Absent Absent Absent Absent
12 275 Combination Present Present Present Present Absent Absent
12 276 PM Present Present Present Absent Absent Absent
12 277 Combination Present Present Absent Absent Absent Absent
12 278 SSG Present Present Absent Absent Absent Absent
12 279 PM Present Present Absent Absent Absent Absent
12 280 SSG Present Present Absent Absent Absent Absent Absent
12 281 Combination Absent Absent Absent Absent Absent Absent
12 282 PM Present Absent Absent Absent Absent Absent
12 283 PM Absent Absent Absent Absent Absent Absent
12 284 Combination Present Present Absent Absent Absent Present
12 285 Combination Present Present Absent Absent Absent Absent
12 286 PM Present Present Present Absent Absent Absent
12 287 SSG Present Present Absent Absent Absent Absent Absent
12 288 Combination Present Present Present Present Absent Absent
12 289 Combination Absent Absent Absent Absent Absent Absent
12 290 SSG Present Present Present Present Present Absent
12 291 SSG Present Absent Absent Absent Absent Absent Absent
12 292 PM Present Present Absent Absent Absent
12 293 SSG Present Present Present Absent Absent Absent
12 294 Combination Present Present Present Absent Absent Absent
12 295 Combination Present Absent Absent Absent Absent
12 296 PM Present Absent Absent Absent Absent Absent
12 297 SSG Present Absent Absent
12 298 PM Present Present Absent Absent Absent Absent
12 299 Combination Present Present Present Absent Absent
12 300 PM Present Present Present Absent Absent Absent
12 301 SSG Present Present Present Absent Absent Absent Absent
12 302 SSG Present Present Present Absent Absent Absent Absent
12 303 PM Present Present Present Present Absent Absent
12 304 Combination Present Present Present Absent Absent Absent
12 305 PM Present Present Present Present Absent Absent
12 306 Combination Present Present Present Absent Absent Absent
12 307 Combination Absent Absent Absent Absent Absent Absent
12 308 PM Present Present Absent Absent Absent Absent
12 309 PM Present Present Absent Absent Absent Absent
12 310 SSG Present Present Absent Absent Absent Absent Absent
12 311 SSG Present Absent Absent Absent Absent Absent Absent
12 312 Combination Absent Absent Absent Absent Absent Absent
12 313 PM Present Present Absent Absent Absent Absent
12 314 SSG Present Absent Absent Absent Absent Absent Absent
12 315 Combination Present Present Present Absent Absent Absent
12 316 SSG Absent Present Absent Absent Absent Absent
12 317 SSG Absent Absent Absent Absent Absent Absent
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Appendix 42: Individual Listing of clinical characteristic, Mucosal pallor and Jaundice
Centre Patient Mucosal Pallor
 number number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
12 318 Combination Present Present Absent Absent Absent Absent
12 319 Combination Present Present Absent Absent Absent Absent
12 320 Combination Present Present Absent Absent Absent Absent
12 321 Combination Present Present Absent Absent Absent Absent
12 322 PM Present Absent Absent Absent Absent Absent
12 323 SSG Present Present Absent Absent Absent Absent Absent
12 324 SSG Present Present Present Absent Absent Absent Absent
12 325 PM Absent Absent Absent Absent Absent Absent
12 326 PM Present Absent Absent Absent Absent Absent
12 327 Combination Absent Absent Absent Absent Absent Absent
12 328 PM Present Present Absent Absent Absent Absent
12 329 SSG Present Absent Present Absent Absent Absent Absent
12 330 PM Absent Absent Absent Absent Absent Absent
23 361 Combination Present Absent Absent Absent Absent Absent
23 362 PM Present Present Absent Absent Absent Absent
23 363 PM Absent Absent Absent Absent Present Absent
23 364 Combination Present Present Absent Absent Present Absent
23 365 SSG Present Present Absent Absent Absent Absent Absent
23 366 Combination Present Present Absent Absent Absent Absent
23 367 SSG Present Present Absent Absent Absent Absent Absent
23 368 PM Present Present Present Present Absent Absent
23 369 Combination Absent Absent Absent Absent Absent Absent
23 370 SSG Present Present Present Present Absent Absent Absent
23 371 PM Present Present Absent Absent Present Absent
23 372 PM Absent Absent Absent Absent Absent Absent
23 373 SSG Present Present Present Absent Absent Absent Absent
23 374 SSG Present Present Present Present Absent Absent Absent
23 375 Combination Present Present Present Absent Absent Absent
23 376 SSG Absent Present Present Present Absent Absent Absent
23 377 Combination Present Absent Absent
23 378 Combination Present Present Present Absent Present Absent
23 379 PM Present Absent Absent Absent Present Absent
23 380 SSG Present Present Present Absent Absent Absent Absent
23 381 PM Present Present Present Absent Absent Absent
23 382 Combination Present Absent Absent Absent Absent Absent
23 383 PM Present Present Absent Absent Absent Absent
23 384 SSG Present Present Absent Absent Absent Absent Absent
23 385 SSG Present Present Absent Absent Present Present Absent
23 386 Combination Present Present Present Absent Absent Absent
23 387 Combination Present Present Present Present Absent Absent
23 388 PM Present Present Present Present Present Absent
23 389 SSG Present Present Present Present Present Absent Absent
23 390 PM Present Present Present Present Absent Absent
23 391 Combination Present Absent Present Present Present Absent
23 392 Combination Present Present Present Absent Absent
23 393 SSG Present Present Present Absent Present Absent Absent
23 394 PM Present Present Present Present Absent Absent
23 395 PM Absent Present Absent Absent Absent Absent
23 396 SSG Present Present Absent Absent Absent Absent Absent
23 397 SSG Present Present Present Absent Present Absent Absent
23 398 Combination Present Present Present Present Absent Absent
23 399 PM Present Present Present Present Present Absent
23 400 PM Present Absent Absent Present Absent Absent
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 number number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
23 401 Combination Present Absent Present Absent Present Present
23 402 Combination Present Present Absent Present Absent Absent
23 403 SSG Present Present Present Present Present Absent Absent
23 404 SSG Present Absent Absent Absent Absent Absent
23 405 PM Present Present Present Absent Absent Absent
34 451 Combination Present Present Absent Absent Absent
34 452 PM Present Present Present Absent
34 453 PM Present Present Absent Absent
34 454 Combination Present Present Present Absent Absent
34 455 PM Absent Absent Absent Absent
34 456 SSG Present Present Present Absent Absent Absent
34 457 Combination Absent Absent Absent Absent
34 458 PM Present Present Absent Absent Absent
34 459 Combination Present Absent Absent Absent Absent Absent
34 460 PM Absent Absent Absent Absent
34 461 SSG Present Present Present
34 462 SSG Absent Absent Absent Absent Absent Absent
34 463 Combination Present Present Present Absent Absent
34 464 SSG Present Present Present Present Absent Absent
34 465 SSG Absent Absent Absent Absent Absent Absent
34 466 Combination Absent Absent Absent Absent
34 467 PM Absent Absent Absent Absent Absent
34 468 Combination Absent Absent Absent Absent Absent
34 469 SSG Absent Absent Absent Absent Absent Absent
34 470 Combination Absent Absent Absent Absent Absent
34 471 PM Absent Absent Absent Absent
34 472 SSG Present Present Present Absent Absent Absent
34 473 PM Absent Absent Absent Absent
34 474 Combination Absent Absent Absent Absent Absent
34 475 PM Present Present Absent Absent
34 476 PM Absent Absent Absent Absent Absent
34 477 SSG Absent Absent Absent Absent Absent Absent
34 478 Combination Present Present Absent Absent Absent
34 479 SSG Present Present Absent Absent Absent Absent
34 480 SSG Present Present Absent Absent Absent Absent
34 481 Combination Present Present Absent Absent Absent
34 482 Combination Absent Absent Absent Absent Absent
34 483 PM Absent Absent Absent Absent Absent
34 484 PM Absent Present
34 485 Combination Present Present Present Absent Absent
34 486 Combination Present Absent Absent Absent Absent
34 487 SSG Absent Absent Absent Absent Absent Absent
34 488 SSG Present Absent Absent Absent Absent Absent Absent
34 489 SSG Present Present Present Absent Absent Absent
34 490 PM Present Present Absent Absent Absent
34 491 PM Present Absent Absent Absent
34 492 PM Absent Absent Absent Absent Absent
34 493 SSG Present Absent Absent Absent Absent Absent
34 494 Combination Present Present Absent Absent Absent
34 495 SSG Present Absent Absent Absent Absent Absent
34 496 SSG Absent Absent Absent Absent Absent Absent
34 497 PM Absent Absent Absent Absent Absent
34 498 SSG Absent Absent Absent Absent Absent Absent
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 number number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
34 499 Combination Absent Absent Absent Absent Absent
34 500 PM Absent Absent Absent Absent Absent
34 501 Combination Absent Present Absent Absent Absent
34 502 Combination Absent Absent Absent Absent Absent
34 503 PM Absent Absent Absent Absent
34 504 Combination Absent Absent Absent Absent
34 505 SSG Absent Absent Absent Absent Absent Absent
34 506 SSG Absent Absent Absent Absent Absent Absent
34 507 SSG Absent Present Present Absent Absent Absent
34 508 PM Present Present Absent Absent
34 509 PM Absent Absent Absent Absent
34 510 Combination Absent Absent Absent Absent Absent
34 511 Combination Present Present Absent Absent Absent
34 512 PM Present Present Absent Absent
34 513 Combination Absent Absent Absent Absent Absent Absent
34 514 SSG Present Absent Absent Absent Absent Absent
34 515 SSG Absent Absent Absent Absent Absent Absent
34 516 PM Absent Absent Absent Absent Absent
34 517 PM Absent Absent Absent Absent
34 518 SSG Absent Absent Absent Absent Absent Absent
34 519 PM Absent Absent Absent Absent Absent
34 520 SSG Absent Present Absent Absent Absent Absent
34 521 PM Present Present Present Absent
34 522 Combination Present Absent Absent Absent
34 523 SSG Present Absent Absent Absent Absent Absent
34 524 Combination Absent Absent Absent Absent Absent
34 525 Combination Absent Absent Absent Absent Absent
34 526 SSG Absent Absent Absent Absent Absent Absent
34 527 Combination Present Present Present Absent Absent
34 528 PM Absent Absent Absent Absent
34 529 Combination Present Present Absent Absent Absent
34 530 Combination Absent Present Absent Absent Absent
34 531 SSG Absent Absent Absent Absent Absent
34 532 Combination Absent Absent Absent Absent Absent
34 533 SSG Absent Absent Absent Absent Absent Absent
34 534 PM Absent Absent Absent Present
34 535 PM Absent Absent Absent Absent Absent
34 536 PM Absent Absent Absent Absent Absent
34 537 SSG Absent Absent Absent Absent Absent Absent
34 538 PM Absent Present Absent Absent
34 539 Combination Absent Absent Absent Absent Absent
34 540 SSG Present Absent Absent Absent Absent Absent
35 646 PM Present Present Present Present Absent
35 647 PM Absent Absent Absent Absent Absent Absent
35 648 Combination Absent Absent Absent Absent Absent Absent
35 649 Combination Present Present Absent Absent Absent Absent
35 650 SSG Present Present Absent Absent Absent Absent Absent
35 651 SSG Present Present Absent Absent Absent Absent Absent
35 652 PM Present Present Present Present Absent
35 653 Combination Present Present Present Present Absent Absent
35 654 SSG Present Present Present Present Absent Absent Absent
35 655 Combination Absent Absent Absent Absent Absent Absent
35 656 SSG Present Present Present Present Absent Absent Absent
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35 657 PM Present Present Present Absent Absent Absent
35 658 Combination Absent Absent Absent Absent Absent Absent
35 659 SSG Present Present Present Absent Absent Absent Absent
35 660 PM Absent Absent Absent Absent Absent Absent
35 661 Combination Absent Absent Absent Absent Absent Absent
35 662 PM Absent Absent Absent Absent Absent Absent
35 663 SSG Absent Absent Absent Absent Absent Absent Absent
35 664 Combination Present Present Absent
35 665 SSG Present Present Present Absent Absent Absent Absent
35 666 SSG Present Present Present Absent Absent Absent Absent
35 667 Combination Absent Absent Absent Absent Absent Absent
35 668 PM Present Present Present Present Absent
35 669 PM Present Present Present Absent
35 670 SSG Absent Absent Absent Absent Absent Absent Absent
35 671 PM Present Present Present Present Absent
35 672 Combination Present Present Absent Absent Absent
35 673 SSG Present Present Absent Absent Absent Absent Absent
35 674 Combination Present Present Present Present Absent Absent
35 675 PM Present Present Absent Absent Absent
35 676 PM Present Present Present Present Absent Absent
35 677 SSG Present Present
35 678 Combination Present Present Present Present Absent Absent
35 679 SSG Present Present Present Present Absent Absent Absent
35 680 Combination Present Present Present Present Absent Absent
35 681 Combination Present Present Present Present Absent Absent
35 682 PM Present Present Present Present Absent
35 683 Combination Absent Absent Absent Absent Absent
35 684 SSG Present Present Present Absent Absent Absent Absent
35 685 PM Present Present Present Absent Absent Absent
35 686 PM Present Present Present Absent Absent Absent
35 687 SSG Absent Absent Present Absent Absent Absent Absent
35 688 PM Present Present Present Present Absent Absent
35 689 Combination Present Present Present Absent Absent Absent
35 690 SSG Present Present Present Absent Absent Absent Absent
LEAP 0104a Appendices
Page 530 of 756
Appendix 42: Individual Listing of clinical characteristic, Mucosal pallor and Jaundice
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent Absent Absent Absent
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Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
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Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent Absent Absent Absent
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
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Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
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Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
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Appendix 42: Individual Listing of clinical characteristic, Mucosal pallor and Jaundice
Centre Patient 




































Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent
Absent Absent Absent Absent Absent Absent Absent
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Appendix 43: Individual listing for clinical characteristic, petichial haemorrhage
Centre Patient Petchial haemorrhage
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 1 PM Absent Absent Absent Absent Absent Absent
11 2 Combination Absent Absent Absent Absent Absent Absent
11 3 Combination Absent Absent Absent Absent Absent Absent
11 4 PM Absent Absent Absent Absent Absent Absent
11 5 PM Absent Absent Absent Absent Absent Absent
11 6 Combination Absent Absent Absent Absent Absent Absent
11 7 PM Absent Absent Absent Absent Absent Absent
11 8 SSG Absent Absent Absent Absent Absent Absent Absent
11 9 SSG Absent Absent Absent Absent Absent Absent Absent
11 10 SSG Absent Absent Absent Absent Absent Absent Absent
11 11 Combination Absent Absent Absent Absent Absent Absent
11 12 Combination Absent Absent Absent Absent Absent Absent
11 13 SSG Absent Absent Absent Absent Absent Absent Absent
11 14 SSG Absent Absent Absent Absent Absent Absent Absent
11 15 PM Absent Absent Absent Absent
11 16 Combination Absent Absent Absent Absent Absent Absent
11 17 Combination Absent Absent Absent Absent Absent Absent
11 18 SSG Absent Absent Absent Absent Absent Absent Absent
11 19 Combination Absent Absent Absent Absent Absent Absent
11 20 SSG Absent Absent Absent Absent Absent Absent Absent
11 21 SSG Absent Absent Absent Absent Absent Absent Absent
11 22 SSG Absent Absent Absent Absent Absent Absent Absent
11 23 PM Absent Absent Absent Absent Absent Absent
11 24 PM Absent Absent Absent Absent Absent Absent
11 25 SSG Absent Absent Absent Absent Absent Absent Absent
11 26 Combination Absent Absent Absent Absent Absent Absent
11 27 PM Absent Absent Absent Absent Absent
11 28 Combination Absent Absent Absent Absent Absent Absent
11 29 PM Absent Absent Absent Absent Absent Absent
11 30 PM Absent Absent Absent Absent Absent Absent
11 31 SSG Absent Absent Absent Absent Absent Absent Absent
11 32 Combination Absent Absent Absent Absent Absent Absent
11 33 SSG Absent Absent Absent Absent Absent Absent Absent
11 34 PM Absent Absent Absent Absent Absent Absent
11 35 SSG Absent Absent Absent Absent Absent Absent Absent
11 36 SSG Absent Absent Absent Absent Absent Absent Absent
11 37 Combination Absent Absent Absent Absent Absent Absent
11 38 PM Absent Absent Absent Absent Absent Present
11 39 PM Absent Absent Absent Absent Absent Absent
11 40 PM Absent Absent Present Absent Absent
11 41 Combination Absent Absent Absent Absent Absent Absent
11 42 Combination Absent Absent Absent Absent Absent Absent
11 43 SSG Absent Absent Absent Absent Absent Absent Absent
11 44 PM Absent Absent Absent Absent Absent Absent
11 45 Combination Absent Absent Absent Absent Absent Absent
11 46 SSG Absent Absent Absent Absent Absent Absent Absent
11 47 SSG Absent Absent Absent Absent Absent
11 48 Combination Absent Absent Absent Absent Absent
11 49 SSG Absent Absent Absent Absent Absent Absent Absent
11 50 PM Absent Absent Absent Absent Absent Absent
11 51 Combination Absent Absent Absent Absent Absent Absent
11 52 PM Absent Absent Absent Absent Absent Absent
11 53 SSG Absent Absent Absent Absent Absent Absent Absent
11 54 PM Absent Absent Absent Absent Absent Absent
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Appendix 43: Individual listing for clinical characteristic, petichial haemorrhage
Centre Patient Petchial haemorrhage
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 55 PM Absent Absent Absent Absent Absent Absent
11 56 SSG Absent Absent Absent Absent Absent Absent Absent
11 57 Combination Absent Absent Absent Absent Absent Absent
11 58 Combination Absent Absent Absent Absent Absent Absent
11 59 PM Absent Absent Absent Absent Absent Absent
11 60 Combination Absent Absent Absent Absent Absent Absent
11 61 PM Absent Absent Absent Absent Absent Absent
11 62 SSG Absent Absent Absent Absent Absent Absent Absent
11 63 SSG Absent Absent Absent Absent Absent Absent Absent
11 64 SSG Absent Absent Absent Absent Absent Absent Absent
11 65 PM Absent Absent Absent Absent
11 66 Combination Absent Absent Absent Absent Absent Absent
11 67 PM Absent Absent Absent Absent Absent Absent
11 68 SSG Absent Absent Absent Absent Absent Absent Absent
11 69 Combination Absent Absent Absent Absent Absent Absent
11 70 Combination Absent Absent Absent Absent Absent Absent
11 71 Combination Absent Absent Absent Absent Absent Absent
11 72 SSG Absent Absent Absent Absent Absent
11 73 PM Absent Absent Absent Absent Absent Absent
11 74 PM Absent Absent Absent Absent Absent Absent
11 75 Combination Absent Absent Absent Absent Absent Absent
11 76 PM Absent Absent Absent Absent Absent Absent
11 77 PM Absent Absent Absent Absent Absent Absent
11 78 SSG Absent Absent Absent Absent Absent Absent Absent
11 79 PM Absent Absent Absent Absent Absent Absent
11 80 PM Absent Absent Absent Absent Absent Absent
11 81 Combination Absent Absent Absent Absent Absent Absent
11 82 SSG Absent Absent Absent Absent Absent Absent Absent
11 83 SSG Absent Absent Absent Absent Absent Absent Absent
11 84 SSG Absent Absent Absent Absent Absent Absent Absent
11 85 SSG Absent Absent Absent Absent Absent Absent
11 86 Combination Absent Absent Absent Absent Absent Absent
11 87 Combination Absent Absent Absent Absent Absent Absent
11 88 PM Absent Absent Absent Absent Absent Absent
11 89 Combination Absent Absent Absent Absent Absent Absent
11 90 Combination Absent Absent Absent Absent
11 91 PM Absent Absent Absent Absent Absent Absent
11 92 Combination Absent Absent Absent Absent Absent Absent
11 93 SSG Absent Absent Absent Absent Absent Absent Absent
11 94 SSG Absent Absent Absent Absent Absent Absent Absent
11 95 SSG Absent Absent Absent Absent Absent Absent Absent
11 96 Combination Absent Absent Absent Absent Absent Absent
11 97 Combination Absent Absent Absent Absent Absent Absent
11 98 PM Absent Absent Absent Absent Absent Absent
11 99 SSG Absent Absent Absent Absent Absent Absent Absent
11 100 PM Absent Absent Absent Absent
11 101 PM Absent Absent Absent Absent Absent Absent
11 102 Combination Absent Absent Absent Absent Absent Absent
11 103 Combination Absent Absent Absent Absent Absent Absent
11 104 PM Absent Absent Absent Absent Absent Absent
11 105 SSG Absent Absent Absent Absent Absent Absent Absent
11 106 Combination Absent Absent Absent Absent Absent Absent
11 107 PM Absent Absent Absent Absent Absent Absent
11 108 PM Absent Absent Absent Absent Absent Absent
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Appendix 43: Individual listing for clinical characteristic, petichial haemorrhage
Centre Patient Petchial haemorrhage
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
11 109 SSG Absent Absent Absent Absent Absent Absent Absent
11 110 PM Absent Absent Absent Absent Absent Absent
11 111 Combination Absent Absent Absent Absent Absent Absent
11 112 Combination Absent Absent Absent Absent Absent Absent
11 113 SSG Absent Absent Absent Absent Absent Absent
11 114 SSG Absent Absent Absent Absent Absent Absent Absent
11 115 Combination Absent Absent Absent Absent Absent Absent
11 116 SSG Absent Absent Absent Absent Absent Absent Absent
11 117 PM Absent Absent Absent Absent Absent
11 118 PM Absent Absent Absent Absent Absent Absent
11 119 SSG Absent Absent Absent Absent Absent Absent Absent
11 120 Combination Absent Absent Absent Absent Absent Absent
11 121 Combination Absent Absent Absent Absent Absent Absent
11 122 SSG Absent Absent Absent Absent Absent
11 123 SSG Absent Absent Absent Absent Absent Absent Absent
11 124 SSG Absent Absent Absent Absent Absent Absent
11 125 SSG Absent Absent Absent Absent Absent Absent Absent
11 126 Combination Absent Absent Absent Absent Absent
11 127 PM Absent Absent Absent Absent Absent Absent
11 128 Combination Absent Absent Absent Absent Absent Absent
11 129 PM Absent Absent Absent Absent Absent Absent
11 130 Combination Absent Absent Absent Absent Absent Absent
11 131 PM Absent Absent Absent Absent Absent Absent
11 132 SSG Absent Absent Absent Absent Absent Absent Absent
11 133 Combination Absent Absent Absent Absent Absent Absent
11 134 PM Absent Absent Absent Absent Absent Absent
11 135 PM Absent Absent Absent Absent Absent Absent
12 241 Combination Absent Absent Absent Absent Absent
12 242 SSG Absent Absent Absent Absent Absent Absent Absent
12 243 PM Absent Absent Absent Absent Absent Absent
12 244 SSG Absent Absent Absent Absent Absent Absent Absent
12 245 PM Absent Absent Absent Absent Absent
12 246 PM Absent Absent Absent Absent Absent
12 247 PM Absent Absent Absent Absent Absent Absent
12 248 PM Absent Absent Absent Absent Absent Absent
12 249 Combination Absent Absent Absent Absent Absent Absent
12 250 SSG Absent Absent Absent Absent Absent Absent Absent
12 251 Combination Absent Absent Absent Absent Absent Absent
12 252 SSG Absent Absent Absent Absent Absent Absent Absent
12 253 SSG Absent Absent Absent Absent Absent Absent Absent
12 254 Combination Absent Absent Absent Absent Absent Absent
12 255 Combination Absent Absent Absent Absent Absent Absent
12 256 Combination Absent Absent Absent Absent Absent Absent
12 257 SSG Absent Absent Absent Absent Absent Absent Absent
12 258 SSG Absent Absent Absent Absent Absent Absent
12 259 PM Absent Absent Absent Absent Absent Absent
12 260 PM Absent Absent Absent Absent Absent
12 261 Combination Absent Absent Absent Absent Absent Absent
12 262 PM Absent Absent Absent Absent Absent Absent
12 263 SSG Absent Absent Absent Absent Absent Absent Absent
12 264 Combination Absent Absent Absent Absent Absent Absent
12 265 SSG Absent Absent Absent Absent Absent
12 266 PM Absent Absent Absent Absent Absent Absent
12 267 SSG Absent Absent Absent Absent Absent Absent Absent
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Appendix 43: Individual listing for clinical characteristic, petichial haemorrhage
Centre Patient Petchial haemorrhage
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
12 268 PM Absent Absent Absent Absent Absent Absent
12 269 Combination Absent Absent Absent Absent Absent Absent
12 270 Combination Absent Absent Absent Absent Absent
12 271 SSG Absent Absent Absent Absent Absent Absent Absent
12 272 PM Absent Absent Absent Absent Absent Absent
12 273 SSG Absent Absent Absent Absent Absent Absent Absent
12 274 SSG Absent Absent Absent Absent Absent Absent Absent
12 275 Combination Absent Absent Absent Absent Absent Absent
12 276 PM Absent Absent Absent Absent Absent Absent
12 277 Combination Absent Absent Absent Absent Absent Absent
12 278 SSG Absent Absent Absent Absent Absent Absent
12 279 PM Absent Absent Absent Absent Absent Absent
12 280 SSG Absent Absent Absent Absent Absent Absent Absent
12 281 Combination Absent Absent Absent Absent Absent Absent
12 282 PM Absent Absent Absent Absent Absent Absent
12 283 PM Absent Absent Absent Absent Absent Absent
12 284 Combination Absent Absent Absent Absent Absent Absent
12 285 Combination Absent Absent Absent Absent Absent Absent
12 286 PM Absent Absent Absent Absent Absent Absent
12 287 SSG Absent Absent Absent Absent Absent Absent Absent
12 288 Combination Absent Absent Absent Absent Absent Absent
12 289 Combination Absent Absent Absent Absent Absent Absent
12 290 SSG Absent Absent Absent Absent Absent Absent
12 291 SSG Absent Absent Absent Absent Absent Absent Absent
12 292 PM Absent Absent Absent Absent Absent
12 293 SSG Absent Absent Absent Absent Absent Absent
12 294 Combination Absent Absent Absent Absent Absent Absent
12 295 Combination Absent Absent Absent Absent Absent
12 296 PM Absent Absent Absent Absent Absent Absent
12 297 SSG Absent Absent Absent
12 298 PM Absent Absent Absent Absent Absent Absent
12 299 Combination Absent Absent Absent Absent Absent
12 300 PM Absent Absent Absent Absent Absent Absent
12 301 SSG Absent Absent Absent Absent Absent Absent Absent
12 302 SSG Absent Absent Absent Absent Absent Absent Absent
12 303 PM Absent Absent Absent Absent Absent Absent
12 304 Combination Absent Absent Absent Absent Absent Absent
12 305 PM Absent Absent Absent Absent Absent Absent
12 306 Combination Absent Absent Absent Absent Absent Absent
12 307 Combination Absent Absent Absent Absent Absent Absent
12 308 PM Absent Absent Absent Absent Absent Absent
12 309 PM Absent Absent Absent Absent Absent Absent
12 310 SSG Absent Absent Absent Absent Absent Absent Absent
12 311 SSG Absent Absent Absent Absent Absent Absent Absent
12 312 Combination Absent Absent Absent Absent Absent Absent
12 313 PM Absent Absent Absent Absent Absent Absent
12 314 SSG Absent Absent Absent Absent Absent Absent Absent
12 315 Combination Absent Absent Absent Absent Absent Absent
12 316 SSG Absent Absent Absent Absent Absent Absent
12 317 SSG Absent Absent Absent Absent Absent Absent
12 318 Combination Absent Absent Absent Absent Absent Absent
12 319 Combination Absent Absent Absent Absent Absent Absent
12 320 Combination Absent Absent Absent Absent Absent Absent
12 321 Combination Absent Absent Absent Absent Absent Absent
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Appendix 43: Individual listing for clinical characteristic, petichial haemorrhage
Centre Patient Petchial haemorrhage
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
12 322 PM Absent Absent Absent Absent Absent Absent
12 323 SSG Absent Absent Absent Absent Absent Absent Absent
12 324 SSG Absent Absent Absent Absent Absent Absent Absent
12 325 PM Absent Absent Absent Absent Absent Absent
12 326 PM Absent Absent Absent Absent Absent Absent
12 327 Combination Absent Absent Absent Absent Absent Absent
12 328 PM Absent Absent Absent Absent Absent Absent
12 329 SSG Absent Absent Absent Absent Absent Absent Absent
12 330 PM Absent Absent Absent Absent Absent Absent
23 361 Combination Absent Absent Absent Absent Absent Absent
23 362 PM Absent Absent Absent Absent Absent Absent
23 363 PM Absent Absent Absent Absent Absent Absent
23 364 Combination Absent Absent Absent Absent Absent Absent
23 365 SSG Absent Absent Absent Absent Absent Absent Absent
23 366 Combination Absent Absent Absent Absent Absent Absent
23 367 SSG Absent Absent Absent Absent Absent Absent Absent
23 368 PM Absent Absent Absent Absent Absent Absent
23 369 Combination Absent Absent Absent Absent Absent Absent
23 370 SSG Absent Absent Absent Absent Absent Absent Absent
23 371 PM Absent Absent Absent Absent Absent Absent
23 372 PM Absent Absent Absent Absent Absent Absent
23 373 SSG Absent Absent Absent Absent Absent Absent Absent
23 374 SSG Absent Absent Absent Absent Absent Absent Absent
23 375 Combination Absent Absent Absent Absent Absent Absent
23 376 SSG Absent Absent Absent Absent Absent Absent Absent
23 377 Combination Absent Absent Absent
23 378 Combination Absent Absent Absent Absent Absent Absent
23 379 PM Absent Absent Absent Absent Absent Absent
23 380 SSG Absent Absent Absent Absent Absent Absent Absent
23 381 PM Absent Absent Absent Absent Absent Absent
23 382 Combination Absent Absent Absent Absent Absent Absent
23 383 PM Absent Absent Absent Absent Absent Absent
23 384 SSG Absent Absent Absent Absent Absent Absent Absent
23 385 SSG Absent Absent Absent Absent Absent Absent Absent
23 386 Combination Absent Absent Absent Absent Absent Absent
23 387 Combination Absent Absent Absent Absent Absent Absent
23 388 PM Absent Absent Absent Absent Absent Absent
23 389 SSG Absent Absent Absent Absent Absent Absent Absent
23 390 PM Absent Absent Absent Absent Absent Absent
23 391 Combination Absent Absent Absent Absent Absent Absent
23 392 Combination Absent Absent Absent Absent Absent
23 393 SSG Absent Absent Absent Absent Absent Absent Absent
23 394 PM Absent Absent Absent Absent Absent Absent
23 395 PM Absent Absent Absent Absent Absent Absent
23 396 SSG Absent Absent Absent Absent Absent Absent Absent
23 397 SSG Absent Absent Absent Absent Absent Absent Absent
23 398 Combination Absent Absent Absent Absent Absent Absent
23 399 PM Absent Absent Absent Absent Absent Absent
23 400 PM Absent Absent Absent Absent Absent Absent
23 401 Combination Absent Absent Absent Absent Absent Absent
23 402 Combination Absent Absent Absent Absent Absent Absent
23 403 SSG Absent Absent Absent Absent Absent Absent Absent
23 404 SSG Absent Absent Absent Absent Absent Absent
23 405 PM Absent Absent Absent Absent Absent Absent
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Appendix 43: Individual listing for clinical characteristic, petichial haemorrhage
Centre Patient Petchial haemorrhage
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
34 451 Combination Absent Absent Absent Absent Absent
34 452 PM Absent Absent Absent Absent
34 453 PM Absent Absent Absent Absent
34 454 Combination Absent Absent Absent Absent Absent
34 455 PM Absent Absent Absent Absent
34 456 SSG Absent Absent Absent Absent Absent Absent
34 457 Combination Absent Absent Absent Absent
34 458 PM Absent Absent Absent Absent Absent
34 459 Combination Absent Absent Absent Absent Absent Absent
34 460 PM Absent Absent Absent Absent
34 461 SSG Absent Absent Absent
34 462 SSG Absent Absent Absent Absent Absent Absent
34 463 Combination Absent Absent Absent Absent Absent
34 464 SSG Absent Absent Absent Absent Absent Absent
34 465 SSG Absent Absent Absent Absent Absent Absent
34 466 Combination Absent Absent Absent Absent
34 467 PM Absent Absent Absent Absent Absent
34 468 Combination Absent Absent Absent Absent Absent
34 469 SSG Absent Absent Absent Absent Absent Absent
34 470 Combination Absent Absent Absent Absent Absent
34 471 PM Absent Absent Absent Absent
34 472 SSG Absent Absent Absent Absent Absent Absent
34 473 PM Absent Absent Absent Absent
34 474 Combination Absent Absent Absent Absent Absent
34 475 PM Absent Absent Absent Absent
34 476 PM Absent Absent Absent Absent Absent
34 477 SSG Absent Absent Absent Absent Absent Absent
34 478 Combination Absent Absent Absent Absent Absent
34 479 SSG Absent Absent Absent Absent Absent Absent
34 480 SSG Absent Absent Absent Absent Absent Absent
34 481 Combination Absent Absent Absent Absent Absent
34 482 Combination Absent Absent Absent Absent Absent
34 483 PM Absent Absent Absent Absent Absent
34 484 PM Absent Absent
34 485 Combination Absent Absent Absent Absent Absent
34 486 Combination Absent Absent Absent Absent Absent
34 487 SSG Absent Absent Absent Absent Absent Absent
34 488 SSG Absent Absent Absent Absent Absent Absent Absent
34 489 SSG Absent Absent Absent Absent Absent Absent
34 490 PM Absent Absent Absent Absent Absent
34 491 PM Absent Absent Absent Absent
34 492 PM Absent Absent Absent Absent Absent
34 493 SSG Absent Absent Absent Absent Absent Absent
34 494 Combination Absent Absent Absent Absent Absent
34 495 SSG Absent Absent Absent Absent Absent Absent
34 496 SSG Absent Absent Absent Absent Absent Absent
34 497 PM Absent Absent Absent Absent Absent
34 498 SSG Absent Absent Absent Absent Absent Absent
34 499 Combination Absent Absent Absent Absent Absent
34 500 PM Absent Absent Absent Absent Absent
34 501 Combination Absent Absent Absent Absent Absent
34 502 Combination Absent Absent Absent Absent Absent
34 503 PM Absent Absent Absent Absent
34 504 Combination Absent Absent Absent Absent
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Appendix 43: Individual listing for clinical characteristic, petichial haemorrhage
Centre Patient Petchial haemorrhage
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
34 505 SSG Absent Absent Absent Absent Absent Absent
34 506 SSG Absent Absent Absent Absent Absent Absent
34 507 SSG Absent Absent Absent Absent Absent Absent
34 508 PM Absent Absent Absent Absent
34 509 PM Absent Absent Absent Absent
34 510 Combination Absent Absent Absent Absent Absent
34 511 Combination Absent Absent Absent Absent Absent
34 512 PM Absent Absent Absent Absent
34 513 Combination Absent Absent Absent Absent Absent Absent
34 514 SSG Absent Absent Absent Absent Absent Absent
34 515 SSG Absent Absent Absent Absent Absent Absent
34 516 PM Absent Absent Absent Absent Absent
34 517 PM Absent Absent Absent Absent
34 518 SSG Absent Absent Absent Absent Absent Absent
34 519 PM Absent Absent Absent Absent Absent
34 520 SSG Absent Absent Absent Absent Absent Absent
34 521 PM Absent Absent Absent Absent
34 522 Combination Absent Absent Absent Absent
34 523 SSG Absent Absent Absent Absent Absent Absent
34 524 Combination Absent Absent Absent Absent Absent
34 525 Combination Absent Absent Absent Absent Absent
34 526 SSG Absent Absent Absent Absent Absent Absent
34 527 Combination Absent Absent Absent Absent Absent
34 528 PM Absent Absent Absent Absent
34 529 Combination Absent Absent Absent Absent Absent
34 530 Combination Absent Absent Absent Absent Absent
34 531 SSG Absent Absent Absent Absent Absent
34 532 Combination Absent Absent Absent Absent Absent
34 533 SSG Absent Absent Absent Absent Absent Absent
34 534 PM Absent Absent Absent Absent
34 535 PM Absent Absent Absent Absent Absent
34 536 PM Absent Absent Absent Absent Absent
34 537 SSG Absent Absent Absent Absent Absent Absent
34 538 PM Absent Absent Absent Absent
34 539 Combination Absent Absent Absent Absent Absent
34 540 SSG Absent Absent Absent Absent Absent Absent
35 646 PM Absent Absent Absent Absent Absent
35 647 PM Absent Absent Absent Absent Absent Absent
35 648 Combination Absent Absent Absent Absent Absent Absent
35 649 Combination Absent Absent Absent Absent Absent Absent
35 650 SSG Absent Absent Absent Absent Absent Absent Absent
35 651 SSG Absent Absent Absent Absent Absent Absent Absent
35 652 PM Absent Absent Absent Absent Absent
35 653 Combination Absent Absent Absent Absent Absent Absent
35 654 SSG Absent Absent Absent Absent Absent Absent Absent
35 655 Combination Absent Absent Absent Absent Absent Absent
35 656 SSG Absent Absent Absent Absent Absent Absent Absent
35 657 PM Absent Absent Absent Absent Absent Absent
35 658 Combination Absent Absent Absent Absent Absent Absent
35 659 SSG Absent Absent Absent Absent Absent Absent Absent
35 660 PM Absent Absent Absent Absent Absent Absent
35 661 Combination Absent Absent Absent Absent Absent Absent
35 662 PM Absent Absent Absent Absent Absent Absent
35 663 SSG Absent Absent Absent Absent Absent Absent Absent
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Appendix 43: Individual listing for clinical characteristic, petichial haemorrhage
Centre Patient Petchial haemorrhage
Number Number Treatment Baseline Day7 Day 14 Day 21 EOT 3 mon FU 6 mon FU
35 664 Combination Absent Absent Absent
35 665 SSG Absent Absent Absent Absent Absent Absent Absent
35 666 SSG Absent Absent Absent Absent Absent Absent Absent
35 667 Combination Absent Absent Absent Absent Absent Absent
35 668 PM Absent Absent Absent Absent Absent
35 669 PM Absent Absent Absent Absent
35 670 SSG Absent Absent Absent Absent Absent Absent Absent
35 671 PM Absent Absent Absent Absent Absent
35 672 Combination Absent Absent Absent Absent Absent
35 673 SSG Absent Absent Absent Absent Absent Absent Absent
35 674 Combination Absent Absent Absent Absent Absent Absent
35 675 PM Absent Absent Absent Absent Absent
35 676 PM Absent Absent Absent Absent Absent Absent
35 677 SSG Absent Absent
35 678 Combination Absent Absent Absent Absent Absent Absent
35 679 SSG Absent Absent Absent Absent Absent Absent Absent
35 680 Combination Absent Absent Absent Absent Absent Absent
35 681 Combination Absent Absent Absent Absent Absent Absent
35 682 PM Absent Absent Absent Absent Absent
35 683 Combination Absent Absent Absent Absent Absent
35 684 SSG Absent Absent Absent Absent Absent Absent Absent
35 685 PM Absent Absent Absent Absent Absent Absent
35 686 PM Absent Absent Absent Absent Absent Absent
35 687 SSG Absent Absent Absent Absent Absent Absent Absent
35 688 PM Absent Absent Absent Absent Absent Absent
35 689 Combination Absent Absent Absent Absent Absent Absent
35 690 SSG Absent Absent Absent Absent Absent Absent Absent
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16.3.7 Adverse event listings (each patient)  
Appendix 44 Listing of adverse events per patient 
Appendix 45 Listing of ECG Findings per patient 
Appendix 46 Listing of chest x-ray finding per patient 
Appendix 47 Listing of audiometry x-ray finding per patient 
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Appendix 44: Listing of adverse events per patient
Cent No Pat No Age Sex Treatment Treatment start 
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11 2 19 Male Comb 18-Jun-05 DROP OF HEMOGLOBIN HAEMOGLOBIN DECREASED 5-Jan-06 Ongoing Moderate None Not related
11 2 19 Male Comb 18-Jun-05 DROP OF PLATLATE PLATELET COUNT DECREASED 5-Jan-06 Ongoing Moderate None Not related
11 3 20 Male Comb 19-Jun-05 EPIGASTRIC PAIN ABDOMINAL PAIN UPPER 19-Jun-05 7-Jul-05 Resolved Mild None Not related
11 3 20 Male Comb 19-Jun-05 ACUTE GASTROENTERITIS DIARRHOEA 6-Jul-05 7-Jul-05 Resolved Mild None Unlikely
11 3 20 Male Comb 19-Jun-05 RAISED SGOT ASPARTATE AMINOTRANSFERASE 25-Jun-05 6-Jul-05 Resolved Mild None Possible
11 3 20 Male Comb 19-Jun-05 RAISED ALP BLOOD ALKALINE PHOSPHATASE 25-Jun-05 6-Jul-05 Resolved Mild None Possible
11 5 10 Female PM 30-Jun-05 CHILS & RIGER CHILLS 8-Jul-05 8-Jul-05 Resolved Mild None Unlikely
11 5 10 Female PM 30-Jun-05 VOMITING VOMITING 8-Jul-05 8-Jul-05 Resolved Moderate None Unlikely
11 7 45 Female PM 2-Jul-05 INJECTION SITE PAIN INJECTION SITE PAIN 13-Jul-05 Ongoing Moderate None Possible
11 7 45 Female PM 2-Jul-05 AIRWAY DISEASE (BRONCHIAL ATHMA ASTHMA 11-Oct-05 8-Nov-05 Resolved Mild None Not related
11 7 45 Female PM 2-Jul-05 UTI (URINARY TRACT INFECTION) URINARY TRACT INFECTION 18-Jan-06 30-Jan-06 Resolved Mild None Not related
11 9 20 Male SSG 3-Jul-05 DYSPEPSIA DYSPEPSIA 8-Jul-05 Ongoing Mild None Not related
11 9 20 Male SSG 3-Jul-05 LEFT LOWER CHEST PAIN CHEST PAIN 8-Jul-05 Ongoing Mild None Not related
11 10 17 Male SSG 3-Jul-05 MALARIA MALARIA 17-Jul-05 20-Jul-05 Resolved Mild None Not related
11 10 17 Male SSG 3-Jul-05 INCREASED SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
27-Jul-05 3-Aug-05 Resolved Moderate None Possible
11 10 17 Male SSG 3-Jul-05 INCREASED SGPT ALANINE AMINOTRANSFERASE 
INCREASED
27-Jul-05 3-Aug-05 Resolved Moderate None Possible
11 11 12 Male Comb 5-Jul-05 INJECTION SITE PAIN INJECTION SITE PAIN 18-Jul-05 Ongoing Mild None Probable
11 11 12 Male Comb 5-Jul-05 ELEVATED LIVER ENZYME(SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
20-Jan-06 Ongoing Moderate None Probable
11 12 18 Male Comb 8-Jul-05 MALARIA MALARIA 14-Jul-05 20-Jul-05 Resolved Mild None Not related
11 12 18 Male Comb 8-Jul-05 LEFT EAR AUDIOMETRIC SHIFT AUDIOGRAM ABNORMAL 14-Jul-05 25-Jul-05 Resolved Moderate None Possible
11 12 18 Male Comb 8-Jul-05 HEADACHE HEADACHE 20-Nov-05 Ongoing Mild None Not related
11 13 40 Female SSG 12-Jul-05 RIGHT EYE PAIN EYE PAIN 1-Aug-05 Ongoing Mild None Not related
11 14 7 Male SSG 12-Jul-05 GIARDIASIS GIARDIASIS 3-Aug-05 8-Aug-05 Resolved Mild None Not related
11 14 7 Male SSG 12-Jul-05 PNEUMONIA PNEUMONIA 10-Aug-05 25-Aug-05 Resolved Moderate None Unlikely
11 16 35 Female Comb 15-Jul-05 UTI URINARY TRACT INFECTION 28-Jul-05 4-Aug-05 Resolved Mild None Not related
11 16 35 Female Comb 15-Jul-05 HOOK WORM HOOKWORM INFECTION 28-Jul-05 31-Jul-05 Resolved Mild None Not related
11 16 35 Female Comb 15-Jul-05 HEADACHE HEADACHE 29-Jul-05 Ongoing Mild None Not related
11 16 35 Female Comb 15-Jul-05 RIGHT AUDIOMETRIC SHIFT AUDIOGRAM ABNORMAL 31-Oct-05 Ongoing Moderate None Probable
11 17 40 Male Comb 19-Jul-05 OVA OF HOOK WORM 1/5 HOOKWORM INFECTION 25-Jul-05 28-Jul-05 Resolved Moderate None Possible
11 17 40 Male Comb 19-Jul-05 LARVEA OF S. STERCORALIS 1/5 STRONGYLOIDIASIS 25-Jul-05 28-Jul-05 Resolved Moderate None Not related
11 17 40 Male Comb 19-Jul-05 COUGH COUGH 1-Aug-05 Ongoing Mild None Unlikely
11 17 40 Male Comb 19-Jul-05 DECREASE IN WBC WHITE BLOOD CELL DECREASED 7-Nov-05 Ongoing Moderate None Possible
11 17 40 Male Comb 19-Jul-05 DECREASE IN PLATELET PLATELET COUNT DECREASED 7-Nov-05 6-Feb-06 Resolved Moderate None Possible
11 18 34 Male SSG 16-Aug-05 HEADACHE HEADACHE 18-Aug-05 19-Aug-05 Resolved Mild None Not related
11 18 34 Male SSG 16-Aug-05 NAUSEA NAUSEA 18-Aug-05 19-Aug-05 Resolved Mild None Unlikely
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11 18 34 Male SSG 16-Aug-05 COMMUNITY ACQUIRED PNEUMONIA PNEUMONIA 15-Dec-05 2-Jan-06 Resolved Mild None Not related
11 19 33 Male Comb 16-Aug-05 PLATLATE(DROP OF PLATLATE) PLATELET COUNT DECREASED 22-Aug-05 Ongoing Severe None Possible
11 19 33 Male Comb 16-Aug-05 INSOMINIA INSOMINIA 18-Aug-05 22-Aug-05 Resolved Mild None Not related
11 19 33 Male Comb 16-Aug-05 ENTAMOEBA HISTOLYTICA DYSENTRY AMOEBIASIS 27-Feb-06 Ongoing Mild None Not related
11 20 7 Male SSG 16-Aug-05 PNEUMONIA PNEUMONIA 9-Sep-05 16-Sep-05 Resolved Moderate None Not related
11 22 11 Male SSG 17-Aug-05 CHILS CHILLS 18-Aug-05 Resolved Mild None Not related
11 22 11 Male SSG 17-Aug-05 VOMITING VOMITING 18-Aug-05 Resolved Mild None Not related
11 23 10 Male PM 20-Aug-05 PAIN AT INJECTION SITE INJECTION SITE PAIN 26-Aug-05 Resolved Mild None Not related
11 24 7 Female PM 20-Aug-05 DIARRHEA DIARRHOEA 20-Aug-05 27-Aug-05 Resolved Mild None Not related
11 25 10 Female SSG 20-Aug-05 INCREASED SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
26-Aug-05 19-Sep-05 Resolved Moderate None Probable
11 25 10 Female SSG 20-Aug-05 INCREASED SGPT ALANINE AMINOTRANSFERASE 
INCREASED
26-Aug-05 19-Sep-05 Resolved Moderate None Probable
11 25 10 Female SSG 20-Aug-05 INTESTINAL PARASITOSIS INFECTION PARASITIC 4-Jan-06 14-Apr-06 Resolved Mild None Not related
11 26 8 Female Comb 25-Aug-05 INJECTION SITE PAIN INJECTION SITE PAIN 31-Aug-05 7-Sep-05 Resolved Mild None Probable
11 27 31 Male PM 19-Sep-05 ACUTE GASTRO ENTERITIS GASTROENTERITIS 20-Sep-05 23-Sep-05 Resolved Mild None Not related
11 27 31 Male PM 19-Sep-05 PAIN AT INJECTION SITE INJECTION SITE PAIN 29-Sep-05 Ongoing Moderate None Probable
11 27 31 Male PM 19-Sep-05 HEADACHE HEADACHE 23-Sep-05 25-Oct-05 Resolved Mild None Unlikely
11 27 31 Male PM 19-Sep-05 SEPSIS SEPSIS 20-Jan-06 27-Jan-06 Resolved Severe None Not related
11 28 13 Male Comb 21-Sep-05 ACUTE GASTROENTERITIS GASTROENTERITIS 24-Sep-05 24-Sep-05 Resolved Mild None Not related
11 28 13 Male Comb 21-Sep-05 PAIN AT INJECTION SITE INJECTION SITE PAIN 27-Sep-05 8-Oct-05 Resolved Mild None Possible
11 31 40 Female SSG 23-Sep-05 ELEVATED LIVER ENZYMES 
(ASYMPTOMATIC)
HEPATIC ENZYME INCREASED 13-Oct-05 Ongoing Mild None Possible
11 33 25 Male SSG 25-Sep-05 ELEVATED LIVER ENZYMES HEPATIC ENZYME INCREASED 1-Oct-05 15-Oct-05 Resolved Mild None Possible
11 33 25 Male SSG 25-Sep-05 REDUCED PLATELATE COUNT PLATELET COUNT DECREASED 8-Oct-05 Ongoing Mild None Possible
11 35 18 Male SSG 27-Sep-05 EPISTAXIS EPISTAXIS 19-Oct-05 21-Oct-05 Resolved Mild None Probable
11 35 18 Male SSG 27-Sep-05 DECREASE IN HGB LEVEL HAEMOGLOBIN DECREASED 11-Jan-06 16-Apr-06 Resolved Moderate None Possible
11 35 18 Male SSG 27-Sep-05 DECREASE IN PLATELET COUNT PLATELET COUNT DECREASED 11-Jan-06 16-Apr-06 Resolved Moderate None Possible
11 35 18 Male SSG 27-Sep-05 DECREASE IN WBC WHITE BLOOD CELL DECREASED 11-Jan-06 16-Apr-06 Resolved Moderate None Possible
11 36 20 Male SSG 28-Sep-05 SEVERE ANEMIA ANAEMIA 4-Oct-05 11-Oct-05 Resolved Moderate None Unlikely
11 37 40 Male Comb 28-Sep-05 VOMITING VOMITING 3-Oct-05 4-Oct-05 Resolved Mild None Unlikely
11 37 40 Male Comb 28-Sep-05 ANOROXIA ANOREXIA 3-Oct-05 4-Oct-05 Resolved Mild None Unlikely
11 37 40 Male Comb 28-Sep-05 VESICULAR SKIN LESION  RASH VESICULAR 7-Oct-05 15-Oct-05 Resolved Mild None Not related
11 37 40 Male Comb 28-Sep-05 INJECTION SITE PAIN INJECTION SITE PAIN 7-Oct-05 15-Oct-05 Resolved Mild None Probable
11 37 40 Male Comb 28-Sep-05 STAGE II HYPERTENSION HYPERTENSION 17-Jan-06 Ongoing Moderate None Not related
11 38 47 Male PM 19-Oct-05 ESOPHAGEAL VARICES VARICES OESOPHAGEAL 29-May-06 Ongoing Moderate None Not related
11 38 47 Male PM 19-Oct-05 DUODENAL ULCER DOUDENAL ULCER 29-May-06 Ongoing Moderate None Not related
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11 39 6 Male PM 19-Oct-05 AUDIOMETRIC SHIFT AUDIOGRAM ABNORMAL 7-Mar-06 22-May-06 Resolved Moderate None Possible
11 39 6 Male PM 19-Oct-05 SINUS ARRYTHMIA SINUS ARRHYTHMIA 6-Mar-06 Ongoing Mild None Possible
11 41 5 Male Comb 20-Oct-05 MALARIA MALARIA 22-Oct-05 24-Oct-05 Resolved Mild None Not related
11 42 30 Male Comb 21-Oct-05 ASYMPTOMATIC ELEVATION OF LIVER 
ENZYMES
HEPATIC ENZYME INCREASED 27-Oct-05 3-Nov-05 Resolved Mild None Possible
11 42 30 Male Comb 21-Oct-05 MALARIA (AMA MALARIA 5-Nov-05 14-Nov-05 Resolved Mild None Not related
11 42 30 Male Comb 21-Oct-05 LOW BACK PAIN BACK PAIN 26-Jan-06 4-Feb-06 Resolved Mild None Not related
11 43 15 Male SSG 28-Oct-05 UTI (PYURIA) URINARY TRACT INFECTION 3-Nov-05 10-Nov-05 Resolved Mild None Not related
11 45 16 Male Comb 28-Oct-05 PAIN OVER INJECTION SITE INJECTION SITE PAIN 10-Nov-05 Ongoing Mild None Possible
11 45 16 Male Comb 28-Oct-05 INTESTINAL PARASITOSIS INFECTION PARASITIC 19-May-06 21-May-06 Resolved Mild None Not related
11 46 6 Female SSG 5-May-06 GIARDIASIS GIARDIASIS 8-May-06 11-May-06 Resolved Mild None Not related
11 47 20 Male SSG 5-May-06 ELEVATED LIVER TRANSAMINASE TRANSAMINASES INCREASED 11-May-06 18-May-06 Resolved Mild None Possible
11 49 7 Male SSG 9-May-06 ELEVATED LIVER TRANSAMINASE LEVEL TRANSAMINASES INCREASED 15-May-06 Ongoing Moderate None Possible
11 51 15 Male Comb 20-May-06 INJECTION SITE PAIN INJECTION SITE PAIN 30-May-06 Ongoing Mild None Possible
11 52 11 Male PM 20-May-06 RAISED TRANSAMINASE LEVEL (SGOT & 
SGPT)
TRANSAMINASES INCREASED 11-Jan-07 22-Jan-07 Resolved Severe None Unlikely
11 53 26 Male SSG 26-May-06 RAISED ALK. PHOSPHATASE LEVEL BLOOD ALKALINE PHOSPHATASE 
INCREASED
8-Jun-06 12-Dec-06 Resolved Moderate None Possible
11 54 24 Male PM 27-May-06 AMOEBIASIS AMOEBIASIS 23-Jun-06 2-Jul-06 Resolved Moderate None Not related
11 54 24 Male PM 27-May-06 MALARIA MALARIA 18-Dec-06 21-Dec-06 Resolved Moderate None Not related
11 54 24 Male PM 27-May-06 DENTAL CARRIES DENTAL CARIES 25-Dec-06 1-Jan-07 Resolved Moderate None Not related
11 57 27 Male Comb 4-Jun-06 RAISED TRANSAMINASE LEVEL TRANSAMINASES INCREASED 14-Jun-06 21-Jun-06 Resolved Moderate None Possible
11 57 27 Male Comb 4-Jun-06 DYSPEPSIA DYSPEPSIA 10-Jun-06 17-Jun-06 Resolved Mild None Probable
11 58 12 Male Comb 6-Jun-06 PAIN AT INJECTION SITE INJECTION SITE PAIN 15-Jun-06 26-Sep-06 Resolved Moderate None Possible
11 58 12 Male Comb 6-Jun-06 RAISED TRANSAMINATE LEVEL TRANSAMINASES INCREASED 19-Jun-06 Ongoing Moderate None Possible
11 58 12 Male Comb 6-Jun-06 RAISED SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
19-Jun-06 13-Dec-06 Resolved Moderate None Possible
11 58 12 Male Comb 6-Jun-06 RAISED SGPT ALANINE AMINOTRANSFERASE 
INCREASED
19-Jun-06 13-Dec-06 Resolved Moderate None Possible
11 59 12 Male PM 13-Jun-06 INJECTION SITE PAIN INJECTION SITE PAIN 25-Jun-06 26-Aug-06 Resolved Mild None Possible
11 59 12 Male PM 13-Jun-06 INCREASED ALK PHOSPHATASE BLOOD ALKALINE PHOSPHATASE 
INCREASED
4-Jul-06 Ongoing Moderate None Possible
11 59 12 Male PM 13-Jun-06 HYPERTENSION HYPERTENSION 4-Jul-06 Ongoing Moderate None Probable
LEAP 0104a Appendices
Page 550 of 756
Appendix 44: Listing of adverse events per patient
Cent No Pat No Age Sex Treatment Treatment start 
date
Adverse Event Preferred term AE start date AE end date Outcome Intensity Action 
taken
Related
11 59 12 Male PM 13-Jun-06 RAISED SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
26-Aug-06 Ongoing Moderate None Probable
11 59 12 Male PM 13-Jun-06 RAISED SGPT ALANINE AMINOTRANSFERASE 
INCREASED
26-Aug-06 Ongoing Moderate None Probable
11 59 12 Male PM 13-Jun-06 RAISED TRANSAMINASE LEVEL (SGOT & 
SGPT)
TRANSAMINASES INCREASED 26-Aug-06 Ongoing Moderate None Probable
11 60 32 Male Comb 13-Jun-06 RAISED TRANSAMINASE LEVEL (SGOT & 
SGPT)
TRANSAMINASES INCREASED 19-Jun-06 28-Sep-06 Resolved Mild None Possible
11 60 32 Male Comb 13-Jun-06 RAISED ALK. PHOSPHATASE BLOOD ALKALINE PHOSPHATASE 
INCREASED
19-Jun-06 18-Dec-06 Resolved Moderate None Possible
11 60 32 Male Comb 13-Jun-06 INJECTION SITE PAIN INJECTION SITE PAIN 22-Jun-06 28-Sep-06 Resolved Mild None Possible
11 61 27 Male PM 13-Jun-06 INJECTION SITE PAIN INJECTION SITE PAIN 24-Jun-06 Ongoing Mild None Possible
11 62 6 Male SSG 16-Jun-06 INJECTION SITE PAIN INJECTION SITE PAIN 22-Jun-06 Ongoing Mild None Possible
11 64 26 Male SSG 22-Jun-06 INJECTION SITE PAIN INJECTION SITE PAIN 6-Jul-06 29-Sep-06 Resolved Mild None Possible
11 67 11 Male PM 1-Jul-06 INJECTION SITE POIN INJECTION SITE PAIN 14-Jul-06 3-Oct-06 Resolved Mild None Possible
11 69 18 Male Comb 15-Jul-06 INJECTION SITE PAIN INJECTION SITE PAIN 27-Jul-06 1-Aug-06 Resolved Mild None Possible
11 69 18 Male Comb 15-Jul-06 GIARDIASIS GIARDIASIS 31-Oct-06 13-Dec-06 Resolved Moderate None Not related
11 70 20 Male Comb 15-Jul-06 RAISED TRANSAMINASE LEVEL TRANSAMINASES INCREASED 21-Jul-06 Ongoing Mild None Possible
11 70 20 Male Comb 15-Jul-06 INJECTION SITE PAIN INJECTION SITE PAIN 25-Jul-06 Ongoing Moderate None Possible
11 70 20 Male Comb 15-Jul-06 SCABIES ACARODERMATITIS 9-Oct-06 2-Jan-07 Resolved Moderate None Not related
11 71 33 Male Comb 22-Jul-06 INJECTION SITE PAIN INJECTION SITE PAIN 4-Aug-06 20-Aug-06 Resolved Mild None Possible
11 71 33 Male Comb 22-Jul-06 DYSPEPSIA DYSPEPSIA 30-Jul-06 8-Aug-06 Resolved Moderate None Probable
11 71 33 Male Comb 22-Jul-06 AMOEBIASIS AMOEBIASIS 21-Aug-06 12-Oct-06 Resolved Moderate None Not related
11 71 33 Male Comb 22-Jul-06 DYSPEPSIE DYSPEPSIA 1-Jan-07 Ongoing Mild None Not related
11 71 33 Male Comb 22-Jul-06 EPISTAXIS EPISTAXIS 12-Feb-07 Ongoing Mild None Not related
11 72 23 Male SSG 22-Jul-06 RAISED TRANSAMINASE LEVEL TRANSAMINASES INCREASED 28-Jul-06 Ongoing Moderate None Possible
11 72 23 Male SSG 22-Jul-06 RAISED ALK. PHOSPHATASE BLOOD ALKALINE PHOSPHATASE 
INCREASED
28-Jul-06 9-Nov-06 Resolved Moderate None Possible
11 72 23 Male SSG 22-Jul-06 RAISED TRANSAMINASE LEVEL (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
28-Jul-06 9-Nov-06 Resolved Moderate None Possible
11 72 23 Male SSG 22-Jul-06 SKIN RASH WHICH IS PAPULONODULAR 
OVER THE FACE (PKDL)
VISCERAL LEISHMANIASIS 9-Oct-06 Ongoing Mild None Possible
11 74 34 Male PM 28-Jul-06 RAISED TRANSAMINASE LEVEL (SGOT & 
SGPT)
TRANSAMINASES INCREASED 3-Aug-06 18-Aug-06 Resolved Moderate None Possible
11 75 25 Male Comb 28-Jul-06 INJECTION SITE PAIN INJECTION SITE PAIN 3-Aug-06 29-Aug-06 Resolved Mild None Possible
11 76 23 Male PM 31-Jul-06 RAISED TRANSAMINASE LEVEL SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
2-Aug-06 21-Aug-06 Resolved Mild None Possible
11 78 30 Male SSG 31-Jul-06 INJECTION SITE PAIN INJECTION SITE PAIN 12-Aug-06 30-Oct-06 Resolved Mild None Possible
11 79 5 Male PM 31-Jul-06 ACUTE GESTROINTERITS GASTROENTERITIS 5-Aug-06 6-Aug-06 Resolved Mild None Possible
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11 79 5 Male PM 31-Jul-06 RAISED TRANSAMINASE LEVEL (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
30-Oct-06 30-Jan-07 Resolved Mild None Probable
11 81 25 Male Comb 6-Aug-06 PAIN AT INJECTION SITE INJECTION SITE PAIN 16-Aug-06 7-Nov-06 Resolved Moderate None Possible
11 82 15 Male SSG 15-Aug-06 RAISED TRANSAMINASE (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
21-Aug-06 13-Nov-06 Resolved Moderate Dose 
Reduced
Possible
11 82 15 Male SSG 15-Aug-06 INJECTION SITE PAIN INJECTION SITE PAIN 4-Sep-06 13-Nov-06 Resolved Mild None Possible
11 83 22 Male SSG 16-Aug-06 PAPULAR RASH W/C ARE DISTRIBUTED 
OVER THE FACE [PKDL GRADE I]
VISCERAL LEISHMANIASIS 13-Dec-06 Ongoing Mild None Possible
11 84 15 Male SSG 18-Aug-06 ATYPICAL PNEUMONIA PNEUMONIA ATYPICAL  PRIMARY 10-Sep-06 15-Nov-06 Resolved Moderate None Unlikely
11 85 20 Male SSG 25-Aug-06 RAISED TRANSAMINASE LEVEL (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
31-Aug-06 21-Nov-06 Resolved Moderate None Possible
11 85 20 Male SSG 25-Aug-06 RAISED ALK PHOSPHATASE BLOOD ALKALINE PHOSPHATASE 
INCREASED
31-Aug-06 21-Nov-06 Resolved Moderate None Possible
11 85 20 Male SSG 25-Aug-06 INJECTION SITE PAIN INJECTION SITE PAIN 7-Sep-06 21-Nov-06 Resolved Moderate None Possible
11 85 20 Male SSG 25-Aug-06 DYSPEPSIA DYSPEPSIA 8-Nov-06 Ongoing Moderate None Probable
11 86 5 Male Comb 29-Aug-06 PAIN AT INJECTION SITE INJECTION SITE PAIN 8-Sep-06 13-Nov-06 Resolved Moderate None Possible
11 87 18 Male Comb 29-Aug-06 RAISED TRANSAMINASE LEVEL (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
4-Sep-06 14-Nov-06 Resolved Moderate None Possible
11 88 25 Male PM 29-Aug-06 ATYPICAL PNEUMONIA PNEUMONIA ATYPICAL  PRIMARY 14-Nov-06 28-Feb-07 Resolved Mild None Not related
11 89 24 Male Comb 2-Sep-06 RAISED TRANSAMINASE LEVEL (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
5-Sep-06 17-Nov-06 Resolved Moderate None Possible
11 89 24 Male Comb 2-Sep-06 INJECTION SITE PAIN INJECTION SITE PAIN 8-Sep-06 17-Nov-06 Resolved Moderate None Possible
11 89 24 Male Comb 2-Sep-06 VOMITING VOMITING 5-Sep-06 5-Sep-06 Resolved Mild None Possible
11 89 24 Male Comb 2-Sep-06 ATYPICAL PNEUMONIA PNEUMONIA ATYPICAL  PRIMARY 17-Oct-06 15-Jan-07 Resolved Moderate None Not related
11 91 35 Male PM 18-Dec-06 PAIN AT INJECTION SITE INJECTION SITE PAIN 29-Dec-06 5-Mar-07 Resolved Mild None Possible
11 91 35 Male PM 18-Dec-06 DYSPEPSIA HO PUD DYSPEPSIA 9-Apr-07 3-Jul-07 Resolved Moderate None Unlikely
11 91 35 Male PM 18-Dec-06 INCREASED CREATINEN BLOOD CREATININE INCREASED 15-Mar-07 6-Sep-07 Resolved Moderate None Possible
11 92 7 Male Comb 31-Dec-06 INJECTION SITE SWEALING INJECTION SITE SWELLING 13-Jan-07 Ongoing Mild None Possible
11 92 7 Male Comb 31-Dec-06 INJECTION SITE PAIN INJECTION SITE PAIN 13-Jan-07 30-Mar-07 Resolved Mild None Possible
11 93 26 Male SSG 2-Jan-07 INJECTION SITE PAIN INJECTION SITE PAIN 15-Jan-07 1-Feb-07 Resolved Mild None Possible
11 95 6 Male SSG 4-Jan-07 RAISED TRANSAMINASE LEVEL 
(SGOT&SGPT)
TRANSAMINASES INCREASED 10-Jan-07 3-Feb-07 Resolved Moderate None Possible
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11 95 6 Male SSG 4-Jan-07 RAISED ALK P BLOOD ALKALINE PHOSPHATASE 
INCREASED
10-Jan-07 3-Feb-07 Resolved Moderate None Possible
11 96 12 Male Comb 20-Jan-07 RAISED LIVER ENZYME (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
26-Jan-07 23-Apr-07 Resolved Moderate None Possible
11 96 12 Male Comb 20-Jan-07 INJECTION SITE PAIN INJECTION SITE PAIN 26-Jan-07 23-Apr-07 Resolved Moderate None Possible
11 96 12 Male Comb 20-Jan-07 RAISED LIVER ENZYME (SGPT) ALANINE AMINOTRANSFERASE 
INCREASED
29-Jan-07 23-Apr-07 Resolved Moderate None Possible
11 97 19 Male Comb 20-Jan-07 RAISED ALK. PHOSPHATASE BLOOD ALKALINE PHOSPHATASE 
INCREASED
26-Jan-07 Ongoing Moderate None Possible
11 98 20 Male PM 24-Jan-07 RAISED TRANSAMINASE LEVEL (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
6-Feb-07 Ongoing Mild None Possible
11 98 20 Male PM 24-Jan-07 URINARY TRACT INFECTION URINARY TRACT INFECTION 8-Feb-07 15-Feb-07 Resolved Moderate None Not related
11 98 20 Male PM 24-Jan-07 RAISED TRANSAMINE LEVEL (SGPT) ALANINE AMINOTRANSFERASE 
INCREASED
25-Apr-07 26-Jul-07 Resolved Mild None Unlikely
11 100 36 Male PM 26-Jan-07 INJECTION SITE PAIN INJECTION SITE PAIN 5-Feb-07 Ongoing Mild None Possible
11 101 22 Male PM 3-Feb-07 RAISED ALK. PHOSPHATASE BLOOD ALKALINE PHOSPHATASE 
INCREASED
9-Feb-07 6-Nov-07 Resolved Mild None Possible
11 101 22 Male PM 3-Feb-07 INJECTION SITE PAIN INJECTION SITE PAIN 13-Feb-07 24-May-07 Resolved Mild None Possible
11 103 28 Male Comb 7-Feb-07 RAISED TRANSAMINASE LEVEL (SGOT 
SGPT)
TRANSAMINASES INCREASED 13-Feb-07 7-May-07 Resolved Mild None Possible
11 103 28 Male Comb 7-Feb-07 INJECTION SITE PAIN INJECTION SITE PAIN 16-Feb-07 7-May-07 Resolved Mild None Possible
11 104 13 Female PM 10-Feb-07 RAISED TRANSAMINASE LEVEL (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
16-Feb-07 20-Feb-07 Resolved Moderate None Possible
11 104 13 Female PM 10-Feb-07 RAISED ALK P BLOOD ALKALINE PHOSPHATASE 
INCREASED
16-Feb-07 3-Mar-07 Resolved Moderate None Possible
11 105 18 Male SSG 24-Feb-07 GRADE I PKDL VISCERAL LEISHMANIASIS 30-Apr-07 Ongoing Moderate None Possible
11 106 18 Male Comb 25-Feb-07 INJECTION SITE PAIN INJECTION SITE PAIN 6-Mar-07 29-Mar-07 Resolved Moderate None Possible
11 108 25 Male PM 2-Mar-07 VIVAX MALARIA MALARIA 23-Mar-07 25-Mar-07 Resolved Mild None Not related
11 109 19 Male SSG 3-Mar-07 ACUTE GASTRO ENTERITES GASTROENTERITIS 9-Mar-07 10-Mar-07 Resolved Mild None Unlikely
11 109 19 Male SSG 3-Mar-07 GIARDIASIS GIARDIASIS 28-Mar-07 2-Apr-07 Resolved Mild None Not related
11 109 19 Male SSG 3-Mar-07 ATYPICAL PNEUMONIA PNEUMONIA ATYPICAL  PRIMARY 26-Mar-07 2-Apr-07 Resolved Mild None Not related
11 109 19 Male SSG 3-Mar-07 HOOKWORM HOOKWORM INFECTION 28-Mar-07 2-Apr-07 Resolved Mild None Not related
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11 110 6 Female PM 3-Mar-07 RAISED TRANSAMINE (SGOT, SGPT) TRANSAMINASES INCREASED 29-May-07 Ongoing Moderate None Probable
11 110 6 Female PM 3-Mar-07 RAISED ALK P BLOOD ALKALINE PHOSPHATASE 
INCREASED
24-Mar-07 27-Aug-07 Resolved Mild None Possible
11 110 6 Female PM 3-Mar-07 RAISED SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
29-May-07 27-Aug-07 Resolved Moderate None Probable
11 110 6 Female PM 3-Mar-07 RAISED SGPT ALANINE AMINOTRANSFERASE 
INCREASED
29-May-07 27-Aug-07 Resolved Moderate None Probable
11 111 19 Male Comb 24-Mar-07 RAISED TRANSAMINASE LEVEL 
(SGOT/SGPT
TRANSAMINASES INCREASED 30-Mar-07 22-Jun-07 Resolved Mild None Possible
11 111 19 Male Comb 24-Mar-07 RAISED ALK P BLOOD ALKALINE PHOSPHATASE 
INCREASED
30-Mar-07 22-Jun-07 Resolved Moderate None Possible
11 112 28 Male Comb 24-Mar-07 RAISED ALK. PHO. BLOOD ALKALINE PHOSPHATASE 
INCREASED
30-Mar-07 30-Jul-07 Resolved Moderate None Possible
11 112 28 Male Comb 24-Mar-07 INJECTION SITE PAIN INJECTION SITE PAIN 30-Mar-07 2-May-07 Resolved Moderate None Possible
11 113 18 Male SSG 28-Mar-07 RAISED TRANSAMIN (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
3-Apr-07 29-Jun-07 Resolved Moderate None Possible
11 113 18 Male SSG 28-Mar-07 RAISED ALK. PHOS. BLOOD ALKALINE PHOSPHATASE 
INCREASED
3-Apr-07 Ongoing Moderate None Possible
11 113 18 Male SSG 28-Mar-07 TAENIASIS TAENIASIS 3-Apr-07 8-Apr-07 Resolved Mild None Not related
11 113 18 Male SSG 28-Mar-07 URTI UPPER RESPIRATORY TRACT 
INFECTION
16-Apr-07 1-Jun-07 Resolved Moderate None Not related
11 113 18 Male SSG 28-Mar-07 INJECTION SITE PAIN INJECTION SITE PAIN 20-Apr-07 Ongoing Moderate None Possible
11 114 25 Male SSG 30-Mar-07 RAISED TRANSAMINE (SGOT, SGPT) TRANSAMINASES INCREASED 5-Apr-07 Ongoing Mild None Possible
11 114 25 Male SSG 30-Mar-07 RAISED ALK.P BLOOD ALKALINE PHOSPHATASE 
INCREASED
5-Apr-07 5-Oct-07 Resolved Mild None Possible
11 114 25 Male SSG 30-Mar-07 RAISED TRANSAMINASE SGPT ALANINE AMINOTRANSFERASE 
INCREASED
5-Apr-07 2-Jul-07 Resolved Mild None Possible
11 114 25 Male SSG 30-Mar-07 RAISED TRANSAMINE SGOT - LEVEL ASPARTATE AMINOTRANSFERASE 
INCREASED
5-Apr-07 Ongoing Mild None Possible
11 115 12 Male Comb 31-Mar-07 ABDOMINAL CRAMP ABDOMINAL PAIN 2-Apr-07 6-Apr-07 Resolved Mild None Unlikely
11 115 12 Male Comb 31-Mar-07 INJECTION SITE PAIN INJECTION SITE PAIN 6-Apr-07 1-May-07 Resolved Moderate None Possible
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11 116 23 Male SSG 31-Mar-07 HERPES ZOSTER HERPES ZOSTER 26-Apr-07 8-May-07 Resolved Moderate None Not related
11 117 22 Male PM 4-Apr-07 URINARY TRACT INFECTION (UTI) URINARY TRACT INFECTION 14-Apr-07 23-Apr-07 Resolved Moderate None Not related
11 117 22 Male PM 4-Apr-07 PERIPHERAL NEUROPATHY NEUROPATHY PERIPHERAL 22-Apr-07 25-May-07 Resolved Mild None Probable
11 118 25 Male PM 19-Apr-07 RAISED TRANSAMINASE LEVEL 
SGOT/SGPT
TRANSAMINASES INCREASED 2-May-07 6-Jul-07 Resolved Mild None Possible
11 118 25 Male PM 19-Apr-07 INJECTION SITE PAIN INJECTION SITE PAIN 25-Apr-07 12-Jun-07 Resolved Mild None Possible
11 119 26 Male SSG 21-Apr-07 PAIN AT INJECTION SITE INJECTION SITE PAIN 3-May-07 15-May-07 Resolved Mild None Possible
11 120 17 Male Comb 21-Apr-07 INJECTION SITE PAIN INJECTION SITE PAIN 26-Apr-07 23-Jun-07 Resolved Moderate None Possible
11 122 20 Male SSG 21-Apr-07 RAISED ALK P BLOOD ALKALINE PHOSPHATASE 
INCREASED
27-Apr-07 Ongoing Moderate None Possible
11 122 20 Male SSG 21-Apr-07 PYOGENIC LYMPHADENITIS LYMPHADENITIS 4-May-07 20-May-07 Resolved Moderate None Not related
11 123 14 Male SSG 28-Apr-07 SWELLING OF LEFT FOREARM 
[CELLULITIS]
CELLULITIS 15-May-07 27-May-07 Resolved Moderate None Not related
11 124 30 Male SSG 21-May-07 RAISED TRANSAMINASE LEVEL [SGOT] ASPARTATE AMINOTRANSFERASE 
INCREASED
27-May-07 10-Jun-07 Resolved Mild None Possible
11 124 30 Male SSG 21-May-07 TRACE PEDAL AND PRETIBIA EDEMA 
(NUTRITIONAL EDEMA)
PERIPHERAL OEDEMA 1-Jun-07 10-Jun-07 Resolved Mild None Not related
11 124 30 Male SSG 21-May-07 CHICKENPOX VARICELLA 13-Jun-07 24-Jun-07 Resolved Moderate None Not related
11 126 23 Male Comb 28-May-07 RAISED TRANSAMINASE (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
6-Jun-07 10-Dec-07 Resolved Mild None Possible
11 126 23 Male Comb 28-May-07 INJECTION SITE PAIN INJECTION SITE PAIN 5-Jun-07 20-Jun-07 Resolved Moderate None Possible
11 126 23 Male Comb 28-May-07 URTI UPPER RESPIRATORY TRACT 
INFECTION
9-Jul-07 6-Aug-07 Resolved Mild None Not related
11 126 23 Male Comb 28-May-07 SGPT (RAISED) ALANINE AMINOTRANSFERASE 
INCREASED
9-Jul-07 10-Dec-07 Resolved Mild None Probable
11 126 23 Male Comb 28-May-07 DYSPEPSIA DYSPEPSIA 10-Nov-07 13-Mar-08 Resolved Mild None Not related
11 127 14 Female PM 28-May-07 RAISED TRANSAMINASE (SGOT & SGPT) TRANSAMINASES INCREASED 10-Jun-07 27-Aug-07 Resolved Mild None Possible
11 128 30 Male Comb 2-Jun-07 INJECTION SITE PAIN INJECTION SITE PAIN 7-Jun-07 25-Jun-07 Resolved Mild None Possible
11 128 30 Male Comb 2-Jun-07 RAISED (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
8-Jun-07 Ongoing Mild None Possible
LEAP 0104a Appendices
Page 555 of 756
Appendix 44: Listing of adverse events per patient
Cent No Pat No Age Sex Treatment Treatment start 
date
Adverse Event Preferred term AE start date AE end date Outcome Intensity Action 
taken
Related
11 128 30 Male Comb 2-Jun-07 URTI UPPER RESPIRATORY TRACT 
INFECTION
8-Jun-07 14-Aug-07 Resolved Mild None Not related
11 128 30 Male Comb 2-Jun-07 RAISED CREATININE BLOOD CREATININE INCREASED 15-Jun-07 19-Jul-07 Resolved Mild None Possible
11 129 31 Male PM 7-Jun-07 ALBUMINURIA (2+) ALBUMINURIA 13-Jun-07 20-Jun-07 Resolved Moderate None Possible
11 129 31 Male PM 7-Jun-07 INJECTION SITE PAIN INJECTION SITE PAIN 24-Jun-07 28-Jun-07 Resolved Mild None Possible
11 130 25 Male Comb 9-Jun-07 RAISED TRANSAMINASE [SGOT] ASPARTATE AMINOTRANSFERASE 
INCREASED
15-Jun-07 19-Nov-07 Resolved Mild None Possible
11 130 25 Male Comb 9-Jun-07 DYSPEPSIA DYSPEPSIA 14-Jun-07 17-Sep-07 Resolved Mild None Possible
11 132 20 Male SSG 16-Jun-07 ABDOMINAL CRAMP ABDOMINAL PAIN 22-Jun-07 27-Jun-07 Resolved Mild None Probable
11 132 20 Male SSG 16-Jun-07 MALARIA MALARIA 19-Nov-07 21-Nov-07 Resolved Moderate None Not related
11 133 20 Male Comb 4-Jul-07 INJECTION SITE PAIN INJECTION SITE PAIN 12-Jul-07 21-Jul-07 Resolved Mild None Possible
11 135 17 Male PM 13-Jul-07 INJECTION SITE PAIN INJECTION SITE PAIN 21-Jul-07 17-Aug-07 Resolved Mild None Possible
12 241 20 Male Comb 29-Jun-05 INJECTION SITE CELLULITIS INJECTION SITE CELLULITIS 12-Jul-05 16-Jul-05 Resolved Mild None Possible
12 242 7 Male SSG 29-Jun-05 URINARY TRACT INFECTION URINARY TRACT INFECTION 17-Jul-05 22-Jul-05 Resolved Mild None Not related
12 242 7 Male SSG 29-Jun-05 CONJECTIVITIS CONJUNCTIVITIS 23-Oct-05 29-Oct-05 Resolved Mild None Not related
12 242 7 Male SSG 29-Jun-05 SKIN LESION SKIN LESION 9-Feb-06 16-Feb-06 Resolved Mild None Unlikely
12 244 20 Male SSG 29-Jun-05 DYSENTRY DYSENTRY 8-Jul-05 12-Jul-05 Resolved Moderate None Unlikely
12 244 20 Male SSG 29-Jun-05 URINARY TRACT INFECTION URINARY TRACT INFECTION 19-Jul-05 24-Jul-05 Resolved Mild None Unlikely
12 244 20 Male SSG 29-Jun-05 FOOT ULCER SKIN ULCER 29-Oct-05 4-Nov-05 Resolved Mild None Not related
12 244 20 Male SSG 29-Jun-05 CONJUCTIVITIS CONJUNCTIVITIS 2-Apr-06 7-Apr-06 Resolved Mild None Not related
12 245 36 Male PM 20-Jul-05 FEVER PYREXIA 18-Nov-05 5-Dec-05 Resolved Moderate None Possible
12 245 36 Male PM 20-Jul-05 PNEUMONIA COUGH 28-Nov-05 4-Dec-05 Resolved Moderate None Not related
12 246 40 Male PM 4-Aug-05 ACUTE GASTRO ENTERITIES GASTROENTERITIS 21-Aug-05 23-Aug-05 Resolved Mild None Unlikely
12 246 40 Male PM 4-Aug-05 HEADACHE HEADACHE 24-Aug-05 25-Aug-05 Resolved Mild None Unlikely
12 246 40 Male PM 4-Aug-05 BACK PAIN BACK PAIN 24-Aug-05 25-Aug-05 Resolved Mild None Unlikely
12 246 40 Male PM 4-Aug-05 CHRONIC DIARRHEA DIARRHOEA 21-Aug-05 25-Nov-05 Resolved Moderate None Unlikely
12 246 40 Male PM 4-Aug-05 DYSENTRY DYSENTRY 4-Nov-05 11-Nov-05 Resolved Moderate None Not related
12 246 40 Male PM 4-Aug-05 TENIA CORPORIS BODY TINEA 4-Nov-05 22-Nov-05 Resolved Mild None Not related
12 247 11 Male PM 28-Sep-05 INJECTION SITE PAIN INJECTION SITE PAIN 10-Oct-05 13-Oct-05 Resolved Mild None Possible
12 247 11 Male PM 28-Sep-05 PNEUMONIA PNEUMONIA 19-Oct-05 22-Oct-05 Resolved Mild None Not related
12 249 16 Male Comb 25-Oct-05 PNEUMONIA PNEUMONIA 1-Mar-06 Ongoing Moderate None Not related
12 249 16 Male Comb 25-Oct-05 FEVER PYREXIA 1-Mar-06 8-Mar-06 Resolved Moderate None Not related
12 250 15 Male SSG 25-Oct-05 OTITIS MEDIA OTITIS MEDIA 17-Nov-05 22-Nov-05 Resolved Mild None Not related
12 251 18 Male Comb 29-Oct-05 OTITIS MEDIA OTITIS MEDIA 11-Nov-05 13-Nov-05 Resolved Moderate None Unlikely
12 251 18 Male Comb 29-Oct-05 PAIN ON INJECTION SITE INJECTION SITE PAIN 10-Nov-05 13-Nov-05 Resolved Mild None Possible
12 253 9 Male SSG 29-Oct-05 COMMON COLD NASOPHARYNGITIS 8-Nov-05 11-Nov-05 Resolved Mild None Not related
12 254 8 Male Comb 29-Oct-05 PAIN ON INJECTION SITE INJECTION SITE PAIN 11-Nov-05 12-Nov-05 Resolved Mild None Possible
12 261 13 Male Comb 3-Jan-06 INJECTION SITE CELLULITIS INJECTION SITE CELLULITIS 16-Jan-06 20-Jan-06 Resolved Moderate None Possible
12 261 13 Male Comb 3-Jan-06 AN AUDIOMETRIC SHIFT AUDIOGRAM ABNORMAL 22-Jul-06 Ongoing Moderate None Unlikely
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12 261 13 Male Comb 3-Jan-06 AUDIOMETRIC SHIFT FROM MODERATE 
TO SEVERE HEARING LOSS
DEAFNESS 19-Apr-06 Ongoing Moderate None Unlikely
12 264 9 Male Comb 15-Feb-06 INJECTION SITE CELLULITIS INJECTION SITE CELLULITIS 4-Mar-06 8-Mar-06 Resolved Mild None Probable
12 265 5 Female SSG 15-Feb-06 CHEILOSIS CHEILOSIS 25-Feb-06 2-Mar-06 Resolved Moderate None Unlikely
12 265 5 Female SSG 15-Feb-06 URINARY TRACT INFECTION URINARY TRACT INFECTION 28-Feb-06 4-Mar-06 Resolved Mild None Unlikely
12 265 5 Female SSG 15-Feb-06 HOSPITAL ACQUIRED PNEUMONIA PNEUMONIA 12-Mar-06 18-Mar-06 Resolved Moderate Drug 
interupt
Probable
12 265 5 Female SSG 15-Feb-06 THROMBOCYTOPENIA THROMBOCYTOPENIA 14-Mar-06 Ongoing Severe Drug Possible
12 268 28 Male PM 10-Mar-06 PAIN AT THE INJECTION SITE INJECTION SITE PAIN 23-Mar-06 23-Mar-06 Resolved Mild None Possible
12 280 5 Male SSG 21-Apr-06 RAISED LIVER FUNCTION TEST (SG0T) ASPARTATE AMINOTRANSFERASE 
INCREASED
27-Apr-06 25-Aug-06 Resolved Mild None Possible
12 280 5 Male SSG 21-Apr-06 RAISED LIVER FUNCTION TEST (SGPT) ALANINE AMINOTRANSFERASE 
INCREASED
27-Apr-06 Ongoing Mild None Possible
12 284 9 Female Comb 20-May-06 EPISTAXIS EPISTAXIS 9-Dec-06 10-Dec-06 Resolved Mild None Unlikely
12 297 29 Male SSG 12-Apr-07 RAISED SERUM AMYLASE LEVEL BLOOD AMYLASE INCREASED 18-Apr-07 Ongoing Moderate None Possible
12 301 25 Male SSG 5-Jun-07 RAISED SERUM AMYLASE BLOOD AMYLASE INCREASED 5-Jul-07 Ongoing Mild None Possible
12 303 25 Female PM 5-Jun-07 CONJUCTIVITIS CONJUNCTIVITIS 1-Oct-07 5-Oct-07 Resolved Mild None Not related
12 307 39 Male Comb 15-Jun-07 GASTRITIS GASTRITIS 22-Jun-07 26-Jun-07 Resolved Mild None Unlikely
12 307 39 Male Comb 15-Jun-07 RAISED SERUM AMYLASE TO 245 BLOOD AMYLASE INCREASED 28-Jun-07 Ongoing Mild None Possible
12 307 39 Male Comb 15-Jun-07 RIGHT SHOULDER PAIN MUSCULOSKELETAL PAIN 1-Oct-07 4-Oct-07 Resolved Mild None Unlikely
12 307 39 Male Comb 15-Jun-07 RAISED SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
1-Oct-07 Ongoing Mild None Unlikely
12 307 39 Male Comb 15-Jun-07 RAISED SGPT ALANINE AMINOTRANSFERASE 
INCREASED
1-Oct-07 Ongoing Mild None Unlikely
12 307 39 Male Comb 15-Jun-07 RAISED SERUM CREATININE BLOOD CREATININE INCREASED 26-Dec-07 Ongoing Mild None Unlikely
12 308 31 Male PM 15-Jun-07 GASTRITIS GASTRITIS 18-Jun-07 22-Jun-07 Resolved Mild None Unlikely
12 308 31 Male PM 15-Jun-07 PNEUMONIA PNEUMONIA 10-Sep-07 20-Oct-07 Resolved Mild None Unlikely
12 308 31 Male PM 15-Jun-07 CHRONIC SINUSITIS CHRONIC SINUSITIS 26-Nov-07 31-Dec-07 Resolved Mild None Not related
12 310 13 Female SSG 16-Jun-07 INJECTION SITE PAIN INJECTION SITE PAIN 6-Jul-07 16-Jul-07 Resolved Mild None Possible
12 312 20 Female Comb 12-Jul-07 RAISED SERUM AMYLASE BLOOD AMYLASE INCREASED 18-Jul-07 Ongoing Mild None Possible
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12 312 20 Female Comb 12-Jul-07 RAISED SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
18-Jul-07 25-Jul-07 Resolved Mild None Unlikely
12 313 25 Male PM 2-Aug-07 RAISED SGOT AND SGPT TRANSAMINASES INCREASED 15-Aug-07 23-Aug-07 Resolved Mild None Possible
12 313 25 Male PM 2-Aug-07 RAISED LIVER FUNCTION TEST(SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
22-Nov-07 Ongoing Mild None Not related
12 313 25 Male PM 2-Aug-07 RAISED SERUM LEVEL OF SGPT ALANINE AMINOTRANSFERASE 
INCREASED
22-Nov-07 Ongoing Mild None Unlikely
12 313 25 Male PM 2-Aug-07 AUDIOMETRIC SHIFT AUDIOGRAM ABNORMAL 21-Feb-08 Ongoing Mild None Unlikely
12 314 18 Male SSG 7-Aug-07 RAISED SERUM AMYLASE BLOOD AMYLASE INCREASED 13-Aug-07 Ongoing Moderate None Possible
12 315 10 Male Comb 29-Aug-07 RAISED SGPT ALANINE AMINOTRANSFERASE 
INCREASED
11-Aug-08 Ongoing Mild None Not related
12 316 36 Male SSG 29-Aug-07 RAISED SERUM CREATININE BLOOD CREATININE INCREASED 28-Dec-07 Ongoing Mild None Unlikely
12 317 4 Male SSG 29-Aug-07 RAISED SERUM LEVEL OF SG0T ASPARTATE AMINOTRANSFERASE 
INCREASED
4-Sep-07 22-Apr-08 Resolved Mild None Possible
12 317 4 Male SSG 29-Aug-07 RAISED SERUM LEVEL OF SGPT ALANINE AMINOTRANSFERASE 
INCREASED
4-Sep-07 Ongoing Mild None Possible
12 319 8 Male Comb 28-Aug-07 RAISED LIVER FUNCTION TEST (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
11-Sep-07 Ongoing Mild None Unlikely
12 320 8 Male Comb 6-Sep-07 RAISED SERUM SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
19-Mar-08 Ongoing Mild None Not related
12 321 8 Male Comb 6-Sep-07 INJECTION SITE PAIN INJECTION SITE PAIN 12-Sep-07 21-Sep-07 Resolved Mild None Possible
12 321 8 Male Comb 6-Sep-07 GIARDIASIS GIARDIASIS 19-Sep-07 24-Sep-07 Resolved Mild None Not related
12 322 16 Female PM 13-Sep-07 GIARDIASIS GIARDIASIS 25-Sep-07 1-Oct-07 Resolved Mild None Unlikely
12 322 16 Female PM 13-Sep-07 AMOEBIASIS AMOEBIASIS 25-Sep-07 1-Oct-07 Resolved Mild None Unlikely
12 322 16 Female PM 13-Sep-07 RAISED SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
26-Sep-07 4-Oct-07 Resolved Mild None Unlikely
LEAP 0104a Appendices
Page 558 of 756
Appendix 44: Listing of adverse events per patient
Cent No Pat No Age Sex Treatment Treatment start 
date
Adverse Event Preferred term AE start date AE end date Outcome Intensity Action 
taken
Related
12 322 16 Female PM 13-Sep-07 RAISED LIVER FUNCTION TEST (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
16-Apr-08 Ongoing Mild None Not related
12 322 16 Female PM 13-Sep-07 RAISED SGPT ALANINE AMINOTRANSFERASE 
INCREASED
16-Apr-08 Ongoing Mild None Possible
12 323 32 Male SSG 20-Sep-07 INJECTION SITE PAIN INJECTION SITE PAIN 3-Oct-07 5-Oct-07 Resolved Mild None Probable
12 323 32 Male SSG 20-Sep-07 RAISED SGPT ALANINE AMINOTRANSFERASE 
INCREASED
26-Sep-07 Ongoing Mild None Possible
12 323 32 Male SSG 20-Sep-07 RAISED SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
3-Oct-07 20-Oct-07 Resolved Mild None Possible
12 323 32 Male SSG 20-Sep-07 RAISED LIVER FUNCTION TEST (SGPT) ALANINE AMINOTRANSFERASE 
INCREASED
16-Apr-08 Ongoing Mild None Not related
12 323 32 Male SSG 20-Sep-07 RAISED SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
16-Apr-08 Ongoing Mild None Possible
12 324 30 Male SSG 20-Sep-07 RAISED SGOT LEVEL ASPARTATE AMINOTRANSFERASE 
INCREASED
26-Sep-07 20-Oct-07 Resolved Mild None Possible
12 324 30 Male SSG 20-Sep-07 RAISED SERUM AMYLASE BLOOD AMYLASE INCREASED 26-Sep-07 Ongoing Mild None Possible
12 324 30 Male SSG 20-Sep-07 AMOEBIASIS AMOEBIASIS 4-Oct-07 11-Oct-07 Resolved Mild None Not related
12 324 30 Male SSG 20-Sep-07 RAISED SERUM AMYLASE BLOOD AMYLASE INCREASED 16-Apr-08 Ongoing Mild None Not related
12 325 22 Male PM 27-Sep-07 RAISED LIVER FUNCTION TEST (SG0T) ASPARTATE AMINOTRANSFERASE 
INCREASED
3-Oct-07 Ongoing Mild None Possible
12 325 22 Male PM 27-Sep-07 RAISED LIVER FUNCTION TEST (SGPT) ALANINE AMINOTRANSFERASE 
INCREASED
3-Oct-07 Ongoing Mild None Possible
12 325 22 Male PM 27-Sep-07 RAISED LIVER FUNCTION TEST (SGPT) ALANINE AMINOTRANSFERASE 
INCREASED
16-Apr-08 Ongoing Mild None Not related
12 325 22 Male PM 27-Sep-07 RAISED SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
16-Apr-08 Ongoing Mild None Possible
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12 326 25 Male PM 3-Oct-07 ASCARIASIS ASCARIASIS 9-Oct-07 11-Oct-07 Resolved Mild None Not related
12 326 25 Male PM 3-Oct-07 OTITIS MEDIA OTITIS MEDIA 13-Oct-07 17-Oct-07 Resolved Moderate None Unlikely
12 326 25 Male PM 3-Oct-07 RAISED SERUM CREATININ BLOOD CREATININE INCREASED 24-Oct-07 29-Oct-07 Resolved Mild None Possible
12 326 25 Male PM 3-Oct-07 AUDIOMETRIC SHIFT OF THE RIGHT EAR AUDIOGRAM ABNORMAL 16-Oct-07 Ongoing Mild None Possible
12 327 14 Male Comb 3-Oct-07 RAISED SGOT LEVEL ASPARTATE AMINOTRANSFERASE 
INCREASED
9-Oct-07 Ongoing Mild None Possible
12 328 14 Male PM 5-Oct-07 INCREASED LIVER FUNTION TEST (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
11-Oct-07 Ongoing Mild None Possible
12 328 14 Male PM 5-Oct-07 INCREASED LIVER FUNTION TEST (SGPT) ALANINE AMINOTRANSFERASE 
INCREASED
11-Oct-07 Ongoing Mild None Possible
12 329 6 Male SSG 10-Oct-07 RAISED SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
16-Oct-07 Ongoing Mild None Possible
12 329 6 Male SSG 10-Oct-07 OTITIS MEDIA OTITIS MEDIA 18-Oct-07 23-Oct-07 Resolved Mild None Not related
12 330 11 Male PM 10-Oct-07 RAISED LIVER FUNCTION TES (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
16-Oct-07 Ongoing Mild None Unlikely
12 330 11 Male PM 10-Oct-07 RAISED LIVER FUNCTION TES (SGPT) ALANINE AMINOTRANSFERASE 
INCREASED
23-Oct-07 31-Oct-07 Resolved Mild None Unlikely
23 361 8 Male Comb 20-Jan-05 MICROSCOPIC HAEMATURIA HAEMATURIA 27-Jan-05 2-Feb-05 Resolved Mild None Not related
23 361 8 Male Comb 20-Jan-05 INCREASED URINE WBC WHITE BLOOD CELLS URINE POSITIVE 27-Jan-05 2-Feb-05 Resolved Mild None Not related
23 362 14 Male PM 20-Jan-05 PNEUMONIA PNEUMONIA 26-Jan-05 1-Feb-05 Resolved Mild None Not related
23 363 5 Female PM 20-Jan-05 FEVER PYREXIA 22-Jan-05 25-Jan-05 Resolved Mild None Not related
23 363 5 Female PM 20-Jan-05 VOMITING VOMITING 23-Jan-05 23-Jan-05 Resolved Mild None Not related
23 363 5 Female PM 20-Jan-05 FEVER PYREXIA 27-Jan-05 27-Jan-05 Resolved Mild None Unlikely
23 363 5 Female PM 20-Jan-05 ELEVATED ALKALINE PHOSPHATASE BLOOD ALKALINE PHOSPHATASE 
INCREASED
26-Jan-05 Ongoing Mild None Probable
23 363 5 Female PM 20-Jan-05 VOMITING VOMITING 8-Feb-05 8-Feb-05 Resolved Mild None Possible
23 364 12 Female Comb 20-Jan-05 EPISTAXIS (NOSE BLEEDING) EPISTAXIS 4-Feb-05 4-Feb-05 Resolved Mild None Probable
23 365 15 Male SSG 20-Jan-05 RAISED CREATININE BLOOD CREATININE INCREASED 2-Feb-05 20-May-05 Resolved Moderate None Probable
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23 366 12 Male Comb 1-Feb-05 RAISED SGOT/AST ASPARTATE AMINOTRANSFERASE 
INCREASED
7-Feb-05 14-Feb-05 Resolved Mild None Probable
23 366 12 Male Comb 1-Feb-05 BILATERAL CONJUNCTIVITIS CONJUNCTIVITIS 4-Aug-05 Ongoing Mild None Not related
23 367 20 Male SSG 1-Feb-05 EPISTAXIS EPISTAXIS 3-Feb-05 3-Feb-05 Resolved Mild None Not related
23 367 20 Male SSG 1-Feb-05 PNEUMONIA PNEUMONIA 26-Feb-05 Ongoing Mild None Not related
23 367 20 Male SSG 1-Feb-05 EPISTAXIS EPISTAXIS 1-Mar-05 1-Mar-05 Resolved Mild None Not related
23 367 20 Male SSG 1-Feb-05 HERPETIC MOUTH ULCER MOUTH ULCERATION 2-Mar-05 4-Mar-05 Resolved Mild None Not related
23 367 20 Male SSG 1-Feb-05 PNEUMONIA PNEUMONIA 9-Feb-05 14-Feb-05 Resolved Mild None Not related
23 367 20 Male SSG 1-Feb-05 EPISTAXIS EPISTAXIS 10-Feb-05 10-Feb-05 Resolved Mild None Not related
23 367 20 Male SSG 1-Feb-05 OTITIS MEDIA OTITIS MEDIA 8-Jun-05 13-Jun-05 Resolved Mild None Not related
23 367 20 Male SSG 1-Feb-05 ALLERGIC CONJUCTIVITIS CONJUNCTIVITIS ALLERGIC 9-Mar-05 14-Mar-05 Resolved Mild None Not related
23 368 16 Female PM 1-Feb-05 RAISED CREATININE BLOOD CREATININE INCREASED 22-Feb-05 26-May-05 Resolved Mild None Probable
23 368 16 Female PM 1-Feb-05 URINARY TRACT INFECTION URINARY TRACT INFECTION 26-May-05 Ongoing Mild None Probable
23 368 16 Female PM 1-Feb-05 RIGHT OTITIS MEDIA OTITIS MEDIA 24-May-05 31-May-05 Resolved Moderate None Not related
23 370 8 Male SSG 4-Feb-05 A FALL WITH BRUISES ON HEAD CHEST 
AND LIPS
CONTUSION 1-Jun-05 23-Sep-05 Resolved Mild None Not related
23 370 8 Male SSG 4-Feb-05 BRADY CARDIA (SINUS) BRADYCARDIA 8-Jun-05 23-Sep-05 Resolved Mild None Possible
23 371 14 Female PM 4-Feb-05 ABDOMINAL PAIN ABDOMINAL PAIN 4-Feb-05 9-Feb-05 Resolved Moderate None Not related
23 371 14 Female PM 4-Feb-05 PERITONITIS PERITONITIS 6-Feb-05 13-Feb-05 Resolved Moderate None Not related
23 371 14 Female PM 4-Feb-05 ASCITES ASCITES 5-Feb-05 19-Feb-05 Resolved Mild None Not related
23 371 14 Female PM 4-Feb-05 ASCARIS ASCARIASIS 4-Feb-05 10-Feb-05 Resolved Mild None Not related
23 371 14 Female PM 4-Feb-05 UPPER RESPIRATORY TRACT INFECTION UPPER RESPIRATORY TRACT 
INFECTION
20-Feb-05 25-Feb-05 Resolved Mild None Not related
23 371 14 Female PM 4-Feb-05 URINARY TRACT INFECTION URINARY TRACT INFECTION 21-Feb-05 30-Jan-06 Resolved Moderate None Not related
23 371 14 Female PM 4-Feb-05 MICROSCOPIC HAEMATURIA HAEMATURIA 26-May-05 Ongoing Mild None Not related
23 371 14 Female PM 4-Feb-05 URTI UPPER RESPIRATORY TRACT 
INFECTION
5-Sep-05 14-Sep-05 Resolved Mild None Not related
23 372 25 Male PM 11-Feb-05 RAISED CREATININE BLOOD CREATININE INCREASED 24-Feb-05 4-Mar-05 Resolved Mild None Possible
23 372 25 Male PM 11-Feb-05 BRADYCARDIA BRADYCARDIA 6-Jun-05 Ongoing Moderate None Probable
23 373 21 Male SSG 18-Feb-05 FACIAL RASH (ACNE) ACNE 9-Mar-05 6-Jul-05 Resolved Mild None Unlikely
23 373 21 Male SSG 18-Feb-05 BRADY CARDIA BRADYCARDIA 6-Jul-05 Ongoing Moderate None Probable
23 374 24 Female SSG 24-Feb-05 URINARY TRACT INFECTION URINARY TRACT INFECTION 7-Mar-05 13-Mar-05 Resolved Mild None Unlikely
23 374 24 Female SSG 24-Feb-05 BLEEDING GUMS GINGIVAL BLEEDING 12-Mar-05 15-Mar-05 Resolved Mild None Unlikely
23 374 24 Female SSG 24-Feb-05 NECK PAINS NECK PAIN 17-Mar-05 21-Mar-05 Resolved Mild None Not related
23 375 12 Male Comb 25-Feb-05 RIGHT EYE CONJUNCTIVITIS CONJUNCTIVITIS 11-Mar-05 14-Mar-05 Resolved Mild None Unlikely
23 376 16 Female SSG 1-Mar-05 FEVER PYREXIA 7-Mar-05 8-Mar-05 Resolved Mild None Probable
23 376 16 Female SSG 1-Mar-05 HEADACHE HEADACHE 7-Mar-05 8-Mar-05 Resolved Mild None Probable
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23 376 16 Female SSG 1-Mar-05 JOINT ACHE ARTHRALGIA 7-Mar-05 8-Mar-05 Resolved Mild None Probable
23 376 16 Female SSG 1-Mar-05 CONJUCTIVITIS RIGHT EYE CONJUNCTIVITIS 28-Mar-05 31-Mar-05 Resolved Mild None Not related
23 377 40 Female Comb 9-Mar-05 ELEVATED AST ASPARTATE AMINOTRANSFERASE 
INCREASED
15-Mar-05 30-Mar-05 Resolved Severe drug 
stopped
Probable
23 378 7 Male Comb 9-Mar-05 VOMITING VOMITING 10-Mar-05 10-Mar-05 Resolved Mild None Unlikely
23 378 7 Male Comb 9-Mar-05 URTI UPPER RESPIRATORY TRACT 
INFECTION
26-Mar-05 30-Mar-05 Resolved Mild None Not related
23 378 7 Male Comb 9-Mar-05 BIL PNEUMONIA PNEUMONIA 6-Jul-05 11-Jul-05 Resolved Moderate None Unlikely
23 379 5 Male PM 10-Mar-05 COUGH COUGH 28-Mar-05 28-Mar-05 Resolved Mild None Not related
23 379 5 Male PM 10-Mar-05 BRUISE LEFT THIGH CONTUSION 30-Mar-05 30-Mar-05 Resolved Mild None Not related
23 379 5 Male PM 10-Mar-05 SEPTIC WOUND LT FOOT WOUND SEPSIS 30-Sep-05 Ongoing Mild None Not related
23 381 13 Male PM 15-Mar-05 RASH ON ARMS AND TRUNK RASH 28-Mar-05 12-Jul-05 Resolved Mild None Possible
23 381 13 Male PM 15-Mar-05 PNEUMONIA PNEUMONIA 12-Jul-05 21-Jul-05 Resolved Moderate None Not related
23 381 13 Male PM 15-Mar-05 MICROSCOPIC HAEMATURIA HAEMATURIA 12-Jul-05 16-Nov-05 Resolved Mild None Unlikely
23 382 15 Male Comb 18-Mar-05 UPPER RESPIRATORY TRACT INFECTION UPPER RESPIRATORY TRACT 
INFECTION
21-Mar-05 31-Mar-05 Resolved Mild None Not related
23 382 15 Male Comb 18-Mar-05 ELEVATED SERUM ALKALINE 
PHOSPHATASE
BLOOD ALKALINE PHOSPHATASE 
INCREASED
31-Mar-05 12-Jul-05 Resolved Moderate None Possible
23 382 15 Male Comb 18-Mar-05 CELLULITIS RT BUTTOCK CELLULITIS 2-Apr-05 Ongoing Mild None Probable
23 383 30 Male PM 5-Apr-05 GLUTEAL TENDERNESS TENDERNESS 18-Apr-05 25-Apr-05 Resolved Moderate None Possible
23 383 30 Male PM 5-Apr-05 HAEMATURIA HAEMATURIA 29-Sep-05 24-Oct-05 Resolved Mild None Probable
23 384 13 Male SSG 5-Apr-05 MACULO-PAPULA RASH - FACE - UPPER RASH MACULO-PAPULAR 11-Apr-05 16-Apr-05 Resolved Mild None Possible
23 384 13 Male SSG 5-Apr-05 FRACTURE OF LEFT RADIUS RADIUS FRACTURE 27-Apr-05 28-Sep-05 Resolved Moderate None Not related
23 384 13 Male SSG 5-Apr-05 PNEUMONIA PNEUMONIA 17-Nov-05 24-Nov-05 Resolved Mild None Not related
23 385 14 Male SSG 7-Apr-05 PNEUMONIA PNEUMONIA 15-Apr-05 21-Apr-05 Resolved Mild None Not related
23 385 14 Male SSG 7-Apr-05 ITCHY SKIN OVER FOREARMS PRURITUS 13-Apr-05 13-Apr-05 Resolved Mild None Probable
23 386 13 Female Comb 19-Apr-05 RAISED LIVER ENZYMES HEPATIC ENZYME INCREASED 25-Apr-05 4-May-05 Resolved Moderate Drug Possible
23 386 13 Female Comb 19-Apr-05 RAISED ALKALINE PHOSPHATASE BLOOD ALKALINE PHOSPHATASE 
INCREASED
19-Aug-05 11-Nov-05 Resolved Moderate None Probable
23 387 15 Female Comb 19-Apr-05 ELEVATED ALKALINE PHOSPHATASE BLOOD ALKALINE PHOSPHATASE 
INCREASED
10-Aug-05 Ongoing Moderate None Probable
23 388 15 Male PM 19-Apr-05 RAISED ALKALINE PHOSPHATASE BLOOD ALKALINE PHOSPHATASE 
INCREASED
28-Sep-05 2-Dec-05 Resolved Mild None Not related
23 391 12 Female Comb 22-Apr-05 ELEVATED SGOT ASPARTATE AMINOTRANSFERASE 
INCREASED
28-Apr-05 5-May-05 Resolved Mild None Probable
23 392 7 Male Comb 22-Apr-05 PNEUMONIA PNEUMONIA 24-Apr-05 29-Apr-05 Resolved Mild None Unlikely
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23 392 7 Male Comb 22-Apr-05 RAISED LIVER ENZYMES (SGOT) ASPARTATE AMINOTRANSFERASE 
INCREASED
28-Apr-05 4-May-05 Resolved Moderate Drug 
interupt
Probable
23 392 7 Male Comb 22-Apr-05 BRUISES ON BOTH LEGS CONTUSION 22-Jul-05 29-Sep-05 Resolved Mild None Not related
23 393 12 Male SSG 22-Apr-05 FACIAL AND UPPER LIMBS RASH RASH 3-May-05 19-May-05 Resolved Mild None Possible
23 394 9 Male PM 26-Apr-05 ABDOMINAL PAIN ABDOMINAL PAIN 30-Apr-05 2-May-05 Resolved Mild None Probable
23 394 9 Male PM 26-Apr-05 LUMBAR PAIN BACK PAIN 1-May-05 1-May-05 Resolved Mild None Not related
23 394 9 Male PM 26-Apr-05 EOSINOPHILIA EOSINOPHILIA 19-Aug-05 Ongoing Moderate None Not related
23 394 9 Male PM 26-Apr-05 ENTAMEBA HISTOLYTICA AMOEBIC DYSENTERY 16-Nov-05 Ongoing Mild None Not related
23 394 9 Male PM 26-Apr-05 MICROSCOPIC HAEMATURIA HAEMATURIA 16-Nov-05 Ongoing Mild None Unlikely
23 394 9 Male PM 26-Apr-05 LEUKOCYTOSIS LEUKOCYTOSIS 16-Nov-05 Ongoing Moderate None Unlikely
23 395 42 Male PM 29-Apr-05 HEADACHE HEADACHE 15-May-05 18-May-05 Resolved Moderate None Unlikely
23 395 42 Male PM 29-Apr-05 FEVER PYREXIA 15-May-05 18-May-05 Resolved Moderate None Unlikely
23 396 16 Male SSG 13-May-05 ACUTE OTITIS MEDIA - LEFT EAR OTITIS MEDIA ACUTE 20-May-05 25-May-05 Resolved Mild None Not related
23 399 6 Male PM 18-May-05 CONJUCTIVITIS LT EYE CONJUNCTIVITIS 14-Oct-05 14-Dec-05 Resolved Mild None Not related
23 399 6 Male PM 18-May-05 WOUND RT BIG TOE LIMB INJURY 14-Oct-05 14-Dec-05 Resolved Mild None Not related
23 400 6 Female PM 3-Jun-05 FEVER PYREXIA 20-Jun-05 20-Jun-05 Resolved Mild None Not related
23 401 40 Male Comb 3-Jun-05 MALAISE MALAISE 20-Dec-05 Ongoing Moderate None Unlikely
23 403 22 Male SSG 4-Jun-05 HEADACHE HEADACHE 5-Jun-05 5-Jun-05 Resolved Mild None Not related
23 403 22 Male SSG 4-Jun-05 ABDOMINAL PAINS ABDOMINAL PAIN 7-Jun-05 7-Jun-05 Resolved Mild None Not related
23 403 22 Male SSG 4-Jun-05 GINGIVITIS GINGIVITIS 8-Jun-05 12-Jul-05 Resolved Moderate None Not related
23 403 22 Male SSG 4-Jun-05 EPISTAXIS EPISTAXIS 21-Jun-05 2-Jul-05 Resolved Moderate None Possible
23 403 22 Male SSG 4-Jun-05 PAPULAR SKIN RASH (GENERALIZED) RASH PAPULAR 18-Jun-05 5-Jul-05 Resolved Moderate None Possible
23 403 22 Male SSG 4-Jun-05 THROMBOCYTOPEANIA THROMBOCYTOPENIA 12-Jan-06 Ongoing Moderate None Not related
23 404 16 Male SSG 4-Jun-05 FACIAL RASH RASH 15-Jun-05 26-Jun-05 Resolved Mild None Possible
23 404 16 Male SSG 4-Jun-05 ELEVATED ALT ALANINE AMINOTRANSFERASE 
INCREASED
17-Jun-05 24-Jun-05 Resolved Mild None Possible
23 405 16 Male PM 10-Jun-05 RAISED ALKALINE PHOSPHATASE BLOOD ALKALINE PHOSPHATASE 
INCREASED
29-Sep-05 Ongoing Moderate None Probable
34 453 4 Male PM 18-Nov-04 MALARIA MALARIA 21-Nov-04 27-Nov-04 Resolved Moderate None Not related
34 454 5 Female Comb 21-Nov-04 PKDL I VISCERAL LEISHMANIASIS 8-Apr-05 Ongoing Mild None Probable
34 455 11 Male PM 19-Nov-04 MALARIA MALARIA 25-Nov-04 4-Dec-04 Resolved Moderate None Not related
34 456 8 Female SSG 19-Nov-04 PKDL GRAD I VISCERAL LEISHMANIASIS 30-Nov-04 19-Dec-04 Resolved Mild None Probable
34 458 12 Female PM 20-Nov-04 MALARIA MALARIA 26-Nov-04 28-Nov-04 Resolved Moderate None Not related
34 459 9 Female Comb 20-Nov-04 PKDL GRAD I WITH MUCOSAL (LIP) 
INVOLVEMENT
VISCERAL LEISHMANIASIS 1-May-05 Ongoing Moderate None Probable
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34 462 4 Female SSG 25-Nov-04 PKDL II VISCERAL LEISHMANIASIS 7-Apr-05 Ongoing Mild None Probable
34 462 4 Female SSG 25-Nov-04 COUGH (URTI?) UPPER RESPIRATORY TRACT 7-May-05 Ongoing Mild None Not related
34 462 4 Female SSG 25-Nov-04 FEVER PYREXIA 25-May-05 7-Jun-05 Resolved Mild None Not related
34 462 4 Female SSG 25-Nov-04 APPETITE LOSS ANOREXIA 25-May-05 7-Jun-05 Resolved Mild Not related
34 463 4 Male Comb 27-Nov-04 CONJUNCTIVITIS CONJUNCTIVITIS 27-Nov-04 29-Nov-04 Resolved Mild None Not related
34 463 4 Male Comb 27-Nov-04 PKDL III (MILD) VISCERAL LEISHMANIASIS 16-Mar-05 Ongoing Mild None Probable
34 464 22 Male SSG 27-Nov-04 COMMON COLD NASOPHARYNGITIS 13-Dec-04 19-Dec-04 Resolved Mild None Not related
34 465 25 Female SSG 29-Nov-04 COMMON COLD NASOPHARYNGITIS 20-Dec-04 21-Dec-04 Resolved Mild None Not related
34 465 25 Female SSG 29-Nov-04 CONJUNCTIVITIS CONJUNCTIVITIS 25-Dec-04 28-Dec-04 Resolved Mild None Not related
34 467 14 Male PM 29-Nov-04 MALARIA MALARIA 8-Dec-04 10-Dec-04 Resolved Moderate None Not related
34 467 14 Male PM 29-Nov-04 PKDL I VISCERAL LEISHMANIASIS 12-Jan-05 Ongoing Mild None Probable
34 469 11 Female SSG 29-Nov-04 MALARIA MALARIA 9-Dec-04 11-Dec-04 Resolved Moderate None Not related
34 469 11 Female SSG 29-Nov-04 COMMON COLD NASOPHARYNGITIS 13-Dec-04 14-Dec-04 Resolved Mild None Not related
34 469 11 Female SSG 29-Nov-04 PKDL I VISCERAL LEISHMANIASIS 1-Feb-05 Resolved Mild None Probable
34 469 11 Female SSG 29-Nov-04 URTI UPPER RESPIRATORY TRACT 
INFECTION
25-Feb-05 Resolved Mild None Not related
34 470 4 Female Comb 29-Nov-04 URTI UPPER RESPIRATORY TRACT 
INFECTION
5-Jun-05 Ongoing Mild None Not related
34 471 13 Male PM 29-Nov-04 MALARIA MALARIA 5-Dec-04 7-Dec-04 Resolved Moderate None Not related
34 477 8 Female SSG 6-Dec-04 MALARIA MALARIA 26-Dec-04 28-Dec-04 Resolved Moderate None Not related
34 477 8 Female SSG 6-Dec-04 MALARIA MALARIA 30-May-05 Ongoing Mild None Not related
34 478 5 Female Comb 7-Dec-04 REPEATED EPISODES OF FEVER AT 
NIGHT
PYREXIA 15-Mar-05 Resolved Mild None Unlikely
34 482 18 Male Comb 10-Dec-04 MALARIA MALARIA 14-Mar-05 16-Mar-05 Resolved Mild None Not related
34 482 18 Male Comb 10-Dec-04 ACNE ACNE 17-Mar-05 Ongoing Mild None Not related
34 483 24 Male PM 10-Dec-04 PNEUMONIA PNEUMONIA 13-Dec-04 19-Dec-04 Resolved Moderate None Not related
34 483 24 Male PM 10-Dec-04 JOINT PAIN ARTHRALGIA 27-Dec-04 29-Dec-04 Resolved Mild None Unlikely
34 485 5 Female Comb 12-Dec-04 MALARIA MALARIA 1-May-05 3-May-05 Resolved Mild None Not related
34 487 12 Male SSG 13-Dec-04 MALARIA MALARIA 2-Jan-05 4-Jan-05 Resolved Moderate None Not related
34 487 12 Male SSG 13-Dec-04 HEADACHE HEADACHE 1-Apr-05 2-Apr-05 Resolved Mild None Not related
34 489 11 Male SSG 16-Dec-04 RIGHT PERICULOS OEDEMALOUS 
PAINFUL SWELLING
SWELLING 27-Dec-04 28-Dec-04 Resolved Mild None Not related
34 492 39 Male PM 19-Dec-04 BLOODY DIARHEA PROBABLY DYSENTRY DYSENTRY 30-Mar-05 11-Apr-06 Resolved Moderate None Not related
34 493 12 Female SSG 17-Dec-04 HYPOGLYCEMIA HYPOGLYCAEMIA 17-Dec-04 17-Dec-04 Resolved Moderate None Not related
34 493 12 Female SSG 17-Dec-04 MALARIA MALARIA 1-Jan-05 3-Jan-05 Resolved Moderate None Not related
34 493 12 Female SSG 17-Dec-04 PKDL I WITH OCULAR + ORAL 
INVOLVEMENT
VISCERAL LEISHMANIASIS 12-Mar-05 18-May-05 Resolved Moderate None Probable
34 494 30 Male Comb 17-Dec-04 CONJUNCTIVITIS CONJUNCTIVITIS 3-Jun-05 Ongoing Mild None Not related
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34 495 6 Female SSG 18-Dec-04 ALLERGIC REACTION (INSECT BITE?) ALLERGY TO ARTHROPOD BITE 24-Dec-04 25-Dec-04 Resolved Mild None Not related
34 495 6 Female SSG 18-Dec-04 COMMON COLD NASOPHARYNGITIS 1-Mar-05 2-Mar-05 Resolved Mild None Not related
34 495 6 Female SSG 18-Dec-04 PKDL I VISCERAL LEISHMANIASIS 17-Feb-05 1-Mar-05 Resolved Mild None Probable
34 496 35 Male SSG 19-Dec-04 BURNING FEET BURNING SENSATION 18-Jan-05 1-Apr-05 Resolved Mild None Unlikely
34 498 10 Female SSG 21-Dec-04 PNEUMONIA PNEUMONIA 18-Jan-05 20-Jan-05 Resolved Moderate None Not related
34 498 10 Female SSG 21-Dec-04 PKDL II VISCERAL LEISHMANIASIS 6-Feb-05 Ongoing Mild None Probable
34 498 10 Female SSG 21-Dec-04 COMMON COLD NASOPHARYNGITIS 4-Feb-05 6-Feb-05 Resolved Mild None Not related
34 499 12 Male Comb 21-Dec-04 MUCOSAL LESIONS IN THE MOUTH ORAL SOFT TISSUE DISORDER 30-Dec-04 Ongoing Mild None Unlikely
34 499 12 Male Comb 21-Dec-04 CUT WOUND RIGHT FOOT SKIN LACERATION 5-Jun-05 6-Jun-05 Resolved Mild None Not related
34 501 9 Male Comb 22-Dec-04 TRAUMA LEFT KNEE WITH TWO 
SUPERFICIAL WOUNDS
SKIN INJURY 7-Jun-05 Ongoing Mild None
34 505 40 Male SSG 28-Dec-04 URINARY TRACT INFECTION URINARY TRACT INFECTION 3-Jan-05 10-Jan-05 Resolved Mild None Not related
34 507 6 Male SSG 31-Dec-04 ABDOMINAL DISTENSION OF UNKNOWN 
ORIGIN
ABDOMINAL DISTENSION 13-Jan-05 15-Jan-05 Resolved Mild None Unlikely
34 507 6 Male SSG 31-Dec-04 MALARIA MALARIA 15-Jan-05 17-Jan-05 Resolved Moderate None Not related
34 507 6 Male SSG 31-Dec-04 PKDL II FACE, ARM, CHEST, BACK VISCERAL LEISHMANIASIS 1-Mar-05 Ongoing Mild None Probable
34 508 4 Male PM 31-Dec-04 SCRATCH WOUND RIGHT FOOT SCRATCH 2-Jan-05 3-Jan-05 Resolved Mild None Not related
34 510 8 Male Comb 1-Jan-05 MALARIA MALARIA 3-Jan-05 5-Jan-05 Resolved Moderate None Not related
34 511 6 Male Comb 1-Jan-05 MALARIA MALARIA 11-Jan-05 13-Jan-05 Resolved Moderate None Not related
34 511 6 Male Comb 1-Jan-05 COMMON COLD NASOPHARYNGITIS 3-Jun-05 Ongoing Mild None Not related
34 512 6 Female PM 2-Jan-05 MALARIA MALARIA 8-Jan-05 10-Jan-05 Resolved Moderate None Not related
34 512 6 Female PM 2-Jan-05 SWELLING AT THE FACE AFTER TRAUMA SWELLING FACE 21-Jan-05 22-Jan-05 Resolved Mild None Not related
34 512 6 Female PM 2-Jan-05 NASAL BLEEDING EPISTAXIS 20-Jan-05 21-Jan-05 Resolved None Unlikely
34 513 10 Male Comb 3-Jan-05 ACUTE WATERY DIARRHOEA DIARRHOEA 7-Jan-05 13-Jan-05 Resolved Moderate None Not related
34 513 10 Male Comb 3-Jan-05 SUPERFICIAL SKIN LESION (NASAL) SKIN LESION 15-Jan-05 19-Jan-05 Resolved Mild None Not related
34 514 7 Male SSG 4-Jan-05 PNEUMONIA PNEUMONIA 29-Jan-05 2-Feb-05 Resolved Moderate None Not related
34 515 10 Male SSG 5-Jan-05 MALARIA MALARIA 13-May-05 15-May-05 Resolved Mild None Not related
34 515 10 Male SSG 5-Jan-05 PKDL II WITH MUCOSAL INVOLVEMENT VISCERAL LEISHMANIASIS 13-Apr-05 Ongoing Moderate None Probable
34 516 15 Male PM 6-Jan-05 COMMON COLD NASOPHARYNGITIS 10-Jan-05 11-Jan-05 Resolved Mild None Not related
34 516 15 Male PM 6-Jan-05 SUPERFICIAL FUNGAL SKIN INFECTION 
(PROBABLY SINCE ADMISSION)
FUNGAL SKIN INFECTION 19-Jan-05 26-Jan-05 Resolved Mild None Unlikely
34 516 15 Male PM 6-Jan-05 HEART BURN DYSPEPSIA 24-Jan-05 25-Jan-05 Resolved Mild None Unlikely
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34 518 4 Male SSG 9-Jan-05 ARTESUNATE RESISTANT MALARIA MALARIA 11-Jan-05 13-Jan-05 Resolved Moderate None Not related
34 518 4 Male SSG 9-Jan-05 MALARIA (TREATED WITH QUININE) MALARIA 18-Jan-05 24-Jan-05 Resolved Moderate Drug 
interupt
Not related
34 518 4 Male SSG 9-Jan-05 PNEUMONIA PNEUMONIA 18-Jan-05 22-Jan-05 Resolved Moderate None Not related
34 518 4 Male SSG 9-Jan-05 COMMON COLD NASOPHARYNGITIS 15-Jan-05 16-Jan-05 Resolved Mild None Not related
34 518 4 Male SSG 9-Jan-05 ECG CHANGES WITH SSG + QUININE => 
SSG STOPPED
ELECTROCARDIOGRAM CHANGE 24-Jan-05 26-Jan-05 Resolved Moderate Drug 
interupt
Probable
34 519 8 Female PM 7-Jan-05 MALARIA MALARIA 13-Jan-05 15-Jan-05 Resolved Moderate None Not related
34 519 8 Female PM 7-Jan-05 HEADACHE HEADACHE 22-Jan-05 23-Jan-05 Resolved Mild None Unlikely
34 519 8 Female PM 7-Jan-05 ABDOMINAL PAIN PARAUMBLICAL ABDOMINAL PAIN 24-Jan-05 25-Jan-05 Resolved Mild None Unlikely
34 519 8 Female PM 7-Jan-05 MALARIA MALARIA 22-Mar-05 25-Mar-05 Resolved Moderate None Not related
34 520 19 Male SSG 11-Jan-05 ACUTE WATERY DIARRHOEA DIARRHOEA 17-Jan-05 18-Jan-05 Resolved Moderate None Not related
34 520 19 Male SSG 11-Jan-05 MUCOID STOOL MUCOUS STOOLS 23-Jan-05 29-Jan-05 Resolved Mild None Not related
34 520 19 Male SSG 11-Jan-05 COMMON COLD UPPER RESPIRATORY TRACT 
INFECTION
28-Jan-05 30-Jan-05 Resolved Mild None Not related
34 520 19 Male SSG 11-Jan-05 BACKACHE BACK PAIN 2-Feb-05 3-Feb-05 Resolved Mild None Unlikely
34 520 19 Male SSG 11-Jan-05 HEADACHE HEADACHE 28-Jan-05 30-Jan-05 Resolved Mild None Not related
34 520 19 Male SSG 11-Jan-05 PKDL I WITH ORAL INVOLVEMENT VISCERAL LEISHMANIASIS 5-May-05 Ongoing Mild None Probable
34 520 19 Male SSG 11-Jan-05 HEADACHE AND VOMITING DIAGNOSED 
AS MALARIA IN RURAL HEALTH CENTER
MALARIA 15-May-05 15-May-05 Resolved Mild None Not related
34 521 5 Male PM 11-Jan-05 MALARIA MALARIA 20-Jan-05 22-Jan-05 Resolved Moderate None Not related
34 522 36 Male Comb 11-Jan-05 ASTHMA ASTHMA 19-Jan-05 20-Jan-05 Resolved Moderate None Possible
34 522 36 Male Comb 11-Jan-05 ASTHMA ASTHMA 24-Jan-05 25-Jan-05 Resolved Moderate None Possible
34 525 8 Male Comb 13-Jan-05 PKDL III VISCERAL LEISHMANIASIS 10-May-05 Ongoing Mild None Probable
34 526 5 Male SSG 14-Jan-05 MALARIA MALARIA 16-Jan-05 18-Jan-05 Resolved Moderate None Not related
34 526 5 Male SSG 14-Jan-05 SUSPECTED TB TUBERCULOSIS 15-May-05 Ongoing Moderate None Not related
34 527 19 Female Comb 15-Jan-05 VOMITING VOMITING 16-Jan-05 17-Jan-05 Resolved Mild None Unlikely
34 527 19 Female Comb 15-Jan-05 PKDL I VISCERAL LEISHMANIASIS 1-Apr-05 8-Apr-05 Resolved Mild None Probable
34 528 6 Male PM 17-Jan-05 ACUTE WATERY DIARRHOEA DIARRHOEA 25-Jan-05 26-Jan-05 Resolved Moderate None Not related
34 529 5 Female Comb 18-Jan-05 COMMON COLD NASOPHARYNGITIS 10-May-05 13-May-05 Resolved Mild None Not related
34 530 22 Male Comb 20-Jan-05 MINIMAL NASAL BLEEDING EPISTAXIS 5-Feb-05 6-Feb-05 Resolved Mild None Unlikely
34 530 22 Male Comb 20-Jan-05 EAR INFECTION EAR INFECTION 14-Apr-05 21-Apr-05 Resolved Mild None Not related
34 532 4 Male Comb 21-Jan-05 PKDL II VISCERAL LEISHMANIASIS 10-May-05 Ongoing Mild None Probable
34 533 10 Male SSG 23-Jan-05 BACK PAIN BACK PAIN 17-Feb-05 17-Feb-05 Resolved Mild None Not related
34 533 10 Male SSG 23-Jan-05 PKDL I VISCERAL LEISHMANIASIS 16-Apr-05 Ongoing Mild None Probable
34 534 7 Male PM 24-Jan-05 PNEUMONIA PNEUMONIA 30-Jan-05 3-Feb-05 Resolved Moderate None Not related
34 534 7 Male PM 24-Jan-05 WEIGHT LOSS (W/H <70%) WEIGHT DECREASED 30-Jan-05 14-Feb-05 Resolved Moderate None Probable
34 535 11 Female PM 24-Jan-05 ACUTE WATERY DIARRHOE DIARRHOEA 6-Feb-05 7-Feb-05 Resolved Moderate None Not related
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34 536 12 Male PM 25-Jan-05 HEADACHE HEADACHE 5-May-05 6-May-05 Resolved Mild None Not related
34 537 4 Female SSG 25-Jan-05 LARYNGITIS LARYNGITIS 12-Feb-05 14-Feb-05 Resolved Mild None Not related
34 538 6 Male PM 26-Jan-05 NASAL BLEEDING EPISTAXIS 30-Jan-05 31-Jan-05 Resolved Moderate None Unlikely
34 539 6 Male Comb 26-Jan-05 COMMON COLD NASOPHARYNGITIS 10-Feb-05 11-Feb-05 Resolved Mild None Not related
34 539 6 Male Comb 26-Jan-05 MALARIA MALARIA 31-May-05 Ongoing Mild None Not related
34 540 11 Female SSG 27-Jan-05 EPIGASTRIC PAIN ABDOMINAL PAIN UPPER 29-Jan-05 31-Jan-05 Resolved Mild None Possible
34 540 11 Female SSG 27-Jan-05 PNEUMONIA PNEUMONIA 9-Feb-05 19-Feb-05 Resolved Moderate None Not related
35 646 16 Male PM 28-Jan-05 SUPPURATIVE OTITIS MEDIA OTITIS MEDIA 3-Feb-05 12-Feb-05 Resolved Moderate None Not related
35 646 16 Male PM 28-Jan-05 PAIN AT THE OF INJECTION INJECTION SITE PAIN 1-Feb-05 1-Feb-05 Resolved Mild None Possible
35 647 23 Male PM 30-Jan-05 PAIN AT THE SITE OF INJECTION INJECTION SITE PAIN 4-Feb-05 4-Feb-05 Resolved Mild None Possible
35 647 23 Male PM 30-Jan-05 UTI URINARY TRACT INFECTION 20-Mar-05 24-Mar-05 Resolved Mild None Unlikely
35 648 5 Male Comb 30-Jan-05 PAIN AT THE SITE OF INJECTION INJECTION SITE PAIN 30-Jan-05 30-Jan-05 Resolved Mild None Possible
35 648 5 Male Comb 30-Jan-05 ASTHMATIC ATTACK ASTHMA 8-Feb-05 16-Feb-05 Resolved Moderate None Unlikely
35 649 13 Female Comb 30-Jan-05 PAIN AT THE SITE OF INJECTION INJECTION SITE PAIN 30-Jan-05 30-Jan-05 Resolved Mild None Possible
35 650 6 Male SSG 30-Jan-05 PAIN AT THE INJECTION SITE INJECTION SITE PAIN 3-Feb-05 3-Feb-05 Resolved Mild None Possible
35 651 5 Male SSG 30-Jan-05 CROUP CROUP INFECTIOUS 10-Feb-05 12-Feb-05 Resolved Mild None Not related
35 651 5 Male SSG 30-Jan-05 MALARIA MALARIA 18-Feb-05 21-Feb-05 Resolved Mild None Not related
35 651 5 Male SSG 30-Jan-05 PAIN AT THE SITE OF INJECTION INJECTION SITE PAIN 3-Feb-05 3-Feb-05 Resolved Mild None Possible
35 651 5 Male SSG 30-Jan-05 PKDL, G2:1 VISCERAL LEISHMANIASIS 15-Jul-05 Ongoing Moderate None Unlikely
35 652 8 Female PM 1-Feb-05 EARACHE RT EAR PAIN 6-Feb-05 11-Feb-05 Resolved Moderate None Not related
35 652 8 Female PM 1-Feb-05 ACUTE OTITIS MEDIA OTITIS MEDIA ACUTE 7-Feb-05 16-Feb-05 Resolved Moderate None Not related
35 653 6 Female Comb 3-Feb-05 PAIN AT THE INJECTION SITE INJECTION SITE PAIN 6-Feb-05 6-Feb-05 Resolved Mild None Probable
35 654 5 Female SSG 3-Feb-05 PURULENT CONJUNCTIVITIS CONJUNCTIVITIS INFECTIVE 21-Feb-05 25-Feb-05 Resolved Mild None Not related
35 654 5 Female SSG 3-Feb-05 PKDL GI VISCERAL LEISHMANIASIS 20-Jul-05 Ongoing Mild None Unlikely
35 655 11 Male Comb 3-Feb-05 PAIN AT THE INJECTION SITE INJECTION SITE PAIN 7-Feb-05 7-Feb-05 Resolved Mild None Probable
35 657 10 Female PM 8-Feb-05 PAIN AT SITE OF INJECTION INJECTION SITE PAIN 12-Feb-05 12-Feb-05 Resolved Mild None Possible
35 658 15 Male Comb 8-Feb-05 PAIN AT THE INJECTION SITE INJECTION SITE PAIN 11-Feb-05 11-Feb-05 Resolved Mild None Probable
35 658 15 Male Comb 8-Feb-05 PAIN AT THE INJECTION SITE INJECTION SITE PAIN 18-Feb-05 20-Feb-05 Resolved Moderate None Probable
35 658 15 Male Comb 8-Feb-05 AMOEBIC DYSENTRY AMOEBIC DYSENTERY 17-Feb-05 21-Feb-05 Resolved Mild None Not related
35 659 6 Male SSG 8-Feb-05 EPISTAXIS EPISTAXIS 13-Feb-05 13-Feb-05 Resolved Mild None Possible
35 659 6 Male SSG 8-Feb-05 PKDL VISCERAL LEISHMANIASIS 4-Apr-05 2-Jul-05 Resolved Moderate None Unlikely
35 662 25 Male PM 20-Feb-05 MALARIA MALARIA 21-Feb-05 24-Feb-05 Resolved Mild None Not related
35 663 48 Male SSG 20-Feb-05 PNEUMONIA PNEUMONIA 23-Feb-05 26-Feb-05 Resolved Moderate None Not related
35 663 48 Male SSG 20-Feb-05 PROLONGED Q-T INTERVAL ELECTROCARDIOGRAM QT PROLONGED 26-Feb-05 5-Mar-05 Resolved Moderate None Probable
35 663 48 Male SSG 20-Feb-05 PROLONGED Q.T INTERVAL ELECTROCARDIOGRAM QT PROLONGED 12-Mar-05 Ongoing Moderate None Probable
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35 663 48 Male SSG 20-Feb-05 ABD. PAIN LT HYPOCHONDRIUM ABDOMINAL PAIN UPPER 15-Jun-05 23-Jun-05 Resolved Mild None Not related
35 664 37 Female Comb 20-Feb-05 HEART BURN DYSPEPSIA 21-Feb-05 26-Feb-05 Resolved Mild None Not related
35 664 37 Female Comb 20-Feb-05 VOMITING VOMITING 21-Feb-05 26-Feb-05 Resolved Mild None Not related
35 666 12 Female SSG 26-Feb-05 PKDL VISCERAL LEISHMANIASIS 15-Jun-05 Ongoing Moderate None Unlikely
35 670 10 Male SSG 3-Mar-05 PKDL VISCERAL LEISHMANIASIS 7-Apr-05 10-Jun-05 Resolved Mild None Unlikely
35 673 11 Female SSG 11-Mar-05 PKDL VISCERAL LEISHMANIASIS 15-Aug-05 1-Oct-05 Resolved Mild None Unlikely
35 677 37 Male SSG 20-Mar-05 EPISTAXIS EPISTAXIS 23-Mar-05 23-Mar-05 Resolved Mild None Unlikely
35 678 15 Male Comb 22-Mar-05 PKDL VISCERAL LEISHMANIASIS 31-Mar-05 28-Apr-05 Resolved Mild None Unlikely
35 679 45 Female SSG 22-Mar-05 PKDL G1 VISCERAL LEISHMANIASIS 29-Sep-05 Ongoing Mild None Unlikely
35 681 16 Male Comb 22-Mar-05 PNEUMONIA PNEUMONIA 27-Mar-05 1-Apr-05 Resolved Mild None Not related
35 683 12 Female Comb 22-Mar-05 MULLOSCUM CONTAGIOSUM MOLLUSCUM CONTAGIOSUM 23-Mar-05 26-Mar-05 Resolved Mild None Not related
35 684 15 Female SSG 9-Apr-05 UN-COMPLICATED MALARIA MALARIA 5-May-05 8-May-05 Resolved Moderate None Not related
35 687 21 Female SSG 13-Apr-05 ALLERGIC BRONCHITIS ALLERGIC BRONCHITIS 16-Apr-05 19-Apr-05 Resolved Mild None Unlikely
35 687 21 Female SSG 13-Apr-05 URINARY TRACT INFECTION URINARY TRACT INFECTION 5-May-05 8-May-05 Resolved Mild None Unlikely
35 687 21 Female SSG 13-Apr-05 LT HYPOCHONDRIAL PAIN ABDOMINAL PAIN UPPER 20-Sep-05 30-Sep-05 Resolved Mild None Not related
35 688 17 Male PM 16-Apr-05 MALARIA MALARIA 15-Sep-05 18-Sep-05 Resolved Mild None Not related
35 690 10 Male SSG 16-Apr-05 EPISTAXIS EPISTAXIS 19-Apr-05 19-Apr-05 Resolved Mild None Possible
35 690 10 Male SSG 16-Apr-05 EPISTAXIS EPISTAXIS 10-May-05 10-May-05 Resolved Mild None Possible
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11 1 PM 17-Jun-05 day 0 Normal
11 1 PM 24-Jun-05 day 7 Normal
11 1 PM 1-Jul-05 day 14 Normal
11 1 PM 9-Jul-05 end day Normal
11 1 PM 5-Oct-05 month 3 Normal
11 1 PM 5-Jan-06 month 6 Normal
11 2 Combination 17-Jun-05 day 0 Normal
11 2 Combination 24-Jun-05 day 7 Normal
11 2 Combination 1-Jul-05 day 14 Normal
11 2 Combination 5-Jul-05 end day Normal
11 2 Combination 29-Sep-05 month 3 Normal
11 2 Combination 6-Jan-06 month 6 Normal
11 3 Combination 17-Jun-05 day 0 Normal
11 3 Combination 25-Jun-05 day 7 Normal
11 3 Combination 2-Jul-05 day 14 Normal
11 3 Combination 6-Jul-05 end day Normal
11 3 Combination 30-Sep-05 month 3 Normal
11 3 Combination 29-Dec-05 month 6 Normal
11 4 PM 27-Jun-05 day 0 Normal
11 4 PM 6-Jul-05 day 7 Normal
11 4 PM 13-Jul-05 day 14 Normal
11 4 PM 21-Jul-05 end day Normal
11 4 PM 31-Dec-05 month 3 Normal
11 4 PM 27-Jan-06 month 6 Normal
11 5 PM 27-Jun-05 day 0 Normal
11 5 PM 6-Jul-05 day 7 Normal
11 5 PM 13-Jul-05 day 14 Normal
11 5 PM 21-Jul-05 end day Normal
11 5 PM 18-Oct-05 month 3 Normal
11 5 PM 15-Feb-06 month 6 Normal
11 6 Combination 27-Jun-05 day 0 Normal
11 6 Combination 8-Jul-05 day 7 Normal
11 6 Combination 15-Jul-05 day 14 Normal
11 6 Combination 19-Jul-05 end day Normal
11 6 Combination 13-Oct-05 month 3 Normal
11 6 Combination 11-Jan-06 month 6 Normal
11 7 PM 1-Jul-05 day 0 Normal
11 7 PM 8-Jul-05 day 7 Normal
11 7 PM 15-Jul-05 day 14 Normal
11 7 PM 23-Jul-05 end day Normal
11 7 PM 21-Oct-05 month 3 Normal
11 7 PM 20-Jan-06 month 6 Normal
11 8 SSG 1-Jul-05 day 0 Normal
11 8 SSG 8-Jul-05 day 7 Normal
11 8 SSG 15-Jul-05 day 14 Abnormal (CS) BRADYCARDIA
11 8 SSG 24-Jul-05 day 21 Normal
11 8 SSG 1-Aug-05 end day Normal
11 8 SSG 31-Oct-05 month 3 Normal
11 8 SSG 30-Jan-06 month 6 Normal
11 9 SSG 1-Jul-05 day 0 Normal
11 9 SSG 9-Jul-05 day 7 Normal
11 9 SSG 16-Jul-05 day 14 Normal
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11 9 SSG 24-Jul-05 day 21 Normal
11 9 SSG 2-Aug-05 end day Normal
11 9 SSG 1-Nov-05 month 3 Normal
11 9 SSG 30-Jan-06 month 6 Normal
11 10 SSG 1-Jul-05 day 0 Normal
11 10 SSG 9-Jul-05 day 7 Normal
11 10 SSG 16-Jul-05 day 14 Normal
11 10 SSG 24-Jul-05 day 21 Normal
11 10 SSG 2-Aug-05 end day Normal
11 10 SSG 1-Nov-05 month 3 Normal
11 10 SSG 30-Jan-06 month 6 Normal
11 11 Combination 1-Jul-05 day 0 Normal
11 11 Combination 11-Jul-05 day 7 Normal
11 11 Combination 18-Jul-05 day 14 Normal
11 11 Combination 22-Jul-05 end day Normal
11 11 Combination 21-Oct-05 month 3 Normal
11 11 Combination 20-Jan-06 month 6 Normal
11 12 Combination 3-Jul-05 day 0 Normal
11 12 Combination 14-Jul-05 day 7 Normal
11 12 Combination 21-Jul-05 day 14 Normal
11 12 Combination 25-Jul-05 end day Normal
11 12 Combination 25-Oct-05 month 3 Normal
11 13 SSG 11-Jul-05 day 0 Normal
11 13 SSG 18-Jul-05 day 7 Normal
11 13 SSG 25-Jul-05 day 14 Normal
11 13 SSG 1-Aug-05 day 21 Normal
11 13 SSG 11-Aug-05 end day Normal
11 13 SSG 6-Feb-06 month 6 Normal
11 14 SSG 7-Jul-05 day 0 Normal
11 14 SSG 18-Jul-05 day 7 Normal
11 14 SSG 25-Jul-05 day 14 Normal
11 14 SSG 1-Aug-05 day 21 Normal
11 14 SSG 11-Aug-05 end day Normal
11 14 SSG 11-Nov-05 month 3 Normal
11 14 SSG 16-Apr-06 month 6 Normal
11 15 PM 11-Jul-05 day 0 Normal NON SPECIFIC ABNORMALITY NON 
SPECIFIC ABNORMALITY (SINUS 
TACHYCARDIA)
11 15 PM 20-Jul-05 day 7 Abnormal (CS) TACHYCARDIA OF 140 BPM
11 15 PM 7-Nov-05 month 3 Normal
11 15 PM 5-Apr-06 month 6 Normal
11 16 Combination 11-Jul-05 day 0 Normal
11 16 Combination 21-Jul-05 day 7 Normal
11 16 Combination 28-Jul-05 day 14 Normal
11 16 Combination 1-Aug-05 end day Normal
11 16 Combination 31-Oct-05 month 3 Normal
11 16 Combination 6-Feb-06 month 6 Normal
11 17 Combination 11-Jul-05 day 0 Normal
11 17 Combination 25-Jul-05 day 7 Normal
11 17 Combination 1-Aug-05 day 14 Normal
11 17 Combination 5-Aug-05 end day Normal
11 17 Combination 7-Nov-05 month 3 Normal
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11 17 Combination 6-Feb-06 month 6 Normal
11 18 SSG 13-Aug-05 day 0 Normal
11 18 SSG 22-Aug-05 day 7 Normal
11 18 SSG 29-Aug-05 day 14 Normal
11 18 SSG 5-Sep-05 day 21 Normal
11 18 SSG 15-Sep-05 end day Normal
11 18 SSG 22-Dec-05 month 3 Normal
11 18 SSG 15-Mar-06 month 6 Abnormal (CS) SINUS BRADYCARDIA
11 19 Combination 15-Aug-05 day 0 Normal
11 19 Combination 22-Aug-05 day 7 Normal
11 19 Combination 29-Aug-05 day 14 Normal
11 19 Combination 2-Sep-05 end day Normal
11 19 Combination 29-Nov-05 month 3 Normal
11 19 Combination 27-Feb-06 month 6 Normal
11 20 SSG 15-Aug-05 day 0 Normal
11 20 SSG 22-Aug-05 day 7 Normal
11 20 SSG 29-Aug-05 day 14 Normal
11 20 SSG 5-Sep-05 day 21 Normal
11 20 SSG 15-Sep-05 end day Normal
11 20 SSG 14-Dec-05 month 3 Normal
11 20 SSG 14-Mar-06 month 6 Normal
11 21 SSG 15-Aug-05 day 0 Normal
11 21 SSG 22-Aug-05 day 7 Normal
11 21 SSG 29-Aug-05 day 14 Normal
11 21 SSG 5-Sep-05 day 21 Normal
11 21 SSG 15-Sep-05 end day Normal
11 21 SSG 22-Dec-05 month 3 Normal
11 21 SSG 15-Mar-06 month 6 Normal
11 22 SSG 16-Aug-05 day 0 Normal
11 22 SSG 23-Aug-05 day 7 Normal
11 22 SSG 30-Aug-05 day 14 Normal
11 22 SSG 6-Sep-05 day 21 Normal
11 22 SSG 16-Sep-05 end day Normal
11 22 SSG 15-Dec-05 month 3 Normal
11 22 SSG 14-Apr-06 month 6 Normal
11 23 PM 18-Aug-05 day 0 Normal
11 23 PM 26-Aug-05 day 7 Normal
11 23 PM 2-Sep-05 day 14 Normal
11 23 PM 10-Sep-05 end day Normal
11 23 PM 11-Jan-06 month 3 Normal
11 23 PM 31-May-06 month 6 Normal
11 24 PM 18-Aug-05 day 0 Normal
11 24 PM 26-Aug-05 day 7 Normal
11 24 PM 2-Sep-05 day 14 Normal
11 24 PM 10-Sep-05 end day Normal
11 24 PM 28-Nov-05 month 3 Normal
11 24 PM 10-Feb-06 month 6 Normal
11 25 SSG 19-Aug-05 day 0 Normal
11 25 SSG 26-Aug-05 day 7 Normal
11 25 SSG 2-Sep-05 day 14 Normal
11 25 SSG 9-Sep-05 day 21 Normal
11 25 SSG 19-Sep-05 end day Normal
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11 25 SSG 3-Jan-06 month 3 Normal
11 25 SSG 14-Apr-06 month 6 Normal
11 26 Combination 24-Aug-05 day 0 Normal
11 26 Combination 31-Aug-05 day 7 Normal
11 26 Combination 7-Sep-05 day 14 Normal
11 26 Combination 11-Sep-05 end day Normal
11 26 Combination 10-Nov-05 month 3 Normal
11 26 Combination 16-Apr-06 month 6 Normal
11 27 PM 16-Sep-05 day 0 Normal
11 27 PM 25-Sep-05 day 7 Normal
11 27 PM 2-Oct-05 day 14 Normal
11 27 PM 10-Oct-05 end day Normal
11 27 PM 30-Jan-06 month 3 Normal
11 28 Combination 16-Sep-05 day 0 Normal
11 28 Combination 27-Sep-05 day 7 Normal
11 28 Combination 4-Oct-05 day 14 Normal
11 28 Combination 8-Oct-05 end day Normal
11 28 Combination 5-Jan-06 month 3 Normal
11 28 Combination 4-Apr-06 month 6 Normal
11 29 PM 21-Sep-05 day 0 Normal
11 29 PM 28-Sep-05 day 7 Normal
11 29 PM 5-Oct-05 day 14 Normal
11 29 PM 13-Oct-05 end day Normal
11 29 PM 9-Jan-06 month 3 Normal
11 29 PM 18-Apr-06 month 6 Normal
11 30 PM 21-Sep-05 day 0 Normal
11 30 PM 28-Sep-05 day 7 Normal
11 30 PM 5-Oct-05 day 14 Normal
11 30 PM 13-Oct-05 end day Normal
11 30 PM 3-Jan-06 month 3 Normal
11 30 PM 14-Apr-06 month 6 Normal
11 31 SSG 21-Sep-05 day 0 Normal
11 31 SSG 29-Sep-05 day 7 Normal SINUS TACHYCARDIA (NOT SIGNIFICANT)
11 31 SSG 6-Oct-05 day 14 Normal
11 31 SSG 13-Oct-05 day 21 Normal
11 31 SSG 23-Oct-05 end day Normal
11 31 SSG 2-Feb-06 month 3 Normal
11 31 SSG 5-Apr-06 month 6 Normal
11 32 Combination 22-Sep-05 day 0 Normal
11 32 Combination 30-Sep-05 day 7 Normal
11 32 Combination 7-Oct-05 day 14 Normal
11 32 Combination 11-Oct-05 end day Normal
11 32 Combination 9-Jan-06 month 3 Normal
11 32 Combination 3-Apr-06 month 6 Normal
11 33 SSG 24-Sep-05 day 0 Normal
11 33 SSG 1-Oct-05 day 7 Normal
11 33 SSG 8-Oct-05 day 14 Normal
11 33 SSG 15-Oct-05 day 21 Normal
11 33 SSG 25-Oct-05 end day Normal
11 33 SSG 23-Jan-06 month 3 Normal
11 33 SSG 16-Apr-06 month 6 Normal
11 34 PM 24-Sep-05 day 0 Normal
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11 34 PM 3-Oct-05 day 7 Normal
11 34 PM 10-Oct-05 day 14 Normal
11 34 PM 18-Oct-05 end day Normal
11 34 PM 17-Jan-06 month 3 Normal
11 34 PM 16-Apr-06 month 6 Normal
11 35 SSG 24-Sep-05 day 0 Normal
11 35 SSG 3-Oct-05 day 7 Normal
11 35 SSG 10-Oct-05 day 14 Normal
11 35 SSG 17-Oct-05 day 21 Normal
11 35 SSG 27-Oct-05 end day Normal
11 35 SSG 11-Jan-06 month 3 Normal
11 35 SSG 16-Apr-06 month 6 Normal
11 36 SSG 27-Sep-05 day 0 Abnormal (CI) NON SPECIFIC T.WAVE CHANGES 
(INVERSION) ON CHEST LEADS -SINUS 
TACHYCARDIA
11 36 SSG 4-Oct-05 day 7 Normal
11 36 SSG 11-Oct-05 day 14 Normal
11 36 SSG 18-Oct-05 day 21 Normal
11 36 SSG 28-Oct-05 end day Normal
11 36 SSG 24-Jan-06 month 3 Normal
11 36 SSG 10-Jun-06 month 6 Normal
11 37 Combination 27-Sep-05 day 0 Normal SINUS TACYCARDIA
11 37 Combination 4-Oct-05 day 7 Normal HRZ 100BPM N- AXIS ST DEPRESSION V1-V3
ASS:-ST DEPRESSION V1-V3
11 37 Combination 11-Oct-05 day 14 Normal
11 37 Combination 15-Oct-05 end day Normal
11 37 Combination 17-Jan-06 month 3 Normal
11 37 Combination 14-Apr-06 month 6 Normal
11 38 PM 17-Oct-05 day 0 Normal
11 38 PM 25-Oct-05 day 7 Abnormal (CI) AR. ATRIAL PREMATURE CONTRUCTION
11 38 PM 1-Nov-05 day 14 Normal
11 38 PM 9-Nov-05 end day Normal
11 38 PM 15-Feb-06 month 3 Normal
11 38 PM 1-Jun-06 month 6 Normal
11 39 PM 17-Oct-05 day 0 Normal
11 39 PM 25-Oct-05 day 7 Normal
11 39 PM 1-Nov-05 day 14 Normal
11 39 PM 9-Nov-05 end day Normal
11 39 PM 6-Mar-06 month 3 Abnormal (CI) SINUS ARRYTHMIA
11 39 PM 23-May-06 month 6 Normal
11 40 PM 19-Oct-05 day 0 Normal
11 40 PM 26-Oct-05 day 7 Normal
11 40 PM 2-Nov-05 day 14 Normal
11 40 PM 14-Apr-06 month 3 Normal
11 40 PM 24-May-06 month 6 Normal
11 41 Combination 19-Oct-05 day 0 Normal
11 41 Combination 26-Oct-05 day 7 Normal
11 41 Combination 2-Nov-05 day 14 Normal
11 41 Combination 6-Nov-05 end day Normal
11 41 Combination 13-Feb-06 month 3 Normal
11 41 Combination 31-May-06 month 6 Normal
11 42 Combination 19-Oct-05 day 0 Normal
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11 42 Combination 27-Oct-05 day 7 Normal
11 42 Combination 3-Nov-05 day 14 Normal
11 42 Combination 7-Nov-05 end day Normal PAC - CLINICALLY INSIGNIFICANT PACS
11 42 Combination 6-Feb-06 month 3 Normal
11 42 Combination 7-Jun-06 month 6 Normal 
11 43 SSG 27-Oct-05 day 0 Normal
11 43 SSG 3-Nov-05 day 7 Normal
11 43 SSG 10-Nov-05 day 14 Normal
11 43 SSG 17-Nov-05 day 21 Normal
11 43 SSG 27-Nov-05 end day Normal
11 43 SSG 22-Feb-06 month 3 Normal
11 43 SSG 24-May-06 month 6 Normal
11 44 PM 27-Oct-05 day 0 Normal
11 44 PM 3-Nov-05 day 7 Normal
11 44 PM 10-Nov-05 day 14 Normal
11 44 PM 18-Nov-05 end day Normal
11 44 PM 15-Feb-06 month 3 Normal
11 44 PM 19-May-06 month 6 Normal
11 45 Combination 27-Oct-05 day 0 Normal
11 45 Combination 3-Nov-05 day 7 Normal
11 45 Combination 10-Nov-05 day 14 Normal
11 45 Combination 14-Nov-05 end day Normal
11 45 Combination 15-Feb-06 month 3 Normal
11 45 Combination 19-May-06 month 6 Normal
11 46 SSG 4-May-06 day 0 Normal
11 46 SSG 11-May-06 day 7 Normal HAS REGURLARY IRREGULAR RYTHM. QRS 
COMES EVERY 3-4 BUT CLINICALLY STABLE 
AND THE PATIENT IS PLAYFUL, NO 
DYSPREA, OR EARLY FATIGIABILITY
11 46 SSG 18-May-06 day 14 Normal HAS STILL SINUS ARRHYTHMIA BUT NO 
CLINICAL SYMPTOMS.
11 46 SSG 25-May-06 day 21 Abnormal (CI) SINUS ARRHYTHMIA
11 46 SSG 4-Jun-06 end day Normal
11 46 SSG 24-Oct-06 month 3 Normal
11 46 SSG 5-Dec-06 month 6 Normal
11 47 SSG 4-May-06 day 0 Normal
11 47 SSG 11-May-06 day 7 Normal
11 47 SSG 18-May-06 day 14 Normal
11 47 SSG 25-May-06 day 21 Normal
11 47 SSG 4-Jun-06 end day Normal
11 48 Combination 4-May-06 day 0 Normal
11 48 Combination 11-May-06 day 7 Normal
11 48 Combination 18-May-06 day 14 Normal
11 48 Combination 22-May-06 end day Normal
11 48 Combination 2-Jan-07 month 6 Normal
11 49 SSG 8-May-06 day 0 Normal
11 49 SSG 15-May-06 day 7 Normal
11 49 SSG 22-May-06 day 14 Normal
11 49 SSG 29-May-06 day 21 Normal
11 49 SSG 8-Jun-06 end day Normal
11 49 SSG 9-Oct-06 month 3 Normal
11 49 SSG 27-Feb-07 month 6 Normal
11 50 PM 17-May-06 day 0 Normal
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11 50 PM 24-May-06 day 7 Normal
11 50 PM 31-May-06 day 14 Normal
11 50 PM 8-Jun-06 end day Normal
11 50 PM 6-Sep-06 month 3 Normal
11 50 PM 11-Dec-06 month 6 Normal
11 51 Combination 19-May-06 day 0 Normal
11 51 Combination 26-May-06 day 7 Normal
11 51 Combination 2-Jun-06 day 14 Normal
11 51 Combination 6-Jun-06 end day Normal
11 51 Combination 7-Sep-06 month 3 Normal
11 51 Combination 2-Jan-07 month 6 Normal
11 52 PM 19-May-06 day 0 Normal
11 52 PM 26-May-06 day 7 Normal
11 52 PM 2-Jun-06 day 14 Normal
11 52 PM 10-Jun-06 end day Normal
11 52 PM 26-Sep-06 month 3 Normal
11 52 PM 11-Jan-07 month 6 Normal
11 53 SSG 25-May-06 day 0 Normal
11 53 SSG 1-Jun-06 day 7 Normal
11 53 SSG 8-Jun-06 day 14 Normal
11 53 SSG 15-Jun-06 day 21 Normal
11 53 SSG 25-Jun-06 end day Normal
11 53 SSG 26-Sep-06 month 3 Normal
11 53 SSG 11-Dec-06 month 6 Normal
11 54 PM 26-May-06 day 0 Normal
11 54 PM 2-Jun-06 day 7 Normal
11 54 PM 9-Jun-06 day 14 Normal
11 54 PM 17-Jun-06 end day Normal
11 54 PM 28-Aug-06 month 3 Normal  
11 54 PM 8-Jan-07 month 6 Normal
11 55 PM 29-May-06 day 0 Normal
11 55 PM 5-Jun-06 day 7 Normal
11 55 PM 12-Jun-06 day 14 Normal
11 55 PM 20-Jun-06 end day Normal
11 55 PM 26-Sep-06 month 3 Normal
11 55 PM 11-Dec-06 month 6 Normal
11 56 SSG 29-May-06 day 0 Normal
11 56 SSG 6-Jun-06 day 7 Normal
11 56 SSG 13-Jun-06 day 14 Normal
11 56 SSG 20-Jun-06 day 21 Normal
11 56 SSG 30-Jun-06 end day Normal
11 56 SSG 28-Sep-06 month 3 Normal
11 56 SSG 14-Dec-06 month 6 Normal
11 57 Combination 3-Jun-06 day 0 Normal
11 57 Combination 10-Jun-06 day 7 Normal
11 57 Combination 17-Jun-06 day 14 Normal
11 57 Combination 21-Jun-06 end day Normal
11 57 Combination 12-Sep-06 month 3 Normal
11 57 Combination 12-Dec-06 month 6 Normal
11 58 Combination 5-Jun-06 day 0 Normal
11 58 Combination 12-Jun-06 day 7 Normal
11 58 Combination 19-Jun-06 day 14 Normal
11 58 Combination 23-Jun-06 end day Normal
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11 58 Combination 26-Sep-06 month 3 Normal
11 58 Combination 13-Dec-06 month 6 Normal
11 59 PM 12-Jun-06 day 0 Normal
11 59 PM 19-Jun-06 day 7 Normal
11 59 PM 26-Jun-06 day 14 Normal
11 59 PM 4-Jul-06 end day Normal
11 59 PM 4-Oct-06 month 3 Normal
11 59 PM 2-Jan-07 month 6 Normal
11 60 Combination 12-Jun-06 day 0 Normal
11 60 Combination 19-Jun-06 day 7 Normal
11 60 Combination 26-Jun-06 day 14 Normal
11 60 Combination 30-Jun-06 end day Normal
11 60 Combination 28-Sep-06 month 3 Normal
11 60 Combination 18-Dec-06 month 6 Normal
11 61 PM 12-Jun-06 day 0 Normal
11 61 PM 19-Jun-06 day 7 Normal
11 61 PM 26-Jun-06 day 14 Normal
11 61 PM 4-Jul-06 end day Normal
11 61 PM 2-Oct-06 month 3 Normal
11 61 PM 2-Jan-07 month 6 Normal
11 62 SSG 15-Jun-06 day 0 Normal
11 62 SSG 22-Jun-06 day 7 Normal
11 62 SSG 29-Jun-06 day 14 Normal
11 62 SSG 6-Jul-06 day 21 Normal
11 62 SSG 16-Jul-06 end day Normal
11 62 SSG 25-Oct-06 month 3 Normal
11 62 SSG 10-Jan-07 month 6 Normal
11 63 SSG 19-Jun-06 day 0 Normal
11 63 SSG 26-Jun-06 day 7 Normal
11 63 SSG 3-Jul-06 day 14 Normal
11 63 SSG 10-Jul-06 day 21 Normal
11 63 SSG 20-Jul-06 end day Normal
11 63 SSG 3-Oct-06 month 3 Normal
11 63 SSG 28-Dec-06 month 6 Normal
11 64 SSG 21-Jun-06 day 0 Normal
11 64 SSG 28-Jun-06 day 7 Normal
11 64 SSG 5-Jul-06 day 14 Normal
11 64 SSG 12-Jul-06 day 21 Normal
11 64 SSG 22-Jul-06 end day Normal
11 64 SSG 29-Sep-06 month 3 Normal
11 64 SSG 14-Dec-06 month 6 Normal
11 65 PM 21-Jun-06 day 0 Normal
11 65 PM 29-Jun-06 day 7 Normal
11 65 PM 6-Jul-06 day 14 Normal
11 65 PM 14-Jul-06 end day Normal
11 66 Combination 22-Jun-06 day 0 Normal
11 66 Combination 29-Jun-06 day 7 Normal
11 66 Combination 6-Jul-06 day 14 Normal
11 66 Combination 10-Jul-06 end day Normal
11 66 Combination 26-Sep-06 month 3 Normal
11 66 Combination 11-Dec-06 month 6 Normal
11 67 PM 30-Jun-06 day 0 Normal
11 67 PM 7-Jul-06 day 7 Normal
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11 67 PM 14-Jul-06 day 14 Normal
11 67 PM 22-Jul-06 end day Normal
11 67 PM 2-Oct-06 month 3 Normal
11 67 PM 2-Jan-07 month 6 Normal
11 68 SSG 7-Jul-06 day 0 Normal
11 68 SSG 14-Jul-06 day 7 Normal
11 68 SSG 21-Jul-06 day 14 Normal
11 68 SSG 28-Jul-06 day 21 Normal
11 68 SSG 7-Aug-06 end day Normal
11 68 SSG 11-Oct-06 month 3 Normal
11 68 SSG 8-Jan-07 month 6 Normal
11 69 Combination 14-Jul-06 day 0 Normal
11 69 Combination 21-Jul-06 day 7 Normal
11 69 Combination 28-Jul-06 day 14 Normal
11 69 Combination 1-Aug-06 end day Normal
11 69 Combination 9-Oct-06 month 3 Normal
11 69 Combination 13-Dec-06 month 6 Normal
11 70 Combination 14-Jul-06 day 0 Normal
11 70 Combination 21-Jul-06 day 7 Normal
11 70 Combination 28-Jul-06 day 14 Normal
11 70 Combination 1-Aug-06 end day Normal
11 70 Combination 9-Oct-06 month 3 Normal
11 70 Combination 2-Jan-07 month 6 Normal
11 71 Combination 21-Jul-06 day 0 Normal
11 71 Combination 28-Jul-06 day 7 Normal
11 71 Combination 4-Aug-06 day 14 Normal
11 71 Combination 8-Aug-06 end day Normal
11 71 Combination 8-Jan-07 month 6 Normal
11 72 SSG 21-Jul-06 day 0 Normal
11 72 SSG 28-Jul-06 day 7 Normal
11 72 SSG 4-Aug-06 day 14 Normal
11 72 SSG 9-Nov-06 month 3 Normal
11 72 SSG 7-Feb-07 month 6 Normal  
11 73 PM 24-Jul-06 day 0 Normal
11 73 PM 31-Jul-06 day 7 Normal
11 73 PM 7-Aug-06 day 14 Normal
11 73 PM 15-Aug-06 end day Normal
11 73 PM 23-Oct-06 month 3 Normal
11 73 PM 2-Apr-07 month 6 Normal
11 74 PM 27-Jul-06 day 0 Normal
11 74 PM 3-Aug-06 day 7 Normal
11 74 PM 10-Aug-06 day 14 Normal
11 74 PM 18-Aug-06 end day Normal
11 74 PM 25-Oct-06 month 3 Normal
11 74 PM 23-Jan-07 month 6 Normal
11 75 Combination 27-Jul-06 day 0 Normal
11 75 Combination 3-Aug-06 day 7 Normal
11 75 Combination 10-Aug-06 day 14 Normal
11 75 Combination 14-Aug-06 end day Normal
11 75 Combination 31-Oct-06 month 3 Normal
11 75 Combination 8-Jan-07 month 6 Normal
11 76 PM 27-Jul-06 day 0 Normal
11 76 PM 6-Aug-06 day 7 Normal
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11 76 PM 13-Aug-06 day 14 Normal
11 76 PM 21-Aug-06 end day Normal
11 76 PM 30-Oct-06 month 3 Normal
11 76 PM 29-Jan-07 month 6 Normal
11 77 PM 29-Jul-06 day 0 Normal
11 77 PM 6-Aug-06 day 7 Normal
11 77 PM 13-Aug-06 day 14 Normal
11 77 PM 21-Aug-06 end day Normal
11 77 PM 30-Oct-06 month 3 Normal
11 77 PM 29-Jan-07 month 6 Normal
11 78 SSG 29-Jul-06 day 0 Normal
11 78 SSG 6-Aug-06 day 7 Normal
11 78 SSG 13-Aug-06 day 14 Normal
11 78 SSG 20-Aug-06 day 21 Normal
11 78 SSG 30-Aug-06 end day Normal
11 78 SSG 30-Oct-06 month 3 Normal
11 78 SSG 29-Jan-07 month 6 Normal
11 79 PM 29-Jul-06 day 0 Normal
11 79 PM 6-Aug-06 day 7 Normal
11 79 PM 13-Aug-06 day 14 Normal
11 79 PM 21-Aug-06 end day Normal
11 79 PM 30-Oct-06 month 3 Normal
11 79 PM 30-Jan-07 month 6 Normal
11 80 PM 2-Aug-06 day 0 Normal
11 80 PM 9-Aug-06 day 7 Normal
11 80 PM 16-Aug-06 day 14 Normal
11 80 PM 24-Aug-06 end day Normal
11 80 PM 23-Nov-06 month 3 Normal
11 80 PM 16-Mar-07 month 6 Normal  
11 81 Combination 5-Aug-06 day 0 Normal
11 81 Combination 12-Aug-06 day 7 Normal
11 81 Combination 19-Aug-06 day 14 Normal
11 81 Combination 23-Aug-06 end day Normal
11 81 Combination 7-Nov-06 month 3 Normal
11 81 Combination 6-Feb-07 month 6 Normal
11 82 SSG 13-Aug-06 day 0 Normal
11 82 SSG 21-Aug-06 day 7 Normal
11 82 SSG 28-Aug-06 day 14 Normal
11 82 SSG 4-Sep-06 day 21 Normal
11 82 SSG 14-Sep-06 end day Normal
11 82 SSG 13-Nov-06 month 3 Normal
11 82 SSG 5-Feb-07 month 6 Normal
11 83 SSG 15-Aug-06 day 0 Normal
11 83 SSG 22-Aug-06 day 7 Normal
11 83 SSG 29-Aug-06 day 14 Normal
11 83 SSG 5-Sep-06 day 21 Normal
11 83 SSG 15-Sep-06 end day Normal
11 83 SSG 13-Nov-06 month 3 Normal
11 83 SSG 13-Feb-07 month 6 Normal
11 84 SSG 13-Aug-06 day 0 Normal
11 84 SSG 24-Aug-06 day 7 Normal
11 84 SSG 31-Aug-06 day 14 Normal
11 84 SSG 7-Sep-06 day 21 Normal
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11 84 SSG 17-Sep-06 end day Normal
11 84 SSG 15-Nov-06 month 3 Normal
11 84 SSG 14-Feb-07 month 6 Normal
11 85 SSG 24-Aug-06 day 0 Normal
11 85 SSG 31-Aug-06 day 7 Normal
11 85 SSG 7-Sep-06 day 14 Normal
11 85 SSG 14-Sep-06 day 21 Normal
11 85 SSG 24-Sep-06 end day Normal
11 85 SSG 21-Nov-06 month 3 Normal
11 86 Combination 28-Aug-06 day 0 Normal
11 86 Combination 4-Sep-06 day 7 Normal
11 86 Combination 11-Sep-06 day 14 Normal
11 86 Combination 15-Sep-06 end day Normal
11 86 Combination 13-Nov-06 month 3 Normal
11 86 Combination 5-Feb-07 month 6 Normal
11 87 Combination 28-Aug-06 day 0 Normal
11 87 Combination 4-Sep-06 day 7 Normal
11 87 Combination 11-Sep-06 day 14 Normal
11 87 Combination 15-Sep-06 end day Normal
11 87 Combination 14-Nov-06 month 3 Normal
11 87 Combination 5-Feb-07 month 6 Normal
11 88 PM 28-Aug-06 day 0 Normal
11 88 PM 4-Sep-06 day 7 Normal
11 88 PM 11-Sep-06 day 14 Normal
11 88 PM 19-Sep-06 end day Normal
11 88 PM 21-Nov-06 month 3 Normal
11 88 PM 27-Feb-07 month 6 Normal
11 89 Combination 28-Aug-06 day 0 Normal
11 89 Combination 8-Sep-06 day 7 Normal
11 89 Combination 15-Sep-06 day 14 Normal
11 89 Combination 19-Sep-06 end day Normal
11 89 Combination 17-Nov-06 month 3 Normal
11 89 Combination 15-Mar-07 month 6 Normal  
11 90 Combination 1-Sep-06 day 0 Normal
11 90 Combination 8-Sep-06 day 7 Normal
11 90 Combination 15-Sep-06 day 14 Normal
11 90 Combination 19-Sep-06 end day Normal
11 91 PM 17-Dec-06 day 0 Normal
11 91 PM 31-Dec-06 day 14 Normal
11 91 PM 8-Jan-07 end day Normal
11 91 PM 18-Jun-07 month 6 Normal
11 92 Combination 30-Dec-06 day 0 Normal
11 92 Combination 13-Jan-07 day 14 Normal
11 92 Combination 17-Jan-07 end day Normal
11 92 Combination 26-Jun-07 month 6 Normal
11 93 SSG 1-Jan-07 day 0 Normal
11 93 SSG 8-Jan-07 day 7 Normal
11 93 SSG 15-Jan-07 day 14 Normal
11 93 SSG 22-Jan-07 day 21 Normal
11 93 SSG 1-Feb-07 end day Normal
11 93 SSG 7-Aug-07 month 6 Normal
11 94 SSG 3-Jan-07 day 0 Normal
11 94 SSG 17-Jan-07 day 14 Normal
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11 94 SSG 3-Feb-07 end day Normal
11 94 SSG 25-Jun-07 month 6 Normal
11 95 SSG 3-Jan-07 day 0 Normal
11 95 SSG 17-Jan-07 day 14 Normal
11 95 SSG 3-Feb-07 end day Normal
11 95 SSG 23-Jun-07 month 6 Normal
11 96 Combination 19-Jan-07 day 0 Normal
11 96 Combination 2-Feb-07 day 14 Normal
11 96 Combination 6-Feb-07 end day Normal
11 96 Combination 6-Sep-07 month 6 Normal
11 97 Combination 19-Jan-07 day 0 Normal
11 97 Combination 2-Feb-07 day 14 Normal
11 97 Combination 6-Feb-07 end day Normal
11 97 Combination 24-Jul-07 month 6 Normal
11 98 PM 23-Jan-07 day 0 Normal
11 98 PM 6-Feb-07 day 14 Normal
11 98 PM 14-Feb-07 end day Normal
11 98 PM 26-Jul-07 month 6 Normal
11 99 SSG 25-Jan-07 day 0 Normal
11 99 SSG 8-Feb-07 day 14 Normal
11 99 SSG 25-Feb-07 end day Normal
11 99 SSG 30-Jul-07 month 6 Normal
11 100 PM 25-Jan-07 day 0 Normal
11 100 PM 8-Feb-07 day 14 Normal
11 100 PM 16-Feb-07 end day Normal
11 101 PM 2-Feb-07 day 0 Normal
11 101 PM 16-Feb-07 day 14 Normal
11 101 PM 24-Feb-07 end day Normal
11 101 PM 6-Nov-07 month 6 Normal
11 102 Combination 2-Feb-07 day 0 Normal
11 102 Combination 16-Feb-07 day 14 Normal
11 102 Combination 20-Feb-07 end day Normal
11 102 Combination 30-Jul-07 month 6 Normal
11 103 Combination 6-Feb-07 day 0 Normal
11 103 Combination 20-Feb-07 day 14 Normal
11 103 Combination 24-Feb-07 end day Normal
11 103 Combination 10-Aug-07 month 6 Normal
11 104 PM 9-Feb-07 day 0 Normal
11 104 PM 23-Feb-07 day 14 Normal
11 104 PM 3-Mar-07 end day Normal
11 104 PM 27-Aug-07 month 6 Normal
11 105 SSG 23-Feb-07 day 0 Normal
11 105 SSG 9-Mar-07 day 14 Normal
11 105 SSG 26-Mar-07 end day Normal
11 105 SSG 26-Aug-07 month 6 Normal
11 106 Combination 24-Feb-07 day 0 Normal
11 106 Combination 10-Mar-07 day 14 Normal
11 106 Combination 14-Mar-07 end day Normal
11 106 Combination 19-Aug-07 month 6 Normal
11 107 PM 24-Feb-07 day 0 Normal
11 107 PM 10-Mar-07 day 14 Normal
11 107 PM 18-Mar-07 end day Normal
11 107 PM 28-Aug-07 month 6 Normal
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11 108 PM 28-Feb-07 day 0 Normal
11 108 PM 15-Mar-07 day 14 Normal
11 108 PM 23-Mar-07 end day Normal
11 108 PM 27-Aug-07 month 6 Normal
11 109 SSG 27-Feb-07 day 0 Normal
11 109 SSG 16-Mar-07 day 14 Normal
11 109 SSG 2-Apr-07 end day Normal
11 109 SSG 5-Aug-07 month 6 Normal
11 110 PM 2-Mar-07 day 0 Normal
11 110 PM 16-Mar-07 day 14 Normal
11 110 PM 24-Mar-07 end day Normal
11 110 PM 27-Aug-07 month 6 Normal
11 111 Combination 23-Mar-07 day 0 Normal
11 111 Combination 6-Apr-07 day 14 Normal
11 111 Combination 10-Apr-07 end day Normal
11 111 Combination 24-Sep-07 month 6 Normal
11 112 Combination 23-Mar-07 day 0 Normal
11 112 Combination 6-Apr-07 day 14 Normal
11 112 Combination 10-Apr-07 end day Normal
11 112 Combination 24-Sep-07 month 6 Normal
11 113 SSG 27-Mar-07 day 0 Normal
11 113 SSG 10-Apr-07 day 14 Normal
11 113 SSG 27-Apr-07 end day Normal
11 114 SSG 28-Mar-07 day 0 Normal
11 114 SSG 12-Apr-07 day 14 Normal
11 114 SSG 29-Apr-07 end day Normal
11 114 SSG 5-Oct-07 month 6 Normal
11 115 Combination 30-Mar-07 day 0 Normal
11 115 Combination 13-Apr-07 day 14 Normal
11 115 Combination 17-Apr-07 end day Normal
11 115 Combination 21-Sep-07 month 6 Normal
11 116 SSG 30-Mar-07 day 0 Normal
11 116 SSG 13-Apr-07 day 14 Normal
11 116 SSG 30-Apr-07 end day Normal
11 116 SSG 1-Nov-07 month 6 Normal
11 117 PM 3-Apr-07 day 0 Normal
11 117 PM 17-Apr-07 day 14 Normal
11 117 PM 25-Apr-07 end day Normal
11 118 PM 18-Apr-07 day 0 Normal
11 118 PM 2-May-07 day 14 Normal
11 118 PM 10-May-07 end day Normal
11 118 PM 19-Sep-07 month 6 Normal
11 119 SSG 20-Apr-07 day 0 Normal
11 119 SSG 4-May-07 day 14 Normal
11 119 SSG 21-May-07 end day Normal
11 119 SSG 29-Oct-07 month 6 Normal
11 120 Combination 20-Apr-07 day 0 Normal
11 120 Combination 4-May-07 day 14 Normal
11 120 Combination 8-May-07 end day Normal
11 120 Combination 29-Oct-07 month 6 Normal
11 121 Combination 20-Apr-07 day 0 Normal
11 121 Combination 4-May-07 day 14 Normal
11 121 Combination 8-May-07 end day Normal
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11 121 Combination 29-Oct-07 month 6 Normal
11 122 SSG 20-Apr-07 day 0 Normal
11 122 SSG 4-May-07 day 14 Normal
11 122 SSG 21-May-07 end day Normal
11 123 SSG 27-Apr-07 day 0 Normal
11 123 SSG 11-May-07 day 14 Normal
11 123 SSG 28-May-07 end day Normal
11 123 SSG 19-Oct-07 month 6 Normal
11 124 SSG 20-May-07 day 0 Normal
11 124 SSG 3-Jun-07 day 14 Normal
11 124 SSG 20-Jun-07 end day Normal
11 124 SSG 7-Apr-08 month 6 Normal
11 125 SSG 23-May-07 day 0 Normal
11 125 SSG 6-Jun-07 day 14 Normal
11 125 SSG 23-Jun-07 end day Normal
11 125 SSG 19-Nov-07 month 6 Normal
11 126 Combination 26-May-07 day 0 Normal
11 126 Combination 10-Jun-07 day 14 Normal
11 126 Combination 14-Jun-07 end day Normal
11 126 Combination 10-Dec-07 month 6 Normal
11 127 PM 26-May-07 day 0 Normal
11 127 PM 10-Jun-07 day 14 Normal
11 127 PM 18-Jun-07 end day Normal
11 127 PM 30-Oct-07 month 6 Normal
11 128 Combination 1-Jun-07 day 0 Normal
11 128 Combination 15-Jun-07 day 14 Normal
11 128 Combination 19-Jun-07 end day Normal
11 128 Combination 16-Nov-07 month 6 Normal 
11 129 PM 6-Jun-07 day 0 Normal
11 129 PM 20-Jun-07 day 14 Normal
11 129 PM 28-Jun-07 end day Normal
11 129 PM 21-Nov-07 month 6 Normal
11 130 Combination 7-Jun-07 day 0 Normal
11 130 Combination 22-Jun-07 day 14 Normal
11 130 Combination 26-Jun-07 end day Normal
11 130 Combination 19-Nov-07 month 6 Normal
11 131 PM 10-Jun-07 day 0 Normal
11 131 PM 24-Jun-07 day 14 Normal
11 131 PM 2-Jul-07 end day Normal
11 131 PM 12-Dec-07 month 6 Normal
11 132 SSG 15-Jun-07 day 0 Normal
11 132 SSG 29-Jun-07 day 14 Normal
11 132 SSG 16-Jul-07 end day Normal
11 132 SSG 19-Dec-07 month 6 Normal
11 133 Combination 3-Jul-07 day 0 Normal
11 133 Combination 17-Jul-07 day 14 Normal
11 133 Combination 21-Jul-07 end day Normal
11 133 Combination 2-Jan-08 month 6 Normal
11 134 PM 10-Jul-07 day 0 Normal
11 134 PM 24-Jul-07 day 14 Normal
11 134 PM 1-Aug-07 end day Normal
11 134 PM 8-Jan-08 month 6 Normal
11 135 PM 12-Jul-07 day 0 Normal
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11 135 PM 26-Jul-07 day 14 Normal
11 135 PM 3-Aug-07 end day Normal
11 135 PM 31-Dec-07 month 6 Normal
12 241 Combination 28-Jun-05 day 0 Normal CLINICALLY NO CARDIAC ABNORMALITY 
DETECTED
12 241 Combination 5-Jul-05 day 7 Normal
12 241 Combination 12-Jul-05 day 14 Normal
12 241 Combination 16-Jul-05 end day Normal
12 241 Combination 9-Feb-06 month 6 Normal
12 242 SSG 28-Jun-05 day 0 Normal
12 242 SSG 5-Jul-05 day 7 Normal
12 242 SSG 12-Jul-05 day 14 Normal
12 242 SSG 19-Jul-05 day 21 Normal
12 242 SSG 29-Jul-05 end day Normal
12 242 SSG 24-Oct-05 month 3 Normal
12 242 SSG 9-Feb-06 month 6 Normal
12 243 PM 28-Jun-05 day 0 Normal
12 243 PM 5-Jul-05 day 7 Normal
12 243 PM 12-Jul-05 day 14 Normal
12 243 PM 20-Jul-05 end day Normal
12 243 PM 4-Nov-05 month 3 Normal
12 243 PM 6-Aug-06 month 6 Normal
12 244 SSG 28-Jun-05 day 0 Normal
12 244 SSG 5-Jul-05 day 7 Normal
12 244 SSG 12-Jul-05 day 14 Normal
12 244 SSG 19-Jul-05 day 21 Normal
12 244 SSG 29-Jul-05 end day Normal
12 244 SSG 29-Oct-05 month 3 Normal
12 244 SSG 6-Apr-06 month 6 Normal
12 245 PM 15-Jul-05 day 0 Normal
12 245 PM 25-Jul-05 day 7 Normal
12 245 PM 1-Aug-05 day 14 Normal
12 245 PM 9-Aug-05 end day Normal
12 245 PM 17-Nov-05 month 3 Normal
12 246 PM 3-Aug-05 day 0 Normal
12 246 PM 10-Aug-05 day 7 Normal
12 246 PM 17-Aug-05 day 14 Normal
12 246 PM 25-Aug-05 end day Normal
12 246 PM 25-Nov-05 month 3 Normal
12 247 PM 12-Sep-05 day 0 Normal
12 247 PM 4-Oct-05 day 7 Normal
12 247 PM 11-Oct-05 day 14 Normal
12 247 PM 19-Oct-05 end day Normal
12 247 PM 18-Jan-06 month 3 Normal
12 247 PM 19-Apr-06 month 6 Normal
12 248 PM 23-Sep-05 day 0 Normal
12 248 PM 30-Sep-05 day 7 Normal
12 248 PM 6-Oct-05 day 14 Normal
12 248 PM 14-Oct-05 end day Normal
12 248 PM 23-Jan-06 month 3 Normal
12 248 PM 19-Apr-06 month 6 Normal
12 249 Combination 24-Oct-05 day 0 Normal
12 249 Combination 31-Oct-05 day 7 Normal
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12 249 Combination 7-Nov-05 day 14 Normal
12 249 Combination 11-Nov-05 end day Normal
12 249 Combination 4-Mar-06 month 3 Normal
12 249 Combination 13-May-06 month 6 Normal
12 250 SSG 24-Oct-05 day 0 Normal
12 250 SSG 31-Oct-05 day 7 Normal
12 250 SSG 7-Nov-05 day 14 Normal
12 250 SSG 14-Nov-05 day 21 Normal
12 250 SSG 24-Nov-05 end day Normal
12 250 SSG 22-Feb-06 month 3 Normal
12 250 SSG 8-Jul-06 month 6 Normal
12 251 Combination 27-Oct-05 day 0 Normal
12 251 Combination 4-Nov-05 day 7 Normal
12 251 Combination 11-Nov-05 day 14 Normal
12 251 Combination 15-Nov-05 end day Normal
12 251 Combination 12-Feb-06 month 3 Normal
12 251 Combination 14-May-06 month 6 Normal
12 252 SSG 27-Oct-05 day 0 Normal
12 252 SSG 11-Nov-05 day 14 Normal
12 252 SSG 18-Nov-05 day 21 Normal
12 252 SSG 28-Nov-05 end day Normal
12 252 SSG 6-Apr-06 month 3 Normal
12 252 SSG 22-Jun-06 month 6 Normal
12 253 SSG 27-Oct-05 day 0 Normal
12 253 SSG 4-Nov-05 day 7 Normal
12 253 SSG 11-Nov-05 day 14 Normal
12 253 SSG 18-Nov-05 day 21 Normal
12 253 SSG 27-Nov-05 end day Normal
12 253 SSG 5-Apr-06 month 3 Normal
12 253 SSG 22-Jun-06 month 6 Normal
12 254 Combination 27-Oct-05 day 0 Normal
12 254 Combination 4-Nov-05 day 7 Normal
12 254 Combination 11-Nov-05 day 14 Normal
12 254 Combination 15-Nov-05 end day Normal
12 254 Combination 12-Feb-06 month 3 Normal
12 254 Combination 24-May-06 month 6 Normal
12 255 Combination 29-Oct-05 day 0 Normal
12 255 Combination 7-Nov-05 day 7 Normal
12 255 Combination 14-Nov-05 day 14 Normal
12 255 Combination 18-Nov-05 end day Normal
12 255 Combination 9-Mar-06 month 3 Normal
12 255 Combination 17-May-06 month 6 Normal
12 256 Combination 17-Nov-05 day 0 Normal
12 256 Combination 24-Nov-05 day 7 Normal SHORT PR INTERVAL
12 256 Combination 30-Nov-05 day 14 Normal SHORT PR INTERVAL
12 256 Combination 5-Dec-05 end day Normal SHORT PR INTERVAL
12 256 Combination 4-Mar-06 month 3 Normal
12 256 Combination 6-Jun-06 month 6 Normal
12 257 SSG 14-Nov-05 day 0 Normal
12 257 SSG 24-Nov-05 day 7 Normal
12 257 SSG 30-Nov-05 day 14 Normal
12 257 SSG 7-Dec-05 day 21 Normal
12 257 SSG 17-Dec-05 end day Normal
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12 257 SSG 19-Apr-06 month 3 Normal
12 257 SSG 14-Jun-06 month 6 Normal
12 258 SSG 30-Nov-05 day 0 Normal
12 258 SSG 12-Dec-05 day 7 Normal
12 258 SSG 19-Dec-05 day 14 Normal
12 258 SSG 26-Dec-05 day 21 Normal
12 258 SSG 5-Jan-06 end day Normal
12 258 SSG 14-Jul-06 month 6 Normal
12 259 PM 26-Dec-05 day 0 Normal
12 259 PM 6-Jan-06 day 7 Normal
12 259 PM 13-Jan-06 day 14 Normal
12 259 PM 20-Jan-06 end day Normal
12 259 PM 8-May-06 month 3 Normal
12 259 PM 27-Jul-06 month 6 Normal
12 260 PM 25-Dec-05 day 0 Normal
12 260 PM 9-Jan-06 day 7 Normal
12 260 PM 16-Jan-06 day 14 Normal
12 260 PM 24-Jan-06 end day Normal
12 260 PM 11-Jul-06 month 6 Normal
12 261 Combination 26-Dec-05 day 0 Normal
12 261 Combination 9-Jan-06 day 7 Normal
12 261 Combination 16-Jan-06 day 14 Normal
12 261 Combination 20-Jan-06 end day Normal
12 261 Combination 19-Apr-06 month 3 Normal
12 261 Combination 21-Jul-06 month 6 Normal
12 262 PM 26-Dec-05 day 0 Normal
12 262 PM 9-Jan-06 day 7 Normal
12 262 PM 16-Jan-06 day 14 Normal
12 262 PM 23-Jan-06 end day Normal
12 262 PM 22-Jun-06 month 3 Normal
12 262 PM 27-Jul-06 month 6 Normal
12 263 SSG 23-Jan-06 day 0 Normal
12 263 SSG 1-Feb-06 day 7 Normal
12 263 SSG 9-Feb-06 day 14 Normal
12 263 SSG 15-Feb-06 day 21 Normal
12 263 SSG 25-Feb-06 end day Normal
12 263 SSG 29-May-06 month 3 Normal
12 263 SSG 25-Aug-06 month 6 Normal
12 264 Combination 11-Feb-06 day 0 Normal
12 264 Combination 21-Feb-06 day 7 Normal
12 264 Combination 28-Feb-06 day 14 Normal
12 264 Combination 4-Mar-06 end day Normal
12 264 Combination 16-Jun-06 month 3 Normal
12 264 Combination 1-Sep-06 month 6 Normal
12 265 SSG 11-Feb-06 day 0 Normal
12 265 SSG 21-Feb-06 day 7 Normal
12 265 SSG 28-Feb-06 day 14 Normal
12 265 SSG 7-Mar-06 day 21 Normal
12 265 SSG 15-Mar-06 end day Normal
12 266 PM 11-Feb-06 day 0 Normal
12 266 PM 21-Feb-06 day 7 Normal
12 266 PM 28-Feb-06 day 14 Normal
12 266 PM 8-Mar-06 end day Normal
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12 266 PM 3-Jun-06 month 3 Normal
12 266 PM 3-Oct-06 month 6 Normal
12 267 SSG 11-Feb-06 day 0 Normal
12 267 SSG 21-Feb-06 day 7 Normal
12 267 SSG 28-Feb-06 day 14 Normal
12 267 SSG 7-Mar-06 day 21 Normal
12 267 SSG 17-Mar-06 end day Normal
12 267 SSG 14-Jun-06 month 3 Normal
12 267 SSG 15-Sep-06 month 6 Normal
12 268 PM 7-Mar-06 day 0 Normal
12 268 PM 17-Mar-06 day 7 Normal
12 268 PM 23-Mar-06 day 14 Normal
12 268 PM 3-Apr-06 end day Normal
12 268 PM 29-Jun-06 month 3 Normal
12 268 PM 26-Sep-06 month 6 Normal
12 269 Combination 15-Mar-06 day 0 Abnormal (CI) SINUS TACHY CARDIA ON ECG BUT IT HAS 
NO CLINICALLY SIGNIFICANT 
ABNORMALITY DETECTED
12 269 Combination 22-Mar-06 day 7 Normal
12 269 Combination 29-Mar-06 day 14 Abnormal (CI) NON SPECIFIC T-WAVE ABNORMALITY
12 269 Combination 3-Apr-06 end day Normal SINUS TACHY CARDIA ABNORMAL RHYTHM 
ECG
12 269 Combination 8-Jul-06 month 3 Normal
12 269 Combination 14-Nov-06 month 6 Normal
12 270 Combination 15-Mar-06 day 0 Normal
12 270 Combination 22-Mar-06 day 7 Normal
12 270 Combination 29-Mar-06 day 14 Normal
12 270 Combination 3-Apr-06 end day Normal
12 270 Combination 10-Oct-06 month 6 Normal
12 271 SSG 27-Mar-06 day 0 Normal
12 271 SSG 6-Apr-06 day 7 Normal
12 271 SSG 14-Apr-06 day 14 Normal
12 271 SSG 21-Apr-06 day 21 Normal
12 271 SSG 30-Apr-06 end day Abnormal (CS) LONG QTC INTERNAL
12 271 SSG 1-Aug-06 month 3 Normal
12 271 SSG 31-Oct-06 month 6 Normal
12 272 PM 6-Apr-06 day 0 Normal
12 272 PM 14-Apr-06 day 7 Abnormal (CI) SHORT QTC INTERVAL
12 272 PM 21-Apr-06 day 14 Abnormal (CI) SHORT QT WAVE BUT CLINICALLY NOT 
SIGNIFICANT
12 272 PM 30-Apr-06 end day Normal
12 272 PM 26-Jun-06 month 3 Normal
12 272 PM 11-Nov-06 month 6 Normal
12 273 SSG 27-Mar-06 day 0 Normal
12 273 SSG 14-Apr-06 day 7 Normal
12 273 SSG 21-Apr-06 day 14 Normal
12 273 SSG 28-Apr-06 day 21 Normal
12 273 SSG 8-May-06 end day Normal
12 273 SSG 8-Aug-06 month 3 Normal
12 273 SSG 11-Nov-06 month 6 Normal
12 274 SSG 6-Apr-06 day 0 Abnormal (CI) MARKED SINUS ARRHYTHMIA
12 274 SSG 14-Apr-06 day 7 Normal
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12 274 SSG 21-Apr-06 day 14 Normal
12 274 SSG 28-Apr-06 day 21 Abnormal (CI) NON SPECIFIC T-WAVE ABNORMALITY
12 274 SSG 8-May-06 end day Normal
12 274 SSG 8-Aug-06 month 3 Normal 1102 SINUS ARRHYTHMIA LONG 
QTCINTERVAL ABNORMAL ECG
12 274 SSG 11-Nov-06 month 6 Normal
12 275 Combination 6-Apr-06 day 0 Normal
12 275 Combination 14-Apr-06 day 7 Normal
12 275 Combination 21-Apr-06 day 14 Normal
12 275 Combination 25-Apr-06 end day Normal
12 275 Combination 25-Jul-06 month 3 Normal
12 275 Combination 25-Oct-06 month 6 Normal
12 276 PM 6-Apr-06 day 0 Normal NONSPECIFIC T-WAVE ABNORMALITY 
BORDERLINE ECG
12 276 PM 14-Apr-06 day 7 Normal
12 276 PM 21-Apr-06 day 14 Normal
12 276 PM 30-Apr-06 end day Normal
12 276 PM 19-Jul-06 month 3 Normal IT WAS DONE AT TIME OF VISIT BUT 
SOURCE DOCUMENT MISPLACED
12 276 PM 31-Oct-06 month 6 Normal
12 277 Combination 19-Apr-06 day 0 Normal
12 277 Combination 27-Apr-06 day 7 Normal
12 277 Combination 5-May-06 day 14 Normal
12 277 Combination 8-May-06 end day Normal
12 277 Combination 7-Aug-06 month 3 Normal
12 277 Combination 11-Nov-06 month 6 Normal
12 278 SSG 19-Apr-06 day 0 Normal
12 278 SSG 27-Apr-06 day 7 Normal
12 278 SSG 5-May-06 day 14 Normal
12 278 SSG 11-May-06 day 21 Normal
12 278 SSG 21-May-06 end day Normal
12 278 SSG 18-Aug-06 month 3 Normal
12 279 PM 19-Apr-06 day 0 Normal
12 279 PM 27-Apr-06 day 7 Normal
12 279 PM 4-May-06 day 14 Normal
12 279 PM 12-May-06 end day Normal
12 279 PM 12-Aug-06 month 3 Normal
12 279 PM 11-Nov-06 month 6 Normal
12 280 SSG day 0 Not Done
12 280 SSG 28-Apr-06 day 7 Normal
12 280 SSG 4-May-06 day 14 Normal
12 280 SSG 12-May-06 day 21 Normal
12 280 SSG 21-May-06 end day Normal
12 280 SSG 25-Aug-06 month 3 Normal
12 280 SSG 22-Nov-06 month 6 Normal
12 281 Combination 19-Apr-06 day 0 Normal
12 281 Combination 27-Apr-06 day 7 Normal
12 281 Combination 5-May-06 day 14 Normal
12 281 Combination 8-May-06 end day Normal TWAVE ABNORMALITY POSSIBLE 
ANTERIOR ISCHEMIA
12 281 Combination 8-Aug-06 month 3 Normal
12 281 Combination 22-Dec-06 month 6 Normal
12 282 PM 28-Apr-06 day 0 Normal
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12 282 PM 4-May-06 day 7 Normal
12 282 PM 11-May-06 day 14 Normal
12 282 PM 19-May-06 end day Normal
12 282 PM 25-Aug-06 month 3 Normal
12 282 PM 20-Dec-06 month 6 Normal
12 283 PM 11-May-06 day 0 Normal
12 283 PM 17-May-06 day 7 Normal
12 283 PM 24-May-06 day 14 Normal
12 283 PM 1-Jun-06 end day Normal
12 283 PM 25-Aug-06 month 3 Normal
12 283 PM 29-Dec-06 month 6 Normal
12 284 Combination 19-May-06 day 0 Normal
12 284 Combination 27-May-06 day 7 Normal
12 284 Combination 3-Jun-06 day 14 Normal
12 284 Combination 6-Jun-06 end day Normal
12 284 Combination 5-Sep-06 month 3 Normal
12 284 Combination 6-Dec-06 month 6 Normal
12 285 Combination 19-May-06 day 0 Normal
12 285 Combination 27-May-06 day 7 Normal
12 285 Combination 2-Jun-06 day 14 Normal
12 285 Combination 6-Jun-06 end day Normal
12 285 Combination 5-Sep-06 month 3 Normal
12 285 Combination 6-Dec-06 month 6 Normal
12 286 PM 26-Dec-06 day 0 Normal
12 286 PM 16-Jan-02 day 14 Normal
12 286 PM 23-Jan-07 end day Normal
12 286 PM 1-May-07 month 3 Normal
12 286 PM 4-Sep-07 month 6 Normal
12 287 SSG 26-Dec-06 day 0 Normal
12 287 SSG 16-Jan-07 day 14 Normal
12 287 SSG 1-Feb-07 end day Normal
12 287 SSG 16-Jun-07 month 3 Normal
12 287 SSG 7-Aug-07 month 6 Normal
12 288 Combination 30-Dec-06 day 0 Normal
12 288 Combination 8-Jan-07 day 7 Normal MINIMAL VOLTAGE  ENTERIA FOR LVH 
MAYBE NORMAL VARIANT BORDER LINE 
ECG
12 288 Combination 16-Jan-07 day 14 Normal SINUS ARRHYTHMIA BORDERLINE ECG
12 288 Combination 19-Jan-07 end day Normal
12 288 Combination 21-Apr-07 month 3 Normal
12 288 Combination 24-Jul-07 month 6 Normal
12 289 Combination 30-Dec-06 day 0 Normal
12 289 Combination 8-Jan-07 day 7 Normal
12 289 Combination 16-Jan-07 day 14 Normal
12 289 Combination 19-Jan-07 end day Normal
12 289 Combination 2-Sep-07 month 6 Normal
12 290 SSG 5-Jan-07 day 0 Normal
12 290 SSG 19-Jan-07 day 14 Normal
12 290 SSG 27-Jan-07 day 21 Normal ECG WAS DONE  FOR CLINICAL REASON
12 290 SSG 6-Feb-07 end day Normal
12 290 SSG 6-Sep-07 month 6 Normal
12 291 SSG 8-Jan-07 day 0 Normal
12 291 SSG 25-Jan-07 day 14 Normal
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12 291 SSG 10-Feb-07 end day Normal
12 291 SSG 4-Sep-07 month 6 Normal
12 292 PM 14-Jan-07 day 0 Normal
12 292 PM 1-Feb-07 day 14 Normal SINUS RHYTHM ABNORMAL ECG
12 292 PM 7-Feb-07 end day Normal
12 292 PM 21-Aug-07 month 6 Normal
12 293 SSG 21-Jan-07 day 0 Normal
12 293 SSG 6-Feb-07 day 14 Normal NON SPECIFIC T-WAVE ABNORMALITY 
BORDER LINE ECG
12 293 SSG 23-Feb-07 end day Normal NON SPECIFIC T WAVE ABNORMALI SINUS 
ARRHYTHMIA
12 293 SSG 6-Sep-07 month 6 Normal
12 294 Combination 20-Feb-07 day 0 Normal
12 294 Combination 7-Mar-07 day 14 Normal
12 294 Combination 12-Mar-07 end day Normal
12 294 Combination 11-Jun-07 month 3 Normal
12 294 Combination 11-Sep-07 month 6 Normal
12 295 Combination 12-Mar-07 day 0 Normal
12 295 Combination 30-Mar-07 day 14 Normal
12 295 Combination 2-Apr-07 end day Normal
12 295 Combination 20-Sep-07 month 6 Normal
12 296 PM 10-Apr-07 day 0 Normal
12 296 PM 25-Apr-07 day 14 Normal
12 296 PM 3-May-07 end day Normal
12 296 PM 31-Jul-07 month 3 Normal
12 296 PM 30-Oct-07 month 6 Normal
12 297 SSG 11-Apr-07 day 0 Normal
12 297 SSG 25-Apr-07 day 14 Normal
12 298 PM 18-Apr-07 day 0 Normal
12 298 PM 4-May-07 day 14 Normal
12 298 PM 12-May-07 end day Normal
12 298 PM 9-Nov-07 month 6 Normal
12 299 Combination 3-Jun-07 day 0 Normal
12 299 Combination 18-Jun-07 day 14 Normal
12 299 Combination 22-Jun-07 end day Normal
12 299 Combination 1-Jan-08 month 6 Normal
12 300 PM 3-Jun-07 day 0 Normal
12 300 PM 18-Jun-07 day 14 Normal
12 300 PM 26-Jun-07 end day Normal
12 300 PM 24-Dec-07 month 6 Normal
12 301 SSG 3-Jun-07 day 0 Normal
12 301 SSG 18-Jun-07 day 14 Normal
12 301 SSG 5-Jul-07 end day Normal
12 301 SSG 4-Feb-08 month 6 Normal
12 302 SSG 3-Jun-07 day 0 Normal
12 302 SSG 18-Jun-07 day 14 Not Done
12 302 SSG 5-Jul-07 end day Normal
12 302 SSG 26-Dec-07 month 6 Normal
12 303 PM 3-Jun-07 day 0 Normal
12 303 PM 18-May-07 day 14 Normal
12 303 PM 26-Jun-07 end day Normal
12 303 PM 26-Dec-07 month 6 Normal
12 304 Combination 3-Jun-07 day 0 Normal
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12 304 Combination 18-Jun-07 day 14 Normal
12 304 Combination 22-Jun-07 end day Normal
12 304 Combination 26-Dec-07 month 6 Normal
12 305 PM 3-Jun-07 day 0 Normal
12 305 PM 18-Jun-07 day 14 Normal
12 305 PM 26-Jun-07 end day Normal
12 305 PM 26-Dec-07 month 6 Normal
12 306 Combination 3-Jun-07 day 0 Normal
12 306 Combination 18-Jun-07 day 14 Normal
12 306 Combination 22-Jun-07 end day Normal
12 306 Combination 26-Dec-07 month 6 Normal
12 307 Combination 13-Jun-07 day 0 Normal
12 307 Combination 28-Jun-07 day 14 Normal
12 307 Combination 2-Jul-07 end day Normal
12 307 Combination 26-Dec-07 month 6 Normal
12 308 PM 13-Jun-07 day 0 Normal
12 308 PM 28-Jun-07 day 14 Normal
12 308 PM 6-Jul-07 end day Normal
12 308 PM 26-Dec-07 month 6 Normal
12 309 PM 16-Jun-07 day 0 Normal
12 309 PM 29-Jun-07 day 14 Normal
12 309 PM 7-Jul-07 end day Normal
12 309 PM 26-Dec-07 month 6 Normal
12 310 SSG 16-Jun-07 day 0 Normal
12 310 SSG 29-Jun-07 day 14 Normal
12 310 SSG 17-Jul-07 end day Normal
12 310 SSG 4-Feb-08 month 6 Normal
12 311 SSG 4-Jul-07 day 0 Normal
12 311 SSG 19-Jul-07 day 14 Normal
12 311 SSG 4-Aug-07 end day Normal
12 311 SSG 11-Mar-08 month 6 Normal
12 312 Combination 10-Jul-07 day 0 Normal
12 312 Combination 25-Jul-07 day 14 Normal
12 312 Combination 29-Jul-07 end day Normal
12 312 Combination 19-Mar-08 month 6 Normal
12 313 PM 31-Jul-07 day 0 Normal
12 313 PM 15-Aug-07 day 14 Normal
12 313 PM 23-Aug-07 end day Normal
12 313 PM 21-Feb-08 month 6 Normal
12 314 SSG 31-Jul-07 day 0 Normal
12 314 SSG 21-Aug-07 day 14 Normal
12 314 SSG 6-Sep-07 end day Normal
12 314 SSG 4-Mar-08 month 6 Normal
12 315 Combination 21-Aug-07 day 0 Normal
12 315 Combination 11-Sep-07 day 14 Normal
12 315 Combination 15-Sep-07 end day Normal
12 315 Combination 11-Aug-08 month 6 Normal  
12 316 SSG 21-Aug-07 day 0 Normal
12 316 SSG 11-Sep-07 day 14 Normal
12 316 SSG 2-Apr-08 month 6 Normal
12 317 SSG 21-Aug-07 day 0 Normal
12 317 SSG 11-Sep-07 day 14 Normal
12 317 SSG 29-Sep-07 end day Normal
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12 317 SSG 22-Apr-08 month 6 Normal
12 318 Combination 28-Aug-07 day 0 Normal
12 318 Combination 11-Sep-07 day 14 Normal
12 318 Combination 15-Sep-07 end day Normal
12 318 Combination 15-Mar-08 month 6 Normal
12 319 Combination day 0 Normal
12 319 Combination 11-Sep-07 day 14 Normal
12 319 Combination 15-Sep-07 end day Normal
12 319 Combination 15-Mar-08 month 6 Normal
12 320 Combination 4-Sep-07 day 0 Normal
12 320 Combination 19-Sep-07 day 14 Normal
12 320 Combination 23-Sep-07 end day Normal
12 320 Combination 19-Mar-08 month 6 Normal
12 321 Combination 4-Sep-07 day 0 Normal
12 321 Combination 19-Sep-07 day 14 Normal
12 321 Combination 23-Sep-07 end day Normal
12 321 Combination 24-Mar-08 month 6 Normal
12 322 PM 11-Sep-07 day 0 Normal
12 322 PM 26-Sep-07 day 14 Normal
12 322 PM 4-Oct-07 end day Normal
12 322 PM 20-Apr-08 month 6 Normal
12 323 SSG 19-Sep-07 day 0 Normal
12 323 SSG 3-Oct-07 day 14 Normal
12 323 SSG 20-Oct-07 end day Normal
12 323 SSG 17-Apr-08 month 6 Normal
12 324 SSG 19-Sep-07 day 0 Normal
12 324 SSG 3-Oct-07 day 14 Normal
12 324 SSG 20-Oct-07 end day Normal
12 324 SSG 17-Apr-08 month 6 Normal
12 325 PM 19-Sep-07 day 0 Normal
12 325 PM 10-Oct-07 day 14 Normal
12 325 PM 18-Oct-07 end day Normal
12 325 PM 17-Apr-08 month 6 Normal
12 326 PM 2-Oct-07 day 0 Normal
12 326 PM 16-Oct-07 day 14 Normal
12 326 PM 24-Oct-07 end day Normal
12 326 PM 20-Apr-08 month 6 Normal
12 327 Combination 2-Oct-07 day 0 Normal
12 327 Combination 16-Oct-07 day 14 Normal
12 327 Combination 20-Oct-07 end day Normal
12 327 Combination 17-Apr-08 month 6 Normal
12 328 PM 3-Oct-07 day 0 Normal
12 328 PM day 14 Not Done
12 328 PM 26-Oct-07 end day Normal
12 328 PM 14-Apr-08 month 6 Normal
12 329 SSG 10-Oct-07 day 0 Normal
12 329 SSG 23-Oct-07 day 14 Normal
12 329 SSG 9-Nov-07 end day Normal
12 329 SSG 5-May-08 month 6 Normal
12 330 PM 10-Oct-07 day 0 Normal
12 330 PM 23-Oct-07 day 14 Normal
12 330 PM 31-Oct-07 end day Normal
12 330 PM 5-May-08 month 6 Normal
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23 361 Combination 18-Jan-05 day 0 Normal
23 361 Combination 26-Jan-05 day 7 Normal
23 361 Combination 2-Feb-05 day 14 Normal
23 361 Combination 6-Feb-05 end day Normal
23 361 Combination 5-May-05 month 3 Normal
23 361 Combination 10-Aug-05 month 6 Normal
23 362 PM 18-Jan-05 day 0 Normal
23 362 PM 26-Jan-05 day 7 Normal
23 362 PM 2-Feb-05 day 14 Normal
23 362 PM 10-Feb-05 end day Normal
23 362 PM 10-May-05 month 3 Normal
23 362 PM 16-Aug-05 month 6 Normal
23 363 PM 18-Jan-05 day 0 Normal
23 363 PM 26-Jan-05 day 7 Normal
23 363 PM 2-Feb-05 day 14 Normal
23 363 PM 10-Feb-05 end day Normal
23 363 PM 5-May-05 month 3 Normal
23 363 PM 10-Aug-05 month 6 Normal
23 364 Combination 18-Jan-05 day 0 Normal
23 364 Combination 26-Jan-05 day 7 Normal
23 364 Combination 2-Feb-05 day 14 Normal
23 364 Combination 6-Feb-05 end day Normal
23 364 Combination 11-May-05 month 3 Normal
23 365 SSG 18-Jan-05 day 0 Normal
23 365 SSG 26-Jan-05 day 7 Normal
23 365 SSG 2-Feb-05 day 14 Normal
23 365 SSG 10-Feb-05 day 21 Normal
23 365 SSG 19-Feb-05 end day Normal
23 365 SSG 20-May-05 month 3 Normal
23 365 SSG 30-Aug-05 month 6 Normal
23 366 Combination 28-Jan-05 day 0 Normal
23 366 Combination 7-Feb-05 day 7 Normal
23 366 Combination 14-Feb-05 day 14 Normal
23 366 Combination 18-Feb-05 end day Normal
23 366 Combination 20-May-05 month 3 Normal
23 366 Combination 19-Aug-05 month 6 Normal
23 367 SSG 28-Jan-05 day 0 Normal
23 367 SSG 7-Feb-05 day 7 Normal
23 367 SSG 14-Feb-05 day 14 Normal
23 367 SSG 21-Feb-05 day 21 Normal
23 367 SSG 3-Mar-05 end day Normal
23 367 SSG 8-Jun-05 month 3 Normal
23 367 SSG 23-Sep-05 month 6 Normal
23 368 PM 28-Jan-05 day 0 Normal
23 368 PM 7-Feb-05 day 7 Normal
23 368 PM 14-Feb-05 day 14 Normal
23 368 PM 22-Feb-05 end day Normal
23 368 PM 26-May-05 month 3 Normal
23 368 PM 5-Sep-05 month 6 Normal
23 369 Combination 28-Jan-05 day 0 Normal
23 369 Combination 10-Feb-05 day 7 Normal
23 369 Combination day 14 Normal
23 369 Combination 21-Feb-05 end day Normal
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23 369 Combination 26-May-05 month 3 Normal
23 369 Combination 30-Aug-05 month 6 Normal
23 370 SSG 28-Jan-05 day 0 Normal
23 370 SSG 10-Feb-05 day 7 Normal
23 370 SSG 17-Feb-05 day 14 Normal
23 370 SSG 24-Feb-05 day 21 Normal
23 370 SSG 6-Mar-05 end day Normal
23 370 SSG 8-Jun-05 month 3 Normal
23 370 SSG 23-Sep-05 month 6 Normal
23 371 PM 4-Feb-05 day 0 Normal
23 371 PM 10-Feb-05 day 7 Normal
23 371 PM 17-Feb-05 day 14 Normal
23 371 PM 25-Feb-05 end day Normal
23 371 PM 26-May-05 month 3 Normal
23 371 PM 5-Sep-05 month 6 Normal
23 372 PM 10-Feb-05 day 0 Normal
23 372 PM 17-Feb-05 day 7 Normal
23 372 PM 24-Feb-05 day 14 Normal
23 372 PM 4-Mar-05 end day Normal
23 372 PM 6-Jun-05 month 3 Abnormal (CS) SINUS BRADYCARDIA OF 49BPM REGULAR
23 372 PM 10-Sep-05 month 6 Abnormal (CS) BRADYCARDIA
23 373 SSG 17-Feb-05 day 0 Normal
23 373 SSG 24-Feb-05 day 7 Normal
23 373 SSG 3-Mar-05 day 14 Normal
23 373 SSG 10-Mar-05 day 21 Normal
23 373 SSG 20-Mar-05 end day Normal
23 373 SSG 6-Jul-05 month 3 Abnormal (CS) SINUS BRADY CARDIA OF 45 BPM
23 373 SSG 24-Oct-05 month 6 Abnormal (CS) BRADY CARDIA 52BPM
23 374 SSG 18-Feb-05 day 0 Normal
23 374 SSG 2-Mar-05 day 7 Normal
23 374 SSG 9-Mar-05 day 14 Normal
23 374 SSG 16-Mar-05 day 21 Normal
23 374 SSG 28-Mar-05 end day Normal
23 374 SSG 27-Jun-05 month 3 Normal
23 374 SSG 30-Sep-05 month 6 Normal
23 375 Combination 25-Feb-05 day 0 Normal
23 375 Combination 3-Mar-05 day 7 Normal
23 375 Combination 10-Mar-05 day 14 Normal
23 375 Combination 14-Mar-05 end day Normal
23 375 Combination 15-Jun-05 month 3 Normal
23 375 Combination 23-Sep-05 month 6 Normal
23 376 SSG 1-Mar-05 day 0 Normal
23 376 SSG 7-Mar-05 day 7 Normal
23 376 SSG 14-Mar-05 day 14 Normal
23 376 SSG 21-Mar-05 day 21 Normal
23 376 SSG 31-Mar-05 end day Normal
23 376 SSG 29-Jun-05 month 3 Normal
23 376 SSG 28-Sep-05 month 6 Normal
23 377 Combination 9-Mar-05 day 0 Normal
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23 377 Combination 15-Mar-05 day 7 Normal
23 377 Combination 23-Sep-05 month 6 Normal
23 378 Combination 9-Mar-05 day 0 Normal
23 378 Combination 15-Mar-05 day 7 Normal
23 378 Combination 22-Mar-05 day 14 Normal
23 378 Combination 26-Mar-05 end day Normal
23 378 Combination 6-Jul-05 month 3 Normal
23 378 Combination 23-Sep-05 month 6 Normal
23 379 PM 10-Mar-05 day 0 Normal
23 379 PM 16-Mar-05 day 7 Normal
23 379 PM 23-Mar-05 day 14 Normal
23 379 PM 31-Mar-05 end day Normal
23 379 PM 29-Jun-05 month 3 Normal
23 380 SSG 15-Mar-05 day 0 Normal
23 380 SSG 21-Mar-05 day 7 Normal
23 380 SSG 28-Mar-05 day 14 Normal
23 380 SSG 4-Apr-05 day 21 Normal
23 380 SSG 14-Apr-05 end day Normal
23 380 SSG 19-Jul-05 month 3 Normal
23 380 SSG 12-Oct-05 month 6 Normal
23 381 PM 15-Mar-05 day 0 Normal
23 381 PM 21-Mar-05 day 7 Normal
23 381 PM 29-Mar-05 day 14 Normal
23 381 PM 5-Apr-05 end day Normal
23 381 PM 12-Jul-05 month 3 Normal
23 381 PM 17-Nov-05 month 6 Normal
23 382 Combination 18-Mar-05 day 0 Normal
23 382 Combination 24-Mar-05 day 7 Normal
23 382 Combination 31-Mar-05 day 14 Normal
23 382 Combination 4-Apr-05 end day Normal
23 382 Combination 12-Jul-05 month 3 Normal
23 382 Combination 30-Sep-05 month 6 Normal
23 383 PM 30-Mar-05 day 0 Normal
23 383 PM 11-Apr-05 day 7 Normal
23 383 PM 18-Apr-05 day 14 Normal
23 383 PM 26-Apr-05 end day Normal
23 383 PM 30-Sep-05 month 3 Normal
23 383 PM 24-Oct-05 month 6 Normal
23 384 SSG 30-Mar-05 day 0 Normal
23 384 SSG 11-Apr-05 day 7 Normal
23 384 SSG 18-Apr-05 day 14 Normal
23 384 SSG 25-Apr-05 day 21 Normal
23 384 SSG 5-May-05 end day Normal
23 384 SSG 28-Sep-05 month 3 Normal
23 384 SSG 17-Nov-05 month 6 Normal
23 385 SSG 30-Mar-05 day 0 Normal
23 385 SSG 13-Apr-05 day 7 Normal
23 385 SSG 20-Apr-05 day 14 Normal
23 385 SSG 27-Apr-05 day 21 Normal
23 385 SSG 7-May-05 end day Normal
23 385 SSG 10-Aug-05 month 3 Normal
23 385 SSG 11-Nov-05 month 6 Normal
23 386 Combination 18-Apr-05 day 0 Normal
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23 386 Combination 25-Apr-05 day 7 Normal
23 386 Combination 11-May-05 day 14 Normal
23 386 Combination 14-May-05 end day Normal
23 386 Combination 19-Aug-05 month 3 Normal
23 386 Combination 11-Nov-05 month 6 Normal
23 387 Combination 18-Apr-05 day 0 Normal
23 387 Combination 25-Apr-05 day 7 Normal
23 387 Combination 2-May-05 day 14 Normal
23 387 Combination 6-May-05 end day Normal
23 387 Combination 10-Aug-05 month 3 Normal
23 387 Combination 11-Nov-05 month 6 Normal
23 388 PM 18-Apr-05 day 0 Normal
23 388 PM 25-Apr-05 day 7 Normal
23 388 PM 2-May-05 day 14 Normal
23 388 PM 10-May-05 end day Normal
23 388 PM 28-Sep-05 month 3 Normal
23 388 PM 2-Dec-05 month 6 Normal
23 389 SSG 18-Apr-05 day 0 Normal
23 389 SSG 26-Apr-05 day 7 Normal
23 389 SSG 3-May-05 day 14 Normal
23 389 SSG 10-May-05 day 21 Normal
23 389 SSG 20-May-05 end day Normal
23 389 SSG 5-Sep-05 month 3 Normal
23 389 SSG 9-Dec-05 month 6 Normal
23 390 PM 18-Apr-05 day 0 Normal
23 390 PM 26-Apr-05 day 7 Normal
23 390 PM 3-May-05 day 14 Normal
23 390 PM 11-May-05 end day Normal
23 390 PM 10-Aug-05 month 3 Normal
23 390 PM 2-Dec-05 month 6 Normal
23 391 Combination 21-Apr-05 day 0 Normal
23 391 Combination 28-Apr-05 day 7 Normal
23 391 Combination 5-May-05 day 14 Normal
23 391 Combination 9-May-05 end day Normal
23 391 Combination 19-Aug-05 month 3 Normal
23 391 Combination 17-Nov-05 month 6 Normal
23 392 Combination 21-Apr-05 day 0 Normal
23 392 Combination 28-Apr-05 day 7 Normal
23 392 Combination 5-May-05 day 14 Normal
23 392 Combination 22-Jul-05 month 3 Normal
23 392 Combination 1-Oct-05 month 6 Normal
23 393 SSG 21-Apr-05 day 0 Normal
23 393 SSG 28-Apr-05 day 7 Normal
23 393 SSG 5-May-05 day 14 Normal
23 393 SSG 12-May-05 day 21 Normal
23 393 SSG 22-May-05 end day Normal
23 393 SSG 19-Aug-05 month 3 Normal
23 393 SSG 17-Nov-05 month 6 Normal
23 394 PM 18-Apr-05 day 0 Normal
23 394 PM 2-May-05 day 7 Normal
23 394 PM 9-May-05 day 14 Normal
23 394 PM 17-May-05 end day Normal
23 394 PM 19-Aug-05 month 3 Normal
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23 394 PM 17-Nov-05 month 6 Normal
23 395 PM 28-Apr-05 day 0 Normal
23 395 PM 5-May-05 day 7 Normal
23 395 PM 12-May-05 day 14 Normal
23 395 PM 20-May-05 end day Normal
23 395 PM 14-Dec-05 month 6 Normal
23 396 SSG 12-May-05 day 0 Normal
23 396 SSG 19-May-05 day 7 Normal
23 396 SSG 26-May-05 day 14 Normal
23 396 SSG 2-Jun-05 day 21 Normal
23 396 SSG 12-Jun-05 end day Normal
23 396 SSG 15-Sep-05 month 3 Normal
23 396 SSG 14-Dec-05 month 6 Normal
23 397 SSG 12-May-05 day 0 Normal
23 397 SSG 19-May-05 day 7 Normal
23 397 SSG 26-May-05 day 14 Normal
23 397 SSG 2-Jun-05 day 21 Normal
23 397 SSG 12-Jun-05 end day Normal
23 397 SSG 15-Sep-05 month 3 Normal
23 397 SSG 14-Dec-05 month 6 Normal
23 398 Combination 18-May-05 day 0 Normal
23 398 Combination 24-May-05 day 7 Normal
23 398 Combination 31-May-05 day 14 Normal
23 398 Combination 4-Jun-05 end day Normal
23 398 Combination 1-Oct-05 month 3 Normal
23 398 Combination 15-Dec-05 month 6 Normal
23 399 PM 16-May-05 day 0 Normal
23 399 PM 24-May-05 day 7 Normal
23 399 PM 31-May-05 day 14 Normal
23 399 PM 8-Jun-05 end day Normal
23 399 PM 14-Oct-05 month 3 Normal
23 399 PM 14-Dec-05 month 6 Normal
23 400 PM 3-Jun-05 day 0 Normal
23 400 PM 9-Jun-05 day 7 Normal
23 400 PM 16-Jun-05 day 14 Normal
23 400 PM 24-Jun-05 end day Normal
23 400 PM 14-Oct-05 month 3 Normal
23 400 PM 12-Jan-06 month 6 Normal
23 401 Combination 2-Jun-05 day 0 Normal
23 401 Combination 9-Jun-05 day 7 Normal
23 401 Combination 16-Jun-05 day 14 Normal
23 401 Combination 20-Jun-05 end day Normal
23 401 Combination 19-Sep-05 month 3 Normal
23 401 Combination 20-Dec-05 month 6 Normal
23 402 Combination 2-Jun-05 day 0 Normal
23 402 Combination 9-Jun-05 day 7 Normal
23 402 Combination 16-Jun-05 day 14 Normal
23 402 Combination 20-Jun-05 end day Normal
23 402 Combination 23-Sep-05 month 3 Normal
23 402 Combination 20-Dec-05 month 6 Normal
23 403 SSG 2-Jun-05 day 0 Normal
23 403 SSG 10-Jun-05 day 7 Normal
23 403 SSG 17-Jun-05 day 14 Normal
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23 403 SSG 24-Jun-05 day 21 Normal
23 403 SSG 4-Jul-05 end day Normal
23 403 SSG 30-Sep-05 month 3 Normal
23 403 SSG 12-Jan-06 month 6 Normal
23 404 SSG 2-Jun-05 day 0 Normal
23 404 SSG 10-Jun-05 day 7 Normal
23 404 SSG 17-Jun-05 day 14 Normal
23 404 SSG 24-Jun-05 day 21 Normal
23 404 SSG 4-Jul-05 end day Normal
23 404 SSG 12-Jan-06 month 6 Normal
23 405 PM 2-Jun-05 day 0 Normal
23 405 PM 16-Jun-05 day 7 Normal
23 405 PM 23-Jun-05 day 14 Normal
23 405 PM 1-Jul-05 end day Normal
23 405 PM 30-Sep-05 month 3 Normal
23 405 PM 5-Jan-06 month 6 Normal
34 451 Combination 16-Nov-04 day 0 Normal
34 451 Combination 30-Nov-04 day 14 Normal
34 451 Combination 4-Dec-04 end day Normal
34 451 Combination 3-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA
34 452 PM 16-Nov-04 day 0 Normal
34 452 PM 30-Nov-04 day 14 Normal
34 452 PM 8-Dec-04 end day Normal
34 453 PM 17-Nov-04 day 0 Normal
34 453 PM 1-Dec-04 day 14 Normal
34 453 PM 9-Dec-04 end day Normal
34 454 Combination 18-Nov-04 day 0 Normal
34 454 Combination 4-Dec-04 day 14 Normal
34 454 Combination 8-Dec-04 end day Normal
34 454 Combination 7-Jun-05 month 6 Abnormal (CI) NEGATIVE TWAVE V1-V4 CLINICALLY WELL
34 455 PM 18-Nov-04 day 0 Normal
34 455 PM 2-Dec-04 day 14 Normal
34 455 PM 11-Dec-04 end day Normal
34 456 SSG 18-Nov-04 day 0 Normal
34 456 SSG 2-Dec-04 day 14 Normal
34 456 SSG 19-Dec-04 end day Normal
34 456 SSG 25-Jan-05 month 3 Normal
34 457 Combination 18-Nov-04 day 0 Normal
34 457 Combination 2-Dec-04 day 14 Normal
34 457 Combination 6-Dec-04 end day Normal
34 458 PM 19-Nov-04 day 0 Normal
34 458 PM 3-Dec-04 day 14 Normal
34 458 PM 11-Dec-04 end day Normal
34 459 Combination 20-Nov-04 day 0 Normal
34 459 Combination 3-Dec-04 day 14 Abnormal (CI) SINUS ARRHYTHMIA
34 459 Combination 7-Dec-04 end day Normal
34 459 Combination 7-Jan-05 month 3 Abnormal (CI) SINUS ARRHYTHMIA
34 459 Combination 3-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA
34 460 PM 22-Nov-04 day 0 Normal
34 460 PM 7-Dec-04 day 14 Normal
34 460 PM 15-Dec-04 end day Normal
34 461 SSG 24-Nov-04 day 0 Normal
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34 461 SSG 10-Dec-04 day 14 Normal
34 462 SSG 24-Nov-04 day 0 Normal
34 462 SSG 8-Dec-04 day 14 Normal
34 462 SSG end day Normal
34 462 SSG 7-Jun-05 month 6 Abnormal (CS) SINUS TACHYCARDIA (BPM. 140/MIN) 
CLINICALLY WELL
34 463 Combination 27-Nov-04 day 0 Normal
34 463 Combination 3-Dec-04 day 7 Abnormal (CI) NEW SINUS ARRHYTHMIA
34 463 Combination 11-Dec-04 day 14 Abnormal (CI) SINUS ARRHYTHMIA (SINCE DAY 7)
34 463 Combination 14-Dec-04 end day Abnormal (CI) SINUS ARRHYTHMIA SINCE DAY 7
34 464 SSG 27-Nov-04 day 0 Normal
34 464 SSG 11-Dec-04 day 14 Normal
34 464 SSG 27-Dec-04 end day Normal
34 464 SSG 2-Jun-05 month 6 Abnormal (CI) RIGHT VENTRICULAR CONDUCTION DELAY
34 465 SSG 27-Nov-04 day 0 Normal
34 465 SSG 12-Dec-04 day 14 Normal
34 465 SSG 29-Dec-04 end day Normal
34 465 SSG 3-Jun-05 month 6 Abnormal (CI) NEGATIVE TWAVE V1-V4 CLINICAL WELL
34 466 Combination 27-Nov-04 day 0 Normal
34 466 Combination 13-Dec-04 day 14 Abnormal (CI) NEW SINUS ARRHYTHMIA
34 466 Combination 17-Dec-04 end day Abnormal (CI) SINUS ARRHYTHMIA
34 467 PM 28-Nov-04 day 0 Normal
34 467 PM 12-Dec-04 day 14 Normal
34 467 PM 20-Dec-04 end day Normal
34 467 PM 5-Feb-05 month 3 Abnormal (CS) SINUS TACHYCARDIA (139 BPM) FIRST 
DEGREE AV BLOCK RIGHT VENTRICULAR 
CONDUCTION DELAY NEG. TWAVE V1-V4 
SHORT QT INTERVAL
34 468 Combination 28-Nov-04 day 0 Normal
34 468 Combination 12-Dec-04 day 14 Normal
34 468 Combination 16-Dec-04 end day Normal
34 468 Combination 4-Jun-05 month 6 Normal
34 469 SSG 28-Nov-04 day 0 Normal
34 469 SSG 12-Dec-04 day 14 Normal
34 469 SSG 29-Dec-04 end day Abnormal (CI) SINUS ARRHYTHMIA (NEW)
34 469 SSG 10-Jun-05 month 6 Normal
34 470 Combination 29-Nov-04 day 0 Normal
34 470 Combination 12-Dec-04 day 14 Normal
34 470 Combination 16-Dec-04 end day Normal
34 470 Combination 7-Jun-05 month 6 Normal
34 471 PM 29-Nov-04 day 0 Normal
34 471 PM 12-Dec-04 day 14 Normal
34 471 PM 20-Dec-04 end day Normal
34 472 SSG 1-Dec-04 day 0 Normal
34 472 SSG 14-Dec-04 day 14 Normal
34 472 SSG 31-Dec-04 end day Abnormal (CI) SINUS ARRHYTHMIA
34 472 SSG 9-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA INCOMPLETE RIGHT 
BUNDLE BRANCH BLOCK CLINICALLY WELL
34 473 PM 1-Dec-04 day 0 Normal
34 473 PM 16-Dec-04 day 14 Normal
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34 473 PM 24-Dec-04 end day Normal
34 474 Combination 3-Dec-04 day 0 Abnormal (CI) ECG: FIRST DEGREE AV-BLOCK, 
CLINICALLY WELL
34 474 Combination 17-Dec-04 day 14 Normal
34 474 Combination 21-Dec-04 end day Normal
34 474 Combination 1-Jun-05 month 6 Normal
34 475 PM 4-Dec-04 day 0 Normal
34 475 PM 18-Dec-04 day 14 Normal
34 475 PM 26-Dec-04 end day Normal
34 476 PM 4-Dec-04 day 0 Normal
34 476 PM 18-Dec-04 day 14 Normal
34 476 PM 26-Dec-04 end day Normal
34 476 PM 10-Jan-05 month 3 Normal
34 477 SSG 6-Dec-04 day 0 Normal
34 477 SSG 19-Dec-04 day 14 Normal
34 477 SSG 5-Jan-05 end day Normal
34 477 SSG 5-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA RIGHT VENTRICULAR 
CONDUCTION DELAY CLINICALLY WELL
34 478 Combination 6-Dec-04 day 0 Normal
34 478 Combination 20-Dec-04 day 14 Normal
34 478 Combination 24-Dec-04 end day Abnormal (CI) SINUS ARRHYTHMIA
34 478 Combination 5-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA RIGHT VENTRICULAR 
CONDUCTION DELAY CLINICALLY WELL
34 479 SSG 8-Dec-04 day 0 Normal
34 479 SSG 21-Dec-04 day 14 Normal
34 479 SSG 7-Jan-05 end day Abnormal (CI) SINUS ARRHYTHMIA
34 479 SSG 1-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA
34 480 SSG 8-Dec-04 day 0 Normal
34 480 SSG 22-Dec-04 day 14 Normal
34 480 SSG 8-Jan-05 end day Abnormal (CI) SINUS ARRHYTHMIA
34 480 SSG 13-Jun-05 month 6 Normal
34 481 Combination 9-Dec-04 day 0 Normal
34 481 Combination 22-Dec-04 day 14 Abnormal (CI) SINUS ARRHYTHMIA (NEW)
34 481 Combination 26-Dec-04 end day Abnormal (CI) SINUS ARRHYTHMIA
34 481 Combination 3-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA
34 482 Combination 9-Dec-04 day 0 Normal
34 482 Combination 23-Dec-04 day 14 Normal
34 482 Combination 27-Dec-04 end day Normal
34 482 Combination 5-Jun-05 month 6 Abnormal (CI) EARLY REPOLARIZATION CLINICALLY WELL
34 483 PM 9-Dec-04 day 0 Normal
34 483 PM 23-Dec-04 day 14 Normal
34 483 PM 31-Dec-04 end day Normal
34 483 PM 31-May-05 month 6 Normal
34 484 PM 11-Dec-04 day 0 Normal
34 485 Combination 11-Dec-04 day 0 Normal
34 485 Combination 25-Dec-04 day 14 Normal
34 485 Combination 29-Dec-04 end day Normal
34 485 Combination 6-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA RIGHT VENTRICULAR 
CONDUCTION DELAY NEG. T IN V1-V4 
CLINICALLY WELL
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34 486 Combination 11-Dec-04 day 0 Normal
34 486 Combination 26-Dec-04 day 14 Normal
34 486 Combination 30-Dec-04 end day Normal
34 486 Combination 6-Jun-05 month 6 Normal
34 487 SSG 12-Dec-04 day 0 Normal
34 487 SSG 26-Dec-04 day 14 Normal
34 487 SSG 12-Jan-05 end day Abnormal (CI) NEW SINUS ARRHYTHMIA
34 487 SSG 2-Jun-05 month 6 Abnormal (CI) RIGHT VENTRICULAR CONDUCTION DELAY
34 488 SSG 13-Dec-04 day 0 Normal
34 488 SSG 27-Dec-04 day 14 Abnormal (CI) SINUS ARRHYTHMIA (NEW)
34 488 SSG 13-Jan-05 end day Abnormal (CI) SINUS ARRHYTHMIA
34 488 SSG 17-Feb-05 month 3 Abnormal (CI) SINUS ARRYTHMIA
34 488 SSG 7-Jun-05 month 6 Abnormal (CI) NEGATIVE TWAVE V1-V4 CLINICALLY WELL
34 489 SSG 15-Dec-04 day 0 Normal
34 489 SSG 29-Dec-04 day 14 Normal
34 489 SSG 15-Jan-05 end day Abnormal (CI) SINUS ARRHYTHMIA (NEW)
34 489 SSG 3-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA
34 490 PM 16-Dec-04 day 0 Abnormal (CI) ECG: FIRST DEGREE AV BLOCK, 
CLINICALLY WELL
34 490 PM 29-Dec-04 day 14 Abnormal (CI) ECG: OCCASIONAL VENTRICULAR 
PREMATURE COMPLEXES, CLINICALLY 
WELL
34 490 PM 6-Jan-05 end day Normal ECG: OCCASIONAL PREMATUR 
VENTRICULAR COMPLEXES, CLINICALLY 
WELL
34 490 PM 15-Jun-05 month 6 Normal
34 491 PM 16-Dec-04 day 0 Normal ECG: OCCASIONAL VENTRICULAR 
PREMATURE COMPLEXES, CLINICALLY 
WELL
34 491 PM 30-Dec-04 day 14 Normal
34 491 PM 7-Jan-05 end day Normal
34 492 PM 16-Dec-04 day 0 Normal
34 492 PM 1-Jan-05 day 14 Normal
34 492 PM 9-Jan-05 end day Normal
34 492 PM 2-Jun-05 month 6 Abnormal (CI) RIGHT VENTRICULAR CONDUCTION DELAY
34 493 SSG 17-Dec-04 day 0 Normal
34 493 SSG 30-Dec-04 day 14 Normal
34 493 SSG 16-Jan-05 end day Normal
34 493 SSG 12-Apr-05 month 3 Abnormal (CI) NEGATIVE TWAVE V1-V4 CLINICALLY WELL
34 494 Combination 17-Dec-04 day 0 Normal
34 494 Combination 30-Dec-04 day 14 Normal
34 494 Combination 3-Jan-05 end day Normal
34 494 Combination 3-Jun-05 month 6 Normal
34 495 SSG 17-Dec-04 day 0 Normal
34 495 SSG 31-Dec-04 day 14 Normal
34 495 SSG 17-Jan-05 end day Abnormal (CI) SINUS ARRHYTHMIA
34 495 SSG 2-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA
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34 496 SSG 18-Dec-04 day 0 Abnormal (CI) ECG: RSR IN LEAD V1 V2, RIGHT 
VENTRICULAR CONDUCTION DELAY, 
CLINICALLY WELL
34 496 SSG 1-Jan-05 day 14 Normal
34 496 SSG 18-Jan-05 end day Abnormal (CI) ECG: RIGHT VENTRICULAR CONDUCTION 
DELAY CLINICALLY WELL
34 496 SSG 2-Jun-05 month 6 Abnormal (CI) RIGHT VENTRICULAR CONDUCTION DELAY
34 497 PM 20-Dec-04 day 0 Normal
34 497 PM 3-Jan-05 day 14 Normal
34 497 PM 11-Jan-05 end day Abnormal (CI) SINUS ARRHYTHMIA (NEW)
34 497 PM 12-Feb-05 month 3 Abnormal (CI) RIGHT VENTRICULAR CONDUCTION DELAY
34 498 SSG 20-Dec-04 day 0 Normal
34 498 SSG 3-Jan-05 day 14 Abnormal (CI) 1-3 PREMATURE VENTRICULAR 
COMPLEXES (NEW) (MINUTE)
34 498 SSG 5-Jun-05 month 6 Abnormal (CI) RIGHT VENTRICULAR CONDUCTION DELAY
34 499 Combination 20-Dec-04 day 0 Normal
34 499 Combination 3-Jan-05 day 14 Normal
34 499 Combination 7-Jan-05 end day Normal
34 499 Combination 6-Jun-05 month 6 Normal
34 500 PM 20-Dec-04 day 0 Normal
34 500 PM 4-Jan-05 day 14 Normal
34 500 PM 12-Jan-05 end day Normal
34 500 PM 7-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA RIGHT VENTRICULAR 
CONDUCTION DELAY CLINICALLY WELL
34 501 Combination 21-Dec-04 day 0 Normal
34 501 Combination 4-Jan-05 day 14 Abnormal (CI) NEW SINUS ARRHYTHMIA
34 501 Combination 8-Jan-05 end day Abnormal (CI) SINUS ARRHYTHMIA
34 501 Combination 8-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA RIGHT VENTRICULAR 
CONDUCTION DELAY
34 502 Combination 22-Dec-04 day 0 Normal
34 502 Combination 5-Jan-05 day 14 Normal
34 502 Combination 9-Jan-05 end day Abnormal (CI) SINUS ARRHYTHMIA
34 502 Combination 8-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA
34 503 PM 24-Dec-04 day 0 Normal
34 503 PM 7-Jan-05 day 14 Abnormal (CI) ECG: FIRST DEGREE AV-BLOCK CLINICALLY 
WELL
34 503 PM 15-Jan-05 end day Abnormal (CI) ECG: RIGHT BUNDLE BRANCH 
CONDUCTION DELAY CLINICALLY WELL
34 504 Combination 26-Dec-04 day 0 Normal
34 504 Combination 9-Jan-05 day 14 Abnormal (CI) SINUS ARRHYTHMIA
34 504 Combination 13-Jan-05 end day Abnormal (CI) SINUS ARRHYTHMIA
34 505 SSG 27-Dec-04 day 0 Normal
34 505 SSG 10-Jan-05 day 14 Normal
34 505 SSG 27-Jan-05 end day Normal
34 505 SSG 1-Jun-05 month 6 Normal
34 506 SSG 30-Dec-04 day 0 Normal
34 506 SSG 13-Jan-05 day 14 Normal
34 506 SSG 30-Jan-05 end day Abnormal (CI) ECG: SINUS ARRHYTHMIA CLINICALLY 
WELL
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34 506 SSG 10-Jun-05 month 6 Normal
34 507 SSG 30-Dec-04 day 0 Normal
34 507 SSG 13-Jan-05 day 14 Normal
34 507 SSG 30-Jan-05 end day Abnormal (CI) ECG: SINUS ARRHYTHMIA CLINICALLY 
WELL
34 507 SSG 31-May-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA
34 508 PM 30-Dec-04 day 0 Normal
34 508 PM 13-Jan-05 day 14 Normal
34 508 PM 21-Jan-05 end day Normal
34 509 PM 31-Dec-04 day 0 Abnormal (CI) SINUS TACHYCARDIA
34 509 PM 15-Jan-05 day 14 Abnormal (CI) SINUS TACHYCARDIA REDUCING (117 BPM)
34 509 PM 23-Jan-05 end day Normal
34 510 Combination 31-Dec-04 day 0 Normal
34 510 Combination 18-Jan-05 end day Abnormal (CI) ECG: RIGHT VENTRICULAR CONDUCTION 
DELAY CLINICALLY WELL
34 510 Combination 13-Jun-05 month 6 Abnormal (CI) RIGHT VENTRICULAR CONDUCTION DELAY
34 511 Combination 1-Jan-05 day 0 Normal
34 511 Combination 14-Jan-05 day 14 Abnormal (CI) ECG: OCCASIONAL PREMATURE 
VENTRICULAR COMPLEXES, CLINICALLY 
WELL
34 511 Combination 18-Jan-05 end day Normal
34 511 Combination 10-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA
34 512 PM 1-Jan-05 day 0 Normal
34 512 PM 15-Jan-05 day 14 Abnormal (CS) SINUS TACHYCARDIA (FREQUENCE 145)
34 512 PM 23-Jan-05 end day Normal
34 513 Combination 2-Jan-05 day 0 Normal
34 513 Combination 16-Jan-05 day 14 Normal
34 513 Combination 20-Jan-05 end day Normal
34 513 Combination 28-Feb-05 month 3 Normal
34 513 Combination 31-May-05 month 6 Normal
34 514 SSG 3-Jan-05 day 0 Normal
34 514 SSG 17-Jan-05 day 14 Normal
34 514 SSG 3-Feb-05 end day Abnormal (CI) ECG: SINUS ARRHYTHMIA, RIGHT 
VENTRICULAR CONDUCTION DELAY 
CLINICALLY WELL
34 514 SSG 7-Jun-05 month 6 Abnormal (CI) RIGHT VENTRICULAR CONDUCTION DELAY 
SINUS ARRHYTHMIA CLINICALLY WELL
34 515 SSG 5-Jan-05 day 0 Normal
34 515 SSG 18-Jan-05 day 14 Normal
34 515 SSG end day Abnormal (CI) ECG: SINUS ARRHYTHMIA CLINICALLY 
WELL
34 515 SSG 14-May-05 month 3 Abnormal (CI) SINUS ARRHYTHMIA
34 516 PM 6-Jan-05 day 0 Abnormal (CI) SINUS ARRHYTHMIA
34 516 PM 19-Jan-05 day 14 Normal
34 516 PM 27-Jan-05 end day Normal
34 516 PM 6-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA
34 517 PM 6-Jan-05 day 0 Normal
34 517 PM 19-Jan-05 day 14 Normal
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34 517 PM 27-Jan-05 end day Abnormal (CI) ECG: SINUS ARRHYTHMIA CLINICALLY 
WELL
34 518 SSG 6-Jan-05 day 0 Normal
34 518 SSG 21-Jan-05 day 14 Normal
34 518 SSG 8-Feb-05 end day Abnormal (CI) ECG: SINUS ARRHYTHMIA
34 518 SSG 4-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA RIGHT VENTRICULAR 
CONDUCTION DELAY
34 519 PM 6-Jan-05 day 0 Normal
34 519 PM 20-Jan-05 day 14 Normal
34 519 PM 28-Jan-05 end day Normal
34 519 PM 3-Apr-05 month 3 Normal
34 520 SSG 10-Jan-05 day 0 Normal
34 520 SSG 24-Jan-05 day 14 Normal
34 520 SSG 10-Feb-05 end day Abnormal (CI) ECG: SINUS ARRHYTHMIA CLINICALLY 
WELL
34 520 SSG 5-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA
34 521 PM 10-Jan-05 day 0 Normal
34 521 PM 24-Jan-05 day 14 Normal
34 521 PM 1-Feb-05 end day Normal
34 522 Combination 11-Jan-05 day 0 Abnormal (CI) ECG: LOW QRS VOLTAGE IN LIMB LEADS 
CLINICALLY WELL
34 522 Combination 24-Jan-05 day 14 Abnormal (CI) ECG: LOW QRS VOLTAGE IN LIMB LEADS, 
PR INTERVAL DROPPED CLINICALLY WELL
34 522 Combination 28-Jan-05 end day Abnormal (CI) ECG: PR INTERVAL DROPPED, LOW QRS 
VOLTAGE IN LIMB LEADS CLINICALLY WELL
34 523 SSG 12-Jan-05 day 0 Normal
34 523 SSG 27-Jan-05 day 14 Abnormal (CI) ECG: FIRST DEGREE AV BLOCK CLINICALLY 
WELL
34 523 SSG 13-Feb-05 end day Normal
34 523 SSG 1-Jun-05 month 6 Normal
34 524 Combination 12-Jan-05 day 0 Normal
34 524 Combination 26-Jan-05 day 14 Normal
34 524 Combination 30-Jan-05 end day Abnormal (CI) ECG: SINUS ARRHYTHMIA CLINICALLY 
WELL
34 524 Combination 5-Jun-05 month 6 Normal
34 525 Combination 12-Jan-05 day 0 Normal
34 525 Combination 26-Jan-05 day 14 Normal
34 525 Combination 30-Jan-05 end day Abnormal (CI) ECG: SINUS ARRHYTHMIA CLINICALLY 
WELL
34 525 Combination 9-Jun-05 month 6 Normal
34 526 SSG 13-Jan-05 day 0 Normal
34 526 SSG 27-Jan-05 day 14 Abnormal (CI) ECG: RIGHT VENTRICULAR CONDUCTION 
DELAY CLINICALLY WELL
34 526 SSG 13-Feb-05 end day Abnormal (CI) ECG: SINUS ARRHYTHMIA, RIGHT 
VENTRICULAR CONDUCTION DELAY 
CLINICALLY WELL
34 526 SSG 4-Jun-05 month 6 Abnormal (CI) RIGHT VENTRICULAR CONDUCTION DELAY 
CLINICALLY WELL
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34 527 Combination 14-Jan-05 day 0 Abnormal (CS) ECG: REENTRY TACHYCARDIA 
(FREQUENCE: 150BPM)DD:SINUS 
TACHYCARDIA POSSIBLE NEGATIVE T 
WAVE IN III, AV+-, V4-V6 CONSISTENT WITH 
LATERAL/INFERIOR ISCHEMIA CLINICALLY 
WELL
34 527 Combination 28-Jan-05 day 14 Abnormal (CI) ECG: RIGHT VENTRICULAR CONDUCTION 
DELAY, POSSIBLE SINUS RHYTHMIA 
FREQUENCE - 114BPM CLINICALLY WELL
34 527 Combination 1-Feb-05 end day Abnormal (CS) ECG: RIGHT VENTRICULAR CONDUCTION 
DELAY POSSIBLE SINUS TACHYCARDIA 
(F:120BPM)
34 527 Combination 31-May-05 month 6 Abnormal (CI) RIGHT VENTRICULAR CONDUCTION DELAY
34 528 PM 16-Jan-05 day 0 Normal
34 528 PM 30-Jan-05 day 14 Normal
34 528 PM 7-Feb-05 end day Abnormal (CI) ECG: SINUS ARRHYTHMIA, RIGHT 
VENTRICULAR CONDUCTION DELAY 
POSSIBLE CLINICALLY WELL
34 529 Combination 17-Jan-05 day 0 Normal
34 529 Combination 31-Jan-05 day 14 Abnormal (CI) ECG: SINUS ARRHYTHMIA, RIGHT 
VENTRICULAR CONDUCTION DELAY 
CLINICALLY WELL
34 529 Combination 4-Feb-05 end day Abnormal (CI) ECG: SINUS ARRHYTHMIA, RIGHT 
VENTRICULAR CONDUCTION DELAY 
CLINICALLY WELL
34 529 Combination 14-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA INCOMPLETE RIGHT 
BUNDLE BRANCH BLOCK
34 530 Combination 19-Jan-05 day 0 Normal
34 530 Combination 2-Feb-05 day 14 Normal
34 530 Combination 6-Feb-05 end day Normal
34 530 Combination 14-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA
34 531 SSG 20-Jan-05 day 0 Normal
34 531 SSG 3-Feb-05 day 14 Normal
34 531 SSG 20-Feb-05 end day Normal
34 532 Combination 20-Jan-05 day 0 Normal
34 532 Combination 3-Feb-05 day 14 Normal
34 532 Combination 7-Feb-05 end day Normal
34 532 Combination 3-Jun-05 month 6 Normal
34 533 SSG 22-Jan-05 day 0 Normal
34 533 SSG 5-Feb-05 day 14 Normal
34 533 SSG 22-Feb-05 end day Normal
34 533 SSG 9-Jun-05 month 6 Abnormal (CI) SINUS ARRHYTHMIA
34 534 PM 23-Jan-05 day 0 Normal
34 534 PM 6-Feb-05 day 14 Normal
34 534 PM 14-Feb-05 end day Abnormal (CS) ECG: SINUS TACHYCARDIA (BPM:150/MIN)
34 535 PM 23-Jan-05 day 0 Normal
34 535 PM 6-Feb-05 day 14 Normal
34 535 PM 14-Feb-05 end day Normal
34 535 PM 25-Mar-05 month 3 Abnormal (CS) SINUS TACHYCARDIA (FREQUENCE 146 
BPM)
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34 536 PM 24-Jan-05 day 0 Abnormal (CI) ECG: INCOMPLETE RIGHT BUNDLE BRANCH 
BLOCK CLINICALLY WELL
34 536 PM 7-Feb-04 day 14 Abnormal (CI) ECG: RIGHT VENTRICULAR CONDUCTION 
DELAY, SINUS ARRHYTHMIA CLINICALLY 
WELL
34 536 PM 15-Feb-05 end day Abnormal (CI) ECG: RIGHT VENTRICULAR CONDUCTION 
DELAY CLINICALLY WELL
34 536 PM 6-Jun-05 month 6 Abnormal (CI) INCOMPLETE RIGHT BUNDLE BRANCH 
BLOCK POSSIBLE CLINICALLY WELL
34 537 SSG 25-Jan-05 day 0 Abnormal (CI) ECG: RIGHT VENTRICULAR CONDUCTION 
DELAY, CLINICALLY WELL
34 537 SSG 7-Feb-05 day 14 Abnormal (CS) ECG: SINUS TACHYCARDIA (F-150BPM) 
CLINICALLY WELL
34 537 SSG 24-Feb-05 end day Normal
34 537 SSG 31-May-05 month 6 Abnormal (CI) #NAME?
34 538 PM 24-Jan-05 day 0 Normal
34 538 PM 8-Feb-05 day 14 Normal
34 538 PM 16-Feb-05 end day Normal
34 539 Combination 25-Jan-05 day 0 Abnormal (CI) SINUS ARRHYTHMIA
34 539 Combination 8-Feb-05 day 14 Normal
34 539 Combination 12-Feb-05 end day Normal
34 539 Combination 5-Jun-05 month 6 Normal
34 540 SSG 26-Jan-05 day 0 Normal
34 540 SSG 9-Feb-05 day 14 Normal
34 540 SSG 26-Feb-05 end day Normal
34 540 SSG 31-May-05 month 6 Normal
35 646 PM 28-Jan-05 day 0 Normal
35 646 PM 3-Feb-05 day 7 Normal
35 646 PM 10-Feb-05 day 14 Normal
35 646 PM 18-Feb-05 end day Normal
35 647 PM 29-Jan-05 day 0 Normal
35 647 PM 5-Feb-05 day 7 Normal
35 647 PM 12-Feb-05 day 14 Normal
35 647 PM 20-Feb-05 end day Normal
35 648 Combination 29-Jan-05 day 0 Normal 
35 648 Combination 5-Feb-05 day 7 Normal
35 648 Combination day 14 Not Done
35 648 Combination 16-Feb-05 end day Normal
35 648 Combination 25-Aug-05 month 6 Normal
35 649 Combination 29-Jan-05 day 0 Normal
35 649 Combination 5-Feb-05 day 7 Normal
35 649 Combination day 14 Not Done
35 649 Combination 16-Feb-05 end day Normal
35 649 Combination 15-Sep-05 month 6 Normal
35 650 SSG 29-Jan-05 day 0 Normal
35 650 SSG 5-Feb-05 day 7 Normal
35 650 SSG 12-Feb-05 day 14 Normal
35 650 SSG 19-Feb-05 day 21 Normal
35 650 SSG 1-Mar-05 end day Normal
35 650 SSG 15-Sep-05 month 6 Normal
35 651 SSG 29-Jan-05 day 0 Normal
35 651 SSG 5-Feb-05 day 7 Normal
35 651 SSG 12-Feb-05 day 14 Normal
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35 651 SSG 19-Feb-05 day 21 Normal
35 651 SSG 1-Mar-05 end day Normal
35 651 SSG 15-Sep-05 month 6 Normal
35 652 PM 31-Jan-05 day 0 Normal
35 652 PM 7-Feb-05 day 7 Normal
35 652 PM 14-Feb-05 day 14 Normal
35 652 PM 22-Feb-05 end day Normal
35 653 Combination 1-Feb-05 day 0 Normal
35 653 Combination 9-Feb-05 day 7 Normal
35 653 Combination 16-Feb-05 day 14 Normal
35 653 Combination 20-Feb-05 end day Normal
35 653 Combination 25-Aug-05 month 6 Normal
35 654 SSG 1-Feb-05 day 0 Normal
35 654 SSG 9-Feb-05 day 7 Normal
35 654 SSG 16-Feb-05 day 14 Normal
35 654 SSG 23-Feb-05 day 21 Normal
35 654 SSG 5-Mar-05 end day Normal
35 654 SSG 19-Sep-05 month 6 Normal
35 655 Combination 1-Feb-05 day 0 Normal
35 655 Combination 9-Feb-05 day 7 Normal
35 655 Combination 16-Feb-05 day 14 Normal
35 655 Combination 20-Feb-05 end day Normal
35 655 Combination 25-Aug-05 month 6 Normal
35 656 SSG 3-Feb-05 day 0 Normal 
35 656 SSG 9-Feb-05 day 7 Normal
35 656 SSG 16-Feb-05 day 14 Normal
35 656 SSG 23-Feb-05 day 21 Normal
35 656 SSG 5-Mar-05 end day Normal
35 656 SSG 17-Oct-05 month 6 Normal
35 657 PM 7-Feb-05 day 0 Normal
35 657 PM 14-Feb-05 day 7 Normal
35 657 PM 21-Feb-05 day 14 Normal
35 657 PM 1-Mar-05 end day Normal
35 657 PM 15-Sep-05 month 6 Normal
35 658 Combination 6-Feb-05 day 0 Normal
35 658 Combination 14-Feb-05 day 7 Normal
35 658 Combination 21-Feb-05 day 14 Normal
35 658 Combination 25-Feb-05 end day Normal
35 658 Combination 25-Aug-05 month 6 Normal
35 659 SSG 7-Feb-05 day 0 Normal
35 659 SSG 14-Feb-05 day 7 Normal
35 659 SSG 21-Feb-05 day 14 Normal
35 659 SSG 28-Feb-05 day 21 Normal
35 659 SSG 10-Mar-05 end day Normal
35 659 SSG 29-Oct-05 month 6 Normal
35 660 PM 10-Feb-05 day 0 Normal
35 660 PM 16-Feb-05 day 7 Normal
35 660 PM 23-Feb-05 day 14 Normal
35 660 PM 3-Mar-05 end day Normal
35 660 PM 15-Sep-05 month 6 Normal  
35 661 Combination 16-Feb-05 day 0 Normal LOW VOLTAGE ECG IN THE LIMB LEADS
35 661 Combination 22-Feb-05 day 7 Normal LOW VOLTAGE QRS IN THE LIMP LEADS 
35 661 Combination 1-Mar-05 day 14 Normal
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35 661 Combination 5-Mar-05 end day Normal
35 661 Combination 24-Sep-05 month 6 Normal
35 662 PM 19-Feb-05 day 0 Normal
35 662 PM 26-Feb-05 day 7 Normal
35 662 PM 5-Mar-05 day 14 Normal
35 662 PM 13-Mar-05 end day Normal 
35 663 SSG 19-Feb-05 day 0 Normal
35 663 SSG 26-Feb-05 day 7 Abnormal (CS) QT LONG THE PATIENT WAS WELL
35 663 SSG 5-Mar-05 day 14 Normal
35 663 SSG 12-Mar-05 day 21 Abnormal (CS) PROLONGED QT INTERVAL. THE WAS WELL
35 663 SSG 22-Mar-05 end day Normal 
35 663 SSG 22-Sep-05 month 6 Normal
35 664 Combination 19-Feb-05 day 0 Normal
35 664 Combination 26-Feb-05 day 7 Abnormal (CS) QT PROLONGATION
35 665 SSG 22-Feb-05 day 0 Normal
35 665 SSG 1-Mar-05 day 7 Normal
35 665 SSG 8-Mar-05 day 14 Normal
35 665 SSG 15-Mar-05 day 21 Normal
35 665 SSG 25-Mar-05 end day Normal
35 665 SSG 23-Oct-05 month 6 Normal  
35 666 SSG 25-Feb-05 day 0 Normal
35 666 SSG 4-Mar-05 day 7 Normal
35 666 SSG 11-Mar-05 day 14 Normal
35 666 SSG 18-Mar-05 day 21 Normal
35 666 SSG 28-Mar-05 end day Normal
35 666 SSG 25-Sep-05 month 6 Normal
35 667 Combination 28-Feb-05 day 0 Normal
35 667 Combination 6-Mar-05 day 7 Normal
35 667 Combination 13-Mar-05 day 14 Normal
35 667 Combination 17-Mar-05 end day Normal
35 667 Combination 27-Oct-05 month 6 Normal
35 668 PM 28-Feb-05 day 0 Normal
35 668 PM 6-Mar-05 day 7 Normal
35 668 PM 13-Mar-05 day 14 Normal
35 668 PM 21-Mar-05 end day Normal
35 668 PM 25-Sep-05 month 6 Normal
35 669 PM 28-Feb-05 day 0 Normal
35 669 PM 6-Mar-05 day 7 Normal
35 669 PM 13-Mar-05 day 14 Normal
35 669 PM 21-Mar-05 end day Normal
35 670 SSG 3-Mar-05 day 0 Normal
35 670 SSG 9-Mar-05 day 7 Normal
35 670 SSG 16-Mar-05 day 14 Normal
35 670 SSG 23-Mar-05 day 21 Normal
35 670 SSG 2-Apr-05 end day Normal
35 670 SSG 17-Oct-05 month 6 Normal
35 671 PM 10-Mar-05 day 0 Normal
35 671 PM 17-Mar-05 day 7 Normal
35 671 PM 24-Mar-05 day 14 Normal
35 671 PM 1-Apr-05 end day Normal
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35 672 Combination 10-Mar-05 day 0 Normal
35 672 Combination 17-Mar-05 day 7 Normal
35 672 Combination 24-Mar-05 day 14 Normal
35 672 Combination 28-Mar-05 end day Normal
35 672 Combination 29-Oct-05 month 6 Normal
35 673 SSG 10-Mar-05 day 0 Normal
35 673 SSG 17-Mar-05 day 7 Normal
35 673 SSG 24-Mar-05 day 14 Normal
35 673 SSG 31-Mar-05 day 21 Normal
35 673 SSG 10-Apr-05 end day Normal
35 673 SSG 17-Oct-05 month 6 Normal
35 674 Combination 11-Mar-05 day 0 Normal
35 674 Combination 19-Mar-05 day 7 Normal
35 674 Combination 26-Mar-05 day 14 Normal
35 674 Combination 30-Mar-05 end day Normal
35 674 Combination 25-Oct-05 month 6 Normal
35 675 PM 13-Mar-05 day 0 Normal
35 675 PM 20-Mar-05 day 7 Normal
35 675 PM 27-Mar-05 day 14 Normal
35 675 PM 4-Apr-05 end day Normal
35 676 PM 19-Mar-05 day 0 Normal
35 676 PM 26-Mar-05 day 7 Normal
35 676 PM 2-Apr-05 day 14 Normal
35 676 PM 10-Apr-05 end day Normal  
35 676 PM 25-Oct-05 month 6 Normal
35 677 SSG 19-Mar-05 day 0 Normal
35 677 SSG 26-Mar-05 day 7 Normal
35 678 Combination 20-Mar-05 day 0 Normal
35 678 Combination 28-Mar-05 day 7 Normal
35 678 Combination 4-Apr-05 day 14 Normal
35 678 Combination 8-Apr-05 end day Normal
35 678 Combination 25-Oct-05 month 6 Normal
35 679 SSG 20-Mar-05 day 0 Normal
35 679 SSG 28-Mar-05 day 7 Normal
35 679 SSG 4-Apr-05 day 14 Normal
35 679 SSG 11-Apr-05 day 21 Normal
35 679 SSG 20-Apr-05 end day Normal
35 679 SSG 25-Oct-05 month 6 Normal
35 680 Combination 21-Mar-05 day 0 Normal
35 680 Combination 28-Mar-05 day 7 Normal
35 680 Combination 4-Apr-05 day 14 Normal
35 680 Combination 8-Apr-05 end day Normal
35 680 Combination 17-Oct-05 month 6 Normal
35 681 Combination 21-Mar-05 day 0 Normal
35 681 Combination 28-Mar-05 day 7 Normal
35 681 Combination 4-Apr-05 day 14 Normal
35 681 Combination 8-Apr-05 end day Normal
35 681 Combination 23-Oct-05 month 6 Normal
35 682 PM 21-Mar-05 day 0 Normal
35 682 PM 28-Mar-05 day 7 Normal FIRST DEGRE AV BLOCK
35 682 PM 4-Apr-05 day 14 Normal
35 682 PM 12-Apr-05 end day Normal FIRST DEGREE AV BLOCK
35 683 Combination 21-Mar-05 day 0 Normal
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35 683 Combination 28-Mar-05 day 7 Normal
35 683 Combination 4-Apr-05 day 14 Normal
35 683 Combination 8-Apr-05 end day Normal
35 683 Combination 29-Oct-05 month 6 Normal
35 684 SSG 8-Apr-05 day 0 Normal
35 684 SSG 15-Apr-05 day 7 Normal
35 684 SSG 22-Apr-05 day 14 Normal
35 684 SSG 29-Apr-05 day 21 Normal
35 684 SSG 9-May-05 end day Normal
35 684 SSG 13-Nov-05 month 6 Normal
35 685 PM 8-Apr-05 day 0 Normal
35 685 PM 15-Apr-05 day 7 Normal
35 685 PM 22-Apr-05 day 14 Normal
35 685 PM 30-Apr-05 end day Normal
35 685 PM 29-Oct-05 month 6 Normal
35 686 PM 13-Apr-05 day 0 Normal
35 686 PM 19-Apr-05 day 7 Normal
35 686 PM 26-Apr-05 day 14 Normal
35 686 PM 4-May-05 end day Normal
35 687 SSG 13-Apr-05 day 0 Normal
35 687 SSG 19-Apr-05 day 7 Normal
35 687 SSG 26-Apr-05 day 14 Normal
35 687 SSG 3-May-05 day 21 Normal
35 687 SSG 13-May-05 end day Normal
35 687 SSG 29-Oct-05 month 6 Normal
35 688 PM 15-Apr-05 day 0 Normal
35 688 PM 22-Apr-05 day 7 Normal
35 688 PM 29-Apr-05 day 14 Normal
35 688 PM 7-May-05 end day Normal
35 688 PM 25-Oct-05 month 6 Normal
35 689 Combination 16-Apr-05 day 0 Normal
35 689 Combination 22-Apr-05 day 7 Normal
35 689 Combination 29-Apr-05 day 14 Normal
35 689 Combination 3-May-05 end day Normal
35 690 SSG 16-Apr-05 day 0 Normal
35 690 SSG 22-Apr-05 day 7 Normal
35 690 SSG 29-Apr-05 day 14 Normal
35 690 SSG 6-May-05 day 21 Normal
35 690 SSG 16-May-05 end day Normal
35 690 SSG 29-Oct-05 month 6 Normal
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11 1 PM 17-Jun-05 Normal
11 3 Combination 17-Jun-05 Normal
11 6 Combination 27-Jun-05 Normal
11 11 Combination 4-Jul-05 Normal
11 14 SSG 8-Jul-05 Normal
11 16 Combination 12-Jul-05 Normal
11 17 Combination 14-Jul-05 Normal
11 31 SSG 21-Sep-05 Normal
11 57 Combination 29-May-06 Normal
11 83 SSG 15-Aug-06 Normal
11 93 SSG 4-Jan-07 Normal
11 105 SSG 16-Feb-07 Normal
12 241 Combination 7-Jun-05 Normal
12 242 SSG 7-Jun-05 Normal
12 243 PM 7-Jun-05 Normal
12 244 SSG 7-Jun-05 Normal
12 245 PM 18-Jul-05 Normal
12 246 PM 2-Aug-05 Normal
12 247 PM 12-Sep-05 Normal
12 248 PM 23-Sep-05 Normal
12 249 Combination 24-Oct-05 Normal
12 250 SSG 24-Oct-05 Normal
12 251 Combination 27-Oct-05 Normal
12 252 SSG 27-Oct-05 Normal
12 253 SSG 27-Oct-05 Normal
12 254 Combination 27-Oct-05 Normal
12 255 Combination 29-Oct-05 Normal
12 256 Combination 14-Nov-05 Normal
12 257 SSG 14-Nov-05 Normal
12 258 SSG 30-Nov-05 Normal
12 259 PM 26-Dec-05 Normal
12 260 PM 26-Dec-05 Normal
12 261 Combination 26-Dec-05 Normal
12 262 PM 26-Dec-05 Normal
12 263 SSG 20-Jan-06 Normal
12 264 Combination 14-Feb-06 Normal
12 265 SSG 8-Feb-06 Normal
12 266 PM 15-Feb-06 Normal
12 267 SSG 11-Feb-06 Normal
12 268 PM 6-Mar-06 Normal
12 269 Combination 13-Mar-06 Normal
12 270 Combination 13-Mar-06 Normal
12 271 SSG 27-Mar-06 Normal
12 272 PM 4-Apr-06 Normal
12 273 SSG 4-Apr-06 Normal
12 274 SSG 4-Apr-06 Normal
12 275 Combination 4-Apr-06 Normal
12 276 PM 4-Apr-06 Normal THERE IS CARDIOMEGALLY BUT NO ACTIVE PARACHYMAL LESION
ON THE LUNG
12 277 Combination 18-Apr-06 Normal
12 278 SSG 17-Apr-06 Normal
12 279 PM 18-Apr-06 Normal
12 280 SSG 18-Apr-06 Normal
12 281 Combination 18-Apr-06 Normal
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12 282 PM 27-Apr-06 Normal
12 283 PM 10-May-06 Normal
12 284 Combination 18-Jun-06 Normal
12 285 Combination 18-May-06 Normal
12 286 PM 22-Dec-06 Normal
12 287 SSG 21-Dec-06 Normal
12 288 Combination 26-Dec-06 Normal
12 289 Combination 26-Dec-06 Normal
12 290 SSG 4-Jan-07 Normal
12 291 SSG 8-Jan-07 Normal
12 292 PM 15-Jan-07 Normal
12 293 SSG 21-Jan-07 Normal
12 294 Combination 19-Feb-07 Normal CARDIOMEGALY
12 295 Combination 11-Mar-07 Normal
12 303 PM 4-Jun-07 Normal
12 304 Combination 5-Jun-07 Normal
12 309 PM 18-Jun-07 Normal
12 314 SSG 30-Aug-07 Normal
12 321 Combination 4-Sep-07 Normal
23 361 Combination 18-Jan-05 Normal
23 362 PM 18-Jan-05 Normal
23 363 PM 18-Jan-05 Normal
23 364 Combination 18-Jan-05 Normal
23 365 SSG 18-Jan-05 Normal
23 366 Combination 28-Feb-05 Normal
23 367 SSG 28-Jan-05 Normal
23 368 PM 28-Jan-05 Normal
23 369 Combination 28-Jan-05 Abnormal BASAL BRONCHO PNEUMONIA
23 370 SSG 28-Jan-05 Abnormal BILATERAL BASAL BRONCHO PNEUMONIA
23 371 PM 4-Feb-05 Normal
23 372 PM 10-Feb-05 Normal
23 373 SSG 17-Feb-05 Normal
23 374 SSG 18-Feb-05 Normal
23 375 Combination 24-Feb-05 Normal
23 376 SSG 24-Feb-05 Normal
23 377 Combination 8-Mar-05 Normal
23 378 Combination 8-Mar-05 Normal
23 379 PM 24-Feb-05 Abnormal FEATURES SUGGESTIVE OF PULMONARY TUBERCULOSIS 
(PATIENT TREATED AS A CASE OF PNEUMONIA)
23 380 SSG 8-Mar-05 Normal
23 381 PM 8-Mar-05 Normal
23 382 Combination 18-Mar-05 Normal
23 383 PM 29-Mar-05 Abnormal PERI-HILAR BRONCHOVASCULAR MARKINGS ARE PROMINENT 
INDICATING AN INFLAMMATORY PROCESS.
23 384 SSG 29-Mar-05 Abnormal BILATERAL BRONCHO-PNEUMONIA
23 385 SSG 1-Apr-05 Abnormal BILATERAL PEVICARDIAC OPACIFICATION. PATIENT TREATED AS 
A CASE OF PNEUMONIA
23 386 Combination 14-Apr-05 Normal
23 387 Combination 14-Apr-05 Normal
23 388 PM 15-Apr-05 Normal
23 389 SSG 18-Apr-05 Normal
23 390 PM 15-Apr-05 Normal
23 391 Combination 20-Apr-05 Normal
23 392 Combination 21-Apr-05 Normal
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23 393 SSG 21-Apr-05 Normal
23 394 PM 18-Apr-05 Abnormal BOTH PRERIHILAN AND RIGHT LOWER ZONE OPACIFIED BUT 
CLEAR COSTOPHENIC ANGLES TAKEN TO BE PNEUMONIA.
23 395 PM 23-Apr-05 Normal
23 396 SSG 12-May-05 Normal
23 397 SSG 12-May-05 Abnormal BASAL PNEUMOTITIS WAS REPORTED
23 398 Combination 16-May-05 Normal
23 399 PM 18-May-05 Normal
23 400 PM 18-May-05 Abnormal INCREASED LUNG MARKINGS  OVER THE RIGHT LUNG BASE. 
FEATURES CONSISTENT WITH RIGHT BASAL PNEUMONIA
23 401 Combination 30-May-05 Normal
23 402 Combination 30-May-05 Normal
23 403 SSG 2-Jun-05 Normal
23 404 SSG 1-Jun-05 Normal
23 405 PM 30-May-05 Abnormal ATYPICAL PNEUMONIA
35 660 PM 8-Feb-05 Normal
35 686 PM 11-Apr-05 Normal
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11 1 PM 17-Jun-05 day 0 Normal
11 1 PM 24-Jun-05 day 7 Normal
11 1 PM 1-Jul-05 day 14 Normal
11 1 PM 9-Jul-05 end day Normal
11 1 PM 6-Oct-05 month 3 Normal
11 1 PM 5-Jan-06 month 6 Normal
11 2 Combination 17-Jun-05 day 0 Normal
11 2 Combination 24-Jun-05 day 7 Normal
11 2 Combination 1-Jul-05 day 14 Normal
11 2 Combination 5-Jul-05 end day Normal
11 2 Combination 30-Sep-05 month 3 Normal
11 2 Combination 6-Jan-06 month 6 Normal
11 3 Combination 18-Jun-05 day 0 Normal
11 3 Combination 25-Jun-05 day 7 Normal
11 3 Combination 2-Jul-05 day 14 Normal
11 3 Combination 6-Jul-05 end day Normal
11 3 Combination 1-Oct-05 month 3 Normal
11 3 Combination 29-Dec-05 month 6 Normal
11 4 PM 27-Jun-05 day 0 Normal
11 4 PM 6-Jul-05 day 7 Normal
11 4 PM 13-Jul-05 day 14 Normal
11 4 PM 21-Jul-05 end day Normal
11 4 PM 31-Dec-05 month 3 Normal
11 4 PM 28-Jan-06 month 6 Normal
11 5 PM 28-Jun-05 day 0 Normal
11 5 PM 6-Jul-05 day 7 Normal
11 5 PM 13-Jul-05 day 14 Normal
11 5 PM 21-Jul-05 end day Abnormal (CI) MILD HEARING LOSS AT 250HZ & 500HZ ON 
THE RIGHT EAR
11 5 PM 18-Oct-05 month 3 Normal
11 5 PM 14-Feb-06 month 6 Normal
11 6 Combination 29-Jun-05 day 0 Normal
11 6 Combination 8-Jul-05 day 7 Normal
11 6 Combination 15-Jul-05 day 14 Normal
11 6 Combination 19-Jul-05 end day Normal
11 6 Combination 17-Oct-05 month 3 Normal
11 6 Combination 10-Jan-06 month 6 Normal
11 7 PM 30-Jun-05 day 0 Normal
11 7 PM 8-Jul-05 day 7 Abnormal (CI) MILD HEARING LOSS  RT EAR - AT 500HZ - 
30DBL  8000HZ - 40DBL LT EAR - AT 500HZ - 
30DBC  8000HZ - 35DBL
11 7 PM 15-Jul-05 day 14 Normal
11 7 PM 23-Jul-05 end day Abnormal (CI) MODERATE DEGREE OF HEARING LOSS AT 
8000HZ
11 7 PM 21-Oct-05 month 3 Normal
11 7 PM 24-Jan-06 month 6 Normal
11 8 SSG 30-Jun-05 day 0 Normal
11 8 SSG 8-Jul-05 day 7 Abnormal (CI) MILD HEARING LOSS LEFT EAR AT 250HZ - 
30DB 500HZ - 35DB 1000HZ - 30DB
11 8 SSG 15-Jul-05 day 14 Normal
11 8 SSG 24-Jul-05 day 21 Normal
11 8 SSG 1-Aug-05 end day Normal
11 8 SSG 31-Oct-05 month 3 Normal
11 8 SSG 30-Jan-06 month 6 Normal
LEAP 0104a Appendices
Page 613 of 756
Appendix 47: Listing of Audiometry findings per patient
Centre Patient Treatment Audiometry Visit Audiometry Comment
Number Number Date Findings
11 9 SSG 30-Jun-05 day 0 Normal
11 9 SSG 9-Jul-05 day 7 Normal
11 9 SSG 16-Jul-05 day 14 Normal
11 9 SSG 24-Jul-05 day 21 Normal
11 9 SSG 2-Aug-05 end day Normal
11 9 SSG 1-Nov-05 month 3 Normal
11 9 SSG 30-Jan-06 month 6 Normal
11 10 SSG 1-Jul-05 day 0 Normal
11 10 SSG 9-Jul-05 day 7 Normal
11 10 SSG 16-Jul-05 day 14 Normal
11 10 SSG 24-Jul-05 day 21 Normal
11 10 SSG 2-Aug-05 end day Normal
11 10 SSG 1-Nov-05 month 3 Normal
11 10 SSG 30-Jan-06 month 6 Normal
11 11 Combination 2-Jul-05 day 0 Normal
11 11 Combination 11-Jul-05 day 7 Normal
11 11 Combination 18-Jul-05 day 14 Normal MILD HEARING LOSS AT LEFT EAR BY 500HZ 
- 35DB RIGHT EAR NORMAL.
11 11 Combination 22-Jul-05 end day Normal
11 11 Combination 21-Oct-05 month 3 Normal
11 11 Combination 21-Jan-06 month 6 Normal
11 12 Combination 7-Jul-05 day 0 Normal
11 12 Combination 14-Jul-05 day 7 Abnormal (CI) MODERATE HEARING LOSS ON LEFT EAR 
8000HZ - 45DB(C)
11 12 Combination 21-Jul-05 day 14 Normal ON HIS LEFT EAR - BY 8000HZ FREQUENCY 
HE HEARD ON 40DB. HIS HEARING LEVEL IS 
ON MILD
11 12 Combination 25-Jul-05 end day Normal ON HIS LEFT EAR - BY 8000HZ FREQUENCY 
ON 40DB. HIS HEARING LEVEL IS ON MILD
11 12 Combination 25-Oct-05 month 3 Normal
11 12 Combination 6-Feb-06 month 6 Normal
11 13 SSG 10-Jul-05 day 0 Normal NORMAL EXCEPT - 8000HZ SHE HEARS ON 
40DBHL IN BOTH LEFT AND RIGHT EAR - 
MILD
11 13 SSG 18-Jul-05 day 7 Normal
11 13 SSG 25-Jul-05 day 14 Normal MODERATE HEARING LOSS AT 8000HZ RT 
BOTH EARS
11 13 SSG 1-Aug-05 day 21 Normal MODERATE HEARING LOSS AT 8000HZ
11 13 SSG 11-Aug-05 end day Normal HEARING LOSS BOTH EAR. ON RIGHT EAR 
250HZ - 50DB, 500HZ - 50DB, 1000HZ - 40DB 
8000HZ - 55DB. ON LEFT EAR 250HZ - 40DB 
500HZ - 35DB 8000HZ - 45DB
11 13 SSG 10-Nov-05 month 3 Normal
11 13 SSG 7-Feb-06 month 6 Normal
11 14 SSG 7-Jul-05 day 0 Normal
11 14 SSG 18-Jul-05 day 7 Normal
11 14 SSG 25-Jul-05 day 14 Normal
11 14 SSG 1-Aug-05 day 21 Normal
11 14 SSG 11-Aug-05 end day Abnormal (CI) HEARING LOSS ON LEFT EAR BY 250HZ - 
30DB ON RIGHT EAR NORMAL
11 14 SSG 11-Nov-05 month 3 Normal
11 14 SSG 16-Apr-06 month 6 Normal
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11 15 PM 13-Jul-05 day 0 Normal
11 15 PM 20-Jul-05 day 7 Normal
11 15 PM 7-Nov-05 month 3 Normal
11 15 PM 6-Apr-06 month 6 Normal
11 16 Combination 14-Jul-05 day 0 Normal
11 16 Combination 21-Jul-05 day 7 Normal
11 16 Combination 28-Jul-05 day 14 Normal
11 16 Combination 1-Aug-05 end day Normal
11 16 Combination 31-Oct-05 month 3 Abnormal (CI) MODERATE HEARING LOSS ON LEFT EAR 
8000HZ - 55 DBHL(AC)
11 16 Combination 6-Feb-06 month 6 Normal
11 17 Combination 16-Jul-05 day 0 Normal
11 17 Combination 25-Jul-05 day 7 Abnormal (CI) LEFT EAR HAS DROPPED TO MODERATE 
LOSS FROM NORMAL AT BASELINE
11 17 Combination 1-Aug-05 day 14 Abnormal (CI) LEFT EAR HAVE MODERATE LOSS ON 8000 
HZ - 45 DB(C)
11 17 Combination 5-Aug-05 end day Normal MILD HEARING LOSS BOTH SIDE OF EAR BY 
8000 HZ LEFT EAR - 40 DB RIGHT EAR - 35 
DB
11 17 Combination 7-Nov-05 month 3 Normal
11 17 Combination 7-Feb-06 month 6 Normal
11 18 SSG 13-Aug-05 day 0 Normal
11 18 SSG 22-Aug-05 day 7 Normal
11 18 SSG 29-Aug-05 day 14 Normal
11 18 SSG 5-Sep-05 day 21 Normal MILD LOSS ON THE LEFT EAR BY 250HZ - 
30DB , 500HZ - 30DB. RIGHT EAR NORMAL
11 18 SSG 15-Sep-05 end day Normal MILD HEARING LOSS ON THE RIGHT EAR BY 
250HZ - 30DB, 500HZ - 30DB & 8000HZ - 30DB. 
LEFT EAR NORMAL
11 18 SSG 22-Dec-05 month 3 Normal
11 18 SSG 15-Mar-06 month 6 Normal
11 19 Combination 15-Aug-05 day 0 Normal
11 19 Combination 22-Aug-05 day 7 Normal
11 19 Combination 29-Aug-05 day 14 Normal MILD HEARING LOSS BOTH EAR BY ON 
RIGHT EAR 8000HZ - 35DB, LEFT EAR 4000HZ 
- 30DB 8000HZ - 35DB.
11 19 Combination 2-Sep-05 end day Normal MILD HEARING LOSS BOTH EARS ON RIGHT 
EAR  4000HZ - 30DB 8000HZ - 35DB ON LEFT 
EAR 4000HZ - 30DB  8000HZ - 40DB
11 19 Combination 29-Nov-05 month 3 Normal
11 19 Combination 28-Feb-06 month 6 Normal
11 20 SSG 14-Aug-05 day 0 Normal
11 20 SSG 22-Aug-05 day 7 Normal
11 20 SSG 29-Aug-05 day 14 Normal
11 20 SSG 5-Sep-05 day 21 Normal
11 20 SSG 15-Sep-05 end day Normal
11 20 SSG 14-Dec-05 month 3 Normal
11 20 SSG 14-Mar-06 month 6 Normal
11 21 SSG 14-Aug-05 day 0 Normal MILD HEARING LOSS ON BOTH EAR ON 
RIGHT EAR 500 HZ - 30 DB HL ON LEFT EAR 
8000 HZ - 40 DB HL
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11 21 SSG 22-Aug-05 day 7 Normal MILD HEARING LOSS ON LEFT EAR 8000 HZ - 
35 DBHL (AC)
11 21 SSG 29-Aug-05 day 14 Normal MILD HEARING LOSS ON LEFT EAR 8000 HZ 
30 DB HL(AC)
11 21 SSG 5-Sep-05 day 21 Normal MILD HEARING LOSS ON BOTH EAR 8000 HZ -
30 DB(C)
11 21 SSG 15-Sep-05 end day Normal MILD HEARING LOSS BOTH EAR. ON THE 
RIGHT EAR BY. 250HZ - 35DB, 500HZ - 40DB, 
1000HZ - 30DB. ON THE LEFT BY. 8000HZ - 
35DB.
11 21 SSG 22-Dec-05 month 3 Normal
11 21 SSG 15-Mar-06 month 6 Normal
11 22 SSG 16-Aug-05 day 0 Normal
11 22 SSG 23-Aug-05 day 7 Normal
11 22 SSG 30-Aug-05 day 14 Normal
11 22 SSG 6-Sep-05 day 21 Normal MILD HEARING LOSS ON THE LEFT EAR BY 
250HZ - 35DB. RIGHT EAR NORMAL
11 22 SSG 16-Sep-05 end day Normal
11 22 SSG 15-Dec-05 month 3 Normal
11 22 SSG 14-Apr-06 month 6 Normal
11 23 PM 18-Aug-05 day 0 Normal
11 23 PM 26-Aug-05 day 7 Normal
11 23 PM 2-Sep-05 day 14 Normal
11 23 PM 10-Sep-05 end day Normal
11 23 PM 11-Jan-06 month 3 Normal
11 23 PM 31-May-06 month 6 Normal
11 24 PM 18-Aug-05 day 0 Normal
11 24 PM 26-Aug-05 day 7 Normal MILD HEARING LOSS BOTH EAR BY - 500HZ - 
30 ON RIGHT EAR - 250HZ - 30 ON LEFT EAR
11 24 PM 2-Sep-05 day 14 Normal
11 24 PM 10-Sep-05 end day Normal MILD HEARING LOSS ON THE LEFT EAR BY 
250HZ - 30DB, 500HZ - 30DB. RIGHT EAR 
NORMAL
11 24 PM 28-Nov-05 month 3 Normal
11 24 PM 10-Feb-06 month 6 Normal
11 25 SSG 19-Aug-05 day 0 Normal
11 25 SSG 26-Aug-05 day 7 Normal HEARING LOSS ON THE LEFT EAR BY 500HZ -
30, 250HZ - 40. MILD
11 25 SSG 2-Sep-05 day 14 Normal
11 25 SSG 9-Sep-05 day 21 Normal
11 25 SSG 19-Sep-05 end day Normal
11 25 SSG 3-Jan-06 month 3 Normal
11 25 SSG 14-Apr-06 month 6 Normal
11 26 Combination 24-Aug-05 day 0 Normal
11 26 Combination 31-Aug-05 day 7 Normal
11 26 Combination 7-Sep-05 day 14 Normal MILD HEARING LOSS ON THE LEFT EAR BY 
8000HZ - 40DB. RIGHT EAR NORMAL
11 26 Combination 11-Sep-05 end day Normal
11 26 Combination 10-Nov-05 month 3 Normal
11 26 Combination 16-Apr-06 month 6 Normal
11 27 PM 17-Sep-05 day 0 Normal MILD HEARING IMPAIRMENT AT RIGHT EAR 
BY 8000HZ - 40DB
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11 27 PM 25-Sep-05 day 7 Normal MILD HEARING LOSS ON LEFT EAR AT 250HZ 
- 30DBHL
11 27 PM 2-Oct-05 day 14 Normal MILD HEARING LOSS ON LEFT EAR 500 AND 
8000HZ - 30 DB(C) AND 250HZ 35DB(C)
11 27 PM 10-Oct-05 end day Normal MILD HEARING LOSS ON LEFT EAR 8000HZ 
40DB(A)
11 27 PM 30-Jan-06 month 3 Abnormal (CI) MILD HEARING LOSS (26 TO 40) FOR THE 
RIGHT EAR AND MODERATE HEARING LOSS 
FOR THE LEFT EAR
11 28 Combination 17-Sep-05 day 0 Normal
11 28 Combination 27-Sep-05 day 7 Normal
11 28 Combination 4-Oct-05 day 14 Normal
11 28 Combination 8-Oct-05 end day Normal
11 28 Combination 5-Jan-06 month 3 Normal
11 28 Combination 4-Apr-06 month 6 Normal
11 29 PM 20-Sep-05 day 0 Normal MILD HEARING LOSS ON LEFT EAR BY 250HZ
- 30DB. RIGHT EAR NORMAL
11 29 PM 28-Sep-05 day 7 Normal MILD HEARING LOSS ON LEFT EAR 500 AND 
1000HZ - 30DBHL (AC)
11 29 PM 5-Oct-05 day 14 Normal MODERATE HEARING LOSS ON LEFT EAR 
ON 2000 AND 8000HZ - 35DBA, ON 500 AND 
4000HZ - 40DBA AND ON 250HZ - 45 DBA
11 29 PM 13-Oct-05 end day Normal
11 29 PM 11-Jan-06 month 3 Normal
11 29 PM 18-Apr-06 month 6 Normal
11 30 PM 22-Sep-05 day 0 Normal MILD HEARING LOSS ON RIGHT EAR BY 
500HZ - 30DB ON LEFT BY 8000HZ - 40DB
11 30 PM 28-Sep-05 day 7 Normal MILD HEARING LOSS ON BOTH EAR ON 
RIGHT EAR 4000 AND 8000HZ - 30 DBA ON 
LEFT EAR 500, 1000, 2000 - 30DBA AND 250 
AND 8000HZ - 35DBA
11 30 PM 5-Oct-05 day 14 Normal MILD HEARING LOSS ON BOTH EAR, LEFT 
EAR 8000HZ - 40DBA AND ON RIGHT EAR 
500HZ - 30DBA
11 30 PM 13-Oct-05 end day Normal MODERATE HEARING LOSS ON LEFT EAR 
8000HZ - 45DB(A)
11 30 PM 3-Jan-06 month 3 Normal
11 30 PM 14-Apr-06 month 6 Normal
11 31 SSG 21-Sep-05 day 0 Normal MILD HEARING LOSS ON BOTH RIGHT AND 
LEFT EAR
11 31 SSG 29-Sep-05 day 7 Normal MILD HEARING LOSS ON LEFT EAR 500 AND 
1000HZ - 30DBHL(AC) AND 250HZ - 
35DBHL(C)
11 31 SSG 6-Oct-05 day 14 Normal MODERATE HEARING LOSS ON LEFT EAR 
4000HZ - 45DBA, 8000HZ - 50DBA AND 250HZ -
55DBA AND 500HZ - 50DBA
11 31 SSG 13-Oct-05 day 21 Normal MODERATE HEARING LOSS ON LEFT EAR 
250HZ - 55DB(A) AND 500HZ - 50DB(A) AND 
MILD HEARING LOSS ON RIGHT EAR
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11 31 SSG 23-Oct-05 end day Normal MILD HEARING LOSS ON LEFT EAR 250 AND 
500HZ - 40DB(A) AND 1000HZ AND 8000HZ - 
35DB(A)
11 31 SSG 3-Feb-06 month 3 Normal
11 31 SSG 7-Apr-06 month 6 Normal
11 32 Combination 22-Sep-05 day 0 Abnormal (CI) MODERATE HEARING LOSS ON RIGHT EAR 
8000HZ - 50DBHL
11 32 Combination 30-Sep-05 day 7 Abnormal (CI) MODERATELY SEVERE ON RIGHT EAR ON 
8000HZ - DBA
11 32 Combination 7-Oct-05 day 14 Normal MILD HEARING LOSS ON BOTH EAR ON 
RIGHT EAR - 250, 500  AND 8000HZ - 30DBA 
AND ON LEFT EAR 250 AND 500HZ - 35DBA
11 32 Combination 11-Oct-05 end day Normal MILD HEARING LOSS ON BOTH EAR ON 
RIGHT EAR 8000HZ - 35DB(A) ON LEFT EAR 
500HZ - 30DB(A) AND 250HZ 35DB(A)
11 32 Combination 10-Jan-06 month 3 Normal
11 32 Combination 3-Apr-06 month 6 Normal
11 33 SSG 24-Sep-05 day 0 Abnormal (CI) MILD HEARING LOSS ON RIGHT EAR 4000HZ -
35DBHL
11 33 SSG 1-Oct-05 day 7 Abnormal (CI) MILD HEARING LOSS ON RIGHT EAR 8000HZ -
30DB(C) AND MODERATE HEARING LOSS ON 
LEFT EAR ON 4000HZ 45DB(C)
11 33 SSG 8-Oct-05 day 14 Normal MILD HEARING LOSS ON 8000HZ - 35DB(A) 
ON RIGHT EAR
11 33 SSG 15-Oct-05 day 21 Normal MILD HEARING LOSS ON RIGHT EAR 4000HZ 
AND 8000HZ - 30DB(A)
11 33 SSG 25-Oct-05 end day Normal
11 33 SSG 24-Jan-06 month 3 Normal
11 33 SSG 16-Apr-06 month 6 Normal
11 34 PM 26-Sep-05 day 0 Abnormal (CI) MILD HEARING LOSS ON LEFT EAR ON 500 
AND 250HZ - 30DBHL(AC)
11 34 PM 3-Oct-05 day 7 Normal
11 34 PM 10-Oct-05 day 14 Normal
11 34 PM 18-Oct-05 end day Normal
11 34 PM 17-Jan-06 month 3 Normal
11 34 PM 16-Apr-06 month 6 Normal
11 35 SSG 25-Sep-05 day 0 Normal MILD HEARING LOSS ON RIGHT EAR 500HZ - 
30DBHL(AC)
11 35 SSG 3-Oct-05 day 7 Abnormal (CI) MODERATE HEARING LOSS ON BOTH EAR 
RIGHT EAR - 8000HZ - 55DB(C) LEFT EAR 
8000HZ - 55DB(C)
11 35 SSG 10-Oct-05 day 14 Normal MILD HEARING LOSS ON BOTH EAR ON LEFT 
EAR 8000HZ - 30DB(A) ON RIGHT EAR 500HZ -
40DB (A) 250HZ - 35DB(A)
11 35 SSG 17-Oct-05 day 21 Normal MILD HEARING LOSS ON LEFT EAR 8000HZ 
30DBA AND ON RIGHT EAR 250HZ AND 
500HZ - 30DBA
11 35 SSG 27-Oct-05 end day Normal
11 35 SSG 11-Jan-06 month 3 Normal
11 35 SSG 16-Apr-06 month 6 Normal
11 36 SSG 27-Sep-05 day 0 Abnormal (CI) MODERATE HEARING LOSS ON LEFT EAR 
8000HZ - 50DBA
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11 36 SSG 4-Oct-05 day 7 Normal MODERATE HEARING LOSS AT LEFT EAR BY 
8000HZ - 45DB. NORMAL AT RIGHT EAR
11 36 SSG 11-Oct-05 day 14 Normal MILD HEARING LOSS ON LEFT EAR 8000HZ - 
35DB(A)
11 36 SSG 18-Oct-05 day 21 Normal MILD HEARING LOSS OF LEFT EAR BY 
8000HZ - 35DB
11 36 SSG 28-Oct-05 end day Normal MILD HEARING LOSS AT LEFT EAR BY 250HZ 
- 30DB(A) & 500HZ  - 30DB(A). RIGHT EAR 
NORMAL.
11 36 SSG 25-Jan-06 month 3 Normal
11 36 SSG 10-Jun-06 month 6 Normal
11 37 Combination 27-Sep-05 day 0 Normal MILD HEARING LOSS FOR RT EAR BY 
8000HZ - 35DBA AND MODERATE FOR LT 
EAR
11 37 Combination 4-Oct-05 day 7 Normal MILD HEARING LOSS AT RIGHT EAR 8000HZ -
30DB BY LEFT EAR 2000HZ - 30DB, 4000HZ - 
45DB 8000HZ - 45DB - MODERATE FOR THE 
RT EAR
11 37 Combination 11-Oct-05 day 14 Normal ON LEFT EAR MODERATE HEARING LOSS 
4000HZ - 50DB(A). 8000HZ - 40DB(A) ON 
RIGHT EAR MILD HEARING LOSS 4000HZ - 
40DB(A)
11 37 Combination 15-Oct-05 end day Normal MODERATE HEARING LOSS ON LEFT EAR 
4000HZ - 50DB(A)
11 37 Combination 17-Jan-06 month 3 Normal
11 37 Combination 14-Apr-06 month 6 Normal
11 38 PM 17-Oct-05 day 0 Normal MODERATE HEARING LOSS ON RIGHT EAR 
8000HZ - 45DB(A) MILD HEARING LOSS ON 
LEFT EAR 4000 AND 8000HZ - 40DB(A)
11 38 PM 25-Oct-05 day 7 Normal MODERATE HEARING LOSS ON BOTH EAR 
RIGHT EAR  8000HZ - 50DBA AND ON LEFT 
EAR 4000HZ - 40DB(A) 8000HZ - 45DB(A)
11 38 PM 1-Nov-05 day 14 Normal MODERATE HEARING LOSS ON BOTH EAR 
ON LEFT EAR 8000HZ - 50 AND ON RIGHT 
EAR 8000HZ - 50DBA
11 38 PM 9-Nov-05 end day Normal MODERATE HEARING LOSS BOTH EAR. AT 
LEFT EAR ON 4000HZ - 40DB(A) & 8000HZ - 
50DB(A). AT RIGHT EAR BY 8000HZ - 50DB(A).
11 38 PM 15-Feb-06 month 3 Normal
11 38 PM 1-Jun-06 month 6 Normal
11 39 PM 18-Oct-05 day 0 Normal MILD HEARING LOSS ON BOTH EAR 250HZ 
AND 2000HZ - 30DBA ON RIGHT EAR 500 AND 
8000HZ - 35DB(A) - RIGHT EAR ON LEFT EAR. 
250HZ AND 8000HZ - 35DB(A)
11 39 PM 25-Oct-05 day 7 Normal MILD HEARING LOSS ON BOTH EAR ON 
RIGHT EAR 8000HZ - 40DB(A) AND ON LEFT 
EAR 250 AND 500HZ - 35DB(A) AND 8000HZ - 
40DB(A) 
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11 39 PM 1-Nov-05 day 14 Normal MILD HEARING LOSS ON BOTH EAR ON 
RIGHT EAR 8000, 500 AND 1000HZ - 40DBA 
ON LEFT EAR 250, 500 AND 8000HZ - 40DBA
11 39 PM 9-Nov-05 end day Normal MILD HEARING LOSS BOTH EAR. AT RIGHT 
EAR BY 250HZ - 30DB(A), 500HZ, 1000HZ - 
30DB(A) & 8000HZ - 35DB(A). AT LEFT EAR BY 
250HZ - 35DB(A)
11 39 PM 7-Mar-06 month 3 Abnormal (CI) MODERATLY - SEVERE ON BOTH EAR ON 
RIGHT EAR 8000HZ - 70 DBHL AND ON THE 
LEFT EAR 4000HZ - 60 DBHL
11 39 PM 22-May-06 month 6 Normal
11 40 PM 19-Oct-05 day 0 Normal
11 40 PM 26-Oct-05 day 7 Normal
11 40 PM 2-Nov-05 day 14 Normal
11 40 PM 14-Apr-06 month 3 Normal
11 40 PM 24-May-06 month 6 Normal
11 41 Combination 19-Oct-05 day 0 Normal MILD HEARING LOSS ON RIGHT EAR 250HZ - 
35DB(A) AND 1000 AND 2000HZ - 30DB(A)
11 41 Combination 26-Oct-05 day 7 Normal
11 41 Combination 2-Nov-05 day 14 Normal
11 41 Combination 6-Nov-05 end day Normal MILD HEARING LOSS BOTH EAR AT LEFT 
EAR BY 500HZ - 35DB(A) 250HZ - 35DB(A). 
RIGHT EAR BY 500HZ - 30DB(A) 250HZ - 
35DB(A)
11 41 Combination 13-Feb-06 month 3 Normal
11 41 Combination 31-May-06 month 6 Normal
11 42 Combination 19-Oct-05 day 0 Normal MODERATE HEARING LOSS ON LEFT EAR 
250 AND 500HZ - 45DB(A)
11 42 Combination 27-Oct-05 day 7 Normal MODERATE HEARING LOSS AT LEFT EAR BY 
250HZ - 45DBA, 500HZ - 40DBA & 1000HZ - 
30DBA. RIGHT EAR NORMAL
11 42 Combination 3-Nov-05 day 14 Normal MILD HEARING LOSS ON LEFT EAR 250 AND 
500HZ - 30DBA
11 42 Combination 7-Nov-05 end day Normal
11 42 Combination 7-Feb-06 month 3 Normal
11 42 Combination 8-Jun-06 month 6 Normal
11 43 SSG 27-Oct-05 day 0 Normal
11 43 SSG 3-Nov-05 day 7 Normal
11 43 SSG 10-Nov-05 day 14 Normal MILD HEARING LOSS ON LEFT EAR 250HZ 
40DBA AND 500HZ - 35DBA
11 43 SSG 17-Nov-05 day 21 Normal MILD HEARING LOSS AT LEFT EAR BY 250HZ 
- DB(A) AND 500HZ - 30DB(A). RIGHT EAR 
NORMAL.
11 43 SSG 27-Nov-05 end day Normal MILD HEARING LOSS ON LEFT EAR ON 250 
AND 500HZ - 40DBA AND 1000HZ - 35DBA
11 43 SSG 23-Feb-06 month 3 Normal
11 43 SSG 25-May-06 month 6 Normal
11 44 PM 27-Oct-05 day 0 Normal
11 44 PM 3-Nov-05 day 7 Normal
LEAP 0104a Appendices
Page 620 of 756
Appendix 47: Listing of Audiometry findings per patient
Centre Patient Treatment Audiometry Visit Audiometry Comment
Number Number Date Findings
11 44 PM 10-Nov-05 day 14 Normal MILD HEARING LOSS ON BOTH EAR RIGHT 
EAR 500HZ - 30DBA LEFT EAR 250HZ - 
30DBA, 500HZ. 35DBA
11 44 PM 18-Nov-05 end day Normal MILD HEARING LOSS AT LEFT EAR BY 250HZ 
- 30DB(A) AND 500HZ - 35DB(A). RIGHT EAR 
NORMAL
11 44 PM 14-Feb-06 month 3 Normal
11 44 PM 19-May-06 month 6 Normal
11 45 Combination 27-Oct-05 day 0 Normal
11 45 Combination 3-Nov-05 day 7 Normal MILD HEARING LOSS ON LEFT EAR ON 
250HZ - 35DBA AND 500HZ - 30DBA
11 45 Combination 10-Nov-05 day 14 Normal MILD HEARING LOSS ON LEFT EAR 250 AND 
500HZ - 40DBA
11 45 Combination 14-Nov-05 end day Normal
11 45 Combination 14-Feb-06 month 3 Normal
11 45 Combination 19-May-06 month 6 Normal
11 46 SSG 4-May-06 day 0 Normal
11 46 SSG 11-May-06 day 7 Normal
11 46 SSG 18-May-06 day 14 Normal
11 46 SSG 25-May-06 day 21 Normal
11 46 SSG 4-Jun-06 end day Normal
11 46 SSG 24-Oct-06 month 3 Normal
11 46 SSG 5-Dec-06 month 6 Normal
11 47 SSG 4-May-06 day 0 Normal
11 47 SSG 11-May-06 day 7 Normal
11 47 SSG 18-May-06 day 14 Normal
11 47 SSG 25-May-06 day 21 Normal
11 47 SSG 4-Jun-06 end day Normal
11 48 Combination 4-May-06 day 0 Normal
11 48 Combination 11-May-06 day 7 Normal
11 48 Combination 18-May-06 day 14 Normal
11 48 Combination 22-May-06 end day Normal
11 48 Combination 2-Jan-07 month 6 Normal
11 49 SSG 8-May-06 day 0 Normal
11 49 SSG 15-May-06 day 7 Normal
11 49 SSG 22-May-06 day 14 Normal
11 49 SSG 29-May-06 day 21 Normal
11 49 SSG 8-Jun-06 end day Normal
11 49 SSG 9-Oct-06 month 3 Normal
11 49 SSG 27-Feb-07 month 6 Normal
11 50 PM 17-May-06 day 0 Normal
11 50 PM 24-May-06 day 7 Normal
11 50 PM 31-May-06 day 14 Normal
11 50 PM 8-Jun-06 end day Normal
11 50 PM 6-Sep-06 month 3 Normal
11 50 PM 11-Dec-06 month 6 Normal
11 51 Combination 19-May-06 day 0 Normal
11 51 Combination 26-May-06 day 7 Normal
11 51 Combination 2-Jun-06 day 14 Normal
11 51 Combination 6-Jun-06 end day Normal
11 51 Combination 7-Sep-06 month 3 Normal
11 51 Combination 2-Jan-07 month 6 Normal
11 52 PM 19-May-06 day 0 Normal
11 52 PM 26-May-06 day 7 Normal
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11 52 PM 2-Jun-06 day 14 Normal
11 52 PM 10-Jun-06 end day Normal
11 52 PM 26-Sep-06 month 3 Normal
11 52 PM 11-Jan-07 month 6 Normal
11 53 SSG 25-May-06 day 0 Normal
11 53 SSG 1-Jun-06 day 7 Normal
11 53 SSG 8-Jun-06 day 14 Normal
11 53 SSG 15-Jun-06 day 21 Normal
11 53 SSG 25-Jun-06 end day Normal
11 53 SSG 26-Sep-06 month 3 Normal
11 53 SSG 11-Dec-06 month 6 Normal
11 54 PM 26-May-06 day 0 Normal
11 54 PM 2-Jun-06 day 7 Normal
11 54 PM 9-Jun-06 day 14 Normal
11 54 PM 17-Jun-06 end day Normal
11 54 PM 28-Aug-06 month 3 Normal  
11 54 PM 9-Jan-07 month 6 Normal
11 55 PM 29-May-06 day 0 Normal
11 55 PM 5-Jun-06 day 7 Normal
11 55 PM 12-Jun-06 day 14 Normal
11 55 PM 20-Jun-06 end day Normal
11 55 PM 26-Sep-06 month 3 Normal
11 55 PM 11-Dec-06 month 6 Normal
11 56 SSG 29-May-06 day 0 Normal
11 56 SSG 6-Jun-06 day 7 Normal
11 56 SSG 13-Jun-06 day 14 Normal
11 56 SSG 20-Jun-06 day 21 Normal
11 56 SSG 30-Jun-06 end day Normal
11 56 SSG 28-Sep-06 month 3 Normal
11 56 SSG 14-Dec-06 month 6 Normal
11 57 Combination 3-Jun-06 day 0 Normal
11 57 Combination 10-Jun-06 day 7 Normal
11 57 Combination 17-Jun-06 day 14 Normal
11 57 Combination 21-Jun-06 end day Normal
11 57 Combination 12-Sep-06 month 3 Normal
11 57 Combination 12-Dec-06 month 6 Normal
11 58 Combination 5-Jun-06 day 0 Normal
11 58 Combination 12-Jun-06 day 7 Normal
11 58 Combination 19-Jun-06 day 14 Normal
11 58 Combination 23-Jun-06 end day Normal
11 58 Combination 26-Sep-06 month 3 Normal
11 58 Combination 13-Dec-06 month 6 Normal
11 59 PM 12-Jun-06 day 0 Normal
11 59 PM 19-Jun-06 day 7 Normal
11 59 PM 26-Jun-06 day 14 Normal
11 59 PM 4-Jul-06 end day Normal
11 59 PM 4-Oct-06 month 3 Normal
11 59 PM 2-Jan-07 month 6 Normal
11 60 Combination 12-Jun-06 day 0 Normal
11 60 Combination 19-Jun-06 day 7 Normal
11 60 Combination 26-Jun-06 day 14 Normal
11 60 Combination 30-Jun-06 end day Normal
11 60 Combination 28-Sep-06 month 3 Normal
11 60 Combination 18-Dec-06 month 6 Normal
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11 61 PM 12-Jun-06 day 0 Normal
11 61 PM 19-Jun-06 day 7 Normal
11 61 PM 26-Jun-06 day 14 Normal
11 61 PM 4-Jul-06 end day Normal
11 61 PM 3-Oct-06 month 3 Normal
11 61 PM 2-Jan-07 month 6 Normal
11 62 SSG 15-Jun-06 day 0 Normal
11 62 SSG 22-Jun-06 day 7 Normal
11 62 SSG 29-Jun-06 day 14 Normal
11 62 SSG 6-Jul-06 day 21 Normal
11 62 SSG 16-Jul-06 end day Normal
11 62 SSG 25-Oct-06 month 3 Normal
11 62 SSG 11-Jan-07 month 6 Normal
11 63 SSG 19-Jun-06 day 0 Normal
11 63 SSG 26-Jun-06 day 7 Normal
11 63 SSG 3-Jul-06 day 14 Normal
11 63 SSG 10-Jul-06 day 21 Normal
11 63 SSG 20-Jul-06 end day Normal
11 63 SSG 3-Oct-06 month 3 Normal
11 63 SSG 28-Dec-06 month 6 Normal
11 64 SSG 21-Jun-06 day 0 Normal
11 64 SSG 28-Jun-06 day 7 Normal
11 64 SSG 5-Jul-06 day 14 Normal
11 64 SSG 12-Jul-06 day 21 Normal
11 64 SSG 22-Jul-06 end day Normal
11 64 SSG 29-Sep-06 month 3 Normal
11 64 SSG 14-Dec-06 month 6 Normal
11 65 PM 21-Jun-06 day 0 Normal
11 65 PM 29-Jun-06 day 7 Normal
11 65 PM 6-Jul-06 day 14 Normal
11 65 PM 14-Jul-06 end day Normal
11 66 Combination 22-Jun-06 day 0 Normal
11 66 Combination 29-Jun-06 day 7 Normal
11 66 Combination 6-Jul-06 day 14 Abnormal (CI) MODERATE HEARING LOSS ON BOTH EAR 
ON 8000HZ - 55DBHL(AC)
11 66 Combination 10-Jul-06 end day Normal
11 66 Combination 26-Sep-06 month 3 Normal
11 66 Combination 11-Dec-06 month 6 Normal
11 67 PM 30-Jun-06 day 0 Normal
11 67 PM 7-Jul-06 day 7 Normal
11 67 PM 14-Jul-06 day 14 Normal
11 67 PM 22-Jul-06 end day Normal
11 67 PM 3-Oct-06 month 3 Normal
11 67 PM 2-Jan-07 month 6 Normal
11 68 SSG 7-Jul-06 day 0 Normal
11 68 SSG 14-Jul-06 day 7 Normal
11 68 SSG 21-Jul-06 day 14 Normal
11 68 SSG 28-Jul-06 day 21 Normal
11 68 SSG 7-Aug-06 end day Normal
11 68 SSG 11-Oct-06 month 3 Normal
11 68 SSG 9-Jan-07 month 6 Normal
11 69 Combination 14-Jul-06 day 0 Normal
11 69 Combination 21-Jul-06 day 7 Normal
11 69 Combination 28-Jul-06 day 14 Normal
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11 69 Combination 1-Aug-06 end day Normal
11 69 Combination 9-Oct-06 month 3 Normal
11 69 Combination 13-Dec-06 month 6 Normal
11 70 Combination 14-Jul-06 day 0 Normal
11 70 Combination 21-Jul-06 day 7 Normal
11 70 Combination 28-Jul-06 day 14 Normal
11 70 Combination 1-Aug-06 end day Normal
11 70 Combination 9-Oct-06 month 3 Normal
11 70 Combination 2-Jan-07 month 6 Normal
11 71 Combination 21-Jul-06 day 0 Normal
11 71 Combination 28-Jul-06 day 7 Normal
11 71 Combination 4-Aug-06 day 14 Normal
11 71 Combination 8-Aug-06 end day Normal
11 71 Combination 20-Oct-06 month 3 Normal
11 71 Combination 8-Jan-07 month 6 Normal
11 72 SSG 21-Jul-06 day 0 Normal
11 72 SSG 28-Jul-06 day 7 Normal
11 72 SSG 4-Aug-06 day 14 Abnormal (CI) MODERATELY SEVERE HEARING LOSS IN 
LEFT EAR AT 8000HZ 65DBHL(AC)
11 72 SSG 9-Nov-06 month 3 Normal
11 72 SSG 7-Feb-07 month 6 Normal
11 73 PM 24-Jul-06 day 0 Normal
11 73 PM 31-Jul-06 day 7 Normal
11 73 PM 7-Aug-06 day 14 Normal
11 73 PM 15-Aug-06 end day Normal
11 73 PM 23-Oct-06 month 3 Normal
11 73 PM 2-Apr-07 month 6 Normal
11 74 PM 27-Jul-06 day 0 Normal
11 74 PM 3-Aug-06 day 7 Normal
11 74 PM 10-Aug-06 day 14 Normal
11 74 PM 18-Aug-06 end day Normal
11 74 PM 25-Oct-06 month 3 Normal
11 74 PM 23-Jan-07 month 6 Normal
11 75 Combination 27-Jul-06 day 0 Normal
11 75 Combination 3-Aug-06 day 7 Normal
11 75 Combination 10-Aug-06 day 14 Normal
11 75 Combination 14-Aug-06 end day Normal
11 75 Combination 31-Oct-06 month 3 Normal
11 75 Combination 9-Jan-07 month 6 Normal
11 76 PM 27-Jul-06 day 0 Normal
11 76 PM 6-Aug-06 day 7 Normal
11 76 PM 13-Aug-06 day 14 Normal
11 76 PM 21-Aug-06 end day Normal
11 76 PM 30-Oct-06 month 3 Normal
11 76 PM 29-Jan-07 month 6 Normal
11 77 PM 30-Jul-06 day 0 Normal
11 77 PM 6-Aug-06 day 7 Normal
11 77 PM 13-Aug-06 day 14 Normal
11 77 PM 21-Aug-06 end day Normal
11 77 PM 30-Oct-06 month 3 Normal
11 77 PM 29-Jan-07 month 6 Normal
11 78 SSG 30-Jul-06 day 0 Normal
11 78 SSG 6-Aug-06 day 7 Normal
11 78 SSG 13-Aug-06 day 14 Normal
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11 78 SSG 20-Aug-06 day 21 Normal
11 78 SSG 30-Aug-06 end day Normal
11 78 SSG 30-Oct-06 month 3 Normal
11 78 SSG 29-Jan-07 month 6 Normal
11 79 PM 29-Jul-06 day 0 Normal
11 79 PM 6-Aug-06 day 7 Normal
11 79 PM 13-Aug-06 day 14 Normal
11 79 PM 21-Aug-06 end day Normal
11 79 PM 30-Oct-06 month 3 Normal
11 79 PM 30-Jan-07 month 6 Normal
11 80 PM 2-Aug-06 day 0 Normal
11 80 PM 9-Aug-06 day 7 Normal
11 80 PM 16-Aug-06 day 14 Normal
11 80 PM 24-Aug-06 end day Normal
11 80 PM 23-Nov-06 month 3 Normal
11 81 Combination 5-Aug-06 day 0 Normal
11 81 Combination 12-Aug-06 day 7 Normal
11 81 Combination 19-Aug-06 day 14 Normal
11 81 Combination 23-Aug-06 end day Normal
11 81 Combination 7-Nov-06 month 3 Normal
11 81 Combination 6-Feb-07 month 6 Normal
11 82 SSG 13-Aug-06 day 0 Normal
11 82 SSG 21-Aug-06 day 7 Normal
11 82 SSG 28-Aug-06 day 14 Normal
11 82 SSG 4-Sep-06 day 21 Normal
11 82 SSG 14-Sep-06 end day Normal
11 82 SSG 13-Nov-06 month 3 Normal
11 82 SSG 5-Feb-07 month 6 Normal
11 83 SSG 15-Aug-06 day 0 Normal
11 83 SSG 22-Aug-06 day 7 Normal
11 83 SSG 29-Aug-06 day 14 Normal
11 83 SSG 5-Sep-06 day 21 Normal
11 83 SSG 15-Sep-06 end day Normal
11 83 SSG 13-Nov-06 month 3 Normal
11 83 SSG 15-Feb-07 month 6 Normal
11 84 SSG 13-Aug-06 day 0 Normal
11 84 SSG 24-Aug-06 day 7 Normal
11 84 SSG 31-Aug-06 day 14 Normal
11 84 SSG 7-Sep-06 day 21 Normal
11 84 SSG 17-Sep-06 end day Normal
11 84 SSG 15-Nov-06 month 3 Normal
11 84 SSG 15-Feb-07 month 6 Normal
11 85 SSG 24-Aug-06 day 0 Normal
11 85 SSG 31-Aug-06 day 7 Normal
11 85 SSG 7-Sep-06 day 14 Normal
11 85 SSG 14-Sep-06 day 21 Normal
11 85 SSG 24-Sep-06 end day Normal
11 85 SSG 21-Nov-06 month 3 Normal
11 86 Combination 28-Aug-06 day 0 Normal
11 86 Combination 4-Sep-06 day 7 Normal
11 86 Combination 11-Sep-06 day 14 Normal
11 86 Combination 15-Sep-06 end day Normal
11 86 Combination 13-Nov-06 month 3 Normal
11 86 Combination 5-Feb-07 month 6 Normal
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11 87 Combination 28-Aug-06 day 0 Normal
11 87 Combination 4-Sep-06 day 7 Normal
11 87 Combination 11-Sep-06 day 14 Normal
11 87 Combination 15-Sep-06 end day Normal
11 87 Combination 14-Nov-06 month 3 Normal
11 87 Combination 5-Feb-07 month 6 Normal
11 88 PM 28-Aug-06 day 0 Normal
11 88 PM 4-Sep-06 day 7 Normal
11 88 PM 11-Sep-06 day 14 Normal
11 88 PM 19-Sep-06 end day Normal
11 88 PM 21-Nov-06 month 3 Normal
11 88 PM 27-Feb-07 month 6 Normal
11 89 Combination 28-Aug-06 day 0 Normal
11 89 Combination 8-Sep-06 day 7 Normal
11 89 Combination 15-Sep-06 day 14 Normal
11 89 Combination 19-Sep-06 end day Normal
11 89 Combination 17-Nov-06 month 3 Normal
11 89 Combination 15-Mar-07 month 6 Normal
11 90 Combination 1-Sep-06 day 0 Normal
11 90 Combination 8-Sep-06 day 7 Normal
11 90 Combination 15-Sep-06 day 14 Normal
11 90 Combination 19-Sep-06 end day Normal
11 91 PM 17-Dec-06 day 0 Normal
11 91 PM 31-Dec-06 day 14 Normal
11 91 PM 8-Jan-07 end day Normal
11 91 PM 18-Jun-07 month 6 Normal
11 92 Combination 30-Dec-06 day 0 Normal
11 92 Combination 13-Jan-07 day 14 Normal
11 92 Combination 17-Jan-07 end day Normal
11 92 Combination 26-Jun-07 month 6 Normal
11 93 SSG 1-Jan-07 day 0 Normal
11 93 SSG 8-Jan-07 day 7 Normal
11 93 SSG 15-Jan-07 day 14 Normal
11 93 SSG 22-Jan-07 day 21 Normal
11 93 SSG 1-Feb-07 end day Normal
11 93 SSG 7-Aug-07 month 6 Normal
11 94 SSG 3-Jan-07 day 0 Normal
11 94 SSG 17-Jan-07 day 14 Normal
11 94 SSG 3-Feb-07 end day Normal
11 94 SSG 25-Jun-07 month 6 Normal
11 95 SSG 3-Jan-07 day 0 Normal
11 95 SSG 17-Jan-07 day 14 Normal
11 95 SSG 3-Feb-07 end day Normal
11 95 SSG 23-Jun-07 month 6 Normal
11 96 Combination 19-Jan-07 day 0 Normal
11 96 Combination 2-Feb-07 day 14 Normal
11 96 Combination 6-Feb-07 end day Normal
11 96 Combination 6-Aug-07 month 6 Normal
11 97 Combination 19-Jan-07 day 0 Normal
11 97 Combination 2-Feb-07 day 14 Normal
11 97 Combination 6-Feb-07 end day Normal
11 97 Combination 24-Jul-07 month 6 Normal
11 98 PM 23-Jan-07 day 0 Normal
11 98 PM 6-Feb-07 day 14 Normal
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11 98 PM 14-Feb-07 end day Normal
11 98 PM 26-Jul-07 month 6 Normal
11 99 SSG 25-Jan-07 day 0 Normal
11 99 SSG 8-Feb-07 day 14 Normal
11 99 SSG 25-Feb-07 end day Normal
11 99 SSG 30-Jul-07 month 6 Normal
11 100 PM 25-Jan-07 day 0 Normal
11 100 PM 8-Feb-07 day 14 Normal
11 100 PM 16-Feb-07 end day Normal
11 101 PM 2-Feb-07 day 0 Normal
11 101 PM 16-Feb-07 day 14 Normal
11 101 PM 24-Feb-07 end day Normal
11 101 PM 6-Nov-07 month 6 Normal
11 102 Combination 2-Feb-07 day 0 Normal
11 102 Combination 16-Feb-07 day 14 Normal
11 102 Combination 20-Feb-07 end day Normal
11 102 Combination 30-Jul-07 month 6 Normal
11 103 Combination 6-Feb-07 day 0 Normal
11 103 Combination 20-Feb-07 day 14 Normal
11 103 Combination 24-Feb-07 end day Normal
11 103 Combination 10-Aug-07 month 6 Normal
11 104 PM 9-Feb-07 day 0 Normal
11 104 PM 23-Feb-07 day 14 Normal
11 104 PM 3-Mar-07 end day Normal
11 104 PM 27-Aug-07 month 6 Normal
11 105 SSG 23-Feb-07 day 0 Normal
11 105 SSG 9-Mar-07 day 14 Normal
11 105 SSG 26-Mar-07 end day Normal
11 105 SSG 27-Aug-07 month 6 Normal
11 106 Combination 24-Feb-07 day 0 Normal
11 106 Combination 10-Mar-07 day 14 Normal
11 106 Combination 14-Mar-07 end day Normal
11 106 Combination 19-Aug-07 month 6 Normal
11 107 PM 24-Feb-07 day 0 Normal
11 107 PM 10-Mar-07 day 14 Normal
11 107 PM 18-Mar-07 end day Normal
11 107 PM 28-Aug-07 month 6 Normal
11 108 PM 28-Feb-07 day 0 Normal
11 108 PM 15-Mar-07 day 14 Normal
11 108 PM 23-Mar-07 end day Normal
11 108 PM 27-Aug-07 month 6 Normal
11 109 SSG 27-Feb-07 day 0 Normal
11 109 SSG 16-Mar-07 day 14 Normal
11 109 SSG 2-Apr-07 end day Normal
11 109 SSG 5-Aug-07 month 6 Normal
11 110 PM 2-Mar-07 day 0 Normal
11 110 PM 16-Mar-07 day 14 Normal
11 110 PM 24-Mar-07 end day Normal
11 110 PM 27-Aug-07 month 6 Normal
11 111 Combination 23-Mar-07 day 0 Normal
11 111 Combination 6-Apr-07 day 14 Normal
11 111 Combination 10-Apr-07 end day Normal
11 111 Combination 24-Sep-07 month 6 Normal
11 112 Combination 23-Mar-07 day 0 Normal
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11 112 Combination 6-Apr-07 day 14 Normal
11 112 Combination 10-Apr-07 end day Normal
11 112 Combination 24-Sep-07 month 6 Normal
11 113 SSG 23-Mar-07 day 0 Normal
11 113 SSG 10-Apr-07 day 14 Normal
11 113 SSG 27-Apr-07 end day Normal
11 114 SSG 28-Mar-07 day 0 Normal
11 114 SSG 12-Apr-07 day 14 Normal
11 114 SSG 29-Apr-07 end day Normal
11 114 SSG 5-Oct-07 month 6 Normal
11 115 Combination 30-Mar-07 day 0 Normal
11 115 Combination 13-Apr-07 day 14 Normal
11 115 Combination 14-Apr-07 end day Normal
11 115 Combination 21-Sep-07 month 6 Normal
11 116 SSG 30-Mar-07 day 0 Normal
11 116 SSG 13-Apr-07 day 14 Normal
11 116 SSG 30-Apr-07 end day Normal
11 116 SSG 1-Nov-07 month 6 Normal
11 117 PM 3-Apr-07 day 0 Normal
11 117 PM 17-Apr-07 day 14 Normal
11 117 PM 25-Apr-07 end day Normal
11 118 PM 18-Apr-07 day 0 Normal
11 118 PM 2-May-07 day 14 Normal
11 118 PM 10-May-07 end day Normal
11 118 PM 19-Sep-07 month 6 Normal
11 119 SSG 20-Apr-07 day 0 Normal
11 119 SSG 4-May-07 day 14 Normal
11 119 SSG 21-May-07 end day Normal
11 119 SSG 29-Oct-07 month 6 Normal
11 120 Combination 20-Apr-07 day 0 Normal
11 120 Combination 4-May-07 day 14 Normal
11 120 Combination 8-May-07 end day Normal
11 120 Combination 29-Oct-07 month 6 Normal
11 121 Combination 20-Apr-07 day 0 Normal
11 121 Combination 4-May-07 day 14 Normal
11 121 Combination 8-May-07 end day Normal
11 121 Combination 29-Oct-07 month 6 Normal
11 122 SSG 20-Apr-07 day 0 Normal
11 122 SSG 4-May-07 day 14 Normal
11 122 SSG 21-May-07 end day Normal
11 123 SSG 27-Apr-07 day 0 Normal
11 123 SSG 11-May-07 day 14 Normal
11 123 SSG 28-May-07 end day Normal
11 123 SSG 19-Oct-07 month 6 Normal
11 124 SSG 20-May-07 day 0 Normal
11 124 SSG 3-Jun-07 day 14 Normal
11 124 SSG 20-Jun-07 end day Normal
11 124 SSG 7-Apr-08 month 6 Normal
11 125 SSG 23-May-07 day 0 Normal
11 125 SSG 6-Jun-07 day 14 Normal
11 125 SSG 23-Jun-07 end day Normal
11 125 SSG 19-Nov-07 month 6 Normal
11 126 Combination 26-May-07 day 0 Normal
11 126 Combination 10-Jun-07 day 14 Normal
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11 126 Combination 14-Jun-07 end day Normal
11 126 Combination 10-Dec-07 month 6 Normal
11 127 PM 26-May-07 day 0 Normal
11 127 PM 10-Jun-07 day 14 Normal
11 127 PM 18-Jun-07 end day Normal
11 127 PM 30-Oct-07 month 6 Normal
11 128 Combination 1-Jun-07 day 0 Normal
11 128 Combination 15-Jun-07 day 14 Normal
11 128 Combination 19-Jun-07 end day Normal
11 128 Combination 16-Nov-07 month 6 Normal
11 129 PM 6-Jun-07 day 0 Normal
11 129 PM 20-Jun-07 day 14 Normal
11 129 PM 28-Jun-07 end day Normal
11 129 PM 21-Nov-07 month 6 Normal
11 130 Combination 7-Jun-07 day 0 Normal
11 130 Combination 22-Jun-07 day 14 Normal
11 130 Combination 26-Jun-07 end day Normal
11 130 Combination 19-Nov-07 month 6 Normal
11 131 PM 10-Jun-07 day 0 Normal
11 131 PM 24-Jun-07 day 14 Normal
11 131 PM 2-Jul-07 end day Normal
11 131 PM 12-Dec-07 month 6 Normal
11 132 SSG 15-Jun-07 day 0 Normal
11 132 SSG 29-Jun-07 day 14 Normal
11 132 SSG 16-Jul-07 end day Normal
11 132 SSG 19-Dec-07 month 6 Normal
11 133 Combination 3-Jul-07 day 0 Normal
11 133 Combination 17-Jul-07 day 14 Normal
11 133 Combination 21-Jul-07 end day Normal
11 133 Combination 2-Jan-08 month 6 Normal
11 134 PM 10-Jul-07 day 0 Normal
11 134 PM 24-Jul-07 day 14 Normal
11 134 PM 1-Aug-07 end day Normal
11 134 PM 8-Jan-08 month 6 Normal
11 135 PM 12-Jul-07 day 0 Normal
11 135 PM 26-Jul-07 day 14 Normal
11 135 PM 3-Aug-07 end day Normal
11 135 PM 31-Dec-07 month 6 Normal
12 241 Combination 26-Jun-05 day 0 Normal 48DB (MODERATE HEARING LOSS)
12 241 Combination 5-Jul-05 day 7 Normal AVERAGE 52 DBHL
12 241 Combination 12-Jul-05 day 14 Normal
12 241 Combination 16-Jul-05 end day Normal LT EAR - 55DB RT EAR - 56
12 241 Combination 9-Feb-06 month 6 Normal
12 242 SSG 26-Jun-05 day 0 Not Done
12 242 SSG 12-Jul-05 day 14 Not Done
12 242 SSG 29-Jul-05 end day Not Done
12 242 SSG 24-Oct-05 month 3 Normal
12 242 SSG 12-Feb-06 month 6 Normal
12 243 PM 26-Jun-05 day 0 Normal 51DB (MODERATE HEARING LOSS)
12 243 PM 5-Jul-05 day 7 Normal RIGHT EAR - 31DB LEFT EAR - 37.5DB (MILD 
HEARING LOSS)
12 243 PM 12-Jul-05 day 14 Normal
12 243 PM 20-Jul-05 end day Normal
12 243 PM 6-Aug-06 month 6 Normal
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12 244 SSG 26-Jun-05 day 0 Normal 45DB (MODERATE HEARING LOSS)
12 244 SSG 5-Jul-05 day 7 Abnormal (CI) HIS AVERAGE OF 1000, 2000, 4000 & 500HZ 
HAS DETERIORATED FROM MODERATE TO 
MODERATELY SEVERE (ONE STEP). BUT 
THE PATIENT DID NOT COMPLAIN OF 
HEARING CAPACITY. AVERAGE 58DBHL
12 244 SSG 12-Jul-05 day 14 Normal
12 244 SSG 19-Jul-05 day 21 Normal
12 244 SSG 29-Jul-05 end day Normal
12 244 SSG 29-Oct-05 month 3 Normal
12 244 SSG 6-Apr-06 month 6 Normal
12 245 PM 16-Jul-05 day 0 Normal
12 245 PM 25-Jul-05 day 7 Normal
12 245 PM 1-Aug-05 day 14 Normal
12 245 PM 9-Aug-05 end day Not Done
12 245 PM 18-Nov-05 month 3 Normal
12 246 PM day 0 Not Done
12 246 PM day 14 Not Done
12 246 PM end day Not Done
12 246 PM 25-Nov-05 month 3 Normal
12 247 PM 23-Sep-05 day 0 Normal RT EAR 8.75 DBHL LT EAR 8.75 DBHL
12 247 PM 4-Oct-05 day 7 Normal RT EAR 6.5 DBHL LT EAR 2.5 DBHL
12 247 PM 11-Oct-05 day 14 Normal RT EAR 13.75 DBHL LT EAR 28(27.75) DBHL
12 247 PM 19-Oct-05 end day Normal AVERAGE RT EAR 15 DBHL LT EAR 10 DBHL
12 247 PM 18-Jan-06 month 3 Normal R EAR HAS MILD TO MODERATE HEARING 
PROBLEM 
12 247 PM 19-Apr-06 month 6 Normal
12 248 PM 22-Sep-05 day 0 Normal RT EAR 19 DBHL LT EAR 36 DBHL
12 248 PM 29-Sep-05 day 7 Normal RT EAR 20 DBHL LT EAR 38.8 DBHL
12 248 PM 6-Oct-05 day 14 Normal RT EAR 24 DBHL LT EAR 37.5 DBHL
12 248 PM 14-Oct-05 end day Normal RT EAR 16 DBHL LT EAR 41 DBHL
12 248 PM 23-Jan-06 month 3 Normal LT EAR HAS MILD HEARING LOSS 
12 248 PM 19-Apr-06 month 6 Normal
12 249 Combination 24-Oct-05 day 0 Normal RT EAR 4DBHL LT EAR 14DBHL
12 249 Combination 31-Oct-05 day 7 Normal RT EAR 8.75 DBHL LT EAR 16.25 DBHL
12 249 Combination 7-Nov-05 day 14 Normal RT EAR 10 DBHL LT EAR 17.5 DBHL
12 249 Combination day 21 Normal
12 249 Combination 11-Nov-05 end day Normal RT EAR 2.5 DBHL LT EAR 23.33DBHL
12 249 Combination 4-Mar-06 month 3 Normal
12 249 Combination 13-May-06 month 6 Normal
12 250 SSG 24-Oct-05 day 0 Normal RT EAR 16.25DBHZ LT EAR 18.75 DBHZ
12 250 SSG 31-Oct-05 day 7 Normal LT EAR 13.75 DBHZ LT EAR 13.75 DBHZ
12 250 SSG 7-Nov-05 day 14 Normal RT EAR 18.75 DBHZ LT EAR 15. DBHZ
12 250 SSG 14-Nov-05 day 21 Normal RT EAR 16.25 DBHL LT EAR 18.75 DBHL
12 250 SSG 24-Nov-05 end day Normal RT EAR 12.5 DBHL (NORM) LT EAR 36.25 
DBHZ (MODERATE)
12 250 SSG 22-Feb-06 month 3 Normal
12 250 SSG 8-Jul-06 month 6 Normal
12 251 Combination 27-Oct-05 day 0 Normal RT EAR - 250 -45DB 8000 - 50DB LEFT EAR - 
250 - 30 8000 - 65DB
12 251 Combination 11-Nov-05 day 14 Not Done
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12 251 Combination 15-Nov-05 end day Normal MILD HEARING LOSS ON BOTH RIGHT AND 
LEFT EAR AT 8000HZ, WHICH IS 35DB
12 251 Combination 12-Feb-06 month 3 Normal
12 251 Combination 14-May-06 month 6 Normal
12 252 SSG 27-Oct-05 day 0 Normal AVERAGE RT 13.33 DBHZ LT 15 DBHZ
12 252 SSG 11-Nov-05 day 14 Normal RT EAR 16.66 DBHZ LT EAR 9.16 DBHZ
12 252 SSG 18-Nov-05 day 21 Normal RT EAR 8.33DBHL LT EAR 10 DBHL
12 252 SSG 28-Nov-05 end day Normal RT EAR 11.66 DBHL LT EAR 0 DBHL
12 252 SSG 6-Apr-06 month 3 Normal
12 252 SSG 22-Jun-06 month 6 Normal
12 253 SSG 27-Oct-05 day 0 Normal
12 253 SSG 11-Nov-05 day 14 Normal RT EAR 19.16 DBHL LT EAR 10.83 DBHL
12 253 SSG 18-Nov-05 day 21 Normal RT EAR  25DBHL LT EAR 21.66 DBHL
12 253 SSG 28-Nov-05 end day Normal RT EAR 16.66 DBHL LT EAR 10 DBHL
12 253 SSG 6-Apr-06 month 3 Normal
12 253 SSG 22-Jun-06 month 6 Normal
12 254 Combination day 0 Not Done
12 254 Combination 11-Nov-05 day 14 Normal RT EAR 14.16 DBHL LT EAR 11.66 DBHL
12 254 Combination 15-Nov-05 end day Normal RT EAR 10 DBHL LT EAR 15.83 DBHL
12 254 Combination 12-Feb-06 month 3 Normal
12 254 Combination 22-May-06 month 6 Normal
12 255 Combination 30-Oct-05 day 0 Normal RT EAR 13.75 DBHL. LT EAR 11.25 DBHL
12 255 Combination 8-Nov-05 day 7 Normal RT EAR 7.5 DBHL LT EAR 4DBHL
12 255 Combination 14-Nov-05 day 14 Normal RT EAR 6.25 DBHL LT EAR 7.5DBHL
12 255 Combination 18-Nov-05 end day Normal RT EAR 6.66 DBHL LT EAR 10 DBHL
12 255 Combination 9-Mar-06 month 3 Normal
12 255 Combination 19-May-06 month 6 Normal
12 256 Combination 14-Nov-05 day 0 Normal LT MILD *RT MODERATELY SEVERE
12 256 Combination 23-Nov-05 day 7 Normal LT EAR 30 DBHL (MILD) RT EAR 61.25 DBHL 
(MODERATELY SEVERE)
12 256 Combination 30-Nov-05 day 14 Normal LT EAR 30 DBHL RT EAR 58.75 DBHL
12 256 Combination 5-Dec-05 end day Normal RT EAR 61.25 DBHL (MODERATELY SEVER) 
LT EAR 32.5 DBHL (MILD)
12 256 Combination 4-Mar-06 month 3 Normal
12 256 Combination 6-Jun-06 month 6 Normal
12 257 SSG 14-Nov-05 day 0 Normal
12 257 SSG 23-Nov-05 day 7 Normal
12 257 SSG 30-Nov-05 day 14 Normal
12 257 SSG 7-Dec-05 day 21 Normal
12 257 SSG 17-Dec-05 end day Normal
12 257 SSG 19-Apr-06 month 3 Normal
12 257 SSG 14-Jun-06 month 6 Normal
12 258 SSG 30-Nov-05 day 0 Normal
12 258 SSG 12-Dec-05 day 7 Normal
12 258 SSG 19-Dec-05 day 14 Normal
12 258 SSG 26-Dec-05 day 21 Normal
12 258 SSG 5-Jan-06 end day Normal
12 258 SSG 12-Jul-06 month 6 Normal
12 259 PM 25-Dec-05 day 0 Normal
12 259 PM 6-Jan-06 day 7 Normal
12 259 PM 13-Jan-06 day 14 Normal
12 259 PM 20-Jan-06 end day Normal
12 259 PM 8-May-06 month 3 Normal
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12 259 PM 28-Jul-06 month 6 Normal
12 260 PM 25-Dec-05 day 0 Normal
12 260 PM 9-Jan-06 day 7 Normal
12 260 PM 16-Jan-06 day 14 Normal
12 260 PM 24-Jan-06 end day Normal
12 260 PM 11-Jul-06 month 6 Normal
12 261 Combination 25-Dec-05 day 0 Normal LT EAR NORMAL R  HAS MODERATE & 
MODERATELY - SEVERE HEARING LOSS
12 261 Combination 9-Jan-06 day 7 Normal LT EAR NORM R EAR MODERATE & 
MODERATELY SEVER HEARING LOSS
12 261 Combination 16-Jan-06 day 14 Normal LT EAR NORMAL HEARING  R EAR 
MODERATE & MODERATELY SEVERE 
HEARING LOSS
12 261 Combination 20-Jan-06 end day Normal LT EAR NORMAL RT EAR HAS MODERATE & 
MODERATELY SEVERE HEARING LOSS
12 261 Combination 19-Apr-06 month 3 Normal THE RIGHT SIDE HEARING ABNORMALITY 
WHICH INITIALLY WAS MODERATE HEARING 
LOSS NOW HAS BECOME IN THE CATEGORY 
OF SEVERE HEARING IN ALL FREQUENCIES 
EXCEPT 250 HZ
12 261 Combination 22-Jul-06 month 6 Abnormal (CI) HAS SEVERE HEARING LOSS ON THE RT 
EAR EXCEPT FOR 250 HZ WHICH IS 
MODERATELY SEVERE - LEFT EAR IS 
NORMAL
12 262 PM 25-Dec-05 day 0 Normal
12 262 PM 9-Jan-06 day 7 Normal
12 262 PM 16-Jan-06 day 14 Normal
12 262 PM 23-Jan-06 end day Normal
12 262 PM 22-Jun-06 month 3 Normal
12 262 PM 28-Jul-06 month 6 Normal
12 263 SSG 22-Jan-06 day 0 Normal
12 263 SSG 1-Feb-06 day 7 Normal
12 263 SSG 9-Feb-06 day 14 Normal
12 263 SSG 16-Feb-06 day 21 Normal
12 263 SSG 25-Feb-06 end day Normal
12 263 SSG 29-May-06 month 3 Normal
12 263 SSG 26-Aug-06 month 6 Normal
12 264 Combination 12-Feb-06 day 0 Normal
12 264 Combination 21-Feb-06 day 7 Normal
12 264 Combination 28-Feb-06 day 14 Normal
12 264 Combination 4-Mar-06 end day Normal
12 264 Combination 16-Jun-06 month 3 Normal R EAR NORMAL LT EAR MODERATES 
HEARING LOSS BUT NO CLINICAL
12 264 Combination 1-Sep-06 month 6 Normal
12 265 SSG 12-Feb-06 day 0 Normal
12 265 SSG 21-Feb-06 day 7 Normal
12 265 SSG 28-Feb-06 day 14 Normal
12 266 PM 12-Feb-06 day 0 Normal
12 266 PM 21-Feb-06 day 7 Normal
12 266 PM 28-Feb-06 day 14 Normal
12 266 PM 8-Mar-06 end day Normal
12 266 PM 5-Jun-06 month 3 Normal
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12 266 PM 3-Oct-06 month 6 Normal
12 267 SSG 8-Feb-06 day 0 Normal
12 267 SSG 21-Feb-06 day 7 Normal
12 267 SSG 28-Feb-06 day 14 Normal
12 267 SSG 7-Mar-06 day 21 Normal
12 267 SSG 17-Mar-06 end day Normal
12 267 SSG 14-Jun-06 month 3 Normal
12 267 SSG 15-Sep-06 month 6 Normal
12 268 PM 7-Mar-06 day 0 Normal
12 268 PM 17-Mar-06 day 7 Normal
12 268 PM 23-Mar-06 day 14 Normal
12 268 PM 31-Mar-06 end day Normal
12 268 PM 29-Jun-06 month 3 Normal
12 268 PM 26-Sep-06 month 6 Normal
12 269 Combination 13-Mar-06 day 0 Normal
12 269 Combination 22-Mar-06 day 7 Normal
12 269 Combination 29-Mar-06 day 14 Normal
12 269 Combination 3-Apr-06 end day Normal
12 269 Combination 8-Jul-06 month 3 Normal
12 269 Combination 14-Nov-06 month 6 Normal
12 270 Combination day 0 Not Done
12 270 Combination day 14 Not Done
12 270 Combination end day Not Done
12 270 Combination 10-Oct-06 month 6 Normal
12 271 SSG 30-Mar-06 day 0 Normal
12 271 SSG 5-Apr-06 day 7 Normal
12 271 SSG 13-Apr-06 day 14 Normal
12 271 SSG 21-Apr-06 day 21 Normal
12 271 SSG 30-Apr-06 end day Normal
12 271 SSG 1-Aug-06 month 3 Normal
12 271 SSG 31-Oct-06 month 6 Normal
12 272 PM day 0 Not Done
12 272 PM 21-Apr-06 day 14 Not Done
12 272 PM end day Not Done
12 273 SSG 8-Apr-06 day 0 Normal
12 273 SSG 14-Apr-06 day 7 Normal
12 273 SSG 21-Apr-06 day 14 Normal
12 273 SSG 28-Apr-06 day 21 Normal
12 273 SSG 8-May-06 end day Normal
12 273 SSG 8-Aug-06 month 3 Normal
12 273 SSG 11-Nov-06 month 6 Normal
12 274 SSG 8-Apr-06 day 0 Normal
12 274 SSG 14-Apr-06 day 7 Normal
12 274 SSG 21-Apr-06 day 14 Normal
12 274 SSG 28-Apr-06 day 21 Normal
12 274 SSG 8-May-06 end day Normal
12 274 SSG 8-Aug-06 month 3 Normal
12 274 SSG 11-Nov-06 month 6 Normal
12 275 Combination 8-Apr-06 day 0 Normal
12 275 Combination 14-Apr-06 day 7 Normal
12 275 Combination 21-Apr-06 day 14 Normal
12 275 Combination 25-Apr-06 end day Normal
12 275 Combination 25-Jul-06 month 3 Normal
12 275 Combination 25-Oct-06 month 6 Normal
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12 276 PM day 0 Not Done
12 276 PM day 14 Not Done
12 276 PM end day Not Done
12 277 Combination 20-Apr-06 day 0 Normal
12 277 Combination 27-Apr-06 day 7 Normal
12 277 Combination 4-May-06 day 14 Normal
12 277 Combination 8-May-06 end day Normal
12 277 Combination 7-Aug-06 month 3 Normal
12 277 Combination 11-Nov-06 month 6 Normal
12 278 SSG 21-Apr-06 day 0 Normal
12 278 SSG 27-Apr-06 day 7 Normal
12 278 SSG 4-May-06 day 14 Normal
12 278 SSG 11-May-06 day 21 Normal
12 278 SSG 21-May-06 end day Normal
12 278 SSG 18-Aug-06 month 3 Normal
12 279 PM 21-Apr-06 day 0 Normal
12 279 PM 27-Apr-06 day 7 Normal
12 279 PM 4-May-06 day 14 Normal
12 279 PM 12-May-06 end day Normal
12 279 PM 12-Aug-06 month 3 Normal
12 279 PM 11-Nov-06 month 6 Normal
12 280 SSG day 0 Not Done
12 280 SSG day 14 Not Done
12 280 SSG end day Not Done
12 281 Combination 20-Apr-06 day 0 Normal
12 281 Combination 27-Apr-06 day 7 Normal
12 281 Combination 4-May-06 day 14 Normal
12 281 Combination 8-May-06 end day Normal
12 281 Combination 8-Aug-06 month 3 Normal
12 281 Combination 22-Dec-06 month 6 Normal
12 282 PM 28-Apr-06 day 0 Normal
12 282 PM 4-May-06 day 7 Normal
12 282 PM 11-May-06 day 14 Normal
12 282 PM 19-May-06 end day Normal
12 282 PM 26-Aug-06 month 3 Normal
12 282 PM 20-Dec-06 month 6 Normal
12 283 PM 11-May-06 day 0 Normal
12 283 PM 17-May-06 day 7 Normal
12 283 PM 24-May-06 day 14 Normal
12 283 PM 1-Jun-06 end day Normal
12 283 PM 26-Aug-06 month 3 Normal
12 283 PM 29-Dec-06 month 6 Normal
12 284 Combination 19-May-06 day 0 Normal
12 284 Combination 27-May-06 day 7 Normal
12 284 Combination 2-Jun-06 day 14 Normal
12 284 Combination 6-Jun-06 end day Normal
12 284 Combination 5-Sep-06 month 3 Normal
12 284 Combination 9-Dec-06 month 6 Normal
12 285 Combination 19-May-06 day 0 Normal
12 285 Combination 26-May-06 day 7 Normal 
12 285 Combination 2-Jun-06 day 14 Normal
12 285 Combination 6-Jun-06 end day Normal
12 285 Combination 5-Sep-06 month 3 Normal
12 285 Combination 6-Dec-06 month 6 Normal
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12 286 PM 28-Dec-06 day 0 Normal
12 286 PM 15-Jan-07 day 14 Normal
12 286 PM 24-Jan-07 end day Normal
12 286 PM 4-Sep-07 month 6 Normal
12 287 SSG 28-Dec-06 day 0 Normal
12 287 SSG 15-Jan-07 day 14 Normal
12 287 SSG 1-Feb-07 end day Normal
12 287 SSG 7-Aug-07 month 6 Normal
12 288 Combination 30-Dec-06 day 0 Normal
12 288 Combination 15-Jan-07 day 14 Normal
12 288 Combination 19-Jan-07 end day Normal
12 288 Combination 24-Jul-07 month 6 Normal
12 289 Combination 30-Dec-06 day 0 Normal
12 289 Combination 15-Jan-07 day 14 Normal
12 289 Combination 19-Jan-07 end day Normal
12 289 Combination 2-Sep-07 month 6 Normal
12 290 SSG 5-Jan-07 day 0 Normal
12 290 SSG 19-Jan-07 day 14 Normal
12 290 SSG 5-Feb-07 end day Normal
12 290 SSG 6-Sep-07 month 6 Normal
12 291 SSG 8-Jan-07 day 0 Normal -LEFT EAR AT 8KHZ IS 30DB
12 291 SSG 24-Jan-07 day 14 Normal
12 291 SSG 10-Feb-07 end day Normal 35 DB - AT 8K DB
12 291 SSG 4-Sep-07 month 6 Normal
12 292 PM 14-Jan-07 day 0 Normal
12 292 PM 31-Jan-07 day 14 Normal
12 292 PM 7-Feb-07 end day Normal
12 292 PM 22-Aug-07 month 6 Normal
12 293 SSG 21-Jan-07 day 0 Normal
12 293 SSG 6-Feb-07 day 14 Normal
12 293 SSG 23-Feb-07 end day Normal
12 293 SSG 6-Sep-07 month 6 Normal
12 294 Combination 21-Feb-07 day 0 Normal
12 294 Combination 7-Mar-07 day 14 Normal
12 294 Combination 12-Mar-07 end day Normal
12 294 Combination 11-Jun-07 month 3 Normal
12 294 Combination 11-Sep-07 month 6 Normal
12 295 Combination 12-Mar-07 day 0 Normal
12 295 Combination 29-Mar-07 day 14 Normal
12 295 Combination 2-Apr-07 end day Normal
12 295 Combination 20-Sep-07 month 6 Normal
12 296 PM 10-Apr-07 day 0 Normal
12 296 PM 25-Apr-07 day 14 Normal
12 296 PM 3-May-07 end day Normal
12 296 PM 1-Aug-07 month 3 Normal
12 296 PM 30-Oct-07 month 6 Normal
12 297 SSG 10-Apr-07 day 0 Normal
12 297 SSG 25-Apr-07 day 14 Normal
12 298 PM 18-Apr-07 day 0 Normal
12 298 PM 4-May-07 day 14 Normal
12 298 PM 12-May-07 end day Normal
12 298 PM 9-Nov-07 month 6 Normal
12 299 Combination 3-Jun-07 day 0 Normal
12 299 Combination 18-Jun-07 day 14 Normal
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12 299 Combination 22-Jun-07 end day Normal
12 299 Combination 1-Jan-08 month 6 Normal
12 300 PM 3-Jun-07 day 0 Normal
12 300 PM 18-Jun-07 day 14 Normal
12 300 PM 26-Jun-07 end day Normal
12 300 PM 24-Dec-07 month 6 Normal
12 301 SSG 3-Jun-07 day 0 Normal
12 301 SSG 18-Jun-07 day 14 Normal
12 301 SSG 5-Jul-07 end day Normal
12 301 SSG 4-Feb-08 month 6 Normal
12 302 SSG day 0 Not Done
12 302 SSG day 14 Not Done
12 302 SSG 5-Jul-07 end day Not Done
12 303 PM 3-Jun-07 day 0 Normal
12 303 PM 18-Jun-07 day 14 Normal
12 303 PM 26-Jun-07 end day Normal
12 303 PM 26-Dec-07 month 6 Normal
12 304 Combination 3-Jun-07 day 0 Normal
12 304 Combination 18-Jun-07 day 14 Normal
12 304 Combination 22-Jun-07 end day Normal
12 304 Combination 26-Dec-07 month 6 Normal
12 305 PM day 0 Not Done
12 305 PM day 14 Not Done
12 305 PM end day Not Done
12 306 Combination day 0 Not Done
12 306 Combination day 14 Not Done
12 306 Combination end day Not Done
12 307 Combination 14-Jun-07 day 0 Normal
12 307 Combination 28-Jun-07 day 14 Normal
12 307 Combination 2-Jul-07 end day Normal
12 307 Combination 26-Dec-07 month 6 Normal
12 308 PM 14-Jun-07 day 0 Normal
12 308 PM 28-Jun-07 day 14 Normal
12 308 PM 6-Jul-07 end day Normal
12 308 PM 26-Dec-07 month 6 Normal
12 309 PM 16-Jun-07 day 0 Normal
12 309 PM 29-Jun-07 day 14 Normal
12 309 PM 7-Jul-07 end day Normal
12 309 PM 26-Dec-07 month 6 Normal
12 310 SSG 16-Jun-07 day 0 Normal
12 310 SSG 29-Jun-07 day 14 Normal
12 310 SSG 17-Jul-07 end day Normal
12 310 SSG 4-Feb-08 month 6 Normal
12 311 SSG 4-Jul-07 day 0 Normal
12 311 SSG 18-Jul-07 day 14 Normal
12 311 SSG 4-Aug-07 end day Normal
12 311 SSG 11-Mar-08 month 6 Normal
12 312 Combination 11-Jul-07 day 0 Normal
12 312 Combination 25-Jul-07 day 14 Normal
12 312 Combination 29-Jul-07 end day Normal
12 312 Combination 19-Mar-08 month 6 Normal
12 313 PM 1-Aug-07 day 0 Normal
12 313 PM 15-Aug-07 day 14 Normal
12 313 PM 23-Aug-07 end day Normal
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12 313 PM 21-Feb-08 month 6 Normal
12 314 SSG 1-Aug-07 day 0 Normal
12 314 SSG 21-Aug-07 day 14 Normal
12 314 SSG 6-Sep-07 end day Normal
12 314 SSG 4-Mar-08 month 6 Normal
12 315 Combination 21-Aug-07 day 0 Normal
12 315 Combination 11-Sep-07 day 14 Normal
12 315 Combination 15-Sep-07 end day Normal
12 315 Combination 11-Aug-08 month 6 Normal
12 316 SSG 21-Aug-07 day 0 Normal
12 316 SSG 11-Sep-07 day 14 Normal
12 316 SSG 2-Apr-08 month 6 Normal
12 317 SSG 21-Aug-09 day 0 Not Done PATIENT IS NOT COOPERATIVE -HAS NO 
CLINICALLY EVIDENT HEARING PROBLEM
12 317 SSG day 14 Not Done
12 317 SSG 29-Sep-07 end day Normal
12 318 Combination 28-Aug-07 day 0 Normal
12 318 Combination 11-Sep-07 day 14 Normal
12 318 Combination 15-Sep-07 end day Normal
12 318 Combination 15-Mar-08 month 6 Normal
12 319 Combination day 0 Normal
12 319 Combination 11-Sep-07 day 14 Normal
12 319 Combination 15-Sep-07 end day Normal
12 319 Combination 15-Mar-08 month 6 Normal
12 320 Combination 5-Sep-07 day 0 Normal
12 320 Combination 19-Sep-07 day 14 Normal
12 320 Combination 23-Sep-07 end day Normal
12 320 Combination 19-Mar-08 month 6 Normal  
12 321 Combination 5-Sep-07 day 0 Normal
12 321 Combination 19-Sep-07 day 14 Normal
12 321 Combination 23-Sep-07 end day Normal
12 321 Combination 24-Mar-08 month 6 Normal
12 322 PM 11-Sep-07 day 0 Normal
12 322 PM 26-Sep-07 day 14 Normal
12 322 PM 4-Oct-07 end day Normal
12 322 PM 20-Apr-08 month 6 Normal
12 323 SSG 19-Sep-07 day 0 Normal
12 323 SSG 3-Oct-07 day 14 Normal
12 323 SSG 20-Oct-07 end day Normal
12 323 SSG 17-Apr-08 month 6 Normal
12 324 SSG 19-Sep-07 day 0 Normal
12 324 SSG 3-Oct-07 day 14 Normal
12 324 SSG 20-Oct-07 end day Normal
12 324 SSG 17-Apr-08 month 6 Normal
12 325 PM 19-Sep-07 day 0 Normal
12 325 PM 10-Oct-07 day 14 Normal
12 325 PM 18-Oct-07 end day Normal
12 325 PM 17-Apr-08 month 6 Normal
12 326 PM 2-Oct-07 day 0 Normal
12 326 PM 16-Oct-07 day 14 Normal -HAS MILD HEARING LOSS LEVEL ON 
AUDIOMETRY FOR HE DEVELOPED OTITIS 
MEDIA 03 DAYS AGO.
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12 326 PM 24-Oct-07 end day Normal
12 326 PM 20-Apr-08 month 6 Normal
12 327 Combination 2-Oct-07 day 0 Normal
12 327 Combination 16-Oct-07 day 14 Normal
12 327 Combination 20-Oct-07 end day Normal
12 327 Combination 17-Apr-08 month 6 Normal
12 328 PM 3-Oct-07 day 0 Normal
12 328 PM day 14 Not Done
12 328 PM 26-Oct-07 end day Normal
12 328 PM 14-Apr-08 month 6 Normal
12 329 SSG 9-Oct-07 day 0 Normal
12 329 SSG 23-Oct-07 day 14 Normal -HAS AUDIOMETRIC SHIFT TO MILD 
HEARING LEVEL FOR HE DEVELOPED OTITIS
MEDIA 04 DAYS AGO
12 329 SSG 30-Oct-07 day 21 Normal
12 329 SSG 9-Nov-07 end day Normal
12 329 SSG 5-May-08 month 6 Normal
12 330 PM 9-Oct-07 day 0 Normal
12 330 PM 23-Oct-07 day 14 Normal
12 330 PM 31-Oct-07 end day Normal
12 330 PM 5-May-08 month 6 Normal
23 361 Combination 18-Jan-05 day 0 Abnormal (CI) LEFT EAR MILD HEARING LOSS FOR LOW 
FREQUENCIES
23 361 Combination 26-Jan-05 day 7 Normal
23 361 Combination 2-Feb-05 day 14 Normal
23 361 Combination 6-Feb-05 end day Normal
23 361 Combination 10-Aug-05 month 6 Normal
23 362 PM 19-Jan-05 day 0 Normal
23 362 PM 26-Jan-05 day 7 Normal
23 362 PM 2-Feb-05 day 14 Normal
23 362 PM 10-Feb-05 end day Normal
23 362 PM 10-May-05 month 3 Normal
23 362 PM 16-Aug-05 month 6 Normal
23 363 PM 18-Jan-05 day 0 Normal
23 363 PM 26-Jan-05 day 7 Normal
23 363 PM 2-Feb-05 day 14 Normal
23 363 PM 10-Feb-05 end day Normal
23 363 PM 10-Aug-05 month 6 Normal
23 364 Combination 18-Jan-05 day 0 Normal
23 364 Combination 26-Jan-05 day 7 Normal
23 364 Combination 2-Feb-05 day 14 Normal
23 364 Combination 6-Feb-05 end day Normal
23 364 Combination 11-May-05 month 3 Normal
23 364 Combination 19-Aug-05 month 6 Normal
23 365 SSG 18-Jan-05 day 0 Normal
23 365 SSG 26-Jan-05 day 7 Normal
23 365 SSG 2-Feb-05 day 14 Normal
23 365 SSG 10-Feb-05 day 21 Normal
23 365 SSG 20-Feb-05 end day Normal
23 365 SSG 20-May-05 month 3 Abnormal (CI) MODERATE HEARING LOSS RT EAR AT 
4000HZ & 8000HZ MILD HEARING LOSS LT 
EAR AT 8000HZ RT - TYMPANIC MEMBRANE - 
MILD INFLAMMATION
23 365 SSG 30-Aug-05 month 6 Normal
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23 366 Combination 28-Jan-05 day 0 Normal
23 366 Combination 7-Feb-05 day 7 Normal
23 366 Combination 14-Feb-05 day 14 Normal
23 366 Combination 18-Feb-05 end day Normal
23 366 Combination 20-May-05 month 3 Normal
23 366 Combination 20-Aug-05 month 6 Normal
23 367 SSG 28-Jan-05 day 0 Normal
23 367 SSG 7-Feb-05 day 7 Normal
23 367 SSG 14-Feb-05 day 14 Normal
23 367 SSG 21-Feb-05 day 21 Normal
23 367 SSG 3-Mar-05 end day Normal
23 367 SSG 8-Jun-05 month 3 Normal
23 367 SSG 23-Sep-05 month 6 Normal
23 368 PM 28-Jan-05 day 0 Normal
23 368 PM 7-Feb-05 day 7 Normal
23 368 PM 17-Feb-05 day 14 Abnormal (CI) MILD HEARING LOSS - RT EAR CAUSED BY A 
PERFORATED RT TYMPANIC MEMBRANE
23 368 PM 23-Feb-05 end day Abnormal (CI) MILD HEARING LOSS RT EAR HAS A   
RUPTURED TYMPANIC MEMBRANE
23 368 PM 26-May-05 month 3 Abnormal (CI) MILD HEARING LOSS LT EAR AT 250HZ, 
500HZ 1000HZ, 2000HZ AND 4000HZ MILD 
HEARING LOSS RT EAR - HAS PERFORATED 
EARDRUM (RT) 20 TO CHRONIC OTITIS 
MEDIA RT EAR, MILD HEARING LOSS AT ALL 
FREQUENCIES. (250HZ, 500HZ, 1000HZ, 
2000HZ, 4000HZ AND 8000HZ)
23 368 PM 6-Sep-05 month 6 Abnormal (CI) MILD TO MODERATE HEARING LOSS RT EAR 
AT 250HZ, 500HZ, AND 1000HZ DUE TO 
RUPTURED RT TYMPANIC MEMBRANE
23 369 Combination 28-Jan-05 day 0 Normal
23 369 Combination 10-Feb-05 day 7 Normal
23 369 Combination 17-Feb-05 day 14 Normal
23 369 Combination 21-Feb-05 end day Normal
23 369 Combination 26-May-05 month 3 Normal
23 369 Combination 30-Aug-05 month 6 Normal
23 370 SSG 28-Jan-05 day 0 Normal
23 370 SSG 10-Feb-05 day 7 Normal
23 370 SSG 17-Feb-05 day 14 Normal
23 370 SSG 24-Feb-05 day 21 Normal
23 370 SSG 6-Mar-05 end day Normal
23 370 SSG 8-Jun-05 month 3 Normal
23 370 SSG 23-Sep-05 month 6 Normal
23 371 PM 4-Feb-05 day 0 Normal
23 371 PM 10-Feb-05 day 7 Normal MILD HEARING LOSS (30DB)
23 371 PM 17-Feb-05 day 14 Normal
23 371 PM 25-Feb-05 end day Normal
23 371 PM 26-May-05 month 3 Normal
23 371 PM 6-Sep-05 month 6 Normal
23 372 PM 10-Feb-05 day 0 Normal
23 372 PM 17-Feb-05 day 7 Normal
23 372 PM 24-Feb-05 day 14 Normal
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23 372 PM 4-Mar-05 end day Normal
23 372 PM 5-Jun-05 month 3 Normal
23 372 PM 8-Sep-05 month 6 Normal
23 373 SSG 17-Feb-05 day 0 Normal
23 373 SSG 24-Feb-05 day 7 Normal
23 373 SSG 3-Mar-05 day 14 Normal
23 373 SSG 10-Mar-05 day 21 Normal
23 373 SSG 20-Mar-05 end day Normal
23 373 SSG 6-Jul-05 month 3 Normal
23 373 SSG 24-Oct-05 month 6 Normal
23 374 SSG 18-Feb-05 day 0 Normal
23 374 SSG 2-Mar-05 day 7 Normal
23 374 SSG 9-Mar-05 day 14 Normal
23 374 SSG 16-Mar-05 day 21 Normal
23 374 SSG 28-Mar-05 end day Normal
23 374 SSG 27-Jun-05 month 3 Normal
23 374 SSG 30-Sep-05 month 6 Normal
23 375 Combination 25-Feb-05 day 0 Normal
23 375 Combination 3-Mar-05 day 7 Normal
23 375 Combination 10-Mar-05 day 14 Normal
23 375 Combination 14-Mar-05 end day Normal
23 375 Combination 15-Jun-05 month 3 Normal
23 375 Combination 23-Sep-05 month 6 Normal
23 376 SSG 1-Mar-05 day 0 Normal
23 376 SSG 7-Mar-05 day 7 Normal
23 376 SSG 14-Mar-05 day 14 Normal
23 376 SSG 21-Mar-05 day 21 Normal
23 376 SSG 31-Mar-05 end day Normal
23 376 SSG 29-Jun-05 month 3 Normal
23 376 SSG 28-Sep-05 month 6 Normal
23 377 Combination 9-Mar-05 day 0 Normal
23 377 Combination 15-Mar-05 day 7 Normal
23 377 Combination 23-Sep-05 month 6 Normal
23 378 Combination 9-Mar-05 day 0 Normal
23 378 Combination 15-Mar-05 day 7 Normal
23 378 Combination 22-Mar-05 day 14 Normal
23 378 Combination 26-Mar-05 end day Normal
23 378 Combination 6-Jul-05 month 3 Normal
23 378 Combination 23-Sep-05 month 6 Normal
23 379 PM 10-Mar-05 day 0 Normal
23 379 PM 16-Mar-05 day 7 Normal
23 379 PM 23-Mar-05 day 14 Normal
23 379 PM 31-Mar-05 end day Normal
23 379 PM 29-Jun-05 month 3 Normal
23 380 SSG 15-Mar-05 day 0 Normal
23 380 SSG 21-Mar-05 day 7 Normal
23 380 SSG 28-Mar-05 day 14 Abnormal (CI) MILD HEARING LOSS - BIL RT EAR 250 AND 
500HZ LT EAR 500HZ
23 380 SSG 4-Apr-05 day 21 Normal MILD LT EAR HEARING LOSS AT 500HZ
23 380 SSG 14-Apr-05 end day Normal
23 380 SSG 19-Jul-05 month 3 Normal
23 380 SSG 12-Oct-05 month 6 Normal
23 381 PM 15-Mar-05 day 0 Normal
23 381 PM 21-Mar-05 day 7 Normal
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23 381 PM day 14 Not Done
23 381 PM 5-Apr-05 end day Normal
23 381 PM 12-Jul-05 month 3 Normal
23 381 PM 17-Nov-05 month 6 Normal
23 382 Combination 18-Mar-05 day 0 Normal
23 382 Combination 24-Mar-05 day 7 Normal
23 382 Combination 31-Mar-05 day 14 Normal
23 382 Combination 4-Apr-05 end day Normal
23 382 Combination 12-Jul-05 month 3 Normal
23 382 Combination 30-Sep-05 month 6 Normal
23 383 PM 4-Apr-05 day 0 Normal
23 383 PM 11-Apr-05 day 7 Normal
23 383 PM 18-Apr-05 day 14 Abnormal (CI) MILD RT HEARING LOSS AT 250HZ, 500HZ 
AND 4000HZ
23 383 PM 26-Apr-05 end day Abnormal (CI) MILD RT HEARING LOSS AT 4000HZ AND 
8000HZ
23 383 PM 30-Sep-05 month 3 Normal
23 383 PM 24-Oct-05 month 6 Normal
23 384 SSG 30-Mar-05 day 0 Normal
23 384 SSG 11-Apr-05 day 7 Normal
23 384 SSG 18-Apr-05 day 14 Normal
23 384 SSG 25-Apr-05 day 21 Normal
23 384 SSG 5-May-05 end day Normal
23 384 SSG 28-Sep-05 month 3 Normal
23 384 SSG 17-Nov-05 month 6 Normal
23 385 SSG 30-Mar-05 day 0 Normal
23 385 SSG 13-Apr-05 day 7 Abnormal (CI) MILD HEARING AT 250HZ AND 500HZ IN THE 
RIGHT EAR IN LEFT EAR MILD HEARING 
LOSS AT 1000HZ
23 385 SSG 20-Apr-05 day 14 Normal
23 385 SSG 27-Apr-05 day 21 Normal
23 385 SSG 7-May-05 end day Normal
23 385 SSG 10-Aug-05 month 3 Normal
23 385 SSG 11-Nov-05 month 6 Normal
23 386 Combination 19-Apr-05 day 0 Normal
23 386 Combination 25-Apr-05 day 7 Abnormal (CI) MILD HEARING LOSS LT EAR AT 1000 AND 
2000 HZ, AND 8000 HZ.
23 386 Combination 11-May-05 day 14 Normal
23 386 Combination 14-May-05 end day Normal
23 386 Combination 19-Aug-05 month 3 Normal
23 386 Combination 11-Nov-05 month 6 Normal
23 387 Combination 19-Apr-05 day 0 Normal
23 387 Combination 25-Apr-05 day 7 Normal
23 387 Combination 2-May-05 day 14 Normal
23 387 Combination 6-May-05 end day Normal
23 387 Combination 10-Aug-05 month 3 Normal
23 387 Combination 11-Nov-05 month 6 Normal
23 388 PM 19-Apr-05 day 0 Normal
23 388 PM 25-Apr-05 day 7 Normal
23 388 PM 2-May-05 day 14 Normal
23 388 PM 10-May-05 end day Normal
23 388 PM 28-Sep-05 month 3 Normal
23 388 PM 2-Dec-05 month 6 Normal
23 389 SSG 19-Apr-05 day 0 Normal
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23 389 SSG 26-Apr-05 day 7 Normal
23 389 SSG 3-May-05 day 14 Normal
23 389 SSG 10-May-05 day 21 Normal
23 389 SSG 20-May-05 end day Normal
23 389 SSG 6-Sep-05 month 3 Normal
23 389 SSG 9-Dec-05 month 6 Normal
23 390 PM 19-Apr-05 day 0 Normal
23 390 PM 26-Apr-05 day 7 Normal
23 390 PM 3-May-05 day 14 Normal
23 390 PM 11-May-05 end day Normal
23 390 PM 10-Aug-05 month 3 Normal
23 390 PM 2-Dec-05 month 6 Normal
23 391 Combination 22-Apr-05 day 0 Normal
23 391 Combination 28-Apr-05 day 7 Normal
23 391 Combination 5-May-05 day 14 Normal
23 391 Combination 9-May-05 end day Normal
23 391 Combination 19-Aug-05 month 3 Normal
23 391 Combination 17-Nov-05 month 6 Normal
23 392 Combination 20-Apr-05 day 0 Normal
23 392 Combination 28-Apr-05 day 7 Normal
23 392 Combination 5-May-05 day 14 Normal
23 392 Combination 22-Jul-05 month 3 Normal
23 392 Combination 30-Sep-05 month 6 Normal
23 393 SSG 21-Apr-05 day 0 Normal
23 393 SSG 28-Apr-05 day 7 Normal
23 393 SSG 5-May-05 day 14 Normal
23 393 SSG 12-May-05 day 21 Normal
23 393 SSG 22-May-05 end day Normal
23 393 SSG 19-Aug-05 month 3 Normal
23 393 SSG 17-Nov-05 month 6 Normal
23 394 PM 25-Apr-05 day 0 Normal
23 394 PM 2-May-05 day 7 Normal
23 394 PM 9-May-05 day 14 Normal
23 394 PM 17-May-05 end day Normal
23 394 PM 19-Aug-05 month 3 Normal
23 394 PM 17-Nov-05 month 6 Normal
23 395 PM 28-Apr-05 day 0 Normal
23 395 PM 5-May-05 day 7 Normal
23 395 PM 12-May-05 day 14 Abnormal (CI) MILD HEARING LOSS RT EAR AT 250 HZ
23 395 PM 20-May-05 end day Normal
23 395 PM 15-Dec-05 month 6 Normal
23 396 SSG 13-May-05 day 0 Normal
23 396 SSG 19-May-05 day 7 Normal
23 396 SSG 26-May-05 day 14 Normal
23 396 SSG 2-Jun-05 day 21 Normal
23 396 SSG 12-Jun-05 end day Normal
23 396 SSG 15-Sep-05 month 3 Normal
23 396 SSG 15-Dec-05 month 6 Normal
23 397 SSG 13-May-05 day 0 Normal
23 397 SSG 19-May-05 day 7 Normal
23 397 SSG 26-May-05 day 14 Normal
23 397 SSG 2-Jun-05 day 21 Normal
23 397 SSG 12-Jun-05 end day Normal
23 397 SSG 15-Sep-05 month 3 Normal
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23 397 SSG 15-Dec-05 month 6 Normal
23 398 Combination 18-May-05 day 0 Normal
23 398 Combination 24-May-05 day 7 Normal
23 398 Combination 31-May-05 day 14 Normal
23 398 Combination 4-Jun-05 end day Normal
23 398 Combination 30-Sep-05 month 3 Normal
23 398 Combination 14-Dec-05 month 6 Normal
23 399 PM 17-May-05 day 0 Normal
23 399 PM 24-May-05 day 7 Normal
23 399 PM 31-May-05 day 14 Normal
23 399 PM 8-Jun-05 end day Normal
23 399 PM 14-Oct-05 month 3 Normal
23 399 PM 15-Dec-05 month 6 Normal
23 400 PM 3-Jun-05 day 0 Normal
23 400 PM 9-Jun-05 day 7 Normal
23 400 PM 16-Jun-05 day 14 Normal
23 400 PM 24-Jun-05 end day Normal
23 400 PM 14-Oct-05 month 3 Normal
23 400 PM 12-Jan-06 month 6 Normal
23 401 Combination 2-Jun-05 day 0 Normal
23 401 Combination 9-Jun-05 day 7 Normal
23 401 Combination 16-Jun-05 day 14 Normal
23 401 Combination 20-Jun-05 end day Normal
23 401 Combination 21-Sep-05 month 3 Normal
23 401 Combination 20-Dec-05 month 6 Normal
23 402 Combination 2-Jun-05 day 0 Normal
23 402 Combination 9-Jun-05 day 7 Normal
23 402 Combination 16-Jun-05 day 14 Normal
23 402 Combination 20-Jun-05 end day Normal
23 402 Combination 23-Sep-05 month 3 Normal
23 402 Combination 20-Dec-05 month 6 Normal
23 403 SSG 2-Jun-05 day 0 Normal
23 403 SSG 10-Jun-05 day 7 Normal
23 403 SSG 17-Jun-05 day 14 Normal
23 403 SSG 24-Jun-05 day 21 Normal
23 403 SSG 4-Jul-05 end day Normal
23 403 SSG 30-Sep-05 month 3 Normal
23 403 SSG 12-Jan-06 month 6 Normal
23 404 SSG 2-Jun-05 day 0 Normal
23 404 SSG 10-Jun-05 day 7 Normal
23 404 SSG 17-Jun-05 day 14 Normal
23 404 SSG 24-Jun-05 day 21 Normal
23 404 SSG 4-Jul-05 end day Normal
23 404 SSG 12-Jan-06 month 6 Normal
23 405 PM 2-Jun-05 day 0 Normal
23 405 PM 16-Jun-05 day 7 Normal
23 405 PM 23-Jun-05 day 14 Normal
23 405 PM 1-Jul-05 end day Normal
23 405 PM 30-Sep-05 month 3 Normal
23 405 PM 5-Jan-06 month 6 Normal
34 Not done
35 646 PM 28-Jan-05 day 0 Normal
35 646 PM 3-Feb-05 day 7 Normal
35 646 PM 10-Feb-05 day 14 Normal
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35 646 PM 18-Feb-05 end day Normal
35 647 PM 29-Jan-05 day 0 Normal
35 647 PM 5-Feb-05 day 7 Normal
35 647 PM 12-Feb-05 day 14 Normal
35 647 PM 20-Feb-05 end day Normal
35 648 Combination 29-Jan-05 day 0 Normal
35 648 Combination 5-Feb-05 day 7 Normal
35 648 Combination day 14 Not Done
35 648 Combination 16-Feb-05 end day Normal
35 648 Combination 25-Aug-05 month 6 Normal
35 649 Combination 29-Jan-05 day 0 Normal
35 649 Combination 5-Feb-05 day 7 Normal
35 649 Combination day 14 Not Done
35 649 Combination 16-Feb-05 end day Normal
35 649 Combination 15-Sep-05 month 6 Normal
35 650 SSG 29-Jan-05 day 0 Normal
35 650 SSG 5-Feb-05 day 7 Normal
35 650 SSG 12-Feb-05 day 14 Normal
35 650 SSG 19-Feb-05 day 21 Normal
35 650 SSG 1-Mar-05 end day Normal
35 650 SSG 15-Sep-05 month 6 Normal
35 651 SSG 29-Jan-05 day 0 Normal
35 651 SSG 5-Feb-05 day 7 Normal
35 651 SSG 12-Feb-05 day 14 Normal
35 651 SSG 19-Feb-05 day 21 Normal
35 651 SSG 1-Mar-05 end day Normal
35 651 SSG 15-Sep-05 month 6 Normal
35 652 PM 31-Jan-05 day 0 Normal
35 652 PM 7-Feb-05 day 7 Normal
35 652 PM 14-Feb-05 day 14 Normal
35 652 PM 22-Feb-05 end day Normal
35 653 Combination 1-Feb-05 day 0 Normal
35 653 Combination 9-Feb-05 day 7 Normal
35 653 Combination 16-Feb-05 day 14 Normal
35 653 Combination 20-Feb-05 end day Normal
35 653 Combination 25-Aug-05 month 6 Normal
35 654 SSG 1-Feb-05 day 0 Normal
35 654 SSG 9-Feb-05 day 7 Normal
35 654 SSG 16-Feb-05 day 14 Normal
35 654 SSG 23-Feb-05 day 21 Normal
35 654 SSG 5-Mar-05 end day Normal
35 654 SSG 19-Sep-05 month 6 Normal
35 655 Combination 1-Feb-05 day 0 Normal
35 655 Combination 9-Feb-05 day 7 Normal
35 655 Combination 16-Feb-05 day 14 Normal
35 655 Combination 20-Feb-05 end day Normal
35 655 Combination 25-Aug-05 month 6 Normal MILD HEARING LOSS ON RT EAR 30 DBHL
35 656 SSG 3-Feb-05 day 0 Normal
35 656 SSG 9-Feb-05 day 7 Normal
35 656 SSG 16-Feb-05 day 14 Normal
35 656 SSG 23-Feb-05 day 21 Normal
35 656 SSG 5-Mar-05 end day Normal
35 656 SSG 17-Oct-05 month 6 Normal
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35 657 PM 7-Feb-05 day 0 Normal 
35 657 PM 14-Feb-05 day 7 Normal
35 657 PM 21-Feb-05 day 14 Normal
35 657 PM 1-Mar-05 end day Normal
35 657 PM 15-Sep-05 month 6 Normal
35 658 Combination 6-Feb-05 day 0 Normal
35 658 Combination 14-Feb-05 day 7 Normal
35 658 Combination 21-Feb-05 day 14 Normal
35 658 Combination 25-Feb-05 end day Normal
35 658 Combination 25-Aug-05 month 6 Normal
35 659 SSG 7-Feb-05 day 0 Normal
35 659 SSG 14-Feb-05 day 7 Normal
35 659 SSG 21-Feb-05 day 14 Normal
35 659 SSG 28-Feb-05 day 21 Normal
35 659 SSG 10-Mar-05 end day Normal
35 659 SSG 29-Oct-05 month 6 Normal
35 660 PM 10-Feb-05 day 0 Normal MILD HEARING IMPAIRMENT
35 660 PM 16-Feb-05 day 7 Normal MILD HEARING IMPAIRMENT
35 660 PM 23-Feb-05 day 14 Normal MODERATE R MILD L
35 660 PM 3-Mar-05 end day Normal
35 660 PM 15-Sep-05 month 6 Normal
35 661 Combination 16-Feb-05 day 0 Normal
35 661 Combination 22-Feb-05 day 7 Normal
35 661 Combination 1-Mar-05 day 14 Normal
35 661 Combination 5-Mar-05 end day Normal
35 661 Combination 24-Sep-05 month 6 Normal
35 662 PM 19-Feb-05 day 0 Normal
35 662 PM 26-Feb-05 day 7 Normal
35 662 PM 5-Mar-05 day 14 Normal
35 662 PM 13-Mar-05 end day Normal
35 663 SSG 19-Feb-05 day 0 Normal
35 663 SSG 26-Feb-05 day 7 Normal
35 663 SSG 5-Mar-05 day 14 Normal
35 663 SSG 12-Mar-05 day 21 Normal 
35 663 SSG 22-Mar-05 end day Normal
35 663 SSG 22-Sep-05 month 6 Normal
35 664 Combination 19-Feb-05 day 0 Normal
35 664 Combination 26-Feb-05 day 7 Normal
35 665 SSG 22-Feb-05 day 0 Normal
35 665 SSG 1-Mar-05 day 7 Normal
35 665 SSG 8-Mar-05 day 14 Normal
35 665 SSG 15-Mar-05 day 21 Normal
35 665 SSG 25-Mar-05 end day Normal
35 665 SSG 23-Oct-05 month 6 Normal
35 666 SSG 25-Feb-05 day 0 Normal
35 666 SSG 4-Mar-05 day 7 Normal
35 666 SSG 11-Mar-05 day 14 Normal
35 666 SSG 18-Mar-05 day 21 Normal
35 666 SSG 28-Mar-05 end day Normal
35 666 SSG 25-Sep-05 month 6 Normal
35 667 Combination 28-Feb-05 day 0 Normal
35 667 Combination 6-Mar-05 day 7 Normal
35 667 Combination 13-Mar-05 day 14 Normal
35 667 Combination 17-Mar-05 end day Normal
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35 667 Combination 27-Oct-05 month 6 Normal
35 668 PM 28-Feb-05 day 0 Normal
35 668 PM 6-Mar-05 day 7 Normal
35 668 PM 13-Mar-05 day 14 Normal
35 668 PM 21-Mar-05 end day Normal
35 668 PM 25-Sep-05 month 6 Normal
35 669 PM 28-Feb-05 day 0 Normal
35 669 PM 6-Mar-05 day 7 Normal
35 669 PM 13-Mar-05 day 14 Normal
35 669 PM 21-Mar-05 end day Normal
35 670 SSG 3-Mar-05 day 0 Normal
35 670 SSG 9-Mar-05 day 7 Normal
35 670 SSG 16-Mar-05 day 14 Normal
35 670 SSG 23-Mar-05 day 21 Normal
35 670 SSG 2-Apr-05 end day Normal
35 670 SSG 17-Oct-05 month 6 Normal
35 671 PM 10-Mar-05 day 0 Normal
35 671 PM 17-Mar-05 day 7 Normal
35 671 PM 24-Mar-05 day 14 Normal
35 671 PM 1-Apr-05 end day Normal
35 672 Combination 10-Mar-05 day 0 Normal
35 672 Combination 17-Mar-05 day 7 Normal
35 672 Combination 24-Mar-05 day 14 Normal
35 672 Combination 28-Mar-05 end day Normal
35 672 Combination 29-Oct-05 month 6 Normal
35 673 SSG 10-Mar-05 day 0 Normal
35 673 SSG 17-Mar-05 day 7 Normal
35 673 SSG 24-Mar-05 day 14 Normal
35 673 SSG 31-Mar-05 day 21 Normal
35 673 SSG 10-Apr-05 end day Normal
35 673 SSG 17-Oct-05 month 6 Normal
35 674 Combination 11-Mar-05 day 0 Normal
35 674 Combination 19-Mar-05 day 7 Normal
35 674 Combination 26-Mar-05 day 14 Normal
35 674 Combination 30-Mar-05 end day Normal
35 674 Combination 25-Oct-05 month 6 Normal 
35 675 PM 13-Mar-05 day 0 Normal
35 675 PM 20-Mar-05 day 7 Normal
35 675 PM 27-Mar-05 day 14 Normal
35 675 PM 4-Apr-05 end day Normal
35 676 PM 19-Mar-05 day 0 Normal
35 676 PM 26-Mar-05 day 7 Normal 
35 676 PM 2-Apr-05 day 14 Normal
35 676 PM 10-Apr-05 end day Normal
35 676 PM 25-Oct-05 month 6 Normal
35 677 SSG 19-Mar-05 day 0 Normal
35 677 SSG 26-Mar-05 day 7 Normal
35 678 Combination 20-Mar-05 day 0 Normal
35 678 Combination 28-Mar-05 day 7 Normal
35 678 Combination 4-Apr-05 day 14 Normal
35 678 Combination 8-Apr-05 end day Normal
35 678 Combination 25-Oct-05 month 6 Normal
35 679 SSG 20-Mar-05 day 0 Normal
35 679 SSG 4-Apr-05 day 7 Normal
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35 679 SSG 4-Apr-05 day 14 Normal 
35 679 SSG 11-Apr-05 day 21 Normal
35 679 SSG 20-Apr-05 end day Normal
35 679 SSG 25-Oct-05 month 6 Normal
35 680 Combination 21-Mar-05 day 0 Normal
35 680 Combination 28-Mar-05 day 7 Normal
35 680 Combination 4-Apr-05 day 14 Normal
35 680 Combination 8-Apr-05 end day Normal
35 680 Combination 17-Oct-05 month 6 Normal
35 681 Combination 21-Mar-05 day 0 Normal
35 681 Combination 28-Mar-05 day 7 Normal
35 681 Combination 4-Apr-05 day 14 Normal
35 681 Combination 8-Apr-05 end day Normal
35 681 Combination 23-Oct-05 month 6 Normal
35 682 PM 21-Mar-05 day 0 Normal
35 682 PM 28-Mar-05 day 7 Normal
35 682 PM 4-Apr-05 day 14 Normal
35 682 PM 12-Apr-05 end day Normal
35 683 Combination 21-Mar-05 day 0 Normal
35 683 Combination 28-Mar-05 day 7 Normal
35 683 Combination 4-Apr-05 day 14 Normal
35 683 Combination 8-Apr-05 end day Normal
35 683 Combination 29-Oct-05 month 6 Normal
35 684 SSG 8-Apr-05 day 0 Normal
35 684 SSG 15-Apr-05 day 7 Normal
35 684 SSG 22-Apr-05 day 14 Normal
35 684 SSG 29-Apr-05 day 21 Normal
35 684 SSG 9-May-05 end day Normal
35 684 SSG 13-Nov-05 month 6 Normal
35 685 PM 8-Apr-05 day 0 Normal
35 685 PM 15-Apr-05 day 7 Normal
35 685 PM 22-Apr-05 day 14 Normal
35 685 PM 30-Apr-05 end day Normal
35 685 PM 29-Oct-05 month 6 Normal
35 686 PM 13-Apr-05 day 0 Normal
35 686 PM 19-Apr-05 day 7 Normal
35 686 PM 26-Apr-05 day 14 Normal
35 686 PM 4-May-05 end day Normal
35 687 SSG 13-Apr-05 day 0 Normal MILD BILATERAL
35 687 SSG 19-Apr-05 day 7 Normal MILD BILATERAL LT 30DB AT 500HZ, AND 35 
DB AT 8000HZ RT 30DB AT 500HZ, 30DB AT 
8000HZ
35 687 SSG 26-Apr-05 day 14 Normal MILD RT EAR 30DB AT BOTH 4000 & 8000HZ
35 687 SSG 3-May-05 day 21 Normal MILD BOTH LT 30 DB AT 500HZ & 1000HZ, 35 
DB AT 250 & 2000HZ, RT 30DB AT 250HZ
35 687 SSG 13-May-05 end day Normal MILD BOTH EARS LT 30DB AT 250HZ, 35DB 
AT 500HZ RT 30DB AT 250HZ,500 & 1000HZ
35 687 SSG 29-Oct-05 month 6 Normal
35 688 PM 15-Apr-05 day 0 Normal
35 688 PM 22-Apr-05 day 7 Normal MILD IMPAIRMENT IN THE LEFT YEAR I.E 35 
DBHL(AC) 500 HZ
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35 688 PM 29-Apr-05 day 14 Normal
35 688 PM 7-May-05 end day Normal
35 688 PM 25-Oct-05 month 6 Normal
35 689 Combination 16-Apr-05 day 0 Normal
35 689 Combination 22-Apr-05 day 7 Normal
35 689 Combination 29-Apr-05 day 14 Normal
35 689 Combination 3-May-05 end day Normal
35 690 SSG 16-Apr-05 day 0 Normal
35 690 SSG 22-Apr-05 day 7 Normal
35 690 SSG 29-Apr-05 day 14 Normal
35 690 SSG 6-May-05 day 21 Normal
35 690 SSG 16-May-05 end day Normal
35 690 SSG 29-Oct-05 month 6 Normal
LEAP 0104a Appendices
Page 648 of 756
Appendix 48 SAE reports 
LEAP 0104a Appendices







Demography:  Age (years):  36  Sex:  M  Race:  African 














































Demography:  Age (years):  7  Sex:  M  Race:  African 





































Demography:  Age (years):  50  Sex:  M  Race:  African 




























Demography:  Age (years):  8  Sex:  F  Race:  African 

































Demography:  Age (years):  31  Sex:  M  Race:  African 































Demography:  Age (years):  20  Sex:  M  Race:  African 































Demography:  Age (years):  23  Sex:  M  Race:  African 
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Demography:    Age (years):  29   Sex:  M  Race:  African 
      Height (cm):  156cm  Weight (kg):  47kg 
Country:    Ethiopia 
Protocol:  A  Multicentre  comparative  trial  of  efficacy  and  safety  of  Sodium 













ZKL  is  a  29  year  old  HIV  negative  male  admitted  on  03.04.2007.    His  baseline  clinical  and 
laboratory evaluation results were within normal  limits.   The splenic aspirate was positive (5+) 
for  VL.    He  was  recruited  into  the  LEAP  0104  study  and  randomized  to  SSG  850mg  on 
12.04.2007.  On day 7 of treatment all clinical and laboratory values were normal except serum 
amylase levels which had increased from 121u/l to 460u/l.  He was strictly followed up. 
On  day  14  of  treatment,  serum  amylase  levels  had  increased  to  638u/l  and  the  patient 
complained of epigastric discomfort and back pain.  All other organ function tests done (i.e. CBC, 
U/A,  ECG)  were  within  normal  limits.    Patient  was  diagnosed  with  pancreatitis  and  was 
withdrawn from treatment and put on conservative management. 
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Demography:  Age (years):  36   Sex:  M  Race:  African 




Protocol:  A  Multicentre  comparative  trial  of  efficacy  and  safety  of  Sodium 













KAG  a  36  year  old male was  admitted  on  19.08.2007 with  an  eight month  history  of  fever, 
headache  and  fatigue.    He  also  complained  of  abdominal  pains  for  four  months  prior  to 
admission.   
On examination spleen size was 18cm.  ECG, urine analysis and audiometry were normal.   KAG 




















Age Sex Treatment Treatment 
start date
Adverse Event Preferred term AE start date AE end date Outcome Intensity Action 
taken
Related
11 15 20 Male PM 14-Jul-05 SEVERE ANEAMIA ANAEMIA 20-Jul-05 27-Jul-05 Severe drug stopped Resolved Possible
11 27 31 Male PM 19-Sep-05 DEATH DEATH 19-Feb-06 19-Feb-06 Severe None Resolved Not related




26-Oct-05 9-Nov-05 Severe drug stopped Resolved Possible
11 47 20 Male SSG 5-May-06 DEATH DEATH 30-Jul-06 30-Jul-06 Severe None Not related
11 72 23 Male SSG 22-Jul-06 SEVERE SEPSIS GI FOCUS(SHOCK) ABDOMINAL SEPSIS 5-Aug-06 14-Aug-06 Severe drug stopped Resolved Unlikely
12 246 40 Male PM 4-Aug-05 SEPSIS OF GI FOCUS ABDOMINAL SEPSIS 12-Jan-06 2-Feb-06 Severe None Resolved Not related
12 265 5 Female SSG 15-Feb-06 ACUTE RENAL FAILURE RENAL FAILURE ACUTE 14-Mar-06 20-Mar-06 Severe drug stopped Resolved Possible
12 297 29 Male SSG 12-Apr-07 PANCREATITIS PANCREATITIS 25-Apr-07 4-May-07 Mild drug stopped Resolved Possible
12 316 36 Male SSG 29-Aug-07 RAISED SERUM AMYLASE BLOOD AMYLASE 
INCREASED
11-Sep-07 25-Sep-07 Severe drug stopped Resolved Probable
23 377 40 Female Combination 9-Mar-05 ELEVATED LIVER ENZYMES HEPATIC ENZYME 
INCREASED
16-Mar-05 29-Mar-05 Moderate drug stopped Resolved Possible
23 397 14 Female SSG 18-May-05 INTRAPERITONEAL BLEED PERITONEAL 
HAEMORRHAGE
12-Jun-05 15-Jun-05 Moderate None Resolved Not related
34 461 50 Male SSG 26-Nov-04 EXTENSIVE EPISTAXIS EPISTAXIS 28-Nov-04 1-Dec-04 Severe None Resolved Not related
34 522 36 Male Combination 11-Jan-05 TB PERICARDITIS PERICARDITIS 
MYCOPLASMAL 
28-Jan-05 Severe None Ongoing Not related
34 534 7 Male PM 24-Jan-05 THREATENED ANAEMIC HEART 
FAILURE
CARDIAC FAILURE HIGH 
OUTPUT
14-Feb-05 Severe None Ongoing Probable
35 664 37 Female Combination 20-Feb-05 BILATERAL ACTIVE PARENCHYMAL 
KIDNEY DISEASE (INTERSTITIAL 
NEPHRITIS)
RENAL FAILURE 26-Feb-05 23-Mar-05 Moderate drug stopped Resolved Probable
35 677 37 Male SSG 20-Mar-05 ACUTE RENAL FAILURE RENAL FAILURE ACUTE 26-Mar-05 31-Mar-05 Severe drug stopped Resolved Probable
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Centre Patient Treatment Haemoglobin (g/dl)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 1 PM 10 10.7 10.4 10.8 10.6 11.3
11 2 Combination 10.7 12.1 13.2 13.1 17.4 8.7
11 3 Combination 8.7 9.2 11.6 13.8 12.3
11 4 PM 6.5 8.3 10.1 10.7 12.9 12.6
11 5 PM 12.3 12.2 10.2 10.9 12.3 12.5
11 6 Combination 5.3 6.1 5 6.8 10.9 11.6
11 7 PM 8.7 8.3 7.6 8.1 10.8 10
11 8 SSG 8.3 9.2 9.7 9.6 9.8 12.7 12.7
11 9 SSG 11.7 12.2 12.3 11.8 11.3 12.7 12
11 10 SSG 12.3 13.5 12.7 13 12.1 14.3 12.8
11 11 Combination 11.8 11.7 13.1 11.6 12.2 13.5
11 12 Combination 10.4 8.2 9.9 10.1 12.7 13.8
11 13 SSG 9.2 8.1 6.7 6.8 6.1 11.8 10.5
11 14 SSG 10.4 11.3 11.3 10.4 11.1 14.2 12.9
11 15 PM 5.2 4 12.5 9.2
11 16 Combination 13.1 11.7 12.4 11.4 12.9 13
11 17 Combination 9.8 10.6 10.6 11.1 10.7 10.4
11 18 SSG 8.5 9.2 9.7 10.8 9.3 8.6 11.8
11 19 Combination 8.1 9.2 8.7 9 10.9 12.2
11 20 SSG 6.3 7.6 7.2 7.4 10.7 8.6 10.5
11 21 SSG 9.4 10.2 9.2 10.2 11 13.2 12.7
11 22 SSG 6.9 8 9.4 10.8 9.8 12.1 12.6
11 23 PM 11.3 9 15.9 14.5 15.5 13.1
11 24 PM 8.9 8 9.6 9.8 10.3 9.3
11 25 SSG 9 6.8 9.1 10.7 12.1 12.3 12.7
11 26 Combination 9.5 10.6 10.3 10.3 11.8 10.3
11 27 PM 8.4 7.4 8.7 8.2 5
11 28 Combination 8.9 9.8 10.4 10.5 13.4 12.9
11 29 PM 7.4 8.4 8.8 9.4 11.7 15.8
11 30 PM 8.6 10.5 10.4 12.5 13.3 13.9
11 31 SSG 7.7 9.2 10.4 9.8 10.8 12.5 13
11 32 Combination 8.7 9.1 11.2 10.9 12.2 13.4
11 33 SSG 8.2 9.7 11.1 12 12.7 13.7 15
11 34 PM 6.3 6 5.4 6.9 9.5 12
11 35 SSG 11.6 13.5 13.4 13.4 12.9 9.2 11.1
11 36 SSG 6.2 4.6 6.5 8 11 13.7 14.2
11 37 Combination 12 11.1 12 11.6 15.1 16.4
11 38 PM 12 13.3 13.4 12.6 12.5 12.5
11 39 PM 8.5 9.4 10.5 11.1 11.3 11.2
11 40 PM 10.2 7.8 8 15.5 13.5
11 41 Combination 11.5 11.7 12.3 12.8 12.9 13.7
11 42 Combination 13.3 13.8 13.7 13.7 16.3 15.8
11 43 SSG 11.4 10.5 10 10.4 10.8 12.2 13.6
11 44 PM 10.1 11.5 11 12 12.2 13.5
11 45 Combination 13.3 13.7 12.8 12.7 13.9 13.8
11 46 SSG 9.6 10.6 11.7 12.1 11.4 12.6 11.8
11 47 SSG 6.2 6.7 8.1 8.7 9.1
11 48 Combination 8.8 8.5 9.4 10.2 13.4
11 49 SSG 7.4 8.3 10.3 11.7 11.7 12.7 12.8
11 50 PM 6.6 6.7 7.5 9.6 12.6 14.4
11 51 Combination 7 8.9 10.4 9.4 12.1 12.9
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11 52 PM 8.4 8.6 8.9 10.3 11.5 12.8
11 53 SSG 6.9 7.3 8.6 10.3 10.2 15 14.1
11 54 PM 9.6 9.1 8.6 9.6 10.4 11
11 55 PM 8 9 9.2 10.7 13 12.9
11 56 SSG 5 4.8 7.9 8.8 9 11.1 11.2
11 57 Combination 6.5 5.4 7.1 8.3 13.5 14.1
11 58 Combination 7.3 7.2 9.8 11.1 14 13
11 59 PM 5.9 6.4 8.9 11.6 11.2 12
11 60 Combination 7.2 6.9 8.4 9.5 15.3 8
11 61 PM 8.8 7.7 9.9 10.5 11.3 13.1
11 62 SSG 6.3 10.1 10.1 10.3 11.3 12.9 14.5
11 63 SSG 9.5 9.8 10.2 10.7 11.1 12.1 14
11 64 SSG 7.3 7.7 7.9 7.7 8.6 14.1 14.9
11 65 PM 7.5 7.1 7.9 9
11 66 Combination 8 7.8 7.9 9.5 14.7 13.6
11 67 PM 9 8.3 10.8 12.4 13.5 13
11 68 SSG 7.6 7.4 10.4 11.3 11.4 13.5 13.6
11 69 Combination 5.1 6.9 8.8 8.5 11.2 11.8
11 70 Combination 6.4 7.4 8 9.3 12.6 14.6
11 71 Combination 8.9 9 10.2 9.8 11.5 10.9
11 72 SSG 10.2 9 9.2 14.3 15.7
11 73 PM 7.4 8.6 11.4 10.9 13.4 15
11 74 PM 11.9 11.6 9.8 12.7 12.9 13.6
11 75 Combination 6 6.3 7.9 8.5 10.9 9.7
11 76 PM 7.8 7.6 8.8 10.7 12.6 14
11 77 PM 10 9.5 9.5 11.1 12.3 14.2
11 78 SSG 6.5 7.3 9.3 9.7 9.4 11.7 14.1
11 79 PM 7.2 6.6 6.6 9.2 9 12.2
11 80 PM 9 9.4 12.5 12.5 13.8 15.3
11 81 Combination 6.9 7.8 9.8 10.2 9.8 14.6
11 82 SSG 6.7 7.2 10.8 10.8 12 12.3 13.8
11 83 SSG 5.5 5.8 6.5 7.7 9.7 12.7 14.1
11 84 SSG 7.2 9.3 10 10.4 10.4 12.2 12.9
11 85 SSG 7.4 6.7 7.3 7 9.2 10.8
11 86 Combination 5.8 5.2 7.3 7.8 9.8 12.1
11 87 Combination 8.8 9.1 9.8 10.7 10.9 14.4
11 88 PM 11.5 11.1 11.6 12.3 14.7 16.6
11 89 Combination 9.2 7.6 10 9.8 12 16.4
11 90 Combination 8.1 7.6 10 9.7
11 91 PM 5.6 7 10 10.8 6.9 7.9
11 92 Combination 7 6.7 10.1 10.8 12.2 12.9
11 93 SSG 8 8.4 9 9.8 11.3 17.6 16.3
11 94 SSG 8.9 11.1 12.7 13.1 13.4 12.3 13.7
11 95 SSG 9.5 11.8 11.6 11.1 11.3 12.3 12.4
11 96 Combination 7.4 8.4 10.7 10.8 12.1 14.1
11 97 Combination 10.1 9.8 10.2 11.9 13.8 13.2
11 98 PM 8.5 7.8 8.6 8.8 12.5 13.6
11 99 SSG 7.4 6.2 8.8 10.3 11 13.2 13.8
11 100 PM 6 7.9 8.5 9.6
11 101 PM 8.7 9 9.3 10.6 15.7 16.5
11 102 Combination 8.3 8.9 10.4 10.2 13.9 14
11 103 Combination 9.2 9.9 11.7 11.7 15.3 15.4
11 104 PM 5.4 6.4 8.6 9.6 11.6 13.2
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11 105 SSG 5.8 6.4 8.2 9.1 10.2 13.4 13.6
11 106 Combination 7.5 8.5 9.1 8.3 14.2 13.8
11 107 PM 9.4 10.5 11.6 13.5 14 14.5
11 108 PM 10.3 8.7 10.5 11.5 13.1 13.2
11 109 SSG 7.8 9.7 10.8 11.8 10.1 14.5 16
11 110 PM 8.2 6.1 7.6 9.4 13 13.3
11 111 Combination 5.4 10.1 10.7 10.9 12.8 15.1
11 112 Combination 9.7 9.2 8.5 9.4 13.2 14.3
11 113 SSG 11.2 9.6 11.2 10.8 9.5 10.7
11 114 SSG 11.2 10 11.4 12.9 11.8 14.9 14.4
11 115 Combination 6 7.2 10.7 10.4 13.4 13.6
11 116 SSG 9.1 8.8 10.4 10.6 11.1 15.6 15.5
11 117 PM 8.7 9.4 12.6 13.4 16.6
11 118 PM 9 10.2 12.6 12.1 12.7 14
11 119 SSG 8.9 8.6 10.3 11.6 12.3 15.3 16.4
11 120 Combination 7.6 9.5 10.2 11.4 13.8 13.9
11 121 Combination 8.6 9.1 10.7 11.4 13.5 13
11 122 SSG 8.1 8.2 9.5 9.5 10.1
11 123 SSG 6.8 8.4 9.6 9.8 10.3 12.8 14.1
11 124 SSG 7.3 6 7.9 8.6 8.8 13.3
11 125 SSG 8.2 9.9 11.4 13.2 13.3 14.2 13.8
11 126 Combination 10.8 10.5 8.6 9.7 7.8
11 127 PM 8.5 8.5 10.3 11.2 13 12.5
11 128 Combination 9.7 9.7 9.3 9 9.3 9.3
11 129 PM 8.7 9.1 9.2 11.6 10.7 12.2
11 130 Combination 11.7 10.8 13.5 13.4 16.2 16.1
11 131 PM 9.1 8.9 10.5 11.4 12.1 12.3
11 132 SSG 7.3 9.6 11.2 10.9 11.5 13.3 7.7
11 133 Combination 6.5 5.4 9.6 8.7 12.7 12.8
11 134 PM 7.7 7 8.6 9.5 10.1 11.2
11 135 PM 7.3 7.6 9.2 8.7 11.8 14.1
12 241 Combination 7.8 6.3 8.3 8.3 17.9
12 242 SSG 7 6.8 7.7 9.5 6 10.9 11.7
12 243 PM 7 7.1 8.5 8.9 10.4 13.4
12 244 SSG 10.3 8.7 9.2 9.3 8.4 9.5 10.7
12 245 PM 5.4 6.8 7.6 8.3 6.5
12 246 PM 6.7 6.6 7.7 7.8 6.8
12 247 PM 5.6 5.8 7.3 8.2 11.6 11.6
12 248 PM 7.2 7.3 9 3.9 15.7 13.7
12 249 Combination 6.8 6.4 4.7 4.8 9.4 10.6
12 250 SSG 5.4 3.8 6.1 7.3 8 10.1 11.8
12 251 Combination 6.7 8.1 8.6 8.8 14 15.3
12 252 SSG 6.3 8.3 9.3 9.4 10.7 11.7 11.6
12 253 SSG 6.3 6.5 7.9 7.9 8.9 9.9 10.7
12 254 Combination 6.2 7 7 8.4 10.4 11.3
12 255 Combination 6 6.8 8.1 8.2 10.5 11.9
12 256 Combination 6.9 7.9 8.2 8.6 13.6 10.8
12 257 SSG 5.4 6.7 8 7.5 8.3 11.2 12.2
12 258 SSG 6.1 6.6 7.4 7.5 9 11.4
12 259 PM 8.1 9.4 9.3 11.4 13.9 10.9
12 260 PM 8.1 9.4 10 10.4 9.1
12 261 Combination 5.4 6.9 8.3 7.7 11 10.8
12 262 PM 8.1 9.1 9.1 11.6 10.7 11.9
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12 263 SSG 9.9 9 10.5 3.8 9.9 13.4 14.8
12 264 Combination 3.9 4.8 7.5 8.8 11.9 13.2
12 265 SSG 5 6.2 6.7 7.5 4.9
12 266 PM 8.9 8.6 8.7 8.7 9.9 14.4
12 267 SSG 13.4 11.7 11.8 12.6 10.5 11.9 13.8
12 268 PM 8.5 8.7 8.1 8.6 12.7 14.2
12 269 Combination 6.5 7.7 8.4 8 11.7 13.6
12 270 Combination 6.1 6.4 6.3 6.8 12.9
12 271 SSG 5.1 5.6 7.7 8.1 6.1 12.4 13.2
12 272 PM 3.9 9.6 7.6 7.7 9.9 10.6
12 273 SSG 7 8.4 8.8 8.8 10.1 12.2 10.6
12 274 SSG 7.9 8.9 9.7 9.6 11.2 13.2 11.8
12 275 Combination 5.9 7.2 7.8 8.5 10.8 13.8
12 276 PM 6.7 10 8.3 9 11.7 10.9
12 277 Combination 4.6 5.3 7.4 7.7 12.3 11.5
12 278 SSG 8.3 7.3 8.8 8.7 10 14.7
12 279 PM 7 6.4 8.2 8.4 8.1 11.2
12 280 SSG 6 7.6 8.8 8.6 9.5 11.6 11.7
12 281 Combination 6.9 8.5 11.5 11.2 13.5 15.2
12 282 PM 5.5 6.5 7.3 6.1 11.5 11.1
12 283 PM 10.6 9.5 16 11.1 15.1 14.1
12 284 Combination 5.6 6.4 6.8 5.7 11.2 7.2
12 285 Combination 4.9 5.8 7.2 6.5 13.6 13
12 286 PM 5.3 5.4 7.3 7.9 11.7 12.8
12 287 SSG 8.7 10.7 9.9 9.6 10.6 13.5 14.2
12 288 Combination 7.9 7.1 8.3 10.6 12 13.9
12 289 Combination 8.6 8.9 9.8 8.8 13.9 14.9
12 290 SSG 7.4 8.5 9.8 10 10.2 13.9
12 291 SSG 6.9 6.6 8.1 9.5 11.1 14.2 15.3
12 292 PM 5.1 6.1 6.9 5.8 14.8
12 293 SSG 6.9 7.3 8 9.9 10.3 14
12 294 Combination 6.1 7.8 9.1 9 11.7 12.2
12 295 Combination 7.8 7.4 8.2 7.6 11.8
12 296 PM 9.7 9.6 11.1 12.4 13.5 13.9
12 297 SSG 10.5 10.4 11.7
12 298 PM 8.2 8.2 9.7 10.5 13.7 14.2
12 299 Combination 6.6 7.2 7.6 10.1 14.5
12 300 PM 8.8 9.2 10.8 11.5 10.6 13.3
12 301 SSG 8 9.3 9.2 7.6 10 14.5 14.4
12 302 SSG 5.3 6 6.5 8.1 8.6 19.9 11.8
12 303 PM 9.1 7.5 9.8 9.7 12.6 14.2
12 304 Combination 7.8 10.7 10.8 10.7 14.1 13.8
12 305 PM 7.2 7.8 8.7 9.8 11.4 12.2
12 306 Combination 5.4 6.1 6.4 7.2 10.8 11.9
12 307 Combination 7.5 7.1 8.1 7.7 12.8 14
12 308 PM 6.4 8.5 9.2 10.2 9.6 15
12 309 PM 8 7.8 9.7 9.8 14.4 15
12 310 SSG 7.1 6.9 7.7 7.6 7.4 13.7 12
12 311 SSG 8.1 9.4 7.8 9.3 9.4 12 12.9
12 312 Combination 6.1 8.3 13.4 9.7 13.5 13.8
12 313 PM 6.7 6.8 9 10.9 15.09 16
12 314 SSG 7.6 8.5 9.6 9.8 10.3 13.2 14.1
12 315 Combination 6 6.7 8.2 8.8 11.6 13.3
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12 316 SSG 9.3 9.5 11.9 14.7 15.2
12 317 SSG 11.5 8.4 8.3 8.2 9.3 13.1
12 318 Combination 8 8.8 11.7 10.9 13.1 13.1
12 319 Combination 6.7 7.8 9.6 9.6 13.1 13.5
12 320 Combination 7.1 8.4 9.1 9.4 14.6 13.9
12 321 Combination 5 7.1 6.7 6.9 11.6 11.4
12 322 PM 8.2 8.1 9.8 11 12.7 12.1
12 323 SSG 9.3 10.2 9.9 10.1 12.4 14.7 13.3
12 324 SSG 8.5 7.8 7.6 8.6 10.5 13.4 14.4
12 325 PM 8.1 8.9 10.4 12.1 14.4 14.7
12 326 PM 6.6 6.1 7.7 7.8 10.6 14.6
12 327 Combination 8.8 9.3 11.1 11.2 13.8 13.8
12 328 PM 5.9 6.1 9.1 10.8 13.6 13.3
12 329 SSG 6.6 7.8 8.3 8.7 8.7 11.1 11.2
12 330 PM 12.9 8.5 9.2 9.6 11.3 10.7
23 361 Combination 6 7 7.9 8.6 11.6 11.4
23 362 PM 7.3 7.8 10.5 10.4 13.5 13
23 363 PM 7.3 8 10.7 11 12.1 12.9
23 364 Combination 7.1 7.8 9.2 10.5 6.6 12.6
23 365 SSG 7.3 8 9.2 10.2 10.6 12.6 12.8
23 366 Combination 10.2 8 9.1 8 11.5 12.3
23 367 SSG 7.9 7.2 8 8.5 7.7 14.5 16
23 368 PM 6.5 6.7 9.5 10.1 12.8 10.6
23 369 Combination 7.4 7.2 8.8 8.7 11.8 11
23 370 SSG 6.3 7.1 7.8 7.9 8.7 12.3 10
23 371 PM 7.2 6.6 8.3 8.3 11.9 12.2
23 372 PM 9.3 10.6 10.5 11.5 16.2 15
23 373 SSG 6.8 5.9 8.8 9.7 11.6 15.2 12.7
23 374 SSG 6.6 5.7 7.2 9 10.2 11.5 12.1
23 375 Combination 7.1 8.1 7.2 9.4 11.7 11.1
23 376 SSG 8.4 7.4 8.6 9.5 10.2 13.1 13
23 377 Combination 5.9 6.6 12.6
23 378 Combination 5.8 5.8 7.3 8.4 7.7 10.7
23 379 PM 7.7 6.1 7.1 11 5.6 12.4
23 380 SSG 5 5.5 8.1 9 9.9 12.2 11.1
23 381 PM 5.9 6.6 7.9 10.4 11 14
23 382 Combination 5.8 6 8.7 8.5 13.8 11.6
23 383 PM 6.7 5.1 6.9 8.7 11.8 13.9
23 384 SSG 9.5 9.3 9.4 10.2 10 12.5 15.2
23 385 SSG 7.6 7.7 7.7 6.9 8.6 12 13
23 386 Combination 7.8 7.5 9.8 11.2 12.7 13.9
23 387 Combination 7 5.7 6.8 6.9 10.5 12.5
23 388 PM 8.4 9.8 11.3 12.1 11.3 13.9
23 389 SSG 6.3 7.9 7.6 9.3 10 11.6 13.4
23 390 PM 7.3 8 9.2 9.5 12.5 15.3
23 391 Combination 7.5 7.9 8.5 8.8 10.4 12
23 392 Combination 6.8 6.5 8.3 10.9 12.4
23 393 SSG 7.1 7.2 8.9 10.1 9.6 10.6 11.6
23 394 PM 5.5 6.5 7.9 9 10.1 10.1
23 395 PM 7.8 8.3 10.1 10.8 12.9 14.2
23 396 SSG 8 7.9 9.1 10.3 11.4 14.9 16.3
23 397 SSG 6.3 7.4 8.4 8.7 9.1 11.8 12
23 398 Combination 5.1 6.5 7.7 9.1 10.9 6.7
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23 399 PM 5.4 4.8 6.8 7.9 7.8 10.4
23 400 PM 6.1 8.2 8.7 10 10.7 13.2
23 401 Combination 9.2 8.5 9.7 10.7 5.3 4.9
23 402 Combination 5.7 7.2 7.5 8.7 12 13.6
23 403 SSG 6.9 6.4 6.9 5.4 5.8 12.5 16.3
23 404 SSG 9.4 9.3 11.2 12.2 12.6 16.1
23 405 PM 7.5 7.9 9.3 8.7 12.1 15.4
34 451 Combination 5.7 6.2 7.7 9.1 12.4
34 452 PM 6.1 6.2 8 10.6
34 453 PM 5.3 6.6 7.1 10
34 454 Combination 7.7 6.7 9.5 10.3 12.4
34 455 PM 7.8 7.1 7.3 8
34 456 SSG 8.1 6 7.6 9 11.1 12.5
34 457 Combination 9.2 9.2 10.1 10.8
34 458 PM 5.2 5.2 6.6 9.5 10.8
34 459 Combination 8.1 8.5 9.4 9.4 12 13.7
34 460 PM 10.4 10.3 11 12.7
34 461 SSG 8.3 7.2 6.1
34 462 SSG 9.8 9.8 11.4 12.1 11.8 12.5
34 463 Combination 7.1 8.1 11.5 10 11
34 464 SSG 6 5.1 6.6 7.5 9.6 15
34 465 SSG 8.5 7.2 8.2 10 10.5 13.5
34 466 Combination 10.5 10.8 11.3 11.3
34 467 PM 7.9 7.1 6.7 9.8 9.6
34 468 Combination 13 12.1 11.9 12.9 12.3
34 469 SSG 8.4 7.3 6.3 7.8 10.5 14.6
34 470 Combination 8.1 9 9.5 11.5 14.1
34 471 PM 8.9 8.2 8.4 10
34 472 SSG 12.3 11.8 11.7 12.4 11.2 12.6
34 473 PM 10.3 9.5 9.5 10.5
34 474 Combination 11.4 10.9 12.2 11.5 14.6
34 475 PM 6.6 7.4 8.5 8.8
34 476 PM 9.5 8.5 10.2 10.6 9.8
34 477 SSG 7.7 8.3 8.6 7.7 8 9.8
34 478 Combination 7.9 8.7 11 11.5 12.3
34 479 SSG 10.9 9.1 10.5 11.2 11.6 10.6
34 480 SSG 9.4 9.7 11.1 12.5 12.5 15.2
34 481 Combination 9 9.7 11.5 13.1 13.1
34 482 Combination 12.2 11.8 12.7 12.1 15.3
34 483 PM 14 13.7 14.9 14.5 14.6
34 484 PM 9.5 6.9
34 485 Combination 6.1 4.5 5.9 6.9 8.6
34 486 Combination 8.3 9.9 11.1 11.6 14.1
34 487 SSG 8.2 8 9.8 10.4 10.9 13.3
34 488 SSG 8 8.5 10.1 10.7 10.1 11.5 11.4
34 489 SSG 8.4 8.3 7.7 9 10 13.1
34 490 PM 7.8 6.3 6.5 8 11.7
34 491 PM 8.4 8.3 8.4 9.6
34 492 PM 12.9 12.4 12.6 12.6 13.5
34 493 SSG 6.8 7.2 8.2 8.3 10.3 11
34 494 Combination 8.7 7.5 9.5 9.8 15.3
34 495 SSG 8 9.2 11.5 12 12.5 11.8
34 496 SSG 11 10 12.1 12.3 12.8 15.3
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34 497 PM 9.1 8.6 9.5 11.3 9.4
34 498 SSG 7.7 8 9.6 12.4 12.6 15.8
34 499 Combination 6.5 8.1 10.1 10.5 13.9
34 500 PM 10.8 11.1 11.6 12.5 13.7
34 501 Combination 8.4 6.7 7.9 9.9 13.2
34 502 Combination 7.4 8.3 9.6 10 14.4
34 503 PM 9.1 9.2 9.3 10.8
34 504 Combination 9.6 10 11 11.2
34 505 SSG 9.1 9 8.9 10.4 11.4 14.5
34 506 SSG 10.5 9.5 10.5 11.1 12.1 13.2
34 507 SSG 7.7 6.3 6.5 7.7 10.6 12.7
34 508 PM 7.5 6.9 8 10.5
34 509 PM 7.5 8 9.7 10.3
34 510 Combination 8.6 8.9 11 10.7 12.7
34 511 Combination 8.2 8.9 9.7 10 12.7
34 512 PM 9.8 8 7.8 10.8
34 513 Combination 6.5 6.9 9.4 9.9 11.4 10.5
34 514 SSG 8.5 9.9 10.2 11.6 11.6 14.1
34 515 SSG 8.9 10 12.9 12.4 12.5 10.5
34 516 PM 9.5 10.2 11 13.4 13.6
34 517 PM 10.2 9.3 10.4 11.7
34 518 SSG 6.4 6.2 7.5 8.1 9.5 12.1
34 519 PM 12.7 10.5 9.4 11.3 9.5
34 520 SSG 12.7 11 11.9 12.9 14.4 16.3
34 521 PM 5.9 5.8 6.6 8.7
34 522 Combination 10.5 11.4 11 11.8
34 523 SSG 6.8 6.4 8.1 9.7 9.7 11.9
34 524 Combination 8.4 9.4 11.3 10.7 13.2
34 525 Combination 9.4 9.7 10.9 11.3 13.8
34 526 SSG 7.8 7.4 8.9 10.9 12.6 10
34 527 Combination 7.3 8.2 9.5 10.5 10.2
34 528 PM 7.2 6.6 7.3 8.4
34 529 Combination 6.3 6.3 9 10.2 12.1
34 530 Combination 7.6 5.8 7.4 8.5 14.5
34 531 SSG 7 6.5 8.6 10.1 9.8
34 532 Combination 8.7 7.4 8.1 8.6 11.2
34 533 SSG 8.4 9.3 10.8 12.8 11.7 14.2
34 534 PM 9 6.2 6.7 4.2
34 535 PM 9.9 10 12.5 11.6 9.1
34 536 PM 10.2 10.7 11.8 11.7 11.5
34 537 SSG 9.7 9.8 12.2 11.9 12.5 13.8
34 538 PM 7.8 6.9 7.9 8.7
34 539 Combination 9.6 10.8 11.5 12.5 9.5
34 540 SSG 7.6 6.9 9 9.3 10.8 12.7
35 646 PM 7.1 6.3 7.9 9.9 11.4
35 647 PM 6.7 5.8 7.4 8.8 9.1 10.5
35 648 Combination 6.7 8.6 9.3 10.4 9.8
35 649 Combination 7.1 7.5 9.9 11.5 10.8
35 650 SSG 9.8 10.9 11.7 12 11.8 10.6 10
35 651 SSG 10 8.7 10.3 9.6 12.3 10.5 8.7
35 652 PM 7.1 7.2 7.1 9.4 11.1
35 653 Combination 6 4.7 7.4 7.8 7.5 8.1
35 654 SSG 5.9 6.7 8 7.8 6.5 8.9 9.1
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35 655 Combination 6.9 8.2 10.7 11 10.8 9.6
35 656 SSG 6.7 4.3 6.9 9.9 8.1 9.2 9.8
35 657 PM 6.7 8.4 10.1 10.4 10.8 10.1
35 658 Combination 11.8 12.5 12.6 13 8.7 9
35 659 SSG 6.9 5.6 9.1 9.1 9.9 9 10.2
35 660 PM 10.6 11.9 11 10.6 10 9.5
35 661 Combination 8.5 8.3 8.8 8.8 8.6 15.9
35 662 PM 7.2 6.5 7.1 11.4 10.8 10.1
35 663 SSG 8.4 6.8 7 8.9 10.7 10.5 11.5
35 664 Combination 6.3 5.9 9.8
35 665 SSG 7.4 8.3 9.2 11 12 11.8 11.5
35 666 SSG 7.3 7.5 8.1 10.6 10.6 7.4 13.3
35 667 Combination 7.2 7.9 8.4 9.2 8.8 9.7
35 668 PM 5.4 6.7 9.3 10.5 11.8
35 669 PM 7.8 8.1 9.6 8.5
35 670 SSG 5.7 5.9 8.5 9.9 10.5 9.8 10.1
35 671 PM 6.2 5.4 7.5 8.1 11
35 672 Combination 5.8 7.2 9 9.1 9.8
35 673 SSG 6.5 7 9.5 8.1 9 8.7 9.6
35 674 Combination 5.8 5.8 7.9 8.4 9 10.2
35 675 PM 8.8 7.3 8.6 10.4 11.4
35 676 PM 7 5.9 7.6 11.4 10.8 10.7
35 677 SSG 5.2 5
35 678 Combination 5.8 6.8 8.2 10.1 9.8 10.2
35 679 SSG 6 6 6.7 9.5 8.8 9 9.8
35 680 Combination 7.1 8.1 8.5 9.1 8.7 9.1
35 681 Combination 7.6 9.7 11.1 11.3 9.2 10.4
35 682 PM 5.6 5.3 6.7 10.8 10.8
35 683 Combination 8 8.4 9.3 9.5 10.1
35 684 SSG 7.9 6.5 6.5 9.1 8.9 9.2 9.8
35 685 PM 7.8 8.4 8.8 11 10.5 10.8
35 686 PM 7.4 8.3 9.8 9.2 8.7 9.6
35 687 SSG 8.5 7.7 8.3 9 6.7 8.3 9.5
35 688 PM 9 8.4 10.7 9.7 9 10.5
35 689 Combination 5.2 5.3 6.9 7.9 8 8.6
35 690 SSG 5.4 5.4 7.8 7.8 8.6 9.1 10.4
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Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 1 PM 2.9 3.8 3.7 4.4 5.4 5.1
11 2 Combination 1.5 1.9 3 2.9 3.1 3.4
11 3 Combination 2.5 2.5 3.5 99 5.3 5.4
11 4 PM 4.7 33 4.1 4.8 5.1 4.6
11 5 PM 5.9 9.9 9 6.2 7 8.1
11 6 Combination 5.36 4 3.1 3.5 7.2 7.3
11 7 PM 3.4 5.1 6.3 6.1 4.4 4
11 8 SSG 2.5 2.4 3.2 2.7 2.9 3.8 3.8
11 9 SSG 4.4 4.3 4.2 3.6 5.7 5.2 4.4
11 10 SSG 9.9 7.7 4.7 4.4 6.7 9.1 8.1
11 11 Combination 9.9 8 8.8 6.4 5.6 5.3
11 12 Combination 4.6 1.7 2.7 3.2 3.5 4.2
11 13 SSG 4.8 6 4.7 4.2 4 5.5 6.7
11 14 SSG 8.5 5.9 5.5 4.9 4.8 7.1 8.2
11 15 PM 3.3 2.8 4.6 5.1
11 16 Combination 4.8 3.2 4.8 5 6 4.9
11 17 Combination 5 4.7 4.5 5.5 3.3 5.3
11 18 SSG 3.1 4.1 3.6 2.9 2.5 2.7 4.9
11 19 Combination 1.9 1.8 2.6 2.4 2.3 3.9
11 20 SSG 5.4 4.5 4.3 4 3.4 6.9 8.4
11 21 SSG 4.7 4.3 4.6 4 5.3 5.5 4.5
11 22 SSG 2 4.5 3.2 4.5 6.4 8.6 7.4
11 23 PM 1.4 1.1 2 4.4 4.6 3.1
11 24 PM 5.6 3.3 4.9 4.2 5.9 4.4
11 25 SSG 2.1 1.4 2.4 3 3.7 6.9 5.5
11 26 Combination 5.2 3.5 4.1 4.4 5.1 6.3
11 27 PM 4.2 5.2 5.5 5.7 2.4
11 28 Combination 4 3.3 3.6 3.7 7.5 7
11 29 PM 3.1 2.9 4.3 3.7 5.3 4
11 30 PM 2.4 4.2 3.1 4 6.9 6.3
11 31 SSG 6.3 5.1 5.8 5.3 5.7 7.9 6
11 32 Combination 1.6 2.9 2.8 2.7 5.8 6.8
11 33 SSG 3.2 2.7 3.3 3.8 3.9 4.1 5.2
11 34 PM 2.1 1.8 2.4 3.1 2.9 3.3
11 35 SSG 5.6 4.9 5.6 6 5.9 3.44 5.5
11 36 SSG 1.1 1 1.3 1.3 3.1 3.6 2.8
11 37 Combination 2.5 2 2.9 3.6 6.4 6.5
11 38 PM 9.6 13 11.5 10 7.5 14
11 39 PM 1.8 1.7 2.6 3.8 4 4.5
11 40 PM 3.7 1.1 2 6.3 7.3
11 41 Combination 6.7 5.7 7.7 6.2 7.8 9.2
11 42 Combination 2.9 3.3 4.9 6 7 4.5
11 43 SSG 4.2 2.8 3.2 2.8 3.4 4.9 5.9
11 44 PM 4.3 4.5 4.8 4.9 6.7 3.8
11 45 Combination 7.3 5 5.4 5.6 7.8 6.2
11 46 SSG 3.8 4.9 5.2 5.3 6.5 7.1 8.1
11 47 SSG 1.2 1.1 2.9 3.4 5.3
11 48 Combination 3.3 2.2 2.9 3.9 6.5
11 49 SSG 2.3 2.6 3.1 4 4.3 5.6 8.7
11 50 PM 1.2 1.1 1.7 3.7 7.1 5.6
11 51 Combination 1.1 3.3 5.3 4 4.4 5.8
11 52 PM 1.8 1.3 1.9 3.6 2.9 3.4
11 53 SSG 1.4 1.78 3 4.7 12.9 3.5 3.2
11 54 PM 3.2 2.7 3.5 3.7 4.6 2.4
11 55 PM 1.7 1.39 1.7 2.5 4.9 6.2
LEAP 0104a Appendices
Page 676 of 756
Appendix 50: Listing of White blood cell count per patient
Centre Patient Treatment White Blood Cell Count (x 103/µL)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 56 SSG 1.1 1.5 3 4.9 6.9 6.8 5.7
11 57 Combination 1.13 1.1 1.7 2.2 4.4 3.9
11 58 Combination 1.9 3.1 5.5 5.14 7.2 5.2
11 59 PM 1.6 2.4 3.2 5.4 3.9 5.6
11 60 Combination 2 2 3.3 2.4 6.6 4.6
11 61 PM 2.1 1.5 3.2 3.4 3.5 6.5
11 62 SSG 1.9 4.4 3.9 6.58 8.4 8.7 7.6
11 63 SSG 2.3 1.7 1.8 1.9 2.1 4.7 4.3
11 64 SSG 1.1 2.9 2.3 3.5 4.2 4.2 5.3
11 65 PM 4.4 3.9 6.6 8.7
11 66 Combination 1.1 1.5 2.09 2.2 4 5.2
11 67 PM 1.9 2.6 5 7.7 6.7 8.5
11 68 SSG 2.5 1.8 3.3 3.4 4.9 7.5 5.1
11 69 Combination 2.4 3 3.2 3.4 4.7 5
11 70 Combination 1.1 1.3 1.9 2.5 8.3 5.9
11 71 Combination 1.6 1.1 1.2 1.3 2.9 2
11 72 SSG 2.6 2.2 2.7 6.9 7.7
11 73 PM 1.6 1.7 3.5 3.7 4.8 5.4
11 74 PM 3.7 2.42 2 3.4 4.3 6.5
11 75 Combination 1.3 1.78 2.7 2.9 4.4 4.6
11 76 PM 1 1.7 2.8 3.1 3.9 5
11 77 PM 2.6 2.2 4.5 4.9 5.3 7.4
11 78 SSG 1.5 1.9 2.2 2.3 2.3 3.9 4.2
11 79 PM 1.1 1.6 2.9 3.4 3.8 5.5
11 80 PM 1.8 2.42 4.5 7.8 10.1 10.5
11 81 Combination 1.7 1.8 2.8 3.1 6.4 6
11 82 SSG 1.4 1.5 2.3 3.4 4.3 6.8 4.7
11 83 SSG 1.6 1.6 1.8 3.4 6.9 7.4 6.3
11 84 SSG 1.5 3.4 4.1 4.8 4.4 10.6 10.7
11 85 SSG 1 1.6 3.6 3.6 6.1 6.8
11 86 Combination 1.1 2.1 2.6 2.1 3.8 3.8
11 87 Combination 1.3 2.7 1.7 3.4 3.6 5
11 88 PM 2.8 2.8 4.5 5.5 9.4 7.4
11 89 Combination 1.5 1.6 2.8 3.7 9 8.6
11 90 Combination 1.8 3.3 3.8 3.4
11 91 PM 1.1 1.6 3.2 5.1 1.5 2.3
11 92 Combination 3.7 2.9 3.6 5.1 10.4 10.3
11 93 SSG 1.9 4.2 4.9 5.1 7.1 7.4 6.5
11 94 SSG 2.6 3.3 4.6 6.5 7.5 8 6.6
11 95 SSG 2.8 3.6 5.4 6.2 8.4 6.5 5.8
11 96 Combination 2.7 6.2 4.4 5.4 7.8 4.9
11 97 Combination 1 2.3 2.9 4 3.9 3.3
11 98 PM 2 1.9 2.3 2.6 7.9 4.6
11 99 SSG 1.3 1.4 2.8 3.3 4 4.6 3.5
11 100 PM 2.1 2.5 3.4 5
11 101 PM 2.4 2.5 3.4 3.7 5.1 7.7
11 102 Combination 1.7 3.5 2.9 3.4 4.9 4.8
11 103 Combination 1.9 2.1 3.2 3.3 3.6 6.3
11 104 PM 1.8 2.9 4.3 6.1 7 6.5
11 105 SSG 1.3 1.6 2.4 2.2 3.3 6.8 4.3
11 106 Combination 1.9 3.8 7.3 5.9 8 5.1
11 107 PM 1.7 2.1 2.8 5 6.4 4.2
11 108 PM 1.7 1.3 2 2.8 2.5 2.9
11 109 SSG 1 2.1 4.2 5.9 5.7 7.4 6.9
11 110 PM 1.6 0.8 1.4 2.4 3.1 3.4
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Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 111 Combination 1 2.7 3.1 3.8 7.9 9
11 112 Combination 1 2.3 2 3.2 2.8 3
11 113 SSG 1.9 2.6 2.9 4.7 8 4.4
11 114 SSG 3.5 2.5 2.8 3.4 4.3 4.9 3.6
11 115 Combination 1.1 1.4 2.2 2 6.3 5
11 116 SSG 2.6 1.8 2.7 3 4.2 5 6.3
11 117 PM 1.2 1.3 3.1 4.8 5.3
11 118 PM 1.8 1.9 2.6 3 3.5 3.1
11 119 SSG 1.6 1.9 2.2 2.8 3.3 4.3 4.6
11 120 Combination 2.3 2.8 3 4.1 4.4 5.6
11 121 Combination 1.6 3.5 2.7 3.4 5.3 6.4
11 122 SSG 1.7 1.9 3.4 4.5 6.1
11 123 SSG 1.7 2.4 2.6 2.7 3.8 4.6 4.8
11 124 SSG 1 2 1.9 1.4 2.5 4.3
11 125 SSG 1.5 2.8 2.3 5.2 4.7 5.9 6.9
11 126 Combination 2.1 1.5 2 2.5 2.9
11 127 PM 1.4 1.4 3.1 4.6 4.1 5.4
11 128 Combination 4.2 3.1 5.8 4.1 5.5 2.6
11 129 PM 1.8 1.6 2.9 3.3 3.2 3.1
11 130 Combination 1.7 1.7 2.9 2.9 6.5 7.1
11 131 PM 3.3 2 4.5 4.2 7.3 6.7
11 132 SSG 1.4 1.4 2.5 4.2 7.4 7.2 2.4
11 133 Combination 1 1 1.9 3 7.6 6.4
11 134 PM 1.3 1.1 1.5 1.5 1.5 1.9
11 135 PM 2.2 2.8 4.2 5 7.3 7
12 241 Combination 7.4 2.34 3 3.6 4.4
12 242 SSG 6.3 2.8 3.5 4.8 5 3.6 8.4
12 243 PM 5.1 2.4 2.9 4.6 4.8 7
12 244 SSG 7.6 2.3 2.8 2.9 3 3.8 5.3
12 245 PM 1.6 2 2.6 3.6 1.6
12 246 PM 3 1.6 2.7 3.3 2.3
12 247 PM 1.9 3.2 2.5 3.8 4.1 4.6
12 248 PM 1.9 1.8 2.8 6.7 5.1 5.3
12 249 Combination 2.8 2.8 3.7 3.6 15.3 4
12 250 SSG 1.5 1.3 1.3 2.1 2.9 3.6 4.8
12 251 Combination 2.1 2.7 3.7 4.4 5.9 8.5
12 252 SSG 1.2 2.3 2.7 2.8 5.5 4.7 3.8
12 253 SSG 1.2 1.2 1.3 1.5 2 3.8 3.3
12 254 Combination 2 2.3 2 3.3 4.7 5.6
12 255 Combination 2 2.6 4.4 5.2 5.2 4.3
12 256 Combination 1 2.2 3.9 4.4 5.4 5.2
12 257 SSG 1.3 2 2.4 2.7 3.3 4.5 5.9
12 258 SSG 2 2.1 2.4 3.3 4.8 7.8
12 259 PM 1.7 1.9 2.4 3.7 3.9 4.8
12 260 PM 2.7 4.1 4.8 4.2 3.3
12 261 Combination 1.4 2.7 4 4.4 6.4 5.8
12 262 PM 2.2 2.6 4.1 4.1 3.8 5.6
12 263 SSG 3 2.6 3.1 9.1 4.6 6.4 7.1
12 264 Combination 3.8 2.7 1.8 3 6.4 6.4
12 265 SSG 1.3 2.1 2.6 1.7 1.4
12 266 PM 4 3.4 4 3.3 3.8 4.7
12 267 SSG 8 4.3 4.8 4.7 5.4 7.3 9.6
12 268 PM 1 1.6 1.4 1.8 3.1 4
12 269 Combination 1.1 1.2 1.9 3.1 4.7 4.2
12 270 Combination 1.1 1.9 2.6 4 4.4
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12 271 SSG 1.3 2.9 4.8 7.9 4.8 9.6 9.6
12 272 PM 1.4 4.5 4.4 5.1 7.4 5.2
12 273 SSG 3.8 4.9 5.9 5.7 6.7 6.3 5.1
12 274 SSG 2.6 2 3.9 2.8 3.4 5.1 3.1
12 275 Combination 1.6 2 2.4 3.3 5.2 5.4
12 276 PM 2.9 3.2 4.6 3.6 5 4.3
12 277 Combination 1.1 1.5 2.8 3.6 5.5 4.6
12 278 SSG 1.7 1.4 2.2 2.8 3.2 5.2
12 279 PM 1.1 1.2 2 2.4 3 3.8
12 280 SSG 1.3 2.9 4.7 4.4 7.3 6.4 8.2
12 281 Combination 1.6 3 5.1 6 6.6 8.6
12 282 PM 1.6 2.4 3.5 3.1 3.3 3.6
12 283 PM 4.1 3.2 2.4 3.7 4 3.6
12 284 Combination 2.5 2.8 3.3 3.7 6.2 2.2
12 285 Combination 2.2 2.4 3.6 3.8 8.6 5.2
12 286 PM 1.7 1.8 2.6 3.1 4.2 4.4
12 287 SSG 3.5 6.1 5.9 5 5.1 6.8 6.8
12 288 Combination 3.6 2.6 3.6 1.9 4.7 5.1
12 289 Combination 1.5 1.4 1.7 4 5 3.6
12 290 SSG 2.3 3.9 3.6 4.2 4.6 6.8
12 291 SSG 1 1.2 1.3 1.4 2.3 3.2 4.7
12 292 PM 1.4 1.4 3.4 2.6 4.4
12 293 SSG 1.7 2.4 3.9 3.8 4.2 5.2
12 294 Combination 1.1 2.8 3.9 3.1 7.3 6.2
12 295 Combination 1.9 1.7 1.9 3 3.2
12 296 PM 2.2 1.8 2.8 3.6 3.3 3.4
12 297 SSG 1.7 3 3.4
12 298 PM 2.3 3.3 5 4.1 7.1 6
12 299 Combination 2 1.9 2.7 2.9 4.3
12 300 PM 2.4 3.5 3.8 5.1 4 5.6
12 301 SSG 1.6 2.8 3.2 6.9 4.1 5.3 6.4
12 302 SSG 2.7 2.4 2.4 3.7 2.7 5.1 5.6
12 303 PM 2.3 1.1 2 2.9 4.1 5.3
12 304 Combination 1 3.5 4.7 5 7.2 6.4
12 305 PM 2.7 3.6 5 6.6 8.8 8
12 306 Combination 1.8 2.7 2.6 3.5 7.4 3.4
12 307 Combination 1.2 1.7 3.5 3.4 4.9 6.2
12 308 PM 1.3 1.7 2.9 3 2 6.5
12 309 PM 1.9 2 4.4 5.6 5.4 6.4
12 310 SSG 2.3 2.7 2.7 2.9 3.2 6.5 5.2
12 311 SSG 1.1 1.6 1.4 3.8 4.4 7.7 9.1
12 312 Combination 1.3 1.6 4.6 3.3 3.9 4.5
12 313 PM 1.2 1.5 3 5 6.2 6.3
12 314 SSG 1.3 1.6 2.1 2.5 2.8 8.1 5.1
12 315 Combination 1.1 1.4 2.3 5.9 4.5 5.3
12 316 SSG 1.7 1.6 3.2 3.9 3.2
12 317 SSG 3.6 2.2 2.6 3.4 5.9 5.9
12 318 Combination 2.8 3.9 5.2 4.2 5.6 5.7
12 319 Combination 1.7 1.7 2.4 3.9 3.7 3.1
12 320 Combination 1.9 3 6.3 6.4 6.9 10.3
12 321 Combination 1.4 1.8 1.9 1.6 4.9 4.7
12 322 PM 1.3 1.3 1.8 3.2 2.6 2.5
12 323 SSG 2.4 2.8 3.2 4 5.4 4.8 5.9
12 324 SSG 2.4 1.4 1.9 2 2.6 3.1 4.4
12 325 PM 1.7 2.1 4 5.4 3.9 5.5
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12 326 PM 1.5 1.5 1.9 2.6 5 8.2
12 327 Combination 2.2 3.2 5.5 4.2 5.2 6.5
12 328 PM 1.2 1 2.1 2.1 2.9 5.2
12 329 SSG 2.7 3.5 3 4.7 4.9 9.7 5.5
12 330 PM 7 2.2 3.2 4.5 5.3 6.2
23 361 Combination 2.33 1.3 4.3 2.6 5 6.6
23 362 PM 2.3 3.2 3.4 3.8 4.3 4.7
23 363 PM 4.7 2.8 6 7 8.8 8.1
23 364 Combination 2.3 2.5 2.9 4 2.1 5.9
23 365 SSG 1.4 2.3 2.8 4.5 3.8 2.8 4.3
23 366 Combination 3 1.9 3.2 3.8 6.6 6.5
23 367 SSG 2.3 2.1 2.4 2.6 3.2 5.2 5.2
23 368 PM 2.8 4.3 5.2 5.5 8.9 8.7
23 369 Combination 2 3.4 4.3 4.9 5.7 4.9
23 370 SSG 2.9 3.9 4.2 5 6.4 9.8 6.7
23 371 PM 1.7 1.7 2.1 3.2 5.7 7.3
23 372 PM 1.8 2.8 3.7 3.6 5.6 4.7
23 373 SSG 1.5 2 2.6 3.6 4.9 5.4 5.2
23 374 SSG 1.8 2.1 2.9 2.5 4.5 4.6 5.4
23 375 Combination 3.5 4.1 4 4.5 6.8 5.9
23 376 SSG 4.7 9 4.2 4.9 6.6 8.1 9.5
23 377 Combination 2.2 2 4.9
23 378 Combination 1.7 2.1 6.2 3.7 3.3 5.1
23 379 PM 3.6 2.9 3.3 4.3 2.7 7.5
23 380 SSG 2.4 2.6 3.3 3.5 4.4 8.7 7.8
23 381 PM 2.4 2.5 2.8 4.6 5.3 5.2
23 382 Combination 3.2 4.5 4 4.7 5.6 6.8
23 383 PM 3.7 2.3 4.2 4 4.5 6.4
23 384 SSG 4.3 3.8 5.5 5 5.4 6.2 15.6
23 385 SSG 3.4 2.6 4.8 3.5 4.1 5.5 6.1
23 386 Combination 2.8 2 3.2 5.1 4.8 4.6
23 387 Combination 1.4 1.3 1.5 1.8 3.4 6
23 388 PM 2 2.7 3 3.6 6.2 4.7
23 389 SSG 2.1 2.8 3.5 4.6 5.3 4.7 5.2
23 390 PM 2.1 2.8 3.9 4.7 5.7 6.7
23 391 Combination 2.6 2.4 2.7 3.4 5.4 4.7
23 392 Combination 3.5 1.4 3 5.3 3.8
23 393 SSG 1.8 2.2 3 3.5 5.1 4.8 4.1
23 394 PM 4 4.4 6.6 6.5 12.6 15.9
23 395 PM 2 2.2 3.7 4.1 5.5 6.1
23 396 SSG 2 2.1 2 3.5 5.4 4.4 5.2
23 397 SSG 1.7 2.2 5 3.8 5.6 6.7 6.7
23 398 Combination 1.7 2.5 2.9 3.2 5.3 3.3
23 399 PM 3.2 3.8 3.9 4.7 5.8 6.4
23 400 PM 1.8 3 3.7 3.6 6.2 8.5
23 401 Combination 5.4 2.6 3.7 3.8 1.9 2.2
23 402 Combination 1.3 2.5 1.7 2.7 3.8 6.4
23 403 SSG 3 2.5 3.6 3.2 2.8 3.9 3.1
23 404 SSG 3.5 3.3 3.4 3.7 4.3 5.6
23 405 PM 3.4 4.7 5.6 5.7 4.8 5.1
34 Not done
35 646 PM 1.2 1.9 3.3 7.5 4.2
35 647 PM 1.5 1.8 3.8 3.3 6.8 4.2
35 648 Combination 2.4 3.8 7.9 6.2 5
35 649 Combination 2.3 2.9 5.8 5.6 4.2
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Appendix 50: Listing of White blood cell count per patient
Centre Patient Treatment White Blood Cell Count (x 103/µL)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
35 650 SSG 2.8 4.3 4.1 6.8 2.8 3.1 3
35 651 SSG 5 5.3 5.1 3.7 13.4 8 4.2
35 652 PM 2.6 4.9 4.8 6.8 3.8
35 653 Combination 2.8 4 3.9 4 3.8 4.3
35 654 SSG 2.5 3.7 5.5 5.4 9.1 5.9 5.2
35 655 Combination 2.4 3 3.9 4.1 4 4.2
35 656 SSG 2.2 4.3 4.1 3.5 6.9 5.1 4.5
35 657 PM 3.4 3.6 7.5 4.7 4.8 4.4
35 658 Combination 2.8 2.7 10.7 10 5.2 4.6
35 659 SSG 2.5 3.4 7.9 8.2 3.6 4.9 3.1
35 660 PM 8.8 9 7.7 8.3 3.8 4
35 661 Combination 2.2 2.3 6.2 6.4 5.2 3.2
35 662 PM 2.8 1.9 2.2 7 5.2 4.5
35 663 SSG 4 2.2 2.8 2.2 2.8 3.2 3.5
35 664 Combination 2.8 2.7 4
35 665 SSG 1.3 6.1 5.6 12.3 4.9 3.6 3.8
35 666 SSG 2.3 2.8 3.2 4.1 5.4 4.4 5
35 667 Combination 2.2 2.8 4.2 5.6 4.6 4
35 668 PM 2.1 2.6 3.5 3.8 4.8
35 669 PM 3.4 3.7 3.1 5.8
35 670 SSG 5.3 5 3.4 3.7 5.5 4.7 3.6
35 671 PM 3.4 3.3 3.9 3.8 5.6
35 672 Combination 2.4 3.2 5.4 5.6 4.3
35 673 SSG 2.6 2.4 3.2 2.3 2.8 3.1 4.1
35 674 Combination 2 2.8 2.4 2.8 3.4 3.8
35 675 PM 8.4 4.7 5.3 7.6 5.2
35 676 PM 2.6 4.1 4.8 9.6 4.5 4.2
35 677 SSG 2.1 4
35 678 Combination 2.6 3.6 3.4 5.6 4.2 4.5
35 679 SSG 2.2 4.5 3.9 4.2 5.8 4.1 4.3
35 680 Combination 3.2 7.1 3.4 4.9 3.6 3
35 681 Combination 1.9 5.2 4.9 5.1 5.3 4.8
35 682 PM 1.9 2.6 3 6.2 4.4
35 683 Combination 4.1 7.7 5 5.4 5
35 684 SSG 3.4 2.9 3.3 4.7 5.2 4.6 4.1
35 685 PM 3 4.2 6 8.4 5.2 5
35 686 PM 1.1 2.6 3.2 4.2 3.6 3.9
35 687 SSG 7.1 2.4 2.6 3.5 6 4 4.4
35 688 PM 2.4 3.7 3.9 5.5 4.8 5
35 689 Combination 2.1 1.7 2.4 2.9 3.6 3
35 690 SSG 2.5 4.1 5.9 5.3 7.4 4.5 5
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Appendix 51: Listing of Platelet count per patient
Centre Patient Platelets (x 103/µL)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 1 PM 175 168 234 265 216 145
11 2 Combination 105 110 137 193 156 56
11 3 Combination 59 51 84 228 159
11 4 PM 108 91 101 181 176 190
11 5 PM 249 157 225 200 249 303
11 6 Combination 78 70 84 101 165 151
11 7 PM 45 66 102 108 100 98
11 8 SSG 121 85 125 143 133 134 134
11 9 SSG 81 84 104 64 83 123 118
11 10 SSG 101 124 126 102 83 144 103
11 11 Combination 263 188 264 241 236 215
11 12 Combination 174 75 121 166 204 222
11 13 SSG 55 54 77 89 101 190 206
11 14 SSG 252 267 284 277 348 290 276
11 15 PM 44 56 134 86
11 16 Combination 204 187 280 193 212 184
11 17 Combination 207 232 279 294 85 333
11 18 SSG 79 114 125 43 150 110
11 19 Combination 143 33 38 56 57 65
11 20 SSG 120 107 155 166 106 167 203
11 21 SSG 106 94 118 152 138 109 122
11 22 SSG 191 174 209 241 246 138 170
11 23 PM 125 97 167 334 292 183
11 24 PM 111 98 151 126 135 151
11 25 SSG 101 88 141 201 118 295 201
11 26 Combination 161 229 296 288 333 227
11 27 PM 93 80 165 204 52
11 28 Combination 47 67 73 88 102 113
11 29 PM 90 91 101 143 150 126
11 30 PM 110 105 202 174 153 214
11 31 SSG 138 273 211 113 162 240 168
11 32 Combination 119 171 179 194 244 226
11 33 SSG 104 122 56 54 135 179 157
11 34 PM 110 95 123 128 152 118
11 35 SSG 139 115 145 152 133 90 150
11 36 SSG 50 86 70 79 134 155 131
11 37 Combination 59 82 143 197 176 142
11 38 PM 881 725 933 874 888 531
11 39 PM 84 95 104 127 163 133
11 40 PM 129 1 1 195 208
11 41 Combination 190 216 270 257 226 155
11 42 Combination 104 161 192 240 172 178
11 43 SSG 84 67 122 96 84 114 110
11 44 PM 125 135 152 138 151 156
11 45 Combination 131 108 157 167 136 128
11 46 SSG 137 183 264 206 350 552 323
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Appendix 51: Listing of Platelet count per patient
Centre Patient Platelets (x 103/µL)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 47 SSG 79 92 107 89 169
11 48 Combination 84 102 115 157 180
11 49 SSG 51 141 224 177 188 129 113
11 50 PM 46 43 86 124 137 121
11 51 Combination 52 150 173 178 120 182
11 52 PM 56 53 62 67 82 97
11 53 SSG 92 74 102 187 209 210 165
11 54 PM 120 113 165 204 188 192
11 55 PM 108 94 152 162 131 95
11 56 SSG 84 86 220 181 220 181 218
11 57 Combination 106 94 226 242 168 104
11 58 Combination 69 101 163 244 270 197
11 59 PM 43 49 210 307 253 161
11 60 Combination 85 98 170 126 190 96
11 61 PM 83 62 125 141 115 150
11 62 SSG 45 33 147 241 219 207 173
11 63 SSG 89 99 127 144 144 146 125
11 64 SSG 46 108 133 200 297 186 150
11 65 PM 173 162 172 214
11 66 Combination 66 103 253 422 217 243
11 67 PM 91 86 166 188 234 308
11 68 SSG 58 141 152 243 218 255 225
11 69 Combination 75 61 79 108 155 184
11 70 Combination 54 77 106 148 134 123
11 71 Combination 76 53 58 75 74 86
11 72 SSG 168 100 132 324 366
11 73 PM 40 49 68 102 97 133
11 74 PM 142 182 205 267 230 216
11 75 Combination 86 120 192 269 158 199
11 76 PM 40 93 99 184 176 191
11 77 PM 111 95 239 196 188 221
11 78 SSG 41 63 59 88 87 131 140
11 79 PM 86 56 94 232 211 270
11 80 PM 62 55 233 203 279 230
11 81 Combination 63 64 165 167 339 207
11 82 SSG 40 82 184 102 288 234 256
11 83 SSG 90 85 101 131 172 122 125
11 84 SSG 46 135 292 336 320 518 303
11 85 SSG 82 86 135 181 200 103
11 86 Combination 41 65 184 266 262 237
11 87 Combination 83 204 102 147 231 255
11 88 PM 88 79 110 144 191 152
11 89 Combination 109 121 176 226 382 252
11 90 Combination 40 61 110 105
11 91 PM 41 158 237 289 135 238
11 92 Combination 99 118 179 207 273 264
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Appendix 51: Listing of Platelet count per patient
Centre Patient Platelets (x 103/µL)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 93 SSG 79 137 138 166 86 169 151
11 94 SSG 93 226 325 317 423 594 381
11 95 SSG 114 172 211 194 222 201 249
11 96 Combination 125 244 324 401 334 270
11 97 Combination 89 183 192 199 218 199
11 98 PM 75 103 290 202 266 197
11 99 SSG 43 100 208 214 201 176 167
11 100 PM 152 188 212 246
11 101 PM 67 65 74 85 94 132
11 102 Combination 66 152 269 260 239 207
11 103 Combination 97 134 225 246 142 156
11 104 PM 47 114 256 403 209 192
11 105 SSG 43 55 167 142 109 182 194
11 106 Combination 112 338 267 222 155 149
11 107 PM 40 74 164 286 206 219
11 108 PM 96 69 119 181 102 130
11 109 SSG 43 149 197 209 234 201 185
11 110 PM 58 38 55 85 137 147
11 111 Combination 51 190 221 219 152 196
11 112 Combination 127 95 241 238 130 193
11 113 SSG 84 168 227 182 268 181
11 114 SSG 215 154 189 169 172 218 152
11 115 Combination 42 66 92 113 195 158
11 116 SSG 99 122 119 198 245 189 224
11 117 PM 55 60 147 221 240
11 118 PM 66 102 161 202 168 144
11 119 SSG 94 197 184 176 177 136 170
11 120 Combination 63 175 200 179 175 244
11 121 Combination 69 195 283 288 327 433
11 122 SSG 41 47 161 235 241
11 123 SSG 70 113 144 129 170 194 189
11 124 SSG 44 65 192 171 177 260
11 125 SSG 167 152 283 280 238 195 187
11 126 Combination 163 104 140 201 109
11 127 PM 62 58 136 185 227 203
11 128 Combination 174 73 288 300 193 132
11 129 PM 130 62 134 213 173 187
11 130 Combination 73 172 227 214 197 230
11 131 PM 117 91 156 163 198 134
11 132 SSG 42 150 131 149 169 196 88
11 133 Combination 56 50 138 182 238 225
11 134 PM 45 22 57 58 110 84
11 135 PM 111 144 227 217 285 246
12 241 Combination 93 158 96 258
12 242 SSG 162 362 341 332 66 357
12 243 PM 105 167 248 206 276
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Appendix 51: Listing of Platelet count per patient
Centre Patient Platelets (x 103/µL)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
12 244 SSG 117 121 177 165 186 209
12 245 PM 60 105 119 143 93
12 246 PM 210 140 268 222 191
12 247 PM 44 71 119 110 206 255
12 248 PM 48 59 117 236 188 168
12 249 Combination 67 108 103 103 174 115
12 250 SSG 52 46 53 104 150 135 143
12 251 Combination 91 143 171 228 211 279
12 252 SSG 85 188 181 219 170 183 172
12 253 SSG 75 104 113 177 150 142 166
12 254 Combination 68 164 195 239 228 182
12 255 Combination 53 98 190 238 207 198
12 256 Combination 66 131 150 234 186 138
12 257 SSG 76 155 195 188 303 263 104
12 258 SSG 107 145 241 226 175 202
12 259 PM 68 107 169 223 233 349
12 260 PM 85 138 168 198 128
12 261 Combination 69 238 283 283 260 189
12 262 PM 164 102 194 292 222 225
12 263 SSG 121 172 229 173 213 272 253
12 264 Combination 59 200 217 128 255 164
12 265 SSG 55 102 134 97 53
12 266 PM 104 128 127 115 130 148
12 267 SSG 189 88 165 136 179 56 133
12 268 PM 57 54 60 86 136 126
12 269 Combination 95 113 208 153 135 148
12 270 Combination 67 132 120 289 237
12 271 SSG 71 110 144 137 214 239 229
12 272 PM 130 106 228 307 205 224
12 273 SSG 118 159 239 217 267 290 252
12 274 SSG 152 157 225 226 221 200 169
12 275 Combination 53 96 98 98 186 207
12 276 PM 101 94 109 162 219 177
12 277 Combination 96 128 300 406 342 273
12 278 SSG 93 129 195 202 234 176
12 279 PM 104 123 217 253 172 199
12 280 SSG 41 66 126 216 179 138 191
12 281 Combination 66 175 289 295 249 258
12 282 PM 108 180 240 274 203 197
12 283 PM 72 60 75 127 144 146
12 284 Combination 111 117 253 309 97 137
12 285 Combination 109 165 293 240 167 323
12 286 PM 87 53 107 140 172 190
12 287 SSG 184 276 288 228 221 239 205
12 288 Combination 189 182 361 236 229 200
12 289 Combination 95 149 210 305 259 239
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Appendix 51: Listing of Platelet count per patient
Centre Patient Platelets (x 103/µL)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
12 290 SSG 88 151 245 285 191 262
12 291 SSG 103 124 149 155 181 172 219
12 292 PM 76 101 308 180 183
12 293 SSG 85 100 265 229 250 207
12 294 Combination 120 297 138 162 192 204
12 295 Combination 123 252 286 255 240
12 296 PM 122 139 245 242 218 237
12 297 SSG 108 262 245
12 298 PM 71 141 198 236 224 276
12 299 Combination 131 136 179 174 170
12 300 PM 85 87 143 168 160 178
12 301 SSG 155 296 291 323 300 270 250
12 302 SSG 180 180 228 258 252 347 359
12 303 PM 84 101 112 77 92 350
12 304 Combination 85 122 224 228 252 221
12 305 PM 144 181 226 228 300 278
12 306 Combination 78 210 254 312 331 218
12 307 Combination 96 144 158 223 194 214
12 308 PM 136 140 151 185 151 257
12 309 PM 113 93 153 175 165 181
12 310 SSG 205 261 228 136 140 211 280
12 311 SSG 132 202 115 202 191 266 267
12 312 Combination 166 100 189 218 226 252
12 313 PM 144 142 231 317 242 261
12 314 SSG 81 116 110 122 136 213 149
12 315 Combination 91 70 177 254 118 133
12 316 SSG 127 156 207 201 157
12 317 SSG 125 182 225 193 242 243
12 318 Combination 110 220 451 407 218 355
12 319 Combination 94 114 215 214 251 260
12 320 Combination 80 198 284 320 280 317
12 321 Combination 123 108 104 151 138 165
12 322 PM 95 103 158 180 178 107
12 323 SSG 71 112 120 144 163 180 187
12 324 SSG 122 108 163 165 191 190 168
12 325 PM 89 98 143 147 159 176
12 326 PM 120 111 197 225 125 178
12 327 Combination 100 341 372 286 261 291
12 328 PM 63 72 100 143 209 220
12 329 SSG 81 159 200 194 283 270 201
12 330 PM 209 181 202 220 316 167
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Appendix 51: Listing of Platelet count per patient
Centre Patient Platelets (x 103/µL)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
23 361 Combination 70 137 100 195 223 195
23 362 PM 104 130 217 188 213 298
23 363 PM 128 157 305 433 288 306
23 364 Combination 106 110 187 179 92 233
23 365 SSG 138 203 265 297 267 143 211
23 366 Combination 129 144 244 243 280 255
23 367 SSG 97 92 101 109 104 111 132
23 368 PM 85 101 177 156 140 128
23 369 Combination 65 83 170 163 202 173
23 370 SSG 99 222 225 233 272 273 159
23 371 PM 86 115 167 155 118 157
23 372 PM 129 116 134 174 198 214
23 373 SSG 103 201 219 204 189 188 152
23 374 SSG 84 133 129 128 172 59 156
23 375 Combination 154 302 297 308 273 265
23 376 SSG 250 212 273 307 292 290 342
23 377 Combination 107 106 235
23 378 Combination 113 115 135 165 164 173
23 379 PM 201 132 165 213 153 232
23 380 SSG 83 80 141 153 141 160 194
23 381 PM 114 119 213 207 190 235
23 382 Combination 87 142 226 210 189 161
23 383 PM 153 186 321 281 253 226
23 384 SSG 118 168 165 159 169 169 207
23 385 SSG 148 141 139 152 175 166 232
23 386 Combination 150 75 213 320 279 273
23 387 Combination 115 82 102 110 122 190
23 388 PM 121 162 220 228 255 202
23 389 SSG 90 218 159 154 267 170 425
23 390 PM 81 126 201 220 152 237
23 391 Combination 159 223 204 215 194 195
23 392 Combination 119 72 139 246 77
23 393 SSG 149 184 254 305 334 283 231
23 394 PM 160 209 229 387 2.54999995 418
23 395 PM 109 76 110 101 138 202
23 396 SSG 95 242 193 152 181 132 181
23 397 SSG 267 414 368 216 195 166 283
23 398 Combination 91 162 187 219 248 186
23 399 PM 86 110 147 249 237 282
23 400 PM 159 84 91 89 131 93
23 401 Combination 114 54 93 103 96 159
23 402 Combination 81 88 165 123 179 243
23 403 SSG 89 77 127 108 181 76 54
23 404 SSG 113 136 226 274 256 276
23 405 PM 153 160 194 189 165 200
34 Not Done
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Appendix 51: Listing of Platelet count per patient
Centre Patient Platelets (x 103/µL)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
35 646 PM 48 57 150 143 236
35 647 PM 5 338 129 151 144 296
35 648 Combination 61 122 215 331 250
35 649 Combination 108 167 197 155 210
35 650 SSG 188 246 275 279 463 278 280
35 651 SSG 247 251 204 108 261 334 312
35 652 PM 110 194 204 251 282
35 653 Combination 139 146 217 230 262 270
35 654 SSG 210 343 470 373 461 448 503
35 655 Combination 110 165 188 210 179 250
35 656 SSG 53 55 79 175 314 219 210
35 657 PM 125 127 174 148 234 303
35 658 Combination 163 197 233 254 284 263
35 659 SSG 149 138 197 173 216 198 202
35 660 PM 123 146 156 121 122 213
35 661 Combination 124 131 280 273 210 296
35 662 PM 58 85 97 126 132 278
35 663 SSG 172 142 153 110 145 210 663
35 664 Combination 105 233 275
35 665 SSG 104 123 452 391 284 210 230
35 666 SSG 64 83 206 191 174 264 576
35 667 Combination 90 85 230 208 301 290
35 668 PM 58 67 154 119 401
35 669 PM 153 164 147 105
35 670 SSG 82 85 166 106 204 301 247
35 671 PM 74 8.2 123 98 286
35 672 Combination 88 83 202 200 210
35 673 SSG 293 551 156 160 164 204 276
35 674 Combination 60 55 200 201 268 302
35 675 PM 199 147 178 278 294
35 676 PM 59 56 69 156 192 205
35 677 SSG 141 95
35 678 Combination 152 160 165 426 305 280
35 679 SSG 91 260 481 123 565 204 236
35 680 Combination 177 255 260 437 310 293
35 681 Combination 61 168 225 227 220 261
35 682 PM 65 132 135 160 297
35 683 Combination 376 567 510 518 410
35 684 SSG 84 111 120 427 173 210 312
35 685 PM 176 125 166 427 317 281
35 686 PM 88 150 117 380 240 205
35 687 SSG 147 202 329 274 535 387 394
35 688 PM 99 183 212 184 210 360
35 689 Combination 164 96 201 219 230 210
35 690 SSG 77 431 210 331 263 303 360
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Appendix 52: Listing of Prothrombin time per patient
Centre Patient Prothrombin time (s)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 20 SSG 14.9
11 23 PM 38.9
11 24 PM 57.5
11 25 SSG 51.2
12 Not Done
23 361 Combination 15.4
23 362 PM 16.8
23 363 PM 16.2
23 364 Combination 15.6
23 365 SSG 16.3
23 367 SSG 19.2
23 368 PM 16.8
23 370 SSG 15.5
23 371 PM 21
23 372 PM 15.9
23 373 SSG 16.2
23 374 SSG 16.5
23 375 Combination 15.5
23 376 SSG 17.5
23 377 Combination 15.3
23 378 Combination 15.5
23 379 PM 15.7
23 380 SSG 14.4
23 381 PM 15.2
23 382 Combination 16.3
23 383 PM 13.7
23 384 SSG 16
23 385 SSG 17.4
23 386 Combination 16
23 387 Combination 16.3
23 388 PM 14.8
23 389 SSG 15.9
23 390 PM 15
23 391 Combination 13.21
23 392 Combination 13.54
23 393 SSG 15.1
23 394 PM 14.9
23 395 PM 14.9
23 396 SSG 15.1
23 397 SSG 12.49
23 398 Combination 15.09
23 399 PM 14.1
23 400 PM 16
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Appendix 52: Listing of Prothrombin time per patient
Centre Patient Prothrombin time (s)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
23 401 Combination 14.22
23 402 Combination 14.3
23 403 SSG 15.6
23 404 SSG 14.6
23 405 PM 15.3
34 Not Done
35 646 PM 13 12 12 10
35 647 PM 11 13 13 12 10
35 648 Combination 13 12 12 10 11
35 649 Combination 12 13 12 11 11
35 650 SSG 12 11 12 10 12 11 11
35 651 SSG 13 12 12 11 11 10 10
35 652 PM 11 11 12 11
35 653 Combination 12 13 11 12 11 11
35 654 SSG 11 11 13 12 12 11 11
35 655 Combination 12 13 12 11 10 11
35 656 SSG 12 12 13 11 12 10 11
35 657 PM 11 12 13 11 11 10
35 658 Combination 13 12 11 12 10 10
35 659 SSG 12 13 12 11 12 11 11
35 660 PM 11 12 12 12 11 11
35 661 Combination 13 12 11 11 11 11
35 662 PM 10 11 12 11 10
35 663 SSG 12 12 11 12 11 11 11
35 664 Combination 13 13
35 665 SSG 12 14 12 12 11 11
35 666 SSG 12 10 12 11 10 10 11
35 667 Combination 13 13 12 11 10 11
35 668 PM 13 10 11 9 11
35 669 PM 11 11 10 11
35 670 SSG 12 10 11 11 11 10 11
35 671 PM 11 10 14 13
35 672 Combination 12 11 12 11 11
35 673 SSG 11 10 13 12 11 12 11
35 674 Combination 13 12 12 11 11 12
35 675 PM 13 12 12 11
35 676 PM 12 11 10 12 11 12
35 677 SSG 13 12
35 678 Combination 11 11 12 13 12 12
35 679 SSG 10 10 10 10 11 12 12
35 680 Combination 10 10 13 13 12 11
35 681 Combination 13 11 11 12 11 12
35 682 PM 12 11 11 10
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Centre Patient Prothrombin time (s)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
35 683 Combination 11 11 13 12 12
35 684 SSG 12 10 10 12 11 11 12
35 685 PM 13 13 10 12 12 12
35 686 PM 11 12 11 12 11
35 687 SSG 11 10 12 11 11 11 11
35 688 PM 10 11 11 10 11 12
35 689 Combination 12 11 11 10 11
35 690 SSG 12 10 12 11 12 11 12
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Appendix 53: Listing of ALT and AST per patient
Centre Patient Aspartate Aminotransferase (U/L)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 1 PM 104 120 63 61 39 32
11 2 Combination 57 88 49 54 22 38
11 3 Combination 96 207 98 98 36 51
11 4 PM 44 31 44 63 38 26
11 5 PM 44 34 34 48 36 28
11 6 Combination 62 57 50 63 35 31
11 7 PM 64 35 36 40 23 16
11 8 SSG 51 42 69 37 42 20 28
11 9 SSG 107 72 70 59 68 104 81
11 10 SSG 60 39 44 129 47 29 19
11 11 Combination 50 55 58 58 51 152
11 12 Combination 55 65 57 62 28 28
11 13 SSG 25 46 39 41 33 18 17
11 14 SSG 25 91 25 56 60 46 41
11 15 PM 52 57 29 27
11 16 Combination 26 50 70 56 8 19
11 17 Combination 21 54 45 48 21 19
11 18 SSG 35 68 71 40 55 106 26
11 19 Combination 26 56 59 55 32 27
11 20 SSG 22 37 31 39 37 37 26
11 21 SSG 32 62 103 82 50 27 29
11 22 SSG 43 72 48 43 34 26 16
11 23 PM 76 54 65 51 34 25
11 24 PM 41 38 48 42 32 26
11 25 SSG 49 311 63 61 37 21 18
11 26 Combination 39 95 73 68 48 41
11 27 PM 17 30 29 31 23
11 28 Combination 29 76 71 63 40 25
11 29 PM 25 51 40 42 22 22
11 30 PM 53 94 69 70 50 40
11 31 SSG 16 14 19 104 67 22 16
11 32 Combination 37 106 85 69 30 26
11 33 SSG 25 80 168 55 61 23 25
11 34 PM 25 36 38 42 31 34
11 35 SSG 25 41 45 42 43 30 36
11 36 SSG 44 17 37 36 52 22 28
11 37 Combination 92 114 66 128 33 38
11 38 PM 52 86 73 47 30 45
11 39 PM 70 71 81 51 30 38
11 40 PM 13 53 46 25 22
11 41 Combination 43 60 48 66 49 51
11 42 Combination 65 166 92 70 26 32
11 43 SSG 31 83 52 48 75 38 28
11 44 PM 29 23 30 27 23 23
11 45 Combination 25 69 58 61 26 26
11 46 SSG 39 55 65 48 49 26 68
11 47 SSG 45 110 67 43 42
11 48 Combination 23 38 76 74 22
11 49 SSG 87 321 50 62 90 30 35
11 50 PM 33 59 38 52 35 42
11 51 Combination 29 26 38 31 24 31
11 52 PM 43 43 70 41 77 629
11 53 SSG 27 46 78 67 29 83 95
11 54 PM 59 58 57 67 36 39
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Appendix 53: Listing of ALT and AST per patient
Centre Patient Aspartate Aminotransferase (U/L)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 55 PM 32 41 53 50 35 28
11 56 SSG 15 35 34 38 36 54 29
11 57 Combination 16 106 71 41 19 28
11 58 Combination 24 42 119 98 67 39
11 59 PM 38 30 52 55 466 224
11 60 Combination 68 145 69 103 41 57
11 61 PM 56 93 80 62 62 57
11 62 SSG 75 71 56 37 39 46 36
11 63 SSG 31 73 62 61 39 25 41
11 64 SSG 98 96 62 63 45 51 90
11 65 PM 31 37 21 40
11 66 Combination 53 89 44 40 26 47
11 67 PM 42 50 50 74 39 38
11 68 SSG 51 48 40 56 40 38 38
11 69 Combination 40 63 81 48 34 59
11 70 Combination 44 123 113 76 40 46
11 71 Combination 39 91 71 98 70 83
11 72 SSG 82 157 178 45 30
11 73 PM 91 45 52 70 43 40
11 74 PM 55 153 79 31 34 23
11 75 Combination 52 82 77 97 45 34
11 76 PM 104 199 99 45 43 28
11 77 PM 43 53 81 78 48 35
11 78 SSG 52 37 62 55 53 30 29
11 79 PM 102 113 66 67 152 54
11 80 PM 21 26 55 52 37 35
11 81 Combination 13 34 74 82 31 39
11 82 SSG 44 158 46 121 107 32 37
11 83 SSG 62 39 38 33 49 47 24
11 84 SSG 61 53 53 49 56 33 48
11 85 SSG 37 136 68 57 93 39
11 86 Combination 98 40 31 58 39 33
11 87 Combination 97 144 131 59 43 35
11 88 PM 84 85 98 59 26 37
11 89 Combination 104 132 71 63 32 35
11 90 Combination 104 42 36 82
11 91 PM 85 39 58 74 18 49
11 92 Combination 81 60 78 57 53 44
11 93 SSG 74 98 46 36 49 47 71
11 94 SSG 76 110 55 56 53 42 50
11 95 SSG 49 120 79 55 34 23 34
11 96 Combination 76 164 74 72 29 30
11 97 Combination 36 75 33 65 52 61
11 98 PM 104 112 125 149 224 55
11 99 SSG 46 87 77 50 49 41 32
11 100 PM 26 33 50 55
11 101 PM 95 86 70 75 61 58
11 102 Combination 51 68 46 52 31 36
11 103 Combination 110 173 85 80 36 39
11 104 PM 44 171 31 39 82 69
11 105 SSG 32 43 47 51 46 31 25
11 106 Combination 107 65 90 54 27 39
11 107 PM 76 43 42 40 35 32
11 108 PM 29 41 54 39 37 35
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Appendix 53: Listing of ALT and AST per patient
Centre Patient Aspartate Aminotransferase (U/L)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 109 SSG 49 82 53 48 51 26 23
11 110 PM 73 98 93 114 212 39
11 111 Combination 75 130 81 57 24 26
11 112 Combination 41 55 38 30 46 44
11 113 SSG 109 188 107 102 117 34
11 114 SSG 62 138 104 130 119 46 28
11 115 Combination 94 76 60 80 51 71
11 116 SSG 67 56 44 56 59 38 37
11 117 PM 76 70 57 56 27
11 118 PM 37 54 127 78 43 48
11 119 SSG 74 65 47 38 46 44 52
11 120 Combination 57 86 43 42 36 32
11 121 Combination 71 55 37 41 50 38
11 122 SSG 109 54 35 34 38
11 123 SSG 48 76 70 67 51 57 42
11 124 SSG 92 160 50 35 33 26
11 125 SSG 100 94 51 35 45 36 30
11 126 Combination 45 113 144 169 51
11 127 PM 58 85 147 68 28 34
11 128 Combination 48 130 120 152 50 46
11 129 PM 26 69 32 39 32 42
11 130 Combination 61 121 60 53 74 47
11 131 PM 63 72 48 71 41 76
11 132 SSG 97 72 39 49 47 40 38
11 133 Combination 48 68 54 48 30 26
11 134 PM 67 96 74 54 95 83
11 135 PM 26 47 60 63 65 42
12 241 Combination 37 54 151 186 37
12 242 SSG 16 19 58 44 32 37 54
12 243 PM 24 24 53 45 38 25.5
12 244 SSG 27 52 216 154 72 23.5 41
12 245 PM 40 21 41.1 39.5 30
12 246 PM 68 74 49 63 128
12 247 PM 42 29 24 31 37 37
12 248 PM 32 37 45.9 36.3 20 20
12 249 Combination 28 100 77 62 46 16.4
12 250 SSG 32 32.5 30 30 29 22.1 19.6
12 251 Combination 74 34 27 59 45 28.5
12 252 SSG 41 33 112 51 28 32 41
12 253 SSG 48 40 47 45 32 27 34.1
12 254 Combination 60 34 218 71 41 33
12 255 Combination 44.8 253 108 103 19 26
12 256 Combination 36 68.8 80 75 9.8 36
12 257 SSG 48 74.1 51 51 38 41 37.9
12 258 SSG 32 38 142 70 31 29
12 259 PM 20 32 43 40 43 26.6
12 260 PM 35 40 54 65 15
12 261 Combination 49 49 64 50.4 34 5
12 262 PM 32 39 60 49 26.7 30
12 263 SSG 28 122 81 48.2 77 30 17.2
12 264 Combination 11 33 88.2 122 54 10
12 265 SSG 14 38 50.4 36 326
12 266 PM 48 56 44.1 35 52 20.2
12 267 SSG 42 85 75.3 61 51 39 31
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12 268 PM 168 136 145 134 51.8 30.3
12 269 Combination 34.5 85 69 56 33 24
12 270 Combination 22 80.2 58 40 38.2
12 271 SSG 73 71 70 48 42 15.8 20
12 272 PM 144 182 188 415 28.4 10
12 273 SSG 14.8 18 108 68.8 113 36.6 15
12 274 SSG 39 74 76 79.3 86 68.1 49
12 275 Combination 78 63 57 67 15.2 20.6
12 276 PM 35 28 44 57 30.9 12
12 277 Combination 59 98 91 95 13.2 16
12 278 SSG 143 139 68 50 53.3 29.4
12 279 PM 20 19 25 39 50.3 28
12 280 SSG 87 297 142 111 120 37.8 33
12 281 Combination 28 69.2 63 46 52.5 33.9
12 282 PM 38.3 43 44 74 18.1 23.6
12 283 PM 26.8 45.4 37.8 52.5 51 34.1
12 284 Combination 29.01 32 42 44 22 23.8
12 285 Combination 45.7 99.6 86 38.7 16.3 20.4
12 286 PM 15.2 18.8 21 26 24.3 20.1
12 287 SSG 81 126 136 118 68 45 40
12 288 Combination 33 71 58 67.4 38.8 32.3
12 289 Combination 19 28.9 51 78 47 31
12 290 SSG 20 67 54 70.8 77.3 48.2
12 291 SSG 27.2 41 49 48.5 39.5 31.4 19.6
12 292 PM 289 379 95.8 34 26.8
12 293 SSG 17.5 21 54.3 46.2 47.1 32.4
12 294 Combination 22.9 27.4 49.5 23 41.1 20.1
12 295 Combination 53.8 102 46.4 49.4 34
12 296 PM 36.5 58 57.8 62.2 30.8 41
12 297 SSG 71.5 70.4 56.8
12 298 PM 37.8 41.6 37.1 32.1 28 39
12 299 Combination 68.4 83.9 94.6 90.6 38
12 300 PM 26.3 27.4 31.2 33.2 86 36
12 301 SSG 26.1 82.8 46.2 30.9 72.4 23 19
12 302 SSG 36.4 47 31.8 26.4 24.1 44 39
12 303 PM 24.6 78.5 74.4 55.4 61 28
12 304 Combination 247 444 132 75.9 33 31
12 305 PM 21.3 47.1 37.2 71.4 33 35
12 306 Combination 21.4 26.3 29.3 26.9 37 35
12 307 Combination 56.3 21 27 40.7 95 42
12 308 PM 16.4 31.2 39.7 40.1 20 31
12 309 PM 47.3 30.7 26.7 52.1 34 29
12 310 SSG 33.4 30.3 36.4 32.1 35.5 47 29
12 311 SSG 55.5 85.8 131 53.5 63 41.5 34.7
12 312 Combination 12.8 103 42 49.7 46 12.8
12 313 PM 42.5 63.6 78.9 56.1 96.2 76
12 314 SSG 65.1 120 91.5 91.9 89.2 25 37
12 315 Combination 42.3 43.1 46.4 47.2 60 23
12 316 SSG 22.5 103 79.1 21 28
12 317 SSG 43.6 90.9 74.5 94 112 43
12 318 Combination 25.1 86.2 42.8 66.9 50 68
12 319 Combination 31.2 36.2 40.2 60 54 46.6
12 320 Combination 40.5 62.4 50 46 41 90
12 321 Combination 32.2 38.9 29 34 42 38
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12 322 PM 37.2 55 144 62.5 35 80
12 323 SSG 65 59 96 90 45 31 78
12 324 SSG 33 103 56 73 32 43 70
12 325 PM 37 54 110 69 20 98
12 326 PM 57 93 36 56 91.4 94
12 327 Combination 45 81 50 90 30 91
12 328 PM 28 40 62 84 38 43
12 329 SSG 44 65 59 81 72 34 33
12 330 PM 86 110 98 91 52 45
23 361 Combination 36 60 103 67 40 37
23 362 PM 69 89 162 146 63 76
23 363 PM 46 126 113 78 48 37
23 364 Combination 72 124 93 88 36 50
23 365 SSG 49 94 90 70 35 67 24
23 366 Combination 66 190 68 40 43 21
23 367 SSG 73 90 43 108 67 56 49
23 368 PM 78 19 110 36 16 18
23 369 Combination 60 78 50 46 37 36
23 370 SSG 83 92 46 60 92 47 46
23 371 PM 42 15 49 30 27 11
23 372 PM 31 61 82 118 42 31
23 373 SSG 65 48 40 48 41 26 34
23 374 SSG 42 92 59 49 35 76 50
23 375 Combination 15 85 53 49 18 32
23 376 SSG 32 61 107 57 74 52 41
23 377 Combination 44 311 22
23 378 Combination 59 63 61 55 29 49
23 379 PM 45 64 65 33 35
23 380 SSG 94 40 97 73 44 57 34
23 381 PM 89 51 70 87 32 30
23 382 Combination 50 74 127 64 26 33
23 383 PM 58 46 68 46 39 42
23 384 SSG 62 76 67 47 53 54 52
23 385 SSG 89 88 95 42 88 39 41
23 386 Combination 83 283 42 58 43 36
23 387 Combination 50 32 99 75 31 35
23 388 PM 76 38 67 53 53 39
23 389 SSG 50 74 77 71 47 37 29
23 390 PM 55 40 47 51 30 17
23 391 Combination 108 136 115 78 48 37
23 392 Combination 62 122 57 70 49
23 393 SSG 20 36 41 41 39 65 69
23 394 PM 100 97 40 56 27 27
23 395 PM 53 43 57 54 38 16
23 396 SSG 77 69 86 58 73 61 42
23 397 SSG 64 68 86 67 79 32 36
23 398 Combination 34 29 46 36 29 22
23 399 PM 32 13 31 45 35 20
23 400 PM 49 31 42 56 60 59
23 401 Combination 34 41 54 56 36 20
23 402 Combination 37 25 42 53 32 23
23 403 SSG 113 57 93 85 71 52 67
23 404 SSG 62 99 82 52 37 38
23 405 PM 40 15 37 39 30 34
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34 451 Combination 55 58.6 42.3 47.8 29.3
34 452 PM 92.6 66.6 77.2 54.2
34 453 PM 76.7 97.9 67 104
34 454 Combination 48.1 57.8 52.4 76.4 34.3
34 455 PM 27.7 36.8 44.9 57.2
34 456 SSG 114 101 50.5 47.7 37.7 49.9
34 457 Combination 39.3 81.4 44 51.8
34 458 PM 42.1 47.2 29.1 56.5 161
34 459 Combination 47.7 91 86.7 76.2 26.8 42
34 460 PM 54.3 74.4 60 71.8
34 461 SSG 41.2 66.7 105
34 462 SSG 73.6 48.5 64.8 54.3 50.5 36.3
34 463 Combination 72.6 85.2 58.1 77.1 29.4
34 464 SSG 52.1 57.2 62.9 37.7 34.7 23.1
34 465 SSG 63.9 79 37.8 39.3 43.9 18.9
34 466 Combination 20.2 65.4 61.2 38.3
34 467 PM 63.4 158 209 122 302
34 468 Combination 86.9 90.1 39.4 38.4 24.9
34 469 SSG 23.6 56.3 95.6 55 39.3 28.6
34 470 Combination 25.3 37.4 60.6 59.3 29.5
34 471 PM 85.3 88.4 92.8 164
34 472 SSG 72.9 116 61.9 72.4 59.7 32.5
34 473 PM 115 87.7 108 157
34 474 Combination 28.2 48.2 53.6 59.4 24.7
34 475 PM 26.5 28 36.8 29.7
34 476 PM 43.4 64.9 315 84.4 90.9
34 477 SSG 89.5 116 52.6 49.4 45.3 29.2
34 478 Combination 39.6 58.1 42 54.6 24.9
34 479 SSG 63.8 72.8 56.1 47.4 94.5 35.7
34 480 SSG 106 190 99.8 83.8 61 27.8
34 481 Combination 77.6 109 54.7 62.9 20.5
34 482 Combination 118 424 71.7 67.3 22.5
34 483 PM 12.7 31.7 38.9 31.8 15.7
34 484 PM 28.6 84.5
34 485 Combination 69.4 104 91.9 75.6 46.4
34 486 Combination 13.2 52.2 39 41.7 54.1
34 487 SSG 58.4 188 62.7 55.4 49.8 26.3
34 488 SSG 19.6 46.6 40.5 51.1 50.9 24.9 85.1
34 489 SSG 22.3 49.5 52.6 26.8 41.1 32.7
34 490 PM 82.4 139 93.1 65.9 27
34 491 PM 26.9 57.3 49.6 70.1
34 492 PM 29.3 72.3 92.7 147 73.2
34 493 SSG 18.6 41.9 37.5 39.1 31.8
34 494 Combination 124 101 44.6 41.6 30.8
34 495 SSG 57.6 60.8 54.7 106 68.2 36.8
34 496 SSG 37.5 181 58.2 47.9 46 21.3
34 497 PM 70.8 37.2 33.5 35.9 56.2
34 498 SSG 19.2 71.9 57.6 100 86.8 22.9
34 499 Combination 57.2 58.8 50.2 79.9 32.7
34 500 PM 52.5 82.3 77.4 71.1 26.1
34 501 Combination 31.2 102 56.1 37.7 79.2
34 502 Combination 101 102 33.2 26.1 11.9
34 503 PM 67.1 117 75.6 85.6
34 504 Combination 30.7 44.6 58.9 79.6
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34 505 SSG 72.9 63.1 49.5 36.3 32.8 44.5
34 506 SSG 98.2 54.8 55.3 43 34.4 51.7
34 507 SSG 81.7 114 54.4 56.7 80.9 52.7
34 508 PM 66.9 121 48.2 75.1
34 509 PM 33.9 22.4 22.3 19.6
34 510 Combination 72.4 78.7 45.3 45 55.9
34 511 Combination 28 57.3 59.1 56.1 33.6
34 512 PM 103 115 47.1 49.3
34 513 Combination 15.8 22.5 29 25 42.3 29.8
34 514 SSG 63.7 104 93.8 77.4 77.1 40.4
34 515 SSG 56.2 43.2 54.3 32.2 29.9 25.9
34 516 PM 25.1 34.6 36.9 39.1 18.6
34 517 PM 47.8 223 191 93.4
34 518 SSG 52.3 48.5 52.8 45.3 40.9 46.4
34 519 PM 59.9 65.7 60.3 55.7 130
34 520 SSG 27.7 133 40.1 69.2 49.3 18.8
34 521 PM 63.7 45.1 74.1 86.8
34 522 Combination 24.1 66.4 68.2 71.3
34 523 SSG 54.5 79.1 74 56.3 78.1 40.3
34 524 Combination 45.8 58.3 64.6 84.1 50
34 525 Combination 103 191 73.3 71.2 31
34 526 SSG 54.7 105 42.9 76.3 110 52.4
34 527 Combination 51.1 104 36.3 48 18.7
34 528 PM 23 39.8 41.6 43.2
34 529 Combination 95.8 51.2 34.8 39.1 29.9
34 530 Combination 116 70.6 61.2 53.5 31.6
34 531 SSG 41.2 94.4 57.9 81.7 88.2
34 532 Combination 96 65.9 36.6 37.6 42.7
34 533 SSG 38.5 54.5 52.7 64.2 52.1 23.6
34 534 PM 122 129 128 78.1
34 535 PM 58.5 66.4 43.3 40.2 34.2
34 536 PM 48.3 34.6 37.7 47.4 31
34 537 SSG 77.8 76.9 47.1 68.8 65.6 37.2
34 538 PM 74 33 39.2 70.6
34 539 Combination 26.7 82.8 77.1 70.8 30.7
34 540 SSG 108 131 52.1 71.5 118 31.7
35 646 PM 12 12 14 12 20
35 647 PM 8 12 15 14 38 18
35 648 Combination 18 18 16 27 18
35 649 Combination 9 20 14 32 19
35 650 SSG 20 18 16 12 16 24 22
35 651 SSG 19 19 16 14 12 30 24
35 652 PM 10 10 16 14 14
35 653 Combination 20 18 17 12 29 20
35 654 SSG 20 19 20 16 14 27 22
35 655 Combination 12 12 15 16 27 20
35 656 SSG 16 9 16 18 16 27 28
35 657 PM 12 14 12 16 41 28
35 658 Combination 6 10 14 16 34 22
35 659 SSG 12 14 17 14 18 20 18
35 660 PM 9 14 12 16 32 24
35 661 Combination 12 10 16 14 24 20
35 662 PM 16 14 18 16 24 12.2
35 663 SSG 17 16 17 18 16 32 30
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35 664 Combination 16 18 14
35 665 SSG 18 20 18 16 12 26 20
35 666 SSG 16 14 18 12 18 38 30
35 667 Combination 10 18 12 16 24 22
35 668 PM 12 18 18 16 30
35 669 PM 16 14 10 14
35 670 SSG 14 14 16 18 17 24 26
35 671 PM 14 18 12 15 13
35 672 Combination 18 16 16 18 24
35 673 SSG 16 12 14 15 18 26 20
35 674 Combination 18 16 18 15 19 20
35 675 PM 18 14 16 15 11
35 676 PM 16 14 15 16 28 24
35 677 SSG 18 16
35 678 Combination 20 17 18 16 20 20
35 679 SSG 18 16 17 15 16 20 18
35 680 Combination 20 20 14 16 24 26
35 681 Combination 28 21 19 19 26 18
35 682 PM 18 14 15 16 12
35 683 Combination 18 18 18 17 20
35 684 SSG 18 16 22 24 23 34 26
35 685 PM 17 16 20 18 26 21
35 686 PM 18 19 26 24 29 20
35 687 SSG 20 19 24 22 39.4 37.2 22
35 688 PM 26 24 22 23 34 22
35 689 Combination 26 22 23 24 30 24
35 690 SSG 27 26 24 25 40.1 36 24
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Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
28 36 28 31 29 21
9 52 31 40 18 13
13 85 56 56 38 44
25 35 72 92 38 28
27 27 26 37 20 17
28 27 39 43 38 34
28 21 23 24 25 11
19 37 58 36 45 16 24
81 56 52 37 34 69 81
29 34 49 113 48 6 12
47 95 55 41 45 108
24 52 33 35 12 18
12 27 23 20 18 14 10
22 92 22 40 40 30 32
15 17 22 18
38 82 111 61 7 13
22 82 63 56 14 18
34 61 82 52 46 115 27
17 28 37 39 19 20
15 35 28 26 23 22 17
21 36 72 71 34 17 17
29 53 46 29 25 16 12
71 48 67 58 30 20
18 23 41 31 17 13
26 143 68 62 33 17 30
30 66 49 39 60 38
6 11 23 17 8
17 37 67 61 20 17
18 39 36 41 12 13
43 58 60 70 37 20
12 11 11 77 45 15 26
38 66 82 66 47 32
28 97 199 31 94 23 21
18 20 24 28 23 30
22 36 24 23 16 20 35
18 11 16 22 44 17 23
44 59 35 187 28 35
40 114 86 38 19 30
73 72 57 43 25 22
17 22 23 23 19
35 42 37 39 42 34
47 143 107 66 17 24
35 74 73 41 42 31 20
15 14 34 19 17 24
26 54 42 36 21 26
33 50 47 36 31 19 36
26 80 43 28 26
24 19 51 43 16
38 174 83 51 72 37 27
12 23 14 27 29 33
9 15 22 15 15 22
28 18 38 30 59 477
14 19 43 41 21 82 56
27 22 30 44 35 36
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Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
15 20 30 39 31 19
10 9 13 17 17 54 45
7 40 48 27 15 31
12 20 104 96 110 32
10 12 42 57 505 258
49 123 66 66 41 39
37 53 56 64 35 51
42 40 26 19 19 46 29
28 60 65 59 32 19 27
28 37 29 28 18 34 52
21 11 17 31
8 33 20 21 29 28
10 23 25 49 32 24
49 32 27 47 39 21 42
16 43 77 45 37 28
13 50 39 31 18 23
14 24 20 29 29 32
44 50 42 30 22
33 26 30 52 38 21
54 121 158 53 36 32
19 40 42 54 29 30
71 122 115 43 37 31
15 19 88 79 35 26
23 30 56 54 47 27 34
31 31 40 49 91 38
13 11 49 46 47 41
10 15 48 60 23 26
16 71 35 83 77 26 29
68 59 36 25 34 84 32
38 37 49 56 39 48 62
23 82 37 29 24 27
25 23 21 25 22 22
28 76 78 73 34 32
76 91 112 74 35 44
69 80 43 35 33 25
18 19 28 51
27 43 58 96 15 33
31 41 88 46 65 33
57 66 36 25 31 33 64
31 64 37 38 15 34 26
38 350 124 58 27 21 23
51 109 87 65 34 19
40 37 25 35 29 35
31 32 39 31 176 24
19 69 60 52 35 34 28
21 18 21 28
19 24 31 34 27 22
28 42 29 45 20 19
111 135 75 73 34 21
21 90 24 28 69 61
12 17 19 24 20 19 16
51 36 38 21 17 16
27 27 27 30 21 17
19 24 36 26 35 22
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Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
38 79 35 42 31 24 21
15 19 38 68 245 31
30 119 83 54 18 20
33 32 29 21 30 31
96 117 64 55 60 29
83 147 86 103 77 38 27
24 33 37 47 24 26
33 43 43 30 31 31 37
27 54 39 31 14
28 43 142 91 32 21
59 52 48 42 50 71 94
40 24 43 38 25 30
23 34 31 30 29 31
28 40 24 20 23
26 50 66 58 38 28 30
27 44 22 20 16 18
31 56 35 27 30 22 18
29 48 74 113 25
31 47 160 72 20 21
34 59 47 61 70 25
13 16 24 29 15 25
17 47 31 30 34 21
24 28 36 55 29 69
21 32 19 21 29 19 14
15 29 37 31 24 24
18 28 33 28 40 54
13 17 34 47 50 19
39 50 217 264 36
12 12 51 39 57 46 52
33 15 33 31 32 26
20 53 210 144 73 16 19
14.8 18 39 63 19
74 81 68 70 50
38 31 22 37 15 26
11 30 54.7 61.4 19 21
39 38 27 51 31 7.9
50 17 15.3 12 28.5 15 18.3
70 46 74 53 39 27.2
33 41 142 37 36 33 34
40 36 38 22 27 29 24
33 28 93 51 21 30.8
17 114 65 81 14 22
24 53 74 43 8.8 28
14 54.7 29 27 21 31 34.4
14 24 154 83 49 33
16 41 50.5 35 47 19
35 45 60 78 9.8
20 51 71 47.4 22 18.5
31 65 64 62 19.3 21
41 124 97 54 66 19.5 21.2
11 25 66 52 44 66.4
10 16 27 39 18.5
43 78 71 32 42.9 29.8
40 61 66 58 53 30 40
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Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
74 70 101 85 47.5 25.6
11 35 47.7 31 12 19
10 38.2 36.9 23 34.5
43.9 31.9 47 41 89 16.1 15
26 64 135 270 18.5 8
13.8 20 61 30.9 89 36.6 13
41 51 53 54.2 63 80.6 46
65 27 27 31 9.96 20.3
15 10 23 33 17.8 9
33 64 67 58 11.3 14
54 74 41 28 25 18.8
12 12 21 23 31.8 24
57 140 76 67 84.2 32.8 34
14 47 51 22 44 25.2
12 16 21 49.7 9.93 10.3
20.5 39 38.8 53 42.5 38.2
8.08 20 33 25 16.9 6.3
31.5 56 64.2 48 17.3 16.3
10.1 8.84 12 18.8 17.4 18.2
25.6 80 106 59 37.8 37 36
17.7 42 39 88.5 47.9 45.8
13.7 29.3 64.3 46 34 29
14.3 35 41 37 39.4 31.1
16.1 28 31 48.4 34.2 39.2 22.1
134 201 108 26 15.1
5.45 18 48 41 31.6 28.4
5.13 14.1 22.2 7 24.2 23.4
23.7 42.2 22.1 30.7 29.2
11.2 12.5 28.2 26.4 10.3 29
41.4 57.8 57.8
14.7 19.4 26.7 24.2 32 41
40.6 41.4 58.1 45.1 28
20.9 22.3 26.4 65.1 72 41
34.2 39.4 29.4 36.1 40.3 20 21
28.4 18.2 39.8 15.7 19.3 34 19
28.9 45.7 39.8 37.3 72 25
87.2 176 49.3 26.9 16 12
18.4 20.3 19.4 24.3 18 17
23.1 24.2 20.2 21.4 24 9
33.4 29 31 37.4 94 37
8 27.2 30.3 31.5 15 19
21.6 26.2 30.1 45.2 26 56
23.6 24.5 43.2 34 30 27 24
38.2 51.7 54 26 24 29 29.3
7.8 62 52 47 31 7.8
23 43.1 84.9 53.6 84.2 94
38.3 163 5 68.2 67 16 20
16.3 13.4 20.3 58 21 41
5 36 60.3 25 24
7.78 91.2 36.5 69 74 49
23.2 34 36 39 47 48
29.4 27 32 36 26 60
25 31.6 38 34 24 36
11.9 12.4 11 16 22 26
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Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
29.6 29 42 47.1 19 52
19 120 84 65 51 39 57
19 44 34 31 19 27 56
38 55 95 83 26 66
28 50 34 42 60.2 63
9 52 44 38 34 34
8 68 29 60 36 29
14 20 26 12 22 21 24
72 70 99 66 46 32
26 28 44 39 15 16
101 54 164 176 18 87
38 41 101 62 33 22
59 82 68 35 26 70
44 39 94 20 15 64 31
22 68 66 42 21 42
21 55 49 36 34 26 22
45 35 75 34 22 10
32 36 27 21 14 28
24 56 30 26 49 21 41
15 13 17 25 10 27
35 50 72 124 21 34
65 61 64 52 32 14 32
23 56 32 29 18 61 21
49 68 32 27 12 12
20 36 107 48 48 15 31
11 284 23
14 25 57 53 14 125
37 17 27 23 14 55
25 22 34 30 17 41 44
42 33 46 94 20 43
37 38 93 47 24 24
22 36 47 36 12 27
28 30 19 25 17 28 43
28 46 50 37 50 18 33
23 166 37 19 53 35
14 27 54 58 46 35
29 34 35 45 25 30
23 61 61 45 35 4 20
22 27 35 4 43 27
57 108 83 63 36 26
40 64 47 79 81
19 26 33 9 46 69 62
13 21 11 31 34 21
31 31 26 35 29 20
54 35 52 52 53 33 37
28 36 29 44 34 25 14
10 10 29 30 38 16
19 39 17 24 45 25
50 9 25 48 53 55
22 37 34 36 18 5
18 55 23 27 16 15
84 33 48 37 35 34 55
55 121 150 90 31 37
15 35 15 25 15 28
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Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
8.48 35.9 38.1 37.7 21.2
27.1 26.2 41.8 56.1
10.2 17.7 31.5 47.4
9.55 31.1 39.9 31.5 22.8
8.37 15.5 23.1 32
59.3 59.9 42 35.7 29.8 39.6
16.6 70.3 41.3 43.3
9.92 16.4 17.1 36.3 89.9
21.6 80.8 111 81.1 20.8 52.7
9.85 29.2 47.2 50.3
15.6 30 31.4
21.2 33.2 34.9 29.4 28.4 26.9
26.4 47.4 47.4 44.9 22.9
20.9 25.1 29.4 25.5 22 16.3
23.9 39.7 25.4 27.6 19.1 14.7
13.8 48.3 38.9 31.1
11.6 39.3 78.7 69.4 66.4
59.9 77.2 36.1 25.7 19.4
12.8 29.2 32.8 19.7 22.2 27.1
12.8 15.4 30.4 34.6 14.9
50.2 67.9 101 166
32.6 78.3 41.3 40.5 33.3 22.8
36.3 43.1 82.4 81.1
15.5 23.6 27.1 31.3 18.5
8.16 10.2 9.5 12.2
30.3 22.5 168 86.9 70
21.8 54 28.7 21 15.7 19.2
8.3 28.1 25.3 28.1 12.2
15.7 51.2 32.7 27.7 37 17.8
97.6 155 105 87.5 65.9 23.1
19.9 43.7 31.4 33.8 18.2
120 442 74.5 49.3 21.8
7.81 17.6 38.4 32.4 8.01
13.9 21.1
18.7 38.8 27.4 23.5 16.5
10.1 26 28 27.9 67.7
18 114 57.4 38.3 31.4 19.1
5 10.8 10.3 17.2 17.5 8.03 33
10.5 22 22.3 19.9 22.1 35.7
18 37 41.3 40.3 17.5
18.7 40.4 42.7 70.6
18.4 47 56.7 95.8 43.9
8.08 18.3 19.4 22.2 18.2
58.1 62.9 30.2 26.9 13.4
17.9 38.1 33.7 69.6 45.1 28.7
27.3 130 61.9 39.4 43.3 24
15.5 26.1 28.3 28.4 28.1
21.5 49.3 31 95.5 99.6 19.5
22.9 27.3 32.7 41.7 37.3
20.3 136 89 87.5 24
11.5 42.2 46.1 34.6 110
34 60 29.7 20.3 10.9
27.6 41.3 38 50.6
13.3 25 47.2 59
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Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
23.6 41.8 34.3 24.9 24.2 33.7
21.3 27.3 22.3 19.9 19.4 31.3
15.5 45.4 22.6 35.7 46.5 57
7.8 16.7 16.9 33.6
15 14 12.3 15.4
37.2 67.8 40.6 30.6 57.4
16.1 55.3 39.2 44.1 24
37.4 43.9 34.5 30.3
9.34 20.4 33 28.8 31.8 31
24.9 43.1 58.6 43.6 54.1 23.8
22.2 41.4 34.5 15 25.8 29.8
19.4 21.1 22.5 23.2 13.4
87.4 112 184 104
11 16.4 19.9 14 16.5 22.2
25.1 41.5 46.6 58.6 21.4
12.1 116 34.4 44.4 28.1 15.6
11.6 16 39.3 60.7
18.5 33.4 27.2 31
23.3 28.2 26.6 24.5 31.2 25.3
19.8 13.7 41.3 58 46.3
88.3 134 58.8 51.4 22.9
20.2 64.2 40.1 55.2 61.5 16
16.4 50.4 25.4 26.1 13.7
12.6 20.8 23.6 23.9
22.9 31.6 33 34.5 20.1
75.3 50.5 59.7 56.3 39.1
27.5 57.8 46.8 53.9 79.7
29.7 35.2 19.3 31.4 17.6
16.9 39.6 46.7 39.3 34.7 16.6
27.3 27.9 54.7 64.1
27.1 93.5 46.2 41.1 14.8
54.1 33.4 30.7 37 22.9
16.9 49.2 51.9 38.2 29.5 27.8
29.1 15.4 19 34.3
27.4 158 73.2 46.4 24.3
25.8 77.5 47.1 45.4 75.2 21.1
15 15 11 10 18
19 15 12 12 30 16
12 12 12 24 20
10 18 10 28 18
18 9 16 10 11 20 17
19 19 16 10 10 26 20
16 16 15 13 12
30 24 20 10 21 18
19 19 18 12 10 21 18
20 18 17 12 22 18
16 10 10 14 12 21 24
15 12 10 14 34 22
20 18 12 10 22 20
10 12 15 12 14 18 16
10 11 10 14 28 20
16 8 12 10 18 18
14 10 16 14 18 11.2
15 12 15 14 12 24 22
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Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
14 16 16
16 14 14 12 10 22 18
14 12 10 10 16 27 28
14 14 10 12 18 19
16 14 10 14 26
12 10 8 12
10 10 12 16 15 20 18
12 14 16 12 12
14 10 12 14 18
10 8 12 13 14 19 18
12 14 18 13 16 18
12 8 10 12 10
10 12 13 12 22 20
20 18
16 15 15 14 18 18
14 12 15 14 15 18 16
16 16 10 13 16 20
20 24 17 17 22 22
14 16 13 14 11
16 20 16 14 16
14 18 20 22 21 27 24
15 14 20 16 22 19
16 16 24 22 24 26
24 17 20 19 26 28 20
24 22 20 21 31 20
24 20 21 22 26 22
26 24 20 23 22.3 28 20
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Appendix 54: Listing of Alkaline Phosphatase per patient
Centre Patient Treatment Alkaline Phosphatase (U/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 1 PM 314 292 595 621 171 183
11 2 Combination 96 108 182 235 198 208
11 3 Combination 261 839 769 769 367 467
11 4 PM 181 375 465 492 860 859
11 5 PM 246 433 299 348 581 557
11 6 Combination 106 230 249 323 412 410
11 7 PM 63 125 146 162 169 173
11 8 SSG 87 184 231 260 248 210 242
11 9 SSG 192 368 390 392 443 731 654
11 10 SSG 172 371 369 347 427 573 377
11 11 Combination 903 839 1013 882 604 460
11 12 Combination 169 257 240 225 383 343
11 13 SSG 142 178 179 198 201 265 204
11 14 SSG 364 453 364 528 550 722 678
11 15 PM 97 104 210 154
11 16 Combination 131 176 328 311 167 129
11 17 Combination 248 449 408 375 230 217
11 18 SSG 144 207 257 247 225 277 183
11 19 Combination 108 131 145 141 155 146
11 20 SSG 238 289 365 369 349 404 494
11 21 SSG 182 242 288 334 328 258 261
11 22 SSG 145 383 179 368 385 481 404
11 23 PM 380 423 425 403 90 437
11 24 PM 169 227 242 219 277 256
11 25 SSG 186 310 294 373 81 554 628
11 26 Combination 549 765 746 610 752 566
11 27 PM 227 322 393 423 422
11 28 Combination 132 295 293 367 534 640
11 29 PM 162 198 205 218 290 185
11 30 PM 382 314 440 691 422 820
11 31 SSG 228 307 338 647 533 197 158
11 32 Combination 359 474 458 426 348 289
11 33 SSG 160 219 357 197 323 317 291
11 34 PM 280 269 329 364 437 376
11 35 SSG 364 379 347 392 521 520 453
11 36 SSG 98 141 188 311 425 498 395
11 37 Combination 171 324 227 179 205 193
11 38 PM 202 359 330 383 230 271
11 39 PM 319 365 360 352 506 437
11 40 PM 302 266 245 737 561
11 41 Combination 540 512 563 552 863 852
11 42 Combination 267 396 398 364 320 311
11 43 SSG 344 297 303 293 286 328 405
11 44 PM 294 369 355 368 370 385
11 45 Combination 166 188 198 91 174 158
11 46 SSG 399 393 451 618 597 503 653
11 47 SSG 189 739 532 290 244
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Appendix 54: Listing of Alkaline Phosphatase per patient
Centre Patient Treatment Alkaline Phosphatase (U/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 48 Combination 246 282 540 495 557
11 49 SSG 313 806 836 666 621 569 510
11 50 PM 529 671 455 384 204 366
11 51 Combination 111 168 207 185 508 548
11 52 PM 192 154 164 161 260 434
11 53 SSG 534 701 876 705 1058 463 360
11 54 PM 1344 823 878 756 755 615
11 55 PM 236 285 429 351 282 262
11 56 SSG 92 122 178 228 270 812 601
11 57 Combination 130 953 739 466 236 238
11 58 Combination 233 262 446 513 688 517
11 59 PM 100 132 279 1849 593 564
11 60 Combination 971 1923 1144 1248 408 343
11 61 PM 329 395 438 440 427 327
11 62 SSG 398 327 293 287 294 533 597
11 63 SSG 205 284 426 473 340 196 146
11 64 SSG 434 592 483 496 378 294 332
11 65 PM 110 149 204 244
11 66 Combination 211 451 333 337 208 172
11 67 PM 102 145 210 263 323 710
11 68 SSG 641 590 584 496 672 468 576
11 69 Combination 163 246 365 366 216 450
11 70 Combination 203 479 225 273 265 346
11 71 Combination 381 498 464 521 609 502
11 72 SSG 1551 2289 1823 725 607
11 73 PM 147 195 232 272 305 326
11 74 PM 158 200 267 212 157 176
11 75 Combination 128 77 239 302 238 139
11 76 PM 270 563 782 487 512 508
11 77 PM 186 173 269 382 592 608
11 78 SSG 146 184 210 254 265 200 257
11 79 PM 183 206 246 363 777 592
11 80 PM 137 91 174 293 568 621
11 81 Combination 311 496 717 702 880 248
11 82 SSG 162 288 416 479 544 587 674
11 83 SSG 1548 4304 2620 1303 771 325 282
11 84 SSG 658 637 641 418 581 627 662
11 85 SSG 486 1619 802 1026 945 287
11 86 Combination 116 192 222 279 546 606
11 87 Combination 181 324 273 510 419 512
11 88 PM 132 101 222 548 184 186
11 89 Combination 1644 1854 780 1527 382 250
11 90 Combination 162 130 230 605
11 91 PM 180 125 249 261 156 346
11 92 Combination 156 160 308 460 590 467
11 93 SSG 1681 1628 943 638 303 364 320
11 94 SSG 439 673 623 508 521 347 443
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Appendix 54: Listing of Alkaline Phosphatase per patient
Centre Patient Treatment Alkaline Phosphatase (U/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 95 SSG 231 1050 884 517 454 397 320
11 96 Combination 110 356 163 467 488 552
11 97 Combination 996 1398 707 534 1063 401
11 98 PM 852 717 686 564 602 453
11 99 SSG 152 455 477 428 428 678 786
11 100 PM 265 223 287 324
11 101 PM 846 1022 923 747 482 254
11 102 Combination 87 309 299 254 336 283
11 103 Combination 681 787 482 407 201 252
11 104 PM 615 1294 680 477 317 366
11 105 SSG 122 348 255 198 196 232 275
11 106 Combination 163 200 152 178 259 227
11 107 PM 205 311 331 367 351 476
11 108 PM 458 609 499 373 361 252
11 109 SSG 432 905 405 351 286 290 336
11 110 PM 312 370 400 946 615 517
11 111 Combination 970 1553 959 637 278 322
11 112 Combination 603 1279 806 629 364 382
11 113 SSG 900 3977 1844 1211 1624 499
11 114 SSG 1334 2010 1727 1253 891 418 250
11 115 Combination 117 145 296 346 509 455
11 116 SSG 242 399 386 424 362 500 366
11 117 PM 101 131 172 163 189
11 118 PM 403 430 810 875 391 381
11 119 SSG 1259 653 464 416 358 249 427
11 120 Combination 208 969 480 427 309 308
11 121 Combination 198 276 300 377 511 298
11 122 SSG 908 1439 945 761 546
11 123 SSG 333 446 505 596 625 833 897
11 124 SSG 657 700 471 394 514 175
11 125 SSG 255 686 596 425 322 374 385
11 126 Combination 152 495 451 465 282
11 127 PM 172 211 561 463 606 607
11 128 Combination 291 573 702 637 435 283
11 129 PM 191 186 223 242 142 199
11 130 Combination 113 254 265 304 312 290
11 131 PM 230 181 318 379 430 467
11 132 SSG 304 338 286 265 279 238 142
11 133 Combination 253 696 473 240 296 292
11 134 PM 342 440 318 235 277 287
11 135 PM 171 168 224 231 283 313
12 241 Combination 124 95 268 274 212
12 242 SSG 160 217 118 285 131 189 252
12 243 PM 139 216 204 91 356 184
12 244 SSG 169 106 264 178 181 221 76.7
12 245 PM 394 185 298.34 229 263
12 246 PM 179 284 439 302 320
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Appendix 54: Listing of Alkaline Phosphatase per patient
Centre Patient Treatment Alkaline Phosphatase (U/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
12 247 PM 93 127 236 107 92 217
12 248 PM 170 134 78.4 82.9 115 98
12 249 Combination 143 273 339 575 179 135
12 250 SSG 140 154 204 134 152 201 182
12 251 Combination 340 700 348 340 567 185
12 252 SSG 668 260 309 292 120 113 567
12 253 SSG 271 498 228 281 182 150 183
12 254 Combination 168 224 1147 909 571 185
12 255 Combination 115 254 305 347 825 572
12 256 Combination 125 117 203 200 135 87.5
12 257 SSG 153 332 314 254 264 163 152
12 258 SSG 149 204 242 217 180 726
12 259 PM 126 240 314.94 150 217 209
12 260 PM 135 178 176 182 202
12 261 Combination 92 211 214 207 231 154
12 262 PM 186 167 159 334 198 224
12 263 SSG 182 128 249 190.7 246 448 97
12 264 Combination 130 165 108 133 121 119
12 265 SSG 148 179 93.9 142 74
12 266 PM 153 154 149 295 157 171.2
12 267 SSG 242 115 114 172 112 287 186
12 268 PM 180 372 420 346 215 448
12 269 Combination 173 324 154 158 257 241
12 270 Combination 101 177 140 142 120
12 271 SSG 104 108 218 185 193 71.5 276
12 272 PM 431 224 240 193 203 168
12 273 SSG 580 34.5 367 156 186 132 196
12 274 SSG 149 125 150 129 168 329 286
12 275 Combination 139 81 100 132 262 346
12 276 PM 62 83 109 91 125 346
12 277 Combination 314 249 249 228 109 244
12 278 SSG 203 354 237 170 113 147
12 279 PM 104 130 129 131 189 394
12 280 SSG 78 855 424 273 256 200 197
12 281 Combination 148 182 177 180 127 139
12 282 PM 80.7 62 79 93.7 101 164
12 283 PM 56.5 102 65.1 62.7 73.2 72.3
12 284 Combination 62.8 107 253 104 229
12 285 Combination 239 312 506 186 239 207
12 286 PM 130 92 104 90.6 73.2 68.1
12 287 SSG 140 180 155 159 145 176 181
12 288 Combination 94 185 145 95 139 194
12 289 Combination 140 83.6 82 173 144 64.4
12 290 SSG 80 203 135 146 131 120
12 291 SSG 187 208 222 170 145 113 119
12 292 PM 351 414 363 163 154
12 293 SSG 88.9 88.6 101 156 163 151
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Appendix 54: Listing of Alkaline Phosphatase per patient
Centre Patient Treatment Alkaline Phosphatase (U/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
12 294 Combination 119 129 177 115 168 140
12 295 Combination 204 142 195 154 125
12 296 PM 103 82.9 107 113 131 125
12 297 SSG 66.6 90.2 87.5
12 298 PM 84.9 73.1 78.1 82.5 130 166
12 299 Combination 434 542 539 452 293
12 300 PM 96 147 165 121 135 191
12 301 SSG 126 134 133 122 136 81.7 79
12 302 SSG 216 219 216 174 106 320 310
12 303 PM 210 245 297 110 210 252
12 304 Combination 146 249 239 136 230 305
12 305 PM 176 87.8 93.4 85.4 410 563
12 306 Combination 168 178 182 188 347 400
12 307 Combination 256 84.5 322 250 325 269
12 308 PM 112 126 133 144 171 205
12 309 PM 210 208 195 91.8 121 243
12 310 SSG 195 184 169.3 73.3 96.7 364 84
12 311 SSG 133 73.1 76 139 132 144 302
12 312 Combination 137 244 182 109 210 137
12 313 PM 124 113 158 151 212 250
12 314 SSG 632 94.7 49.6 72.7 76.2 78.4 211
12 315 Combination 39.4 46.2 87 96 226 105
12 316 SSG 150 172 184 185 176
12 317 SSG 73 19 39 49 51.4 310
12 318 Combination 69.4 72 84 99 210 34
12 319 Combination 101 108 116 120 300 116
12 320 Combination 199 207 162 136 194 136
12 321 Combination 52 69 125 82.5 185 86
12 322 PM 129 149 160 142 200 239
12 323 SSG 220 144 310 357 218 109 168
12 324 SSG 136 163 210 252 250 145 105
12 325 PM 281 135 280 140 110 158
12 326 PM 420 390 534 296 182 196
12 327 Combination 130 136 280 302 182 167
12 328 PM 121 160 212 210 120 180
12 329 SSG 153 265 302 250 232 210 296
12 330 PM 565 190 420 122 131 242
23 361 Combination 92.4 228 336 231 495 504
23 362 PM 77 341 370 409 654 738
23 363 PM 108 403 550 551 661 1073
23 364 Combination 208 329 315 376 264 598
23 365 SSG 62 363 372 387 396 569 353
23 366 Combination 221 570 272 162 478 574
23 367 SSG 588 644 360 578 427 379 230
23 368 PM 279 491 725 474 252 156
23 369 Combination 188 213 224 196 528 408
23 370 SSG 367 688 293 403 569 688 550
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Appendix 54: Listing of Alkaline Phosphatase per patient
Centre Patient Treatment Alkaline Phosphatase (U/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
23 371 PM 114 89 96 138 233 149
23 372 PM 283 256 260 153 246 250
23 373 SSG 172 175 404 312 284 124 231
23 374 SSG 324 695 210 276 245 221 239
23 375 Combination 369 541 342 364 612 185
23 376 SSG 252 203 375 372 460 752 434
23 377 Combination 152 643 430
23 378 Combination 189 364 428 401 269 581
23 379 PM 225 348 382 525 193 558
23 380 SSG 185 318 367 470 697 733 650
23 381 PM 328 217 294 373 189 413
23 382 Combination 351 716 1040 747 474 433
23 383 PM 482 420 590 420 182 191
23 384 SSG 390 562 340 421 476 665 777
23 385 SSG 288 399 374 198 592 722 662
23 386 Combination 246 697 554 533 943 796
23 387 Combination 223 266 275 271 1118 888
23 388 PM 315 365 466 486 754 552
23 389 SSG 246 583 454 498 653 764 533
23 390 PM 223 320 235 225 342 256
23 391 Combination 593 576 520 496 572 764
23 392 Combination 808 913 675 671 608
23 393 SSG 261 312 338 568 527 459 564
23 394 PM 200 283 412 479 485 520
23 395 PM 537 385 305 293 231 126
23 396 SSG 471 300 292 367 294 440 395
23 397 SSG 247 585 282 310 403 651 458
23 398 Combination 203 196 249 251 289 113
23 399 PM 355 269 293 372 431 521
23 400 PM 603 270 265 249 429 396
23 401 Combination 218 209 263 267 170 116
23 402 Combination 175 264 215 306 656 738
23 403 SSG 418 277 366 287 666 412 396
23 404 SSG 414 476 487 302 319 362
23 405 PM 393 381 369 369 1156 1053
34 451 Combination 118 410 389 320 378
34 452 PM 231 320 466 365
34 453 PM 289 290 375 412
34 454 Combination 162 337 347 360 456
34 455 PM 187 212 222 226
34 456 SSG 320 402 566 583 676 817
34 457 Combination 146 509 361 295
34 458 PM 173 278 283 403 488
34 459 Combination 204 227 319 346 503 589
34 460 PM 230 456 594 478
34 461 SSG 366 1060 636
34 462 SSG 273 357 448 450 472 357
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Appendix 54: Listing of Alkaline Phosphatase per patient
Centre Patient Treatment Alkaline Phosphatase (U/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
34 463 Combination 497 1220 615 712 547
34 464 SSG 333 338 403 333 278 160
34 465 SSG 271 691 344 344 336 219
34 466 Combination 388 346 408 403
34 467 PM 328 1320 2020 1100 1210
34 468 Combination 300 502 305 247 167
34 469 SSG 246 336 556 379 381 508
34 470 Combination 235 409 522 402 318
34 471 PM 238 357 317 292
34 472 SSG 344 421 451 420 402 362
34 473 PM 286 303 373 342
34 474 Combination 381 357 274 276 351
34 475 PM 217 91.3 210 237
34 476 PM 297 356 392 525 632
34 477 SSG 163 241 253 294 292 282
34 478 Combination 229 240 195 198 243
34 479 SSG 248 321 338 424 523 356
34 480 SSG 435 523 606 622 513 636
34 481 Combination 444 854 556 509 442
34 482 Combination 297 832 455 394 337
34 483 PM 176 196 250 189 179
34 484 PM 382 205
34 485 Combination 311 355 516 450 596
34 486 Combination 229 369 389 376 433
34 487 SSG 180 299 336 468 549 655
34 488 SSG 303 419 389 521 655 514 550
34 489 SSG 349 370 420 386 413 467
34 490 PM 258 564 938 507 474
34 491 PM 588 1170 1230 1270
34 492 PM 209 313 268 338 440
34 493 SSG 145 214 256 332 347
34 494 Combination 277 566 348 306 222
34 495 SSG 247 384 409 491 411 470
34 496 SSG 179 347 234 284 251 217
34 497 PM 146 192 241 209 214
34 498 SSG 301 473 582 704 569 593
34 499 Combination 353 407 458 526 629
34 500 PM 361 467 604 609 588
34 501 Combination 292 478 511 485 671
34 502 Combination 264 334 348 307 451
34 503 PM 293 357 376 379
34 504 Combination 275 365 410 475
34 505 SSG 142 215 212 184 182 225
34 506 SSG 242 287 426 494 637 561
34 507 SSG 192 965 673 650 654 413
34 508 PM 177 205 243 373
34 509 PM 328 496 402 290
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Appendix 54: Listing of Alkaline Phosphatase per patient
Centre Patient Treatment Alkaline Phosphatase (U/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
34 510 Combination 253 367 438 471 551
34 511 Combination 447 628 532 575 608
34 512 PM 253 307 296 379
34 513 Combination 337 447 373 309 583 565
34 514 SSG 447 1020 853 526 591 681
34 515 SSG 184 260 270 153 253 258
34 516 PM 532 478 427 412 466
34 517 PM 375 594 674 461
34 518 SSG 164 286 353 383 344 607
34 519 PM 305 408 576 460 302
34 520 SSG 172 665 369 269 244 197
34 521 PM 223 222 453 524
34 522 Combination 278 330 280 313
34 523 SSG 472 479 325 355 398 545
34 524 Combination 270 288 388 409 625
34 525 Combination 643 751 599 582 479
34 526 SSG 288 379 444 483 620 307
34 527 Combination 332 1400 627 442 179
34 528 PM 275 263 299 255
34 529 Combination 346 575 621 749 619
34 530 Combination 159 240 236 248 164
34 531 SSG 300 759 617 504 494
34 532 Combination 260 321 277 451 775
34 533 SSG 357 430 422 432 515 505
34 534 PM 176 229 241 340
34 535 PM 178 426 419 323 185
34 536 PM 469 359 331 309 351
34 537 SSG 285 930 644 486 355 352
34 538 PM 390 489 486 610
34 539 Combination 498 491 552 548 360
34 540 SSG 340 1930 1420 856 1220 975
35 Not Done
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Appendix 55: Listing of Amylase per patient
Centre Patient Amylase (U/L)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 Not done
12 241 Combination 114 91.5 19.2 29
12 242 SSG 64 95.7 14.8 95.7 30.4 59.43
12 243 PM 14 14 14
12 244 SSG 61.1 76.4 33.9 78.5 40.7 134
12 245 PM 16.2 16.3 36.9 33.5
12 246 PM 50.3 50.9 51.7 50.5 49
12 247 PM 41 14 55 37.4
12 248 PM 26.5 30 42 39.8 29
12 249 Combination 30.4 68.8 61.4 67.2 111 87.1
12 250 SSG 30 20.2 57.3 125 81 85.7
12 251 Combination 37.4 96.3 4.6 22.5 140 121
12 252 SSG 30.6 106 103 137 203 130
12 253 SSG 27.8 15.6 17.6 109 268 291
12 254 Combination 14 71.8 72.4 85 221 227
12 255 Combination 14 28.2 28.8 23.6 114 88.3
12 256 Combination 31 70 14 66 101
12 257 SSG 29.8 109 317 289 20
12 258 SSG 111 305 242 195 160
12 259 PM 71.3 65.7 80.9 79 44
12 260 PM 86.3 103 79.2
12 261 Combination 67.4 237 129 161
12 262 PM 149 196 140 125
12 263 SSG 129 195 143 174 142
12 264 Combination 235 234 128
12 265 SSG 108 100 203 138 1140
12 266 PM 237 94.7 105 86.5 90
12 267 SSG 138 155 151 130 117
12 268 PM 153 166 210 153 218
12 269 Combination 147 29.8 272 292 45
12 270 Combination 67.3 190 123 128 124
12 271 SSG
12 272 PM 78
12 273 SSG 28.9 28
12 274 SSG 30.5 54
12 275 Combination
12 276 PM 77.7
12 277 Combination 41.2 89.4 114
12 278 SSG 141 71.5 157
12 279 PM 79.6 108 64
12 280 SSG 14 31.7 53.3
12 281 Combination 40.9 34.4
12 282 PM 14 14 59.4
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Appendix 55: Listing of Amylase per patient
Centre Patient Amylase (U/L)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
12 283 PM 53.5 210 139
12 284 Combination 62.8
12 285 Combination 131 384
12 286 PM 45 44.2 42.8 55.8
12 287 SSG 291 216 255 221 96
12 288 Combination 49.6 56.1 58 116 65.6 68.3
12 289 Combination 52.1 90 12 61.7 92 114
12 290 SSG 74 104 152 128 143 94
12 291 SSG 76 107 96 82 94 138 88.6
12 292 PM 93 81.5 96 87 144
12 293 SSG 86 151 1.55 148 108 173
12 294 Combination 32.4 101 94 142 86
12 295 Combination 139 170 125 254 105
12 296 PM 101 72.6 94.3 91.3 113 83
12 297 SSG 121 460 638
12 298 PM 62.9 61.9 92.5 87.6 73 57
12 299 Combination 113 116 111
12 300 PM 104 106 153 169 83
12 301 SSG 115 120 303 97 66
12 302 SSG 69.3 71.2 107 86 88
12 303 PM 67.4 105 135 113 117
12 304 Combination 90.8 94.2 105 104
12 305 PM 82.1 83.4 108 119 89
12 306 Combination 67.4 70.3 61 79
12 307 Combination 245 380 141 103
12 308 PM 173 178 80 94
12 309 PM 87.4 94.8 66 72
12 310 SSG 143 159 160 102 81
12 311 SSG 65.7 117 122 108 121 94 70
12 312 Combination 54 542 438 312 98 54
12 313 PM 162 131 160 152 102 107
12 314 SSG 99.8 388 587 615 540 182 112
12 315 Combination 66 107 118 64 89 105
12 316 SSG 108 492 990 255 230 234
12 317 SSG 69 76.9 132 90 112 203
12 318 Combination 77 134 106 80 40 56
12 319 Combination 66 142 115 97 105 76
12 320 Combination 123 212 144 162 110 101
12 321 Combination 74.5 136 113 99 103 99
12 322 PM 89 74 59 94 75 104
12 323 SSG 74 136 140 168 84 73 111
12 324 SSG 119 190 181 210 189 125 203
12 325 PM 110 175 143 103 96 138
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Appendix 55: Listing of Amylase per patient
Centre Patient Amylase (U/L)
Number Number Treatment Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
12 326 PM 93 101 110 194 114 143
12 327 Combination 63 114 179 87 83 169
12 328 PM 45 68 66 75 55 37
12 329 SSG 44 68 57 74 86 74 104
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Appendix 56: Listing of Bilirubin per patient
Centre Patient Treatment Bilirubin (µmol/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 1 PM 5.1 13.7 6.8 10.3 10.3
11 2 Combination 10.3 18.8 13.7 13.7 13.7
11 3 Combination 12.0 20.5 20.5 5.1 10.3
11 4 PM 18.8 15.4 30.8 20.5 17.1
11 5 PM 10.3 5.1 13.7 6.8 5.1
11 6 Combination 22.2 20.5 18.8 10.3 8.6
11 7 PM 17.1 17.1 22.2 8.6 10.3
11 8 SSG 15.4 18.8 13.7 10.3 8.6 12.0
11 9 SSG 10.3 1.7 15.4 6.8 15.4 10.3
11 10 SSG 6.8 1.7 5.1 3.4 8.6 10.3
11 11 Combination 6.8 3.4 10.3 6.8 3.4 5.1
11 12 Combination 17.1 10.3 10.3 8.6 10.3
11 13 SSG 25.7 23.9 29.1 18.8 29.1 12.0 12.0
11 14 SSG 6.8 6.8 6.8 5.1 6.8 8.6 5.1
11 15 PM 15.4 25.7 13.7 20.5
11 16 Combination 5.1 5.1 8.6 10.3 8.6 6.8
11 17 Combination 13.7 12.0 8.6 8.6 10.3 6.8
11 18 SSG 5.1 5.1 8.6 15.4 15.4 8.6 12.0
11 19 Combination 15.4 6.8 17.1 15.4 15.4 10.3
11 20 SSG 20.5 8.6 12.0 15.4 18.8 17.1 12.0
11 21 SSG 10.3 3.4 13.7 13.7 17.1 12.0 15.4
11 22 SSG 3.4 6.8 5.1 6.8 12.0 5.1 5.1
11 23 PM 5.1 5.1 5.1 6.8 10.3 8.6
11 24 PM 6.8 13.7 13.7 12.0 12.0 13.7
11 25 SSG 3.4 6.8 6.8 5.1 8.6 5.1 6.8
11 26 Combination 6.8 6.8 6.8 6.8 3.4 6.8
11 27 PM 12.0 18.8 12.0 12.0 8.6
11 28 Combination 10.3 8.6 15.4 8.6 8.6 8.6
11 29 PM 15.4 18.8 17.1 15.4 15.4 10.3
11 30 PM 8.6 10.3 1.7 5.1 1.7 3.4
11 31 SSG 6.8 3.4 6.8 5.1 5.1 8.6 12.0
11 32 Combination 8.6 3.4 10.3 8.6 10.3 10.3
11 33 SSG 12.0 6.8 6.8 10.3 10.3 10.3 12.0
11 34 PM 20.5 20.5 22.2 22.2 12.0 12.0
11 35 SSG 17.1 12.0 12.0 13.7 13.7 17.1 22.2
11 36 SSG 12.0 8.6 10.3 6.8 10.3 6.8 8.6
11 37 Combination 18.8 10.3 10.3 6.8 12.0 17.1
11 38 PM 5.1 6.8 8.6 8.6 8.6 1.7
11 39 PM 3.4 5.1 5.1 5.1 5.1 5.1
11 40 PM 5.1 8.6 10.3 10.3 10.3
11 41 Combination 5.1 5.1 3.4 5.1 3.4 5.1
11 42 Combination 3.4 6.8 13.7 12.0 12.0 8.6
11 43 SSG 15.4 18.8 17.1 15.4 15.4 10.3 17.1
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Appendix 56: Listing of Bilirubin per patient
Centre Patient Treatment Bilirubin (µmol/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 44 PM 13.7 15.4 13.7 15.4 10.3 10.3
11 45 Combination 10.3 8.6 10.3 10.3 12.0 10.3
11 46 SSG 6.8 8.6 3.4 6.8 3.4 5.1 6.8
11 47 SSG 1.7 8.6 10.3 10.3 10.3
11 48 Combination 10.3 3.4 10.3 12.0 15.4
11 49 SSG 6.8 12.0 5.1 6.8 6.8 3.4 6.8
11 50 PM 8.6 8.6 12.0 13.7 13.7 8.6
11 51 Combination 10.3 6.8 8.6 6.8 6.8 6.8
11 52 PM 5.1 10.3 12.0 6.8 10.3 8.6
11 53 SSG 18.8 13.7 17.1 15.4 18.8 15.4 25.7
11 54 PM 13.7 8.6 8.6 8.6 6.8 8.6
11 55 PM 13.7 17.1 12.0 12.0 27.4 22.2
11 56 SSG 8.6 5.1 6.8 5.1 5.1 6.8 8.6
11 57 Combination 6.8 6.8 8.6 5.1 6.8 13.7
11 58 Combination 8.6 6.8 6.8 10.3 5.1 6.8
11 59 PM 5.1 6.8 6.8 8.6 6.8 6.8
11 60 Combination 15.4 10.3 13.7 6.8 13.7 18.8
11 61 PM 8.6 8.6 5.1 6.8 6.8 12.0
11 62 SSG 12.0 3.4 5.1 8.6 3.4 5.1 6.8
11 63 SSG 6.8 5.1 5.1 5.1 5.1 8.6 12.0
11 64 SSG 12.0 17.1 15.4 15.4 12.0 12.0 6.8
11 65 PM 5.1 6.8 5.1 5.1
11 66 Combination 5.1 6.8 8.6 8.6 15.4 5.1
11 67 PM 6.8 8.6 12.0 8.6 8.6 6.8
11 68 SSG 8.6 5.1 5.1 6.8 8.6 6.8 5.1
11 69 Combination 23.9 15.4 22.2 23.9 18.8 12.0
11 70 Combination 10.3 10.3 25.7 13.7 18.8 27.4
11 71 Combination 6.8 5.1 5.1 6.8 12.0 15.4
11 72 SSG 8.6 3.4 15.4 5.1 10.3
11 73 PM 8.6 8.6 12.0 13.7 6.8 8.6
11 74 PM 8.6 13.7 5.1 10.3 12.0 3.4
11 75 Combination 8.6 12.0 8.6 8.6 12.0 12.0
11 76 PM 8.6 12.0 13.7 15.4 18.8 12.0
11 77 PM 3.4 5.1 5.1 5.1 5.1 3.4
11 78 SSG 10.3 8.6 10.3 12.0 10.3 13.7 15.4
11 79 PM 5.1 6.8 3.4 5.1 6.8 6.8
11 80 PM 6.8 6.8 5.1 6.8 5.1 3.4
11 81 Combination 10.3 8.6 8.6 8.6 8.6 8.6
11 82 SSG 6.8 3.4 6.8 8.6 1.7 5.1 1.7
11 83 SSG 13.7 18.8 12.0 10.3 1.7 8.6 3.4
11 84 SSG 18.8 8.6 5.1 10.3 6.8 5.1 3.4
11 85 SSG 27.4 12.0 12.0 8.6 10.3 15.4
11 86 Combination 3.4 5.1 5.1 6.8 3.4 3.4
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Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 87 Combination 3.4 3.4 5.1 1.7 6.8 3.4
11 88 PM 12.0 12.0 12.0 12.0 10.3 12.0
11 89 Combination 17.1 6.8 8.6 10.3 10.3 13.7
11 90 Combination 15.4 10.3 10.3 10.3
11 91 PM 17.1 8.6 12.0 13.7 22.2 10.3
11 92 Combination 8.6 5.1 8.6 1.7 3.4 5.1
11 93 SSG 13.7 12.0 8.6 8.6 8.6 13.7 15.4
11 94 SSG 5.1 1.7 3.4 3.4 3.4 3.4 6.8
11 95 SSG 5.1 1.7 3.4 6.8 1.7 3.4 5.1
11 96 Combination 6.8 6.8 5.1 5.1 3.4
11 97 Combination 15.4 6.8 5.1 6.8 8.6 5.1
11 98 PM 39.3 25.7 17.1 13.7 8.6 12.0
11 99 SSG 6.8 5.1 12.0 8.6 10.3 10.3 6.8
11 100 PM 8.6 6.8 6.8 5.1
11 101 PM 15.4 20.5 13.7 13.7 17.1 18.8
11 102 Combination 25.7 10.3 8.6 8.6 6.8 6.8
11 103 Combination 15.4 12.0 13.7 10.3 20.5 18.8
11 104 PM 8.6 8.6 5.1 5.1 5.1 5.1
11 105 SSG 12.0 8.6 12.0 13.7 10.3 10.3 8.6
11 106 Combination 17.1 10.3 3.4 15.4 17.1 23.9
11 107 PM 6.8 5.1 3.4 6.8 8.6 6.8
11 108 PM 10.3 8.6 8.6 6.8 8.6 10.3
11 109 SSG 6.8 5.1 8.6 13.7 5.1 5.1 6.8
11 110 PM 17.1 13.7 13.7 13.7 13.7 12.0
11 111 Combination 8.6 12.0 15.4 15.4 25.7 23.9
11 112 Combination 10.3 13.7 6.8 8.6 10.3 15.4
11 113 SSG 10.3 13.7 10.3 8.6 8.6 6.8
11 114 SSG 5.1 6.8 6.8 8.6 10.3 10.3 8.6
11 115 Combination 13.7 8.6 1.7 8.6 8.6 6.8
11 116 SSG 10.3 8.6 6.8 8.6 8.6 8.6 12.0
11 117 PM 6.8 12.0 13.7 15.4 13.7
11 118 PM 12.0 10.3 10.3 13.7 10.3 8.6
11 119 SSG 18.8 13.7 13.7 12.0 10.3 10.3 13.7
11 120 Combination 8.6 6.8 6.8 8.6 8.6 8.6
11 121 Combination 3.4 8.6 5.1 5.1 1.7 17.1
11 122 SSG 15.4 8.6 6.8 6.8 6.8
11 123 SSG 13.7 8.6 12.0 5.1 12.0 8.6 8.6
11 124 SSG 13.7 13.7 10.3 8.6 6.8 13.7
11 125 SSG 10.3 10.3 8.6 10.3 10.3 10.3 10.3
11 126 Combination 6.8 6.8 5.1 8.6 8.6
11 127 PM 8.6 10.3 13.7 12.0 6.8 6.8
11 128 Combination 10.3 6.8 6.8 6.8 3.4 6.8
11 129 PM 10.3 15.4 12.0 10.3 13.7 18.8
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Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 130 Combination 1.7 6.8 10.3 10.3 8.6 12.0
11 131 PM 6.8 5.1 6.8 8.6 6.8 3.4
11 132 SSG 6.8 10.3 10.3 12.0 10.3 6.8 17.1
11 133 Combination 13.7 10.3 10.3 3.4 10.3 5.1
11 134 PM 20.5 20.5 18.8 13.7 15.4 15.4
11 135 PM 10.3 8.6 8.6 12.0 12.0 8.6
12 241 Combination 5.1 5.1 8.6 6.8 17.1
12 242 SSG 3.4 3.4 3.4 5.1 5.1 12.0 13.7
12 243 PM 5.1 3.4 5.1 8.6 5.1 10.4
12 244 SSG 15.4 8.6 10.3 10.3 6.8 13.7 22.2
12 245 PM 13.7 15.4 17.1 10.3 17.1
12 246 PM 8.6 5.1 5.1 10.3 6.8
12 247 PM 5.1 5.1 13.7 14.5 6.8 7.9
12 248 PM 5.1 6.8 17.1 16.2 15.7 17.1
12 249 Combination 13.7 17.3 3.4 8.6 23.9 8.6
12 250 SSG 10.3 12.3 5.1 6.8 5.1 20.0 14.0
12 251 Combination 23.9 18.8 3.4 6.8 18.8 13.0
12 252 SSG 20.5 20.5 6.8 16.1 8.6 8.6 10.3
12 253 SSG 3.4 5.1 5.1 15.7 10.3 12.0 18.1
12 254 Combination 5.1 6.8 5.1 8.6 19.2 17.4
12 255 Combination 22.7 5.1 13.7 16.4 13.7 14.7
12 256 Combination 8.6 6.8 8.6 6.8 17.4 15.4
12 257 SSG 8.9 7.0 10.3 8.6 18.5 17.4 21.6
12 258 SSG 5.1 10.3 6.8 13.3 15.9 9.7
12 259 PM 11.1 19.7 3.4 6.8 13.7 15.9
12 260 PM 14.4 5.1 10.3 10.3 16.2
12 261 Combination 17.4 6.8 6.8 15.4 18.1 12.0
12 262 PM 27.7 10.3 3.4 10.3 14.0 14.0
12 263 SSG 10.3 13.7 10.3 8.6 20.5 13.7 3.4
12 264 Combination 12.0 8.6 14.2 19.0 10.3 13.7
12 265 SSG 10.3 10.3 18.6 15.1 14.0
12 266 PM 13.7 5.1 27.4 15.4 16.8 28.6
12 267 SSG 20.5 12.0 20.0 15.4 17.4 10.3 10.3
12 268 PM 5.1 20.5 6.8 8.6 20.5 19.5
12 269 Combination 6.8 8.9 13.0 6.8 13.7 13.7
12 270 Combination 8.6 10.9 12.0 12.0 13.0
12 271 SSG 13.7 16.8 6.8 14.7 13.3 17.6 13.7
12 272 PM 8.6 3.4 14.0 11.6 13.0 10.3
12 273 SSG 17.8 6.8 22.2 18.1 17.1 13.0 6.8
12 274 SSG 10.3 5.1 10.3 12.0 12.0 9.9 8.6
12 275 Combination 17.4 6.8 8.6 10.1 10.6 15.4
12 276 PM 17.4 13.7 20.5 13.7 12.0 13.7
12 277 Combination 14.7 12.1 20.0 19.8 12.5 12.0
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Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
12 278 SSG 8.2 20.4 25.7 20.5 16.9 27.4
12 279 PM 12.3 8.6 15.7 15.4 15.4 13.7
12 280 SSG 11.5 29.8 24.6 20.5 14.9 15.4 20.7
12 281 Combination 8.6 12.8 24.6 17.4 13.5 12.8
12 282 PM 20.5 16.6 22.9 25.7 20.2
12 283 PM 14.4 39.0 15.1 14.2 9.4 13.7
12 284 Combination 9.7 9.9 8.2 10.6 18.1 17.1
12 285 Combination 18.1 15.7 10.3 13.3 15.6 17.4
12 286 PM 24.3 16.4 21.4 19.5 15.4 13.7
12 287 SSG 16.4 23.9 20.2 15.9 16.8 15.7 13.7
12 288 Combination 12.3 12.0 12.8 15.9 15.9 9.6
12 289 Combination 24.1 19.8 18.6 14.5 15.4 13.9
12 290 SSG 15.4 14.0 17.1 20.0 16.4 10.9
12 291 SSG 18.8 13.7 13.7 17.1 16.8 11.3 9.6
12 292 PM 18.8 23.9 25.7 27.4 17.1
12 293 SSG 20.9 19.2 16.9 15.4 16.6 9.4
12 294 Combination 18.0 17.1 14.7 16.4 11.3 9.9
12 295 Combination 13.7 12.5 10.3 13.5 11.3
12 296 PM 17.6 13.5 16.2 15.4 10.1 12.0
12 297 SSG 19.8 15.7 20.0
12 298 PM 17.1 15.4 14.5 15.4 15.2 10.6
12 299 Combination 13.0 24.1 23.3 17.4 17.4
12 300 PM 9.2 10.8 10.6 11.8 12.3
12 301 SSG 10.1 10.6 12.7 14.4 15.4 14.0 11.8
12 302 SSG 16.8 13.0 13.7 14.7 14.5 12.1 8.6
12 303 PM 14.0 13.3 14.0 12.1 9.9 8.6
12 304 Combination 12.5 13.3 13.7 13.0 12.7 15.4
12 305 PM 9.9 10.3 11.6 12.0 14.0 10.3
12 306 Combination 18.3 17.4 17.4 17.1 15.4 12.0
12 307 Combination 13.0 11.5 13.0 13.3 11.5 10.3
12 308 PM 20.2 15.7 8.2 16.4 13.5 8.6
12 309 PM 17.6 16.9 17.1 15.2 13.7 13.7
12 310 SSG 12.5 13.7 14.7 15.7 8.6 15.4 12.3
12 311 SSG 14.9 8.6 10.6 16.4 16.8 9.6 20.5
12 312 Combination 17.1 12.1 12.3 12.7 12.1 17.1
12 313 PM 8.6 8.9 8.6 13.7 12.3 11.5
12 314 SSG 8.7 16.4 11.6 9.6 9.6 9.2 12.0
12 315 Combination 11.5 10.6 12.8 11.8 12.1 15.7
12 316 SSG 8.6 11.8 16.9 8.6 11.8
12 317 SSG 20.0 16.9 16.4 13.7 13.9 11.5
12 318 Combination 12.3 11.6 9.9 10.6 10.6 22.2
12 319 Combination 15.6 8.7 8.9 9.1 10.3 18.8
12 320 Combination 15.6 16.4 11.5 11.3 12.1 22.2
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12 321 Combination 8.7 9.6 10.4 10.6 14.7 10.6
12 322 PM 16.8 12.3 11.8 12.0 13.9 5.1
12 323 SSG 14.7 12.0 15.4 15.2 18.8 10.3 6.8
12 324 SSG 14.0 14.0 14.4 14.0 13.7 8.7 13.7
12 325 PM 11.3 10.6 12.3 15.4 15.1 13.7
12 326 PM 11.8 12.3 13.7 15.4 13.3 6.8
12 327 Combination 15.1 15.7 8.6 17.1 10.6 12.0
12 328 PM 15.4 14.7 10.1 13.2 10.4 11.3
12 329 SSG 11.6 13.7 12.0 12.3 13.0 11.3 12.7
12 330 PM 12.3 8.6 11.6 10.4 10.6 8.9
23 361 Combination 11.4 11.0 1.0 5.0 11.0 12.0
23 362 PM 12.4 11.0 1.0 17.0 12.0 14.0
23 363 PM 11.4 41.0 0.0 13.0 11.0 14.0
23 364 Combination 10.9 8.0 0.0 9.0 12.0 3.0
23 365 SSG 6.2 7.0 0.0 10.0 8.0 13.0 9.0
23 366 Combination 5.0 1.0 14.0 13.0 9.0 5.0
23 367 SSG 10.0 13.0 10.0 9.0 6.0 11.0 9.0
23 368 PM 8.0 10.0 12.0 9.0 5.0 10.0
23 369 Combination 6.0 6.0 5.0 6.0 6.0 11.0
23 370 SSG 5.0 6.0 5.0 8.0 2.0 7.0 8.0
23 371 PM 2.0 16.0 10.0 19.0 13.0 18.0
23 372 PM 6.0 10.0 8.0 14.0 12.0 18.0
23 373 SSG 9.0 8.0 9.0 13.0 13.0 14.0 30.0
23 374 SSG 11.0 8.0 8.0 1.0 6.0 2.0 9.0
23 375 Combination 8.0 6.0 10.0 2.0 11.0 11.0
23 376 SSG 9.0 7.0 9.0 6.0 8.0 8.0 6.0
23 377 Combination 10.0 6.0 9.0
23 378 Combination 6.0 4.0 7.0 1.0 5.0 5.0
23 379 PM 8.0 1.0 9.0 10.0 5.0 5.0
23 380 SSG 8.0 8.0 2.0 6.0 8.0 4.0 6.0
23 381 PM 3.0 6.0 8.0 10.0 6.0 9.0
23 382 Combination 1.0 13.0 12.0 9.0 8.0 37.0
23 383 PM 8.0 6.0 6.0 6.0 13.0 11.0
23 384 SSG 12.0 10.0 9.0 10.0 9.0 9.0 5.0
23 385 SSG 7.0 7.0 5.0 14.0 7.0 9.0 8.0
23 386 Combination 9.0 11.0 15.0 19.0 29.0 12.0
23 387 Combination 12.0 10.0 10.0 10.0 9.0 9.0
23 388 PM 4.0 8.0 7.0 9.0 6.0 6.0
23 389 SSG 4.0 5.0 6.0 5.0 5.0 6.0 8.0
23 390 PM 11.0 16.0 12.0 12.0 17.0 11.0
23 391 Combination 11.0 12.0 12.0 12.0 4.0 17.0
23 392 Combination 6.0 4.0 4.0 4.0 5.0
23 393 SSG 8.0 8.0 7.0 8.0 8.0 3.0 17.0
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23 394 PM 5.0 6.0 6.0 2.0 2.0 5.0
23 395 PM 9.0 7.0 6.0 7.0 8.0 6.0
23 396 SSG 10.0 8.0 6.0 12.0 13.0 16.0 16.0
23 397 SSG 9.0 8.0 14.0 13.0 13.0 4.0 16.0
23 398 Combination 5.0 7.0 3.0 7.0 6.0 6.0
23 399 PM 8.0 11.0 8.0 8.0 11.0 7.0
23 400 PM 8.0 11.0 16.0 20.0 13.0 13.0
23 401 Combination 16.0 15.0 13.0 10.0 16.0 18.0
23 402 Combination 23.0 7.0 17.0 16.0 30.0 24.0
23 403 SSG 64.0 34.0 26.0 20.0 17.0 21.0 39.0
23 404 SSG 6.0 7.0 8.0 10.0 9.0 8.0
23 405 PM 21.0 19.0 19.0 15.0 39.0 37.0
34 451 Combination 11.0 8.6 8.6 8.6 8.6
34 452 PM 10.0 9.8 8.6 9.5
34 453 PM 8.6 11.8 8.6 9.0
34 454 Combination 10.4 8.6 8.6 10.2 8.6
34 455 PM 8.6 8.6 8.6 8.6
34 456 SSG 8.6 8.6 8.6 8.6 8.6 8.6
34 457 Combination 14.1 8.6 8.6 8.6
34 458 PM 8.6 8.6 8.6 8.6 8.6
34 459 Combination 8.6 8.6 8.6 8.6 8.6 8.6
34 460 PM 13.8 8.9 9.0 8.6
34 461 SSG 8.6 11.9 10.2
34 462 SSG 8.9 8.6 10.2 8.6 8.6 8.6
34 463 Combination 10.5 16.8 8.6 8.6 8.6
34 464 SSG 17.4 11.8 21.4 11.7 9.5 29.4
34 465 SSG 8.6 8.6 8.6 8.6 8.6 8.6
34 466 Combination 8.6 8.6 8.6 8.6
34 467 PM 10.0 9.8 10.5 8.6 20.2
34 468 Combination 8.6 8.6 9.5 8.6 8.6
34 469 SSG 8.6 8.6 8.6 8.6 8.6 9.4
34 470 Combination 8.6 8.6 8.6 8.6 8.6
34 471 PM 8.6 8.7 8.6 8.6
34 472 SSG 8.6 8.6 8.6 8.6 8.6 8.6
34 473 PM 24.5 10.1 8.6 8.6
34 474 Combination 12.5 8.6 8.6 8.6 8.6
34 475 PM 8.6 8.6 8.6 8.6
34 476 PM 16.6 16.9 8.6 10.7 8.7
34 477 SSG 24.3 13.9 18.0 27.4 12.9 28.7
34 478 Combination 17.6 8.6 8.6 8.6 8.6
34 479 SSG 8.6 8.6 8.6 8.6 8.6 8.6
34 480 SSG 9.6 8.6 8.6 9.0 8.6 8.6
34 481 Combination 8.6 15.8 8.6 8.6 8.6
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34 482 Combination 8.6 8.6 8.6 8.6 8.6
34 483 PM 10.4 8.6 8.6 8.6 10.2
34 484 PM 12.9 15.2
34 485 Combination 23.6 27.5 30.8 8.6 40.0
34 486 Combination 8.6 8.6 8.6 8.6 8.6
34 487 SSG 8.6 8.6 8.6 8.6 8.6 8.6
34 488 SSG 8.6 8.6 8.6 8.6 8.6 8.6 8.6
34 489 SSG 8.6 8.6 8.6 8.6 8.6 12.1
34 490 PM 8.6 8.6 8.6 8.7 10.0
34 491 PM 12.3 16.8 11.5 11.9
34 492 PM 11.3 8.6 10.5 14.3
34 493 SSG 10.7 8.6 8.6 8.6 8.6
34 494 Combination 11.9 8.6 8.6 8.6 30.8
34 495 SSG 8.6 8.6 8.6 8.6 8.6 8.6
34 496 SSG 8.6 8.6 8.6 8.6 8.6 8.6
34 497 PM 22.9 8.6 14.2 16.0 14.6
34 498 SSG 8.6 8.6 8.6 8.6 8.6 10.9
34 499 Combination 8.6 8.6 8.6 8.6 8.6
34 500 PM 8.6 8.6 8.6 8.6 8.6
34 501 Combination 8.6 8.6 8.6 8.6 8.6
34 502 Combination 8.6 8.6 8.6 8.6
34 503 PM 8.6 8.6 9.9 9.7
34 504 Combination 8.6 8.6 8.6 8.6
34 505 SSG 10.2 8.6 8.6 8.9 8.6 9.9
34 506 SSG 12.7 8.6 8.6 8.6 8.6
34 507 SSG 8.6 8.6 8.6 8.6 8.6 8.6
34 508 PM 14.9 8.6 8.6 11.4
34 509 PM 19.7 10.4 9.2 8.6
34 510 Combination 11.9 8.6 8.6 8.6 8.6
34 511 Combination 8.6 8.6 8.6 8.6 8.6
34 512 PM 11.4 8.6 8.6
34 513 Combination 8.6 8.6 8.6 8.6 8.6 8.6
34 514 SSG 8.6 8.6 8.6 526.0 8.6 8.6
34 515 SSG 9.5 8.6 8.6 8.6 8.6 8.6
34 516 PM 8.6 8.6 8.6 8.6 8.6
34 517 PM 9.8 8.6 8.6 8.6
34 518 SSG 8.6 8.6 12.9 11.2 9.4 10.6
34 519 PM 8.6 8.6 8.6 8.6 8.6
34 520 SSG 8.6 8.6 8.6 8.6 9.0 8.6
34 521 PM 8.6 8.6 8.6 8.6
34 522 Combination 35.1 21.6 22.6 20.9
34 523 SSG 8.6 8.6 8.6 8.6 8.6 8.6
34 524 Combination 8.6 8.6 8.6 8.6 8.6
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34 525 Combination 8.6 8.6 8.6 8.6
34 526 SSG 8.6 8.6 8.6 8.6 9.9 8.6
34 527 Combination 8.6 8.6 8.6 8.6 8.8
34 528 PM 11.9 9.2 10.9 8.6
34 529 Combination 10.7 8.6 8.6 8.6 8.6
34 530 Combination 16.8 12.5 8.6 8.6 14.6
34 531 SSG 8.6 8.6 8.6 8.6 8.6
34 532 Combination 8.6 8.6 8.6 8.6 8.6
34 533 SSG 8.6 8.6 8.6 8.6 8.6 8.6
34 534 PM 8.6 8.6 10.8 9.4
34 535 PM 8.6 10.2 8.6 8.6 8.9
34 536 PM 8.6 8.6 11.2 9.6 10.8
34 537 SSG 8.6 12.6 8.6 8.6 8.6 13.2
34 538 PM 8.6 8.6 8.6 8.6
34 539 Combination 8.6 8.6 8.6 8.6 15.2
34 540 SSG 9.4 16.0 9.7 8.6 11.6 8.6
35 646 PM 15.4 10.3 6.8 5.1 6.8
35 647 PM 12.0 17.1 13.7 5.1 12.0 5.1
35 648 Combination 15.4 13.7 6.8 10.3 10.3
35 649 Combination 17.1 13.7 13.7 12.0 8.6
35 650 SSG 13.7 12.0 8.6 13.7 10.3 8.6 8.6
35 651 SSG 17.1 17.1 6.8 5.1 6.8 12.0 8.6
35 652 PM 10.3 6.8 6.8 13.7 3.4
35 653 Combination 15.4 15.4 13.7 13.7 12.0 8.6
35 654 SSG 6.8 8.6 12.0 17.1 17.1 6.8 6.8
35 655 Combination 12.0 13.7 12.0 10.3 12.0 8.6
35 656 SSG 13.7 12.0 15.4 17.1 8.6 6.8 8.6
35 657 PM 8.6 12.0 13.7 17.1 13.7 10.3
35 658 Combination 17.1 13.7 17.1 15.4 13.7 10.3
35 659 SSG 13.7 12.0 13.7 15.4 15.4 12.0 10.3
35 660 PM 15.4 12.0 10.3 13.7 10.3 8.6
35 661 Combination 3.4 13.7 10.3 10.3 8.6 10.3
35 662 PM 5.1 6.8 8.6 6.8 8.6 5.1
35 663 SSG 5.1 5.1 8.6 5.1 17.1 10.3 6.8
35 664 Combination 6.8 8.6 6.8
35 665 SSG 15.4 17.1 12.0 12.0 8.6 6.8 8.6
35 666 SSG 10.3 10.3 5.1 6.8 10.3 6.8 10.3
35 667 Combination 8.6 10.3 8.6 3.4 6.8 8.6
35 668 PM 17.1 13.7 10.3 8.6 6.8
35 669 PM 13.7 12.0 8.6 12.0
35 670 SSG 12.0 12.0 8.6 8.6 13.7 8.6 6.8
35 671 PM 12.0 5.1 8.6 10.3 6.8
35 672 Combination 15.4 5.1 13.7 15.4 10.3
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Centre Patient Treatment Bilirubin (µmol/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
35 673 SSG 8.6 8.6 13.7 15.4 12.0 10.3 8.6
35 674 Combination 12.0 8.6 12.0 10.3 12.0 12.0
35 675 PM 8.6 8.6 5.1 10.3 6.8
35 676 PM 12.0 8.6 8.6 10.3 8.6 8.6
35 677 SSG 5.1 13.7
35 678 Combination 6.8 15.4 12.0 13.7 12.0 10.3
35 679 SSG 6.8 10.3 6.8 10.3 6.8 8.6 6.8
35 680 Combination 15.4 10.3 8.6 6.8 8.6 6.8
35 681 Combination 5.1 10.3 6.8 6.8 8.6 10.3
35 682 PM 5.1 10.3 8.6 12.0 3.4
35 683 Combination 5.1 10.3 10.3 8.6 8.6
35 684 SSG 5.1 13.7 10.3 6.8 8.6 8.6 10.3
35 685 PM 6.8 17.1 15.4 6.8 8.6 8.6
35 686 PM 13.7 13.7 12.0 8.6 6.8 8.6
35 687 SSG 12.0 15.4 10.3 13.7 10.3 6.8 8.6
35 688 PM 12.0 6.8 5.1 10.3 8.6 6.8
35 689 Combination 17.1 15.4 12.0 5.1 10.3 8.6
35 690 SSG 12.0 10.3 6.8 10.3 12.0 8.6 8.6
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Centre Patient Treatment Creatinine (µmol/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 1 PM 88.4 97.2 106.1 106.1 106.1 88.4
11 2 Combination 88.4 106.1 88.4 97.2 97.2 97.2
11 3 Combination 88.4 79.6 79.6 79.6 79.6 70.7
11 4 PM 88.4 88.4 79.6 79.6 79.6 70.7
11 5 PM 53.0 70.7 70.7 70.7 61.9 70.7
11 6 Combination 61.9 61.9 70.7 79.6 61.9 70.7
11 7 PM 70.7 88.4 88.4 88.4 70.7 88.4
11 8 SSG 106.1 106.1 88.4 88.4 97.2 97.2 88.4
11 9 SSG 97.2 97.2 97.2 97.2 97.2 79.6 88.4
11 10 SSG 61.9 79.6 88.4 79.6 88.4 79.6 70.7
11 11 Combination 70.7 79.6 70.7 70.7 61.9 61.9
11 12 Combination 88.4 97.2 114.9 88.4 97.2 97.2
11 13 SSG 97.2 79.6 79.6 88.4 79.6 70.7 79.6
11 14 SSG 70.7 61.9 70.7 61.9 70.7 70.7 70.7
11 15 PM 106.1 106.1 88.4 88.4
11 16 Combination 88.4 79.6 88.4 88.4 88.4 79.6
11 17 Combination 106.1 88.4 79.6 106.1 88.4 88.4
11 18 SSG 97.2 97.2 79.6 97.2 88.4 97.2 88.4
11 19 Combination 97.2 97.2 88.4 114.9 97.2 106.1
11 20 SSG 88.4 70.7 61.9 70.7 70.7 70.7 79.6
11 21 SSG 88.4 88.4 88.4 88.4 106.1 79.6 79.6
11 22 SSG 70.7 70.7 70.7 70.7 61.9 61.9 79.6
11 23 PM 79.6 70.7 70.7 70.7 70.7 88.4
11 24 PM 61.9 70.7 70.7 53.0 70.7 70.7
11 25 SSG 70.7 70.7 61.9 79.6 61.9 61.9 88.4
11 26 Combination 79.6 79.6 79.6 79.6 61.9 79.6
11 27 PM 97.2 88.4 88.4 79.6 79.6
11 28 Combination 70.7 79.6 79.6 70.7 70.7 79.6
11 29 PM 88.4 97.2 88.4 88.4 97.2 97.2
11 30 PM 70.7 70.7 61.9 61.9 61.9 70.7
11 31 SSG 97.2 79.6 79.6 70.7 79.6 79.6 114.9
11 32 Combination 79.6 79.6 88.4 79.6 79.6 88.4
11 33 SSG 88.4 88.4 88.4 114.9 70.7 88.4 97.2
11 34 PM 97.2 97.2 97.2 97.2 97.2 106.1
11 35 SSG 70.7 70.7 70.7 61.9 61.9 79.6 79.6
11 36 SSG 88.4 79.6 79.6 79.6 79.6 79.6 97.2
11 37 Combination 106.1 114.9 106.1 88.4 106.1 114.9
11 38 PM 79.6 70.7 79.6 88.4 106.1 141.4
11 39 PM 70.7 70.7 61.9 70.7 88.4 70.7
11 40 PM 79.6 79.6 70.7 70.7 79.6
11 41 Combination 61.9 61.9 61.9 61.9 61.9 70.7
11 42 Combination 88.4 79.6 88.4 79.6 79.6 88.4
11 43 SSG 70.7 70.7 70.7 88.4 79.6 79.6 97.2
11 44 PM 70.7 79.6 70.7 88.4 88.4 88.4
11 45 Combination 79.6 88.4 70.7 79.6 79.6 88.4
11 46 SSG 79.6 79.6 79.6 79.6 70.7 72.5 76.0
11 47 SSG 106.1 106.1 79.6 97.2 88.4
11 48 Combination 79.6 79.6 97.2 88.4 86.6
11 49 SSG 88.4 79.6 88.4 79.6 70.7 70.7 70.7
11 50 PM 132.6 114.9 106.1 97.2 94.6 66.3
11 51 Combination 88.4 79.6 70.7 79.6 89.3 84.9
11 52 PM 97.2 79.6 79.6 79.6 88.4 79.6
11 53 SSG 132.6 106.1 97.2 97.2 123.8 97.2 97.2
11 54 PM 106.1 106.1 114.9 97.2 106.1 106.1
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Centre Patient Treatment Creatinine (µmol/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 55 PM 88.4 88.4 88.4 97.2 97.2 88.4
11 56 SSG 97.2 97.2 88.4 88.4 88.4 106.1 88.4
11 57 Combination 97.2 106.1 97.2 106.1 103.4 89.7
11 58 Combination 79.6 79.6 79.6 79.6 79.6 78.7
11 59 PM 97.2 88.4 88.4 106.1 85.7 69.0
11 60 Combination 53.0 106.1 97.2 106.1 106.1 88.4
11 61 PM 44.2 132.6 132.6 132.6 114.9 106.1
11 62 SSG 70.7 70.7 88.4 79.6 70.7 61.9 64.5
11 63 SSG 114.9 114.9 123.8 123.8 114.9 106.1 97.2
11 64 SSG 123.8 97.2 106.1 106.1 106.1 114.9 97.2
11 65 PM 88.4 88.4 88.4 79.6
11 66 Combination 97.2 106.1 106.1 106.1 79.6 65.4
11 67 PM 114.9 88.4 88.4 79.6 79.6 83.1
11 68 SSG 97.2 70.7 70.7 79.6 76.0 70.7 78.7
11 69 Combination 97.2 88.4 79.6 79.6 79.6 85.7
11 70 Combination 123.8 106.1 97.2 97.2 94.6 85.7
11 71 Combination 106.1 97.2 97.2 92.8 97.2 127.3
11 72 SSG 106.1 123.8 106.1 97.2 96.4
11 73 PM 106.1 79.6 101.7 106.1 85.7 79.6
11 74 PM 123.8 123.8 114.9 106.1 97.2 87.5
11 75 Combination 114.9 97.2 106.1 97.2 106.1 155.6
11 76 PM 97.2 93.7 88.4 88.4 70.7 89.3
11 77 PM 106.1 95.5 97.2 85.7 70.7 80.4
11 78 SSG 114.9 96.4 106.1 97.2 97.2 88.4 88.4
11 79 PM 88.4 91.1 88.4 94.6 70.7 70.7
11 80 PM 88.4 94.6 79.6 87.5 79.6 72.5
11 81 Combination 114.9 114.9 114.9 114.9 141.4 98.1
11 82 SSG 88.4 78.7 88.4 80.4 89.3 70.7 66.3
11 83 SSG 88.4 88.4 84.9 75.1 97.2 97.2 84.9
11 84 SSG 106.1 84.9 88.4 87.5 70.7 79.6 72.5
11 85 SSG 114.9 114.9 108.7 97.2 97.2 97.2
11 86 Combination 88.4 88.4 77.8 70.7 79.6 75.1
11 87 Combination 123.8 96.4 112.3 91.1 88.4 87.5
11 88 PM 106.1 112.3 102.5 85.7 88.4 91.1
11 89 Combination 106.1 106.1 106.1 114.9 97.2 93.7
11 90 Combination 79.6 79.6 79.6 79.6
11 91 PM 106.1 97.2 106.1 102.5 102.5 137.9
11 92 Combination 84.9 61.9 70.7 69.0 61.9 73.4
11 93 SSG 88.4 78.7 83.1 87.5 91.9 86.6 95.5
11 94 SSG 61.9 70.7 53.9 64.5 70.7 64.5 60.1
11 95 SSG 70.7 44.2 61.9 63.6 61.9 64.5 65.4
11 96 Combination 61.9 83.1 67.2 71.6 72.5 70.7
11 97 Combination 70.7 93.7 84.0 82.2 86.6 77.8
11 98 PM 63.6 81.3 81.3 87.5 81.3 79.6
11 99 SSG 79.6 97.2 93.7 94.6 90.2 77.8 82.2
11 100 PM 88.4 103.4 105.2 109.6
11 101 PM 97.2 78.7 94.6 91.1 91.9 96.4
11 102 Combination 88.4 73.4 89.3 71.6 91.9 79.6
11 103 Combination 104.3 90.2 79.6 91.9 93.7 79.6
11 104 PM 68.1 88.4 82.2 83.1 70.7 71.6
11 105 SSG 83.1 79.6 85.7 67.2 77.8 85.7 70.7
11 106 Combination 116.7 107.0 61.9 89.3 88.4 98.1
11 107 PM 87.5 87.5 61.9 96.4 89.3 95.5
11 108 PM 97.2 86.6 86.6 92.8 95.5 87.5
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Centre Patient Treatment Creatinine (µmol/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 109 SSG 88.4 80.4 75.1 83.1 90.2 77.8 88.4
11 110 PM 67.2 63.6 65.4 64.5 73.4 57.5
11 111 Combination 87.5 79.6 89.3 75.1 80.4 83.1
11 112 Combination 100.8 106.1 99.9 110.5 96.4 79.6
11 113 SSG 99.9 84.9 88.4 87.5 90.2 78.7
11 114 SSG 70.7 79.6 87.5 70.7 79.6 90.2 80.4
11 115 Combination 79.6 82.2 74.3 76.9 77.8 72.5
11 116 SSG 88.4 104.3 107.0 102.5 116.7 94.6 94.6
11 117 PM 93.7 86.6 88.4 84.0 82.2
11 118 PM 88.4 109.6 88.4 88.4 85.7 72.5
11 119 SSG 91.9 77.8 82.2 81.3 91.1 89.3 79.6
11 120 Combination 99.0 87.5 86.6 84.9 92.8 88.4
11 121 Combination 70.7 61.9 71.6 68.1 71.6 70.7
11 122 SSG 97.2 79.6 93.7 84.9 92.8
11 123 SSG 103.4 89.3 87.5 88.4 107.0 85.7 79.6
11 124 SSG 107.0 92.8 91.9 88.4 94.6 83.1
11 125 SSG 88.4 93.7 97.2 99.9 81.3 76.0 79.6
11 126 Combination 112.3 118.5 114.9 108.7 95.5
11 127 PM 99.0 96.4 101.7 95.5 69.0 61.9
11 128 Combination 132.6 97.2 147.6 173.3 70.7 95.5
11 129 PM 106.1 114.9 101.7 98.1 98.1 88.4
11 130 Combination 79.6 84.9 83.1 84.9 76.9 76.0
11 131 PM 68.1 84.9 49.5 70.7 73.4 69.0
11 132 SSG 110.5 97.2 105.2 101.7 87.5 81.3 83.1
11 133 Combination 112.3 92.8 90.2 61.9 89.3 76.0
11 134 PM 88.4 91.1 82.2 91.1 88.4 93.7
11 135 PM 88.4 123.8 106.1 105.2 107.9 98.1
12 241 Combination 75.8 70.0 61.6 72.0 70.7
12 242 SSG 81.8 47.0 34.2 34.3 63.0 43.6 54.8
12 243 PM 78.9 69.7 47.9 51.5 55.9 44.0
12 244 SSG 51.3 51.2 58.6 38.6 76.0 56.2 60.7
12 245 PM 65.0 62.0 96.3 69.6 110.2
12 246 PM 6.7 96.0 105.0 101.0 88.0
12 247 PM 38.5 62.0 68.6 58.4 55.7 36.2
12 248 PM 58.4 95.0 69.0 72.3 70.7 41.5
12 249 Combination 86.1 56.0 87.3 90.7 52.2 47.7
12 250 SSG 75.3 50.5 61.1 44.0 84.0 46.9 52.8
12 251 Combination 72.2 80.0 72.9 47.9 61.0 59.2
12 252 SSG 56.9 62.6 91.0 50.1 51.6 78.3 52.8
12 253 SSG 47.7 41.5 46.2 63.1 44.2 87.1 44.0
12 254 Combination 46.4 47.4 40.8 58.4 56.6 44.2
12 255 Combination 55.4 65.5 44.0 58.5 81.3 53.0
12 256 Combination 48.5 73.0 49.6 89.0 50.4 44.2
12 257 SSG 46.8 85.0 62.0 60.1 74.3 53.9 50.2
12 258 SSG 49.0 40.7 44.2 44.0 44.2 44.0
12 259 PM 73.4 70.7 61.2 69.8 53.0 74.8
12 260 PM 61.2 88.4 106.1 44.2 44.9
12 261 Combination 68.7 114.9 90.2 50.4 141.4 50.4
12 262 PM 51.6 97.2 84.0 41.5 44.0 50.2
12 263 SSG 61.9 53.0 60.1 44.2 52.2 52.2 60.0
12 264 Combination 70.7 43.3 60.1 53.0 45.7 58.0
12 265 SSG 76.9 60.1 37.1 64.5 341.0
12 266 PM 46.0 69.0 60.1 105.2 53.0 67.0
12 267 SSG 60.1 61.9 58.3 82.2 77.8 65.1 69.0
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Centre Patient Treatment Creatinine (µmol/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
12 268 PM 106.1 71.6 72.5 55.7 64.4 79.3
12 269 Combination 90.2 76.0 78.7 79.6 57.0 63.0
12 270 Combination 81.3 61.0 171.5 44.2 63.2
12 271 SSG 64.5 61.9 56.6 67.2 89.3 48.4 64.0
12 272 PM 44.2 42.4 44.2 137.0 44.2 56.0
12 273 SSG 44.2 87.5 46.0 44.2 53.0 44.2 54.0
12 274 SSG 74.3 38.9 40.7 44.2 49.3 44.2 52.0
12 275 Combination 83.1 56.6 44.2 85.7 53.7 62.0
12 276 PM 46.9 21.2 44.2 66.3 44.2 64.0
12 277 Combination 90.2 68.1 51.3 61.0 51.9 60.0
12 278 SSG 104.3 90.2 65.4 76.0 76.9 62.0
12 279 PM 82.2 61.0 57.5 55.7 88.0 62.0
12 280 SSG 38.9 44.2 44.2 44.2 44.2 52.0
12 281 Combination 99.9 57.5 44.2 58.3 44.2
12 282 PM 44.2 49.5 46.0 44.2 58.0
12 283 PM 70.7 77.8 70.7 67.2 72.0 78.3
12 284 Combination 44.2 44.2 104.0 44.2 97.1
12 285 Combination 65.4 61.0 61.9 51.3 83.6
12 286 PM 66.3 47.7 52.0 50.0 85.0 57.0
12 287 SSG 63.5 45.8 52.0 53.4 59.4 63.4 58.2
12 288 Combination 42.0 44.2 45.0 58.8 44.2 44.2
12 289 Combination 62.0 55.7 60.0 48.0 52.0 62.6
12 290 SSG 52.5 51.5 46.2 52.0 61.2 50.2
12 291 SSG 74.3 68.0 55.0 72.0 76.0 51.2 50.0
12 292 PM 103.0 96.0 92.1 61.2 68.0
12 293 SSG 52.7 51.7 54.1 44.2 56.0 44.2
12 294 Combination 50.0 44.2 50.0 88.4 49.0 46.2
12 295 Combination 44.2 45.1 53.0 48.2 40.4
12 296 PM 52.3 47.3 51.8 49.4 56.0 81.6
12 297 SSG 70.3 76.4 81.9
12 298 PM 56.3 61.2 54.5 56.3 54.0 76.2
12 299 Combination 58.8 62.4 64.9 63.4 101.0
12 300 PM 63.5 64.2 66.3 74.2 54.6 74.2
12 301 SSG 74.2 67.3 69.4 51.3 56.2 66.0 61.2
12 302 SSG 50.2 56.3 53.4 61.3 66.6 56.9 93.0
12 303 PM 63.4 72.3 81.4 69.4 54.2 91.4
12 304 Combination 77.6 79.4 80.4 77.4 59.2 74.2
12 305 PM 63.1 66.4 69.3 67.3 47.1 79.4
12 306 Combination 44.2 63.4 69.8 70.4 53.0 68.0
12 307 Combination 64.3 104.3 94.6 83.4 72.1 135.0
12 308 PM 80.9 76.4 64.3 66.1 71.4 118.0
12 309 PM 95.0 87.4 74.3 76.6 60.4 74.0
12 310 SSG 67.4 70.3 64.6 74.2 59.4 75.7 69.2
12 311 SSG 44.2 54.0 61.0 44.2 46.1 44.0 62.0
12 312 Combination 68.0 54.8 44.8 45.2 74.2 68.0
12 313 PM 61.2 85.8 92.8 104.0 92.3 74.2
12 314 SSG 71.0 69.8 80.0 70.2 68.4 66.4 70.4
12 315 Combination 44.2 48.4 34.9 60.4 61.0 88.4
12 316 SSG 44.2 52.4 56.9 114.5 44.2
12 317 SSG 58.0 54.2 62.4 66.2 64.1 53.9
12 318 Combination 46.4 51.2 52.4 54.3 64.1 78.0
12 319 Combination 46.2 50.3 52.1 60.4 48.0 79.3
12 320 Combination 44.2 48.4 52.0 64.0 81.2 77.0
12 321 Combination 46.0 50.4 51.2 56.4 69.1 56.4
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12 322 PM 54.2 61.8 63.4 61.8 53.4 53.0
12 323 SSG 57.8 54.2 60.9 42.9 94.9 41.0 44.2
12 324 SSG 61.4 53.4 59.4 89.2 95.0 46.0 61.9
12 325 PM 61.7 66.9 54.2 50.4 49.1 70.7
12 326 PM 60.1 62.2 52.9 115.0 92.0 70.7
12 327 Combination 62.4 64.1 41.8 63.2 52.0 44.2
12 328 PM 54.1 88.4 56.3 74.6 61.2 53.9
12 329 SSG 81.3 71.7 72.4 37.1 81.1 72.1 60.1
12 330 PM 80.0 58.5 83.0 61.4 54.2 46.0
23 361 Combination 85.0 92.0 128.0 85.0 67.0 61.0
23 362 PM 95.0 128.0 80.0 120.0 72.0 71.0
23 363 PM 96.0 86.0 92.0 102.0 61.0 55.0
23 364 Combination 94.0 92.0 81.0 80.0 81.0 58.0
23 365 SSG 101.0 123.0 170.0 166.0 138.0 114.0 91.0
23 366 Combination 105.0 86.0 86.0 101.0 87.0 58.0
23 367 SSG 112.0 102.0 123.0 117.0 104.0 97.0 83.0
23 368 PM 114.0 106.0 88.0 142.0 102.0 95.0
23 369 Combination 102.0 93.0 92.0 109.0 90.0 80.0
23 370 SSG 156.0 102.0 125.0 88.0 88.0 88.0 68.0
23 371 PM 115.0 108.0 114.0 115.0 122.0 100.0
23 372 PM 130.0 130.0 141.0 127.0 100.0 95.0
23 373 SSG 113.0 110.0 93.0 100.0 68.0 89.0 83.0
23 374 SSG 91.0 123.0 115.0 97.0 98.0 86.0 69.0
23 375 Combination 77.0 105.0 93.0 119.0 77.0 83.0
23 376 SSG 112.0 104.0 101.0 136.0 96.0 88.0 65.0
23 377 Combination 108.0 107.0 66.0
23 378 Combination 133.0 69.0 87.0 81.0 78.0 60.0
23 379 PM 117.0 70.0 88.0 79.0 104.0 71.0
23 380 SSG 87.0 102.0 72.0 68.0 80.0 73.0 51.0
23 381 PM 83.0 86.0 92.0 83.0 89.0 73.0
23 382 Combination 96.0 92.0 98.0 84.0 94.0 96.0
23 383 PM 85.0 96.0 92.0 96.0 93.0 105.0
23 384 SSG 84.0 105.0 77.0 90.0 76.0 65.0 69.0
23 385 SSG 103.0 94.0 95.0 92.0 57.0 61.0 84.0
23 386 Combination 91.0 71.0 78.0 81.0 58.0 75.0
23 387 Combination 90.0 95.0 81.0 77.0 70.0 65.0
23 388 PM 82.0 71.0 61.0 58.0 65.0 99.0
23 389 SSG 85.0 85.0 72.0 68.0 95.0 75.0 2.9
23 390 PM 95.0 83.0 73.0 83.0 61.0 64.0
23 391 Combination 97.0 84.0 82.0 101.0 56.0 66.0
23 392 Combination 66.0 67.0 71.0 73.0 60.0
23 393 SSG 75.0 72.0 71.0 77.0 100.0 64.0 73.0
23 394 PM 86.0 79.0 74.0 68.0 60.0 66.0
23 395 PM 95.0 81.0 86.0 107.0 109.0 96.0
23 396 SSG 89.0 72.0 94.0 117.0 119.0 71.0 86.0
23 397 SSG 70.0 85.0 98.0 96.0 97.0 71.0 81.0
23 398 Combination 78.0 82.0 89.0 90.0 80.0 88.0
23 399 PM 68.0 79.0 83.0 84.0 70.0 75.0
23 400 PM 68.0 71.0 64.0 62.0 68.0 67.0
23 401 Combination 114.0 103.0 106.0 100.0 113.0 83.0
23 402 Combination 110.0 96.0 94.0 100.0 75.0 72.0
23 403 SSG 113.0 99.0 116.0 87.0 93.0 72.0 84.0
23 404 SSG 123.0 121.0 115.0 98.0 112.0 113.0
23 405 PM 94.0 90.0 92.0 111.0 66.0 82.0
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34 451 Combination 44.2 44.2 44.2 44.2 44.2
34 452 PM 44.2 44.2 44.2 44.2
34 453 PM 44.2 44.2 44.2 44.2
34 454 Combination 44.2 44.2 44.2 44.2 44.2
34 455 PM 44.2 44.2 44.2 44.2
34 456 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 457 Combination 73.7 46.9 44.2 44.2
34 458 PM 44.2 44.2 44.2 44.2 44.2
34 459 Combination 46.9 44.2 44.2 44.2 44.2 44.2
34 460 PM 44.2 44.2 44.2 44.2
34 461 SSG 74.3 82.5 82.6
34 462 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 463 Combination 44.2 44.2 44.2 44.2 44.2
34 464 SSG 56.6 65.9 54.0 46.3 50.3 78.5
34 465 SSG 57.2 44.3 44.2 44.2 44.2 52.2
34 466 Combination 44.2 44.2 44.2 44.2
34 467 PM 45.5 44.2 44.2 44.2 51.2
34 468 Combination 44.6 44.2 44.2 44.2 44.2
34 469 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 470 Combination 44.2 44.2 44.2 44.2 44.2
34 471 PM 46.7 44.2 45.8 44.2
34 472 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 473 PM 44.2 44.2 44.2 44.2
34 474 Combination 44.2 44.2 44.2 44.2 44.2
34 475 PM 44.2 44.2 44.2 44.2
34 476 PM 44.2 44.2 44.2 44.2 44.2
34 477 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 478 Combination 44.2 44.2 44.2 44.2 44.2
34 479 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 480 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 481 Combination 44.2 44.2 44.2 44.2 44.2
34 482 Combination 71.9 65.6 49.3 48.5 45.5
34 483 PM 53.7 48.7 50.3 44.2 44.2
34 484 PM 44.2 44.2
34 485 Combination 44.2 44.2 44.2 44.2 44.2
34 486 Combination 44.2 44.2 44.2 44.2 44.2
34 487 SSG 69.7 44.2 44.2 44.2 44.2 44.2
34 488 SSG 44.2 44.2 44.2 44.2 44.2 44.2 44.2
34 489 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 490 PM 44.2 44.2 44.2 44.2 44.2
34 491 PM 109.6 85.1 86.9 81.8
34 492 PM 69.8 78.7 76.6 72.0 85.6
34 493 SSG 44.2 44.2 44.2 44.2 44.2
34 494 Combination 70.9 49.7 47.4 48.7 73.8
34 495 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 496 SSG 78.9 53.0 49.8 44.2 53.6 57.4
34 497 PM 63.9 50.5 50.2 52.6 64.4
34 498 SSG 45.7 44.2 44.2 44.2 44.2 44.2
34 499 Combination 44.3 44.2 44.2 44.2 44.2
34 500 PM 44.2 44.2 44.2 44.2 44.2
34 501 Combination 47.1 44.2 44.2 44.2 44.2
34 502 Combination 44.2 44.2 44.2 44.2 44.2
34 503 PM 44.2 45.3 44.2 44.2
34 504 Combination 44.2 44.2 44.2 44.2
LEAP 0104a Appendices
Page 734 of 756
Appendix 57: Listing of Creatinine and BUN per patient
Centre Patient Treatment Creatinine (µmol/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
34 505 SSG 67.4 49.0 45.2 44.2 44.2 65.9
34 506 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 507 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 508 PM 44.2 44.2 44.2 44.2
34 509 PM 64.1 44.4 44.2 44.2
34 510 Combination 44.2 44.2 44.2 44.2 44.2
34 511 Combination 44.2 44.2 44.2 44.2 44.2
34 512 PM 44.2 44.2 44.2 44.2
34 513 Combination 44.2 44.2 44.2 44.2 44.2 44.2
34 514 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 515 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 516 PM 44.2 44.2 44.2 44.2 44.2
34 517 PM 53.4 44.2 44.2 44.2
34 518 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 519 PM 44.2 44.2 44.2 44.2 44.2
34 520 SSG 97.2 71.4 44.6 47.6 44.2 79.9
34 521 PM 44.2 44.2 44.2 44.2
34 522 Combination 61.9 56.9 62.6 56.0
34 523 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 524 Combination 44.2 44.2 44.2 44.2 44.2
34 525 Combination 44.2 44.2 44.2 44.2 44.2
34 526 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 527 Combination 57.2 44.2 44.2 44.2 44.2
34 528 PM 44.2 44.2 44.2 44.2
34 529 Combination 44.2 44.2 44.2 44.2 44.2
34 530 Combination 84.2 51.4 46.4 44.2 44.2
34 531 SSG 44.2 44.2 44.2 44.2 44.2
34 532 Combination 44.2 44.2 44.2 44.2 44.2
34 533 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 534 PM 44.2 44.2 44.2 45.3
34 535 PM 44.2 44.2 44.2 44.2 44.2
34 536 PM 44.2 44.2 44.2 44.2 44.2
34 537 SSG 44.2 44.2 44.2 44.2 44.2 44.2
34 538 PM 44.2 44.2 44.2 44.2
34 539 Combination 44.2 44.2 44.2 44.2 44.2
34 540 SSG 45.2 44.2 44.2 44.2 44.2 44.2
35 646 PM 132.6 88.4 88.4 61.9 53.0
35 647 PM 114.9 132.6 88.4 88.4 70.7 44.2
35 648 Combination 114.9 88.4 70.7 44.2 44.2
35 649 Combination 132.6 88.4 88.4 88.4 61.9
35 650 SSG 70.7 132.6 88.4 88.4 70.7 53.0 44.2
35 651 SSG 114.9 44.2 44.2 44.2 70.7 44.2 35.4
35 652 PM 114.9 88.4 70.7 70.7 35.4
35 653 Combination 114.9 88.4 70.7 61.9 53.0 44.2
35 654 SSG 88.4 88.4 70.7 88.4 106.1 70.7 53.0
35 655 Combination 88.4 44.2 44.2 61.9 44.2 35.4
35 656 SSG 114.9 44.2 61.9 44.2 61.9 61.9 53.0
35 657 PM 88.4 61.9 70.7 70.7 88.4 44.2
35 658 Combination 106.1 70.7 70.7 61.9 44.2 44.2
35 659 SSG 88.4 70.7 70.7 44.2 70.7 53.0 44.2
35 660 PM 88.4 70.7 88.4 70.7 53.0 44.2
35 661 Combination 70.7 70.7 88.4 88.4 70.7 53.0
35 662 PM 88.4 88.4 79.6 97.2 70.7 35.4
35 663 SSG 106.1 88.4 88.4 123.8 106.1 79.6 88.4
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35 664 Combination 88.4 309.4 61.9
35 665 SSG 106.1 70.7 106.1 44.2 44.2 61.9 53.0
35 666 SSG 88.4 70.7 26.5 61.9 88.4 79.6 53.0
35 667 Combination 70.7 70.7 88.4 106.1 70.7 61.9
35 668 PM 106.1 106.1 88.4 88.4 53.0
35 669 PM 61.9 53.0 53.0 88.4
35 670 SSG 61.9 53.0 53.0 44.2 88.4 70.7 53.0
35 671 PM 70.7 70.7 88.4 88.4 53.0
35 672 Combination 106.1 35.4 44.2 53.0 61.9
35 673 SSG 70.7 70.7 53.0 88.4 79.6 70.7 53.0
35 674 Combination 53.0 88.4 70.7 79.6 44.2 53.0
35 675 PM 88.4 70.7 88.4 70.7 44.2
35 676 PM 88.4 53.0 79.6 70.7 61.9 44.2
35 677 SSG 88.4 291.7
35 678 Combination 70.7 88.4 70.7 70.7 53.0 53.0
35 679 SSG 70.7 53.0 79.6 70.7 88.4 79.6 61.9
35 680 Combination 70.7 88.4 79.6 70.7 53.0 44.2
35 681 Combination 35.4 53.0 61.9 70.7 53.0 44.2
35 682 PM 26.5 53.0 70.7 70.7 35.4
35 683 Combination 26.5 53.0 61.9 70.7 53.0
35 684 SSG 70.7 53.0 70.7 88.4 88.4 53.0 35.4
35 685 PM 70.7 53.0 61.9 88.4 70.7 53.0
35 686 PM 70.7 53.0 70.7 88.4 70.7 53.0
35 687 SSG 35.4 88.4 70.7 61.9 53.0 44.2 53.0
35 688 PM 61.9 70.7 106.1 88.4 61.9 53.0
35 689 Combination 61.9 70.7 53.0 61.9 44.2 44.2
35 690 SSG 61.9 70.7 88.4 88.4 88.4 70.7 61.9
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Blood Urea Nitrogen (mmol/L)
Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
12.05 6.13 5.48 5.88 6.21
8.76 4.71 4.24 4.31 3.25
9.49 5.29 5.29 4.34 2.99
4.64 4.78 4.75 5.48 4.16
4.89 3.58 4.42 4.60 4.24
4.31 4.49 4.27 4.56 4.89
5.40 7.12 6.43 6.32 1.86
5.11 5.59 5.33 5.22 5.55 4.34
5.18 5.40 5.70 5.11 5.22 4.64
4.02 5.00 4.24 4.60 4.64 3.87
4.09 4.02 3.98 3.72 3.61 4.86
5.51 6.32 5.40 6.10 5.37
4.86 4.89 4.49 3.87 4.16 3.98 4.02
4.42 4.31 4.42 4.34 4.78 3.43 3.80
5.07 4.71 4.53 4.24
4.93 4.71 4.64 4.27 5.18 4.24
5.51 5.04 5.33 5.95 5.99 4.05
5.29 5.22 5.62 5.51 4.49 2.96 3.36
4.82 5.84 6.43 5.95 2.63 4.05
4.78 4.93 5.22 4.20 4.16 3.14 3.76
4.60 5.07 5.29 4.75 5.73 2.81 3.54
4.20 4.27 5.11 4.24 4.08 2.34 3.94
4.42 4.75 5.15 4.16 3.94 5.77
4.75 5.00 5.40 4.07 2.45 4.02
3.43 3.58 3.87 2.99 3.75 2.77 3.07
5.18 5.00 4.53 4.67 4.78 4.49
5.32 4.34 4.09 5.29 2.56
5.79 4.60 5.18 4.24 5.48 5.11
4.97 5.91 5.66 5.59 5.70 2.70
4.86 5.11 4.24 5.15 1.72 3.14
5.18 5.04 4.75 5.26 4.27 4.42 3.69
6.94 4.02 5.07 4.97 5.33 3.98
4.64 3.43 4.16 5.18 5.00 2.74 3.98
5.51 5.33 5.29 5.26 3.10 4.16
3.54 3.83 4.13 4.75 3.98 5.15 3.43
6.21 4.16 3.72 4.02 5.15 4.53 5.77
4.93 7.12 5.07 5.48 1.68 3.25
5.66 4.78 5.81 6.13 4.67 6.48
5.95 4.97 5.29 4.05 6.54 4.71
5.26 4.34 4.53 3.91 3.72
5.40 4.27 0.26 3.10 5.04 5.15
5.40 4.31 0.37 3.36 3.94 4.27
4.82 3.80 3.50 3.03 1.52 3.94 4.24
6.39 5.18 5.22 2.15 6.75 6.39
5.33 4.16 3.87 4.49 4.49 5.81
4.89 3.14 3.72 4.71 4.64 4.16 6.28
4.42 3.40 3.40 5.22 4.60
4.67 4.53 12.30 4.75 4.56
5.07 4.56 7.27 4.93 4.09 4.75 6.81
6.61 6.06 4.86 5.62 3.91 5.04
4.49 5.51 4.27 3.94 4.84 4.82
6.46 6.83 5.51 6.17 6.57 6.35
5.33 6.17 4.45 5.15 4.89 4.56 4.42
6.39 4.93 2.89 5.55 5.59 5.48
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Blood Urea Nitrogen (mmol/L)
Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
4.31 2.24 2.80 5.04 5.15 4.60
5.29 3.32 4.38 5.18 4.78 4.56 3.51
3.16 6.43 5.00 6.17 6.11 5.16
2.46 2.36 4.82 4.99 4.71 4.05
2.64 5.26 5.77 5.22 4.34 4.78
3.10 6.79 5.81 5.51 4.78 5.36
2.70 6.39 6.39 5.95 4.09 5.07
4.75 3.87 5.04 4.60 3.80 6.43 5.37
6.06 5.44 5.55 4.89 4.20 5.15 4.76
5.73 5.45 4.60 5.55 4.42 5.88 5.50
5.07 6.75 6.02 4.86
5.51 4.78 5.59 5.99 5.33 3.69
5.00 6.41 5.37 4.56 5.40 5.18
6.03 2.99 4.16 3.90 4.05 6.65 4.38
5.40 4.53 4.46 5.18 4.34 4.78
5.88 5.48 3.98 4.75 6.64 4.97
5.07 3.67 4.53 3.91 4.49 4.45
4.64 3.91 4.02 4.20
4.78 3.66 4.06 4.38 4.05 3.82
6.50 5.16 3.21 4.64 6.68 6.94
5.00 3.90 3.50 5.99 5.44 5.40
4.64 5.48 6.79 6.06 5.91 6.24
5.22 5.81 7.96 5.99 5.55 5.53
6.75 4.89 5.91 3.54 3.80 3.76 4.48
4.24 4.89 6.43 6.90 4.16 5.16
5.15 4.80 4.89 4.82 6.63 5.30
5.48 5.88 4.16 4.60 5.28 4.21
6.28 4.34 4.38 4.94 1.27 3.91 5.58
4.31 4.13 4.09 3.72 4.49 4.31 5.13
6.72 4.09 3.72 5.45 3.29 5.44 5.26
4.42 2.99 3.35 3.25 4.72 3.88
6.28 8.35 3.79 3.37 5.00 4.60
7.23 7.17 4.20 4.79 5.00 5.06
4.27 5.75 4.43 3.90 4.46 4.03
5.88 3.68 4.88 3.13 4.01 4.95
6.64 3.99 5.81 2.57
6.28 5.74 5.88 6.21 5.36 6.39
4.45 2.97 4.56 5.55 3.68 5.36
4.53 4.80 4.11 4.38 4.38 5.41 5.62
4.64 6.54 4.44 4.49 4.53 3.60 3.91
6.82 3.80 6.00 6.24 5.50 6.83 7.12
4.24 4.83 5.02 5.43 4.57 6.55
4.22 3.55 5.57 4.54 4.26 5.77
5.22 4.44 5.11 6.36 4.40 4.16
4.70 3.98 5.17 4.48 4.82 5.78 5.15
4.40 4.75 5.88 6.90
4.79 3.44 5.04 4.41 3.97 4.82
4.49 4.77 5.26 4.28 6.88 6.94
5.54 4.50 3.90 4.62 7.09 6.64
5.32 5.77 5.41 5.45 6.05 6.10
5.07 4.54 4.50 4.56 5.02 3.75 4.86
6.50 5.16 4.89 0.81 5.33 7.19
6.13 5.68 5.13 5.31 4.59 5.84
2.72 5.51 5.79 4.67 5.75 6.02
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Blood Urea Nitrogen (mmol/L)
Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
5.76 4.40 4.82 4.56 4.44 4.89 5.07
5.29 4.42 4.74 4.47 4.48 6.64
4.44 2.75 4.27 3.81 6.00 6.75
4.25 4.33 3.41 3.73 5.77 7.03
4.30 4.01 3.57 3.92 3.65 5.99
4.22 4.19 4.47 4.23 4.17 5.30 5.46
7.96 4.29 4.15 4.18 5.47 6.83
4.56 3.84 4.21 4.53 4.71 5.51 5.15
4.87 3.95 4.26 4.41 4.14
4.49 4.71 5.98 5.69 5.08 5.11
5.52 4.71 4.49 4.99 5.07 5.07 5.55
4.61 3.84 4.80 5.03 5.22 4.89
3.88 4.45 5.02 5.46 4.89 5.66
5.73 4.45 4.47 5.37 4.71
5.84 4.85 5.24 5.16 5.07 5.55 5.27
4.66 3.76 3.65 3.68 4.52 14.10
4.31 4.13 4.49 5.35 4.88 4.96 5.33
4.98 4.85 5.21 5.31 5.95
5.36 4.64 6.60 6.36 4.86 4.02
5.24 4.44 8.00 9.82 4.86 4.68
5.36 6.13 5.40 5.87 7.41 6.28
5.36 4.42 4.65 4.99 5.73 7.78
5.72 4.66 6.31 5.58 6.50 4.86
6.37 5.25 4.66 4.29 4.86 6.86 5.99
5.94 5.00 4.93 5.18 5.44 4.97
4.60 5.77 5.48 5.22 6.47 4.74
3.80 5.07 5.15 5.48 4.60 4.82
11.68 5.48 6.57 4.75 10.95
7.67 4.02 5.84 4.38 4.38 12.78 10.22
11.32 7.30 6.57 10.22 5.11 6.94
5.84 3.29 6.94 5.11 5.84 13.03 9.93
5.48 8.03 6.21 5.48 5.84
10.95 11.68 15.33 16.06 12.05
6.21 9.49 7.30 13.84 14.60 10.22
6.21 9.13 12.78 11.94 5.48 9.49
12.78 12.92 13.14 9.49 9.49 10.70
10.59 9.68 8.65 5.48 10.22 10.37 11.68
12.05 5.84 10.22 8.03 8.40 11.83
6.94 5.11 4.38 8.76 9.49 11.46 12.41
9.60 6.57 4.38 5.84 8.03 11.25 10.22
9.75 5.84 6.94 5.11 9.49 7.30
11.98 10.81 4.02 5.48 12.05 8.03
5.84 9.49 10.95 12.05 12.05 6.94
4.38 8.76 7.30 12.41 10.22 11.32 10.95
6.21 9.86 6.94 11.68 9.60 10.22
11.68 11.68 9.86 5.84 9.49 13.14
11.68 11.68 16.06 10.95 9.49
14.97 9.86 9.49 12.05 9.49 6.21
11.68 11.68 13.36 7.67 9.49 9.49
6.94 9.13 10.22 12.96 20.23 11.68 5.84
10.95 6.57 12.19 7.30 11.10 10.59
9.86 9.13 13.11 15.26 90.18
7.67 5.11 10.70 16.03 7.67 6.57
10.95 6.57 10.73 11.68 9.64 13.51 5.11
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Blood Urea Nitrogen (mmol/L)
Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
8.25 10.04 9.64 8.91 16.43 6.57
11.54 7.30 11.03 11.57 8.40 10.95
13.73 9.78 9.49 8.76 7.67
9.49 10.37 9.78 7.30 10.22 10.22 10.95
8.25 8.65 10.92 17.52 10.22 8.76
10.59 8.84 10.04 8.76 9.49 5.11 9.49
11.50 7.30 9.35 9.49 0.20 6.21 9.49
10.66 7.67 9.38 14.17 11.68 11.32
7.48 6.94 8.07 11.68 6.57 11.68
12.89 12.05 11.21 10.95 11.68 10.95
13.87 15.33 14.93 10.95 10.11 3.65
11.83 10.95 17.20 18.99 6.94 8.76
7.56 8.11 10.37 12.23 13.03 8.40
10.51 9.86 13.44 13.14 5.84
8.76 14.82 10.95 9.93 5.11
11.79 13.14 14.60 9.13 6.21 9.02
13.18 13.87 7.67 6.21 13.87
12.41 15.33 7.30 8.40 6.21
12.27 10.11 12.78 11.87 7.48 12.45
8.77 11.57 12.05 8.73 9.20 10.70 11.68
10.44 10.00 8.40 8.76 8.29 7.34
9.49 10.08 9.86 11.32 7.74 7.34
8.54 10.22 10.22 9.38 9.86 9.49
9.64 10.59 9.13 10.04 10.59 10.62 8.54
17.89 12.67 13.69 11.68 10.95
8.03 8.76 9.49 10.59 11.32 10.59
12.01 8.73 8.76 12.92 8.18 9.57
8.32 8.54 8.84 7.30 7.08
8.58 9.31 10.99 14.02 7.67 8.76
10.70 8.84 8.25
10.48 9.53 8.98 9.64 9.86 7.74
14.86 15.12 13.47 11.46 10.22
12.34 10.73 9.64 10.70 9.86 8.03
11.83 11.39 10.08 11.39 10.66 7.30 8.40
14.28 14.68 11.43 11.10 11.94 8.84 8.76
13.14 11.83 10.70 10.00 8.80 9.86
8.18 8.62 9.64 8.87 7.38 21.54
9.57 7.30 8.43 10.62 9.16 6.94
12.49 12.27 11.46 11.06 8.76 11.32
12.45 13.80 14.38 12.89 13.40 11.68
9.82 12.85 13.22 10.66 8.03 21.54
15.30 15.12 16.87 14.09 11.03 13.51
9.97 9.13 10.62 11.06 11.10 9.86 8.03
9.75 7.30 8.76 73.39 10.59 7.74 6.57
11.03 10.59 9.86 9.60 12.41 11.03
11.94 11.68 11.83 13.07 10.15 8.76
11.32 12.41 10.95 11.32 11.32 9.49 9.86
10.88 10.81 11.72 14.38 11.68 8.76
12.49 13.91 14.68 8.76 11.35
12.27 13.22 11.83 13.22 13.98 10.22
9.89 10.66 11.46 12.49 11.32 7.67
8.76 10.22 10.95 12.41 9.86 8.40
10.66 11.10 12.41 9.86 11.68 13.14
14.90 15.12 10.59 10.22 12.41 10.22
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Blood Urea Nitrogen (mmol/L)
Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
8.18 9.49 9.86 10.33 8.76 9.13
11.32 8.76 13.14 8.76 10.22 10.59 7.67
11.68 12.41 13.14 12.41 8.76 12.05 7.30
7.30 9.49 9.86 10.92 9.89 6.57
15.33 16.06 11.83 10.22 9.86 10.59
12.23 14.31 9.93 6.94 7.67 8.03
13.51 8.76 9.38 7.30 9.49 8.76
8.03 12.38 7.67 11.68 10.73 7.81 13.51
7.30 10.33 8.76 9.89 8.76 10.22
2.80 4.12 5.30 5.04 5.92 3.52
3.30 4.38 5.00 3.60 4.55 4.43
4.10 5.72 1.99 6.31 5.29 2.44
3.50 3.50 4.40 1.90 3.95 3.06
4.60 3.69 2.99 3.50 2.65 3.43 3.21
7.40 3.01 2.13 2.34 3.69 2.46
4.34 1.90 6.63 4.96 3.92 5.54 3.73
5.10 5.90 5.60 5.80 7.02 4.06
3.65 4.72 2.97 2.50 3.28 1.88
3.80 8.25 5.80 2.60 2.00 4.82 3.43
4.21 7.43 7.16 2.17 4.16 2.49
3.50 5.00 2.30 7.60 3.51 3.66
6.36 1.03 2.76 3.20 2.98 4.58 4.98
2.99 2.68 5.20 4.74 2.06 2.91 3.55
4.45 4.83 4.63 1.89 5.12 5.00
5.57 1.04 2.60 4.27 6.75 2.76 2.72
4.37 2.77 4.38
3.79 1.75 3.73 2.52 5.79 4.82
3.46 2.72 2.20 4.46 4.19 4.01
2.45 2.80 2.50 3.66 4.72 2.31 5.42
2.03 2.27 4.91 4.41 1.98 2.19
3.66 2.20 4.19 3.49 3.76 3.66
5.95 5.16 6.15 5.16 4.41 2.26
3.87 4.54 3.96 3.36 5.08 2.88 2.35
5.45 4.32 4.85 5.85 5.27 4.87 2.76
2.89 2.60 3.73 3.14 5.51 3.16
3.39 3.38 2.39 4.48 3.27 2.33
1.99 2.37 1.66 4.67 3.52 9.87
2.60 4.60 2.86 5.44 5.34 3.43 6.03
3.05 3.89 3.38 5.09 1.84 2.45
3.33 5.68 4.55 2.36 3.57 2.25
2.32 3.59 3.59 1.90 5.25
3.99 2.81 5.27 2.88 1.61 3.06 2.63
2.98 2.72 2.76 5.47 5.63 3.02
3.61 3.20 1.99 3.29 4.57 2.93
2.23 4.87 2.68 4.96 3.52 3.41 2.05
2.66 3.50 3.71 4.73 4.17 3.81 3.48
2.40 3.67 4.65 4.65 2.97 2.80
2.79 3.25 5.45 4.27 5.25 3.70
3.69 2.58 4.87 6.00 4.55 3.64
7.40 3.84 6.22 1.88 5.49 3.53
7.68 3.50 4.28 2.22 4.49 4.20
4.87 3.92 3.28 4.94 3.20 3.80 2.90
6.66 5.19 7.47 6.14 3.00 4.23
4.65 6.19 5.11 4.66 3.28 3.96
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Blood Urea Nitrogen (mmol/L)
Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU






























































































Blood Urea Nitrogen (mmol/L)

















6.10 3.83 9.38 4.86 8.76
10.30 9.13 6.68 12.52 9.24 6.57
7.19 8.00 4.97 8.76 7.30
4.67 5.07 5.48 10.84 8.07
3.83 6.86 5.48 8.76 9.24 7.52 7.30
4.27 3.43 3.65 6.83 7.78 10.00 8.76
5.11 5.59 6.46 13.40 7.30
4.53 4.56 4.67 5.33 7.34 6.57
4.02 3.83 6.64 7.78 9.86 9.24 10.15
5.04 3.98 6.13 7.48 8.84 6.57
14.09 8.58 6.21 7.27 9.35 7.67 6.94
3.72 7.30 10.33 8.29 10.84 7.67
6.21 5.48 9.13 9.86 11.68 8.76
4.34 4.38 18.26 11.68 11.65 9.20 7.38
7.41 3.69 8.76 11.39 9.64 7.30
5.18 10.95 10.22 10.37 9.13 13.36
10.22 8.76 9.13 10.22 9.13 6.75
13.14 8.76 7.08 7.48 10.37 9.20 6.90
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Blood Urea Nitrogen (mmol/L)
Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
12.05 37.24 6.43
10.95 9.24 11.87 10.70 9.75 8.14 7.67
10.30 9.75 6.06 8.29 6.79 7.30 9.57
8.76 9.86 7.63 7.05 7.30 8.03
9.75 10.00 9.78 10.66 7.96
10.66 10.59 11.46 6.10
7.27 10.59 6.10 5.44 6.54 7.59 7.30
9.89 9.68 12.45 10.62 7.59
15.12 9.24 10.48 10.59 7.45
13.58 7.05 6.72 7.63 7.23 7.30 6.79
6.54 5.70 7.05 8.11 7.52 8.47
12.74 7.12 11.10 8.29 6.64
9.35 7.30 7.48 8.32 7.01 8.76
14.97 70.10
10.66 5.07 6.21 5.59 6.64 7.30
13.22 8.47 7.27 9.46 11.68 8.03 6.94
7.78 7.63 7.45 7.12 6.64 7.45
13.87 6.79 5.99 6.10 6.79 7.30
14.68 14.86 14.53 10.55 6.79
17.34 6.79 6.57 6.61 7.30
6.61 8.76 5.07 5.59 6.06 7.01 7.30
9.13 11.10 13.69 12.67 9.64 8.76
8.14 8.84 10.15 9.53 7.67 8.76
14.46 11.43 11.68 8.94 11.32 9.13 7.67
8.18 9.13 9.13 8.58 7.30 9.20
12.85 12.16 11.10 11.90 7.30 6.75
12.27 11.17 9.64 10.48 11.68 9.49 8.03
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Appendix 58: Listing of globulin per patient
Centre Patient Treatment Globulin (mg/dL)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 N/A not done
12 N/A Combination not done
23 361 Combination 51.6 82 67 43 33 20
23 362 PM 68.3 80 71 80 47 40
23 363 PM 56.5 61 76 68 36 25
23 364 Combination 19.9 59 53 55 54 29
23 365 SSG 67.1 113 91 87 68 31 33
23 366 Combination 88 71 77 79 31 30
23 367 SSG 69 92 56 104 36 31 25
23 368 PM 87 49 94 41 39 22
23 369 Combination 75 75 125 78 35 31
23 370 SSG 68 72 49 21 71 49 34
23 371 PM 85 74 48 44 92 73
23 372 PM 83 81 46 96 35 48
23 373 SSG 36 36 41 25 65 46 52
23 374 SSG 60 50 93 57 40 21 33
23 375 Combination 78 42 52 66 48 21
23 376 SSG 103 26 53 78 66 39 80
23 377 Combination 65 91 26
23 378 Combination 104 59 56 31 52 34
23 379 PM 82 88 68 62 81 51
23 380 SSG 68 53 62 60 66 50 26
23 381 PM 67 61 40 60 46 37
23 382 Combination 71 40 69 67 51 22
23 383 PM 48 86 85 86 35 51
23 384 SSG 84 92 84 90 78 71 71
23 385 SSG 85 93 101 42 84 40 51
23 386 Combination 71 80 61 77 32 59
23 387 Combination 88 78 78 87 57 26
23 388 PM 58 27 40 34 49 43
23 389 SSG 107 139 91 74 63 31 26
23 390 PM 87 121 95 86 41 33
23 391 Combination 89 78 85 78 47 62
23 392 Combination 43 55 78 51 22
23 393 SSG 55 44 63 65 43 40 73
23 394 PM 64 70 73 66 23 82
23 395 PM 76 65 77 75 69 13
23 396 SSG 77 80 70 66 65 39 26
23 397 SSG 49 73 65 47 42 42 22
23 398 Combination 76 78 91 62 65 67
23 399 PM 81 74 94 63 51 32
23 400 PM 39 54 40 67 42 40
23 401 Combination 46 58 68 56 71 63
23 402 Combination 63 82 58 77 27 50
23 403 SSG 77 77 102 90 20 53 51
23 404 SSG 62 75 72 100 40 49
23 405 PM 87 83 105 87 48 44
34 N/A Not done
35 Not done
35 679 SSG 3.4
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Appendix 59: Listing of Albumin per patient
Centre Patient Treatment Albumin (mg/dl)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 Not done
12 Not done
23 361 Combination 40.8 27 26 41 37 40
23 362 PM 33.7 19 29 28 40 36
23 363 PM 40.3 28 28 31 34 37
23 364 Combination 44.6 26 39 33 15 36
23 365 SSG 38.7 30 29 30 30 41 46
23 366 Combination 14 16 18 33 35 34
23 367 SSG 15 22 26 20 24 39 35
23 368 PM 19 24 26 25 41 37
23 369 Combination 18 18 25 23 45 35
23 370 SSG 13 24 19 35 29 27 29
23 371 PM 32 28 48 39 21 34
23 372 PM 33 25 31 30 47 46
23 373 SSG 19 19 37 32 25 21 26
23 374 SSG 14 24 42 30 42 39 34
23 375 Combination 19 33 16 25 43 31
23 376 SSG 31 16 32 32 34 34 31
23 377 Combination 13 12 42
23 378 Combination 27 15 25 34 24 39
23 379 PM 20 20 27 31 34 40
23 380 SSG 20 24 29 30 30 27 37
23 381 PM 32 19 26 29 22 32
23 382 Combination 21 24 24 23 30 37
23 383 PM 25 29 13 29 35 39
23 384 SSG 20 21 19 27 29 34 34
23 385 SSG 19 23 20 19 25 37 37
23 386 Combination 21 24 35 18 36 27
23 387 Combination 19 35 27 23 20 38
23 388 PM 21 43 31 39 43 36
23 389 SSG 15 20 25 38 35 44 43
23 390 PM 14 19 24 28 32 78
23 391 Combination 20 34 25 28 29 28
23 392 Combination 19 20 29 24 41
23 393 SSG 23 32 40 33 41 35 32
23 394 PM 21 23 23 35 31 27
23 395 PM 24 25 23 31 28 44
23 396 SSG 17 26 24 30 31 38 45
23 397 SSG 17 24 34 36 29 33 41
23 398 Combination 18 21 29 31 28 22
23 399 PM 22 26 27 35 28 28
23 400 PM 24 18 42 28 34 34
23 401 Combination 29 23 39 36 21 21
23 402 Combination 24 26 33 36 39 32
23 403 SSG 20 11 22 16 73 27 34
23 404 SSG 22 22 38 33 40 31
23 405 PM 17 30 18 28 32 33
34 N/A Not done
35 646 PM 22 29 30 43 34
35 647 PM 27 25 29 36 43 30
35 648 Combination 29 33 30 41 34
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Appendix 59: Listing of Albumin per patient
35 649 Combination 23 23 29 33 30
35 650 SSG 35 37 36 50 42 38 30
35 651 SSG 33 35 36 41 43 37 30
35 652 PM 33 30 30 42 41
35 653 Combination 25 27 30 30 28 30
35 654 SSG 25 28 31 54 43 41 36
35 655 Combination 24 28 29 29 36 27
35 656 SSG 26 23 28 33 38 31 29
35 657 PM 33 30 41 38 42 30
35 658 Combination 26 28 40 40 39 30
35 659 SSG 30 28 45 42 39 28 30
35 660 PM 32 30 42 42 36 29
35 661 Combination 30 24 37 41 33
35 662 PM 32 31 36 41 32
35 663 SSG 29 24 22 38 32 28 32
35 664 Combination 36 35 32
35 665 SSG 37 42 29 42 33 31 29
35 666 SSG 27 25 37 42 48 32 33
35 667 Combination 36 38 41 43 40 34
35 668 PM 29 36 41 40 31
35 669 PM 32 31 38 33
35 670 SSG 34 31 39 40 46 35 32
35 671 PM 22 32 31 34 32
35 672 Combination 22 30 34 36 35
35 673 SSG 38 36 41 42 38 34 32
35 674 Combination 32 30 35 37 32 38
35 675 PM 34 30 33 41 36
35 676 PM 34 31 34 35 34 34
35 677 SSG 29 31
35 678 Combination 24 27 32 39 30 33
35 679 SSG 30 31 33 42 30 28
35 680 Combination 23 28 34 42 36 32
35 681 Combination 33 37 38 39 30 33
35 682 PM 34 35 37 41 38
35 683 Combination 35 32 38 37 34
35 684 SSG 38 40 35 34 36 32 34
35 685 PM 39 39 32 43 36 32
35 686 PM 37 33 43 37 32 28
35 687 SSG 36 35 37 39 32 29 31
35 688 PM 41 41 43 42 36 32
35 689 Combination 38 27 30 38 30 32
35 690 SSG 3.8 32 39 41 37 30 26
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Appendix 60: Listing of Total protein per patient
Centre Patient Treatment Total Protein (g/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
11 Not done
12 241 Combination 68 76 83 86 72
12 242 SSG 65 96 76 76 92 82 84
12 243 PM 60 80 85 87 70 70
12 244 SSG 74 56 67 62 78 70 70
12 245 PM 82 60 95 100 90
12 246 PM 100 74 70 80
12 247 PM 80 72 70 86 70
12 248 PM 86 80 60
12 249 Combination 69 70 72 80 70 80
12 250 SSG 79 70 70 80 70 70 80
12 251 Combination 100 90 80 80 100 60
12 252 SSG 59 70 90 100 70 70 80
12 253 SSG 68 80 110 120 70 70 70
12 254 Combination 58 80 90 70 100 80
12 255 Combination 80 65 80 110 70 90
12 256 Combination 90 70 90 80 70 60
12 257 SSG 90 80 100 80 110 70 70
12 258 SSG 80 64 62 80 72 80
12 259 PM 84 68 90 70 80
12 260 PM 110 100 74 80 70
12 261 Combination 80 90 85 82 70 70
12 262 PM 70 70 60 70 70
12 263 SSG 60 70 88 78 80 70
12 264 Combination 70 80 70 60
12 265 SSG 80 100 100
12 266 PM 92 75 68 60 70
12 267 SSG 84 80 82 78 70
12 268 PM 60 60 90 80 70 60
12 269 Combination 60 70 90 90 70 70
12 270 Combination 80 88 86 70
12 271 SSG 70 60 80 70 80
12 272 PM 80 70 80 70 60
12 273 SSG 80 80 80 80 90 80 90
12 274 SSG 70 70 70 80 70 70 60
12 275 Combination 90 90 60 90 80 80
12 276 PM 70 70 80 70 70 70
12 277 Combination 80 80 80 90 70 70
12 278 SSG 70 70 70 80 80 73
12 279 PM 70 75 80 80 80
12 280 SSG 50 70 80 80 70 68
12 281 Combination 70 80 80 90 90
12 282 PM 90 80 110 90 70
12 283 PM 70 80 80 80
12 284 Combination 70 80 60 70 70
12 285 Combination 90 90 70 80 70
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Appendix 60: Listing of Total protein per patient
Centre Patient Treatment Total Protein (g/L)
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Appendix 60: Listing of Total protein per patient
Centre Patient Treatment Total Protein (g/L)
Number Number Baseline Day 7 Day 14 Day 21 EOT 3 Mon FU 6 Mon FU
35 646 PM 65 57 63 76 62
35 647 PM 71 69 76 95 72 66
35 648 Combination 75 76 76 80 62
35 649 Combination 68 87 90 77 62
35 650 SSG 77 76 69 75 80 72 58
35 651 SSG 80 62 69 70 77 72 59
35 652 PM 70 77 73 80 68
35 653 Combination 77 73 80 76 67 60
35 654 SSG 61 76 76 78 66 80
35 655 Combination 61 63 80 78 81 54
35 656 SSG 63 63 62 73 80 68 62
35 657 PM 80 76 69 77 74 62
35 658 Combination 72 90 76 72 61 54
35 659 SSG 75 69 73 77 74 61 58
35 660 PM 59 69 67 74 72 60
35 661 Combination 84 80 86 84 76 67
35 662 PM 75 73 70 75 76 66
35 663 SSG 75 73 70 72 70 57 48
35 664 Combination 77 75 58
35 665 SSG 59 80 74 82 72 68 58
35 666 SSG 75 72 75 69 71 64 47
35 667 Combination 75 77 77 76 71 68
35 668 PM 75 78 77 72 47
35 669 PM 77 72 77 68
35 670 SSG 77 72 75 68 73 68 64
35 671 PM 72 80 75 72 58
35 672 Combination 74 66 68 70 62
35 673 SSG 74 68 77 75 68 62 59
35 674 Combination 77 71 70 69 61 66
35 675 PM 75 51 64 73 66
35 676 PM 76 64 77 73 68 70
35 677 SSG 68 72
35 678 Combination 49 51 64 67 65 68
35 679 SSG 51 66 76 73 64 60
35 680 Combination 63 61 68 67 64 58
35 681 Combination 70 66 67 68 72 64
35 682 PM 76 74 65 77 66
35 683 Combination 78 77 70 72 68
35 684 SSG 68 71 76 80 70 60
35 685 PM 74 68 71 80 72 66
35 686 PM 71 76 80 79 68 60
35 687 SSG 51 76 78 69 64 58 64
35 688 PM 66 74 69 77 67 60
35 689 Combination 69 68 64 73 58 61
35 690 SSG 69 67 73 77 66 62 60
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Appendix 61: Listing of urinary protein per patient
Centre Patient Treatment Dipstick Urinalysis - Urinary Protein 
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
11 1 PM positive positive negative negative negative negative
11 2 Combination negative negative negative negative negative negative
11 3 Combination negative negative negative negative negative negative
11 4 PM negative negative negative negative negative negative
11 5 PM negative negative negative negative negative negative
11 6 Combination negative negative negative negative negative negative
11 7 PM negative negative negative negative negative negative
11 8 SSG negative negative negative negative negative negative negative
11 9 SSG negative negative negative negative positive negative negative
11 10 SSG negative negative negative negative negative negative negative
11 11 Combination negative negative negative negative negative negative
11 12 Combination negative negative negative negative negative negative
11 13 SSG negative positive negative positive positive negative negative
11 14 SSG negative negative negative negative negative negative negative
11 15 PM negative negative negative negative
11 16 Combination negative negative negative negative negative negative
11 17 Combination negative negative negative negative negative negative
11 18 SSG negative negative negative positive negative negative negative
11 19 Combination negative negative negative negative negative negative
11 20 SSG negative negative negative negative negative negative negative
11 21 SSG negative negative positive negative negative negative negative
11 22 SSG negative negative negative negative negative negative negative
11 23 PM negative negative negative negative negative negative
11 24 PM negative negative negative negative negative negative
11 25 SSG negative positive negative negative positive negative negative
11 26 Combination negative negative negative negative negative negative
11 27 PM negative negative negative negative negative
11 28 Combination negative negative negative negative negative negative
11 29 PM negative negative negative negative negative negative
11 30 PM negative negative negative negative negative negative
11 31 SSG negative negative negative negative negative negative negative
11 32 Combination negative negative negative negative negative negative
11 33 SSG negative negative negative negative negative negative negative
11 34 PM not done negative negative negative negative negative
11 35 SSG negative negative negative negative negative negative negative
11 36 SSG negative negative negative negative negative negative negative
11 37 Combination negative negative negative negative negative negative
11 38 PM negative negative negative negative negative negative
11 39 PM negative negative negative negative negative negative
11 40 PM negative negative negative negative negative
11 41 Combination negative negative negative negative negative negative
11 42 Combination negative negative negative negative negative negative
11 43 SSG negative negative negative negative negative negative negative
11 44 PM negative negative negative negative negative negative
11 45 Combination negative negative negative negative negative negative
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Appendix 61: Listing of urinary protein per patient
Centre Patient Treatment Dipstick Urinalysis - Urinary Protein 
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
11 46 SSG negative negative negative negative negative negative negative
11 47 SSG negative negative negative negative negative
11 48 Combination negative negative negative negative negative
11 49 SSG negative negative negative negative negative negative negative
11 50 PM negative negative negative negative negative negative
11 51 Combination negative negative negative negative negative negative
11 52 PM negative negative negative negative negative negative
11 53 SSG negative negative negative negative negative negative negative
11 54 PM negative negative negative negative negative negative
11 55 PM negative negative negative negative negative negative
11 56 SSG negative negative negative negative negative positive negative
11 57 Combination negative negative negative negative negative negative
11 58 Combination negative negative negative negative negative negative
11 59 PM negative negative negative negative negative negative
11 60 Combination negative negative negative negative negative negative
11 61 PM negative negative negative negative negative positive
11 62 SSG negative negative negative negative negative negative negative
11 63 SSG negative negative negative negative negative negative negative
11 64 SSG negative negative negative negative negative negative negative
11 65 PM negative negative negative negative
11 66 Combination negative negative negative negative negative negative
11 67 PM negative negative negative negative negative negative
11 68 SSG negative negative negative negative negative negative negative
11 69 Combination negative negative negative negative negative negative
11 70 Combination negative negative negative negative negative negative
11 71 Combination negative negative negative negative negative positive
11 72 SSG negative negative negative negative negative
11 73 PM negative negative negative negative negative negative
11 74 PM negative negative negative negative negative positive
11 75 Combination negative negative negative negative negative negative
11 76 PM negative negative negative negative negative negative
11 77 PM negative negative negative negative negative negative
11 78 SSG negative negative negative negative negative negative negative
11 79 PM negative negative negative negative negative negative
11 80 PM negative negative negative negative negative negative
11 81 Combination negative negative negative negative negative negative
11 82 SSG negative negative negative negative negative negative negative
11 83 SSG negative negative negative negative negative negative negative
11 84 SSG positive negative negative negative positive negative negative
11 85 SSG positive positive negative negative negative negative
11 86 Combination positive negative negative negative negative negative
11 87 Combination positive negative negative negative negative negative
11 88 PM negative negative negative negative negative negative
11 89 Combination negative negative negative negative negative negative
11 90 Combination negative negative negative negative
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Appendix 61: Listing of urinary protein per patient
Centre Patient Treatment Dipstick Urinalysis - Urinary Protein 
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
11 91 PM positive negative positive negative positive positive
11 92 Combination negative negative negative negative negative negative
11 93 SSG negative negative negative negative negative negative negative
11 94 SSG negative negative negative negative negative negative negative
11 95 SSG negative negative negative negative negative negative negative
11 96 Combination positive negative negative negative negative negative
11 97 Combination negative positive negative negative negative negative
11 98 PM negative negative positive positive negative negative
11 99 SSG negative negative positive negative negative negative negative
11 100 PM negative negative negative positive
11 101 PM positive negative negative negative negative negative
11 102 Combination positive negative negative negative negative negative
11 103 Combination positive negative negative negative negative negative
11 104 PM negative negative negative negative negative negative
11 105 SSG positive negative negative negative negative negative negative
11 106 Combination positive negative negative negative negative negative
11 107 PM positive negative negative negative negative negative
11 108 PM negative negative negative negative negative negative
11 109 SSG negative negative negative negative negative negative negative
11 110 PM positive negative negative negative negative negative
11 111 Combination negative negative negative negative negative negative
11 112 Combination negative positive negative negative negative negative
11 113 SSG negative negative negative negative negative negative
11 114 SSG negative negative negative negative negative negative negative
11 115 Combination positive negative negative negative negative negative
11 116 SSG positive negative negative negative negative negative negative
11 117 PM negative positive negative negative negative
11 118 PM negative negative negative negative negative negative
11 119 SSG positive negative negative negative negative negative negative
11 120 Combination positive negative negative negative negative negative
11 121 Combination negative negative negative negative negative negative
11 122 SSG positive negative negative negative negative
11 123 SSG negative negative negative negative negative negative negative
11 124 SSG positive negative negative negative negative negative
11 125 SSG positive positive negative negative negative negative negative
11 126 Combination negative negative negative negative negative
11 127 PM positive positive negative negative negative negative
11 128 Combination negative positive positive positive negative negative
11 129 PM positive positive negative negative negative negative
11 130 Combination negative negative negative negative negative negative
11 131 PM positive negative negative negative negative negative
11 132 SSG positive negative negative negative negative negative negative
11 133 Combination negative negative negative negative negative negative
11 134 PM positive positive negative negative negative negative
11 135 PM negative negative negative negative negative negative
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Appendix 61: Listing of urinary protein per patient
Centre Patient Treatment Dipstick Urinalysis - Urinary Protein 
 Number Number Baseline Day 7 Day 14 Day 21 EOT 3Mon FU 6Mon FU
12 241 Combination negative positive positive positive positive
12 242 SSG negative negative negative not done negative negative negative
12 243 PM positive negative negative negative negative negative
12 244 SSG negative negative negative negative negative negative negative
12 245 PM negative negative positive negative positive
12 246 PM negative negative negative negative negative
12 247 PM negative negative negative negative negative positive
12 248 PM negative negative negative negative negative negative
12 249 Combination negative negative negative positive negative negative
12 250 SSG negative negative negative negative negative positive negative
12 251 Combination positive positive positive positive negative negative
12 252 SSG negative negative negative negative negative positive negative
12 253 SSG positive negative positive negative negative negative negative
12 254 Combination positive positive negative negative negative negative
12 255 Combination positive negative negative negative negative positive
12 256 Combination negative negative positive positive negative negative
12 257 SSG positive negative negative negative negative negative negative
12 258 SSG negative negative not done negative not done negative
12 259 PM not done not done negative not done negative negative
12 260 PM not done positive positive positive positive
12 261 Combination negative negative negative negative negative negative
12 262 PM negative negative negative negative positive negative
12 263 SSG positive negative negative positive positive negative positive
12 264 Combination negative negative negative positive negative negative
12 265 SSG negative negative positive positive
12 266 PM negative negative negative negative negative negative
12 267 SSG negative negative negative negative negative positive negative
12 268 PM negative negative negative negative negative negative
12 269 Combination negative negative negative negative negative negative
12 270 Combination positive negative negative negative negative
12 271 SSG positive negative negative negative negative negative negative
12 272 PM positive negative negative positive negative negative
12 273 SSG negative negative negative negative negative negative negative
12 274 SSG negative negative negative negative negative negative negative
12 275 Combination negative negative positive positive positive negative
12 276 PM negative negative negative negative negative negative
12 277 Combination positive positive negative positive negative negative
12 278 SSG positive positive negative positive positive negative
12 279 PM negative positive negative positive negative negative
12 280 SSG negative positive negative positive negative negative negative
12 281 Combination positive negative negative positive negative negative
12 282 PM negative negative positive positive negative negative
12 283 PM positive positive negative negative negative negative
12 284 Combination not done negative negative negative negative negative
12 285 Combination positive positive positive negative negative negative
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